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Abstract	
	
Background	
UK	 health	 policy	 places	 digital	 technology	 developments	 at	 the	 heart	 of	
plans	to	improve	health,	increase	access	and	reduce	cost.	Electronic	health	
(eHealth)	and	mobile	health,	offer	opportunities	 to	 revolutionise	 the	way	
services	 for	 sexually	 transmitted	 infections	 (STIs)	 are	 delivered.	
Developments	 include	 point-of-care	 and	 self-tests,	 and	 online	 treatment	
through	eHealth	clinics.	Such	innovations	offer	potential	benefits	including	
increased	 testing	 uptake,	 higher	 treatment	 rates	 and	 reduced	 disease	
transmission.		
	
This	thesis	explored	the	impact	of	the	adoption	of	remote	self-testing	and	
an	eHealth	clinic	(for	remote	treatment	and	contact	tracing)	into	pathways	
for	the	management	of	asymptomatic	genital	Chlamydia	Trachomatis.	
	
Research	Outputs	
Young	 people’s	 preferences:	 A	 discrete	 choice	 experiment	 (DCE)	 that	
quantified	which	factors	are	important	to	1,230	young	people	in	chlamydia	
testing	and	treatment	pathways.	This	mixed-methods	approach	included:	
• Literature	reviews	to	inform	the	‘long	list’	of	potential	attributes	
• Focus	 groups	 with	 young	 people	 aged	 16-24	 to	 elicit	 views	 on	
attributes	which	are	important	in	STI	services	
• Expert	groups	to	provide	a	policy/	service	perspective		
• Cognitive	 testing	 to	 inform	 the	 development	 of	 the	 DCE	
questionnaire	
• National	DCE	of	16-24	year	olds	using	online	research	panel.	
	
Technology	costs	and	benefits:	An	early	economic	evaluation	to	assess	the	
costs	and	benefits	of	introducing	an	eHealth	clinic	for	chlamydia	treatment,	
and	extended	to	explore	the	considerations	for	a	fully	remote	self-testing	
and	treatment	pathway.	This	has	been	informed	by	two	literature	reviews	
exploring	costs	and	consequences	and	a	primary	costing	study.		
	
Results	
The	 DCE	 found	 that	 test	 accuracy,	 followed	 by	 time	 to	 result	 were	 the	
strongest	attributes	influencing	preferences.		
	
The	 economic	 evaluation	 identified	 that	 online	 care	 is	 cost	 saving	
compared	 with	 existing	 practice	 however	 further	 work	 is	 required	 to	
understand	the	impact	on	health	outcomes.		
	
The	 thesis	 findings	should	help	 inform	adoption	of	new	technologies	 into	
mainstream	chlamydia	testing	and	treatment	pathways.	
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Glossary	of	Terms	
Term	 Definition	within	Thesis	
Asymptomatic	 Individuals	testing	for	chlamydia	who	have	no	symptoms.	
eSTI2		 The	research	consortium	which	is	developing	self-testing	
and	eHealth	solutions	for	STI	testing	and	treatment.	
Further	information	about	the	consortium	is	included	in	
Appendix	1.	
False	Negative	(FN)	 A	test	result	which	incorrectly	identifies	the	individual	as	
being	disease	free	when	they	have	the	disease.	
False	Positive	(FP)	 A	test	result	which	incorrectly	identifies	the	individual	as	
having	the	disease	when	they	are	disease	free.	
Fully	Remote	
Online	Pathway	
The	conceptual	full	pathway	for	chlamydia	which	includes	
a	self-test	which	interfaces	with	the	online	chlamydia	care	
pathway	(OCCP).	
Negative	
Predictive	Value	
(NPV)	
The	percentage	of	negative	results	that	are	true	negative	
results.	
Online	Chlamydia	
Care	Pathway	
(OCCP)	
A	product	developed	by	the	eSTI2	research	consortium.	It	
commences	at	results	notification	and	concludes	at	
partner	notification.	This	technology	was	tested	in	an	
exploratory	pilot	study	and	data	collected	within	the	study	
is	used	to	inform	the	costing	study	in	this	thesis.	The	OCCP	
is	an	eHealth	clinic	which	is	optimized	for	use	on	a	mobile	
phone	internet	browser.	
Positive	Predictive	
Value	(PPV)	
The	percentage	of	positive	results	that	are	true	positive	
results.	
	
Remote	Care	
Pathway	
Non-face-to-face	pathways	where	patients	are	not	
required	to	attend	a	healthcare	setting	for	diagnosis	or	
treatment.	This	can	include	services	delivered	online,	via	
telephone,	video-conferencing,	instant	messaging	etc.	
Screening	 Testing	of	individuals	who	are	asymptomatic.	The	term	is	
used	both	within	the	context	of	the	National	Chlamydia	
Screening	Programme	(NCSP)	and	asymptomatic	
individuals	attending	health	care	settings	for	testing	
regardless	of	whether	they	fit	within	the	definition	of	the	
NCSP.	
Self-Sampling	 The	process	by	which	the	individual	takes	their	own	
sample.	The	sample	is	processed	by	a	laboratory	and	
results	interpreted	by	a	healthcare	professional.	
Self-Test	 A	test	where	the	sample	is	taken	and	the	result	is	
interpreted	by	the	user.	Whilst	work	has	been	undertaken	
to	develop	a	test	as	part	of	the	eSTI2	research	programme,	
no	self-test	product	is	currently	available	which	meets	the	
standards	for	use	within	the	NHS.	
Symptomatic	 Individuals	testing	for	chlamydia	who	have	symptoms	of	
an	infection	(which	may	or	may	not	be	chlamydia).	
True	Negative	(TN)	 A	test	result	which	correctly	identifies	the	individual	as	
being	disease	free.	
True	Positive	(TP)	 A	test	result	which	correctly	identifies	the	individual	as	
having	the	disease.	
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1 CHAPTER	1	–	INTRODUCTION	
“One	 of	 the	 greatest	 opportunities	 of	 the	 21st	 century	 is	 the	 potential	 to	
safely	 harness	 the	 power	 of	 the	 technology	 revolution,	 which	 has	
transformed	 our	 society,	 to	meet	 the	 challenges	 of	 improving	 health	 and	
providing	better,	safer,	sustainable	care	for	all”.		
(National	Information	Board,	2014:6).	
	
The	World	Health	Organisation	(WHO)	 identify	that	the	population	at	risk	
of	sexually	transmitted	infections	(STIs)	will	continue	to	grow	considerably	
as	a	result	of	“social,	demographic	and	migratory	trends”	 (WHO,	2007:3),	
and	 that	whilst	 the	developing	world	 is	 subject	 to	 the	greatest	burden	of	
disease,	 STIs	 and	 their	 associated	 complications	 will	 remain	 a	 significant	
public	health	problem	for	all	countries	(WHO,	2013).		
	
Chlamydia	is	the	most	commonly	diagnosed	sexually	transmitted	infection	
(STI)	 in	 England,	 the	 European	 Union	 (EU)	 and	 the	 USA,	 with	 rates	 of	
reported	diagnoses	continuing	to	increase	(ECDC,	2014).	In	England	young	
people	 aged	 15-24	 account	 for	 61%	 of	 chlamydia	 cases	 (Public	 Health	
England,	 2016b).	 Whilst	 easy	 to	 treat	 with	 a	 single	 dose	 antibiotic,	 it	 is	
largely	asymptomatic	and	can	result	in	serious	long	term	consequences	for	
women	 in	 particular,	 including	 pelvic	 inflammatory	 disease	 (PID),	 ectopic	
pregnancy	and	infertility	(WHO,	2012).	The	resultant	complications	present	
a	 significant	 economic	burden	 to	health	 services	 and	 the	wider	 economy	
compared	with	the	costs	of	screening	for	the	disease	(ECDC,	2014).	Despite	
the	introduction	of	the	National	Chlamydia	Screening	Programme	(NCSP)	in	
England	in	2003	for	16-24	year	olds,	uptake	of	opportunistic	screening	for	
chlamydia	remains	low.	
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Advancements	 in	 technology,	 particularly	 electronic	 health	 (eHealth)	 and	
mobile	health	(mHealth),	have	already	opened	up	a	wide	range	of	options	
to	revolutionise	the	way	that	aspects	of	STI	testing	and	treatment	services	
are	delivered.	 These	 include	 the	development	of	 point-of-care	 (POC)	 and	
self-tests,	and	online	treatment	pathways	either	through	eHealth	clinics	or	
smartphone	applications	 (apps).	 Such	 innovations	may	offer	 a	number	of	
potential	 benefits	 for	 service	 delivery	 including	 increased	 testing	 uptake,	
higher	treatment	rates	and	reduced	disease	transmission.		
	
This	 thesis	 presents	 the	 doctoral	 research	 undertaken	 to	 inform	 the	
understanding	 of	 young	 people’s	 preferences	 for	 new	 STI	 testing	 and	
treatment	services	and	the	costs	and	consequences	of	the	introduction	of	
self-tests	 and	 eHealth	 clinics,	 with	 a	 specific	 focus	 on	 services	 for	 the	
testing	and	treatment	of	chlamydia.		
	
1.1 Setting	the	Scene	
Chlamydia	 Trachomatis	 is	 the	 most	 commonly	 diagnosed	 STI	 in	
England	 (PHE,	 2016a).	 Whilst	 genital	 chlamydia	 trachomatis	 is	 the	
most	 frequently	 diagnosed,	 	 pharyngeal	 and	 rectal	 infections	 also	
occur.	 For	 the	 purposes	 of	 this	 thesis,	 chlamydia	 and	 chlamdial	
infection	 refer	 to	 genital	 chlamydia	 trachomatis	 only.	 Within	
mainstream	 sexual	 health	 services	 in	 England	 over	 434,000	 new	
diagnoses	of	STIs	were	made	 in	2015,	46%	 (200,288)	of	 these	were	
chlamydia	(Public	Health	England,	2016b).	Young	people	aged	15-24	
experience	 the	 highest	 rates	 of	 STI	 diagnosis	 with	 61%	 of	 all	
chlamydia	 diagnoses	 made	 in	 2015	 in	 this	 age	 range	 (ibid.).	 STI	
diagnoses	within	 this	 age	 range	 have	 risen	 consistently	 for	 the	 last	
five	years,	although	recently,	the	number	of	chlamydia	diagnoses	has	
decreased	slightly	(ibid.).		
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The	 recommendation	 of	 NCSP	 is	 that	 sexually	 active	 young	 people	
should	be	screened	for	chlamydia	annually,	on	change	of	partner	or	
three	months	after	a	positive	test	result	(ibid).	Data	for	2015	indicate	
that,	based	on	an	assumption	of	one	test	per	person,	32%	of	females	
and	 13%	 of	 males	 within	 the	 target	 age	 range	 were	 tested	 for	
chlamydia	(ibid.).	The	Public	Health	Outcomes	Framework	(PHOF)	for	
England	 has	 a	 specific	 target	 for	 Chlamydia	 diagnosis	 within	 the	
central	 objective	 to	 protect	 population	 health,	 with	 a	 target	
detection	rate	of	2,300	per	100,000	population	within	the	15-24	age	
range	(Department	of	Health,	2013c).	In	2015	only	20%	of	upper	tier	
local	 authorities	 (LA)	 achieved	 this	 target	 (Public	 Health	 England,	
2016b).	 Data	 demonstrates	 a	 strong	 correlation	 between	 testing	
coverage	and	chlamydia	detection	rates	(ibid.).	
	
Estimates	of	the	cost	of	treatment	and	economic	burden	associated	
with	 chlamydia	 are	 limited.	 The	most	 recent	work	 by	Development	
Economics	 refreshes	 the	 approach	 taken	 by	 the	 North	West	 Public	
Health	 Observatory	 in	 2005.	 This	 reflects	 2011	 data	 and	 estimates	
the	 direct	 medical	 costs	 per	 identified	 case	 of	 chlamydia	 to	 be	
£796.87	 (£176.86	 million	 annualised	 amount)	 (Development	
Economics,	2013).	Detailed	scenario	estimation	was	included	in	their	
report,	 which	 demonstrated	 that	 if	 growth	 in	 detection	 rate	
continued	 at	 2002-2011	 levels	 and	 access	 to	 services	 continued	 on	
the	same	basis,	 the	annual	direct	medical	cost	 for	 the	 treatment	of	
chlamydia	 in	 2015	 would	 be	 £249.8	 million	 and	 2020	 would	 be	
£387.4	million	(ibid.).		
	
As	 outlined	 briefly	 above,	 new	 digital	 technologies	 may	 have	 the	
potential	 to	 increase	 testing	 coverage	 and	 treatment	 rates	 and	
therefore	 reduce	 disease	 transmission	 particularly	within	 the	 16-24	
age	 range.	 Data	 on	 internet	 usage	 published	 by	 the	 Office	 for	
National	Statistics	 (ONS)	 supports	 this,	demonstrating	high	 levels	of	
accessibility	to	the	required	base	technology:	
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• Internet	 access	 is	 now	 available	 in	 89%	 of	 households	 with	
99%	 of	 households	 with	 children	 having	 an	 internet	
connection,	
• 75%	 of	 the	 adult	 population	 now	 report	 accessing	 the	
internet	via	a	mobile	device	such	as	a	smartphone	or	tablet,	
however	 this	 percentage	 is	 much	 higher	 in	 the	 16-24	 age	
range	at	97%,		
• 82%	 of	 the	 adult	 population	 now	 access	 the	 internet	 daily	
(Office	for	National	Statistics,	2016b).		
	
Advancements	in	technology	including	fibre	optic	broadband,	fourth	
generation	 (4G)	 mobile	 networks	 and	 public	 Wi-Fi	 hotspots	 are	
improving	speed	of	access	to	internet	content.	However,	despite	the	
growth	in	internet	use	for	many	activities	of	daily	life	such	as	banking	
and	food	shopping,	this	pace	of	adoption	has	not	been	realised	in	the	
delivery	 of	 healthcare	 services:	 “the	 consumer	 experience	 of	 care	
services	 remains	 much	 as	 it	 was	 before	 the	 mobile	 phone	 and	
internet	 became	 commonplace”	 (National	 Information	 Board,	
2014:8).	
	
1.2 The	Research	Problem	
Low	 uptake	 of	 chlamydia	 testing	 services	 as	 outlined	 previously	
represents	both	an	individual	and	population	health	problem.	As	well	
as	the	financial	costs	of	diagnosing	and	treating	chlamydial	infection,	
there	 are	 also	 the	 economic	 consequences	 of	 untreated	 infection,	
including	further	transmission.		
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Research	suggests	that	there	are	many	factors	which	prevent	young	
people	accessing	sexual	health	services,	 including	chlamydia	testing.	
These	 can	 include	 tangible	 service	 properties	 such	 as	 location	 of	
service,	 and	 personal	 factors	 including	 the	 stigma	 associated	 with	
attendance,	embarrassment	and	fear	of	being	recognised	or	privacy	
concerns	 (Booth	et	 al.,	 2013,	 Friedman	and	Bloodgood,	 2013,	Balfe	
and	 Brugha,	 2009).	 The	 findings	 of	 previous	 studies	 are	 discussed	
further	in	Chapter	4.		
	
Within	the	context	of	service	delivery,	sexual	health	services	are	one	
of	 the	 only	 open	 access	 diagnostic	 services	 available	 within	 the	
National	Health	Service	(NHS),	that	 is,	 the	 individual	can	 initiate	the	
test	without	a	referral	from	a	healthcare	professional.	There	is	a	key	
question	 as	 to	 the	 role	of	 new	 technology	 in	 the	delivery	of	 sexual	
health	 services,	 particularly	 in	 the	 use	 of	 remote	 care	 pathways1	
which	 both	 the	 development	 of	 self-tests	 and	 eHealth/mHealth	
solutions	 form	 part	 of	 -	 will	 they	 increase	 uptake	 of	 testing	 and	
treatment	by	young	people	 for	 chlamydia	 infections	and	are	 they	a	
cost-effective	way	of	delivering	a	health	service?	There	are	currently	
no	published	studies	that	explore	young	people’s	preferences	for	the	
use	 of	 a	 remote	 clinical	 pathway	 involving	 self-testing	 and	 online	
clinical	management	 for	 the	 testing	and	 treatment	of	chlamydia,	or	
whether	this	is	a	cost-effective	service	delivery	model.		
	
Whilst	there	are	examples	of	smartphone	diagnostics	and	apps	being	
marketed	to	consumers,	adoption	of	similar	technologies	by	the	NHS	
in	 2016	 is	 low.	 At	 the	 time	 of	 writing	 this	 thesis	 there	 are	 no	
smartphone	diagnostic	apps	made	available	by	the	NHS	for	patients	
to	 use	 and	 the	 NHS	 apps	 library	 has	 been	 withdrawn,	 removing	
access	 to	 the	 limited	 number	 available	 which	 focused	 on	 health	
information	and	symptom	recording	(NHS	England,	2015).		
																																																						
1	Remote	care	pathways	can	be	defined	as	non	face-to-face	pathways	where	patients	are	not	
required	to	attend	a	healthcare	setting	for	diagnosis	or	treatment.	This	can	include	services	delivered	
online,	via	telephone,	instant	messaging	or	videoconferencing.		
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1.3 Aims	of	Research		
The	 aim	 of	 this	 research	 was	 to	 explore	 the	 costs	 and	 benefits	 of	
integrated	 online	 chlamydia	 testing	 and	 treatment	 within	 an	 early	
health	 technology	 assessment	 (eHTA)	 framework.	 The	 research	
undertaken	had	the	following	objectives:	
	
• To	 assess	 which	 attributes	 influence	 young	 people’s	
preferences	for	the	testing	and	treatment	of	chlamydia	and	
to	 explore	 their	 implications	 for	 the	development	of	 sexual	
health	services	in	England		
• To	explore	the	likely	costs	of	implementing	online	chlamydia	
treatment	in	mainstream	sexual	health	services	in	England	
• To	develop	an	economic	model	to	assess	the	likely	costs	and	
benefits	 of	 implementing	 a	 fully	 remote,	 integrated	 online	
pathway	including	self-testing.	
	
Consideration	 is	 given	 to	 the	 limitations	 of	 the	 work	 and	 its	
implications	 for	 the	 commissioning	 and	 delivery	 of	 sexual	 health	
services	within	England,	as	well	as	areas	for	further	research.	
	
Figure	1.1	provides	an	overview	of	the	conceptual	elements	of	a	fully	
remote	chlamydia	self-testing	and	treatment	pathway,	and	figure	1.2	
illustrates	a	fully	integrated	remote	pathway	flow	chart.	
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Figure	1.1	-	Components	of	a	Fully	Integrated	Remote	Pathway	for	the	Testing	&	Treatment	of	Chlamydia	
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Figure	1.2	–	Fully	Integrated	Remote	Pathway	Flow	Chart	
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There	 are	 two	 separate	 technologies	within	 the	 fully	 integrated	 pathway	
which	are	at	different	stages	of	development	–	the	online	chlamydia	care	
pathway	 (OCCP)	 and	 the	 self-test.	 The	 key	 terms	 in	 relation	 to	 the	
technologies	 and	 the	 pathway	which	 are	 used	 throughout	 the	 thesis	 are	
defined	in	glossary	of	terms	on	page	13.	
	
1.4 Overview	of	Thesis	Structure	
The	 following	 chapter	 (Chapter	 2)	 provides	 more	 detailed	
background	to	a	number	of	the	key	issues	introduced	in	section	1.1.	
Chapter	3	outlines	the	theoretical	framework	for	Health	Technology	
Assessment	 (HTA)	 and	 eHTA,	 considering	 the	 current	 stage	 of	
technology	 development.	 It	 also	 presents	 the	methods	 selected	 to	
address	 the	 research	 objectives	 and	 summarises	 the	 scope	 of	
research	undertaken	as	part	of	this	doctoral	research.	
	
Chapter	 4	 presents	 current	 research	 evidence	 on	 individuals’	
preferences	 for	 accessing	 testing	 and	 treatment	 services	 for	 STIs,	
including	 the	 service	 attributes	 which	might	 influence	 preferences.	
Chapter	 5	 presents	 the	 findings	 of	 qualitative	 research	 including	
focus	 groups	 and	 expert	 groups	 undertaken	 to	 develop	 the	 main	
themes	 and,	 from	 them,	 identify	 the	 attributes	 and	 levels	 for	
inclusion	 in	 the	 Discrete	 Choice	 Experiment	 (DCE).	 This	 leads	 into	
Chapter	6	which	describes	the	experimental	design,	results,	analysis	
and	conclusions	of	the	DCE.		
	
Chapter	 7	 explores	 the	 costs	 associated	with	 the	OCCP	 exploratory	
study	and	presents	the	outcome	of	the	costing	study	including	a	cost	
analysis	of	the	OCCP	and	review	of	intermediate	outcomes.	Chapter	
8	 builds	 on	 this,	 extending	 the	 work	 into	 an	 economic	 model	 to	
explore	 the	 impact	of	both	 the	OCCP	and	a	 fully	 integrated	 remote	
pathway.		
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Chapter	9	reflects	on	the	findings	of	this	research	more	generally	and	
their	 implication	 for	 sexual	 health	 services,	 drawing	 out	 the	 key	
conclusions	and	recommendations	for	further	research.		
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2 CHAPTER	2	–	BACKGROUND	TO	THE	RESEARCH		
2.1 Introduction	
The	purpose	of	this	chapter	is	to	frame	the	context	for	the	research	
presented	 in	 subsequent	 chapters.	 It	 provides	 evidence	 on	 the	
current	position	in	respect	of	policy,	definitions	and	key	data	that	run	
throughout	the	chapters	in	this	thesis.		
	
An	 analysis	 of	 the	 evolution	 of	 eHealth	 and	 mHealth	 is	 given,	 set	
within	the	framework	of	policy	and	practice	of	healthcare	in	England	
and	learning	from	international	developments.	Next,	a	review	of	key	
aspects	 of	 sexual	 health	 services	 in	 England	 is	 presented,	 including	
both	 the	 general	 policy	 position	 for	 sexual	 health	 services,	 with	 a	
specific	 focus	on	chlamydia	where	appropriate,	drawing	out	current	
practice	 and	 an	 overview	 of	 the	 implementation	 of	 eHealth	 and	
mHealth.		
	
2.2 History	of	Digital	Technology	
From	 the	 initial	 creation	 of	 the	 concept	 of	 the	 world	 wide	 web	 in	
1989	 to	 an	 estimated	 3.2	 billion	 users	 world-wide	 in	 2015	 (BBC,	
2015),	 the	 internet	 creates	 opportunities	 for	 open	 access	 to	
information	 and	 services	 in	 ways	 that	 were	 previously	 unfeasible,	
through	 other	 communications	 media.	 The	 transition	 to	 digital	
mobile	networks	in	the	early	1990s,	enabled	an	expansion	of	service	
providers	 and	 growth	 in	 the	phone	development	market	 as	well	 as	
the	introduction	of	mobile	data	services	in	1999	(OFCOM,	2012).		
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The	 transition	 through	 mobile	 network	 types	 from	 general	 packet	
radio	service	(GPRS),	to	third	generation	(3G)	and	4G	networks	over	
the	last	10	years,	coupled	with	the	significant	growth	in	smartphones	
since	the	launch	of	the	iPhone	in	2007,	has	led	to	an	explosion	in	the	
growth	 of	 mobile	 phone	 use	 for	 data	 services	 such	 as	 email	 and	
internet	 services	 (Fiordelli	 et	 al.,	 2013).	 A	 further	 addition	 to	
smartphone	services	 is	 the	 ‘app’	–	 software	designed	 specifically	 to	
run	 on	 a	 device	 such	 as	 a	 mobile	 phone.	 Estimates	 in	 June	 2016	
suggest	that	1.5	million	apps	are	available	in	the	Apple	app	store	and	
since	 its	 launch	 in	 2008	 130	 billion	 downloads	 have	 been	 made	
(Statistica,	2016a).	Whilst	Apple	led	the	field,	apps	are	now	available	
on	 other	 smartphone	 operating	 systems.	 Google	 Play,	 which	 is	 the	
leading	 app	 store	 for	 android	 (an	 alternative	 operating	 system	 to	
Apple’s)	devices,	 has	2	million	apps	available	 in	 its	 store	 (Statistica,	
2016b).	
	
To	set	the	context	of	digital	technology	access	in	the	UK,	building	on	
the	 data	 introduced	 in	 Chapter	 1,	 data	 from	 the	 Office	 of	
Communications	 (OFCOM)	 which	 regulates	 the	 communications	
market	in	the	UK,	identified	that	at	the	end	of	2015	there	were	91.5	
million	 active	 mobile	 phone	 subscriptions	 (OFCOM,	 2016).	 The	
quarterly	‘Technology	Tracker’	trends	survey	published	by	Ipsos	Mori	
identified	that	in	quarter	2	of	2016:	
• internet	 access	 across	 gender	 and	 socioeconomic	 status	 for	
15-24	 year	 olds	 is	 consistently	 high,	 with	 the	 lowest	 access	
rate	 in	females	aged	15-24,	socioeconomic	status	D	and	E	at	
96%	
• smartphone	 ownership	 across	 gender	 and	 socioeconomic	
status	is	also	high	with	94%	of	males	and	95%	of	females	aged	
15-24	 owning	 a	 smartphone.	 The	 lowest	 rates	 of	 ownership	
within	 this	 age	 group	 are	males,	 socioeconomic	 status	 D&E	
(91%)	(Ipsos	Mori,	2016).		
	
		 41	
	
Disparities	 in	 overall	 mobile	 internet	 usage	 and	 smartphone	
ownership	present	an	important	consideration	in	the	development	of	
mHealth	interventions.	Whilst	apps	have	the	benefit	of	being	able	to	
utilise	features	of	the	phone	such	as	the	camera	(a	potential	option	
for	 the	 analysis	 of	 test	 results),	 websites	 optimised	 for	 use	 on	 a	
mobile	 phone	 are	 accessible	 by	 all	 operating	 platforms	 therefore	
extending	the	user	base	(We	are	Apps,	2013).		
	
The	ONS	data	for	the	UK	published	for	2016	shows	an	increase	in	the	
reported	use	of	the	 internet	to	find	health	 information	from	18%	in	
2007	to	51%	in	2016	(Office	for	National	Statistics,	2016b).	There	are	
a	 number	 of	 published	 studies	 which	 demonstrate	 a	 preference	
among	 patients	 and	 citizens	 for	 the	 use	 of	 the	 internet	 to	 source	
information	about	health	conditions.	A	literature	review	published	in	
2011	 by	 the	 European	 Centre	 for	 Disease	 Prevention	 and	 Control	
(ECDC)	found	that	use	for	this	purpose	was	growing	rapidly	amongst	
patients,	 carers,	 and	 their	 friends	 and	 relatives,	 with	 women	 and	
those	 more	 highly	 educated	 more	 likely	 to	 search	 for	 health	
information	online	(Higgins	et	al.,	2011).		
	
2.3 Digital	Health	
This	 section	 considers	 the	key	 concepts	and	definitions	used	 in	 this	
thesis	 in	 greater	 depth.	 It	 is	 recognised	 that	 due	 to	 the	 relative	
newness	 of	 the	 digital	 field	 there	 is	 an	 absence	 of	 “commonly	
accepted	or	industry	wide	meaning”	(Wragge	&	Co	and	ECH	Alliance,	
2014:7)	as	well	as	no	definition	within	UK	or	EU	law	(ibid.).		
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There	are	many	terms	used	to	describe	the	use	of	digital	technology	
within	 the	delivery	of	healthcare.	The	common	overarching	 term	 in	
use	in	most	current	policy	documents	is	‘digital	health’,	although	no	
consistent	definition	 is	offered	within	 these.	One	definition,	offered	
by	 Kostkova	 is	 “the	 use	 of	 information	 and	 communications	
technologies	 to	 improve	 human	 health,	 healthcare	 services,	 and	
wellness	 for	 individuals	 and	across	 populations”	 (Kostkova,	 2015:1).	
Many	other	 terms	are	also	 in	use,	 such	as	 telemedicine,	 telehealth,	
telecare,	connected	health,	eHealth	and	mHealth.		
	
The	WHO	offers	a	definition	of	telemedicine	as	“the	delivery	of	health	
care	 services,	 where	 distance	 is	 a	 critical	 factor,	 by	 all	 health	 care	
professionals	using	 information	and	communication	technologies	for	
the	 exchange	 of	 valid	 information	 for	 diagnosis,	 treatment	 and	
prevention	of	disease	and	 injuries,	 research	and	evaluation,	 and	 for	
the	continuing	education	of	health	care	providers,	all	in	the	interests	
of	advancing	the	health	of	individuals	and	their	communities”	(WHO,	
2010:9).	
	
It	 is	 recognised	 that	 there	 are	 similarities	 in	 the	 use	 of	 the	 terms	
telemedicine	and	telehealth,	with	van	Dyk	noting	that	delivery	over	a	
distance	 is	 a	 common	 feature	 of	 both	 telemedicine	 and	 telehealth	
(van	 Dyk,	 2014),	 and	 Bashshur	 and	 colleagues	 suggested	 that	
“conceptually,	 telemedicine	 is	 to	 telehealth	 what	 medicine	 is	 to	
health”	(Bashshur	et	al.,	2011:487).	A	white	paper	by	Wragge	and	Co	
draws	out	 a	 key	distinction	 in	 the	use	of	 the	 terms	 suggesting	 that	
telemedicine	 is	 used	 to	 describe	 “the	 provision	 of	 a	 regulated	
healthcare	service”	 (Wragge	&	Co	and	ECH	Alliance,	2014:10)	whilst	
telehealth	refers	to	the	remote	monitoring	of	physiological	data.	This	
contrasts	with	 telecare	 that	 focuses	on	monitoring	of	 the	 individual	
living	in	their	own	home.		
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The	 definition	 of	 telecare	 offered	 by	 the	 Telecare	 Services	
Association	 is	 “support	 and	 assistance	 provided	 at	 a	 distance	 using	
information	 and	 communication	 technology.	 It	 is	 the	 continuous,	
automatic	 and	 remote	monitoring	 of	 users	 by	means	 of	 sensors	 to	
enable	 them	to	continue	 living	 in	 their	own	home,	while	minimising	
risks…”	(Telecare	Services	Association,	2015).	
	
Deloitte	 UK	 offer	 a	 definition	 of	 connected	 health	 as	 “connected	
health	 or	 technology	 enabled	 care	 (TEC)	 is	 the	 collective	 term	 for	
telecare,	 telehealth,	 telemedicine,	 mHealth,	 digital	 health	 and	
eHealth	services.	TEC	involves	the	convergence	of	health	technology,	
digital,	 media	 and	 mobile	 telecommunications	 and	 is	 increasingly	
seen	 as	 an	 integral	 part	 of	 the	 solution	 to	many	 of	 the	 challenges	
facing	 the	 health,	 social	 care	 and	 wellness	 sectors,	 especially	 in	
enabling	 more	 effective	 integration	 of	 care”	 (Deloitte	 Centre	 for	
Health	Solutions,	2015:1).		
	
The	terms	eHealth	and	mHealth	have	been	more	recently	introduced	
with	 eHealth	 first	 being	 discussed	 in	 the	 late	 1990s	 and	 mHealth	
becoming	 more	 established	 following	 the	 new	 generation	 of	
smartphone	and	tablet	technology	which	became	mainstream	in	the	
mid	2000s.	A	summary	of	the	key	features	and	types	of	technology	is	
presented	in	table	2.1.	
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	 Telemedicine	 eHealth	 mHealth	
Key	Features	 Linked	directly	
to	clinical	service	
delivery	
Broad	scope	
including	other	non-
clinical	IT	solutions	
within	health	
Subset	of	eHealth	
involving	use	of	
mobile	devices	such	
as	phones	or	tablets	
Examples	 • Virtual	
Clinics	
• Remote	
monitoring	
• Electronic	Health	
Records	
• ePrescribing	
• eCommerce	
within	health	
• Health	
information	
• Delivery	of	web-
based	services/	
interventions	
• SMS	
Appointment	
Reminders	
• Apps	–	health	
information,	
public	health	
interventions,	
monitoring	
• Remote	
monitoring	
• Diagnostics		
Table	2.1	-	Features	of	Telemedicine,	eHealth	&	mHealth	
The	 founding	 definition	 of	 eHealth	 was	 proposed	 by	 Eysenbach	 as	
“an	emerging	 field	 in	 the	 intersection	of	medical	 informatics,	 public	
health	 and	 business,	 referring	 to	 health	 services	 and	 information	
delivered	or	enhanced	through	the	internet	and	related	technologies.	
In	 a	 broader	 sense,	 the	 term	 characterises	 not	 only	 a	 technical	
development,	but	also	a	state-of-mind,	a	way	of	thinking,	an	attitude	
and	 a	 commitment	 for	 networked,	 global	 thinking,	 to	 improve	
healthcare	 locally,	 regionally,	 and	 worldwide	 by	 using	 information	
and	communication	technology”	(Eysenbach,	2001:e20).	
	
In	undertaking	its	second	global	survey	on	eHealth	the	World	Health	
Organisation	 (WHO)	 recognised	 the	 absence	 of	 a	 standardised	
definition	 of	mHealth,	 choosing	 to	 define	 it	 as	 “Medical	 and	 public	
health	practice	supported	by	mobile	devices,	such	as	mobile	phones,	
patient	 monitoring	 devices,	 personal	 digital	 assistants	 (PDAs)	 and	
other	 wireless	 devices”	 (WHO,	 2011a:2).	 A	 more	 concise	 definition	
offered	by	Free	and	colleagues	 is	“the	use	of	mobile	computing	and	
communication	technologies	in	healthcare	and	public	health”	(Free	et	
al.,	2013b).	
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MHealth	 is	 closely	 aligned	 with	 other	 health	 technologies,	
particularly	 eHealth	 and	 telemedicine	 with	 the	 mobile	 device	
enabling	existing	 technologies	 to	be	utilised	 in	 a	different	way,	 e.g.	
remote	 monitoring,	 as	 well	 as	 extending	 the	 scope	 of	 technology	
available	for	use,	as	illustrated	in	table	2.1.	The	pace	of	change	in	the	
development	 of	 mobile	 technologies	 has	 presented	 significant	
opportunities	 for	 the	 growth	 of	 mHealth	 initiatives,	 making	 the	
categories	 considered	 by	 the	 WHO	 survey	 in	 2009	 seem	 almost	
obsolete.		
	
2.3.1 Digital	Health	Policy	in	the	NHS	in	England	
NHS	 health	 policy	 has	 incorporated	 these	 technological	 advances.	
The	publication	in	1998	of	‘Information	for	Health	–	An	Information	
Strategy	 for	 the	 Modern	 NHS	 1998-2005’	 set	 out	 a	 commitment	
from	the	Department	of	Health	to	delivering,	amongst	other	things	
“lifelong	 electronic	 health	 records	 for	 every	 person	 in	 the	
country…fast	and	convenient	public	access	to	information	and	care	
through	 on-line	 information	 services	 and	 telemedicine”	
(Department	of	Health,	1998:9).	
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Much	of	 the	early	digital	health	policy	 in	 the	NHS	was	centred	on	
addressing	the	IT	infrastructure	and	system	deficits	within	hospitals	
and	primary	care.	The	NHS	Plan	was	 the	 first	major	general	policy	
document	to	acknowledge	the	need	for	modern	IT	systems	in	both	
general	practice	and	hospitals	 (Department	of	Health,	2000).	 	 The	
plan	 included	 reference	 to	 a	 vision	 where	 self-care	 and	 self-
management	 would	 be	 facilitated	 through	 the	 NHS	 Direct	
telephone	and	 internet	site,	and	 information	technology	would	be	
used	to	enable	patients	to	email	or	phone	GPs	and	practice	nurses	
for	 advice	 and	 support	 for	 self-management,	 and	 to	 receive	 their	
test	results	at	home.	Digital	television	was	also	envisaged	as	a	key	
enabler	in	the	delivery	of	self-care	(ibid).		
	
From	 a	 policy	 perspective,	 over	 the	 period	 2000-2010,	 the	 focus	
remained	 on	 the	 integration	 of	 systems	 through	 the	 work	 of	
Connecting	 for	Health	 (CfH)	 in	delivering	 the	National	 Programme	
for	 IT	 (NPfIT).	 This	 included	 the	development	and	 implementation	
of	 systems	 linking	 both	 primary	 and	 secondary	 care	 including	 the	
NHS	 Care	 Records	 Service,	 Choose	 and	 Book	 and	 the	 Electronic	
Prescribing	 Services	 (EPS)	 (National	 Audit	 Office,	 2006,	 National	
Audit	Office,	2008,	National	Audit	Office,	2011).		
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The	publication	of	‘Innovation,	Health	and	Wealth’	in	2011	led	to	a	
notable	policy	shift	away	from	a	focus	on	IT	systems	for	the	NHS	to	
the	 adoption	 of	 innovations	 which	 could	 impact	 directly	 on	 the	
provision	of	patient	care.	The	‘digital	by	default’	 initiative	was	first	
introduced	in	this	policy	document	and	reinforced	the	vision	in	the	
original	NHS	Plan	(2000)	that	“for	many	people	who	use	electronic	
media	as	part	of	 their	daily	 lives,	 the	ability	 to	use	email	 for	non-
confidential	 communications,	 or	 to	 have	 a	 remote	 consultation	
using	 telephone	 or	 online	 technology	 would	 offer	 a	 much	 more	
convenient	way	of	accessing	NHS	services.	The	NHS	can	do	more	to	
drive	down	the	level	of	inappropriate	and	unnecessary	face-to-face	
contacts”	(Department	of	Health,	2011:27).		
	
The	shift	away	from	IT	systems	was	reinforced	by	the	publication	of	
‘Digital	 First’	 in	 2012	 which	 aimed	 to	 “make	 available	 the	 digital	
means	 (channels,	 content,	 services)	 for	 the	 general	 public	 to	
manage	 their	 healthcare	 digitally	 wherever	 possible	 and	 provide	
the	mechanisms	and	support	that	ensure	they	can	migrate	to	these	
digital	channels	as	their	preferred	manner	to	engage”	(Department	
of	 Health,	 2012:3).	 	 Ten	 high	 impact	 digital	 initiatives	 were	 cited	
which	 incorporated	 the	 use	 of	 eHealth	 and	 mHealth	 solutions,	
including	 using	 online	 and	 telephone	 triage,	 online/	 remote	
consultation	and	short	message	service	(SMS)	reminders	to	deliver	
an	estimated	£3bn	in	savings	for	the	NHS	(ibid.).		
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During	 this	 period,	 digital	 health	 initiatives	 also	 began	 to	 spread	
into	service	and	condition	specific	policies,	 including	sexual	health,	
to	 be	 outlined	 further	 in	 section	 2.4.1.	 These	 were	 incorporated	
into	 healthcare	 contracting	 arrangements	 through	 service	
specifications,	enhanced	services	and	commissioning	for	quality	and	
innovation	 schemes	 (CQUINs).	 The	 NHS	 five	 year	 forward	 view,	
published	 by	 NHS	 England	 in	 2014,	 also	 gave	 a	 commitment	 to	
expanding	the	use	of	digital	technology	in	the	NHS	recognising	the	
role	of	 a	 range	of	eHealth	and	mHealth	 solutions	 including	health	
apps,	 online	 GP	 appointments	 and	 patients	 having	 full	 access	 to	
their	electronic	health	record	(NHS	England,	2014).	The	subsequent	
National	 Information	 Board	 (NIB)	 report	 published	 later	 that	 year	
built	on	 this	 commitment	outlining	 the	practical	 arrangements	 for	
taking	 forward	 this	 programme	 of	 work	 (National	 Information	
Board,	2014).		
	
2.3.2 NHS	Adoption	of	Telemedicine,	eHealth	and	mHealth	in	
England	
The	 adoption	 of	 telemedicine,	 eHealth	 and	 mHealth	 at	 a	 system	
level	within	the	NHS	and	other	health	systems	has	proved	to	be	a	
challenge	 with	 limited	 evaluation	 of	 cost-effectiveness.	 A	 2011	
WHO	 global	 survey	 was	 the	 first	 to	 comprehensively	 identify	
barriers	 to	adoption	of	mHealth	by	health	systems	 internationally.	
Competing	 priorities	 within	 the	 health	 system	 were	 identified	 as	
the	most	significant	barrier	to	the	adoption	of	mHealth	(52%),	with	
lack	 of	 knowledge	 about	 how	 mHealth	 can	 be	 utilised	 and	 its	
contribution	 to	 health	 outcomes,	 lack	 of	 policy	 on	 mHealth	
initiatives	at	a	national	level,	and	poor	data	on	cost-effectiveness	of	
mHealth	 interventions	being	the	most	commonly	cited	reasons	for	
not	pursuing	mHealth	interventions	(WHO,	2011a).	
	
	 	
		 49	
In	England,	with	the	exception	of	a	few	major	 initiatives	that	have	
been	 adopted	 fairly	 consistently	 across	 the	NHS,	 for	 example	 text	
message	 appointment	 reminders,	 the	 adoption	 of	 eHealth	 and	
mHealth	 has	 followed	 a	 path	 of	 small	 scale,	 localised,	 initiatives	
with	minimal	structured	evaluation,	this	 is	not	dissimilar	to	that	of	
other	 nations	 (ibid.).	 Sustained	 adoption	 has	 been	 heavily	
influenced	 by	 clinicians	 with	 for	 example,	 access	 to	 choose	 and	
book,	 the	 system	 for	 booking	 online	 hospital	 appointments,	
reducing	when	the	 financial	 incentive	 for	GP	practice	participation	
ceased.	 The	 Whole	 System	 Demonstrator	 (WSD)	 project	 was	 the	
largest	 randomised	 control	 trial	 (RCT)	 undertaken	 in	 England	
designed	to	explore	the	costs	and	benefits	of	using	telehealth	and	
telecare	 alongside	 the	 standard	 interventions.	 The	 trial	 covered	
patients	in	three	areas	with	one	or	more	of	the	following	conditions	
–	chronic	obstructive	pulmonary	disease,	heart	failure	or	diabetes,	
and	 considered	 the	 effect	 of	 telehealth	 on	 access	 to	 primary,	
secondary	and	 social	 care	 services.	 The	 cost	effectiveness	analysis	
identified	that	telehealth	was	unlikely	to	be	cost-effective	where	it	
was	 provided	 as	 an	 addition	 to	 standard	 care	 (Henderson	 et	 al.,	
2013).		
	
Evidence	on	the	adoption	of	eHealth	and	mHealth	within	 the	NHS	
for	the	diagnosis,	treatment	and	management	of	long-term	medical	
conditions	 indicates	 that	widespread	adoption	 is	minimal.	The	NIB	
report	published	in	2014	acknowledged	that,	despite	commitments	
given	 over	 the	 previous	 years	 in	 national	 policy,	 from	 a	 patient	
perspective	 “the	 consumer	 experience	 of	 care	 services	 remains	
much	as	 it	was	before	the	mobile	phone	and	the	 internet	became	
commonplace.	 For	 care	 professionals,	 from	 social	 workers	 to	
doctors	 and	 nurses,	 the	 arrival	 of	 the	 digital	 age	 has	 often	 been	
experienced	 not	 as	 a	 force	 for	 good	 but	 rather	 as	 an	 intrusive	
additional	 burden	 in	 an	 already	 pressured	 existence”	 (National	
Information	Board,	2014:8).	
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An	internet	search	was	undertaken	to	identify	examples	of	eHealth	
and	mHealth	adoption	within	the	NHS	by	searching	for	online	NHS	
clinics.	 This	 returned	 a	 high	 proportion	 of	 results	 in	 the	 top	 100	
relating	 to	either	general	practice,	mental	health	or	 sexual	health.		
In	general	practice,	since	2013,	there	are	increasing	examples	of	the	
use	 of	 e-consultation,	 in	 part	 driven	 by	 opportunities	 through	
initiatives	such	as	the	Prime	Minister’s	Challenge	Fund	(PMCF).	An	
evaluation	of	 the	use	of	e-consultation	 in	primary	care	 found	 that	
60%	 of	 e-consultations	 were	 closed	 remotely,	 80%	 of	 e-
consultations	 that	 required	 a	 call	 back	 were	 closed	 remotely	 and	
18%	of	users	who	had	planned	to	book	a	face-to-face	appointment	
did	not	require	one	(The	Hurley	Group,	2014).	A	second	area	where	
an	 online	 service	 presence	 has	 been	 adopted	 is	 mental	 health	
services,	with	services	such	as	Big	White	Wall	leading	the	way	with	
online	 therapy	 appointments	 delivered	 by	 instant	message,	 video	
or	audio	services	(Big	White	Wall,	2016).	Examples	of	the	adoption	
of	eHealth	and	mHealth	within	sexual	health	services	are	presented	
in	section	2.4.6.	
	
In	order	to	influence	the	adoption	of	health	apps,	in	2013,	the	NHS	
launched	 its	 apps	 library,	 incorporating	 a	 range	 of	 approved	 apps	
which	had	been	evaluated	and	endorsed	by	the	NHS	(NHS	England,	
2015).	Little	information	was	available	on	the	accreditation	process,	
and	there	was	no	indication	that	apps	had	been	assessed	for	cost-
effectiveness.	 The	 library	 was	 widely	 criticised	 with	 significant	
concerns	raised	regarding	data	privacy;	89%	of	apps	that	sent	data	
to	online	services	and	66%	of	apps	 that	sent	personal	 information	
were	 found	 not	 to	 use	 encryption	 and	 no	 apps	 encrypted	
information	stored	on	 the	device	 (Huckvale	et	al.,	2015).	The	NHS	
apps	library	was	removed	in	2015	in	order	to	enable	the	apps	to	be	
reviewed	against	an	as	yet	unpublished	set	of	criteria	(NHS	England,	
2015).		
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2.3.3 eHealth	and	mHealth	Products	
There	 is	 considerable	 evidence	 in	 grey	 literature	 of	 a	 growing	
eHealth/	mHealth	market,	that	is	products	and/or	services	targeted	
directly	 to	 the	 patient	 or	 general	 public,	 or	 products	 in	 an	 early	
stage	of	development	which	are	not	at	the	clinical	trial	stage.	A	grey	
literature	 search	 using	 Google	 was	 undertaken	 following	 the	
principles	 outlined	 in	 the	 Canadian	 Agency	 for	 Drugs	 and	
Technologies	 in	 Health	 (CADTH)	 checklist	 for	 grey	 literature	
(CADTH,	2013).	 This	 approach	was	 selected	 to	 focus	on	 trade	and	
technology	 websites	 as	 the	 pace	 of	 technology	 development	 far	
outstrips	 the	 time	 lag	 for	publishing	 journal	articles.	The	objective	
of	 the	 search	 was	 to	 identify	 eHealth	 and	 mHealth	 products	 for	
diagnosis,	monitoring	and	treatment,	specifically	to	determine	what	
technologies	are	under	development	and	whether	these	are	aimed	
at	the	healthcare	provider	market	or	the	general	public.		
	
The	search	terms	used	were:	
• health	apps	
• smartphone	diagnostics	healthcare	
• online	clinics	healthcare.	
	
The	search	terms	were	selected	to	reflect	the	topics	of	interest	and	
to	 minimise	 overlap	 in	 search	 results.	 The	 searches	 were	
undertaken	 on	 14	 February	 2016.	 The	 top	 100	 results	 returned	
were	 reviewed	 to	 identify	 their	 content,	 as	 recommended	 by	
CADTH	(2013)	and	are	summarised	into	themes	as	follows:		
• health	 apps	 –	 links	 to	 app	 stores,	 news	 articles	 from	
mainstream	news	websites,	blogs	and	news	articles	on	trade	
websites,	 app	 review	 websites	 (reviews	 by	 users),	
government	 and	 health	 service	 websites	 principally	
promoting	 the	 use	 of	 health	 apps	 from	 the	 UK,	 USA	 and	
Australasia,	
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• smartphone	diagnostics	healthcare	–	blogs	and	mainstream	
news	 articles	 on	 smartphone	 diagnostics	 for	 health,	 press	
releases	 and	 websites	 for	 companies	 and	 research	
organisations	developing	smartphone	diagnostics,	
• online	 clinics	 health	 –	 private	 providers	 of	 online	 clinics	 in	
the	UK	and	USA,	NHS	service	websites	offering	online	clinic	
booking,	 news	 articles	 about	 online	 health	 clinics	 from	UK	
and	USA.	
	
The	 top	 100	 results	 from	 the	 smartphone	 diagnostics	 healthcare	
Google	search	(excluding	blogs	and	other	commentaries)	identified	
the	following	diagnostics	in	varying	stages	of	development:	
• Colorimetrix	 –	 app	 developed	 by	 Cambridge	 University	 to	
read	 colorimetric	 tests	 including	 a	 capability	 to	 diagnose	
HIV,	tuberculosis	and	malaria,	and	to	monitor	diabetes	and	
kidney	disease	(University	of	Cambridge,	2014)	
• Peek	Vision	–	a	device	which	sits	over	a	smartphone	camera	
and	 enables	 the	 diagnosis	 of	 eye	 conditions	 including	
glaucoma,	 macular	 degeneration	 and	 diabetic	 retinopathy	
(Peek	Vision,	2015)	
• QPoC	 –	 point	 of	 care	 platform	 which	 can	 analyse	 DNA	 in	
under	 15	 minutes.	 Whilst	 the	 device	 does	 not	 link	 to	 a	
smartphone	it	does	enable	remote	point	of	care	testing	for	
infectious	diseases,	cancer	and	pharmacogenetics	(Quantum	
MDx,	2015)		
• ELISA	 Platform	 –	 platform	 which	 links	 to	 a	 smartphone	
which	 can	 interpret	 Enzyme	 Linked	 Immunosorbent	Assays	
(ELISA)	including	HIV,	West	Nile	virus	and	hepatitis	B	(UCLA,	
2015)	
• Smartphone	 dongle	 for	 interpreting	 ELISA	 results	 for	
infectious	diseases	(Medical	Express,	2015)	
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• OJ-Bio	Xtalline	handheld	diagnostic	device	–	interfaces	with	
a	smartphone	for	the	detection	of	protein	biomarkers	(News	
Medical,	2015)	
• Smartphone	 based	 diagnostic	 for	 preeclampsia	 –	 journal	
abstract	 summarising	 the	effectiveness	of	 an	app	 for	using	
the	Congo	Red	Dot	test	to	diagnose	preeclampsia	(Jonas	et	
al.,	2015)	
• MobiUS	 Scanner	 –	 ultrasound	 scanner	 that	 plugs	 into	 a	
smartphone	 to	 enable	 phone	 to	 be	 used	 as	 an	 ultrasound	
device	(MobiSante,	2015).	
	
The	 technologies	 identified	 are	 at	 varying	 stages	 of	 development	
and	none	of	the	sites	reviewed	referenced	use	within	the	NHS.	The	
products	appear	to	be	targeted	towards	either	developing	countries	
or	the	US	market.	
	
Considering	 patients	 as	 consumers,	 there	 are	 a	 large	 number	 of	
health	 and	 wellness	 apps	 available	 in	 the	 Apple	 and	 Google	 Play	
App	 Stores.	 Xu	 and	 Liu	 created	 a	 central	 health	 related	 app	
repository	in	2015	using	apps	from	the	Apple	App	store	and	Google	
Play	 store	 in	 the	 USA,	 China,	 Japan,	 Brazil	 and	 Russia	 and	
systematically	 analysed	 them	 to	 evaluate	 their	 strengths	 and	
weaknesses	(Xu	and	Liu,	2015).	Despite	estimates	being	as	high	as	
100,000	 medical	 and	 fitness	 apps,	 their	 analysis	 concluded	 that	
there	are	only	21,121	unique	 (not	duplicated)	medical	apps	 in	 the	
Apple	 App	 store	 and	 5,378	medical	 apps	 in	 the	 Google	 Play	 App	
store	in	the	US	(ibid.).		
	
In	addition	to	apps,	there	are	a	number	of	smartphone	‘add-ons’	–	
wearables	 such	 as	watches,	 and	 connected	 devices	 such	 as	 blood	
pressure	monitors	 that	 increase	 the	 ‘medical	 functionality’	 of	 the	
smartphone.	 These	 have	 primarily	 been	 targeted	 at	 individual	
consumers	 rather	 than	 featuring	 as	 a	 part	 of	 health	 services.	
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However,	 looking	 to	 the	 American	 healthcare	 system,	 Price	
Waterhouse	Coopers	(PWC)	have	predicted	2016	will	see	a	growth	
in	the	use	of	such	devices.	“Connected	otoscopes,	activity	trackers,	
scales,	 health	 apps,	 algorithm-based	 symptom	 checkers	 and	 on-
demand	e-visits	are	being	offered	directly	to	consumers.	Clinicians	
are	sending	patients	with	chronic	conditions	home	with	connected	
pacemakers,	 ECG	 monitors,	 glucose	 trackers	 and	 other	 remote	
monitoring	devices.”	(Price	Waterhouse	Coopers,	2015).		
	
The	 impact	 of	 this	 type	 of	 technology	 adoption	 was	 in	 part	
measured	 through	 the	WSD	 RCT	 in	 England,	 however	 as	 the	 trial	
commenced	 in	 2008,	 much	 of	 the	 technology	 piloted	 has	 been	
superseded.	 Of	 the	 smartphone-based	 diagnostics	 and	 eHealth	
solutions	 reviewed,	 so	 far	 none	 has	 attempted	 to	 integrate	
diagnosis	 and	 treatment	 for	 infectious	 diseases.	 In	 addition,	 no	
apps	 have	 been	 identified	 that	 prescribe	 a	 prescription	 only	
medicine	without	 the	 input	 of	 a	 clinician.	 There	 are	 a	 number	 of	
websites	that	enable	access	to	prescribed	medicine	without	a	face-
to-face	 consultation	 for	 example	 Dr	 Thom	 however,	 every	
individual	 submission	 is	 reviewed	 by	 a	 GP	 prior	 to	 a	 prescription	
being	issued	(Lloyds	Pharmacy,	2016).		
	
2.4 Sexual	Health	Context	
Alongside	 the	 changing	 digital	 context	 there	 have	 been	 several	
changes	in	the	organisation	and	delivery	of	sexual	health	services	in	
England.	 The	 following	 sections	 introduce	 the	 policy	 and	
commissioning	 context	 for	 sexual	 health	 services,	 and	 the	
epidemiology,	clinical	management	and	pathways	for	the	testing	and	
treatment	 of	 chlamydia,	 the	 disease	 which	 is	 the	 focus	 of	 the	
technology	development	presented	in	this	research.		
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2.4.1 Sexual	Health	Policy	in	England	
The	 first	 strategy	 for	 sexual	 health	 and	 HIV	 in	 England	 was	
published	 in	 2001	 against	 a	 national	 backdrop	 of	 increasing	 STI	
rates,	 high	 rates	 of	 unplanned	 pregnancies	 and	 attendances	 at	
Genito-Urinary	Medicine	(GUM)	clinics	doubling	in	the	preceding	10	
years	 (Department	 of	 Health,	 2001).	 The	 strategy	 reflected	 the	
approach	 of	 the	 NHS	 Plan	 and	 its	 overarching	 direction	 was	 to:	
“redesign	services	around	the	people	who	use	them”	and	aimed	to:	
• “improve	services,	information	and	support	for	all	who	need	
them;	
• reduce	inequalities	in	sexual	health;	and	
• improve	 health,	 sexual	 health	 and	wellbeing”	 (Department	
of	Health,	2001:12).	
		
Together	 with	 its	 implementation	 plan,	 published	 the	 following	
year,	priorities	for	action	included:	
• placing	 a	 focus	 on	 prevention	 and	 health	 promotion,	
ensuring	that	 information	 is	available	for	people	to	be	able	
to	make	informed	decisions,	
• modernising	 service	 delivery	 to	 enable	 more	 choice	 for	
people	wanting	to	access	sexual	health	services	through	the	
identification	 of	 commissioning	 leads	 for	 sexual	 health,	
creation	 of	 clinical	 networks	 for	 sexual	 health	 and	 piloting	
new	models	of	delivery	e.g.	one-stop	shops,	
• structuring	 sexual	 health	 services	 within	 local	 health	
economies	into	the	three	service	levels	(basic,	intermediate	
and	specialist)	that	are	still	used	today,	
• introducing	 the	 intention	 to	 launch	 the	NCSP	 (Department	
of	Health,	2001,	Department	of	Health,	2002).	
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The	 implementation	of	 this	 strategy	and	 the	 issues	 arising	 from	 it	
can	 be	 charted	 through	 the	 Health	 Select	 Committee	 Reports	 on	
sexual	 health	 and	 HIV/	 AIDS	 and	 the	 government’s	 response	 to	
them.	The	Health	Select	Committee	report	published	in	2003	stated	
that	 “nothing	 in	 the	evidence	we	have	 received	 convinces	us	 that	
sexual	 health	 is	 yet	 accorded	 the	 priority	 it	 deserves…	 Despite	 a	
considerable	 investment	by	 the	government	 in	 targets	 to	 improve	
access	to	care	and	to	improve	health,	sexual	health	is	an	area	which	
seems	 to	 have	 fallen	 completely	 through	 the	 net…	We	 therefore	
recommend	that	the	Government	takes	urgent	steps	to	ensure	that	
access	 to	 high-quality	 sexual	 health	 services	 is	 prioritised	 and	
resourced.”	 (House	 of	 Commons.	 	 Select	 Committee	 on	 Health,	
2003:93).	
	
The	 government	 response	 to	 this	 in	 the	 areas	 of	 STI	 testing	 and	
treatment	included:	
• the	continued	roll	out	of	the	NCSP	to	an	additional	10	areas,	
• additional	 investment	 in	 Genito-Urinary	 Medicine	 (GUM)	
services	to	increase	capacity	and	reduce	waiting	times,	
• the	introduction	of	the	GUM	48-hour	access	targets,	
• additional	 investment	 to	 support	 laboratories	 moving	 to	
Nucleic	Acid	Amplification	Tests	(NAATs)	for	chlamydia	(HM	
Government,	2003).	
	
The	 2005	 report	 of	 the	 Health	 Select	 Committee	 which	 explored	
developments	 in	 Sexual	 Health	 and	 HIV/	 AIDS	 policy	 applauded	
Government	 investment	 and	 action	 in	 terms	 of	 waiting	 times	
however	 it	 drew	 attention	 to	 a	 number	 of	 outstanding	 issues	
including:	
• ability	of	the	NHS	to	achieve	the	timescale,		
• continued	use	of	sub-optimal	tests	for	chlamydia	
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• failure	 of	 Primary	 Care	 Trusts	 (PCTs)	 to	 ensure	 additional	
government	 funding	 for	 sexual	 health	 services	 is	 actually	
being	spent	on	sexual	health	services,	
• inadequate	 access	 to	 chlamydia	 screening	 for	 high	 risk	
populations	 (House	 of	 Commons.	 	 Select	 Committee	 on	
Health,	2005).	
	
The	government	response	to	this	included:	
• an	 additional	 £300	 million	 investment	 in	 sexual	 health	
services	to	ensure	that	GUM	services	could	achieve	the	48-
hour	access	target	by	March	2008,	
• accelerating	 the	 roll	 out	 of	 the	 NCSP	 so	 that	 100%	 of	
England	was	covered	by	March	2007,	
• further	investment	to	support	the	migration	of	laboratories	
to	 the	 use	 of	 NAATs	 for	 chlamydia	 and	mandatory	 use	 of	
NAATs	as	part	of	the	NCSP	(HM	Government,	2005).	
	
There	was	then	a	12-year	gap	between	the	publication	of	the	first	
dedicated	sexual	health	strategy	in	2001,	and	the	publication	of	the	
Framework	 for	 Sexual	Health	 Improvement	 in	 England	 in	 2013,	 in	
readiness	 for	 the	 devolution	 of	 public	 health	 commissioning	
budgets	 to	 local	 authorities	 later	 that	 year.	 This	 stressed	 the	
importance	 of	 access	 to	 services	 and	 reducing	 STI	 rates	 as	 key	
objectives	 in	achieving	the	ambition	to	“improve	the	sexual	health	
of	 the	 whole	 population”	 (Department	 of	 Health,	 2013b:10).	 It	
recognised	 the	 role	 that	 technology	could	have	 in	 supporting	 self-
care	for	sexual	health	and	future	developments	that	would	impact	
on	 service	delivery,	 including	point	of	 care	 testing	 (POCT)	and	 the	
developing	mobile	technology	and	smartphone	apps	for	STI	testing.		
	
The	2013	strategy	considered	sexual	health	at	different	life-stages,	
and	 for	 the	 16-24	 age-range	 highlighted	 the	 need	 to	 prioritise	
prevention	and	ensure	all	young	people:	
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• are	informed	so	that	they	can	make	responsible	decisions,	
• can	access	appropriate	sexual	health	services,	
• have	their	sexual	health	needs	met	(ibid.).		
	
To	support	the	aim	of	reducing	STIs,	and	recognising	that	chlamydia	
is	the	most	prevalent	STI	in	England	with	rates	higher	within	the	16-
24	age-range	than	any	other,	chlamydia	detection	rates	within	the	
16-24	age-range	has	been	set	as	a	PHOF	target	for	local	authorities	
in	 England	 (ibid).	 The	 target	detection	 rate	 is	 2,300	diagnoses	per	
100,000	population	as	this	is	the	rate	determined	by	mathematical	
modelling	 to	 achieve	 a	 reduction	 in	 chlamydia	 prevalence	
(Department	of	Health,	2016b).	
	
The	 NCSP	 featured	 heavily	 within	 the	 2013	 framework	 to	 reduce	
rates	of	STIs	stating	that	in	taking	the	programme	forward	in	terms	
of	service	delivery	there	should	be	a	focus	on:	
• “integrating	 screening	 into	 wider	 sexual	 health	 service	
provision	 and	 increasing	 screening	 in	 primary	 care,	
particularly	general	practice;	
• restricting	 outreach	 screening	 to	 those	 young	 people	 with	
limited	access	to	sexual	health	services;	
• expanding	 internet	 testing	 services,	 which	 are	 particularly	
attractive	to	young	men;	
• promoting	 annual	 screening	 for	 young	 people	 (and	
additional	 testing	 on	 each	 change	 of	 partner)…”	
(Department	of	Health,	2013a:29).		
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2.4.2 Sexual	Health	Commissioning	in	England	
As	 noted	 by	 the	 Health	 Select	 Committee	 2003	 report,	 the	 first	
national	 strategy	 for	 sexual	 health	 and	 HIV	 placed	 considerable	
emphasis	 on	 PCTs,	 the	 then	 commissioners	 of	 services,	 to	
implement	 the	 strategy.	 To	 support	 implementation	 the	
Department	 of	 Health	 and	 NCSP	 issued	 several	 best	 practice	
documents	for	PCTs	to	assist	with	their	implementation	of	the	new	
service	 requirements	 through	 commissioning	 arrangements.	
Commissioning	 responsibility	 continued	 with	 PCTs	 until	 the	
implementation	of	 the	Health	and	Social	Care	Act	2012,	which	 led	
to	the	responsibility	for	commissioning	sexual	health	services	being	
split	across	three	organisations	 in	an	area	–	Local	Authorities(LAs),	
Clinical	Commissioning	Groups	(CCGs)	and	NHS	England	(NHSE).	The	
changes	 came	 into	 effect	 on	 1	 April	 2013	 and	 the	 responsibilities	
are	summarised	in	table	2.2.	This	has	produced	a	fragmentation	in	
the	delivery	of	services,	most	notably	a	split	in	responsibility	for	the	
treatment	 of	 HIV	 from	 other	 STIs	 and	 created	 a	 more	 complex	
landscape	for	technology	developers	to	navigate	depending	on	the	
scope	of	their	development.		
Local	Authority	 NHS	England	 CCGs	
• STI	testing	and	treatment,	
chlamydia	testing	as	part	of	
the	National	Chlamydia	
Screening	Programme	and	
HIV	testing	
• Any	sexual	health	specialist	
services,	including	young	
people’s	sexual	health	and	
teenage	pregnancy	
services,	outreach,	HIV	
prevention	and	sexual	
health	promotion	work,	
services	in	schools,	colleges	
and	pharmacies	
• HIV	treatment	
and	care,	
including	post-
exposure	
prophylaxis	after	
sexual	exposure	
• Promotion	of	
opportunistic	
testing	and	
treatment	for	
STIs,	and	patient	
requested	
testing	by	GPs	
• STI	testing	
and	
treatment	as	
part	of	the	
abortion	
pathway	
Table	2.2	-	Sexual	Health	Commissioning	Responsibilities	from	April	2013	taken	from	
(Department	of	Health,	2013a:16)	
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2.4.3 Epidemiology	&	Clinical	Management	of	Chlamydia	
The	research	presented	in	this	thesis	explored	the	adoption	of	two	
new	 technologies	 into	 chlamydia	 testing	and	 treatment	pathways.	
One	 of	 the	 key	 challenges	 in	 achieving	 a	 reduction	 in	 chlamydial	
infection	 is	 the	 lack	 of	 symptoms.	 In	many	 cases	 people	 infected	
with	 chlamydia	 remain	asymptomatic,	 in	others	 symptoms	appear	
weeks	 or	 months	 after	 infection	 (FPA,	 2013).	 It	 is	 estimated	 that	
70%-80%	 of	 young	 people	 with	 chlamydia	 will	 be	 asymptomatic	
with	 transmission	possible	 through	unprotected	sex	 (Public	Health	
England,	2014d).		
	
Actions	to	reduce	the	transmission	of	STIs	are	varied	and	impact	on	
different	 elements	 of	 the	 transmission	 dynamic.	 For	 example,	
increasing	 the	 use	 of	 condoms	 will	 reduce	 the	 likelihood	 of	
infection,	 targeted	 health	 promotion	 initiatives	 and	 partner	
notification	may	also	impact	on	the	rate	of	change	of	partners,	and	
increasing	 testing	 within	 the	 population	 will	 contribute	 to	 a	
reduction	 in	 the	 duration	 of	 infectiousness.	 For	 chlamydia	 in	
England	 the	NCSP	 has	 a	 key	 role	 to	 play	 in	 reducing	 transmission	
through	its	aim	to	screen	16-24	year	olds	annually	or	on	change	of	
partner	 (Public	 Health	 England,	 2016b).	 Introduced	 in	 2003,	 the	
NCSP	 is	 fundamentally	 different	 to	 all	 the	 other	 screening	
programmes	 in	operation	 for	 adults	because	 it	 is	 screening	 for	 an	
infectious	disease.		
	
It	 is	 also	 an	 opportunistic	 rather	 than	 population	 based	 screening	
programme	 meaning	 its	 target	 population	 are	 not	 invited	 to	
participate	 in	 screening	 directly	 through	 a	 recall	 programme.	 As	
well	 as	 securing	 a	 reduction	 in	 the	 prevalence	 of	 chlamydia,	 its	
objectives	 include	 informing	 sexually	 active	 under	 25	 year	 olds	
about	 chlamydia,	 normalising	 chlamydia	 screening	 and	 ensuring	
they	have	access	to	services	(NCSP,	2012a).		
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Fewer	young	people	are	taking	up	chlamydia	testing,	and	there	has	
been	 reduction	 in	 positive	 diagnoses,	 although	 the	 pattern	 is	
complex.	 In	2015	there	were	200,288	new	diagnoses	of	chlamydia	
(Public	Health	England,	2016b).	The	four	years’	data	available	from	
current	reporting	systems	indicate	a	small	decline	 in	the	detection	
rate	overall.	Comparing	2014	and	2015	data,	the	detection	rates	are	
declining	 in	the	under	25	population	and	increasing	 in	the	over	25	
population,	 although	 the	 number	 of	 diagnoses	 made	 is	 still	
significantly	higher	 in	 the	15-24	age	 range	 (Public	Health	England,	
2016d).		
	
In	respect	of	the	NCSP,	Public	Health	England	(PHE)	report	the	data	
captured	 for	 chlamydia	 tests	 aligned	 to	 the	 15-24	 age	 range	
separately.	 The	 headline	 data	 shows	 that	 in	 2015	 1,538,819	 tests	
were	undertaken	 in	 the	15-24	population,	with	a	 total	 of	 129,022	
positive	tests	(Public	Health	England,	2016b).	Assuming	one	test	per	
person,	 this	 equates	 to	 22.5%	 of	 the	 population	 tested	 –	 13%	 of	
males	and	32%	of	females	in	the	age	range	(ibid.).	Considering	the	
reduction	in	testing	and	diagnoses	over	the	previous	three	years	in	
the	15-24	age	range,	PHE	suggest	that	the	decline	is	a	true	decline	
“mostly	 attributable	 to	 fewer	 tests	 in	 non-specialist	 SHCs	 and	
community	venues	which	may	be,	in	part,	a	result	of	the	integration	
of	sexual	health	services	in	a	number	of	programme	areas”	(Public	
Health	England,	2016b:18).		
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Performance	 against	 the	 PHOF	 chlamydia	 detection	 rate	 indicator	
has	also	steadily	declined	over	the	 last	 three	years	as	summarised	
in	 table	 2.3.	 This	 deterioration	 in	 performance	 has	 been	
consistently	 attributed	 to	 the	 relationship	 between	 testing	
coverage	 and	 diagnosis	 rate	 (Public	 Health	 England,	 2016b).	
However,	 no	 link	 has	 been	 established	 between	 the	 transfer	 of	
commissioning	responsibility	from	the	NHS	to	LAs	which	took	place	
in	2013.		
	
	 2013	 2014	 2015	
Local	Authority	detection	rate	
per	100,000	
2,088	 2,035	 1,887	
%	of	Local	Authorities	
achieving	PHOF	indicator	
30%	 29%	 20%	
Table	2.3	-	PHOF	Achievement	Data(Public	Health	England,	2016b,	Public	Health	England,	
2015,	Public	Health	England,	2014d)	
	
The	detection	 rate	per	 100,000	population	 remains	highest	 in	 the	
under	25	population.	The	highest	rate	is	within	the	20-24	age	range	
for	 both	 men	 and	 women	 with	 a	 detection	 rate	 of	 1,693.8	 per	
100,000	for	men	and	2,557.0	per	100,000	for	women	(Public	Health	
England,	 2016d).	 There	 is	 an	 even	 more	 marked	 difference	 in	
detection	 rates	between	men	and	women	 in	 the	15-19	 age	 range	
with	 the	 female	 detection	 rate	 per	 100,000	 significantly	 higher	 at	
2,463.8	 compared	 with	 824.4	 per	 100,000	 for	males	 in	 the	 same	
age	range	(ibid).		
	
Of	the	diagnoses	in	2015	with	gender	recorded,	58%	were	made	in	
females	 (ibid.).	 Information	 regarding	 the	 ethnic	 origin	 of	 the	
population	 who	 tested	 positive	 is	 limited	 with	 34%	 of	 diagnoses	
made	 in	 2015	having	 an	ethnic	 origin	 as	 ‘unknown’;	 although	 this	
was	 an	 improvement	 on	 previous	 years	 (Public	 Health	 England,	
2016e).	 Of	 those	 with	 their	 ethnicity	 recorded,	 51%	 were	
categorised	as	White,	8%	as	Black	or	Black	British,	2%	as	Asian	or	
Asian	British,	3%	as	mixed	ethnic	origin	and	2%	as	‘other’	(ibid.).	
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Information	collected	as	part	of	 the	NCSP	 for	 the	15-24	age-range	
shows	variation	between	regions	in	testing	for	chlamydia	from	19%	
in	the	West	Midlands	and	East	of	England	to	27%	in	London	(Public	
Health	 England,	 2016b).	 This	 data	 shows	 that	 despite	 the	 aims	 of	
the	NCSP,	testing	uptake	to	the	desired	levels	is	not	being	achieved.	
In	developing	new	technology	 ‘will	people	use	 it?’	 is	an	 important	
consideration	 for	 both	 technology	 developers	 to	 optimise	 their	
technology,	 and	 both	 commissioners	 and	 providers	 in	
understanding	the	likely	impact	of	technology	introduction.		
	
Estimates	of	the	underlying	prevalence	of	chlamydia	in	England	are	
limited.	Whilst	 PHE	 collect	 data	 on	 the	population	 tested	 and	 the	
positive	 test	 results	 this	does	not	equate	 to	prevalence	within	 the	
overall	 population.	 Mathematical	 modelling	 has	 identified	 that	 a	
detection	 rate	 of	 2,300	 per	 100,000	 population	 is	 required	 to	
deliver	 to	 a	 sustained	 reduction	 in	 chlamydia	 prevalence	
(Department	of	Health,	2016b)	which	is	the	rationale	for	the	PHOF	
standard.	 The	 most	 comprehensive	 study	 of	 prevalence	 is	 the	
National	Survey	of	Sexual	Attitudes	and	Lifestyle	(NATSAL),	which	is	
conducted	every	ten	years.	The	results	from	NATSAL-3	(undertaken	
during	2010-2012)	estimated	a	prevalence	rate	of	1.5%	in	men	and	
1.1%	 in	women	 (Sonnenberg	 et	 al.,	 2013).	 This	was	 higher	within	
the	20-24	age-range	in	men	and	the	18-19	age	range	in	women	with	
estimated	 prevalence	 of	 3.4%	 and	 4.7%	 respectively	 (ibid).	
Prevalence	 is	 an	 important	 factor	 in	 estimating	 test	 performance	
and	 the	 long-term	 complications	 associated	 with	 untreated	
chlamydia.	This	is	explored	further	in	Chapter	8.	
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2.4.4 Pathways	for	the	Testing	&	Treatment	of	Chlamydia	
Service	 delivery	 pathways	 for	 the	 testing	 and	 treatment	 of	
chlamydia	currently	vary	from	locality	to	locality	depending	on	the	
models	commissioned	by	the	LA	and	can	involve	single	or	multiple	
service	 providers.	 Examples	 of	 pathway	 options	 for	 chlamydia	
testing	 and	 treatment	 are	 shown	 on	 in	 figure	 2.1,	 including	GUM	
clinic,	 GP,	 Contraceptive	 and	 Sexual	 Health	 (CaSH)	 and	 NCSP	
internet	 testing.	 The	proposed	 fully	 integrated	 remote	pathway	 is	
also	illustrated	alongside	this.		The	pathways	illustrated	are	for	the	
testing	 and	 treatment	 of	 asymptomatic	 patients.	 These	 pathways	
have	 been	 examined	 as	 part	 of	 the	 costing	 study	 and	 the	 two	
selected	as	comparator	pathways	are	outlined	further	in	Chapter	7.		
They	have	been	broken	down	 into	 six	 stages	 to	 ease	 comparison,	
and	 these	 stages	 are	 referred	 to	 throughout	 the	 thesis	 in	 the	
discussion	of	pathways.		
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Figure	2.1	-	Example	Chlamydia	Testing	&	Treatment	Pathways	
		 66	
	
	
2.4.5 Diagnostic	Testing	for	Chlamydia	
A	 number	 of	 organisations	 are	 involved	 in	 determining	 standards	
and	 practice	 for	 chlamydia	 testing.	 Standards	 for	 microbiology	
investigations	 are	 published	 by	 PHE	 in	 association	 with	 the	 Royal	
College	 of	 Pathologists	 and	 other	 professional	 bodies,	 and	 testing	
guidelines	for	chlamydia	are	published	by	the	British	Association	of	
Sexual	Health	and	HIV	(BASHH)	(BASHH,	2010).	The	Medicines	and	
Healthcare	 Products	 Regulatory	 Agency	 (MHRA)	 also	 play	 an	
indirect	 role	 in	 the	 approval	 of	 products	 in	 line	 with	 the	 In	 Vitro	
Diagnostic	(IVD)	Medical	Devices	Directive	(MHRA,	2006).	It	appears	
that	 the	 majority	 of	 STI	 tests	 within	 the	 UK	 are	 analysed	 in	 a	
laboratory	setting.	NAATs	are	the	standard	required	by	the	NHS	for	
testing	 for	 chlamydia	 because	 they	 are	 recognised	 to	 have	 higher	
sensitivity	 and	 specificity	 than	 Enzyme	 Immunoassays	 (EIAs)	
(BASHH,	2010).		
	
For	chlamydia,	NAATs	can	be	undertaken	using	a	range	of	specimen	
types,	 the	 recommended	 type	 for	 women	 is	 a	 vaginal	 or	
endocervical	 swab	 and	 men	 first	 catch	 urine	 or	 urethral	 swab	
(BASHH,	 2010,	 Public	 Health	 England,	 2014c).	 It	 is	 a	 requirement	
that	 the	 test	 must	 deliver	 a	 Positive	 Predictive	 Value	 (PPV)	 of	
greater	 than	 90%	 or	 an	 additional	 confirmatory	 test	 is	 required	
(ibid.).	The	BASHH	UK	testing	guidelines	for	chlamydia	identify	four	
laboratory	based	NAATs	tests	which	are	commonly	used	 in	the	UK	
(BASHH,	2010).	
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STI	 testing	 was	 traditionally	 associated	 with	 clinician-collected	
samples	 however	 the	 development	 of	 NAATs	 testing	 has	 enabled	
patients	to	provide	their	own	samples	for	the	testing	of	chlamydia	
and	 gonorrhoea.	 Studies	 have	 shown	 that	 the	 performance	 of	
NAATs	on	self-collected	urine,	urethral	or	vaginal	swabs	 is	at	 least	
comparable	with	 clinician-collected	 samples	 (Graseck	 et	 al.,	 2011,	
Sexton	et	al.,	2013,	Hocking	et	al.,	2013).	
	
Advances	 in	 technology	have	 also	 enabled	 testing	 to	move	out	 of	
the	 laboratory	 and	 closer	 to	 the	 patient.	 A	 systematic	 review	 of	
studies	 published	 between	 2010	 and	 2015	 identified	 10	 POCT	 for	
chlamydia,	 with	 the	 authors	 identifying	 two	 tests	 –	 the	 ‘Cepheid	
GeneXpert’	 and	 ‘aQcare	 Chlamydia	 TRF	 kit’	 with	 a	 PPV	 of	 above	
90%	 and	 sensitivity	 and	 specificity	 comparable	 with	 laboratory	
based	NAATs	tests	(de	Cortina	et	al.,	2016).	The	remaining	tests	did	
not	compare	favourably	with	laboratory	based	NAATs	due	to	either	
a	low	sensitivity	or	PPV	(ibid.).		
	
In	January	2013	Cepheid	announced	that	they	had	secured	US	Food	
and	 Drug	 Administration	 (FDA)	 approval	 for	 their	 GeneXpert	
combined	chlamydia	and	gonorrhoea	test	(Cepheid,	2013).	The	FDA	
categorised	 this	 test	 as	 a	 ‘test	 of	 moderate	 complexity’	 which	
meant	 it	 could	 be	 used	 in	 the	 USA	 within	 a	 hospital	 setting,	
however	 it	did	not	meet	the	requirements	of	a	 ‘waived	test’	–	“so	
simple	and	accurate	as	to	render	the	likelihood	of	erroneous	results	
by	 the	 user	 negligible”	 (Cepheid,	 2013:240).	 This	 is	 currently	 the	
only	NAAT	POCT	 for	 chlamydia	 approved	by	 the	 FDA,	 comparable	
data	 for	 the	MHRA	 is	 not	 publicly	 available	 on	 their	website.	 The	
test	operates	on	the	same	principle	as	laboratory	based	testing	but	
can	 be	 used	within	 a	 clinic	 setting	 and	 provides	 results	within	 90	
minutes	of	testing.		
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Advances	 in	 microfluidic	 technologies	 have	 seen	 initial	 proof	 of	
concept	 for	a	number	of	 lab-on-a-chip	 technologies	 in	other	areas	
such	as	hospital	acquired	infection,	tuberculosis	and	HIV	(Niemz	et	
al.,	2011).	However,	it	is	recognised	that	NAATs	are	one	of	the	most	
challenging	 tests	 for	 this	 type	 of	 development	 “due	 to	 additional	
steps	required	for	sample	pre-treatment	(e.g.	cell	sorting,	isolation,	
and	 lysis,	 as	 well	 as	 nucleic	 acid	 extraction),	 signal	 amplification	
(due	to	low	physiological	concentrations)	and	target	contamination	
and	instability”	(Niemz	et	al.,	2011:2124).	
	
There	are	currently	no	NAAT	self-test	products	available	 for	home	
use	that	deliver	a	chlamydia	test	result.	There	are	examples	of	self-
tests	 available,	 for	 example,	 Accunon	 Diagnostics	 Ltd	 offer	 home	
testing	 kits	 that	 deliver	 results	 in	 15	 minutes	 for	 diagnosing	
Chlamydia,	 Gonorrhoea,	 Hepatitis	 B,	 Hepatitis	 C	 and	 Syphilis,	
however	 these	 test	 kits	 are	 antibody	 (EIA)	 tests	 (Accunon	
Diagnostics	 Ltd,	 2013).	 As	 highlighted	 previously	 the	 performance	
of	EIA	tests	is	inferior	to	NAAT	tests	and	there	are	no	EIA	tests	that	
are	 recommended	 for	 use	 in	 the	 UK	 testing	 guidelines	 (BASHH,	
2010).	For	the	self-test	kits	 that	are	available	there	 is	currently	no	
mHealth	example	providing	diagnosis	via	a	mobile	phone.		
	
2.4.6 Application	of	New	Technologies	in	Service	Delivery	
Pathways	
As	highlighted	in	section	2.3.2	sexual	health	services	are	one	of	the	
areas	where	there	is	widespread	adoption	of	eHealth	and	mHealth	
services	 within	 England,	 both	 within	 mainstream	 sexual	 health	
services	and	in	privately	provided	sexual	health	services.		
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Focusing	in	the	first	instance	on	mainstream	sexual	health	services,	
results	notification	by	text	message	has	been	adopted	in	many	NHS	
clinics	since	the	mid	2000s	 in	response	to	the	drive	to	achieve	the	
48-hour	 access	 target.	 	 Furthermore,	 an	 online	 search	 in	 2015	
identified	 a	 number	 of	 NHS	 providers	 offering	 some	 additional	
aspect	of	online	sexual	health	services.	These	included	appointment	
booking,	 online	 triage	 (directing	 to	 the	 most	 appropriate	 service	
e.g.	 http://www.icash.nhs.uk)	 and	 online	 clinics	 (via	 instant	
message	e.g.	https://www.sexualhealthvirtualclinic.co.uk).		
	
As	 highlighted	 in	 section	 2.4.5	 there	 are	 currently	 no	 self-tests	
(stage	2	in	figure	2.1)	available	for	chlamydia	which	have	a	suitable	
accuracy.	 There	 is	 however	 a	 self-test	 option	 available	 for	HIV.	 In	
April	 2014,	 regulations	were	 relaxed	 to	 allow	 the	 sale	of	HIV	 self-
test	 kits	 in	 England.	 There	 is	 currently	 one	 CE	 marked	 self-test	
available,	 the	 Biosure	 HIV	 self-test	 (National	 AIDS	 Trust,	 2015).	
However,	 although	 the	 self-test	 can	 indicate	 that	 a	 person	 may	
have	HIV,	a	confirmatory	laboratory	test	is	still	required	(ibid).	
	
In	respect	of	test	ordering	and	testing	(stages	1	and	2	in	figure	2.1),	
many	 localities	 use	 an	 online	 service	 for	 chlamydia	 (and	 in	 some	
cases	 gonorrhoea)	 testing	 for	 the	 16-24-year-old	 population.	
Services	 such	 as	 freetest.me	 and	 checkurself.org.uk	 enable	 online	
ordering	 of	 a	 test	 kit	 for	 self-sampling	 and	 provide	 a	 freepost	
envelope	 for	 the	 sample	 to	be	 sent	 to	 the	 laboratory	 for	analysis.	
Freetest.me	 also	 provides	 an	 online	 results	 notification	 service.	
Data	 published	 by	 PHE	 indicates	 that	 5%	 of	 chlamydia	 tests	
undertaken	as	part	of	the	NCSP	were	ordered	online	(Public	Health	
England,	2016b).	Both	services	provide	stage	1	and	2	(figure	2.1)	in	
the	pathway	only,	they	do	not	incorporate	the	treatment	(stage	4)	
online.		
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There	are	 some	examples	of	broader	eHealth	and	mHealth	 sexual	
health	 service	 provision	 in	mainstream	 sexual	 health	 services.	 For	
example,	checkurself	launched	a	new	service	in	2016	for	a	number	
of	London	boroughs	which	includes	over	25s	and	a	broader	range	of	
STI	 tests	 including	HIV,	 chlamydia,	 gonorrhoea,	Hepatitis	 B	 and	C,	
and	syphilis		(Checkurself,	2016).		
	
However,	 there	are	more	extensive	examples	of	 integrated	online	
provision	 in	 the	 private	 healthcare	 sector,	 with	 several	 online	
pharmacies	 including	 Lloyds,	 Boots	 and	 Superdrug	 offering	 online	
testing	 and	 treatment	 (stages	 1-5,	 figure	 2.1).	 For	 stages	 1	 and	2,	
the	 online	 testing	 component	 operates	 the	 same	 model	 as	
checkurself	 and	 freetest.me	 and	 for	 stage	 3,	 results	 are	 made	
available	 online.	 The	 treatment	 component	 (stage	 4)	 is	 offered	
differently	to	the	NCSP	internet	testing	services,	with	patients	able	
to	 complete	 an	 online	 form	 to	 secure	 treatment	 for	 chlamydia,	
gonorrhoea,	 herpes	 and	 genital	 warts	 which	 is	 reviewed	 by	 a	 GP	
(Lloyds	 Pharmacy,	 2016).	 In	 2015,	 private	 sector	 online	 sexual	
health	 treatment	 services	 came	 under	 heavy	 criticism	 for	 the	
prescription	 of	 oral	 antibiotics	 for	 the	 treatment	 of	 gonorrhoea	
(Kirkland,	 2015,	 BASHH,	 2011).	 Oral	 treatment	may	 be	 ineffective	
due	 to	 antimicrobial	 resistance	 and	 sub-optimal	 when	 compared	
with	 the	 national	 treatment	 guidelines	 for	 gonorrhoea	 (BASHH,	
2011,	Kirkland,	2015).	Whilst	this	is	occurring	in	the	private	sector,	
there	 is	 no	 evidence	 of	 this	 occurring	 in	 the	 treatment	 of	
gonorrhoea	in	mainstream	sexual	health	services.	
	
There	 are	 limited	 examples	 of	 the	 use	 of	 POCT	 in	 mainstream	
sexual	health	services	for	chlamydia	(services	A,B	&	C	in	figure	2.1).	
A	published	service	evaluation	of	the	use	of	the	Cepheid	GeneXpert	
undertaken	 in	 a	 UK	 GUM	 clinic	 found	 that	 due	 to	 the	 90	minute	
processing	time	only	14.3%	of	males	and	28.6%	of	 females	waited	
to	receive	their	results	(Harding-Esch,	2013).		
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2.4.7 Considerations	in	the	Cost-Effectiveness	of	Chlamydia	
Testing	&	Treatment	
Over	 the	 past	 25	 years	 there	 has	 been	 a	 wealth	 of	 literature	
published	exploring	the	costs	and	benefits	of	chlamydia	testing	and	
treatment,	much	of	this	focused	on	the	 impact	of	opportunistic	or	
population	based	screening	programmes.	Starting	with	 the	 testing	
stage	 of	 the	 pathway	 Hislop	 and	 colleagues	 have	 explored	 the	
impact	of	introducing	EIA	POCT	into	family	planning	settings	in	the	
UK	 and	 concluded	 that	 this	 is	 not	 presently	 clinically	 or	 cost-
effective	 (Hislop	 et	 al.,	 2010).	 This	 is	 in	 contrast	 to	 Turner	 and	
colleagues	 who	 find	 that	 the	 new	 generation	 NAAT	 POCT	 are	
potentially	 cost	 saving	 with	 a	 small	 increase	 in	 QALYs	 and	 major	
outcomes	 averted	 (Turner	 et	 al.,	 2014).	 The	 primary	 difference	
between	the	 two	studies	 is	 the	performance	characteristics	of	 the	
tests	considered,	the	EIA	POCT	considered	by	Hislop	and	colleagues	
has	 a	 considerably	 lower	 sensitivity	 and	 specificity	 than	 the	NAAT	
POCT	considered	by	Turner	and	colleagues.		
	
To	 illustrate	 another	 potential	 impact	 of	 test	 performance	
characteristics	 on	 the	 cost-effectiveness	 of	 chlamydia	 testing,	 Gift	
and	colleagues	explored	the	‘rapid	test	paradox’	using	a	scenario	in	
which	 laboratory	 tests	 have	 greater	 sensitivity	 than	 rapid	 tests	
however	the	loss	to	follow	up	is	greater.	Their	findings	suggest	that	
if	 there	 is	a	 loss	 to	 follow	up	of	greater	 than	35%,	a	 less	 sensitive	
rapid	 test	 (63%	 v’s	 94%)	 would	 lead	 to	 the	 treatment	 of	 more	
chlamydia	 positive	 patients	 than	 the	 laboratory	 test	 (Gift	 et	 al.,	
1999).			
	
	 	
		 72	
Fewer	studies	have	considered	integrated	online	provision	(service	
model	D	&	E	in	figure	2.1).	One	study	in	America	has	explored	the	
cost-effectiveness	of	 internet	based	sample	collection	versus	clinic	
based	 testing	 and	 found	 the	 internet	 based	 strategy	 to	 be	 cost-
effective	 (Huang	 et	 al.,	 2011).	 Two	 studies	 have	 been	 identified	
considering	 the	use	of	 the	 internet	 in	a	 full	 chlamydia	 testing	and	
treatment	 pathway,	 the	 UK	 based	 study	 concluding	 the	 pathway	
piloted	 is	 not	 clinically	 or	 cost	 effective	 compared	 to	 the	 existing	
NCSP	 pathway	 (Bracebridge	 et	 al.,	 2012),	 and	 an	 American	 based	
study	 operating	 a	 similar	 pathway	 concluding	 that	 it	 has	 the	
potential	to	be	a	cost-effective	alternative	to	clinic	based	screening	
(Spielberg	et	al.,	2014).	Neither	of	 these	studies	however	consider	
an	 eHealth	 solution	 which	 enables	 the	 prescribing	 of	 chlamydia	
treatment	without	the	involvement	of	a	prescriber.		
	
Two	 systematic	 reviews	 of	 the	 cost-effectiveness	 of	 chlamydia	
screening	 have	 both	 concluded	 that	 chlamydia	 screening	 is	 cost-
effective.	One	covering	the	period	1990-2000	(Honey	et	al.,	2002),	
and	 one	 covering	 the	 period	 until	 August	 2004	 (Roberts	 et	 al.,	
2006).	Subsequent	to	this	review,	the	European	Centre	for	Disease	
Prevention	 and	 Control	 (ECDC)	 published	 a	 comprehensive	
literature	review	examining	chlamydia	control	in	Europe.	As	part	of	
this	 literature	 review,	 they	 updated	 the	 Roberts	 and	 colleagues	
review	 to	 February	 2012.	 This	 update	 identified	 a	 further	 10	
studies,	 all	 except	 one	 demonstrated	 that	 a	 form	 of	 chlamydia	
screening,	for	example	female	only	or	male	and	female,	repeated	or	
one-off	opportunistic	would	be	cost-effective	(ECDC,	2014).			
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2.5 Summary	
This	 chapter	 has	 set	 the	 scene	 for	 the	 research	 presented	 in	 this	
thesis.	Despite	 it	being	almost	fifteen	years	since	the	first	published	
definition	of	eHealth,	there	is	a	limited	evidence	base	demonstrating	
effectiveness.	The	pace	of	technology	development	means	that	there	
are	 constantly	 new	 products	 for	 evaluation,	 which	 set	 against	 the	
time	 constraints	 of	 traditional	 approaches	 to	 clinical	 and	 economic	
evaluation	are	the	most	likely	reason	there	is	an	absence	of	a	strong	
evidence	 base	 upon	 which	 the	 NHS	 and	 other	 health	 systems	 can	
take	 decisions	 to	 commission	 eHealth	 and	 mHealth	 technologies.	
However,	 this	 lack	 of	 evidence	 base	must	 be	 balanced	 against	 the	
potential	 of	 the	 new	 technology	 particularly	 given	 the	 high	
proportion	of	the	population	with	access	to	the	base	technology	e.g.	
the	internet	and	a	smartphone	within	England.		
	
Strategies	for	increasing	testing	and	treatment	uptake	for	chlamydia	
are	 of	 importance	 to	 sexual	 health	 commissioners,	 against	 a	
backdrop	of	both	declining	test	uptake	and	an	increasing	proportion	
of	LAs	failing	to	achieve	the	chlamydia	detection	rate	PHOF	indicator.	
As	well	as	being	aligned	to	DH	digital	policy,	eHealth	and	self-testing	
are	 recognised	 future	developments	 that	will	 have	a	 key	 impact	on	
service	 delivery	 within	 the	 current	 government	 framework	 for	
improving	the	sexual	health	of	the	population.		
		
A	review	of	the	availability	of	eHealth/	mHealth	and	testing	products	
has	 not	 identified	 any	 NAAT	 self-tests	 for	 chlamydia,	 or	 eHealth	
delivery	models	that	remove	a	clinician	from	the	care	of	the	patient	
where	it	is	safe	to	do	so,	as	an	OCCP	would	do,	but	it	has	identified	a	
small	number	of	examples	of	the	use	of	eHealth	within	both	NHS	and	
private	 sector	 sexual	 health	 services.	 No	 self-test	 kits	 have	 been	
identified	which	meet	the	chlamydia	test	standards	identified	for	use	
in	England.		
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Within	 the	 context	 of	 current	 healthcare	 policy,	 availability	 of	
products	 and	 service	 delivery	 models	 for	 chlamydia	 testing	 and	
treatment	there	are	two	important	considerations	identified	for	this	
research.	 Firstly,	 whether	 if	 the	 new	 technology	were	 available	 for	
testing	and	treatment,	would	it	be	used	by	the	target	population	and	
secondly	would	it	be	cost	saving	and	improve	outcomes	compared	to	
existing	service	options.		The	next	chapter	sets	out	the	methods	used	
to	address	the	overall	research	objectives	outlined	in	section	1.3.	
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3 CHAPTER	3	–	METHODS	
3.1 Introduction	
“There	 are	 two	 key	 gaps	 in	 the	 translation	 of	 health	 research	 into	
improvements	 in	 practice	 that	 generate	 health	 and	 economic	
benefits:	 translating	 ideas	 from	 basic	 and	 clinical	 research	 into	 the	
development	 of	 new	 products	 and	 approaches	 to	 treatment	 of	
disease	 and	 illness;	 and	 implementing	 those	 new	 products	 and	
approaches	into	clinical	practice”	(Cooksey,	2006:35).	
	
The	 purpose	 of	 this	 chapter	 is	 to	 outline	 the	 overarching	methods	
and	approach	used	to	address	the	research	objectives:	
• To	 assess	 which	 attributes	 influence	 young	 people’s	
preferences	for	the	testing	and	treatment	of	chlamydia	and	to	
explore	 their	 implications	 for	 the	 development	 of	 sexual	
health	services	in	England,		
• To	explore	 the	 likely	 costs	of	 implementing	online	 chlamydia	
treatment	in	mainstream	sexual	health	services	in	England,	
• To	develop	an	economic	model	 to	assess	 the	 likely	costs	and	
benefits	 of	 implementing	 a	 fully	 remote,	 integrated	 online	
pathway,	including	self-testing.	
	
This	chapter	sets	out	the	methods	selected	for	this	research	and	the	
rationale	for	this,	the	role	of	the	researcher	and	how	this	shaped	the	
research	 undertaken.	 Several	 methods	 were	 used	 in	 this	 doctoral	
research	 including	 literature	 reviews,	 focus	 and	 expert	 groups,	
cognitive	 testing,	 discrete	 choice	 experiment,	 interviews,	 pathway	
mapping,	 costing	 and	 economic	 modelling.	 Further	 information	 on	
the	detailed	implementation	is	presented	in	the	relevant	chapter.	
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3.2 Overview	of	Research	
As	 an	 NHS	 manager,	 undertaking	 research	 that	 will	 add	 to	 the	
evidence	 base	 to	 inform	 decision	 making	 by	 commissioners	 and	
service	leads	on	pathway	redesign	was	a	key	driver	in	the	finalisation	
of	the	research	questions	and	selection	of	methods	for	this	doctoral	
research.	A	pragmatic	approach	was	adopted	to	address	the	research	
questions,	 recognising	 that	 this	 is	 highly	 aligned	 to	 the	 mixed	
methods	approach	adopted.		
	
The	chlamydia	testing	and	treatment	pathways	being	explored	in	this	
thesis	are	undoubtedly	complex	interventions,	defined	by	the	MRC	as	
“interventions	 with	 several	 interacting	 components”	 (Medical	
Research	Council,	2008:6).	They	further	outline	the	issues	associated	
with	 evaluating	 this	 type	 of	 intervention	 as	 being	 “the	 difficulty	 of	
standardising	 the	 design	 and	 delivery	 of	 interventions,	 their	
sensitivity	 to	 features	 of	 the	 local	 context,	 the	 organisational	 and	
logistical	 difficult	 of	 applying	 experimental	 methods	 to	 service	 or	
policy	 change,	 and	 the	 length	 and	 complexity	 of	 the	 causal	 chains	
linking	 intervention	 with	 outcome”	 (ibid.).	 This	 research	 was	
conducted	within	 the	 context	of	 the	 framework	of	HTA,	 specifically	
eHTA.	Whilst	 not	 conducting	 a	 full	 eHTA,	 the	 research	 focused	 on	
two	elements	to	inform	an	eHTA	–	a	DCE	to	measure	young	people’s	
preferences	(to	 inform	likely	uptake)	and	early	economic	evaluation	
(to	 estimate	 the	 costs	 and	 consequences	 associated	 with	 different	
pathways).		
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A	 number	 of	 individual	 pieces	 of	 research	 were	 undertaken	 which	
came	together	to	inform	both	the	DCE	and	the	economic	evaluation,	
including	 a	 link	 between	 the	 two	 where	 the	 probabilities	 derived	
from	the	DCE	results	were	used	 to	 inform	sensitivity	analysis	 in	 the	
economic	 evaluation.	 To	 guide	 the	 reader	 through	 the	 following	
sections,	 a	 summary	of	 the	 research	undertaken	by	 the	author	and	
presented	in	this	thesis	is	outlined	in	table	3.1.	This	doctoral	research	
was	 undertaken	 as	 part	 of	 a	 UKCRC	 strategic	 grant	 aimed	 at	
developing	 a	 fully	 remote	 online	 pathway	 for	 STI	 testing	 and	
treatment.	A	more	detailed	description	of	the	full	work	programme	is	
included	in	Appendix	1.		
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Research/	Study	 Role	in	Design	 Role	in	Data	Collection	 Role	in	Analysis	
DCE	Literature	
Reviews	
I	designed	the	literature	review	protocols	for	the	two	
literature	reviews	which	enabled	the	identification	of	the	
long	list	of	attributes	for	the	DCE	
I	ran	the	searches	in	electronic	databases	and	recorded	
outputs	in	Endnote	X6.	I	applied	the	inclusion	and	
exclusion	criteria	to	arrive	at	the	final	set	of	included	
studies.	
I	extracted	data	from	the	included	articles	and	
applied	a	quality	checklist	to	the	stated	preference	
studies	literature	review.	
DCE	Focus	Groups	 I	developed	the	study	protocol	for	the	development	of	the	
DCE	questionnaire	which	included	the	topic	guide,	
participant	information	leaflets	and	ethics	committee	
requirements.		
I	conducted	and	transcribed	the	four	focus	groups.	 I	developed	the	coding	framework	and	analysed	the	
focus	group	transcripts.	
DCE	Expert	Groups	 Part	of	the	study	protocol	outlined	above.	 I	led	the	expert	groups	and	summarised	the	key	
discussion	points.		
I	synthesised	the	findings	alongside	other	data	
sources	to	inform	the	final	selection	of	attributes	and	
levels	
DCE	Cognitive	
Testing	
Part	of	the	study	protocol	outlined	above	 I	undertook	the	cognitive	interviews		 I	analysed	the	cognitive	interviews	and	modified	the	
DCE	questionnaire	based	on	the	analysis.	
DCE	Questionnaire	
Design	
I	developed	the	final	DCE	questionnaire	design	and	secured	
ethics	committee	approval	for	its	conduct	including	the	
development	of	the	study	protocol.	
I	worked	with	an	independent	research	company	and	
used	their	online	consumer	panel.	The	company	
provided	the	raw	data	from	the	completed	
questionnaires.	
I	undertook	the	validity	checks	and	analysis	of	the	
questionnaire	data.	
Costing	Study	–	
Literature	Reviews	
I	designed	the	literature	review	protocols	for	the	literature	
reviews	to	review	health	economic	models	for	chlamydia	
and	identify	parameter	inputs	for	the	model.	
I	ran	the	searches	in	electronic	databases	and	recorded	
outputs	in	Endnote	X7.	I	applied	the	inclusion	and	
exclusion	criteria	to	arrive	at	the	final	set	of	included	
studies.	
I	extracted	data	from	the	included	articles.	
Costing	Study	–	
Primary	Data	
Collection	
I	developed	the	study	protocol	and	secured	ethics	approval	
for	the	collection	of	the	primary	data	(interviews)	on	the	
resource	inputs,	performance	and	costs	of	comparator	
pathways	for	the	economic	analysis	
I	undertook	the	interviews	and	mapped	pathways	 I	used	the	data	sourced	to	build	up	cost	inputs	for	the	
costing	study	and	undertook	sensitivity	analysis	on	
identified	parameters.	
Economic	Evaluation	 I	conceptualised	and	built	the	economic	model	 I	undertook	the	literature	reviews	to	parameterise	the	
model		
I	undertook	the	validity	checks,	analysed	the	data	
from	the	model	and	undertook	sensitivity	analysis	on	
identified	parameters.		
Table	3.1	-	Summary	of	Research	Undertaken	and	Presented	in	this	Thesis	
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The	 remainder	 of	 this	 chapter	 presents	 the	 background	 to	 the	
theoretical	 framework	 for	 the	 consideration	 of	 the	 research	
objectives,	 the	 methods	 selected	 and	 the	 justification	 for	 the	
selection	of	these	methods.		
	
3.3 Health	Technology	Assessment	
The	evaluation	of	new	healthcare	technology,	be	that	drugs,	devices,	
diagnostics,	 procedures	 or	 other	 interventions,	 and	 its	 impact	 on	
clinical	 care	 pathways	 is	 desirable	 prior	 to	 large-scale	
implementation	 within	 the	 NHS	 to	 minimise	 the	 associated	 risk.	
Szczepura	 and	Kankaanpää	 recognise	 that	HTA	has	 the	potential	 to	
address	 the	 translational	 research	 deficit	 identified	 by	 Cooksey	 in	
that	 it	 presents	 an	 opportunity	 to	 “look	 before	 you	 leap”	 into	
widespread	 implementation	 of	 a	 new	 technology	 within	 a	 health	
service	(Szczepura	and	Kankaanpää,	1996:5).	
	
eHTA	 recognises	 the	 value	 of	 an	 assessment	 of	 the	 likely	 costs	 for	
technology	developers	in	particular	(Pietzsch	and	Paté-Cornell,	2008).	
An	 insight	 into	 the	 cost	 impact	 of	 the	 implementation	 of	 the	
technology	to	the	healthcare	system	can	inform	future	development	
and	 likely	 issues	 to	 be	 addressed	 to	 achieve	 adoption.	 This	 section	
sets	 out	 the	 background	 to	 HTA,	 giving	 context	 to	 the	 research	
included	in	this	doctoral	thesis.		
	
HTA	 is	 “the	 systematic	 process	 by	 which	 the	 direct	 and	 indirect	
consequences	of	a	particular	technology	are	assessed;	it	is	concerned	
with	evaluating	the	safety,	effectiveness,	and	cost-effectiveness,	and	
(where	 appropriate)	 the	 social,	 ethical	 and	 legal	 impact	 of	 a	
technology”	 (Szczepura	 and	 Kankaanpää,	 1999:4-5).	 EUnetHTA,	 a	
network	of	European	HTA	agencies,	cites	the	aim	of	HTA	as	being	“to	
inform	 the	 formulation	 of	 safe,	 effective,	 health	 policies	 that	 are	
patient	 focused	 and	 seek	 to	 achieve	 best	 value”	 (EUnetHTA,	
2015a:e1).		
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Goodman	extends	 this,	acknowledging	 that	 there	are	many	reasons	
that	HTAs	are	undertaken	including	to	advise	or	inform:		
• whether	 a	 technology	 should	 be	 approved	 by	 a	 regulatory	
agency	or	adopted	by	a	health	care	system	e.g.	whether	the	
NHS	should	fund,	
• guideline	 development	 on	 the	 use	 of	 a	 technology	 within	
clinical	practice,	
• manufacturers	 on	 the	 development	 of	 a	 technology	 and	 its	
positioning	within	the	market	(Goodman,	2014).	
	
Within	the	context	of	the	reason	for	undertaking	an	HTA,	Goodman	
identified	three	‘basic	orientations	to	HTA’:	
• Technology-oriented	 -	 to	 explore	 the	 impact	 of	 a	 specific	
healthcare	technology,	
• Problem-oriented	–	to	identify	solutions	to	a	specific	problem,	
for	the	management	of	a	particular	condition,	
• Project-oriented	–	to	adopt	a	 local	 focus	e.g.	to	consider	the	
adoption	of	a	technology	by	a	particular	organisation	(ibid.).		
	
Within	 the	 context	 of	 these	 orientations	 the	 most	 commonly	
recognised	 application	 of	 HTA	 is	 the	 technology	 oriented	 approach	
undertaken	by	HTA	agencies.		
	
The	 definition	 outlined	 by	 EUnetHTA	 offers	 some	 insight	 into	 the	
scope	of	 information	 considered	within	 an	HTA,	 however	 there	 are	
variations	within	 the	clarification	of	scope	of	what	HTA	assesses,	as	
outlined	in	the	table	3.2:	
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Scope	of	HTA	Assessment	 Source	
“May	 involve	 the	 investigation	 of	 one	 or	more	 properties,	
impacts,	 or	 other	 attributes	 of	 health	 technologies	 or	
applications.	In	general	these	include	the	following:	
• Technical	properties	
• Safety	
• Efficacy	and/	or	effectiveness	
• Economic	attributes	or	impacts	
• Social,	legal,	ethical	and/or	political	impacts”	
	
(Goodman,	2014:II5-6)		
“Domains	of	an	HTA:	
• Health	problem	and	current	use	of	technology	
• Description	 and	 technical	 characteristics	 of	 the	
technology	
• Safety	
• Clinical	Effectiveness	
• Costs	and	economic	evaluation	
• Ethical	analysis	
• Organisational	aspects	
• Social	aspects	
• Legal	aspects”	
(EUnetHTA,	2015b:6)	
“Definition	of	the	research	questions:	
• Safety	
• Efficacy/	Effectiveness	
• Psychological/	Social/	Ethical	
• Organisational/	Professional	
• Economic”	
(Busse	et	al.,	
2002:365)	
Table	3.2	-	Scope	of	Health	Technology	Assessment	(Busse	et	al.,	2002,	Goodman,	2014,	
EUnetHTA,	2015b)	
	
Within	 the	 scope	 outlined	 in	 table	 3.2	 there	 are	 a	 number	 of	
outcomes	that	can	form	part	of	the	HTA	which	are	summarised	in	the	
figure	3.1:	
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Figure	3.1	-	Summary	of	Outcomes	Considered	in	HTA	adapted	from	Busse	et	al.,	(2002),	
Goodman,	(2014),	EUnetHTA,	(2015b)	
	
	 	
Safety
•Mortality
•Morbidity
•Judgement	of	the	acceptability	of	risk
Efficacy/	
Effectiveness
•Benefit	of	using	technology	under	ideal	conditions	and/	or	real	world	conditions
•Change	in	e.g.	mortality,	morbidity,	disability	resulting	from	the	condition
•Change	in	quality	of	life,	quality	adjusted	life	years	
Costs	&	
Economic	
Evaluation
•Comparison	of	costs	and	outcomes	between	new	technology	and	current	
practice
Social/	
Psychological
•Patient/	Carer	considerations	in	respect	of	the	technology
•Postitioning	of	technology	in	society	- impact	of	its	implementation
•Patient	acceptance,	compliance,	satisfaction,	demand,	preferences
Organisational
/	Professional
•Impact	on	pathways	e.g.	outpatient	attendances,	length	of	stay
•Service	utilisation
•Change	in	service	requirements	e.g.	staff,	location,	equipment
Legal
•Impact	on	legal	rights	of	patients	e.g.	informed	consent,	privacy	and	
confidentiality
•Impact	of	legal	aspects	of	the	delivery	of	healthcare	e.g.	regulatory	approval,	
market	regultation
Technical
•Performance	characteristics	of	the	technology	e.g.	scale	up,	manufacturing,	
reliability,	ease	of	use,	maintenance
Ethical
•Outcomes	relating	to	both	the	implications	of	implementing	and	not	
implementing	the	technology
•Consideration	of	social	norms	and	values
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In	 England,	 the	 National	 Institute	 of	 Health	 and	 Care	 Excellence	
(NICE)	 carries	 out	 evaluation	 of	 the	 key	 innovative	 or	 high	 impact	
technologies.	 NICE	 operate	 a	 number	 of	 technology	 assessment	
programmes	including:	
• the	technology	appraisal	programme	(TA),	
• the	medical	technologies	evaluation	programme	(MTEP),	
• the	diagnostics	assessment	programme	(DAP),	
• the	highly	specialised	technologies	programme	(HST),	
• the	interventional	procedures	programme	(IP)	(NICE,	2015).	
	
It	 is	 a	 requirement	 for	 commissioners	 in	 England	 to	 comply	 with	
recommendations	made	in	respect	of	drugs	and	devices	through	the	
TA	 and	HST	 programmes	within	 three	months	 of	 recommendation.	
However,	 the	 recommendations	of	all	other	 technology	assessment	
programmes	 are	 advisory	 only	 at	 the	moment,	 that	 is	 the	 decision	
rests	with	 the	 commissioner,	 be	 that	 NHSE,	 CCGs	 or	 the	 LA	 (ibid.).	
Regardless	of	 the	decision	 taken	 in	 respect	of	 a	new	 technology	by	
commissioners,	 individual	 clinical	 practice	 of	 medical	 staff	 is	 a	
significant	factor	in	medical	technology	uptake.		
	
Diagnostic	 technology	evaluation	 is	undertaken	 through	 the	DAP	or	
MTEP.	 To	 date	 no	 evaluation	 of	 an	 eHealth	 or	mHealth	 technology	
has	been	considered	by	NICE.	Work	is	ongoing	between	a	number	of	
agencies	 including	 NICE,	 PHE,	 NHS	 England	 and	 NHS	 Digital	 on	 the	
processes	and	methods	for	the	evaluation	of	apps	(Osipenko,	2016).	
	
Whilst	 it	 is	 recognised	 that	 the	 theory	 that	 NICE	 technology	
assessments	 will	 act	 as	 “filters	 for	 new	 technology	 and	 then	 as	
catalysts	 for	adoption”	 (Liddell	et	al.,	2008:viii)	 there	are	 limitations	
due	to	NICE’s	capacity	to	evaluate	only	a	limited	number	of	products.	
Many	 other	 technologies	 end	 up	 in	 the	 hands	 of	 hundreds	 of	
commissioning	and	provider	organisations	where	 local	decisions	are	
required.		
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This	has	 implications	both	for	NICE	recommended	technologies	that	
are	 not	 subject	 to	 mandatory	 funding	 (MTEP/DAP/IP	
recommendations)	 and	 for	 the	 many	 technologies	 that	 are	 not	
assessed	by	NICE.	
	
For	 healthcare	 commissioning	 organisations	 the	 approach	 taken	 is	
normally	 set	 out	 within	 policies	 on	 in	 year	 service	 developments	
which	 restrict	 how	 new	 service	 developments	 are	 adopted,	 for	
example,	 NHS	 England’s	 Policy	 on	 ‘in	 year’	 service	 developments	
(NHS	 England,	 2013)	 and	 Clinical	 Priorities	 Advisory	 Group	 (NHS	
England,	2016).	Within	local	authorities	commissioning	decisions	are	
made	 within	 the	 committee	 governance	 structure	 with	 elected	
members	determining	the	outcome.	
	
For	healthcare	provider	organisations	adoption	 is	normally	assessed	
through	 the	 business	 case	 process,	 whereby	 directorate	 teams	
develop	 a	 business	 case	 which	 identifies	 the	 costs,	 benefits	 and	
service	 delivery	 implications	 of	 the	 adoption	 of	 a	 new	 technology.	
Whilst	 variable	 in	 scale,	 business	 cases	 broadly	 cover	 the	 key	
principles	set	out	in	the	green	book	(HM	Treasury,	2013).	
	
Considering	the	HTA	process	for	the	fully	remote	integrated	pathway	
(pathway	 E,	 stages	 1	 and	 2	 in	 figure	 2.1),	 should	 the	 associated	
diagnostic	technologies	be	considered	by	NICE	they	would	fall	within	
the	scope	of	the	MTEP	or	DAP.		These	would	most	likely	be	subject	to	
local	evaluation	by	commissioners	and	providers.		
	
In	 terms	 of	 the	 OCCP	 (pathway	 E,	 stage	 3	 onwards	 in	 figure	 2.1),	
whilst	 there	 are	well-established	 programmes	 for	 the	 evaluation	 of	
pharmaceutical	 products,	 and	 to	 a	much	 lesser	 extent	 devices	 and	
diagnostics,	health	technology	assessment	and	economic	evaluation	
of	 online	 provision	 (eHealth	 and	 mHealth	 initiatives)	 is	 largely	
untested	(Tate	et	al.,	2009,	Free	et	al.,	2013a).		
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This	 view	 is	 reinforced	 by	 the	 WHO	 who	 identify	 that	 the	
implementation	 of	mHealth	 is	 taking	 place	 through	 localised,	 small	
scale	 pilots	 on	 an	 ad	 hoc	 basis	 with	 minimal	 evaluation	 (WHO,	
2011a).	
	
Kidholm	and	colleagues	undertook	work	with	stakeholders	and	user	
groups	 to	 consider	 the	 application	 of	 the	 EUnetHTA	 core	model	 to	
telemedicine,	their	resulting	MAST	model	is	outlined	in	figure	3.2:	
	
Figure	3.2	-	The	Elements	of	the	MAST	model	for	Telemedicine	HTA.	Source:	(Kidholm	et	al.,	
2012:47)	
	
The	 principal	 differences	 between	 the	MAST	model	 and	 the	 EUnet	
HTA	model	 are	 a	 reduction	 in	 the	 number	 of	 domains	 through	 the	
consolidation	 of	 the	 health	 problem	 and	 technology	 characteristics	
into	one	component,	and	the	rationalisation	of	the	ethical,	social	and	
legal	aspects	 into	another.	 	A	 ‘patient	perspectives’	 component	has	
been	added,	noting	that	this	was	a	specific	request	resulting	from	the	
stakeholder	 work,	 driven	 by	 a	 belief	 that	 the	 model	 required	
simplification	 (Kidholm	et	 al.,	 2012).	No	 published	 studies	 could	 be	
identified	which	used	the	MAST	model	as	a	framework	for	HTA.			
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3.4 Early	Health	Technology	Assessment	
Unlike	 HTA,	 there	 is	 no	 standard	 definition	 offered	 within	 the	
literature	 for	 eHTA.	 Pietzsch	 and	 Paté-Cornell	 identify	 the	 aim	 of	
eHTA	 as	 being	 the	 same	 as	 HTA,	 only	 it	 is	 an	 assessment	 of	 the	
likelihood	of	the	safety,	effectiveness	and	cost-effectiveness	of	a	new	
technology	 (Pietzsch	 and	 Paté-Cornell,	 2008).	 Literature	 on	 the	
methods	 and	 practice	 of	 eHTA	has	 emerged	 in	 recent	 years,	 borne	
out	 of	 the	 recognition	 of	 the	 uncertainty	 faced	 by	 developers	 in	
waiting	 for	 regulatory	 approval.	 Pietzsch	 and	 Paté-Cornell	 highlight	
that	this	uncertainty	could	be	reduced	by	undertaking	eHTA	“at	the	
time	 when	 major	 investment	 and	 design	 decisions	 are	 made”	
(Pietzsch	and	Paté-Cornell,	2008:36).	In	considering	the	scope	of	HTA	
and	eHTA,	Pietzsch	and	Paté-Cornell	identify	the	following	similarities	
and	differences,	summarised	in	table	3.3:	
	 HTA	 eHTA	
Aim	 Assess	safety,	effectiveness,	
and	cost-effectiveness	profiles	
of	a	new	technology	
Assess	(likely)	safety,	
effectiveness,	and	cost-
effectiveness	profiles	of	a	
new	technology	
Decision	
Support	
Decision	support	for	
regulators,	payers	and	patients	
about	market	clearance,	
payment	and	usage	of	a	
technology	
Decision	support	for	
manufacturers	and	
investors	about	design	and	
management	of	a	
technology,	as	well	as	
regulatory	and	
reimbursement	strategy	
Available	
Evidence	
Usually	evidence	from	clinical	
studies	performed	with	new	
technology	
Evidence	from	early	bench	
and	animal	testing,	early	
clinical	experience,	and	
from	previous	generations	
of	the	technology	
Influence	on	
Technology	
Performance	
Limited	or	no	influence	on	
clinical	performance	of	a	new	
technology	
Potentially	significant	
influence	on	(future)	clinical	
performance	of	a	new	
technology	
Table	3.3	-	Similarities	and	Differences	between	HTA	and	eHTA.	Taken	form	Pietzsch	&	Paté-
Cornell,	(2008:37)	
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Ijzerman	 and	 Steuten	 (2011)	 break	 this	 down	 further,	 proposing	
three	 stages	 of	 HTA	 within	 the	 four	 stages	 of	 the	 product	
development	 lifecycle	–	very	eHTA,	eHTA	and	HTA	 (figure	3.3).	This	
has	rarely	been	seen	in	practice	 in	published	literature,	for	example	
Dong	and	Buxton’s	early	 assessment	of	 the	 likely	 cost-effectiveness	
of	 computer-assisted	 total	 knee	 replacement	 (Dong	 and	 Buxton,	
2006),	 O’Prinsen	 and	 colleagues	 consideration	 of	 a	 new	 medical	
technology	 for	 stroke	 rehabilitation	 (O'Prinsen	 et	 al.,	 2009),	 and	
Vallejo-Torres	and	colleagues	application	of	a	 three-stage	economic	
evaluation	to	absorbable	pins	for	Hallux	Valgus	(Vallejo-Torres	et	al.,	
2011).	
	
Cosh	and	colleagues	 identified	a	decision	 framework	 for	 companies	
considering	 investing	 in	new	medical	technology	(Cosh	et	al.,	2007).	
This	 includes	 strategic	 consideration,	 clinical	 problem	 definition,	
headroom	 analysis,	 return-on-investment	 analysis	 and	 further	
economic	evaluation,	positioning	 the	use	of	 the	model	at	 the	eHTA	
stage.	
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Figure	3.3	-	Applying	HTA	to	Stages	of	Product	Development.	Source:	Ijzerman	and	Steuten,	2011:335	
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The	 evolution	 of	HTA	 and	 economic	 evaluation	 is	 centred	 primarily	
on	 the	 evaluation	 of	 drugs	 rather	 than	 devices	 or	 other	 health	
technologies	 such	as	 telemedicine,	 eHealth	or	mHealth	 (Tate	et	 al.,	
2009,	Free	et	al.,	2013).	Pecchia	and	Craven	identify	a	number	of	key	
factors	which	impact	on	HTA	that	differ	between	the	drug	and	device	
product	 groups	 including	 product	 life	 cycle,	 clinical	 evaluation,	 use	
issues	and	cost	(Pecchia	and	Craven,	2012).		
	
Whilst	no	published	studies	were	identified	which	apply	the	use	of	an	
iterative	 economic	 evaluation	 approach	 in	 the	 development	 of	 an	
e/mHealth	 intervention,	 there	 is	 some	 evidence	 of	 the	 adoption	 of	
this	 approach	 in	 respect	 of	 biomedical	 devices.	 Considering	 the	
differences	highlighted,	eHealth	and	mHealth	technologies	with	their	
constantly	evolving	product	and	‘user	dependent	efficacy’	are	much	
more	 closely	 aligned	 with	 devices	 than	 drugs	 (Pecchia	 and	 Craven	
2012).		
	
This	is	also	consistent	with	a	lack	of	published	economic	evaluations	
of	 eHealth	 and	 mHealth.	 A	 review	 of	 the	 cost-effectiveness	 of	
internet	interventions	published	in	2009	concluded	that	“whilst	there	
is	 a	 growing	 body	 of	 outcome	 literature	 on	 internet	 interventions,	
this	review	reveals	that	only	a	limited	number	of	studies	so	far	have	
attempted	to	incorporate	economic	endpoints	into	the	analyses	and	
most	have	significant	shortcomings”	 (Tate	et	al.	2009:42).	 	A	recent	
systematic	 review	 of	 literature	 on	 the	 cost-effectiveness	 of	
telemedicine,	 eHealth	 and	mHealth	 systems	 found	 that	 there	were	
too	 few	studies,	many	of	poor	quality,	 to	determine	whether	 these	
technologies	are	cost-effective	(de	la	Torre-Díez	et	al.,	2015).		
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An	 earlier	 scoping	 review	 undertaken	 as	 part	 of	 this	 doctoral	
research	 (not	 included	 in	 the	 thesis)	 in	 2013	 to	 identify	 whether	
eHealth/mHealth	 initiatives	for	diagnosis,	treatment	and	monitoring	
are	 cost	 effective	 identified	 only	 three	 economic	 evaluations,	
reported	 alongside,	 but	 secondary	 to,	 the	 clinical	 effectiveness	
evaluation	(Ryan	et	al.,	2012,	van	Os-Medendorp	et	al.,	2012,	 Isetta	
et	al.,	2013).	
	
3.5 Approaches	to	Economic	Evaluation		
Economic	evaluation	is	defined	by	Drummond	and	colleagues	as	“the	
comparative	analysis	of	the	alternative	courses	of	action	in	terms	of	
both	their	costs	and	consequences”	(Drummond	et	al.,	2015:4).	They	
identify	 five	principal	 approaches	 to	 the	measurement	of	 costs	 and	
consequences	 in	economic	evaluation,	noting	 that	 in	all	 cases	 costs	
are	 valued	 as	 monetary	 units,	 however	 the	 identification	 and	
measurement	 of	 consequences	 is	 different,	 depending	 on	 the	
approach.	The	authors	acknowledge	the	growth	of	a	further	form	of	
economic	evaluation	-	cost-consequence	analysis	which	 is	a	 form	of	
cost-effectiveness	 analysis.	 The	 types	 of	 economic	 evaluation	 are	
presented	in	table	3.4.	
	
Type	of	
Economic	
Evaluation	
Defining	Features	 Example	in	an	STI	context	
Cost	Analysis	 Consequences	are	not	
included	in	the	analysis	
Cost	analysis	of	the	
Prevention	of	Pelvic	
Infection	Trial,	explored	the	
impact	of	chlamydia	
screening	on	pelvic	
inflammatory	disease	
(Aghaizu	et	al.,	2011)	
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Type	of	
Economic	
Evaluation	
Defining	Features	 Example	in	an	STI	context	
Cost	
Minimisation	
Analysis	
(CMA)	
Consequences	between	the	
alternatives	under	
consideration	are	“broadly	
equivalent”	(Drummond	et	
al,	2015:6),	therefore	the	
analysis	is	reduced	to	a	
comparison	of	costs	
Cost	minimisation	analysis	
to	compare	12	or	24	weeks	
of	drug	therapy	for	
Hepatitis	C	(De	Compadri	
et	al.,	2008)	
Cost	
Effectiveness	
Analysis	(CEA)	
One	consequence,	the	same	
for	both	alternatives,	which	
is	measured	in	natural	units	
(e.g.	increase	in	cases	
detected)	
Cost	effectiveness	analysis	
of	screening	for	chlamydia	
by	internet	ordered	self-
sample	compared	with	
clinic	based	clinician	
sample	(Huang	et	al.,	2011)		
Cost	Utility	
Analysis	
(CUA)	
Single	or	multiple	effects	
which	do	not	have	to	be	
common	to	both	
alternatives.	Effects	are	
measured	in	‘healthy	years’,	
usually	quality	adjusted	life-
years	(QALYs)	
The	costs	and	cost	
effectiveness	of	
introducing	an	
opportunistic	screening	
programme	in	Ireland	
(Gillespie	et	al.,	2012)	
Cost	Benefit	
Analysis	(CBA)	
Single	or	multiple	effects	
which	do	not	have	to	be	
common	to	both	
alternatives.	Effects	are	
measured	in	monetary	
units.		
Cost	benefit	analysis	of	
screening	all	15-24	
pregnant	women	in	the	
USA	for	chlamydia	
(Ditkowsky	et	al.,	2017)	
Cost	
Consequence	
Analysis	(CCA)	
This	is	a	form	of	CEA	and	
takes	the	form	of	“a	
comparative	evaluation	of	
the	costs	and	resource	use	
consequences	of	two	or	
more	interventions	
considered	alongside	the	
relevant	clinical	benefits”	
(NICE	2011b:25).	This	
enables	the	decision	maker	
to	“make	their	own	trade-
off	between	effects”	
(Drummond	et	al.,	
2005:103).	
Comparison	of	the	costs	
and	outcomes	of	two	STI	
screening	interventions	
undertaken	in		a	football	
club	setting	(Jackson	et	al.,	
2015)	
Table	3.4	-	Types	of	Economic	Evaluation	(Drummond	et	al.,	2005,	Drummond	et	al.,	2015)	
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The	 primary	 form	 of	 economic	 evaluation	 adopted	 by	 NICE	 in	 its	
HTA	 programmes	 is	 CUA,	 with	 the	 main	 technology	 appraisal	
programmes	all	 incorporating	this	approach,	with	the	exception	of	
the	MTEP	which	 uses	 CCA	 (NICE,	 2011b).	 The	 rationale	 for	 this	 is	
not	explained	in	full,	although	it	 is	stated	that	this	approach	is	the	
most	appropriate	for	HTA	within	this	programme.		
	
Whilst	NICE’s	focus	in	economic	evaluation	is	on	the	final	HTA	stage	
(figure	 3.3),	 when	 the	 technology	 is	 sufficiently	 developed	 to	 be	
adopted	by	 the	NHS,	 Sculpher	and	colleagues	had	earlier	outlined	
the	 benefits	 of	 adopting	 an	 iterative	 approach	 to	 economic	
evaluation	which	 can	 also	 be	 aligned	 to	 earlier	 stages	 of	 product	
development.	They	argue	that	“just	as	clinical	evaluation	progresses	
through	 various	 stages,	 with	 the	 choice	 of	 research	 method	
depending	 on	 the	 maturity	 of	 the	 technology	 and	 the	 nature	 of	
existing	uncertainties,	economic	evaluation	too	should	be	viewed	as	
a	continuous	process	over	time,	progressing	from	early	 ‘indicative’	
studies	to	rigorous	comparative	analysis”	(Sculpher	et	al.,	1997:26).	
Their	four-stage	approach	is	summarised	in	figure	3.4:	
	
		 93	
	
Figure	3.4	-	Stages	of	Economic	Evaluation	in	Health	Technology	Assessment,	adapted	from	Sculpher	
et	al.,	(1997:27)	
	
The	 stages	 of	 economic	 evaluation	 outlined	 by	 Sculpher	 and	
colleagues	can	be	aligned	with	the	four	stages	of	product	research	
and	HTA	types	outlined	by	Ijzerman	and	Steuten,	as	summarised	in	
table	3.5:	
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Stage	 Product	
Development	
Stage	
Health	Technology	
Assessment	Type	
Economic	
Evaluation	Stage	
1	 Basic	Research	 Very	early	HTA	 Early	
Developmental	
2	 Translational	
Research	
Early	HTA	 Maturing	Innovation	
3	 Clinical	Research	 Mainstream	HTA	 Close	to	Widespread	
Diffusion	
4	 Access	&	Pricing	 Mainstream	HTA	 Moving	into	Practice	
Table	3.5	-	Mapping	Stages	of	Product	Development,	HTA	and	Economic	Evaluation	
(Ijzerman	&	Steuten,	2011,	Sculpher	et	al.,	1997)	
	
Hartz	and	John	explored	the	contribution	of	economic	evaluation	to	
decision	 making	 in	 the	 early	 stages	 of	 product	 development	 and	
noted	the	following	key	areas	where	it	is	applied:	
• “Strategic	research	and	development	decision	making	
• Pre-clinical	preliminary	market	assessments	
• Go/	 no-go	 decisions,	 identification	 of	 potentially	 success	
projects	
• Development	of	future	trial	design	
• Assessment	of	future	reimbursement	and	pricing	scenarios	
• Price	determination”	(Hartz	and	John,	2008:466-468).	
	
Through	their	literature	review,	Hartz	and	John	identified	a	number	
of	 techniques	 used	 in	 early	 economic	 evaluation	 including	 early	
economic	modelling,	Bayesian	decision	theory,	value	of	information	
analysis	 and	 clinical	 trial	 simulation.	 However,	 of	 the	 83	 papers	
included	 in	 their	 review,	 70%	were	 early	 economic	 evaluations	 of	
drugs	and	30%	were	other	interventions	including	“surgery,	imaging	
or	 novel	 products	 of	 systems”	 (Hartz	 and	 John,	 2008:469).	 It	 is	
recognised	 that	 those	 different	 categories	 of	 interventions	 have	
different	needs	from	eHTA,	including	economic	evaluation	(Pecchia	
and	Craven,	2012).		
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For	 medical	 devices,	 Girling	 and	 colleagues	 have	 developed	 a	
framework	 to	 undertake	 early	 economic	 evaluation	 (Girling	 et	 al.,	
2010).	 	 They	 used	 a	 two-stage	 model	 based	 on	 the	 product	
development	 cycle,	 with	 investment	 decision	 gates	 at	 the	 end	 of	
the	concept	stage	(Stage	1	 in	table	3.5)	and	clinical	research	stage	
(Stage	3	in	table	3.5).		
	
The	method	used	to	underpin	the	model	is	headroom	analysis	and	
the	 key	 difference	 between	 the	 two	 stages	 in	 the	 model	 is	 the	
consideration	 of	 different	 forms	 of	 uncertainty:	 developmental	
uncertainty	“those	aspects	of	product	design	and	performance	that	
will	 be	 resolved	 during	 the	 development	 phase”	 (Girling	 et	 al.,	
2010:586),	 and	 post-market	 uncertainty	 “those	 aspects	 of	
commercial	 performance	 that	 will	 not	 be	 resolved	 in	 time	 to	
influence	the	decision	to	launch	the	product	into	the	marketplace”	
(ibid.),	 for	 example	 price	 and	 volume	 of	 sales.	 Headroom	 can	 be	
defined	as	“the	most	the	manufacturer	could	charge	whilst	securing	
funding	from	the	care	provider”	(Girling	et	al.,	2015:332).			
	
It	is	suggested	that	the	time	to	calculate	headroom	is	at	the	market	
entry	 point	 (ibid.),	 however	 Vallejo-Torres	 highlight	 its	 successful	
use	 during	 the	 first	 stage	 of	 a	 three-stage	 iterative	 economic	
evaluation	alongside	a	product	development	 (Vallejo-Torres	et	 al.,	
2011).	
	
Considering	 the	 technologies	 included	 in	 the	 fully	 remote	 online	
pathway	 (Pathway	 E	 in	 figure	 2.1)	 against	 the	 stages	 outlined	 in	
table	3.5,	they	are	currently	at	different	stages	of	development:	
• Self-test	–	The	self-test	is	at	a	very	early	development	stage.	
Techniques	 for	 the	 component	 elements	 of	 self-tests	 are	
still	 being	 developed	 e.g.	 sample	 collection	 and	
amplification	(eSTI2	Consortium,	2011).		
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• OCCP	–	A	basic	product	exists	which	has	been	piloted	in	an	
exploratory	 study	 in	 the	 NHS,	 generating	 preliminary	 data	
about	its	effectiveness	(Estcourt	et	al.,	2015a).		
	
This	assessment	of	 the	product	development	stage	has	been	used	
to	 inform	 the	 selection	 of	methods	 for	 considering	 the	 costs	 and	
benefits	 of	 implementing	 the	 new	 technologies	 outlined	 in	 the	
following	section.		
	
3.5.1 Methods	Chosen	for	Exploring	the	Costs	and	Benefits	of	
implementing	a	Fully	Remote	Online	Pathway	for	
Chlamydia	
The	 methods	 finally	 selected	 reflect	 the	 stage	 of	 technology	
development,	 and	 specific	methodological	 issues	 identified	 in	 the	
consideration	of	the	costs	and	benefits	of	asymptomatic	chlamydia	
testing	 and	 treatment.	 There	 are	 two	 linked	 pieces	 of	 research	
presented	in	this	thesis,	firstly	a	preliminary	evaluation	of	the	costs	
and	 outcomes	 for	 the	 delivery	 of	 an	 OCCP	 which	 is	 presented	 in	
Chapter	7.		
	
This	 included	 some	data	 from	an	exploratory	 study	undertaken	 in	
London	 by	 the	 eSTI2	 consortium.	 Secondly,	 Chapter	 8	 outlines	 an	
economic	model	 for	 a	 fully	 remote	 online	 pathway	 (Pathway	 E	 in	
figure	 2.1)	 to	 explore	 the	 costs	 and	 consequences	 of	 the	
introduction	of	this.	The	model	considered	the	longer-term	impact	
of	the	health	complications	associated	with	untreated	chlamydia.		
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Methods	 for	 costing	 health	 services	 and	 their	 strengths	 and	
weaknesses	 are	well	 documented	 in	 the	 literature	 (Drummond	 et	
al.,	2015,	Gray	et	al.,	2011,	Mogyorosy	and	Smith,	2005).	There	is	a	
consensus	that	there	are	three	distinct	steps	within	the	process	of	
costing–	identification,	measurement	and	valuation	(Drummond	et	
al.,	2015,	Gray	et	al.,	2011).	However,	Mogyorosy	&	Smith	suggest	
two	 further	steps	prior	 to	commencing	costing	 that	have	a	critical	
role	to	play	in	setting	the	perspective	of	the	costing	and	framing	the	
service	to	enable	the	accurate	identification	of	costs.	Their	five	step	
approach	 is	 summarised	 in	 figure	 3.5	 and	 further	 information	 on	
the	detail	of	each	stage	is	outlined	in	7.2.1.	
	
	
Figure	3.5	-	Process	of	Costing,	adapted	from	Mogyorosy	&	Smith,	2005	
	
A	primary	costing	study	was	undertaken	to	enable	the	calculation	of	
costs	 to	 be	 included	 in	 the	 economic	 model	 and	 to	 ensure	 that	
costs	are	 reflective	of	 current	 service	delivery	models.	Drummond	
and	 colleagues	 identify	 a	 scale	 of	 precision	 to	 healthcare	 costing	
from	average	daily	cost	 to	micro-costing	 (Drummond	et	al.,	2005),	
whilst	 Brouwer	 and	 colleagues	 recognise	 that	 in	 practice	 the	
majority	of	economic	evaluations	use	a	combination	of	approaches	
from	this	scale	(Brouwer	et	al.,	2001).		
Definition	of	decision	problem	
and	objectives	of	costing
Description	of	service	being	
costed
Identification	of	resource	
items	and	units	of	measure
Measurement	of	resource	use
Assignment	monetary	value	to	
resources
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A	 pragmatic	 approach	 was	 adopted	 to	 costing	 the	 OCCP	 and	
comparator	pathways,	in	line	with	the	type	of	economic	evaluation	
for	 stage	 II	 of	 technology	development	 identified	by	 Sculpher	 and	
colleagues.	 They	 recognise	 that	 in	 respect	 of	 the	 identification	 of	
costs	there	is	greater	access	to	“individual	patient	data	on	the	costs	
and	 outcomes	 of	 the	 new	 technology”	 however	 that	 “stage	 II	
estimates	 of	 cost-effectiveness	 are	 unlikely	 to	 be	 definitive”	
(Sculpher	et	al.,	1997:27).	Further	 information	on	the	detail	of	the	
costing	methods	used	is	contained	in	section	7.2.	
	
Careful	 consideration	was	 given	 to	 the	 selection	 of	 the	 economic	
model	 used	 to	 assess	 the	 likely	 costs	 and	 benefits	 of	 a	 fully	
integrated	online	testing	and	treatment	service	for	chlamydia.	The	
use	 of	 static	 versus	 dynamic	 models	 in	 considering	 the	 cost-
effectiveness	 of	 interventions	 for	 infectious	 diseases	 is	 widely	
debated.	 A	 literature	 review	 was	 undertaken,	 and	 the	 result	
presented	 in	 section	 7.4.4.	 This	 identified	 that,	 for	 evaluating	 the	
cost-effectiveness	 of	 chlamydia	 testing	 and	 treatment,	 both	 types	
of	models	are	in	us:	static	models	(Althaus	et	al.,	2014,	Hislop	et	al.,	
2010,	Turner	et	al.,	2011,	Turner	et	al.,	2014)	and	dynamic	models	
(Adams	 et	 al.,	 2007,	 Looker	 et	 al.,	 2015,	 Low	 et	 al.,	 2007).	 A	
separate	 published	 literature	 review	 exploring	 the	 cost-
effectiveness	 of	 chlamydia	 screening	 identified	 that	 six	 out	 of	 ten	
studies	 used	 dynamic	models	 and	 four	 used	 static	models	 (ECDC,	
2014).	
	
Economic	models	can	be	broadly	categorised	as	illustrated	in	figure	
3.6.	Brennan	and	colleagues	argue	that	it	is	the	responsibility	of	the	
model	 developer	 rather	 than	 the	 policy	 maker	 to	 determine	 the	
type	of	model	being	used,	and	“advocate	the	use	of	simple	models	
that	 still	 accurately	 reflect	 disease	 progression	 and	 health	 care	
delivery	 to	 the	 extent	 needed	 by	 a	 given	 decision	 problem”	
(Brennan	et	al.,	2006:1307).			
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This	 view	 is	 supported	 by	 Pitman	 and	 colleagues	 who	 note	 that	
dynamic	models	 are	 important	when	 the	 intervention	 impacts	 on	
the	 transmission	 of	 the	 disease,	 however	 they	 suggest	 that	 static	
models	 are	 acceptable	 where	 “their	 projections	 suggest	 that	 an	
intervention	 is	 cost-effective	 and	 dynamic	 effects	 would	 further	
enhance	 this”	 (Pitman	 et	 al.,	 2012:829),	 proposing	 the	 use	 of	
dynamic	 modelling	 to	 supplement	 static	 models	 which	 indicate	
borderline	cost-effectiveness	(ibid.).	
	
	
Figure	3.6	-	Taxonomy	of	Model	Structures,	Source:	Brennan	et	al.,	2006:1297	
	
	 	
	 	 	 A	 B	 C	 D	
	 	 	 Cohort/	aggregate	level	/	counts	 Individual	Level	
	 	 	
Expected	value,	
continuous	state,	
deterministic	
Markovian,	
discrete	state,	
stochastic	
Markovian,	
discrete	state,	
individuals	
Non-
Markovian,	
discrete	state,	
individuals	
1	
No	Interaction	
Allowed	
Untimed	
Decision	tree	
rollback		
Simulated	
decision	tree		
Individual	sampling	model	(ISM);	
simulated	patient-level	decision	
tree	(SPLDT)	
2	 Timed	
Markov	model	
(evaluated	
deterministically)	
Simulated	
Markov	model		
ISM:	Simulated	patient	level	
Markov	model	(SPLMM)	
(variations	as	in	quadrant	below	
for	patient	level	models	with	
interaction)	
3	
Interaction	
Allowed	
Discrete	Time	
System	dynamics	
(finite	difference	
equations)	
Discrete	time	
Markov	chain	
model		
Discrete	time	
individual	
event	history	
model		
Discrete	
individual	
simulation	
4	 Continuous	Time	
System	dynamics	
(ordinary	
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Roberts	 concluded	 that	 in	 order	 to	 avoid	 misleading	 results,	
transmission	dynamic	models	should	be	used	to	evaluate	the	cost-
effectiveness	of	chlamydia	screening	programmes.	To	illustrate	the	
difference	between	 the	 static	 and	dynamic	modelling	approaches,	
Roberts	 created	 three	 models,	 two	 static	 and	 one	 transmission	
dynamic	 to	 compare	 the	 cost-effectiveness	 of	 non-selective	
proactive	 screening,	 with	 no	 organised	 screening	 (Roberts,	 2008).	
This	 identified	base	case	results	 from	the	three	models	as	follows:	
Static	 1	 -	 £8,474	 per	 major	 outcome	 averted	 (MOA),	 Static	 2	 -	
£13,344	 per	 MOA	 and	 Dynamic	 -	 £19,300	 per	 MOA.	 Roberts	
explains	 the	 difference	 in	 results	 as	 being	 attributable	 to	 the	
comparator	 option	 not	 being	 the	 same	 –	 the	 static	models	 had	 a	
comparator	of	no	screening,	whereas	the	dynamic	model	assumed	
a	background	level	of	opportunistic	screening,	plus	the	difference	in	
approach	 to	 the	 application	 of	 discounting	 between	 static	 and	
dynamic	models	(ibid.).		
	
Whilst	 it	 is	 recognised	 that	 dynamic	models	 are	 superior	 to	 static	
models	 for	 modelling	 infectious	 diseases	 (Barton	 et	 al.,	 2004,	
Roberts,	 2008)	 it	 also	 recognised	 that	 they	 are	 more	 complex,	
costlier	 and	 time	 consuming	 to	 develop.	 In	 the	 present	 study,	 a	
decision	analytic	model	was	selected	for	the	following	reasons:	
• This	 is	 an	 early	 stage	 evaluation	 of	 a	 new	 technology	 and	
therefore	 the	objective	 is	 to	demonstrate	 the	 likely	 impact	
on	 costs	 and	 outcomes	 to	 inform	 future	 research	 and	
development		
• Data	 for	 parametrising	 a	model	 about	 the	 new	 technology	
are	somewhat	limited,	with	no	data	on	self-testing	(Stages	1	
and	2	in	pathway	E,	figure	2.1)	and	some	initial	exploratory	
study	 results	 and	 costings	 for	 OCCP	 (Stages	 3	 to	 5	 in	
pathway	E,	figure	2.1).		
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• It	 is	 not	 yet	 known	 how	 the	 availability	 of	 self-tests	 may	
influence	sexual	behaviours,	risk	taking	and	testing	patterns,	
all	 of	 which	 would	 be	 material	 considerations	 within	 a	
dynamic	 model	 to	 inform	 parameters	 such	 as	 partner	
change	rate.		
	
In	 terms	 of	 quantifying	 benefits,	 Drummond	 and	 colleagues	
categorise	outcomes	into	intermediate	and	final,	with	intermediate	
outcomes	 representing	 a	 measure	 which	 indicates	 a	 change	 in	
health	outcome	e.g.	improvement	in	CD4	count	(a	measure	of	how	
well	 the	 immune	 system	 is	working	 in	patients	with	HIV)	 versus	a	
final	 outcome	 e.g.	 survival	 or	 health	 related	 quality	 of	 life	
(Drummond	 et	 al.,	 2015).	 	 Process	 measures	 may	 also	 be	 an	
important	consideration	in	the	evaluation	of	a	complex	intervention	
(Moore	et	al.,	2015).	Process	measures	typically	 include	aspects	 in	
relation	 to	 “service	 organisation,	 delivery	 and	 use”	 (Bowling,	
2009:11).	 Use,	 i.e.	 testing	 and	 treatment	 uptake,	 are	 key	
parameters	 impacting	 both	 costs	 and	 outcomes	 within	 the	
economic	evaluation	undertaken	in	this	thesis.			
	
The	outcome	metric	 for	economic	evaluation	preferred	by	NICE	 is	
the	quality	adjusted	life	year	(QALY)	as	it	a	common	unit	of	measure	
which	 enables	 comparison	 of	 outcomes	 between	 different	 health	
care	 interventions	 (Gray	 et	 al.,	 2011).	 QALYs	 are	 calculated	 by	
multiplying	 the	health	state	outcome	 (represented	on	a	scale	of	1	
for	 perfect	 health	 to	 0	 which	 is	 death)	 by	 the	 time	 spent	 in	 that	
state	 (Drummond	 et	 al.,	 2015).	 The	 difference	 in	 QALYs	 for	 an	
intervention	is	shown	in	figure	3.7:	
	
	
		 102	
			
Figure	3.7	-	QALYs	gained	from	an	intervention,	taken	from	Drummond	et	al.,	2015:9.	
	
Whilst	it	is	recognised	that	QALYs	are	the	outcome	metric	preferred	
by	NICE,	the	ECDC	argue	that	use	of	cost	per	QALY	to	measure	the	
effectiveness	 of	 chlamydia	 screening	 is	 inappropriate	 because	
“undiagnosed	 asymptomatic	 chlamydia	 infections	 do	 not	 affect	
quality	of	 life.	The	complications	of	chlamydia	are	also	rarely	fatal.	
The	impact	of	chlamydia	is	therefore	mainly	through	morbidity	and	
decreases	 in	 quality	 of	 life	 resulting	 from	 PID	 and	 its	 sequelae”	
(ECDC,	2014:44).		
	
A	recent	systematic	review	of	economic	evaluations	has	examined	
the	 use	 of	 QALYs	 and	 valuation	 of	 health	 states	 associated	 with	
chlamydia	and	the	consequences	of	untreated	infection	(Jackson	et	
al.,	2014).	Of	the	19	included	studies	in	this	review,	11	studies	cited	
the	same	source	of	QALY	information	from	an	Institute	of	Medicine	
study	 (ibid.).	 The	 reviewers	 highlight	 methodological	 concerns	
associated	with	 valuing	 short-term	 health	 states	 for	 chlamydia	 as	
those	 highlighted	 by	 the	 ECDC	 and	 also	 draw	 out	 the	 issue	 of	
delayed	(long	term)	complications	of	the	disease	occurring,	in	many	
cases,	years	after	the	initial	infection	(ibid.).		
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Jackson	 and	 colleagues	 argue	 that	 further	 research	 is	 required	 to	
enable	more	robust	health	state	measurements	to	enable	economic	
evaluations	for	chlamydia	screening	to	be	conducted	in	accordance	
with	NICE	standards	 (ibid.).	 	Owing	 to	 the	concerns	highlighted	by	
the	 ECDC	 and	 Jackson	 and	 colleagues,	 a	 proxy	measure	 of	 health	
outcomes	 (health	complications	of	untreated	chlamydia)	has	been	
selected	over	QALYs	as	 the	outcome	measure	 in	 this	analysis.	The	
health	complications	included	in	the	economic	model	are:	
• Pelvic	Inflammatory	Disease	(PID)	
• Infertility	
• Ectopic	Pregnancy	
• Pre-term	Rupture	of	Membranes	(PROM)	
• Neonatal	Conjunctivitis	
• Neonatal	Pneumonia	
• Epididymitis.	
	
Figure	3.8	outlines	the	research	methods	chosen	to	parametrise	the	
economic	 model,	 recognising	 the	 early	 stage	 of	 technology	
development.	 Given	 the	 absence	 of	 a	 self-test,	 a	 hypothetical	
scenario	was	used	 in	order	to	demonstrate	the	 impact	of	variance	
on	test	performance	characteristics.	
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Figure	3.8	-	Research	methods	used	to	parameterise	the	model	
	
A	 key	 feature	 of	 early	 economic	 evaluation	 is	 that	 it	 is	 indicative	
rather	than	definitive	and	significant	parameter	uncertainty	is	one	of	
the	main	 reasons	 for	 this	 (Sculpher	 et	 al.,	 1997).	 The	 aim	 of	 early	
economic	evaluation	is	to	provide	an	indication	of	the	likely	costs	and	
benefits	 of	 a	 new	 technology	 and	 to	 identify	 areas	 for	 further	
consideration	 for	 technology	 developers.	 Therefore,	 sensitivity	
analysis	 has	 been	 undertaken	 as	 part	 of	 both	 the	 costing	 study	
presented	 in	 Chapter	 7	 and	 the	 economic	 modelling	 in	 Chapter	 8.	
Reference	was	made	 to	both	 the	NICE	MTEP	methods	 guide	 (NICE,	
2011)	 and	 the	 ISPOR	 good	 research	 practices	 for	 parameter	
estimation	 and	 uncertainty	 (Briggs	 et	 al.,	 2012)	 to	 inform	 the	
selection	of	 the	methods.	One	way	sensitivity	analysis	was	 selected	
as	 the	method	 so	 that	 the	 impact	 of	 varying	 individual	 parameters	
can	be	seen	on	the	key	outcomes	to	provide	insight	into	the	impact	
on	both	costs	and	outcomes.	It	was	concluded	that	an	understanding	
of	the	impact	at	an	individual	level	would	be	most	beneficial	in	future	
technology	development.		
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Detailed	 information	 on	 the	 methods	 for	 the	 development	 and	
parametrisation	 of	 the	 model,	 and	 validity	 checks	 are	 included	 in	
section	8.2.	
	
3.6 Methods	for	the	Measurement	of	Healthcare	Preferences	
STI	testing	services	are	not	subject	to	gatekeeping	by	referral	from	a	
clinician,	 they	 are	 therefore	 directly	 dependent	 on	 individuals’	
preferences.	 Probabilities	 of	 uptake	 are	 key	 parameters	 within	 the	
economic	model	and	early	insight	into	the	attributes	which	are	most	
influential	 in	 determining	whether	 individuals	would	 use	 a	 new	 STI	
self-test	 and	 treatment	 pathway	 will	 therefore	 be	 helpful	 in	
informing	 product	 development	 and	 the	 assumptions	 used	 in	 any	
later	economic	modelling.	 	 It	 is	also	recognised	that	“aligning	health	
care	policy	with	patient	preferences	could	improve	the	effectiveness	
of	 health	 care	 interventions	 by	 improving	 adoption	 of,	 satisfaction	
with,	 and	 adherence	 to	 clinical	 treatments	 or	 public	 health	
programmes”	(Bridges	et	al.,	2011:404).		
	
There	are	a	wide	variety	of	approaches	that	might	have	been	used	in	
preference	 elicitation	 in	 this	 study.	 A	 summary	 of	 the	 techniques	
used	 in	 healthcare	 identified	 in	 a	 systematic	 review	 (Ryan	 et	 al.,	
2001)	is	provided	in	table	3.6.	
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Quantitative	Methods	 Qualitative	Methods	
• Ranking	Techniques	
• Simple	ranking	exercise	
• Qualitative	discriminative	process	
• Conjoint	analysis	ranking	exercises	
• Rating	Techniques	
• Rating	scales	(visual	analogue	scales)	
• Rating	scales	within	conjoint	analysis	
studies	
• Schedule	for	the	evaluation	of	
individual	quality	of	life	
• Likert	scale	
• Semantic	differential	technique	
• Guttman	scales	
• Satisfaction	surveys	
• SERVQUAL	(service	quality)	
• Choice	based	techniques	
• Simple	choice	exercise	
• Random	paired	scenarios	
• Conjoint	analysis	choice-based	
questions	(discrete	or	graded)	
• Analytic	hierarchy	process	
• Standard	gamble	
• Time	trade	off	
• Person	trade	off	
• Willingness	to	pay	
• Measure	of	value	
• Allocation	of	points	
• Individual	approaches	
• One	to	one	interviews	
• Dyadic	interview	
• Case	study	analysis	
• Delphi	technique	
• Complaints	procedures	
• Group	based	
approaches	
• Focus	groups	
• Concept	mapping	
• Citizens’	juries	
• Consensus	panels	
• Public	meetings	
• Nominal	group	
technique	
	
Table	3.6	-	Summary	of	Methods	Identified	for	Eliciting	Patient	Preferences	in	Healthcare.	
Source:	Ryan	et	al.,	2001	
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HTA	 recognises	 that	 patient	 preferences	 must	 be	 taken	 into	
consideration,	 reflecting	 the	 importance	 of	 acceptability	 of	 a	 new	
technology	 (Drummond	 et	 al.,	 2013).	 From	 the	 list	 of	 methods	
identified	 for	 capturing	 patient	 preferences	 Ryan	 and	 colleagues	
concluded	that	there	is	no	single	method	which	is	best,	but	highlight	
that	 “conjoint-based	methods	 (including	 ranking,	 rating	and	 choice-
based),	willingness	to	pay,	standard	gamble	and	time	trade-off	of	the	
quantitative	 techniques	 and	 one-to-one	 interviews,	 focus	 groups,	
Delphi	 technique	and	 citizens’	 juries	of	 the	qualitative	methods	are	
recommended”	(Ryan	et	al.,	2001:iv).		
	
More	 recently,	 Drummond	 and	 colleagues	 also	 point	 to	 the	 lack	 of	
methodological	consensus	on	how	to	incorporate	patients’	views	into	
the	HTA	process	and	called	 for	 the	development	of	methods	 in	 this	
area	 (Drummond	 et	 al.,	 2013).	 They	 propose	 the	 use	 of	 systematic	
reviews	 of	 primary	 and	 secondary	 evidence	 on	 patients’	
perspectives.		
	
Choice	 based	 methods	 are	 recognised	 as	 being	 acceptable	 to	
participants	“on	 the	basis	 that	 they	present	 them	with	 the	 types	of	
decisions	they	face	on	a	daily	basis.	It	is	this	argument	that	has	led	to	
the	choice	based	technique	being	preferred	over	ranking	and	rating	
approaches”	 (Ryan	 et	 al.,	 2001:31).	 However,	 the	 same	 review’s	
conclusions	 note	 that	 that	 choice-based	 methods	 require	 further	
exploration,	 rather	 than	 give	 an	 explicit	 recommendation	 for	 their	
use	 as	 a	 quantitative	 preference	 elicitation	 method.	 Since	 the	
publication	 of	 this	 review	 fifteen	 years	 ago	 there	 has	 been	 a	
significant	increase	in	the	use	of	this	method	within	healthcare	from	
34	studies	between	1990	and	2000,	to	179	between	2009	and	2012	
(Clark	et	al.,	2014).		
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Conjoint	analysis	based	methods	have	been	used	widely	in	a	range	of	
non-health	areas	 including	marketing	and	transport	(Hall	et	al.,	2004)	
and	 product	 development	 (Bridges,	 2003),	 with	 Hall	 and	 colleagues	
highlighting	 their	 benefit	 when	 evaluating	 “new	 products	 and	
programs	 where	 market	 information	 is	 not	 available”	 (Hall	 et	 al.,	
2004:1026).	Bridges	and	colleagues	(2011)	highlight	two	categories	of	
stated	preference	methods:	
• methods	using	ranking,	rating	or	choice	designs	which	 include	
conjoint	analysis,	discrete	choice	experiments	or	stated-choice	
methods,	and	
• methods	which	use	the	“direct	elicitation	of	monetary	values	of	
an	 intervention”	 (Bridges	 et	 al.,	 2011:404)	 which	 include	
contingent	valuation	and	willingness	to	pay	methods.	
		
Focusing	 specifically	 on	 the	definitions	 of	 the	 first	 category,	 Carson	
and	 Louviere	 (2011)	 point	 to	 inconsistency	 in	 the	 use	 of	 language	
with	 terms	 such	 as	 conjoint	 analysis	 and	DCE	used	 interchangeably	
(Carson	 and	 Louviere,	 2011).	 They	 define	 the	 origins	 of	 conjoint	
analysis	 within	 the	 marketing	 field,	 defining	 it	 as	 a	 term	 used	 to	
“refer	 to	 the	 specific	method	 of	 eliciting	 preferences	 derived	 from	
conjoint	 measurement”	 (Carson	 and	 Louviere,	 2011:5).	 In	 contrast	
they	 highlight	 that	 DCEs	 have	 a	 theoretical	 basis	 in	 random	 utility	
theory	 and	 define	 them	 as	 “	 a	 general	 preference	 elicitation	
approach	 that	asks	agents	 to	make	choice[s]	between	 two	or	more	
discrete	alternatives	where	at	least	one	attribute	of	the	alternative	is	
systematically	 varied	 across	 respondents	 in	 such	 a	 way	 that	
information	 related	 to	 preference	 parameters	 of	 an	 indirect	 utility	
function	can	be	inferred”	(ibid.	p5).	
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Bridges	points	to	a	number	of	advantages	of	using	stated	preference	
methods	 in	 health	 care	 evaluation	 over	 cost-effectiveness	 analysis.	
These	include	the	ability	of	stated	preference	methods	to	focus	on	all	
relevant	 aspects	 of	 an	 intervention	 rather	 than	 a	 single	 outcome	
measure,	 their	ability	to	 incorporate	patient/	consumer	preferences	
at	the	centre	of	the	analysis,	and	the	ability	to	compare	interventions	
and	identify	improvements	(Bridges,	2003).	It	is	also	recognised	that	
these	 methods	 can	 add	 value	 where	 population	 uptake	 is	 key	 to	
achieving	 cost-effectiveness	 through	 offering	 insight	 into	 attributes	
which	 the	 population	 value	 other	 than	 health	 outcomes,	 e.g.	
convenience,	waiting	times	(Hall	et	al.,	2004,	Ryan,	2004).		
	
Bryan	 and	Dolan	 (2004)	 consider	 some	of	 the	disadvantages	 to	 the	
use	 of	 DCEs	 in	 particular	 in	 evaluating	 health	 care,	 they	 identify	 a	
range	of	limitations	including:		
• ‘normative	 issues’	 –	 the	majority	 of	 published	 DCEs	 sample	
service	users	rather	than	the	general	population	which	limits	
their	transferability	when	considering	uptake	of	services,		
• the	‘cognitive	burden’	placed	on	respondents	and	the	number	
of	 discrete	 choices	 included	 in	 the	 survey	 may	 lead	 to	
respondents	not	completing	the	survey	accurately	
• the	generalizability	of	results	(Bryan	and	Dolan,	2004).		
	
The	use	of	conjoint	analysis	choice	based	questions	(table	3.6)	in	the	
form	 of	 a	 DCE	 approach	 was	 selected	 for	 this	 thesis	 over	 other	
preference	methods	because	it	is	a	technique	that	allows	insight	into:	
• the	relative	importance	of	a	range	of	attributes	that	make	up	
a	product	and/	or	service		
• which	attributes	people	may	be	willing	to	trade		
• the	 uptake	 of	 a	 particular	 product	 or	 service	 (Lancsar	 and	
Louviere,	2008).		
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This	method	was	recognised	as	being	particularly	valuable	within	the	
context	of	eHTA	as	it	has	the	potential	to:	
• inform	the	design	of	the	new	technology	
• offer	 insight	 into	 characteristics	 which	 will	 inform	 pathway	
design	
• provide	evidence	on	acceptability	and	potential	uptake.	
	
3.6.1 Methods	for	Conducting	the	Discrete	Choice	Experiment	
A	 DCE	 is	 a	 prospective	 mixed	 methods	 study	 that	 comprises	 a	
number	 of	 stages;	 the	 stages	 identified	 by	 Ryan	 and	 colleagues	
have	 been	 overlaid	 by	 the	 research	methods	 to	 be	 used	 in	 figure	
3.9:	
	
	
	
Figure	3.9	-	Stages	in	Conducting	a	Discrete	Choice	Experiment	(Ryan	et	al.,	2008)	
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This	 approach	 is	 defined	 as	 an	 exploratory	 sequential	 mixed	
methods	 design	 by	 Cresswell	 who	 highlights	 it	 as	 an	 approach	
which	 is	 helpful	 for	 the	 development	 of	 a	 quantitative	 survey	
instrument	 based	 on	 the	 findings	 of	 a	 qualitative	 stage	 (Creswell,	
2014).	This	is	summarised	in	figure	3.10:	
	
	
Figure	3.10	-	Exploratory	sequential	mixed	methods	design	(Cresswell,	2014:22)	
	
The	 use	 of	 a	 qualitative	 data	 collection	 stage	 for	 the	 selection	 of	
attributes	 and	 levels	 has	 varied	over	 time	with	 a	 recent	 literature	
review	of	the	use	of	DCEs	in	healthcare	identifying	that	qualitative	
methods	were	used	to	inform	attribute	selection	in	69%	of	studies	
between	 2001	 and	 2008	 and	 51%	 of	 studies	 between	 2009	 and	
2012,	and	level	selection	of	33%	and	40%	respectively	(Clark	et	al.,	
2014).		
	
The	 literature	 review	 did	 not	 indicate	 how	 included	 studies	
identified	 attributes	 and	 levels	 if	 not	 using	 qualitative	 methods,	
however,	Bridges	and	colleagues	have	 listed	potential	methods	as	
“literature	review	and	other	evidence	on	the	impact	of	the	disease	
and	 the	 nature	 of	 the	 health	 technology	 being	 assessed.	
Consultation	 with	 clinical	 experts,	 qualitative	 research	 or	 other	
preliminary	studies	can	provide	the	basis	for	identifying	the	full	set	
of	 attributes	 (and	 even	possible	 attribute	 levels)	 that	 characterize	
the	 profiles	 to	 be	 evaluated”	 (Bridges	 et	 al.,	 2011:405-406).	 The	
focus	 in	 this	 list	 is	 largely	 on	 clinical	 experts,	 whereas	 for	 the	
asymptomatic	pathway	redesign	being	considered	in	this	thesis,	the	
young	person’s	views	are	essential.		
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Qualitative	 research	 with	 young	 people	 was	 identified	 to	 be	
essential	 in	 the	 identification	 of	 attributes	 and	 levels	 in	 this	
research	with	 a	 second	 stage	 review	with	 experts	 because	 of	 the	
number	of	potential	attributes	and	levels	that	could	be	included.	In	
considering	 which	 qualitative	 research	 method	 was	 most	
appropriate	 to	 inform	 the	 selection	 of	 attributes	 for	 the	 DCE,	 a	
number	 of	 factors	 were	 taken	 into	 consideration	 as	 described	
below.	These	 included	the	topic	(STI	testing),	the	target	age	group	
for	 participation	 in	 the	 research	 (young	 people	 aged	 16-24)	 and	
how	 the	 outputs	 will	 be	 used,	 for	 example	 to	 inform	 the	
optimisation	of	service	delivery	pathways.		
	
Whilst	both	Bridges	and	colleagues	 (2011)	and	Lancsar	&	Louviere	
(2008)	acknowledge	the	contribution	of	qualitative	research	to	the	
identification	 and	 selection	 of	 attributes	 and	 levels,	 Ryan	 and	
colleagues	 (2008)	 single	 out	 focus	 groups	 as	 being	 particularly	
helpful	 in	DCEs	 to	 inform	the	 identification	of	attributes,	attribute	
levels	 and	 interaction	 effects	 (Ryan	 et	 al.,	 2008).	 Coast	 and	
colleagues	 explored	 the	 use	 of	 two	 methods	 in	 attribute	
development	(interviews	or	focus	groups)	and	concluded	that	there	
is	 a	 need	 for	 further	 research	 to	 explore	 whether	 the	 method	
chosen	leads	to	a	variance	in	attributes	selected	(Coast	et	al.,	2012).	
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Qualitative	 research	 methods	 literature	 was	 explored	 to	
understand	whether	there	were	any	notable	benefits	in	the	use	of	a	
particular	 method	 in	 undertaking	 research	 with	 the	 selected	 age	
range.	However,	there	were	no	findings	from	this	which	supported	
the	selection	of	one	method	over	another	based	on	age.	Kirk	noted	
in	 her	 literature	 review	 exploring	 methodological	 issues	 in	
conducting	 qualitative	 research	 with	 young	 people	 and	 children	
that	there	are	more	similarities	in	undertaking	qualitative	research	
with	 young	 people	 compared	 with	 adults	 than	 there	 are	
differences.	 The	 main	 differences	 relate	 to	 psychological	
development	 -	 the	 differing	 perspectives	 on	 the	 world,	 cognitive	
development	 and	 ability	 to	 communicate,	 and	 adaptation	 of	
methods	to	enable	participation	(Kirk,	2007).	
	
In	 undertaking	 qualitative	 research	 with	 young	 people	 Millward	
notes	that	there	has	been	considerable	interest	in	the	use	of	focus	
groups	to	elicit	views	from	this	population,	stating	that	the	interest	
is	 “mainly	 derived	 from	 the	potential	 of	 focus	 groups	 to	 generate	
discussion	 about	 semi-public	 issues,	 content	 that	might	 otherwise	
be	difficult	to	obtain	from	children	and	young	people	in	one-to-one	
interviews”	(Millward,	2012:435).		
	
In	 considering	 whether	 focus	 groups	 were	 the	 most	 appropriate	
method	 to	 use	 for	 DCE	 attribute	 development	 it	 was	 noted	 that	
focus	 groups	 are	 commonly	 used	 as	 a	 first	 step	 in	 general	
questionnaire	 development	 (Millward,	 2012),	 for	 exploring	
attitudes	 relating	 to	a	 specific	 topic	 (Barbour	and	Kitzinger,	1999),	
and	for	exploring	views	and	experience	of	health	services	(Kitzinger,	
1995).		
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The	benefits	that	focus	groups	offer	to	the	research	over	and	above	
other	qualitative	methods	are	 that	 the	group	situation	can	enable	
people	 to	 “explore	 and	 clarify	 their	 views”	 (Kitzinger,	 1995:299),	
reflect	 on	 the	 views	 of	 others	 and	 consider	 their	 own	 position	
further	 (Finch	 et	 al.,	 2014),	 and	 the	 method	 unsurprisingly	
encourages	 dialogue	 which	 questions,	 as	 it	 is	 highly	 unlikely	 that	
everyone	in	the	group	will	be	in	agreement	initially	(Barbour,	2007).	
However,	 a	 key	 risk	 is	 that	 the	 focus	 group	may	 stifle	 individuals	
who	disagree	with	the	majority	(Kitzinger,	1995).		
	
Methodological	texts	also	suggest	that	focus	groups	are	recognised	
as	a	method	which	 is	particularly	effective	when	tackling	sensitive	
issues	(Bowling,	2009),	with	specific	reference	made	to	research	in	
the	 area	 of	 sexual	 health	 and	 HIV	 (Barbour,	 2007,	 Barbour	 and	
Kitzinger,	 1999).	 Therefore,	 taking	 into	 consideration	 the	 benefits	
outlined	above,	 focus	groups	were	selected	over	 interviews	as	the	
method	 of	 qualitative	 research	 to	 support	 attribute	 development	
and	selection.		
	
To	 inform	the	selection	of	attributes	and	 levels	 for	 the	DCE,	 three	
separate	 but	 linked	 pieces	 of	 research	 were	 undertaken,	
summarised	in	table	3.7:	
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Table	3.7	-	Summary	of	research	undertaken	to	inform	the	selection	of	attributes	and	levels	
	
From	 the	 initial	 background	 knowledge	 acquired	 through	 the	
mapping	 of	 clinical	 pathways	 it	was	 apparent	 that	 the	 breadth	 of	
potential	 attributes	 which	 could	 be	 included	 in	 the	 DCE	 far	
outweighed	what	 is	was	 feasible	 to	 include	 in	 the	DCE	 taking	 into	
account	 both	 product	 and	 service	 characteristics.	 Therefore,	
considerable	 importance	was	placed	on	the	selection	of	attributes	
and	levels	to	minimise	the	risks	associated,	principally	respondents	
making	 assumptions	 about	 missing	 attributes	 (Klojgaard	 et	 al.,	
2012,	Lancsar	and	Louviere,	2008).		 	
Research	 Objectives	
Literature	Reviews	 • To	identify	a	long	list	of	attributes	
• To	identify	potential	levels		
• To	identify	gaps	in	knowledge		
• To	inform	the	development	of	the	focus	
groups	
Focus	Groups	 • To	identify	which	factors	are	important	
to	young	people	in	choosing	to	use	
sexual	health	services	
• To	gain	insight	into	the	reasons	for	the	
importance	of	factors	
• Rational	for	trading	between	factors	
and	prioritisation	
• How	participants	articulate	views	on	
factors		
Expert	Groups	 • To	add	current	NHS/	Policy	perspective	
to	inform	the	final	selection	of	
attributes	and	levels	for	the	DCE	
alongside	the	findings	from	the	focus	
groups	
• To	test	the	selection	of	attributes	
against	the	best	practice	requirements	
identified	by	Bridges	and	colleagues	
(Bridges	et	al.,	2011)		
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The	 detailed	methods	 for	 the	DCE	 questionnaire	 design	 stage	 are	
outlined	further	in	section	6.2.	A	generic	main	effects	questionnaire	
design	 was	 chosen	 to	 understand	 the	 component	 attributes	 of	
importance	 to	 young	 people.	 The	 questionnaire	 was	 constructed	
using	 a	 pairwise	 choice	 with	 opt	 out	 to	 reduce	 the	 risk	 of	 social	
desirability	 bias,	 using	 full	 profiles,	 that	 is,	 including	 all	 attributes	
being	 considered	 in	 the	 study.	 Cognitive	 testing	was	used	 to	pilot	
the	questionnaire	to	evaluate	the	cognitive	burden	of	questionnaire	
completion	 and	 whether	 respondents	 could	 comprehend	 the	
breadth	of	attributes	when	making	choices.	
	
3.7 Ethical	Considerations	
Ethical	approval	was	granted	by	the	Biomedical	&	Scientific	Research	
Ethics	 Committee	 (BSREC)	 at	 the	 University	 of	 Warwick	 for	 the	
studies	as	indicated	in	table	3.8:		
Study	 BSREC	Reference	 Approval	
Letter	
Patient	Preferences	for	Sexually	
Transmitted	Infection	Testing	&	
Treatment	–	Pilot	Phase	
REGO-2014-694	 Appendix	2	
Patient	Preferences	for	Sexually	
Transmitted	Infection	Testing	&	
Treatment	–	Final	DCE	
REGO-2015-1647	 Appendix	3	
Identification	of	pathways,	costs	and	
performance	monitoring	data	for	
Chlamydia	Testing	and	Treatment	
REGO-2015-1497	 Appendix	4	
Table	3.8	-	Summary	of	Ethical	Approval	
	
3.7.1.1 Consent	
Informed	 consent	 was	 recorded	 for	 all	 focus	 group,	 cognitive	
interview	and	costing	 study	participants.	A	 statement	of	 consent	
was	 included	 at	 the	 start	 of	 the	online	DCE	questionnaire	which	
made	it	clear	that	by	continuing	participants	were	consenting	for	
their	 response	 to	 be	 used	 as	 outlined	 in	 the	 participant	
information	leaflet.	
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Specific	consideration	was	given	to	the	issues	regarding	consent	of	
16-18	year	olds.	The	guidance	provided	by	the	MRC	states	that	for	
research	 covered	 by	 the	 clinical	 trials	 regulations	 a	 minor	 is	
defined	as	someone	under	the	age	of	16	and	“where	common	law	
applies	–	all	 situations	not	 covered	by	 the	Regulations	–	 the	 law	
states	that	the	age	of	majority	is	18.	Whilst	not	considered	to	have	
fully	reached	adulthood,	young	people	between	the	age	of	16	and	
18	 are	 presumed	 to	 be	 competent	 to	 give	 consent”	 (Medical	
Research	Council,	2007:23).		
	
Young	people	are	considered	competent	to	consent	to	have	sex	at	
age	 16	 and	 they	 can	 choose	 to	 access	 NHS	 STI	 testing	 and	
treatment	 services	 (including	 ordering	 postal	 chlamydia	 testing	
kits	 from	 the	 NCSP)	 without	 their	 parents	 being	 informed	 or	
requiring	their	consent.	As	the	research	involved	talking	to	16-18	
year	 olds	 about	 their	 preferences	 for	 STI	 testing	 and	 treatment	
services,	 and	 within	 the	 context	 of	 the	MRC	 guidance,	 parental	
consent	 was	 not	 required	 in	 addition	 to	 participant	 consent	 for	
this	study.		
	
3.7.1.2 Sensitivity	of	Topic	
For	 participants	 in	 the	 focus	 groups	 and	 cognitive	 testing	
interviews	 the	only	potential	 risk	 identified	was	 that	participants	
may	 regard	 the	 topic	 of	 STI	 testing	 and	 treatment	 to	 be	
embarrassing	 or	 sensitive.	 Participants	were	made	 aware	 of	 the	
topic	 in	advance	and	that	discussion	centred	on	the	attributes	of	
testing	 and	 treatment	 services,	 and	 what	 may	 influence	 their	
decision	to	use	them.	Participants	were	also	reminded	during	the	
introduction	 to	 the	 focus	group	and	 interviews	 that	 if	 they	were	
not	 comfortable	with	 answering	 a	question	or	 taking	part	 in	 the	
discussion	 they	 did	 not	 have	 to.	 For	 participants	 completing	 the	
DCE	online	the	same	issue	exists	however	they	had	the	option	to	
drop	out	of	the	questionnaire	at	any	point	prior	to	completion.	
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For	 participants	 in	 the	 costing	 study,	 no	 sensitive	 issues	 were	
identified	as	their	participation	related	directly	to	their	job	role.	
	
3.7.1.3 Expenses	&	Payments	
Participants	 in	 the	 focus	 groups	 and	 cognitive	 interviews	 were	
offered	 a	 £10	 shopping	 voucher	 in	 recognition	 of	 their	 time	
commitment.	 Participants	 in	 the	 final	 online	 DCE	 were	 offered	
reimbursement	in	accordance	with	the	predefined	criteria	used	by	
Youthsight	of	1	point	(equivalent	to	£1)	for	completion	of	a	survey	
of	 up	 to	 20	 minutes	 in	 length.	 Points	 are	 then	 exchanged	 for	
Amazon	Vouchers.	No	participant	in	the	costing	study	was	offered	
reimbursement	 as	 their	 participation	was	 linked	 directly	 to	 their	
job	role.		
	
3.8 Summary		
This	chapter	has	introduced	HTA,	specifically	eHTA	as	the	overarching	
framework	for	the	consideration	of	the	research	questions	explored	
in	 this	 thesis.	Whilst	 the	methods	 used	 for	 undertaking	HTA	 at	 the	
end	of	the	technology	development	process	(at	the	point	of	market	
access)	 are	 well	 defined	 and	 utilised	 by	 agencies	 such	 as	 NICE,	
published	 research	 on	 the	 methods	 and	 application	 of	 eHTA	 are	
limited,	particularly	in	respect	of	telemedicine,	eHealth	and	mHealth.		
It	 is	 important	 to	 recognise	 that	 the	 research	 presented	 addresses	
some,	 but	 not	 all	 aspects	 of	 eHTA,	 with	 the	 safety	 and	 clinical	
effectiveness	 of	 the	 OCCP	 and	 self-test	 being	 developed	 being	
assessed	by	other	researchers	within	the	eSTI2	consortium.	
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The	 technology	being	considered	 in	 this	 thesis	has	been	 situated	 in	
the	 appropriate	 stage	 of	 technology	 development	 to	 inform	 the	
selection	of	methods	to	address	the	research	questions.	This	chapter	
has	provided	an	overview	of	the	key	considerations	for	the	selection	
of	the	methods	to	answer	the	research	questions	within	the	context	
of	 eHTA.	 As	 outlined,	 both	 the	 DCE	 and	 economic	 evaluation	 are	
comprised	of	a	number	of	component	pieces	of	 research	which	are	
presented	in	the	following	chapters,	each	chapter	includes	a	detailed	
outline	of	 the	methods	 selected	and	 the	 justification	of	 the	choices	
made.	 The	 next	 chapter,	 Chapter	 4,	 introduces	 the	 two	 literature	
reviews	 undertaken	 to	 understand	 patient	 preferences	 for	 and	
acceptability	 of	 STI	 testing	 and	 treatment	 and	 to	 identify	 the	 ‘long	
list’	of	attributes	for	consideration	in	the	DCE.		
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4 CHAPTER	4	–	LITERATURE	REVIEWS	TO	INFORM	
SELECTION	OF	POTENTIAL	ATTRIBUTES	FOR	THE	DCE	
	
4.1 Introduction	
This	 chapter	 describes	 two	 separate	 literature	 reviews	 that	 were	
undertaken	 to	 inform	 the	 DCE	 study	 design	 and	 the	 selection	 of	 a	
‘long	list’	of	potential	attributes	for	the	DCE:	
i. a	review	of	the	use	of	stated	preference	studies	for	STI	testing	
and	 treatment	 services	 adopting	 a	 systematic	 review	
approach	
ii. a	 scoping	 review	 of	 other	 studies	 exploring	 the	 preferences	
and	acceptability	of	STI	testing	and	treatment	services.	
	
The	 literature	reviews	had	different	objectives.	The	objective	of	 the	
first	 literature	review	was	to	 identify	and	appraise	published	studies	
in	order	to	inform	the	methods	used	for	the	design	and	development	
of	 the	 proposed	 DCE	 and	 to	 explore	 evidence	 on	 which	 attributes	
influence	 patient	 and	 clinician	 preferences	 for	 the	 testing	 and	
treatment	of	STIs.	The	desired	outcomes	would	both	contribute	to	a	
‘long	list’	of	potential	attributes	and	inform	the	development	of	the	
planned	 DCE.	 The	 objective	 of	 the	 second	 literature	 review	was	 to	
identify	which	factors	influence	individuals’	decisions	to	access	testing	
and	 treatment	 services	 for	 STIs.	 The	 desired	 outcome	 of	 this	
literature	review	was	solely	to	contribute	to	the	‘long	list’	of	potential	
attributes	for	the	DCE.	
	
Consideration	 was	 given	 to	 the	 methods	 for	 undertaking	 the	
literature	 reviews	using	Grant	&	Booth’s	 typology	of	 reviews	 (Grant	
and	Booth,	2009).	For	the	first	review	a	systematic	review	approach	
was	 adopted,	 which	 conformed	 to	 the	 methods	 outlined	 in	 the	
Cochrane	 Handbook	 for	 the	 Systematic	 Review	 of	 Interventions	
(Higgins	and	Green,	2011)	where	possible.		
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For	 the	 second	 review	 a	 scoping	 review	 was	 undertaken.	 This	 is	
defined	 by	 Grant	 and	 Booth	 as	 “a	 preliminary	 assessment	 of	 the	
potential	 size	 and	 scope	 of	 available	 research	 literature.	 It	 aims	 to	
identify	the	nature	and	extent	of	research	evidence	(usually	including	
ongoing	research)”	(Grant	and	Booth,	2009:101).	A	weakness	of	this	
approach	 is	that	 it	does	not	 include	an	assessment	of	the	quality	of	
studies	which	may	lead	to	bias,	however	since	the	aim	of	this	second	
review	was	to	add	to	the	‘long	list’	of	potential	attributes,	the	quality	
of	 a	 study	 was	 less	 relevant.	 The	 overall	 aim	 was	 to	 produce	 a	
comprehensive	list	of	potential	attributes	to	form	the	framework	for	
focus	group	discussion.		
	
Adapting	the	approach	in	the	Cochrane	Handbook	and	the	Preferred	
Reporting	Items	for	Systematic	Reviews	and	Meta-Analysis	(PRISMA)	
statement	 (Moher	 et	 al.,	 2009),	 review	 processes	 consisted	 of	 the	
following	stages:	
• defining	the	review	question	and	formulating	the	criteria	 for	
including	studies;	
• literature	searches;	
• selection	of	studies	to	include	in	the	review;	
• data	extraction;		
• quality	assessment;	
• synthesis.	
	
Quality	 assessment	 was	 undertaken	 for	 the	 first	 review	 only,	
recognising	 the	 aim	 was	 to	 learn	 from	 the	 application	 of	 stated	
preference	methods	 to	 inform	 the	 design	 and	 development	 of	 the	
planned	 DCE	 as	 well	 as	 the	 creation	 of	 a	 ‘long	 list’	 of	 potential	
attributes.		
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4.2 Literature	Review	I:	Use	of	Stated	Preference	Studies	for	
STI	Testing	&	Treatment	Services	
As	outlined	in	the	previous	section	the	objective	of	the	first	literature	
review	 was	 to	 identify	 and	 appraise	 published	 studies	 exploring	
which	 attributes	 influence	 patient	 and	 clinician	 preferences	 for	 the	
testing	and	treatment	of	STIs.		
	
4.2.1 Methods	Adopted	for	the	Literature	Review	
The	inclusion	criteria	were	identified	as:	
• any	stated	preference	study	within	the	scope	of	STI	 testing	
and	treatment	services.	This	included	but	was	not	limited	to	
products	 (e.g.	 tests,	 drugs,	 condoms,	 microbicides)	 and	
services	 (e.g.	 screening	 and	 screening	 programmes,	 and	
service	providers	e.g.	GPs,	CaSH	clinics	and	GUM	clinics);	
• There	 was	 no	 date	 limiter,	 with	 all	 published	 studies	
included	to	end	of	2014.	
	
Exclusion	criteria	included	studies:	
• not	related	to	humans;	
• not	published	in	English;	
• from	 outside	 of	 the	 OECD	 High	 Income	 Countries	 (see	
Appendix	5	for	list);	
• not	 related	 to	 the	 diagnosis	 or	 treatment	 of	 STIs	 (e.g.	
vaccinations).		
	
The	 review	 was	 registered	 in	 the	 International	 Register	 of	
Prospective	 Systematic	 Reviews	 (PROSPERO),	 reference	
CRD42014014862.	
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4.2.2 Search	Strategy	
The	following	databases	were	searched	on	28	April	2014	to	identify	
studies	published	to	the	end	of	2013,	the	saved	database	searches	
were	 re-run	 in	 April	 2015	 to	 search	 for	 any	 studies	 meeting	 the	
inclusion	 criteria	 published	 between	 1	 January	 and	 31	 December	
2014	and	no	further	studies	were	identified:	
• Medline	
• EMBASE	
• CINAHL	
• Web	of	Science	
• Econlit	
• PsycINFO	
• Cochrane	Library	(incorporating	the	following	databases):	
o Cochrane	Database	of	Systematic	Reviews	
o Cochrane	Central	Register	of	Controlled	Trials	
o Cochrane	Methodology	Register	
o Database	of	Abstracts	of	Reviews	of	Effects	
o Health	Technology	Assessment	Database	
o NHS	Economic	Evaluation	Database	
	
The	key	search	terms	and	their	abbreviated	database	entry	(where	
applicable)	 are	 summarised	 in	 table	 4.1.	 	 Search	 terms	 were	
identified	from	books	and	published	research	outlining	methods	for	
DCEs	(Ryan	et	al.,	2008,	McIntosh	et	al.,	2010,	Lancsar	and	Louviere,	
2008,	 Bridges	 et	 al.,	 2011,	 Clark	 et	 al.,	 2014).	 Searches	 were	
structured	 to	 meet	 the	 search	 requirements	 of	 the	 respective	
database	and	terms	expanded	where	the	facility	existed	to	do	this.		
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Category	 Search	Terms	Entered	
STIs	 Sexually	transmitted	
STI	
STD	
Sexual	health	
	 AND	
Stated	 Preference	
Studies	
Stated	preference	
Stated	choice	
Discrete	choice	
DCE	
Conjoint	analysis	
Contingent	valuation	
Willingness	to	pay	
WTP	
Willingness	to	accept	
WTA	
Visual	analogue	scale	
VAS	
Rating	scale	
Magnitude	estimation	
Standard	gamble	
Time	trade	off	
TTO	
Person	trade	off	
PTO	
Functional	measurement	
Paired	comparison	(pairwise	comparison*)	
Pairwise	choice	(pairwise	choice*)	
Conjoint	measurement	
Part	worth	utilities	(part	worth	util*)	
Conjoint	studies	(conjoint	stud*)	
Conjoint	choice	
Choice	exercise	(choice	exercise*)	
Random	paired	scenario	(scenario*)	
Payment	card	
Allocation	of	point	(allocation	of	point*)	
Analytic	hierarchy	process	
Measure	of	value	
Table	4.1	-	Search	Terms	
An	 example	 search	 strategy	 from	 Medline	 is	 included	 in	
Appendix	 6.	 Individual	 STIs	 (e.g.	 Chlamydia)	 were	 not	
included	 in	 the	 search	 strategy,	 as	 it	 was	 determined	 that	
attributes	and	levels	could	potentially	be	identified	from	any	
STI/	sexual	health	product	or	service.	
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The	 results	 were	 imported	 into	 Endnote	 x6	 for	 Mac	 and	
duplicates	 removed.	 Abstracts	 were	 reviewed	 and	 articles	
excluded	for	the	reasons	identified	in	section	4.3.1.	
	
4.2.3 Search	Results	
The	initial	search	identified	4,657	records	and	312	duplicates	were	
removed	 in	Endnote	 leaving	4,345	for	 initial	 review.	The	titles	and	
abstracts	were	reviewed	for	each	exclusion	criterion	in	turn;	leaving	
a	total	of	10	studies	that	met	the	inclusion	criteria.	Bibliographies	of	
the	 included	 papers	 were	 then	 reviewed	 and	 this	 identified	 a	
further	two	studies	which	met	the	 inclusion	criteria	 (Phillips	et	al.,	
2002,	Ryan	and	Watson,	2009),	 taking	the	total	number	of	studies	
included	 to	 12.	 A	 second	 reviewer	 confirmed	 that	 all	 studies	met	
the	 inclusion	 criteria.	 The	 search	 results	 are	 illustrated	 in	 the	
PRISMA	flowchart,	figure	4.1.	
	
The	reasons	for	the	exclusion	of	studies	at	the	screening	stage	are	
summarised	in	table	4.2:	
Reasons	for	Exclusion	at	Screening	Stage	 Number	of	
Studies	Excluded	
Studies	that	do	not	relate	to	STI	testing	and	
treatment	services	
3,532	
Not	a	stated	preference	study	 785	
Not	a	high	income	study		 6	
Studies	not	related	to	mainstream	service	delivery	
e.g.	vaccination	
12	
	 Table	4.2	-	Reasons	for	the	Exclusion	of	Papers	at	Screening	Stage	
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Figure	4.1	-	PRISMA	Flowchart	of	Included	Studies	
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4.2.4 Data	Extraction	
The	 data	 extraction	 form	 was	 designed	 to	 take	 into	 account	 the	
review	 question.	 It	 captured	 key	 study	 characteristics	 and	 the	
quality	 requirements.	 Recognising	 the	 benefits	 of	 electronic	 data	
capture	 “Use	 of	 an	 electronic	 form	 has	 the	 added	 advantage	 of	
being	able	to	combine	data	extraction	and	data	entry	into	one	step,	
and	 to	 facilitate	data	analysis	and	 the	production	of	 results	 tables	
for	 the	 final	 report”	 (Centre	 for	 Reviews	 and	 Dissemination,	
2009:Section	 1.3.3).	 The	 data	 extraction	 form	 is	 included	 in	
Appendix	7.	These	forms	were	reproduced	in	Excel	for	Mac	2011	to	
facilitate	 data	 analysis.	 Data	 extraction	 was	 checked	 by	 a	 second	
reviewer.		
	
4.2.5 Key	Findings	
In	 total	 12	 studies	 met	 the	 inclusion	 criteria;	 six	 focusing	 on	 STI	
testing	 (general	 STI	 testing,	 HIV	 testing	 and	 chlamydia	 screening),	
four	 exploring	 preferences	 for	 STI	 treatment	 (HIV	 and	 genital	
herpes)	 and	 two	 exploring	 preferences	 for	 an	 intervention	 to	
prevent	the	transmission	of	STIs	(microbicide	development).	These	
are	 summarised	within	 the	 context	 of	 a	 sexual	 health	 pathway	 in	
figure	 4.2.	 Of	 studies	 included:	 11	 focused	 on	 the	 patient/service	
user	 perspective	 and	 one	 explored	 a	 clinician	 perspective;	 eight	
focused	 on	 existing	 services/	 treatments	 and	 four	 explored	 the	
introduction	 of	 new	 options	 (POCT,	 Self-testing	 for	 HIV	 and	
microbicide	use	for	STI	prevention).		
	
Two	of	the	studies	contained	a	strong	methods	perspective,	that	is	
the	primary	focus	of	the	publication	was	on	exploring	the	method,	
rather	 than	 reporting	 the	 study	 findings	 themselves	 –	 adaptive	
conjoint	 analysis	 (Beusterien	 et	 al.,	 2005),	 and	 comparison	 of	
payment	 card	 contingent	 valuation	 and	 DCE	 (Ryan	 and	 Watson	
2009).			
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A	 summary	 of	 the	 studies	 included	 in	 the	 review	 is	 presented	 in	
table	4.3.	
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Figure	4.2	-	Included	Studies	Grouped	by	Stages	in	the	Sexual	Health	Pathway.	
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Table	4.3-	Summary	of	Included	Studies	
	
	 	
Ref	 Author	 Study	Focus	 Type	of	Stated	
Preference	Study	
Year	of	
study	
Country	of	
study	
Sample	
Size	
1	 Albus	et	al.	
(2005)	
	
Preferences	for	
medical	and	
psychosocial	
support	in	HIV	
infected	patients	
Conjoint	Analysis	 2001	 Germany	 163	
2	 Beusterien	et	
al.	(2005)	
	
Patient	
preferences	for	HIV	
medications	
Adaptive	Conjoint	
Analysis	
Not	
stated	
USA	 35	
3	 Hauber	et	al.	
(2009)	
	
	
Preferences	of	
Antiretroviral-
Naïve	African	
Americans	for	HIV	
Treatments	
Conjoint	Analysis	 2006-
2007	
USA	 153	
4	 Hsieh	et	al.	
(2011)		
Qualities	of	a	POCT	
for	clinicians	and	
others	offering	STI	
testing	
Discrete	Choice	
Experiment	
2009	 Worldwide	
(majority	
USA)	
218	
5	 Llewellyn	et	
al.	(2013)	
	
Service	preferences	
for	testing	for	STIs	
Discrete	Choice	
Experiment		
2011	 England	 233	
6		 Miners	et	al.	
(2012)	
User	preferences	
for	STI	testing	
services	
Discrete	Choice	
Experiment		
2010	 England	 3358	
7	 Phillips	et	al.	
(2002)	
	
User	preferences	
for	HIV	test	
methods	
Conjoint	Analysis	 1999-
2000	
USA	 365	
8	 Ryan	and	
Watson	
(2009)	
	
Women’s	
preferences	for	
chlamydia	
screening	
Payment	Card	
Contingent	
Valuation	
Discrete	Choice	
Experiment	
Not	
stated	
Scotland	 174	
9	 Scalone	et	al.	
(2011)		
	
	
Patient	
preferences	for	
genital	herpes	
treatment	
Discrete	Choice	
Experiment	
2004	 UK	&	USA	 154	
10	 Tanner	et	al.	
(2008)		
	
Vaginal	
Microbicide	
Preferences	
Conjoint	Analysis	 Not	
stated	
USA	 405	
11	 Watson	et	
al.,	(2009)	
Experience	factors	
in	the	provision	of	
chlamydia	
screening	
Discrete	Choice	
Experiment		
2002	 Scotland	 126	
12	 Young	Holt	
et	al.	(2006)	
	
Microbicide	
preference	among	
young	women	in	
California	
Conjoint	analysis	 Not	
stated	
USA	 321	
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Of	the	included	studies,	five	were	reported	as	DCEs,	six	as	conjoint	
analysis	(one	of	which	was	adaptive	conjoint	analysis)	and	one	as	a	
comparison	between	a	DCE	and	payment	card	contingent	valuation.	
There	 were	 significant	 differences	 in	 the	 sample	 sizes	 included	 –	
from	35	(reported	as	an	adaptive	conjoint	analysis	feasibility	study)	
to	3,358	(large	scale	DCE	across	a	number	of	service	delivery	sites).		
	
Table	4.4	summarises	the	range	of	attributes	and	demographic	sub-
groups	 included.	Not	unsurprisingly	 given	 the	 focus	of	 the	 studies	
there	is	a	spread	in	the	type	of	characteristics	considered:	
• Service	 Characteristics	 (Albus	 et	 al.,	 2005,	 Llewellyn	 et	 al.,	
2013,	Miners	et	al.,	2012)		
• Product	Characteristics	(Hsieh	et	al.,	2011,	Young	Holt	et	al.,	
2006,	Tanner	et	al.,	2008)		
• Mix	of	Service	&	Product	Characteristics	(Phillips	et	al.,	2002,	
Ryan	and	Watson	2009,	Watson	et	al.,	2009)	
• Medication	 Characteristics	 and	 Side	 Effects	 (Beusterien	 et	
al.,	2005,	Scalone	et	al.,	2011,	Hauber	et	al.,	2009).		
	
It	 should	 be	 noted	 that	 of	 the	 studies	 included,	 Llewellyn	 et	 al	
(2013)	used	the	questionnaire	developed	by	Miners	et	al	(2012)	 in	
their	 study	 (and	 acknowledge	 this),	 and	 the	 attributes	 and	 levels	
used	 in	 the	 Ryan	 and	 Watson	 (2009)	 and	 Watson	 et	 al	 (2009)	
studies	were	the	same,	although	there	was	no	explicit	statement	in	
either	paper	acknowledging	this.		
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There	has	 been	 some	debate	over	 the	use	of	 a	 ‘cost’	 attribute	 to	
assess	willingness-to-pay	 (WTP)	 in	 conjoint	analysis,	particularly	 in	
countries	 like	 the	 UK	 where	 healthcare	 is	 free	 at	 the	 point	 of	
delivery.	 	 Clark	 and	 colleagues	 noted	 that	 the	 “proportion	 of	DCE	
studies	using	either	a	‘per	WTP’	or	a	‘monetary	welfare	measure’	as	
their	 primary	 outcome	 has	 fallen”	 (Clark	 et	 al	 2014:13)	 and	
suggested	that	 this	could	be	due	to	concerns	regarding	the	use	of	
DCEs	to	obtain	WTP	and	the	presentation	of	attributes	within	DCEs	
(ibid.).	
	
Of	 the	 four	 identified	 studies	 undertaken	 solely	 in	 the	 UK,	 two	
included	 a	 cost	 attribute	 (Ryan	 and	Watson,	 2009,	Watson	 et	 al.,	
2009)	 and	 two	 studies	 excluded	 a	 cost	 attribute	 (Llewellyn	 et	 al.,	
2013,	Miners	et	al.,	2012).	Miners	and	colleagues	highlighted	that	a	
cost	 attribute	 was	 excluded	 because	 “strong	 objections	 to	 the	
notion	of	‘cost’	in	the	context	of	STI	testing	were	raised	in	most	of	
the	 focus	 groups”	 (Miners	 et	 al.,	 2012:511).	 Ryan	 and	 Watson’s	
paper	compared	the	use	of	payment	card	contingent	valuation	and	
a	DCE	to	elicit	WTP	data	from	the	same	sample,	whilst	Watson	and	
colleagues	 paper	 included	 cost	 of	 screening	 as	 one	 of	 the	 five	
attributes	in	their	DCE.	Neither	reported	concerns	over	inclusion	of	
a	cost	attribute	within	their	papers,	however	neither	indicated	that	
they	 had	 included	 patients	 or	 public	 in	 the	 selection	 of	 the	
attributes	for	inclusion	within	the	studies.	
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Ref	 Author	 Study	Focus	 Attributes	 Demographics	
1	 Albus	et	
al.,	(2005)	
	
Preferences	for	medical	and	
psychosocial	support	in	HIV	
infected	patients	
• Information	
• Counselling	
• Consultation	Hours	
• Age	
• Sex	
• Ethnicity	
• Time	since	diagnosis	
• Treatment	in	this	clinic	
• Matriculation	standard	
• Currently	employed	
• Receiving	pension	
• Income	less	than	€1,000	
2	 Beusterien	
et	al.,	
(2005)	
	
Patient	preferences	for	HIV	
medications	
• Moderate	to	severe	diarrhoea	
• Moderate	to	severe	nausea	
• Moderate	to	severe	vomiting	
• Moderate	to	severe	rash	
• Moderate	to	severe	jaundice	
• Moderate	to	severe	dizziness	
• Moderate	to	severe	depression	
• Moderate	to	severe	sleep	problems	
• Virologic	failure	
• Increasing	cholesterol	
• Chance	of	developing	resistance	
• Regimen	convenience	
	
• Ethnicity	
• Employment	status	
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Ref	 Author	 Study	Focus	 Attributes	 Demographics	
3	 Hauber	et	
al.	(2009)	
	
	
Patient	Preference	for	HIV	
treatments	
• Chance	that	medicine	doesn’t	work	
• Chance	of	allergic	reaction	
• Chance	of	bone	damage	
• Chance	of	kidney	damage	
• What	happens	if	you	have	bone	or	kidney	
damage	
• Age	
• Gender	
• Highest	Education	Level	
• Employment	Status	
• Years	of	HIV	Positive	Status	
4	 Hsieh	et	
al.,	(2011)	
Qualities	of	a	POCT	for	clinicians	
and	others	offering	STI	testing	
• Sensitivity	
• Specificity	
• Cost		
• Time	
• Gender	
• Country/Continent	of	Residence	
• Profession	
• Location	of	Practices	
• Primary	Practice	
• Medicaid/	Medicare	Provider	
5	 Llewellyn	
et	al.,	
(2013)	
	
Service	preferences	for	testing	
for	STIs	
• Time	to	appointment	
• Results	waiting	time	
• Comprehensiveness	of	results	
• Staff	knowledge	
• Comprehensiveness	of	testing	
• Results	reporting	method	
	
	
• Age	
• Sex	
• Ethnicity	
• Sexual	Preference	
• Believes	currently	has	STI	symptoms	
• Previous	STI	test	
• Previous	treatment	for	STI	
• Previously	tested	at	GP	surgery	
• Previously	testing	at	STI/GUM	clinic	
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Ref	 Author	 Study	Focus	 Attributes	 Demographics	
6	 Miners	et	
al.,	(2012)	
User	preferences	for	STI	testing	
services	
• Time	to	appointment	
• Results	waiting	time	
• Comprehensiveness	of	results	
• Staff	knowledge	
• Comprehensiveness	of	testing	
• Results	reporting	method	
• Age	
• Sex	
• Ethnicity	
• Sexual	Preference	
• Highest	Qualification	
• Employment	Status	
• Number	of	Previous	STI	Tests	
• Number	of	Previous	STI	Treatments	
• Believes	currently	has	STI	Symptoms	
7	 Phillips	et	
al.,	(2002)	
	
User	preferences	for	HIV	test	
methods	
• Location	
• Price	
• Ease	of	Collection	
• Timeliness/Accuracy	
• Privacy/	Anonymity	
• Counselling	
• Age	
• Gender	
• Ethnicity	
• Sexual	Preference	
• Education	
• Income	
8	 Ryan	and	
Watson,	
(2009)	
	
Women’s	preferences	for	
chlamydia	screening	
• Place	of	Screening	
• Type	of	Screening	Test	
• Cost	to	you	of	Screening	Test	
• Risk	of	Pelvic	Inflammatory	Disease	(PID)	
if	you	have	Chlamydia	and	are	not	
treated	
• Support	of	trained	health	care	advisor	
when	you	receive	results	
• Age	
• Employment	
• Education	
• Income	
• Relationship	Status	
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Ref	 Author	 Study	Focus	 Attributes	 Demographics	
9	 Scalone	et	
al.,	(2011)	
	
	
Patient	preferences	for	genital	
herpes	(GH)	treatment	
• Chance	of	a	GH	recurrence	in	the	next	12	
months	
• Chance	of	transmission	of	GH	virus	to	an	
uninfected	partner	in	the	next	12	months	
• Chance	of	becoming	infected	with	HIV	in	
the	next	12	months	
• Number	of	tablets	taken	daily	
• Number	of	tablets	taken	daily	during	
each	recurrence	
• Cost	of	GH	treatment	per	month	
• Gender	
• Age	
• Marital	Status	
• Relationship	Status	
• Income	
• Age	at	Diagnosis	of	GH	
• Number	of	outbreaks	in	previous	12	months	
• Number	of	subjects	according	to	the	number	of	
outbreaks	
• Time	from	the	last	outbreak	to	heal	
• Level	of	pain/discomfort	during	outbreaks	
• No	of	GP/STI	clinic	visits	in	last	12	months	
• Current	medication	for	GH	
• Satisfaction	with	treatment	
10	 Tanner	et	
al.,	(2008)	
	
Microbicide	Preferences	among	
adolescent	women	
• Contraception	
• Timing	
• Side	Effects	
• Target	STIs	
• Age	
• Race	
• Ethnicity	
• Sexual	Intercourse	
• Hormonal	Contraceptive	Use	
11	 Watson	et	
al.,	(2009)	
	
Experience	factors	in	the	
provision	of	chlamydia	screening	
• Place	of	Screening	
• Type	of	Screening	
• Cost	to	you	of	Screening	
• Risk	of	PID	
• Support	of	a	Trained	Health	Care	Advisor	
	
• Age	
• Employment	
• Education	
• Income	
• Method	of	Contraception	
• Relationship	Status	
• Smoker	
• Previously	diagnosed	with	Chlamydia	
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Ref	 Author	 Study	Focus	 Attributes	 Demographics	
12	 Young	
Holt	et	al	
(2006)	
	
Microbicide	preference	among	
young	women	in	California	
• Spectrum	of	disease	protection	
• Method	of	distribution	
• Efficacy	levels	
• Applicator	type	
• Leakage/	messiness	
• Duration	of	activity		
• Race/	ethnicity	
• Age	
• Relationship	status	
• Ever	had	an	STI	
• Concern	about	STIs	
• Pregnancy	
• Concern	about	pregnancy	
• Type	of	sex	practiced	with	steady	partner	
• Type	of	sex	practiced	with	casual	partner	
• Condom	use	
Table	4.4	-	Attributes	and	Demographics	Analysed	
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4.2.6 Quality	Assessment	
No	 reporting	 checklist	 was	 identified	 which	 was	 suitable	 for	
assessing	 the	 reporting	 of	 stated	 preference	 studies.	 	 Literature	
reviews	 of	 DCEs	 in	 health	 economics	 (Ryan	 and	 Gerard,	 2003,	 de	
Bekker-Grob	 et	 al.,	 2010,	 Clark	 et	 al.,	 2014)	 centred	 primarily	 on	
three	key	aspects:	experimental	design,	estimation	procedures	and	
validity	 because	 of	 the	 ongoing	 methodological	 debate	 in	 these	
areas	 (de	Bekker-Grob	et	al.,	2010).	These	 literature	 reviews	were	
helpful	 in	 understanding	 advances	 in	 the	 methodology	 and	
utilisation	 of	 DCEs	 over	 time	 but	 did	 not	 offer	 insight	 into	 the	
quality	or	recommend	good	practice	for	reporting	of	studies.		
	
The	 International	 Society	 for	 Pharmacoeconomics	 and	 Outcomes	
Research	(ISPOR),	recognised	the	benefit	that	a	“structure	to	guide	
the	 development,	 analysis	 and	 publication	 of	 conjoint	 analyses	 in	
health	care	studies”	would	offer,	established	a	task	force	to	explore	
good	research	practices	for	conjoint	analysis	 (Bridges	et	al.,	2011).	
The	 intent	of	 the	checklist	produced	was	 to	offer	a	view	on	 ‘good	
research	 practice’	 rather	 than	 define	 best	 practice	 (ibid.).	 A	 pilot	
evaluation	 of	 the	 ISPOR	 checklist	 on	 articles	 published	 between	
1980	 and	 2008	 found	 that	 studies	 generally	 reported	 less	 than	
suggested	by	the	checklist,	in	particular	in	the	areas	of	methods	to	
generate	 experimental	 design	 and	 reporting	 design	 properties	
(Marshall	et	al.,	2009).		
	
In	considering	how	to	assess	the	quality	of	articles	 included	 in	the	
present	 review,	 reference	 was	 made	 to	 the	 EQUATOR	 network	
‘Library	 of	 Health	 Research	 Reporting’	 (EQUATOR	Network,	 2014)	
and	the	Critical	Appraisal	Skills	Programme	(CASP)	(Critical	Appraisal	
Skills	 Programme,	 2014).	 The	 ISPOR	 checklist	was	 selected	 as	 it	 is	
equally	 applicable	 to	 DCEs	 and	 other	 types	 of	 conjoint	 analysis	
(Bridges	et	al.,	2011).		 	
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It	should	be	noted	that	all	of	the	studies	included	were	commenced	
prior	to	the	publication	of	the	final	ISPOR	checklist	and	that	the	lack	
of	reporting	in	an	article	does	not	mean	that	the	criterion	was	not	
adequately	 considered	 in	 the	 study	 design	 and	 development.	 In	
utilising	 the	 checklist	 consideration	 was	 given	 to	 the	 30	 sub-
questions	 under	 the	 10	 items	 on	 the	 checklist	 because	 of	 the	
breadth	of	good	practice	cited	under	each	heading	on	the	checklist,	
to	identify	whether	there	were	common	themes	at	a	lower	level.	A	
full	 breakdown	 of	 the	 checklist	 is	 included	 in	 Appendix	 8	 and	
summarised	at	an	aggregated	level	in	the	following	sections.		
	
4.2.6.1 Research	Question	
All	of	the	studies	set	out	a	research	question	although	this	was	not	
always	presented	 in	 the	 form	of	a	 testable	hypothesis.	However,	
in	all	cases	the	question	enabled	a	hypothesis	to	be	deduced.		
	
The	 context	 of	 the	 study	 was	 clear	 and	 the	 study	 perspective	
described	 (for	 example	 patient	 or	 healthcare	 professionals’	
perspective)	 in	 11	 of	 the	 12	 included	 studies.	 However,	 the	
rationale	 for	 using	 conjoint	 analysis	 was	 not	 always	 clearly	
identified	(three	out	of	twelve),	in	particular	why	it	was	preferred	
to	other	methods	which	could	be	used	(Bridges	et	al.,	2011).		
	
4.2.6.2 Attributes	&	Tasks	
The	majority	 of	 the	 studies	 (nine	 out	 of	 twelve)	 provided	 some	
information	 on	 the	 approach	 used	 to	 identify	 the	 attributes	
included	 in	 the	 study.	Methods	 used	 included	 literature	 review,	
gathering	 information	 on	 the	 product	 e.g.	 side	 effects,	 and	
consultation	with	clinical	experts.		
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Of	the	studies	involving	patients/	service	users,	seven	(Albus	et	al.,	
2005,	 Hauber	 et	 al.,	 2009,	 Llewellyn	 et	 al.,	 2013,	 Miners	 et	 al.,	
2012,	 Phillips	 et	 al.,	 2002,	 Tanner	 et	 al.,	 2008,	 Young	Holt	 et	 al,	
2006)	 undertook	 qualitative	 research	 with	 users	 to	 inform	 the	
development	of	 their	questionnaire.	 It	 should	be	noted	 that	one	
study	(Llewellyn	et	al.,	2013)	included	no	information	on	attribute	
selection	 and	 construction	 of	 tasks,	 instead	making	 reference	 to	
the	study	published	by	Miners	and	colleagues	(2012).		
	
Of	the	twelve	studies	 included,	seven	centred	on	‘real’	attributes	
and	 five	 introduced	 a	 hypothetical	 element,	 for	 example,	
extended	 service	 offer	 (Albus	 et	 al.,	 2005,),	 POCT	 parameters	
(Hsieh	 et	 al.,	 2011),	 HIV	 self-testing	 (Phillips	 et	 al.,	 2002)	 and	
product	characteristics	of	microbicides	(Tanner	et	al.,	2008,	Young	
Holt	et	al.,	2006).		
	
The	 numbers	 of	 attributes	 and	 levels	 varied	 significantly	 across	
the	studies.	The	range	in	the	number	of	attributes	was	from	three	
to	 twelve,	 with	 five	 of	 the	 studies	 having	 six	 attributes.	 The	
number	 of	 levels	 within	 each	 attribute	 again	 varied	 significantly	
with	 the	 range	 being	 two	 to	 nine.	 Good	 practice	 (Bridges	 et	 al.,	
2011)	suggests	 that	 the	 inclusion	and	exclusion	of	attributes	and	
levels	should	be	clearly	justified.	In	the	studies	reviewed	there	was	
only	 one	 (Miners	 et	 al.,	 2012)	 which	 provided	 examples	 of	 the	
selection	and	de-selection	of	attributes.	In	respect	of	the	selection	
of	levels	some	evidence	was	provided	in	nine	studies	but	no	study	
provided	a	clear	justification	of	the	level	selection	for	all	included	
attributes.		
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4.2.6.3 Construction	of	Tasks,	Experimental	Design	&	Preference	
Elicitation	
These	 sections	 of	 the	 checklist	 cover	 aspects	 that	 centre	 on	 the	
justification	of	the	experimental	design	including	whether	a	full	or	
partial	 profile	 was	 selected,	 the	 number	 of	 profiles	 included	 in	
each	 task,	 whether	 an	 opt-out	 option	 was	 considered	 and	
whether	 the	 number	 of	 conjoint	 tasks	 included	was	 appropriate	
(Bridges	 et	 al.,	 2011).	 It	 also	 includes	 whether	 appropriate	
information	was	given	 to	explain	 the	questionnaire	and	whether	
an	appropriate	elicitation	format	was	used.		
	
In	 all	 studies	 limited	 information	 was	 provided	 on	 these	 topic	
areas	 with	 only,	 for	 example,	 three	 studies	 (Albus	 et	 al.,	 2005,	
Phillips	 et	 al.,	 2002,	 Young	 Holt	 et	 al.,	 2006)	 providing	 a	 full	
justification	of	the	number	of	attributes	and	profiles	 in	each	task	
and	only	 three	 studies	 (Llewellyn	et	al.,	2013,	Ryan	and	Watson,	
2009,	 Scalone	 et	 al.,	 2011)	 discussing	 the	 use	 of	 an	 opt	 out	 or	
status	quo	question.	
	
The	reporting	of	consideration	of	alternative	experimental	designs	
was	 limited	with	only	 two	studies	 (Miners	et	al.,	2012,	Ryan	and	
Watson,	 2009)	 discussing	 this	 issue	 in	 detail,	 although	 a	 further	
four	made	 a	 brief	 reference	 to	 experimental	 design.	 Half	 of	 the	
studies	reported	consideration	of	the	number	of	conjoint	tasks	to	
be	 included	 in	 the	 study.	 Of	 the	 DCEs	 included,	 all	 used	 paired	
choice	 with	 two	 providing	 an	 opt	 out	 to	 take	 account	 of	 a	
participant	preferring	a	no	test/	no	treatment	option	(Llewellyn	et	
al.,	 2013,	 Scalone	 et	 al.,	 2011).	 The	 number	 of	 choice	 questions	
ranged	from	nine	to	24.	Of	the	twelve	studies	reviewed:	
• three	used	 rating	 scales	 (Albus	et	al.,	2005,	Tanner	et	al.,	
2008,	Young	Holt	et	al.,	2006),	
• one	 included	 questions	 based	 on	 ranking,	 rating	 and	
choice	(Beusterien	et	al.,	2005),		
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• four	used	paired	choices	(Hauber	et	al.,	2009,	Hsieh	et	al.,	
2011,	Miners	et	al.,	2012,	Phillips	et	al.,	2002),	
• two	used	paired	 choices	 and	an	opt	out	 (Llewellyn	et	 al.,	
2013,	Scalone	et	al.,	2011),	
• two	used	binary	choice	(yes/no)	for	each	individual	profile	
(Ryan	and	Watson	2009,	Watson	et	al.,	2009).	
	
In	 respect	 of	 preference	 elicitation	 very	 little	 information	 was	
provided	in	articles	on	the	motivation	and	explanation,	elicitation	
format	 or	 qualifying	 questions,	 and	 where	 reported	 this	 only	
covered	part	of	the	conjoint	analysis	checklist	sub-question.		As	a	
result	 it	 is	 difficult	 to	 comment	on	how	 studies	 addressed	 these	
aspects.	In	section	10,	the	checklist	points	to	the	option	available	
(in	 most	 cases)	 of	 publishing	 the	 questionnaire	 on	 the	 journal’s	
website	 as	 supplementary	 data	 (Bridges	 et	 al.,	 2011);	 of	 the	
studies	 included	 only	 three	 (Hsieh	 et	 al.,	 2011,	 Scalone	 et	 al.,	
2011,	Watson	et	al.,	2009)	published	supplementary	information.	
	
4.2.6.4 Instrument	Design	&	Data	Collection	
All	 studies	 recognised	 the	 importance	 of	 eliciting	 socio-
demographic	and	health	status	information	to	enable	exploration	
of	 preferences	based	on	 these	 criteria.	All	 of	 the	 studies	 (where	
the	 study	 included	 both	 sexes)	 except	 one	 (Beusterien	 et	 al.,	
2005)	 considered	 gender	 a	 key	 demographic.	Of	 the	 five	 studies	
which	 explored	 STI	 testing	 with	 service	 users	 (Llewellyn	 et	 al.,	
2013,	Miners	et	al.,	2012,	Phillips	et	al.,	2002,	Ryan	and	Watson,	
2009,	Watson	 et	 al.,	 2009)	 two	 studies	 considered	 previous	 STI	
testing	 history	 (Llewellyn	 et	 al.,	 2013,	 Miners	 et	 al.,	 2012)	 and	
three	 studies	 sought	 information	 on	 the	 sexual	 preference	 of	
participants	(Llewellyn	et	al.,	2013,	Miners	et	al.,	2012,	Phillips	et	
al.,	2002).		
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With	 respect	 to	 the	 provision	 of	 contextual	 information	 to	
respondents	to	ensure	that	they	have	a	consistent	understanding	
of	 the	 attributes	 and	 levels	 within	 the	 tasks,	 very	 limited	
information	was	provided,	with	only	one	study	(Young	Holt	et	al.,	
2006)	providing	sufficient	information	about	this	within	the	article	
to	 enable	 assessment	 against	 the	 checklist	 criteria.	 Similarly,	
limited	 information	 was	 provided	 on	 the	 level	 of	 burden	 of	 the	
data	 collection	 instrument	 with	 the	 published	 information	
predominantly	 relating	 to	 the	 incentive	 for	 participating	 in	 the	
study	(Beusterien	et	al.,	2005,	Llewellyn	et	al.,	2013,	Young	Holt	et	
al.,	2006).	
	
In	 terms	 of	 data	 collection,	 five	 of	 the	 studies	 reported	 some	
justification	of	the	sampling	strategy	and	inclusion	criteria.	Sample	
size	 is	 perhaps	 the	 element	 of	 the	 sample	 recruitment	 strategy	
which	 is	 worthiest	 of	 discussion	 within	 this	 section.	 All	 papers	
reported	 their	 sample	 size,	 and	 the	majority	 commented	on	 the	
basis	 for	 including/	 excluding	 returned	 questionnaires	 e.g.	
incomplete	 responses	 (Albus	 et	 al.,	 2005,	 Hsieh	 et	 al.,	 2011,	
Phillips	 et	 al.,	 2002),	 illogical	 responses	 (Miners	 et	 al.,	 2012,	
Beusterien	 et	 al.,	 2005),	 identical	 ratings	 for	 all	 profiles	 (Young	
Holt	 et	 al.,	 2006).	 As	 noted	 in	 table	 4.3	 there	 are	 significant	
variations	for	sample	size	in	the	studies	included	in	the	literature	
review	–	from	35	to	3,348.		
	
The	 good	 practice	 checklist	 cites	 Orme’s	 recommendation	 of	
“sample	sizes	of	at	least	300	with	a	minimum	of	200	respondents	
per	group	for	subgroup	analysis”	(Bridges	et	al.,	2011:409).	On	this	
basis	 it	 can	 be	 seen	 that	 only	 a	 third	 of	 the	 studies	 exceed	 the	
suggested	 minimum	 number	 of	 responses	 (Miners	 et	 al.,	 2012,	
Phillips	 et	 al.,	 2002,	 Tanner	 et	 al.,	 2008	 and	 Young	 Holt	 et	 al.,	
2006).	
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In	addition,	 it	 should	be	noted	 that	all	 studies	used	convenience	
samples,	and	of	the	nine	studies	based	on	patients/	service	users	
only	 two	 studies	 incorporated	 people	 without	 the	 condition	 or	
those	who	were	not	 current	 service/	product	users	 (Llewellyn	et	
al.,	2013,	Young	Holt	et	al.,	2006).		
	
In	terms	of	questionnaire	completion,	there	were	varied	methods	
used	 across	 the	 12	 studies	 with	 one	 study	 using	 face-to-face	
completion	with	trained	interviewer	(Young	Holt	et	al.,	2006),	five	
completion	of	paper	based	questionnaires	in	waiting	rooms	(Albus	
et	 al.,	 2005,	 Miners	 et	 al.,	 2012,	 Phillips	 et	 al.,	 2002,	 Ryan	 and	
Watson,	 2009,	 Watson	 et	 al.,	 2009),	 three	 were	 on	 line	
questionnaires	 (Hsieh	et	al.,	2011,	Llewellyn	et	al.,	2013,	Scalone	
et	al.,	2011),	two	used	a	computer	guided	self-interview	technique	
(Beusterien	et	al.,	2005,	Tanner	et	al.,	2008)	and	one	did	not	state	
the	method	used	(Hauber	et	al.,	2009).		
	
With	regards	to	ethical	considerations	all	studies	bar	two	(Scalone	
et	 al.,	 2001,	 Tanner	 et	 al.,	 2008)	 included	 information	 on	 ethics	
approval	within	the	published	article.	
	 	
4.2.6.5 Statistical	Analyses,	Results	&	Conclusions	
Across	 the	 12	 studies,	 all	 reported	 the	 characteristics	 of	 the	
respondent	sample,	although	consideration	of	the	generalizability	
of	 results	was	more	 limited.	Due	 to	 the	methods	used	 to	 recruit	
participants,	none	had	information	on	people	who	had	declined	to	
complete	 the	 survey	 making	 comparisons	 between	 responders	
and	non-responders	impossible.		
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Half	of	the	studies	used	respondent	characteristics	to	inform	sub-
group	analysis	but	only	two	reported	the	results	of	statistical	tests	
undertaken	on	 the	 sample	population.	 In	one,	 logistic	 regression	
was	used	to	assess	whether	there	were	any	statistically	significant	
differences	 between	 demographic	 groups	 which	 predicted	
completeness	of	response	(Miners	et	al.,	2012)	and	in	the	other	a	
Kruskal-Wallis	 test	 was	 used	 to	 assess	 significant	 differences	
between	 the	 “characteristics	 of	 the	 full	 and	 reduced	 samples”	
(Ryan	and	Watson,	2009:394).	
	
The	majority	of	 studies	 (nine	out	of	 twelve)	 reported	 the	 checks	
undertaken	on	 validity,	with	more	 than	one	 check	being	used	 in	
some	cases.	Checks	included:	
• Face	 validity	 of	 the	 results/	 Consistency	 with	 theoretical	
predictions	(Beusterien	et	al.,	2005,	Llewellyn	et	al.,	2013,	
Miners	 et	 al.,	 2012,	 Phillips	 et	 al.,	 2002,	 Scalone	 et	 al.,	
2011),		
• Percentage	 of	 questions	 answered	 illogically/	 consistency	
check	 (Beusterien	 et	 al.,	 2005,	 Llewellyn	 et	 al.,	 2013,	
Miners	et	al.,	2012,	Phillips	et	al	2002,	Ryan	and	Watson,	
2009,	Young	Holt	et	al.,	2006),		
• Selection	 of	 same	 option/	 monotone	 response	 (Albus	 et	
al.,	2005,	Ryan	and	Watson,	2009,	
• Tests	for	dominance	(Hauber	et	al.,	2009,	Llewellyn	et	al.,	
2013,	Miners	et	al.,	2012.	
	
Only	one	study	explored	external	validity	(Watson	et	al.,	2009)	by	
offering	 the	participants	an	option	of	 screening	 reflecting	one	of	
the	 profiles	 in	 the	 study	 immediately	 following	 questionnaire	
completion.	This	was	achieved	by	the	respondent	completing	the	
questionnaire	in	the	waiting	room	of	a	family	planning	clinic.		
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Just	over	half	of	the	studies	reported	whether	effects	and	dummy	
coding	 was	 used	 for	 variables,	 with	 three	 using	 effects	 coding	
(Phillips	et	al.,	2002,	Ryan	and	Watson,	2009,	Watson	et	al.,	2009),	
four	 using	 dummy	 coding	 (Hsieh	 et	 al.,	 2011,	 Llewellyn	 et	 al.,	
2013,	Miners	et	al.,	2012,	Young	Holt	et	al.,	2006)	and	five	(Albus	
et	al.,	2005,	Beusterien	et	al.,	2005,	Hauber	et	al.,	2009,	Scalone	et	
al.,	2011,	Tanner	et	al.,	2008)	not	reporting	the	method	used.		
	
Again,	there	was	variation	in	the	models	used	to	analyse	the	data	
and	 the	 primary	 outcome	measures	 reported,	 as	 summarised	 in	
table	4.5:	
	
Ref	 Author	 Questionnaire	
Type	
Model	Used	 Primary	Reported	
Outcome(s)	
1	 Albus	et	al.,	
(2005)	
	
Rating	Scale	 Not	stated	–	
Sawtooth	Software	
(CVA	system)	used	
for	analysis	
Relative	healthcare	
preferences	derived	from	
conjoint	analysis.	No	unit	
of	measure	indicated	
2	 Beusterien	
et	al.,	
(2005)	
	
Paired	Choice	 Not	stated	–	ACA	
Version	3.5	
(Sawtooth	Software	
Inc.)	generated	utility	
values	for	all	levels	
included	
Median	“percent	
importance”	estimates	for	
each	attribute	
3	 Hauber	et	
al.	(2009)	
	
	
Paired	Choice	 Multivariate,	random	
parameters,	or	mixed	
logit	regression	
Importance	ratings	for	
each	attribute	(including	
95%	CI)	
Maximum	acceptable	risk	
(including	95%	CI)	
4	 Hsieh	et	al.,	
(2011)	
Paired	Choice	 Conditional	Logistic	
Regression	
Odds	Ratio	and	p<0.05	for	
each	attribute	level	
5	 Llewellyn	et	
al.,	(2013)	
Paired	Choice	
with	Opt	Out	
Multinomial	Logistic	
Regression	
Odds	Ratio,	95%	CI	and	p-
value	for	each	attribute	
level	
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Ref	 Author	 Questionnaire	
Type	
Model	Used	 Primary	Reported	
Outcome(s)	
6	 Miners	et	
al.,	(2012)	
Paired	Choice	 Random	Effects	
Logistic	Regression	
Unadjusted	Odds	Ratios,	
95%	CI	and	p-value	for	
each	attribute	level	
Adjusted	Odds	Ratios,	95%	
CI	and	p-value	for	each	
attribute	level	(adjusted	
for	age,	sex,	CASH,	MSM,	
no	of	previous	tests,	
symptoms	of	STIs,	
education	and	
employment	status)	
	
	
Odds	Ratios	for	sub-group	
preferences	with	95%	CI	
7	 Phillips	et	
al.,	(2002)	
	
Paired	Choice	 Random	Effects	
Probit	Model	
Coefficient,	standard	
error,	WTP	compared	to	
baseline	with	95%	CI	for	
each	attribute	level	
8	 Ryan	and	
Watson,	
(2009)	
	
Binary	Choice	 Logit	Model		 Coefficient	and	t-statistic	
for	basic	model	and	
income	interaction	model,	
maximum	WTP	estimates	
with	95%	CI	for	each	
attribute	level	
9	 Scalone	et	
al.,	(2011)	
	
	
Paired	Choice	
with	Opt	Out	
(no	
treatment)	
option	
Mixed	Logit	Model	 Estimated	means	and	
standard	deviation	of	
coefficients	
Maximum	willingness	to	
pay	mean	and	95%	CI	
Predicted	uptake	rates	for	
treatment	options	in	
different	cost	scenarios	
10	 Tanner	et	
al.,	(2008)	
	
Rating	Scale	 Not	stated	 Part	worth	utility	scores	
for	each	attribute	level	
11	 Watson	et	
al.,	(2009)	
	
Binary	Choice	 Logit	Model	 Coefficient	and	t-statistic	
for	basic	model	and	
interaction	model,	mean	
WTP	estimates	with	95%	
CI	for	each	attribute	level	
Predicted	test	uptake	
12	 Young	Holt	
et	al	(2006)	
	
Rating	Scale	 Logistic	Regression	 Median	relative	
importance	of	attributes	
Median	of	attribute	level’s	
part	worths	
Table	4.5	-	Summary	of	model	used	and	primary	reported	outcomes	
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Although	 Bridges	 and	 colleagues	 provide	 a	 brief	 summary	 of	
models	that	can	be	used	in	conjoint	analysis	(Bridges	et	al.,	2011),	
they	 do	 not	 offer	 an	 opinion	 on	 a	 preferred	model	 for	 different	
scenarios.	 This	 has	 been	 considered	 in	more	 detail	 by	 Ryan	 and	
colleagues	 who	 outlined	 the	 strengths	 and	 weaknesses	 of	
different	model	types	and	suggested	binary	probit	or	logit	models	
for	 binary	 choice	 and	 paired	 choice	 questionnaires,	 and	
multinomial	 logit	 model	 for	 scenarios	 involving	 three	 or	 more	
choices	(Ryan	et	al.,	2008).	For	the	studies	included	in	the	present	
review,	 where	 a	 model	 was	 specified	 in	 the	 article	 these	 were	
consistent	 with	 the	 categorisation	 outlined	 by	 Ryan	 and	
colleagues.		
	
The	majority	of	studies	reported	their	findings	within	the	context	
of	the	original	research	question,	although	four	(Albus	et	al.,	2005,	
Beusterien	 et	 al.,	 2005,	 Hsieh	 et	 al.,	 2011,	 Tanner	 et	 al.,	 2008)	
either	 did	 not	 clearly	 report	 their	 results	 or	 the	 statistical	
uncertainty	 associated	 with	 results.	 All	 studies	 presented	
conclusions	 supported	 by	 evidence	 and	 the	 majority	 situated	
these	 within	 the	 context	 of	 existing	 published	 findings.	 All	
discussed	the	limitations	of	their	study	and	all	but	two	(Beusterien	
et	 al,	 2005,	Hauber	et	 al.,	 2009)	discussed	 the	generalizability	of	
findings.				
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4.2.6.6 Study	Presentation	
The	 final	 area	of	 the	 checklist	 relates	 to	 the	presentation	of	 the	
study	 (Bridges	 et	 al.,	 2011).	 In	 all	 cases	 the	 papers	 clearly	
articulated	a	perceived	need	for	the	study,	identifying	gaps	in	the	
literature	that	had	been	addressed.		In	terms	of	the	presentation	
of	the	study,	there	was	a	notable	difference	in	the	construction	of	
articles	between	 journals,	 in	particular	 those	published	 in	health	
economic	 journals	 (Beusterien	 et	 al.,	 2005,	 Ryan	 and	 Watson,	
2009,	 Watson	 et	 al.,	 2009)	 compared	 with	 specialist	 clinical	
journals,	 however	 the	 summary	 of	 the	 assessment	 against	 the	
checklist	 (Appendix	 8)	 did	 not	 identify	 any	 pattern	 of	 reporting	
specific	 to	 health	 economic	 journals	 compared	 with	 specialist	
clinical	 journals.	 The	 checklist	 identifies	 the	 need	 to	 ensure	 the	
definition	of	terms	used.	This	was	something	not	consistently	seen	
across	the	articles.		
	
The	 checklist	 also	 highlights	 that	 “a	 reviewer	 cannot	 provide	 a	
meaningful	review	of	a	conjoint	analysis	paper	without	seeing	the	
format	 and	 framing	 of	 the	 questions	 that	 generated	 the	 data.”	
(Bridges	et	al.,	2011:411).	As	highlighted	only	 two	studies	 (Hsieh	
et	al.,	2011,	Scalone	et	al.,	2011)	 included	the	questionnaire	as	a	
supplementary	 document	 on	 the	 journal’s	 website,	 although	
Watson	and	colleagues	(2009)	stated	that	it	could	be	provided	on	
request.		
	
Finally	all	papers	provided	some	information	on	the	impact	of	the	
research	either	in	terms	of	the	methodology	or	the	significance	of	
the	 results	 for	 service	 providers,	 technology	 manufacturers	 or	
policy	makers.		
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4.2.7 Discussion	
The	review	highlighted	a	number	of	considerations	for	the	design	of	
the	DCE	including:	
• Selection	 of	 attributes	 and	 levels	 –	 a	 priority	 for	 the	 DCE	
being	 developed	 is	 that	 it	 considers	 the	 impact	 of	 new	
technology	on	existing	service	pathways,	that	 is,	action	can	
be	taken	as	a	result	of	the	findings	to	improve	services;	
• Sampling	 strategy	 –	 to	 reflect	 the	 point	 highlighted	 above,	
to	realise	the	economic	and	public	health	benefit,	a	primary	
consideration	 needs	 to	 be	 understanding	 the	 needs	 of	
people	who	have	not	previously	accessed	services	as	well	as	
the	selection	of	subgroups	for	analysis;	
• Background	information	and	explanation	of	tasks	–	this	was	
not	an	area	which	was	easy	to	assess	in	the	reviewed	studies	
owing	 to	 the	 lack	 of	 information	 in	 articles,	 however,	 to	
minimise	 the	 risks	 associated	 with	 assumptions	 regarding	
potential	attributes	not	 included	 in	the	DCE	 is	one	which	 is	
essential.	
	
The	 studies	 reviewed	 varied	 in	 the	 degree	 to	 which	 they	 were	
applicable	to	all	stages	of	a	model	of	fully	remote	online	provision	
(Pathway	 E,	 figure	 2.1).	 Of	 the	 studies	 identified,	 only	 one	
considered	self-testing	 (Phillips	et	al.,	2002).	This	 is	self-testing	 for	
HIV,	 an	 incurable	 STI,	 which	 may	 in	 turn	 be	 an	 attribute	 which	
influences	 whether	 people	 would	 want	 to	 self-test.	 This	 was	
undertaken	at	a	time	when	self-testing	for	HIV	was	in	development	
but	before	the	technology	was	FDA	approved,	and	before	the	time	
that	smartphones	were	available	as	a	possible	solution	for	this	type	
of	testing.	One	study	considered	POCT	(Hsieh	et	al.,	2011),	however	
the	sample	for	this	study	was	clinicians	who	currently	undertake	STI	
testing	rather	than	the	population	being	tested.	
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Two	studies	considered	self-sampling	for	chlamydia	screening	(Ryan	
and	Watson,	2009,	Watson	et	al.,	2009)	both	of	which	 found	 that	
screening	 at	 home	 “decreases	 the	 general	 preference	 for	
screening”	(Watson	et	al.,	2009:622).	Two	studies	(Llewellyn	et	al.,	
2013,	 Miners	 et	 al.,	 2012)	 explored	 preference	 for	 testing	 within	
the	 context	 of	 current	 STI	 services	 but	 did	 not	 incorporate	
hypothetical	 scenarios	 based	 on	 new	 technology	 e.g.	 POCT,	 self-
testing	or	treatment	availability	via	an	eHealth/mHealth	solution.		
	
Whilst	 Phillips	 and	 colleagues	 identified	 that	 “instant	 home	 tests	
would	become	at	least	as	preferred	as	the	baseline	scenario	(public	
clinic	 tests)	 if	 they	were	highly	 accurate	 and	 cost	 $10”	 (Phillips	 et	
al.,	 2002:1697),	 no	 studies	 were	 identified	 which	 explored	
preferences	 for	 testing	 for	 STIs	 incorporating	 the	 potential	 new	
options	 offered	 by	 rapid	 POCT	 in	 community	 locations	 or	 self-
testing.		
	
Within	the	studies	identified	which	considered	STI	testing,	only	one	
study	 (Llewellyn	 et	 al.,	 2013)	 sought	 to	 include	 non-service	 users	
within	 the	 sample,	 all	 other	 samples	 were	 drawn	 from	 people	
known	to	have	the	condition,	current	service	users	or	attendees	for	
other	 linked	 services	e.g.	 family	planning.	This	 is	 significant	within	
the	 context	 of	 new	 technology	 development	 for	 asymptomatic	
pathways	 where	 the	 economic	 and	 public	 health	 benefit	 may,	 in	
part,	 be	 delivered	 through	 increasing	 the	 uptake	 of	 testing	 and	
treatment.		
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Applying	 the	 ISPOR	 good	 practice	 checklist	 as	 a	 mechanism	 for	
assessing	 the	 quality	within	 the	 reporting	 of	 the	 conjoint	 analysis	
provided	 a	 useful	 framework	 for	 exploring	 the	 strengths	 and	
weaknesses	 of	 the	 studies.	 One	 of	 the	 main	 limitations	 in	 the	
majority	of	published	studies	was	a	lack	of	justification	provided	for	
the	chosen	options	e.g.	attribute	selection,	choice	of	experimental	
design,	mode	of	administration.	This	was	also	reflected	in	a	review	
of	 conjoint	 analysis	 studies	 for	 colorectal	 cancer	 screening	 which	
applied	 the	 ISPOR	 checklist	 as	 a	 framework	 for	 reviewing	 the	
studies	(Ghanouni	et	al.,	2013).	
	
Finally,	 the	 findings	 from	 the	 literature	 review	 also	 point	 to	 a	
number	of	potential	attributes	(table	4.4)	to	be	included	in	the	‘long	
list’	 for	 the	discrete	choice	experiment	 including	 test	performance	
characteristics,	time	to	result,	range	of	STIs	tested	for	and	location	
of	 services.	 These	 were	 explored	 in	 more	 detail	 in	 the	 second	
literature	review.	
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4.3 Literature	Review	II	–	Preferences	and	Acceptability	of	
Main	Stream	Sexual	Health	Services	
As	 outlined	 in	 section	 4.1	 the	 objective	 of	 the	 second	 literature	
review	 was	 to	 identify	 which	 factors	 might	 influence	 individuals’	
decisions	 to	 access	 testing	 and	 treatment	 services	 for	 STIs.	 The	
desired	 outcome	 of	 this	 literature	 review	was	 to	 contribute	 to	 the	
‘long	list’	of	potential	attributes	for	the	DCE.	
	
The	rationale	for	broadening	the	literature	search	is	in	recognition	of	
the	broader	preference	elicitation	techniques	identified	by	Ryan	and	
colleagues	(2001),	which	could	inform	the	identification	of	attributes	
including	research	published	on	acceptability,	patient	choice,	uptake	
and	access.	
	
Attributes	 can	 be	 defined	 as	 the	 product	 specific	 features	 that	 are	
evaluated	 in	 the	 DCE	 and	 levels	 are	 the	 variation	 within	 each	
attribute	 (Szeinbach	 et	 al.,	 2011).	 Attributes	 are	 comprised	 of	 a	
number	 of	 levels	 (e.g.	 for	 time	 to	 result,	 the	 levels	 would	 be	 a	
selection	 of	 times	 to	 result).	 Levels	 must	 be	 “plausible,	 actionable	
and	capable	of	being	traded”	(Ryan,	1999:445).	Ryan	and	colleagues	
note	 that	 there	 are	 no	 specific	 rules	 for	 determining	 the	 attributes	
and	levels	included	in	a	DCE,	defining	a	good	experiment	as	one	“that	
has	a	sufficiently	rich	set	of	attributes	and	choice	contexts,	together	
with	 enough	 variation	 in	 the	 attribute	 levels	 necessary	 to	 produce	
meaningful	 behavioural	 responses	 in	 the	 context	 of	 the	 strategies	
under	study”	(Ryan	et	al	2008:17).	
	
Other	 key	 issues	 relating	 to	 attribute	 development	 have	 been	
identified	by	Coast	and	colleagues	as:	
• “What	should	attributes	look	like?	
• Should	qualitative	methods	be	used	and	to	what	extent?	
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• What	 are	 the	 advantages	 and	 disadvantages	 of	 different	
qualitative	methods	for	developing	attributes?	
• How	 should	 attribute	 development	 be	 reported?”	 (Coast	 et	
al.,	2012:732).	
	
	
4.3.1 Methods	Adopted	for	Literature	Review	
Learning	was	applied	from	the	review	of	stated	preference	studies	
in	 determining	 the	 inclusion	 and	 exclusion	 criteria	 for	 this	 second	
scoping	 review.	 In	 particular,	 in	 the	 selection	 of	 studies	 involving	
product	characteristics	for	new	technologies.	
	
The	inclusion	criteria	were	identified	as:	
• any	 study	 which	 indicates	 individuals’	 preferences	 or	
acceptability	of	STI	testing	and/	or	treatment	services	
• studies	published	between	Jan	2004-Sept	2014	
• conference	 abstracts,	 where	 the	 abstract	 enabled	 the	
extraction	of	information	on	study	focus	and	key	findings.		
	
The	date	 range	 for	 the	 literature	 review	was	 selected	 to	 limit	 the	
volume	of	results	identified	to	the	last	10	years.	This	recognised	the	
fact	 that	 the	 previous	 literature	 review	 only	 identified	 one	 stated	
preference	 study	 which	 met	 the	 inclusion	 criteria	 pre-2004,	 and	
that	 none	 of	 the	 studies	 identified	 included	 relevant	 new	
technologies	e.g.	internet	or	smartphone	based	services.		
	
The	exclusion	criteria	were	identified	as	any	study:	
• not	published	in	English	
• not	related	to	humans	
• not	related	to	preferences	for	sexual	health	services	
• from	 outside	 of	 the	 OECD	 High	 Income	 Country	 List	 (see	
Appendix	5)	
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• not	 related	 directly	 to	 testing	 and/	 or	 treatment	 provision	
e.g.	drug	characteristics,	health	promotion	interventions		
• not	 offering	 a	 perspective	 provided	 by	 service	 user/	
potential	service	user	e.g.	clinician	
• focused	on	non-mainstream	service	provision	e.g.	STI	testing	
in	 A&E,	 dedicated	 service	 provision	 for	 specific	 high	 risk	
groups	 such	 as	 men	 recently	 released	 from	 prison,	 sex	
workers,	injecting	drug	users.	
	
4.3.2 Search	Strategy	
The	key	search	terms	included	were:	
• Sexually	 transmitted	 infections,	 sexually	 transmitted	
diseases,	sexual	health	
• Test,	treatment,	service	
• Patient	preference,	acceptability,	choice,	uptake,	access.	
	
Individual	 STIs	 (e.g.	 Chlamydia)	 were	 not	 included	 in	 the	 search	
strategy,	 as	 it	 was	 determined	 that	 attributes	 and	 levels	 could	
potentially	 be	 identified	 from	 any	 STI/	 sexual	 health	 product	 or	
service.	The	Medline	search	strategy	is	included	in	Appendix	9.	
	
A	smaller	selection	of	databases	was	chosen	for	this	scoping	review,	
with	 the	 databases	 selected	 being	 those	 which	 had	 generated	 a	
high	return	rate	of	relevant	articles	in	the	first	literature	review	and	
encompassing	 journals	 where	 research	 relating	 to	 nursing,	 AHPs	
and	psychology	is	published.		
The	three	databases	searched	were:	
• Medline	
• CINAHL	
• PsycINFO.	
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4.3.3 Search	Results	
The	 initial	 search	 identified	 8,057	 records	 and	 1,057	 duplicates	
were	removed	in	Endnote	leaving	6,959	for	initial	review.	The	titles	
and	abstracts	were	reviewed	by	a	single	reviewer	for	each	exclusion	
criterion	 in	turn;	 leaving	a	total	of	135	studies	 for	 full	 text	 review.	
Three	papers	were	excluded	at	 this	 stage,	 resulting	 in	132	 studies	
identified.	 Given	 the	 volume	 of	 papers	 meeting	 the	 inclusion	
criteria	 a	 bibliographic	 search	 of	 included	 studies	 was	 not	
undertaken.	 The	 search	 results	 are	 presented	 in	 the	 PRISMA	
flowchart	 in	 figure	4.3.	Reasons	 for	 the	exclusion	of	papers	at	 the	
screening	stage	are	outlined	in	table	4.6,	and	at	the	full	text	review	
stage	in	table	4.7.	
	
Reasons	for	Exclusion	at	Screening	Stage	 Number	of	Studies	
Excluded	
Studies	that	do	not	relate	to	preferences	for	
sexual	health	services	
6,664	
Not	OECD	High	Income	Country	 67	
Studies	that	do	not	relate	directly	to	testing	and	
treatment	provision	e.g.	drug	properties,	side	
effects,	health	promotion	interventions		
42	
Studies	that	do	not	focus	on	mainstream	service	
provision	e.g.	STI	testing	in	EMU	or	A&E,	or	are	
dedicated	service	provision	for	specific	high	risk	
groups	e.g.	men	recently	released	from	prison,	
sex	workers,	injecting	drug	users	
51	
Table	4.6	-	Reasons	for	the	exclusion	of	papers	at	screening	stage	
	
Study	Excluded	 Reason	
Menon-Johansson	et	al	
(2010)	
Study	based	on	activity	data	not	patient	
preference	
O’Dowd	(2011)	 Commentary	on	a	report	published	by	
the	Health	Protection	Agency	
Sonnenberg	et	al	(2013)	 Study	does	not	include	data	on	
preferences	for	accessing	testing	and	
treatment	services	
Table	4.7	-	Reasons	for	exclusion	of	studies	at	full	text	review	stage	
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Figure	4.3	-	PRISMA	Flowchart	of	Included	Studies	
	
4.3.4 Data	Extraction	
As	the	purpose	of	the	review	was	to	identify	potential	attributes	for	
inclusion	in	the	DCE	the	data	extraction	was	limited	to	the	following	
characteristics:		
• study	focus	
• study	type	
• population	studied	
• country	of	study	
• key	findings.		
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Studies	were	then	categorised	based	on	the	following	parameters:	
• Parameter	 1	 -	 population	 studied	 –	 service	 users,	 general	
population,	unclear,	
• Parameter	2	-	whether	the	study	considered	HIV	only,	
• Parameter	 3	 -	 whether	 the	 study	 focused	 on	 product	 or	
service	 characteristics,	 or	 values	 beliefs,	 perceptions	 and	
behaviours,	
• Parameter	 4	 -	 whether	 the	 study	 focused	 on	 a	 single	
product	 or	 characteristic	 or	whether	 it	 encompassed	more	
than	one	aspect	of	the	pathway	in	figure	2.1,	
• Parameter	 5	 -	 whether	 the	 study	 introduced	 a	 “new	
technology”.	New	technologies	were	defined	to	include:	the	
internet,	point-of-care	testing	and	self-testing.		
	
All	 studies,	 which	 focused	 on	 product	 or	 service	 characteristics,	
were	examined	in	greater	detail.	Data	was	extracted	on	the	primary	
focus	of	the	study.	Studies	were	categorised	as:	
o self-sampling	
o self-sampling	(home-testing	pathways)	
o HIV	POCT/	rapid	testing	
o POCT	–	Other	STIs	
o HIV	self-testing	
o other	STI	self-testing	
o test	location	
o test	collection	point	
o results	notification	
o consultation	method	
o treatment	location	
o partner	notification	
o clinic	models	
o multiple	aspects	of	pathway	
o other.	
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Finally,	 using	 the	 information	 extracted,	 potential	 attributes	 or	
factors	informing	attributes	were	drawn	out	from	the	literature.		
	
The	 data	 was	 extracted	 into	 an	 Excel	 spreadsheet	 for	 analysis.	 A	
review	of	 the	quality	 of	 the	papers,	 examination	of	 bias	 and	data	
analysis	 was	 not	 undertaken	 as	 the	 outcome	 of	 this	 would	 not	
change	the	identification	of	potential	attributes	for	inclusion	in	the	
DCE.	A	 summary	of	all	 included	studies	which	 shows:	 study	 focus,	
key	 findings,	 potential	 attributes	 and	 factors	 informing	 attributes	
identified	is	included	in	Appendix	10.	
	
4.3.5 Key	Findings	
Of	 132	 papers	 reviewed,	 broadly	 equal	 numbers	 (57	 versus	 62)	
were	 classified	 under	 Parameter	 1	 as	 service	 users	 and	 general	
population	 respectively	 (43%	 versus	 47%).	 In	 13	 studies	 the	
population	 studied	was	 unclear;	 in	 a	 number	 of	 cases	 these	were	
systematic	reviews	which	included	studies	from	both	classifications.	
Thirty-one	studies	(23%)	considered	HIV	only	(Parameter	2).	
	
The	majority	of	studies	identified,	93	(70%),	focused	on	product	and	
service	 characteristics,	 whilst	 30%	 focused	 on	 values,	 beliefs,	
perceptions	 and	 behaviours	 relating	 to	 accessing	 sexual	 health	
services,	 but	 did	 not	 report	 specifically	 on	 product	 or	 service	
characteristics.	 Four	 of	 the	 93	 focused	 on	 product	 and	 service	
characteristics	 also	 included	 some	 findings	 in	 respect	 of	 values,	
beliefs,	perceptions	and	behaviours	(Parameter	3).		
	
Of	 the	 93	 studies	 reporting	 on	 acceptability	 or	 preferences	 for	
product	 or	 service	 characteristics,	 77	 studies	 (83%)	 focused	 on	 a	
single	 product	 or	 service	 characteristic	 e.g.	 self-sampling,	 location	
of	test,	results	notification,	and	31	studies	(33%)	introduced	a	new	
technology	(Parameter	4).		
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The	primary	focus	of	studies	was	categorised	as	shown	in	table	4.8:	
Study	Category	 Number	of	
Studies	
Percentage	
of	Studies	
Self-Sampling	 7	 8%	
Self-Sampling	(home-testing	pathways)	 10	 11%	
HIV	POCT/	Rapid	Testing	 9	 10%	
POCT	other	STIs	 3	 3%	
HIV	Self-Testing	 6	 6%	
Other	STI	Self-Testing	 3	 3%	
Test	Location	 17	 18%	
Test	Collection	Point	 1	 1%	
Results	Notification	 6	 6%	
Consultation	Method	 2	 2%	
Treatment	Location	 1	 1%	
Partner	Notification	 7	 8%	
Clinic	Models	 7	 8%	
Multiple	Aspects	of	Pathway	 13	 14%	
Other	 2	 2%	
Table	4.8	-	Categorisation	of	Study	Focus	of	Included	Studies	(note	percentages	do	not	sum	
to	100%	due	to	rounding)	
	
Whilst	a	number	of	 the	 studies	 identified	 include	 the	 introduction	
of	a	new	technology	(Parameter	5)	including	use	of	some	aspects	of	
eHealth	and	mHealth	these	did	not	reflect	all	the	core	features	of	a	
fully	 integrated	 online	 pathway,	 particularly	 online	 treatment	
consultation.	 In	 respect	 of	 remote	 self-testing,	 reviewing	 the	 22	
studies	which	considered	sampling	methods	for	STIs	other	than	HIV,	
analysis	 identified	 that	 self-testing/	 self-sampling	 was	 acceptable,	
see	table	4.9.	
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Analysis	 of	 the	 93	 studies	 which	 focused	 on	 product	 or	 services	
characteristics	shows	that	17	(18%)	focused	on	some	aspect	of	self-
sampling,	 12	 (13%)	 on	 POCT	 and	 nine	 (10%)	 on	 aspects	 of	 self-
testing,	see	table	4.8.	A	total	of	17	(18%)	focused	on	test	 location.	
Only	 six	 (6%)	 focused	on	 the	 next	 stage	 in	 the	 pathway	 shown	 in	
figure	 2.1,	 results	 notification.	 The	 consultation	 method	 and	
treatment	 location	 were	 considered	 in	 three	 (3%)	 of	 studies	 and	
partner	notification	in	seven	(7%),	other	studies	focused	on	clinical	
models	or	multiple	aspects	of	the	pathway	in	figure	2.1.	
Study	Findings	 Studies	
Studies	finding	self-
testing	acceptable	
Huppert	et	al.	(2012)	
Krause	et	al.	(2013)		
Studies	finding	self-
sampling	acceptable		
Brown	et	al.	(2010)	
Doshi	et	al.	(2008)	
Fernando	and	Thompson	(2013)	
Fielder	et	al.	(2013)	
Gaydos	et	al.	(2006)	
Gotz	et	al.	(2005)	
Graseck	et	al.	(2010b)	
Graseck	et	al.	(2010a)	
Hoebe	et	al.	(2006)	
Iles	and	Oakeshott	(2005)	
Jones	et	al.	(2013)	
Llewellyn	et	al.	(2009)	
Rosenberger	et	al.	(2011)	
Saunders	et	al.	(2012)	
Shih	et	al.	(2011)	
Soni	and	White	(2011)	
Wayal	et	al.	(2009)	
Studies	finding	clinician	
collected	samples	
preferred	
Anhang	et	al.	(2005)	
Basta	et	al.	(2009)	
Roth	et	al.	(2011)	
Table	4.9	-	Summary	of	Published	Studies	on	the	Acceptability	of	Self-Sampling	
and	Self-Testing	
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Table	 4.10	 provides	 more	 details	 on	 the	 findings	 of	 studies	
considering	 a	 preference	 for	 testing	 location.	 These	 included	 the	
studies	 considering	 preferences	 for	 where	 the	 test	 itself	 was	
undertaken.	In	respect	of	where	the	test	kit	was	collected	from,	one	
study	 explored	 this	 for	 young	men,	 identifying	 that	 the	 preferred	
collection	points	were	GUM,	GP	practice	and	pharmacy	 (Saunders	
et	al	2012)	which	reflects	the	findings	of	Wayal	and	colleagues	who	
found	 that	 MSM	 preferred	 testing	 kits	 to	 be	 made	 available	 in	
medical	locations	rather	than	‘social’	locations	(Wayal	et	al.,	2011).	
Other	 studies	 have	established	 the	 acceptability	 of	 internet-based	
access	 to	 testing	 i.e.	ordering	 the	 test	online	 (Gaydos	et	al.,	2006,	
Gilbert	 et	 al.,	 2013,	 Kwan	 et	 al.,	 2012,	 Shoveller	 et	 al.,	 2009,	
Tomnay	et	al.,	2014),	and	pharmacy	collection	(Gudka	et	al.,	2013).	
	 	
		 164	
	
Location	of	Test	 Studies	Indicating	Preference	for	
Location	
Home	(self-test)	 Greacen	et	al.	(2013)	
Home	(self-sample)	 Gotz	et	al	(2005)	
Graseck	et	al	(2010)	
Graseck	et	al	(2010)	
Greenland	et	al.	(2011)	
Holloway	et	al.	(2011)	
Llewellyn	et	al	(2009)	
Novak	and	Karlsson	(2006)	
Shih	et	al	(2011)	
Skala	et	al.	(2012)	
Tebb	et	al.	(2004)	
Home	(outreach	service)	 Sena	et	al.	(2010)	
GP	practice	 Gray	et	al.	(2009)	
Hogan	et	al.	(2010)	
Iles	and	Oakeshott	(2005)	
Prost	et	al.	(2009)	
General	Clinic/	Health	
Centre	
Ashby	et	al.	(2012)	
	
Sexual	Health/	GUM	Clinic	 Hambly	and	Luzzi	(2006)	
Jerome	et	al.	(2009)	
Koester	et	al.	(2013)	
Llewellyn	et	al.	(2012)	
Saadatmand	et	al.	(2012)	
Abortion	Clinic	 Norman	et	al.	(2004)	
Outreach/	Community	
Based	
	
Friedman	and	Bloodgood	(2013)	
Hawk	(2013)	
Hengel	et	al.	(2013)	
Lambert	et	al.	(2005)	
Marrazzo	and	Scholes	(2008)	
Prost	et	al.	(2007)	
Sena	et	al	(2010)	
Vaughan	et	al.	(2010)	
Table	4.10	–	Studies	indicating	a	preference	for	testing	location	
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Balfe	 and	 colleagues	 identified	 four	 reasons	 why	 young	 people	
choose	to	test	for	STIs	-	a	‘transitional	moment’	e.g.	ceasing	to	use	
condoms	with	a	partner,	unprotected	sex,	symptoms	of	an	STI,	or	if	
a	 requirement	 of	 their	 employment	 (Balfe	 and	 Brugha,	 2009).	
Equally,	 many	 of	 the	 included	 studies	 which	 focused	 on	 values,	
beliefs,	 perceptions	 and	 behaviours	 identified	 key	 reasons	 why	
people	 do	 not	 choose	 to	 test	 for	 STIs.	 Table	 4.11	 provides	 a	
breakdown	of	these	reasons.	
	
Preferences	for	Service	
Types	and	Reasons	for	Not	
Testing	
Studies	Citing	
Embarrassment	 Booth	et	al.	(2013)	
Chaudhary	et	al.	(2008)	
Ingram	and	Salmon	(2010)	
Leston	et	al.	(2012)	
Lindberg	et	al.	(2006)	
Mills	et	al.	(2006)	
Samangaya	(2007)	
Access	&	Convenience	 Ashby	et	al.	(2012)	
Friedman	and	Bloodgood	(2013)	
Greacen	et	al.	(2013)	
Gudka	et	al.	(2013)	
Hitchings	et	al.	(2009)	
Hottes	et	al.	(2012)	
Oliver	de	Visser	and	O'Neill	(2013)	
Prost	et	al.	(2009)	
Shoveller	et	al.	(2012)	
Vaughan	et	al.	(2010)	
Stigma	 Balfe	and	Brugha	(2009)	
Balfe	and	Brugha	(2011)	
Fakoya	et	al.	(2008)	
Glasman	et	al.	(2010)	
Lindberg	et	al.	(2006)	
Mills	et	al.	(2006)	
Pavlin	et	al.	(2006)	
Rose	et	al.	(2008)	
Wong	et	al.	(2012)	
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Preferences	for	Service	
Types	and	Reasons	for	Not	
Testing	
Studies	Citing	
Privacy/	Confidentiality/	
Anonymity	Concerns	
Anhang	et	al.	(2005)	
Baraitser	et	al.	(2011)	
Balfe	et	al.	(2010)	
Balfe	and	Brugha	(2011)	
Fernando	and	Clutterbuck	(2008)	
Friedman	and	Bloodgood	(2013)	
Greacen	et	al.	(2013)	
Hambly	and	Luzzi	(2006)	
Hitchings	et	al.	(2009)	
Hottes	et	al.	(2012)	
Ingram	and	Salmon	(2007)	
Ingram	and	Salmon	(2010)	
Jerome	et	al.	(2009)	
Knapp	and	Anaya	(2010)	
Krause	et	al.	(2013)	
Leston	et	al.	(2012)	
Lindberg	et	al.	(2006)	
Lorimer	and	McDaid	(2013)	
Pavlin	et	al.	(2006)	
Prost	et	al.	(2007)	
Shoveller	et	al.	(2009)	
Shoveller	et	al.	(2012)	
Tomnay	et	al.	(2014)	
Vaughan	et	al.	(2010)	
Being	Judged/	Shame	 Balfe	and	Brugha	(2009)	
Lindberg	et	al.	(2006)	
Oliver	de	Visser	and	O’Neill	(2013)	
Invulnerability/	Perceived	
Risk	
Balfe	and	Brugha	(2009)	
Deblonde	et	al.	(2010)	
Mullins	et	al.	(2012)	
Rose	et	al	(2008)	
Lack	of	Knowledge	 Chaudhary	et	al.	(2008)	
Rose	et	al.	(2008)	
Discrimination	 de	Wit	and	Adam	(2008)	
Fakoya	et	al	(2008)	
Fear	 Fakoya	et	al.	(2008)	
Mills	et	al.	(2006)	
Pavlin	et	al.	(2006)	
Rose	et	al.	(2008)	
Wong	et	al.	(2012)	
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Preferences	for	Service	
Types	and	Reasons	for	Not	
Testing	
Studies	Citing	
Staff	Attitude	 Hambly	and	Luzzi	(2006)	
Ingram	and	Salmon	(2007)	
Knapp	and	Anaya	(2010)	
Llewellyn	et	al	(2012)	
Confidence	 Huppert	et	al.	(2011)	
Incentivisation	 Lee	et	al.	(2014)	
Table	4.11	-	Preferences	for	Service	Types	&	Reasons	for	Not	Testing	
Of	the	43	studies	 included	in	the	table	above,	the	most	frequently	
cited	 reason	 was	 privacy,	 confidentiality	 or	 anonymity	 concerns,	
identified	 in	 24	 studies	 (56%).	 This	 was	 followed	 by	 access	 and	
convenience	of	services,	cited	by	10	of	the	43	studies	(23%),	stigma,	
identified	 in	 nine	 studies	 (20%),	 and	 embarrassment,	 cited	 as	 a	
reason	in	seven	studies	(16%).			
	 	
4.3.6 Identification	of	the	List	of	Potential	Attributes		
The	 findings	of	 both	 literature	 reviews,	 along	with	other	 key	data	
sources	 including	 clinical	 guidelines	 and	 test	 performance	 data,	
were	mapped	 to	 the	 key	 stages	 in	 the	 STI	 testing	 and	 treatment	
pathway	 shown	 in	 figure	 2.1.	 In	 considering	 the	 inclusion	 of	
potential	attributes	 in	this	 list	the	following	selection	criteria	were	
used.	Attributes	were	 included	 in	 the	 list	 of	 potential	 attributes	 if	
they	were:	
• From	 the	 stated	 preference	 studies	 literature	 review,	
directly	 related	 to	 the	 provision	 of	 testing	 and	 treatment	
services	for	STIs	in	England	
• From	 the	 broader	 preference	 literature	 review	 directly	
related	to	the	provision	of	testing	and	treatment	services	for	
STIs	in	England	
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• Could	 be	 inferred	 from	 the	 studies	 considering	 values,	
beliefs,	 perceptions	 e.g.	 stigma	 associated	 with	 testing	 for	
STIs.	 Location	 of	 testing	 and	 how	 you	 access	 a	 healthcare	
professional	 may	 impact	 on	 stigma	 associated	 with	
attending	sexual	health	service	clinic	venues.	
	
The	attribute	long	list,	along	with	preliminary	definitions,	is	set	out	
in	table	4.12:	
Potential	Attribute	 Preliminary	Definition	
Sample	Collection	Method	 How	your	sample	is	provided	e.g.	self-sample,	
you	see	a	healthcare	professional	and	they	take	
the	sample	for	you	
Range	of	STIs	Tested	for	 Which	STIs	you	get	tested	for	e.g.	one	STI,	some	
STIs,	most	STIs,	all	STIs,	specific	named	STIs	
Where	you	do	the	Test	 Where	you	do	your	test	e.g.	self-test	at	home,	
self-sample	at	home	and	send	off	for	analysis,	
attend	GP	practice,	community	service,	sexual	
health	service	
Time	to	Result	 How	long	it	takes	from	providing	the	sample	to	
getting	the	result	e.g.	15	mins,	1	hour,	2	hours,	
24	hours,	7	days,	14	days		
Test	Accuracy	 How	accurate	the	test	result	is	e.g.	could	be	
defined	as	sensitivity,	specificity,	false	positive,	
false	negative	etc.		
Results	Notification	 How	you	get	your	results	e.g.	text,	email,	phone	
call,	internet	etc.	
Access	to	a	Health	Care	
Professional	when	you	get	
your	result		
Whether	you	have	access	to	a	healthcare	
professional	for	advice	when	you	get	your	result.	
Treatment	Consultation	
Method	
How	you	have	your	consultation	for	treatment	
e.g.	online	consultation,	phone	consultation,	
video	consultation,	face-to-face	
Where	you	go	to	get	
treatment	
If	you	need	to	see	a	healthcare	professional	in	
person	for	treatment	where	you	go	e.g.	GP,	
sexual	health	clinic	
Partner	Notification	
Method	
How	you	notify	your	partner	of	your	diagnosis	
e.g.	in	person,	by	phone,	by	text,	partner	notified	
by	a	service	provider	
Type	of	Health	Care	
Professional	
The	type	of	healthcare	professional	delivering	
your	care	e.g.	Pharmacist,	GP,	nurse,	sexual	
health	consultant	
Knowledge	of	Health	Care	
Professional	
Whether	the	health	care	professional	has	
specialist	knowledge	of	STIs	
Table	4.12	-	Long	List	of	Potential	Attributes	
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The	 ‘long	 list’	 of	 potential	 attributes	 identified	 in	 table	 4.12	 was	
taken	forward	into	focus	groups	with	young	people	as	described	in	
the	next	chapter.		
	
4.4 Summary	
Bridges	 and	 colleagues	 identify	 the	 need	 to	 ensure	 the	 use	 of	 an	
evidence	base	on	the	“potential	range	of	preferences	and	values	that	
people	may	hold”	 (Bridges	et	al.,	2011:405).	They	suggest	 literature	
review,	other	evidence	on	the	impact	of	disease	or	health	technology	
being	 assessed,	 expert	 opinion,	 qualitative	 research	 and	 other	
preliminary	 studies	 as	 the	 primary	 sources	 for	 attribute	
identification.	 The	 value	 of	 the	 qualitative	 research	 process	 in	 DCE	
questionnaire	design	is	summarised	by	KlØjgaard	and	colleagues	who	
recognised	 that	 their	 phased	 approach	 to	 qualitative	 research	
(incorporating	 a	 number	 of	 qualitative	 techniques)	 in	 attribute	 and	
level	 selection	and	questionnaire	design	had	a	direct	 impact	on	 the	
final	 questionnaire	 as	 understanding	 and	 insight	 would	 have	 been	
missed	had	the	qualitative	methods	been	restricted	to	one	approach	
(Kløjgaard	et	al.,	2012).		
	
Whilst	 the	 importance	 of	 qualitative	 research	 in	 DCE	 questionnaire	
design	 is	 recognised,	 there	 is	 little	 guidance	 on	 how	 the	 research	
undertaken	should	be	applied	in	the	final	selection	of	attributes	and	
levels	(Coast	and	Horrocks,	2007).	The	ISPOR	good	practice	checklist	
for	conjoint	analysis	highlighted	qualitative	research	as	being	a	good	
practice	for	the	selection	of	attributes,	alongside	clinical	experts	and	
other	 studies,	 for	 both	 the	 selection	 of	 attributes	 and	 potential	
attribute	levels	(Bridges	et	al.,	2011).			
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The	publication	of	 information	 regarding	 the	 selection	of	 attributes	
and	levels	is	problematic	with	little	or	no	information	being	published	
as	 part	 of	 the	 reporting	 of	 a	 DCE	 (ibid).	 A	 recent	 review	 of	 DCE	
studies	 in	 health	 economics	 found	 a	 decrease	 in	 the	 use	 of	
qualitative	 methods	 for	 attributes	 selection	 in	 studies	 published	
during	2001-2008	 (69%)	 to	51%	 in	 studies	published	between	2009	
and	2012.		
	
Conversely	 the	use	of	 qualitative	methods	 to	 inform	 level	 selection	
increased	between	 the	 two	periods	 from	33%	 for	 studies	published	
during	 2001-2008	 to	 40%	 for	 studies	 published	 between	 2009	 and	
2012	 (Clark	 et	 al.,	 2014).	 This	 makes	 it	 difficult	 for	 the	 reader	 to	
consider	the	implications	of	the	selection	of	attributes	and	levels	on	
the	 interpretation	 and	 limitations	 of	 the	 DCE	 study	 (Coast	 and	
Horrocks,	 2007).	 The	 question	 remains	 as	 to	 the	 degree	 to	 which	
DCEs	are	sensitive	to	the	process	used	to	develop	attributes	(Coast	et	
al.,	2012).	
	
A	key	question	in	the	selection	of	attributes	 is	the	balance	between	
what	 is	 important	 in	 the	 context	 of	 the	 policy/	 service	 perspective	
and	the	perspective	of	the	respondent	(Bridges	et	al.,	2011,	Lancsar	
and	 Louviere,	 2008).	 It	 is	 suggested	 that	 “the	 eventual	 balance	 of	
these	competing	objectives	must	be	guided	by	the	research	question	
and	the	study	perspective”	(Bridges	et	al.,	2011:405).	It	is	recognised	
that	 it	 is	 not	 always	 possible	 to	 include	 all	 relevant	 attributes	 and	
levels	 within	 the	 DCE	 and	 Lancsar	 and	 Louviere	 suggest	 that	 DCEs	
need	 to	 both	 capture	 sufficient	 relevant	 attributes	 to	 avoid	
respondents	 making	 assumptions	 regarding	 missing	 attributes	 of	
importance	 and	 that	 levels	 are	 sufficiently	 different	 to	 avoid	
respondents	 discounting	 attributes	 because	 of	 little	 difference	
(Lancsar	and	Louviere,	2008).		
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Bridges	and	colleagues	suggest	that	the	approach	to	mitigate	this	 is	
that	 “attributes	 central	 to	 the	 research	 question	 or	 to	 the	 decision	
context	must	either	be	included	or	held	constant	across	all	profiles.”	
(Bridges	et	al.,	2011:405).		
	
Having	undertaken	two	literature	reviews	to	inform	the	identification	
of	the	‘long	list’	of	attributes,	Chapter	5	outlines	the	qualitative	work	
undertaken	to	inform	the	final	selection	of	attributes	and	levels	to	be	
used	 in	 the	DCE.	 This	 includes	 the	 use	 of	 focus	 groups	 to	 seek	 the	
views	of	young	people	on	the	‘long	list’,	and	exploring	the	findings	of	
these	 with	 expert	 groups	 to	 incorporate	 the	 policy	 and	 service	
perspective	 to	 inform	 a	 final	 selection	 of	 sensible	 attributes	 and	
levels	using	an	evidence	synthesis	process.		
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5 CHAPTER	5	–	SELECTING	THE	ATTRIBUTES	&	LEVELS	–	
FINDINGS	FROM	THE	FOCUS	GROUPS	AND	EXPERT	
GROUPS	
	
5.1 Introduction	
This	chapter	builds	on	the	information	presented	in	Chapter	3	which	
outlines	 the	 rationale	 for	 the	 use	 of	 focus	 groups	 to	 inform	 the	
development	 of	 the	 DCE,	 presenting	 the	 research	 undertaken	 to	
inform	 the	 selection	 of	 attributes	 from	 the	 ‘long	 list’	 identified	 in	
Chapter	 4,	 and	 identification	 of	 levels	 through	 the	 use	 of	 focus	
groups,	 expert	 groups	 and	 evidence	 synthesis.	 This	 chapter	 is	
structured	into	four	parts:	first,	the	focus	group	research	undertaken	
with	 young	 people	 is	 presented.	 This	 includes	 the	 detail	 of	 the	
methods	used,	how	the	 focus	groups	were	conducted	and	analysed	
and	 the	 findings	 from	 this	 research.	 Second,	 the	 findings	 from	 the	
focus	 groups	 are	 used	 to	 inform	 the	 development	 of	 the	 expert	
groups	 which	 follow	 in	 this	 chapter.	 Third,	 the	 synthesis	 of	 the	
findings	 from	 the	 focus	 groups	 and	 expert	 groups	 to	 finalise	 the	
selection	 of	 attributes	 and	 levels	 is	 presented.	 Finally,	 the	 chapter	
concludes	 with	 a	 summary	 of	 the	 attributes	 and	 levels	 selected	 to	
move	forward	into	the	DCE	presented	in	Chapter	6.	
	
5.2 Focus	Groups	
	
5.2.1 Focus	Group	Objectives	
As	 outlined	 in	 section	 3.6.1	 focus	 groups	 were	 selected	 to	
contribute	to	the	design	of	the	DCE.	The	objectives	were:	
	
Primary	Objective:		
• To	 identify	 which	 the	 themes	 and	 factors	 young	 people	
consider	 important	 when	 choosing	 whether	 to	 test	 for	
sexually	transmitted	infections	
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Secondary	Objectives:	
• To	gain	insight	into:	
o Reasons	for	importance	of	factors	
o Rationale	 for	 trading	 between	 factors	 and	
prioritisation	
o How	 participants	 articulate	 views	 and	 opinions	 on	
these	themes/	factors.	
	
Participant	inclusion	criteria	set	for	the	focus	groups	were:	
• Between	the	ages	of	16	and	24	
• Ability	to	speak	English	
• Able	to	consent.	
	
Exclusion	criteria	were:	
• People	under	the	age	of	16	and	over	the	age	of	25	
• People	 requiring	 any	 form	 of	 interpreting/	 translation	
services	to	participate	
• People	unable	to	give	consent.	
	
In	 total,	 four	 focus	 groups	 were	 undertaken	 involving	 21	 young	
people,	the	composition	of	the	focus	groups	is	summarised	in	table	
5.1.	
Focus	Group	 No	of	
Participants	
Gender		 Age	
Range	
Group	Type	
1	 6	 4F,	2M	 16-17	 Existing	Group	
2	 5	 3F,	2M	 17-18	 Existing	Group	
3	 3	 3M	 18-24	 Self-selected	
4	 7	 7F	 19-23	 Self-selected	
		Table	5.1	-	Focus	Group	Composition	
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5.2.2 Focus	Group	Methods	
5.2.2.1 Sampling	
Whilst	consideration	was	given	to	a	number	of	sampling	methods,	
convenience	sampling	was	ultimately	chosen	for	this	research	due	
to	the	challenges	with	accessing	the	population	and	being	able	to	
undertake	purposive	sampling	within	 the	time	constraints	of	 this	
phase	 of	 the	 research.	 The	 convenience	 sampling	 approach	 is	
defined	 as	 selection	 based	 on	 who	 is	 available,	 they	 self-select	
into	the	sample.	Whilst	it	is	recognised	that	the	main	limitation	of	
this	approach	is	the	impact	on	the	validity	(Finch	et	al.,	2014)	and	
generalizability	 (Babbie,	 2012),	 it	 is	 noted	 that	 this	 sampling	
method	is	useful	in	questionnaire	design	(ibid).	
	
In	order	to	mitigate	the	limitation,	consideration	was	given	to	the	
principal	 criteria	of	 relevance	within	 the	16-24	age	 range.	Whilst	
research	 does	 suggest	 there	 are	 differences	 in	 preferences	
between	demographic	groups	for	different	testing	and	treatment	
services	(Iles	&	Oakeshott,	2005,	Lorimer	et	al.,	2009)	there	is	also	
evidence	 that	 other	 factors	 may	 be	 more	 significant	 such	 as	
relationship	 status	 (Balfe	 and	 Brugha,	 2009).	 The	 population	 of	
interest	for	this	research	was	the	16-24	age	range	since	this	is	the	
population	 with	 the	 highest	 rates	 of	 diagnosis	 of	 STIs	 (PHE,	
2016b);	 the	 greatest	 frequency	 of	 change	 of	 partner	 (Mercer	 et	
al.,	 2013),	 and	 are	 the	 highest	 users	 of	 smartphone	 technology	
and	the	internet	(Office	for	National	Statistics,	2016b)	on	which	a	
new	remote	online	pathway	is	dependent.		
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5.2.2.2 Focus	Group	Design	
Since	language	use	is	important	when	engaging	participants	in	the	
focus	groups	(Krueger	and	Casey,	2000),	research	was	undertaken	
to	 align	 the	 language	 and	 content	 to	 ensure	 relevance	 to	 the	
‘target’	population	age	range,	in	order	to	pitch	the	content	of	the	
focus	group	at	an	appropriate	level.	Websites	were	reviewed	that	
were	designed	 for	 the	 study	population	age	 range	 to	 inform	 the	
style,	use	of	language	and	content	for	the	planned	focus	groups.		
	
Those	reviewed	included	BBC	Radio	1	and	BBC	Radio	1	Newsbeat,	
Respect	 Yourself	 (the	 Warwickshire	 relationships	 and	 sex	
education	website)	and	Brook	(a	national	charity	with	a	focus	on	
sexual	 health	 services	 for	 under	 25s).	 Market	 analysis	 data	 was	
reviewed	 to	 identify	 the	 most	 commonly	 used	 technology	 and	
social	media	within	 the	 age	 range,	 along	with	 the	most	 popular	
television	viewing.	The	design	and	style	of	language	for	the	focus	
groups	was	then	amended	to	suit,	taking	into	account	this	review.	
	
When	 planning	 the	 focus	 groups,	 time	was	 allowed	 before	 each	
focus	group	began	to	enable	participants	to	review	the	participant	
information	 leaflet,	 formally	 consent	 to	 take	 part,	 and	 for	 the	
volunteers	 to	 complete	 the	 demographic	 information.	 The	
introduction	 was	 planned	 to	 be	 brief,	 thanking	 participants	 for	
their	 input,	outlining	 the	purpose	of	 the	 focus	group	and	setting	
out	the	ground	rules	for	participation.	These	included:	
• Confidentiality	 –	 ‘what	 happens	 in	 the	 room	 stays	 in	 the	
room’,	
• Respect	for	the	views	of	others,	
• Clarification	on	the	nature	of	the	discussions	and	that	you	
can	leave	if	you	want	to,	
• Recording	 of	 the	 discussion,	 if	 possible	 to	 try	 and	 avoid	
speaking	over	each	other	(adapted	from	Finch	et	al.,	2014).	
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5.2.2.3 The	Use	of	Vignettes	and	Pilot	of	Development	
It	was	decided	not	to	use	one	general,	opening	topic	but	rather	to	
set	the	scene	in	the	context	of	the	upcoming	questions	and	tasks	
for	 the	 focus	group.	This	was	because	 in	designing	the	questions	
there	 was	 a	 logical	 flow	 through	 the	 vignettes	 into	 the	 later	
questions	 and	 related	 exercise	 and	 it	 was	 believed	 that	 the	
vignettes	 would	 offer	 an	 easy	 route	 into	 the	 topic.	 The	 scene	
setting	 drew	 on	 the	 views	 of	 a	 small	 number	 of	 clinical	 staff	
working	 in	 sexual	 health	 services	 in	 London,	 based	 on	 their	
experience	 of	 what	 prompts	 young	 people	 to	 attend	 clinic.	
References	were	made	to	Facebook	specifically	because	this	was	
proportionately	 the	 most	 used	 social	 networking	 site	 (Ipsos	
MediaCT,	2015).			
	
In	 developing	 the	 focus	 group	 topic	 guide	 a	 key	 point	 was	
identifying	 the	 questions	 to	 use.	 Recognising	 the	 need	 for	
questions	 to	 be	 open-ended,	 and	 structured	 in	 such	 a	 way	 that	
participants	would	be	willing	to	respond	to	them	(Barbour,	2007),	
careful	 consideration	 was	 given	 as	 to	 how	 to	 link	 them	 to	 the	
vignettes	 and	 frame	 their	 content	 with	 the	 other	 connecting	
dialogue.		
	
To	 make	 sure	 that	 the	 vignettes	 were	 credible	 and	 authentic	
(O'Dell	 et	 al.,	 2012),	 prior	 consultation	 was	 undertaken	 with	 a	
small	group	of	clinical	staff	working	on	the	related	eSTI2	research	
project.	 This	 included	 two	 GUM	 consultants,	 a	 research	 nurse	
working	in	the	field	and	a	sexual	health	advisor.	An	afternoon	was	
spent	talking	through	the	plans	including	the	number	of	vignettes	
and	 the	 degree	 of	 detail	 required.	 Following	 this	 the	 author	
drafted	 three	 vignettes	 –	 one	 describing	 a	 GUM	 clinical	 care	
pathway,	 one	 describing	 an	 NCSP	 internet	 testing	 pathway	 and	
one	describing	a	 fully	 remote	online	 self-testing	and	clinical	 care	
pathway,	as	envisaged	by	the	overall	eSTI2	consortium.		
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The	fully	remote	online	pathway	vignette	was	informed	by	a	Prezi	
animation	 developed	 by	 another	 eSTI2	 researcher	 used	 as	 an	
introduction	 to	 the	 human	 computer	 interaction	 focus	 groups.	
The	 other	 two	 were	 developed	 based	 on	 what	 happens	 to	
someone	if	they	choose	to	test	at	a	sexual	health	clinic,	or	through	
one	 of	 the	 NCSP	 internet	 testing	 pathways	 both	 of	 which	 are	
comparators	within	the	OCCP	exploratory	study.		
	
The	author	drafted	three	vignettes	which	were	then	circulated	to	
the	 small	 group	 of	 clinical	 staff	 for	 review.	 The	 vignettes	 were	
then	amended	taking	 into	account	this	 feedback.	 It	 is	 recognised	
that	 it	 is	 important	 for	 vignettes	 to	 be	 “easily	 followed	 and	
understood,	 and	 are	 internally	 consistent	 and	 not	 too	 complex”	
(Barter	 and	 Renold,	 2000:314).	 Thus,	 care	 was	 taken	 to	 ensure	
that	the	vignettes	were	written	impersonally,	as	a	walk-through	of	
what	would	happen	if	a	participant	chose	that	route	to	test	for	an	
STI,	 rather	 than	 to	 shape	 them	 around	 a	 hypothetical	 person.	 It	
was	 felt	 that	 the	 focus	 needed	 to	 be	 on	 the	 pathway	 itself,	 and	
therefore	to	write	the	vignette	as	a	story	about	a	proposed	person	
might	detract	from	this.	
	
The	author	decided	to	read	out	the	vignettes	to	the	focus	groups	
rather	than	use	media	such	as	animation,	flip	charts,	storyboards	
or	 videos.	 The	 reason	 for	 this	 was	 two-fold,	 firstly	 the	 level	 of	
detail	did	not	lend	itself	to	flip	charts	or	storyboards,	and	secondly	
animation	 and	 videos	 introduced	 reliance	 on	 further	 technology	
(other	than	a	recording	device)	and	the	rooms	used	for	any	such	
focus	group	might	not	be	able	to	support	this.	The	vignettes	used	
vary	in	length	as	outlined	in	table	5.2:	
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Vignette		 No	of	Words	
1.	Sexual	Health	Clinic	 422	
2.	NCSP	Internet	Testing	Pathway	 306	
3.	Fully	Remote	Online	Pathway	 349	
Table	5.2	-	Length	of	Vignettes.	For	full	text	see	Appendix	11	
	
The	 first	 vignette	 is	 longer	 in	 length	 since	 it	 contains	 additional	
information	which	 is	referred	to	 in	vignettes	two	and	three,	thus	
attempting	 to	 avoid	 direct	 repetition	 in	 the	 second	 and	 third	
vignettes.		
	
5.2.2.4 Focus	Group	Structure	
Following	 the	 introduction,	 all	 participants	 were	 asked	 to	 give	
their	name	and	to	confirm	that	they	understood	the	ground	rules.	
The	 topic	 guide	 for	 the	 first	 focus	 group	 acknowledged	 that	 this	
was	a	pre-existing	group	therefore	individual	introductions	would	
not	be	necessary.	 The	 topic	 guide	was	adapted	 for	 the	 final	 two	
focus	groups	as	participants	selected	themselves	by	responding	to	
an	 online	 advert.	 It	 was	 decided	 to	 amend	 the	 introductory	
section	slightly	to	ask	participants	to	introduce	themselves	to	the	
group	as	part	of	the	confirmation	process.	A	broader	introductory	
task	 was	 not	 included	 as	 the	 facilitator	 aimed	 to	 encourage	
informal	dialogue	prior	to	the	commencement	of	the	focus	group	
between	participants.		
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The	overall	structure	of	the	focus	group	was	to	ask	each	group	of	
participants	the	same	questions	after	each	of	the	three	vignettes,	
opening	 by	 asking	 if	 there	was	 anything	 to	 ask	 about	what	 they	
had	been	 told.	 It	was	 important	 to	 check	 comprehension	 at	 this	
stage	 since	 it	 was	 anticipated	 that	 the	 majority	 of	 participants	
would	not	 have	previously	 used	 sexual	 health	 services.	 The	next	
question	 asked	 about	 each	 vignette	 was	 ‘can	 you	 think	 of	 the	
things	 in	 the	 example	 that	might	make	 a	 difference	 to	whether	
you	decided	to	use	 this	 service?	What	do	you	particularly	 like	or	
don’t	 like?’,	 thus	aiming	 to	prompt	 the	participants	 to	 reflect	on	
the	vignette	they	have	just	listened	to,	in	order	to	start	to	identify	
factors.		
	
The	 second	 part	 of	 the	 focus	 group	 centred	 on	 exploring	 these	
factors	 in	 more	 detail	 using	 a	 further	 three	 questions,	 again	 to	
draw	 out	 the	most	 important	 ones.	 It	 started	 with	 a	 paragraph	
which	 asked	 participants	 to	 reflect	 and	 compare	 the	 factors,	 to	
think	 about	 whether	 there	 was	 one	 particular	 thing	 about	 an	
option	 that	 makes	 it	 more	 attractive	 than	 another,	 or	 to	 think	
about	if	there	were	things	that	would	be	important	which	haven’t	
been	 covered	 by	 the	 examples	 talked	 through.	 Two	 explicit	
questions	were	 asked	 about	what	 the	most	 important	 factors	 in	
making	 a	 choice	 about	which	 service	 to	 use	were	 and	why,	 and	
whether	 they	 could	 think	 of	 any	 other	 factors	 about	 the	 service	
that	had	not	been	talked	about	so	far	that	would	be	important	in	
deciding	whether	to	access	that	service.		
	
The	final	question	in	this	section	was	to	run	through	factors	other	
people	had	identified	as	being	important	in	making	a	decision	that	
had	not	come	out	of	the	discussions,	and	participants	were	asked	
to	 shout	 out	whether	 they	 thought	 they	were	 important	 or	 not	
and	why.	These	factors	were	drawn	from	the	literature	reviews.	
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The	 questions	 were	 written	 to	 be	 open	 ended	 and	 in	 language	
appropriate	 to	 the	 participants	 as	 is	 identified	 good	 practice	 for	
focus	groups	 (Millward,	2012,	Krueger	and	Casey,	2000).	For	 this	
part	 of	 the	 focus	 group,	 cards	with	 factors	 on	were	 prepared	 in	
advance	 and	 held	 by	 the	 facilitator.	 These	 cards	were	 based	 on	
the	 factors	 identified	 in	 the	 vignettes,	 and	 other	 known	 factors	
from	 the	 literature	 review	 which	 were	 not	 included	 in	 the	
vignettes.	 These	 primarily	 related	 to	 product	 characteristics	 e.g.	
sampling	method	and	test	accuracy.		
	
The	final	task	within	the	focus	group	was	a	prioritisation	task.	This	
was	 selected	 because	 task	 based	 activities	 can	 stimulate	
discussion	 in	 focus	 groups	 in	 a	 way	 that	 asking	 open	 ended	
questions	cannot	(Krueger	and	Casey,	2000).	The	exercise	was	not	
intended	to	be	a	formal	ranking	exercise.	The	task	was	modelled	
in	 the	 style	 of	 an	 X-Factor	 results	 show	 (reality	 TV	 show)	 with	
participants	asked	to	work	as	a	group	with	the	cards	used	during	
the	 second	 stage	of	 the	 focus	group	eliminating	one	 factor	 from	
the	bottom	two	each	time	to	get	ultimately	get	to	a	‘winner’.	The	
X-Factor	was	 chosen	as	 it	was	 the	highest	 rated	UK	 talent	 series	
within	the	16-34	age	range	(Freemantle	Media	UK,	2014)	and	was	
the	 most	 “tweeted	 about”	 TV	 show	 during	 2013-14	 (Haggerty,	
2014).		
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The	 topic	 guide	 ended	with	 thanking	 participants	 for	 their	 time,	
setting	 it	 in	 the	 context	 of	 what	 will	 happen	 next	 and	 how	 the	
outputs	will	 be	 used,	 and	 offering	 them	 the	 opportunity	 to	 add	
anything	else	before	the	group	concluded.	The	guide	was	written	
as	a	full	script	to	act	as	an	aide	memoir	for	the	facilitator	however	
it	 was	 planned	 only	 to	 read	 the	 ground	 rules	 and	 vignettes	
verbatim.	 The	 topic	 guide	was	 reviewed	by	 the	PhD	 supervisors,	
and	tested	informally	on	research	colleagues	who	have	experience	
of	 working	 with	 young	 people	 to	 check	 comprehension	 and	
language.	 Final	 amendments	 were	made	 prior	 to	 the	 first	 focus	
group.	A	copy	of	the	full	topic	guide	is	included	in	Appendix	11.		
	
5.2.2.5 Data	Management	and	Analysis	
“Focus	groups	can	provide	a	rich,	complex	and	extensive	data	set	
for	social	researchers.	However,	many	of	the	potential	advantages	
of	 these	 data	 are	 lost	 in	 the	 absence	 of	 appropriate	methods	 of	
analysis”	(Frankland	and	Bloor,	1999:144-5).	
	
Thematic	 analysis	was	 selected	 as	 the	 core	 approach	 to	 analyse	
the	 focus	 group	 data	 recognising	 that	 this	 is	 one	 of	 the	 three	
‘main	methods’	 for	analysing	 focus	group	data	 (Silverman,	2014)	
and	is	the	method	most	closely	aligned	to	that	used	to	design	the	
focus	 group.	 In	 managing	 and	 analysing	 the	 data	 the	 process	
outlined	 in	 the	 figure	 5.1	 was	 adopted	 to	 ensure	 the	 effective	
management	 and	 analysis	 of	 the	 focus	 group	 data.	 This	 was	
selected	 as	 it	 summarises	 a	 recognised	 process	 for	 the	
management	of	qualitative	data	(Spencer	et	al.,	2014b).	
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Both	 Saldana	 and	 Morgan	 recognise	 the	 need	 to	 ensure	 that	
coding	 and	 analysis	 are	 appropriate	 for	 and	 aligned	 to	 the	
research	 question	 and	 the	 information	 requirements	 of	 the	
project	 (Morgan,	 1997,	 Saldana,	 2013).	 In	 taking	 forward	 the	
preliminary	 coding	 undertaken	 on	 the	 hard	 copy	 transcripts,	
consideration	 was	 given	 to	 the	 coding	 approach	 that	 would	 be	
applied	 and	 its	 impact	 on	 the	 analysis.	 The	 specific	 purpose	 of	
undertaking	 the	 focus	 groups	was	 to	 identify	 the	 attributes	 that	
are	important	to	young	people	in	accessing	sexual	health	services.	
The	outputs	were	used	to	inform	the	development	of	a	DCE	and	it	
was	recognised	that	the	focus	groups	may	yield	other	information	
useful	to	its	design	including	the	development	of	the	introductory	
information,	and	input	into	attribute	levels.		
	
Considering	 Saldana’s	 first	 cycle	 coding	 methods,	 three	 specific	
coding	types	were	identified	as	being	relevant	to	the	coding	of	the	
focus	group	data	–	descriptive	coding,	emotion	coding	and	values	
coding	(Saldana,	2013).	These	are	defined	in	table	5.3:	
	
Coding	Type	 Definition	
Descriptive	
Coding	
Summarises	the	topic	of	the	discussion	(rather	than	
its	content)	
Emotion	Coding	 Summarises	the	emotions	expressed	by	
participants	in	relation	to	the	topic	
Values	Coding	 Summarises	the	values,	attitudes	and	beliefs	
expressed	by	the	participants	in	the	discussions	
Table	5.3	-	Definition	of	Coding	Types	(Saldana,	2013)	
	
Descriptive	 coding	was	 used	 to	 focus	 on	 specific	 properties	 that	
were	discussed	in	respect	of	the	tests	and	services.	Many	of	these	
codes	 were	 identified	 a	 priori	 as	 they	 centred	 on	 tangible	 and	
known	factors	that	were	identified	as	part	of	the	literature	review	
and	focus	group	development.		
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Emotion	 coding	 and	 values	 coding	 were	 used	 to	 capture	 the	
participants’	beliefs,	feelings	and	perceptions	on	their	views	of	the	
specific	attributes	and	properties.	Saldana	draws	attention	to	the	
importance	 of	 coding	 both	 values	 and	 emotions	 in	 research	 as	
participants’	 actions	 and	 views	 cannot	 be	 separated	 from	 one	
another.	 “Since	emotions	are	a	universal	human	experience,	our	
acknowledgement	of	 them	 in	our	 research	provides	deep	 insight	
into	the	participants’	perspectives,	worldviews	and	life	conditions”	
(Saldana,	2013:106).	These	codes	were	identified	on	the	first	read	
through	of	the	transcripts.	
	
	
		 185	
	
	
	
	
	
Figure	5.1	-	Process	for	Managing	&	Analysing	the	Data.	Source:	Spencer	et	al.,	2014b:280	
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5.2.3 Conducting	the	Focus	Groups	
In	 order	 to	 identify	 ways	 to	 access	 the	 population,	 a	 group	 of	
experienced	 researchers	 in	 the	 field,	 based	 at	 the	 Studies	 in	
Adolescent	 Sexual	 Health	 (SASH)	 Group	 at	 Coventry	 University,	
were	 approached	 for	 additional	 advice	 into	what	worked	well	 for	
them	 when	 gaining	 access	 to	 young	 people	 to	 participate	 in	
research.	Their	suggestions	included	targeting	the	education	sector	
(sixth	 form,	 further	 education	 colleges	 and	 universities)	 and	 the	
voluntary	sector	(youth	projects	and	the	youth	organisations).	
	
Recognising	 the	 reliance	 on	 participants	 choosing	 to	 opt	 in,	
approaches	were	made	in	a	staged	way	to	enable	the	management	
of	 recruitment	 to	 ensure	 a	 spread	 of	 responses	 across	 the	 age	
range.	 The	 following	demographic	 information	was	 captured	 from	
participants:		
• Age		
• Gender		
• Ethnic	group	
• Sexual	preference	
• Whether	previously	tested	for	an	STI	
• Highest	qualification		
• Employment	status.	
	
Initial	 contact	 was	 made	 with	 organisations	 working	 with	 the	
younger	end	of	the	age	range	including	schools	with	sixth	forms	and	
youth	organisations.	A	 standard	cover	 letter,	 along	with	a	 copy	of	
the	 participant	 information	 leaflet	was	 sent	 to	 contacts	 identified	
from	the	organisations’	websites.		
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Once	 the	 first	 two	 focus	 groups	were	 undertaken,	 the	 participant	
demographic	 information	was	 reviewed	which	 confirmed	 that	 the	
majority	 of	 participants	 were	 aged	 16-17,	 therefore	 subsequent	
organisations	targeted	enabled	the	recruitment	of	participants	over	
the	age	of	18,	including	further	education	colleges	and	universities.	
The	same	standard	cover	 letter	and	participant	 information	 leaflet	
was	sent.	A	point	of	 interest	from	reflection	on	the	first	two	focus	
groups	was	the	interaction	between	the	participants.	The	two	focus	
groups	were	formed	from	a	pre-existing	group	(participants	known	
to	 one	 another	 in	 advance)	 and	 considering	 the	 methodological	
literature	 on	 this	 topic	 the	 author	 decided,	 if	 possible,	 to	 seek	
participants	who	were	not	 part	 of	 a	 pre-existing	 group	 to	 explore	
whether	this	was	significant	in	the	findings.		
	
The	 recruitment	 of	 participants	 through	 organisations	 addressed	
some	 of	 the	 key	 issues	 with	 group	 composition,	 particularly	 by	
recruiting	through	organisations	where	young	people	already	share	
common	 ground,	 either	 through	 attendance	 at	 the	 same	
educational	establishment	or	participation	in	the	same	youth	group	
or	project.		
	
Recruitment	into	the	focus	groups	provided	to	be	more	challenging	
than	 originally	 anticipated,	 with	 difficulties	 in	 securing	 access	 to	
relevant	people	following	the	 initial	contact	 letter	by	telephone	or	
by	 email.	 Non-response	 was	 a	 greater	 issue	 than	 negative	
responses.	The	 initial	group	to	engage	was	a	youth	organisation,	a	
pre-existing	group	of	young	people	who	meet	fortnightly.	Members	
of	 the	 youth	 organisation	were	 identified	 as	 predominantly	 16-17	
years	 old	 and	 female	 during	 the	 initial	 organisation	 of	 the	 group.	
The	final	two	focus	groups	were	recruited	by	online	advertising	at	a	
university.	 Participants	 opted	 into	 both	 focus	 groups,	 the	 youth	
organisation	 via	 a	 decision	 to	 attend	 on	 the	 scheduled	 night,	 and	
the	university	via	response	to	an	advertisement.	
		 188	
	
Finch	and	colleagues	outline	five	key	practicalities	to	consider	when	
organising	 a	 focus	 group	 –	 timing,	 venue,	 ‘hosting’	 the	 group,	
observers	and	co-moderators	and	 recording	 (Finch	et	al.,	2014).	 It	
was	 recognised	 that	 the	 timing	 and	 venue	 for	 the	 focus	 groups	
would	be	determined	by	the	organisations	agreeing	to	participate.	
The	author	was	able	to	be	flexible	to	meet	the	requirements	of	the	
participants	both	in	terms	of	timing	of	focus	groups	and	venues.	In	
terms	 of	 ‘hosting’	 the	 group,	 chocolates	were	 provided	 as	 people	
arrived	at	the	focus	group	whilst	they	were	reading	and	completing	
the	consent	and	demographic	 information.	 ‘Love	2	Shop’	vouchers	
(£10)	were	offered	to	focus	group	participants,	as	a	small	token	of	
their	 time.	 A	 record	 of	 the	 voucher	 distribution	 was	 kept	 for	
research	 audit	 and	 to	 meet	 current	 institutional	 financial	
regulations.		
	
Given	 the	 amount	 of	 information	 being	 imparted,	 accompanying	
written	materials	were	developed	for	participants.	These	were:	
• A	printed	summary	slide	of	each	of	the	three	vignettes,	
• A	 comparative	 table,	 drawing	 out	 the	 key	 features	 of	 the	
pathway,	and	what	happens	in	each	of	the	three	vignettes.		
	
The	 written	 materials	 were	 on	 the	 table	 ready	 for	 each	 of	 the	
participants	at	the	start	of	the	focus	group.		
	
The	author	was	 the	 facilitator	 for	 all	 four	 focus	 groups.	 The	 room	
was	organised	so	that	seating	was	in	a	circle	and	the	facilitator	sat	
with	 the	group	as	part	of	 the	 circle.	 The	 focus	 groups	were	audio	
recorded	 using	MP3	 equipment.	 All	 equipment	was	 tested	 before	
each	 focus	 group	 then	 placed	 centrally	 within	 the	 group	 to	
maximise	 the	 quality	 of	 recording	 of	 participants.	 The	 four	 focus	
groups	varied	in	 length	slightly	with	the	shortest	being	60	minutes	
and	18	seconds,	and	the	longest	being	65	minutes	and	45	seconds.	
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This	provided	a	total	of	just	over	four	hours’	data	and	amounted	to	
approximately	 32,500	words	 and	 83	 pages	 of	 data	 for	 qualitative	
analysis.	
	
In	 total	 there	were	21	participants	across	 the	 four	 focus	groups,	a	
summary	 of	 the	 number	 of	 participants	 and	 their	 gender	 is	
provided	in	table	5.1.	The	socio-demographic	characteristics	of	the	
focus	group	participants	are	outlined	in	table	5.4.	
 Number	 %	
Age 
16-17	 11	 52	
18-24	 10	 48	
Gender	
Female	 14	 67	
Male	 7	 33	
Ethnicity	
White	 10	 48	
Asian/	Asian	British	 10	 48	
Black/	African/	Caribbean/	British	 1	 5	
Sexuality	
Heterosexual	 17	 81	
Homosexual	 2	 10	
Bi-Sexual	 2	 10	
Tested	for	STI	Previously	
Tested	 4	 19	
Not	Tested	 17	 81	
Highest	Educational	Attainment	
GCSE	 6	 29	
A-Level	 11	 52	
Diploma	 1	 5	
Degree	 2	 10	
Post-Graduate	 1	 5	
Employment	Status	
Student	 19	 90	
Unemployed	 1	 5	
Employed	 1	 5	
Table	5.4	–	Socio-Demographic	Characteristics	of	Focus	Group	Participants	(note	
percentages	may	not	sum	due	to	rounding)	 	
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5.2.4 Data	Management		
Adopting	the	process	outlined	above	(figure	5.1),	 the	transcription	
process	 provided	 an	 important	 key	 part	 of	 data	 familiarisation	
stage.	 All	 focus	 group	 data	 was	 transcribed	 by	 the	 author,	 thus	
providing	 a	 valuable	 opportunity	 to	 listen	 to	 the	 recordings	 first	
hand,	 and	 therefore	 becoming	more	 familiar	with	 the	 contents	 in	
preparation	 for	 the	 main	 analysis.	 Notes	 on	 non-verbal	
communication	 were	 incorporated	 at	 this	 stage,	 thus	 helping	 to	
develop	preliminary	categories	for	qualitative	analysis	coding.		
	
The	transcription	process	was	undertaken	using	the	audio	playback	
function	in	NVivo	for	Mac	2010,	dictated	into	Microsoft	Word	using	
Dragon	Dictate.	All	focus	group	meetings	were	transcribed	verbatim	
excluding	 the	 introduction	 and	 conclusion	 given	 by	 the	 facilitator,	
and	 the	 use	 of	 vignettes	 read	 out	 to	 all	 four	 focus	 groups.	 Notes	
were	made	in	the	transcripts	for	any	other	aspects	of	the	recording	
e.g.	 laughter,	 non-verbal	 communication	 noted	 by	 the	 researcher	
during	 the	 focus	 group	 and	 content	 which	 was	 inaudible	 due	 to	
‘group	noise’.		
	
These	transcripts	were	then	hand	checked	for	errors	by	listening	to	
all	 the	 recordings	 and	 annotating	 any	 corrections	 needed	 in	 hard	
copy,	 prior	 to	 updating	 the	 electronic	 copy.	 This	 review	 process	
enabled	 the	 initial	 identification	 of	 topics	 to	 code.	 These	 hard	
copies	were	annotated	with	potential	codes	initially	falling	into	two	
categories:	
• Observations/	statements	made	by	focus	group	members;	
• Questions	asked	of	the	facilitator	by	focus	group	members.	
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5.2.5 Data	Analysis	
The	thematic	analysis	coding	was	split	to	examine	questions	asked	
and	 observational	 statements	 separately	 to	 distinguish	 between	
points	of	 clarification	and	views	on	potential	 factors.	 	An	 iterative	
approach	 was	 adopted,	 reviewing	 each	 focus	 group	 transcript	 in	
order.	 On	 completion	 of	 each	 focus	 group	 transcript	 review,	 the	
outputs	were	entered	into	Mindjet	MindManager.	This	enabled	the	
collation	 of	 initial	 thoughts	 on	 codes	 from	 the	 first	 review	 of	 the	
transcripts	into	an	electronic	format	which	was	then	visually	sorted	
into	groups	and	subgroups	to	inform	the	development	of	the	initial	
coding	framework.	Detail	of	the	initial	codes	is	shown	in	figure	5.2.	
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Figure	5.2	-	Draft	Coding	Framework2
																																																						
2	RSE	–	Relationships	&	Sex	Education,	STI	–	Sexually	Transmitted	Infection,	HCP	–	Health	Care	Professional,	PN	–	Partner	Notification	
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This	 structure	 was	 then	 input	 into	 NVivo	 10	 for	 Mac	 (QSR	
International)	 and	 a	 coding	 directory	 was	 drafted	 to	 assist	 with	
consistency	in	the	subsequent	application	of	thematic	codes.		
		
The	process	of	indexing	(or	coding)	the	data	took	place	in	NVivo	10.	
The	opportunity	was	taken	to	code	the	data	‘from	scratch’	against	
the	draft	coding	framework	rather	than	referring	back	to	notes	on	
initial	 codes	made	 on	 the	 hard	 copy	which	were	 used	 to	 develop	
the	 draft	 coding	 framework.	 This	 provided	 the	 opportunity	 to	
identify	 areas	 coded	 differently	 and	 then	 to	 consider	 the	 reasons	
for	 this.	 One	 important	 point	 to	 note	 is	 that	 the	 ranking	 exercise	
undertaken	 at	 the	 end	 of	 the	 focus	 group	 to	 stimulate	 discussion	
was	 coded	 in	 a	 slightly	 different	 way	 to	 the	 main	 focus	 groups.	
Specifically,	coding	focused	on	statements	made	by	the	participants	
which	 added	 depth	 to	 the	 understanding	 of	 why	 they	 thought	 a	
factor	was	important	rather	than	just	an	indication	of	their	view	on	
its	relative	importance.		
	
Two	queries	were	 then	 run	 in	NVivo,	 the	 first	 to	 sort	 the	 data	 to	
enable	the	researcher	to	review	the	data	by	code,	and	the	second	a	
matrix	query	to	examine	the	utilisation	of	codes	within	and	across	
focus	groups.	This	was	undertaken	to	aid	consideration	on	whether	
rationalisation	or	expansion	of	the	coding	framework	was	required.		
		
As	a	result	of	reviewing	the	results	of	the	two	queries	a	number	of	
modifications	were	made	to	the	coding	framework:	
• Rationalisation	 of	 codes	 where	 grouping	 could	 be	 made	
without	loss	of	fidelity;	
• Realignment	of	sub-codes	within	coding	framework;	
• Adjustments	 to	 names	 of	 sub-codes	 for	 participant	
questions	and	observations	made	by	participants	to	enable	
more	effective	thematic	analysis	across	codes.	
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Revisions	were	made	to	the	coding	framework	in	MindManager	to	
review	prior	to	completing	the	changes	 in	NVivo	10.	Queries	were	
re-run	 to	 enable	 review	 of	 the	 data	 extracts	 within	 the	 revised	
themes.	The	revised	coding	framework	is	shown	in	figure	5.3.	
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Figure	5.3	-	Revised	Coding	Framework3
																																																						
3	-	RSE	–	Relationships	&	Sex	Education,	STI	–	Sexually	Transmitted	Infection,	HCP	–	Health	Care	Professional,	PN	–	Partner	Notification	
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All	data	were	then	analysed	at	focus	group	level,	that	is,	the	group	
is	the	unit	of	analysis	rather	than	the	individual	participant	(Spencer	
et	al.,	2014a)	and	data	summaries	by	code	were	organised	by	focus	
group.	A	summary	of	the	high	level	themes	and	coding	categories	is	
shown	in	table	5.5:	
	 Brief	Description	of	Codes	
Category	–	Product	&	Service	Attributes	
Theme	-	HCP	and	Service	
Delivery	
Tangible	service	characteristics	relating	to	
health	care	professionals	and	service	delivery	
(excluding	testing)	
Theme	-	Time		 All	aspects	associated	with	time	involved	in	
testing	and	treatment	for	STIs	
Theme	-	Testing	 Specific	to	the	test	element	of	the	pathway,	
test	properties,	sample	collection,	results	
notification	
Category	–	User	Impact	
Theme	-	Emotions,	
Beliefs	and	Perceptions	
Values,	attitudes,	beliefs	and	emotions	in	
respect	of	sexual	health	services.	Personal	
reflections	and	reflections	on	others’	
behaviours	and	views	on	services	
Theme	-	Tangible	Impact	 Physical	(rather	than	emotional)	factors	
having	an	impact	on	the	user		
Category	–	Participant	Questions	
Theme	-	Participant	
Questions	
Questions	asked	of	the	focus	group	facilitator,	
seeking	to	provide	clarity	on	an	aspect	of	STIs	
or	service	delivery	
Table	5.5	-	High	Level	Coding	Categories	and	Themes	
Data	 summaries	 in	 conjunction	 with	 matrix	 coding	 queries	 were	
used	 to	 structure	 the	 analysis.	 Starting	 initially	 with	 the	 factors	
relating	 to	 the	 service	 and	 product	 characteristics	 the	 most	
frequently	coded	sub-themes,	common	to	the	majority	or	all	focus	
groups	were	reviewed	to	identify:	
• what	participants	said	about	a	particular	factor,	
• variation	 within	 and	 between	 groups	 in	 their	 views	 of	 a	
particular	sub-theme,	
• how	 they	 linked	 (or	 did	 not	 link)	 the	 sub-theme	 to	 other	
sub-themes	or	themes	(e.g.	values	or	emotions).	
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This	 enabled	 the	 findings	 to	 be	 grouped	 into	 three	 overarching	
categories	for	further	exploration,	outlined	in	detail	in	section	5.2.6.	
Participant	 questions	 was	 established	 as	 a	 separate	 theme	
recognising	their	potential	contribution	to	the	development	of	the	
background	 and	 introductory	 information	 for	 the	 DCE,	 as	 well	 as	
identifying	potential	 attributes	 and	 levels.	 The	discussion	 seeks	 to	
build	 on	 this,	 offering	 explanation	 for	 the	 linkages	 found	 and	
exploring	the	impact	of	the	use	of	the	focus	group	method	including	
the	 role	 of	 the	 facilitator,	 the	 use	 of	 vignettes	 and	 the	 impact	 of	
group	dynamics	on	the	findings.	The	discussion	of	the	strengths	and	
limitations	of	this	research	are	presented	in	section	5.2.7.	
	
5.2.6 Findings	
The	findings	were	grouped	into	the	three	categories	identified	from	
coding	 the	 focus	 groups	 as	 outlined	 in	 table	 5.5.	 The	 categories	
build	 on	 each	 other	 but	 are	 presented	 in	 this	 section	 in	 order	 of	
frequency.	 Firstly,	 exploring	 the	 individual	 product/	 service	
characteristics	 of	 sexual	 health	 services	 and	 whether	 the	 focus	
group	participants	considered	them	important	and	how	they	traded	
between	 them.	 The	 second	 category	 built	 on	 this	 and	 considered	
the	 impact	 of	 values,	 beliefs,	 perceptions	 and	 emotions	 in	 the	
participants’	 consideration	of	 importance	–	whether	 there	was	an	
indicator	 as	 to	 what	 drives	 their	 view	 on	 importance.	 The	 final	
category	 looked	 at	 the	 understanding	 of	 STIs	 and	 sexual	 health	
services	and	how	this	may	shape	or	influence	views.	The	findings	in	
the	following	sections	are	presented	by	category	using	the	colours	
assigned	 in	figure	5.3	to	 link	the	quotes	to	categories;	sub-themes	
(codes)	 are	highlighted	 in	bold	 and	 italics,	with	 supporting	quotes	
from	 focus	 group	 participants	 provided	 for	 each	 point	made.	 The	
sub-themes	are	presented	 in	order	of	 frequency	of	discussion	and	
follow	the	natural	linkages	made	by	focus	group	participants.	
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5.2.6.1 Category	-	Product	and	Service	Attributes	
Time	 to	 result	 was	 the	 most	 consistently	 discussed	 sub-theme	
across	 all	 four	 focus	 groups.	 The	 vignettes	 presented	 three	
pathway	options	with	time	to	result	at	15	minutes,	7	days	and	14	
days.	The	view	across	all	 four	groups	was	generally	consistent	 in	
the	 consideration	 that	 the	 quicker	 results	 were	 available	 the	
better:	
“It’s	good	though	that	they	do	find	out	in	seven	days”	FG1,	Female,	age	
16	or	17	
	
“I	 think	 what	 I	 like	 about	 this	 because	 I’ve	 been	 going	 on	 about	 it	 is	
timing,	 I	mean	15	minutes	 compared	 to	14	days	and	7	days	 like	 I’ll	 be	
more	likely	to	use	that	service	because	you	get	it	in	…”	FG2,	Male,	17	
	
However,	 this	 was	 by	 no	 means	 universal	 with	 one	 participant	
equating	time	to	result	with	accuracy,	indicating	a	preference	for	a	
longer	waiting	time:	
“I	 mean	 like,	 compared	 to	 like	 I	 feel	 it’s	 it	 might	 be	 more	 accurate	
because	it	takes	like	14	days	to	actually	like	go	through	a	proper	test	and	
stuff”	FG4,	Female,	19	
	
The	main	reason	indicated	for	preferring	a	shorter	waiting	time	is	
due	to	worry	and	anxiety	about	what	the	result	will	be:	
“…	 and	 then	 you’re	 waiting	 those	 seven	 days,	 I	 think	 it’s	 just	 the	
worrying	bit	that	would	get	to	me,	like	worrying	if	you’ve	got	it	what	you	
do,	how	would	you	react	and	cope	FG2,	Male,	17	
	
“…	 it	might	 become	 clear	 in	 your	workplace	or	 at	 home	and	 social	 life	
that	clearly	you’re	anxious	because	it’s	hard	isn’t	it	to	think	that	you	are	
going	to	forget	for	two	weeks	the	fact	that	you	sent	off	a	test	for	an	STI”	
FG1,	Male,	16	
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Consideration	 of	 trade-offs	 for	 time	 to	 result	were	 highlighted	 by	
participants,	 particularly	 test	 accuracy,	 range	 of	 tests	 and	
knowledge	of	the	HCP:	
	
“…	15	minutes	 is	 nothing	 it’s	 in	 comparison	 to	 two	weeks	or	a	week	 if	
that	so	this	one	is	brilliant	for	time	I	suppose,	but	maybe	not	as	good	for	
really…	don’t	know	how	you	say	it,	accuracy?”	FG1,	Male,	17	
	
“…	because	waiting	time	is	a	huge	deal	because	I’d	just	be	worrying	for	
those	14	days	or	 those	15	minutes	but	 I’d	 rather	 it	be	15	minutes,	erm	
then	 I’d	be	very	conscious	of	 if	 I’m	not	getting	tested	 for	certain	 things	
and	then	I’d	be	very	conscious	of	how	accurate	it	is,	so	I	think	overall	I’d	
probably	go	for	the	sexual	health	clinic…”	FG2,	Male,	17	
	
“…	but	as	he	said	before	if	you’ve	got	to	wait	longer	but	the	person	like	
that	 is	 going	 to	 be	 telling	 you	 has	 more	 knowledge	 surely…”	 FG1,	
Female,	Age	16	or	17	
	
“Although	 it’s	 more	 convenient	 considering	 the	 fact	 you	 get	 to	 do	
everything	over	the	Internet	and	if	that	takes	seven	days	and	this	takes	
14	 days	 from	 your	 home	 it’s	 always	more	 convenient	 and	 it	 saves	 you	
travel	 cost	 and	 everything,	 but	 er	 yes,	 I	 think	 erm	 if	 you	 would	 cover	
more	tests	it	would	definitely	be	better”	FG3,	Male,	24	
	
Time	to	result	dominated	discussion	compared	to	other	aspects	of	
time	involved	within	the	pathway	such	as	clinic	waiting	time	with	
one	participant	acknowledging:	
“so	 if	 the	 waiting	 time	 were	 shorter	 I	 would	 definitely	 think	 of	 going	
more	often…”		FG4,	Female,	21	
	
and	total	pathway	time:	
“It	takes	ages,	in	theory	it	could	take	like	17	days…because	you	have	to	
order	it	as	well”	FG1,	Male,	17	
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These	 findings	 are	 in	 line	 with	 findings	 from	 other	 published	
studies	which	 recognise	 that	 reduced	waiting	 time	enhances	 the	
acceptability	 of	 a	 service	 e.g.	 self-management	 within	 a	 GUM	
clinic	 (Baraitser	 et	 al.,	 2011,	 Fernando	 and	 Thompson,	 2013,	
Martin	 et	 al.,	 2013),	 within	 mainstream	 sexual	 health	 services	 -	
speed	 of	 service	 and	 time	 to	 result	 being	 the	 second	 and	 third	
most	 important	aspects	of	care	 (Hitchings	et	al.,	2009)	and	rapid	
testing	within	primary	care	(Schwandt	et	al.,	2012).	
	
Reduced	 time	 to	 result	has	been	 found	 to	be	both	an	 important	
factor	 in	 acceptability	 of	 HIV	 testing	 in	 community	 locations	
(Guenter	 et	 al.,	 2008)	 and	 HIV	 testing	 in	 general	 (Peralta	 et	 al.,	
2007,	 Tomnay	 et	 al.,	 2014,	 Turner	 et	 al.,	 2013),	 although	 other	
research	has	found	that	in	the	case	of	rapid	testing	for	HIV	time	is	
preferable	 to	 enable	 an	 individual	 to	 come	 to	 terms	 with	 the	
impact	of	the	result	outcome	(Cohall	et	al.,	2010).		
	
Test	 accuracy	 also	 featured	 consistently	 in	 the	 discussion	 as	 an	
important	 factor	 for	young	people.	On	reflection,	 this	 sub-theme	
stands	out	because	it	was	introduced	into	the	discussion	by	young	
people	 in	 three	 out	 of	 four	 focus	 groups,	 although	 it	 did	 not	
feature	 in	the	vignettes.	Concern	that	the	result	would	be	wrong	
and	confusion	that	the	tests	would	not	be	100%	accurate	featured	
in	all	four	discussions	among	participants:	
“Well	 I	 would	 say	 like	 reliability	 because	 you	 don’t	 want	 to	 think	 you	
have	an	STI	when	you	actually	don’t”	FG1,	Female,	17	
	
“…	it	doesn’t	really	matter,	it’s	all	about	the	same	accuracy”	FG1,	Male,	
17	
	
“Are	the	ones	at	clinics	more	accurate	than	home	tests?”	FG1,	Male,	16	
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“I’d	order	online	if	that	would	be	more	likely	to	be	accurate”	FG2,	Male,	
17	
	
“Why	don’t	they	just	do	like	three	or	four	tests	when	someone	goes	in	to	
ensure	the	accuracy	is	going	on?”	FG2,	Male,	17	
	
“I	 think	 it’s	 not	 really	 something	 that	 you	 can	 have	 that	 isn’t	 accurate	
because	 it’s	 like	 obviously	 a	 lot	 of	 the	 time	 you	 don’t	 recognise	 the	
symptoms,	 you	 don’t	 know	 that	 there	 any	 symptoms	 and	 it’s	 not	 like	
being	pregnant	where	if	you’re	throwing	up	every	morning	it’s	probably	
quite	likely…”	FG2,	Female,	17	
	
“that	is,	that	is	quite	important	but	again	it	depends	on	if	you’re	saying	
that	the	clinic	is	99%	and	this	is	95%	then	I	think	I’d	still	be	inclined	but	if	
there	is	a	larger	difference	then…”	FG3,	Male,	18	
	
“Yeah	 the	 accuracy,	 it’s	 erm,	 I	 don’t	 mind	 1	 or	 2%	 of	 difference	 but	
because	erm	this	is	convenient	you	get	the	results	within	15	minutes,	but	
the	rest	is	like	a	week	or	two...”	FG4,	Female,	age	unknown	
	
Consideration	 was	 given	 to	 what	 accuracy	 means	 in	 terms	 of	
results,	 this	 was	 expressed	 by	 participants	 in	 terms	 of	 false	
negatives	 and	 false	 positives.	 Concerns	 erred	 slightly	 more	
towards	 false	negatives,	 i.e.	being	 told	 that	 you	do	not	have	 the	
disease	when	you	actually	do:	
	
“Well	 the	 reverse	 of	 that	 as	well	 as	 if	 it	 comes	 back	 negative	 and	 you	
actually	have	one…”	FG1,	Male,	17	
	
“…because	 it’s	 like	 obviously	 a	 lot	 of	 the	 time	 you	 don’t	 recognise	 the	
symptoms	you	don’t	know	that	there	are	any	symptoms…”	FG2,	Female,	
17	
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	“…	and	I	would	be	worried	especially	if	it	was	a	negative	result	because	I	
wouldn’t	 be	 sure,	 what	 if	 I	 still	 had	 it	 you	 know	 the	 disease?”	 FG4,	
Female,	age	unknown	
	
“Well	I	would	say	that	like	reliability	because	you	don’t	want	to	think	you	
have	an	STI	when	you	actually	don’t”	FG1,	Female,	17	
	
“…	they	would	interpret	that	as	like,	well	I	still	might	not	have	Chlamydia	
or	gonorrhoea,	and	 then	 they	 just	go	 to	 the	doctors	and	 this	would	be	
pointless…”	FG2,	Male,	17	
	
One	 participant	 highlighted	 concern	 about	 the	 impact	 of	 false	
positives	in	respect	of	treatment,	but	no	concerns	were	expressed	
by	participants	in	respect	of	the	‘life	impact’	a	false	positive	result	
could	have	for	either	themselves	or	their	partners:	
“So	couldn’t	an	issue	be	that	if	you,	if	you	were	tested	positive	but	like	it	
was	a	false	positive	that	getting	like	a	prescription	on	your	smartphone	
that	would	cause	issues	that	like	you’re	like	going	for	treatment	that	you	
don’t	need?”	FG1,	Female,	Age	16	or	17	
	
Participants	 highlighted	 their	 ways	 of	 compensating	 for	 accuracy	
concerns	 through	multiple	 testing	 and	 testing	 through	more	 than	
one	 route.	 In	 their	 comments,	 there	 was	 a	 clear	 underlying	
perception	 that	 the	 self-test	 would	 be	 less	 accurate	 than	 a	 test	
undertaken	at	a	clinic:	
“So	you	could	always	 take	two	tests	home,	 that’s	what	 I’m	going	with,	
you	might	as	well…”	FG1,	Male,	17	
	
“Can	you	not	do	it	several	times,	test	yourself	several	times	if	you	get	the	
same	result	then…”	FG3,	Male,	20	
	
“…	I’m	not	sure	how	much	I	would	trust	it	because	it’s	just	technological	
based,	I	would	rather	go	and	see	a	professional	just	to	make	sure	those	
are	the	right	results…”	FG4,	Female,	Age	unknown	
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“…it	would	be	good	to	recommend	for	them	to	either	do	another	test	or	
go	somewhere	else,	to	get	another	one…”	FG2,	Female,	17	
	
Again,	 the	 desire	 for	 an	 accurate	 test	 result	 among	 individuals	
considering	 testing	 for	 STIs	 had	 been	 identified	 in	 other	 peer	
reviewed	research,	although	the	number	of	studies	exploring	this	
is	 significantly	 fewer	 than	 those	 considering	 time	 to	 result.	
Llewellyn	and	colleagues	identified	concerns	regarding	accuracy	of	
home	sampling	kits	impacted	on	their	acceptability	to	MSM,	as	did	
Rompalo	and	colleagues	in	their	study	exploring	the	acceptability	
of	home	testing	POCT	within	the	general	population	(Llewellyn	et	
al.,	2009,	Rompalo	et	al.,	2013).	
	
The	range	of	tests	was	also	an	attribute	central	 to	discussions	 in	
all	 four	 focus	groups.	Participants’	 lack	of	prior	knowledge	about	
STIs	 was	 a	 common	 sub-theme	 in	 discussing	 the	 range	 of	 tests,	
particularly	whether	they	would	be	experiencing	symptoms:	
“Yeah	 definitely	 if	 you	 don’t	 know	 what	 you	 had	 and	 you	 had	 no	
symptoms	 it	would	probably	be	better	 to	have	more	 tests	 than…”	FG1,	
Female,	17	
	
whether	the	infections	were	treatable:	
“I	 think	 what	 you’re	 getting	 tested	 for	 cos	 even	 though	 those	 two	 do	
chlamydia	 and	 gonorrhoea	 the	 fact	 that	 HIV	 is	 the	 worst	 one	 in	 that	
you’ve	got	it	for	the	rest	of	your	life	and	that	isn’t	getting	tested	in	either	
of	these	I	think	is	quite	bad…”	FG2,	Female,	17	
	
and	 the	 assumption	 that	 a	 negative	 result	 for	 one	 STI	would	 be	
interpreted	that	they	are	negative	for	all	STIs:	
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“Yet	 people	might	 interpret	 that	 as	 they’re	 the	only	 two	 you	 could	get	
because	there	are	some	people	who	might	actually	think	wow	these	are	
the	only	 two	which	 I	 could	get	because	 I	 couldn’t,	 they	might	not	even	
bother	 to	 test	 for	 anything	 else	 just	 because	 that’s	 negative…”	 FG2,	
Female,	17	
	
“I	 think	 the	choice	here	 is	not	much,	you	 just	get	 tested	 for	 just	 two	of	
the	 STIs	 so	 that	 again	 is	 something	 that	 has	 to	 be	 taken	 into	
consideration	you	may	have	something	else”	FG3,	Male,	24	
	
Peace	 of	 mind	 (reassurance)	 was	 identified	 as	 being	 the	
overarching	reason	for	participants’	preference	for	more	tests:	
“…I’d	 be	 very	 conscious	 of	 if	 I’m	 not	 getting	 tested	 for	 certain	 things”	
FG2,	Male,	17	
	
“…	 but	 then	 you	 have	 two	 out	 of	 so	many	 that	 haven’t	 been	 tested,	 I	
think	 I’d	 go	 for	 the	 first	 one	 just	 to	have	a	 safe	mind,	 to	make	 sure…”	
FG3,	Male,	20	
	
“…	but	depending	on	the	situation	I	think	I’d	still	feel	uncomfortable	not	
knowing	if	I’ve	been	checked	for	other	things	too…”	FG3,	Male,	20	
	
“…well	 I	 think	 if	you	get	 tested	 for	more	erm	kinds	of	STIs	you’re	more	
like	assured	of	your	health	conditions”	FG4,	Female,	age	unknown	
	
	
Range	of	 tests	was	 identified	as	an	attribute	 in	both	Miners	and	
colleagues	 and	 Llewellyn	 and	 colleagues	 DCE	 exploring	 user	
preferences	for	testing	for	STIs.	They	 identified	participants	were	
2.19	 and	4.06	 times	more	 likely	 to	 choose	 services	which	 tested	
for	all	STIs	rather	than	some	STIs	respectively	(Miners	et	al.,	2012,	
Llewellyn	et	al.,	2013).		
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In	itself	this	finding	is	misleading	as	current	clinical	guidelines	are	
such	 that	 the	 range	of	STIs	 tested	 for	 in	a	GUM	clinic	are	a	core	
four	 (Chlamydia,	 Gonorrhoea,	 HIV	 and	 Syphilis),	 and	 any	 further	
tests	 undertaken	 are	 selected	based	on	 the	 risk	 exposure	of	 the	
patient	 (BASHH,	 2006).	 The	 qualitative	 research	 undertaken	 by	
Llewellyn	 and	 colleagues	 to	 enable	 the	 development	 of	 the	 DCE	
highlights	the	range	of	tests	offered	as	being	a	factor	in	choosing	
to	attend	a	GUM	clinic	 rather	 than	a	GP	 (Llewellyn	et	 al.,	 2012).	
This	was	also	borne	out	in	a	study	by	Hambly	and	Luzzi	exploring	
patient	preferences	 for	GUM	or	GP	based	sexual	health	services.	
They	 found	 that	 59%	 of	 patients	 preferred	 to	 attend	 GUM	
compared	with	30%	preferring	GP	services	and	the	range	of	tests	
was	identified	as	an	important	factor	in	this	decision	(Hambly	and	
Luzzi,	2006).	
	
Peace	 of	 mind	 (reassurance)	 was	 also	 reflected	 in	 considering	
access	to	a	healthcare	professional:	
“I	 think	 a	 disadvantage	 of	 this	 one	 would	 be	 that	 like	 medical	
reassurance	 because	 you’re	 not	 really	 in	 contact	 with	 a	 medical	
professional	so…”	FG1,	Female,	age	16	or	17	
	
“I	think	 just	going	to	a	clinic	seeing	a	professional	about	 it	 I	 think	 it’s	a	
bit	more	reassuring	in	a	sense	if	you	do	have	it	or	you	don’t	have	it	then	
there’s	someone	right	there…”	FG1,	Female,	age	16	or	17	
	
“I	feel	like	someone	talking	to	me	is	more,	I	feel	more	reassured…”	FG4,	
Female,	age	unknown	
	
“I	 think	 if	 for	 me	 it’s	 more	 comfortable	 to	 get	 professional	 walk	 you	
through	the	processes	and	and	to	give	you	kind	of	psychological	support	
some	 time	 because	 you,	 you	 might	 be	 feeling	 some	 uneasiness	 or	
depression	when	you	get	STI	tests…”	FG4,	Female,	age	unknown	
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However,	 this	was	 balanced	 by	 participants	 highlighting	 a	 desire	
for	privacy	and	embarrassment/	discomfort	at	discussing	their	sex	
lives	with	an	HCP:	
“Some	people	don’t	like…	feel	awkward,	they	might	not	want	to	speak	to	
anyone	 about,	 like	 a	 doctor	 or	 a	 nurse,	 they	 might	 rather	 do	 it	
themselves…”	FG2,	Female,	17	
	
“If	you’ve	got	to	say	to	someone,	 if	you’re	uncomfortable	about	talking	
about	sex,	you	are	going	to	say	to	someone	when	was	the	last	time	you	
had	 sex,	 and	 if	 you	use	protection,	 and	whether	 they’re	 your	partner…	
That’s	a	bit	like,	some	people	might	feel	uncomfortable	doing	that”	FG2,	
Female,	17	
	
“…and	 if	 you’re	 just	 answering	on	 the	app	 it	might	 be	a	 bit	more,	 you	
know	comfortable…	less	intimidating”	FG2,	Female,	17	
	
“I	think	maybe	even	with	the	doctor	that	could	be	a	bit	awkward	if	you	
have	to	tell	 them	about	your	sexual	past,	some	people	might	not	really	
like	that…”	FG3,	Male,	20	
	
Participants	 provided	 insight	 into	 access	 to	 a	 healthcare	
professional	generally	within	the	pathway,	access	to	a	health	care	
professional	 when	 they	 got	 their	 results,	 sample	 collection	
method	 -	whether	the	test	sample	was	a	self-sample	or	taken	by	
an	HCP,	and	treatment	consultation	method	–	how	they	engaged	
with	an	HCP	to	get	treatment.		
	
In	 respect	of	sample	collection	method	 the	 input	of	an	HCP	 into	
taking	 the	 sample	 was	 not	 considered	 important	 with	 one	
reference	to	HCP	input	being	beneficial:	
	
“…	 so	 there’s	 less	 privacy	 but	 maybe	 they	 know	 what	 they’re	 doing	
better	 than	 you	 would	 if	 you	 were	 doing	 the	 test	 yourself	 so…”	 FG4,	
Female,	21	
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This	 is	 borne	 out	 by	 the	majority	 of	 published	 studies	 that	 have	
found	 self-sampling	 and/	 or	 self-testing	 to	 be	 acceptable	 in	
asymptomatic	patients	as	summarised	in	table	4.9.	
	
Whereas	 being	 able	 to	 access	 a	 healthcare	 professional	 when	
they	 got	 their	 results	 was	more	 important	 than	 at	 the	 point	 of	
taking	the	test:	
“especially	if	you’re	positive”	FG1,	Male,	16	
	
“…I	think	that	if	it	says	that	you’re	positive	then	you’re	like	what	do	I	do	
now,	 I	 think	 sometimes	 it	 would	 be	 better	 if	 there	 was	 someone	 that	
rang	you	and	talked	through	your	options”	FG2,	Female,	17	
	
“talking	to	a	person	definitely	feels	better	as	I	mentioned	erm	I	think	yes	
I	 do	 support	 the	 fact	 that	 you	 should	be	able	 to	 talk	 to	 someone	 right	
after	your	results	come	back”	FG3,	Male,	24	
	
Again,	this	 is	supported	by	the	published	research	findings	which	
express	concern	at	the	lack	of	access	to	a	healthcare	professional	
including	 Bilardi	 and	 colleagues	 who	 found	 that	 HIV	 self-testing	
would	 be	 valuable	 but	 could	 not	 replace	 existing	 testing	 routes	
due	to	the	lack	of	professional	expertise	and	support	(Bilardi	et	al.,	
2013),	 and	 Greacen	 and	 colleagues	 who	 found	 that	 those	 not	
interested	 in	HIV	self-testing	cited	not	wanting	to	be	alone	when	
getting	results	as	a	limiting	factor	(Greacen	et	al.,	2013).	Prost	et	al	
(2007)	 found	 that	 post-test	 support	 was	 a	 limiting	 factor	 in	
outreach	 for	 HIV	 rapid	 testing.	 In	 considering	 more	 general	 STI	
testing	support	for	individual’s	receiving	a	positive	result	has	been	
identified	 as	 a	 concern	 for	 the	 acceptability	 of	 internet	 based	
testing	 and	 other	 remote	 care	 pathways	 (Hottes	 et	 al.,	 2012,	
Llewellyn	et	al.,	2009).		
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Despite	 the	 desire	 to	 have	 access	 to	 a	 healthcare	 professional	
when	they	got	their	results	how	they	were	notified	of	their	results	
(results	 notification)	 was	 considered	 a	 sub-theme	 of	 low	
importance	when	it	comes	to	making	a	decision	on	whether	to	use	
a	service	with	a	number	of	comments	along	similar	lines:	
“As	long	as	I	know	I	don’t	really	mind”	FG1,	Male,	17	
	
“….Ok	 I	 think	the	option	of	getting	a	text,	getting	a	call,	getting	on	the	
app	they’re	all	very	similar	to	me	to	be	honest,	that	wouldn’t	bother	me	
too	much”	FG3,	Male,	20	
	
However	participants	in	one	focus	group	did	highlight	a	difference	
of	opinions	in	results	notification	for	positive	rather	than	negative	
results:	
“Or	does	 it	depend	how	serious	 it	 is	though	like…	because	 if	 it’s	serious	
then	I’d	rather	have	a	phone	call	than	a	text”	FG1,	Female,	17	
	
“It	would	be	quite,	I	don’t	know	serious,	as	to	get	a	text	to	say	you’ve	got	
HIV	or	you’re	HIV	positive”	FG1,	Male,	16	
	
“Well	it’s	still	a	personal	conversation,	it’s	a	lot	better	than	a	text	to	say	
you’ve	got	syphilis,	best	of	luck”	FG1,	Male,	16	
	
Considerable	 research	 has	 been	 undertaken	 on	 patient	
preferences	 for	 results	 notification	 for	 STIs,	 this	 has	 found	 that	
people	 want	 to	 be	 notified	 of	 all	 results	 (including	 negatives)	
rather	than	just	positives	(Brown	et	al.,	2008,	Miners	et	al.,	2012,	
Patel	 et	 al.,	 2006),	 and	 generally	 prefer	 a	 remote	 notification	
method	 such	 as	 text	 for	 negative	 results	 and	 in	 person	method	
such	 as	 phone	 for	 positive	 results	 (Martin	 et	 al.,	 2013,	
Saadatmand	et	al.,	2012).		
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A	 number	 of	 studies	 have	 looked	 at	 preference	 for	method	 and	
results	 (based	 on	 the	 number	 of	 studies)	 have	 identified	 a	
preference	 for	 phone,	 (Holloway	 et	 al	 2011),	 with	 Knussen	 and	
Flowers	noting	a	preference	for	calling	in	rather	than	being	called	
(Knussen	and	Flowers,	2007),	text	(Miners	et	al.,	2012),	accessing	
a	website	to	get	results	(Ling	et	al.,	2010)	or	email	(Brugha	et	al.,	
2011).	
	
Within	 treatment	 consultation	 method	 (online,	 phone,	 face-to-
face)	how	access	 to	a	healthcare	professional	was	provided	was	
not	a	major	consideration	within	any	of	the	focus	groups	however	
participants	expressed	some	clear	individual	preferences:	
	
“Personally	I	wouldn’t	Skype	over	syphilis”	FG1,	Male,	17	
	
“I	 couldn’t	 take	 anyone	 seriously	 if	 I	 was	 on	 my	 bed	 [with	 someone]	
telling	me	I’ve	got	HIV”	FG1,	Male,	17	
	
“I	 definitely	 have	 a	 preference	 and	 that	would	 be	 at	 the	 clinic.	 I	 don’t	
particularly	like	talking	to	people	on	the	phone,	personally	I	don’t	know	
why,	I	don’t	know	what	it	is	but	I	just	don’t	like	talking	to	people	on	the	
phone	and	over	the	Internet	it’s	the	same	kind	of	thing	you	don’t	feel	like	
you’re	 talking	 to	 a	 real	 person,	 anything	 that	we’re	 agreeing	here	 it	 is	
nice	to	talk	to	a	real	person”	FG3,	Male,	18	
	
This	 is	 in	contrast	 to	a	small	number	of	specific	studies	exploring	
telemedicine	 options	 within	 sexual	 health	 services	 for	 young	
people.	Garrett	and	colleagues	found	that	young	people	preferred	
in	 person	 consultation	 (85%),	 compared	with	 63%	 for	 telephone	
consultation	 and	 29%	 video	 consultation	 (Garrett	 et	 al.,	 2011).	
This	 view	was	different	 in	a	 subsequent	 study	considering	young	
people	 in	 rural	 locations	 who	 identified	 that	 telephone	
consultation	was	 preferable	 to	 face-to-face	 consultation	 (Garrett	
et	al.,	2012).	
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Within	 the	 context	 of	 access	 to	 a	 healthcare	 professional	 two	
other	 related	 attributes	 were	 discussed	 knowledge	 of	 the	
healthcare	professional	(specialist	knowledge	of	STIs)	and	type	of	
healthcare	 professional	 (e.g.	 doctor,	 nurse	 or	 pharmacist).	 The	
degree	 of	 importance	 placed	 upon	 knowledge	 varied	 between	
focus	groups	and	participants	within	focus	groups:	
	
“As	important	as	getting	the	test	results	is,	it’s	quite	useless	if	you	get	a	
positive	 result	 and	 the	person	 you	go	 to	 see	has	 rather	 vague	or	 basic	
knowledge…”	FG1,	Male,	16	
	
“I	 don’t	 think	 this	matters	 because	 you’re	 getting	 the	 test	 done	 so	 the	
knowledge	of	the	healthcare	professional	you	go	and	see	doesn’t	matter	
you,	until	you	find	out	what	your	results	are”	FG1,	Female,	age	16	or	17	
	
“But	surely	the	person	in	healthcare,	healthcare	is	not	really	easy	to	get	
into	if	you	can	be	in	it	you	are	going	to	be	trained.	If	you	go	ok	I’ve	come	
back	positive	for	chlamydia	they’re	not	going	to	go	I	dunno	what	that	is”	
FG1,	Male,	17	
	
This	assumption	about	the	being	a	healthcare	professional	 is	also	
reflected	 in	 the	 impact	of	 views	on	 trust	 in	 the	NHS.	 In	effect,	 it	
can	 be	 seen	 to	 mitigate	 the	 importance	 of	 an	 attribute	 within	
focus	group	discussions:	
“I	think	I	was	going	to	say	the	answer	is	if	it	was	really	that	threatening	
then	they	would	deliver	it	faster”	FG1,	Male,	17	
	
“it	would	be	by	the	NHS	I	suppose	so…”	FG3,	Male,	20	
	
“I	think	erm,	 I	kind	of	trust	the	NHS	to	 look	after	me	in	whatever	way	I	
need	to	be	looked	after…”	FG3,	Male,	18	
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Although	 the	 views	 were	 mixed	 on	 type	 of	 healthcare	
professional,	 when	 it	 came	 to	 the	 group	 ranking	 task,	 type	 of	
healthcare	 professional	 was	 ranked	 below	 knowledge	 of	 the	
healthcare	professional	in	three	out	of	the	four	focus	groups:	
“well	all	that	said	I’d	rather	see	a	sexual	health	specialist	than	a	GP.	If	I	
had	my	suspicions	and…”	FG1,	Male,	17	
	
“…specialist	 would	 always	 be	 better	 but	 then	 again	 erm	 it’s	 not	 a	 big	
deal	I	don’t	think”	FG3,	Male,	24	
	
“I	 would	 prefer	 a	 doctor	 compared	 to	 a	 nurse	 I	 think	 they	 are	 more	
experienced	 and	 can	 like,	 can	 understand	 your	 situation	 and	 the	
symptoms	of	your	infection	maybe”	FG4,	Female,	age	unknown	
	
Drawing	together	the	published	literature	on	type	and	knowledge	
of	 healthcare	 professional,	 Baker	 and	 colleagues	 found	 that	
patients	were	 comfortable	 consulting	with	 GPs	 on	 STIs,	 and	 this	
increased	 if	 the	GP	had	a	 specialist	 qualification	 in	 sexual	 health	
and	reduced	if	they	knew	the	GP	socially	(Baker	et	al.,	2013)	whilst	
Gray	 and	 colleagues	 noted	 a	 higher	 percentage	 of	 people	
identifying	their	GP	as	their	preference	for	accessing	sexual	health	
services	(Gray	et	al	2009).		
	
Hambly	and	Luzzi	 identified	specialist	knowledge	as	being	one	of	
the	most	 important	 factors	 identified	 by	 patients	 in	 considering	
their	 preferences	 for	 GUM	 services	 compared	 with	 GP	 services	
(Hambly	 and	 Luzzi	 2006),	 a	 view	 supported	 by	 the	 findings	 of	
Miners	 and	 colleagues	 and	 Llewellyn	 and	 colleagues	 who	 found	
that	 ‘perceived	 expertise’	 was	 a	 key	 preference	 expressed	 by	
people	when	choosing	between	GUM	and	GP	services	(Miners	et	
al	 2012	 and	 Llewellyn	 et	 al	 2013),	 and	 Tomnay	 and	 colleagues	
found	that	generalist	rather	than	specialist	sexual	health	services	
was	a	barrier	to	online	STI	testing	(Tomnay	et	al	2014).		
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However,	Hitchings	and	colleagues	found	that	‘technical	expertise’	
was	 one	 of	 the	 least	 valued	 aspects	 of	 sexual	 health	 services	
(Hitchings	et	al	2009).		
	
Through	 the	 focus	 group	 discussions	 an	 overlap	 between	 the	
location	of	treatment	(outlined	 in	the	vignettes	as	completion	of	
online	 consultation	 pathway,	 GP	 or	 pharmacist	 consultation	 or	
attend	a	sexual	health	clinic)	and	treatment	consultation	method	
(online,	by	phone,	in	person)	as	factors	was	identified.	Views	were	
mixed	on	the	importance	of	location	of	treatment	as	an	attribute:	
	
“I	think	the	smartphone	way	is	better	in	that	sense”	FG1,	Female,	age	16	
or	17	
	
“When	you’ve	got	 it,	 you	got	 to	 find	 treatment	 so	doesn’t	 really	affect	
your…”	FG1,	Female,	age	16	or	17	
	
“I’d	rather	go	to	a	GP	than	have	to	go	to	a	sexual	health	clinic	because	
there’s	more	stigma	with	a	sexual	health	clinic	whereas…”	FG2,	Male,	17	
	
As	a	route	to	treatment	one	focus	group	highlighted	the	potential	
abuse	of	an	online	consultation:	
	“so	you	know	where	you	have	to	answer	questions	in	the	app	you,	what	
if	you	lied,	how	would	you…?”	FG2,	Female,	18	
	
“but	if	there	is	someone	there	you	are	less	likely	to	lie…”	FG2,	Female,	18	
	
“yeah	and	I	think	people	always	misuse	stuff	like	apps”	FG2,	Male,	17	
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No	 studies	 are	 thought	 to	 have	 published	 results	 specifically	
exploring	preferences	for	where	people	attend	for	treatment	once	
they	 have	 had	 a	 positive	 test	 result	 or	 how	 they	 access	 a	
healthcare	 professional	 for	 treatment	 outside	 of	 the	 studies	
exploring	 preferences	 for	 accessing	 sexual	 health	 services	 in	
general	terms	outlined	previously.		
	
Location	of	 test	 (e.g.	 self-test	at	home,	 self-sample	at	home	and	
send	 away	 for	 analysis,	 attend	GP	 practice,	 attend	 sexual	 health	
clinic)	 was	 discussed	 and	 was	 seemed	 to	 be	 considered	 an	
attribute	 of	 lower	 importance	 through	 the	 discussions	 than	
location	 of	 treatment,	 however	 through	 completing	 the	 ranking	
exercise	 as	 a	 group	 this	 was	 reversed.	 Within	 these	 discussions	
participants	 focused	 more	 on	 location	 of	 test	 as	 being	 the	
collection	point	for	the	test	e.g.	shops	or	ordering	online,	with	the	
actual	 location	 that	 the	 test	 was	 undertaken	 garnering	 more	
discussion	in	connection	with	sample	collection	method:	
	
“I	 like	 that	 you	 have	 the	 option	 to	 order	 online	 as	well	 because	 then	 I	
know	some	people	might	find	it	awkward	to	go	to	the	shop	and	pick	one	
up…”	FG3,	Male,	20	
	
“I	 find	 it	a	bit	embarrassing	maybe	going	up	to	a	shop	and	and	picking	
up	 you	 know	 the	 test	 product	 that	 everyone	 would	 see	 what	 I’m	 you	
know,	what	I’m	buying”	FG4,	Female,	21	
	
Discussion	 took	 place	 within	 Focus	 Group	 2	 about	 the	 need	 to	
make	STI	 testing	kits	more	widely	available	 to	 reduce	 the	stigma	
associated	 with	 testing	 including	 suggestions	 of	 schools,	 youth	
centres	and	public	toilets:	
	
“…more	commonplace	like,	 if	 I	saw	like	STI	tests	everywhere,	 I’d	just	be	
like	oh	yeah,	there’s	another	STI	test…”	FG2,	Male,	17	
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Of	 the	 points	made	 in	 respect	 of	 the	 location	 of	where	 the	 test	
would	be	undertaken,	Focus	Group	2	highlighted	an	indication	of	a	
preference	for	remote	testing	over	clinic	based	testing:	
	
“We	all	 know	 that	 if	 you	go	 to	 the	 hospital	 you’re	 in	 there	 for,	 bloody	
days	just	to	have	a	blood	test	taken…”	FG2,	Female,	17	
	
“…but	I	think	it’s,	it’s	more	comfortable	I’d	say,	you	can	do	it	in	your	own	
home…”	FG2,	Female,	17	
	
Finally,	how	 you	 tell	 your	 partners	was	 considered	 by	 the	 focus	
group	participants	as	being	of	lower	importance	than	the	majority	
of	 other	 attributes	 in	 the	 discussions	 and	 it	 was	 ranked	 in	 the	
lower	 half	 of	 factors	 in	 the	 ranking	 exercise.	 The	 discussions	
highlighted	 mixed	 views	 on	 partner	 notification	 ranging	 from	
participants	 expressing	 a	 view	 that	 they	 should	 not	 be	 told	 via	
text,	indicating	a	preference	for	telling	partners	face-to-face:	
	
“Personally	 for	me	telling	 then	over	 text	 is	a	 lot	worse	 than	 just	seeing	
them	it’s	like	hey	baby	you’ve	got	syphilis”	FG1,	Male,	17	
	
“It’s	not	something	you	really	want	to	say	over	text	is	it?”	FG2,	Female,	
17	
	
“Another	thing	like	we	looked	at	each	other	so	funny	when	you	can	just	
send	like	your	partner	just	like	this…”	FG2,	Male,	17	
	
“Can	you	 imagine	 if	 you’re	out	and	you	got	 that…	you’d	be	 like	what’s	
this?	Oh	my	God…”	FG2,	Female,	17	
	
With	one	participant	acknowledging	that	the	new	eHealth	service:	
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“…definitely	removes	the	pressure	from	it	especially	if	like	going	to	tell	a	
partner…”	FG2,	Male,	17	
	
Whereas	 other	 participants	 acknowledged	 a	 preference	 for	 a	
clinician	to	notify	their	partners	for	them:	
“I	 quite	 like	 the	 part	 where	 the	 doctor	 will	 tell…	 notify	 your	 partner	
about	 it	 that	 you	 don’t	 have	 to	 tell	 your	 partner	 directly	 by	 yourself”	
FG4,	Female,	age	unknown	
	
“…	I	don’t	think	it’s	quite	a	good	idea	to	like	tell	your	partner	by	yourself,	
it	kind	of,	it	doesn’t	give	you	choice	to	avoid	those	uneasy	and…	like	you	
have	to	 tell	your	partners	yourself	but	 in	 the	previous	scenario	you	can	
help	from	the	advisors”	FG4,	Female,	age	unknown.	
	
Apoola	 and	 colleagues	 identified	 that	 preferences	 for	 partner	
notification	 vary	 depending	 on	whether	 the	 respondents	 viewed	
themselves	as	the	index	patient	or	a	contact	(Apoola	et	al.,	2007).	
Gotz	and	colleagues	 identified	that	an	online	partner	notification	
tool	was	particularly	 suited	 to	patients	who	were	notifying	more	
than	one	partner	(Gotz	et	al.,	2014),	while	Mimiaga	and	colleagues	
noted	a	‘broad	acceptance’	of	 internet	based	partner	notification	
(Mimiaga	et	al.,	2008).	However,	Kerani	and	colleagues	found	that	
men	were	less	likely	to	seek	care	than	if	they	were	notified	by	an	
e-card	 compared	 to	 direct	 notification	 (Kerani	 et	 al.,	 2013),	 and	
Shivasankar	 and	 colleagues	 noted	 a	 preference	 for	 traditional	
partner	referral	(Shivasankar	et	al.,	2008).		
	
Gursahaney	 and	 colleagues	 found	 that	 patient	 delivered	 partner	
notification	 was	 more	 successful	 where	 people	 were	 in	
established	 relationships	 (Gursahaney	 et	 al.,	 2011),	 a	 view	
indirectly	 supported	by	 Jones	and	 colleagues	who	 identified	 that	
third	party	partner	notification	was	preferred	if	the	partner	was	a	
casual	partner	(Jones	et	al.,	2013).	
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This	 completes	 the	 summary	 of	 the	 findings	 into	 participants’	
views	on	product/	service	characteristics	introduced	into	the	focus	
groups	by	the	 facilitator,	either	 through	the	vignettes	or	 through	
the	 subsequent	 group	questions.	Of	 note	 is	 that	 participants	 did	
introduce	two	factors	themselves	that	had	not	been	identified	by	
the	 facilitator	 prior	 to	 running	 the	 focus	 groups	 –	 data	 security	
and	staff	attitude.		
	
Data	 Security	 and	 aspects	 of	 it	 such	 as	 data	 sharing	 with	 other	
health	 services,	 and	 security	 on	 smartphones	 was	 raised	 by	
participants	 in	 all	 four	 focus	 groups.	 The	 issues	 ranged	 from	 the	
security	of	the	app/eHealth	clinic	itself:	
“I	 think	 there	 is	 always	 the	 risk	 of	 security	 of	 using	 smartphones	 and	
apps	and	that	might	not	be	an	issue	but	it	could	be	…”	FG1,	Female,	17	
	
“I	think	like	a	really	small	thing	about	it	is	just	the	confidentiality	aspect	
that	like	if	someone’s	going	through	your	phone,	because	I	don’t	know	if	
the	app	saves	your	erm	answers	or	your	results	or	if	you	do	really	want	it	
to	 be	 confidential	 your	 friends	 might	 see	 it	 or	 something	 and…”	 FG4,	
Female,	age	unknown	
	
to	perceptions	of	 a	 greater	degree	of	 confidentiality	 afforded	by	
face-to-face	and	clinic	services:	
	
“…	when	you’re	talking	to	erm	erm	to	someone	personally	and	erm	I	and	
when	 you’re	 in	 contact	 with	 them	 erm	 and	 you’re	 sure	 that	 the	
information	will	be	confidential…”	FG3,	Male,	24	
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“I	 think	 when	 someone	 don’t	 want	 other	 people	 to	 know	 about	 them	
going	 to	 see	 the	 clinic	 they	 won’t	 do	 it	 online,	 just	 everything’s	 got	 a	
record	 and	 erm	 it’s	 probably,	 I	 don’t	 know,	 more	 dangerous,	 it’s	 less	
confidential	than	the,	it	seems	like	less	confidential	than	the	clinic”	FG4,	
Female,	unknown	
	
Three	 studies	 identified	 in	 the	 literature	 review	 identified	
confidentiality	 and	 privacy	 concerns	 to	 be	 a	 barrier	 to	 internet	
based	chlamydia	testing	(Lorimer	and	McDaid,	2013,	Hottes	et	al.,	
2012,	Tomnay	et	al.,	2014)	however	 this	 is	not	highlighted	as	an	
issue	in	other	studies	where	participants	value	the	convenience	of	
this	service	option	(Greacen	et	al.,	2013,	Kwan	et	al.,	2012,	Novak	
and	Karlsson,	2006,	Shoveller	et	al.,	2012).	
	
Staff	 attitude	 was	 raised	 as	 an	 issue	 in	 one	 focus	 group,	 drawn	
from	the	personal	reflections	of	participants	who	had	either	used	
testing	services	or	accompanied	friends	to	sexual	health	services:	
“First	impressions,	I	think	counter	staff,	right,	I	just	thought	of	this,	when	
I	got	tested	right,	the	first	impression	I	had	of	the	staff	was	so	rude,	like	
they	they	just	didn’t	smile	and	make	you	feel	welcoming	or	reassuring	so	
I	think	that’s	a	key	little	bit	there	which	I	would	prefer”	FG2,	Male,	17	
	
“…like	I	remember	when	my	friend	went	to	get	the	morning	after	pill	and	
she	was	worried	 that	 she	 had	 an	 STI,	 erm	 and	 like	 the	woman	 at	 the	
counter	was	 like	 ‘oh	 is	 this	 for	 you’	 and	 she	made	 like	 really	 sarcastic	
comments	and	that	really	puts	people	off	like,	I	think	people	who	work	in	
sexual	 health,	 should,	 like	 not	 that	 they’re	 nasty	 but	 like	 everyone…	
should	be	more	considerate”	FG2,	Male,	17	
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Staff	 attitude,	 for	 example,	 friendliness	 and	 empathy,	 has	 been	
identified	 as	 important	 in	 a	 number	 of	 studies	 (see,	 for	 example,	
Hambly	 and	 Luzzi	 (2006);	 Ingram	 and	 Salmon	 (2007);	 and	 Knapp	
and	Anaya	(2010)).	Staff	gender	was	also	identified	as	an	important	
factor	 in	 a	 study	 on	 sexual	 health	 service	 design	 in	 which	 young	
people	ranked	factors	of	importance	(Jerome	et	al.,	2009).		
	
5.2.6.2 Category	-	User	Impact	
In	understanding	why	participants	placed	importance	on	particular	
product/	 service	 characteristics,	 their	 preference	was	 considered	
in	 the	 context	 of	 their	 broader	 statements	 and	 the	 group	
discussion.	 This	broadly	 fell	 into	 two	 themes	 related	 to	 impact	–	
emotions,	beliefs	and	perceptions	(the	emotional	impact)	and	the	
tangible	impact	of	testing	(the	user	impact)	Again,	a	matrix	coding	
query	 was	 used	 to	 map	 frequency	 of	 codes	 falling	 into	 these	
themes.	Starting	with	the	emotional	impact	theme,	worry	was	the	
emotion	mentioned	most	 frequently	 for	 making	 a	 choice	 in	 the	
consideration	 of	 the	 importance	 of	 an	 attribute	 in	 making	 a	
decision	be	that	waiting	for	results	(the	most	common),	the	range	
of	STIs	you	get	tested	for	or	the	‘fit’	of	a	service	to	their	personal	
circumstance:	
“…	 and	 then	 you’re	 waiting	 those	 seven	 days,	 I	 think	 it’s	 just	 the	
worrying	bit	that	would	get	to	me,	like	worrying	if	you’ve	got	it	what	you	
do,	how	would	you	react	and	cope”	FG2,	Male,	17	
	
“well	obviously	because	I’ve	been	nagging	on	about	it	all	night	tonight,	it	
would	definitely	be	the	time	and	the	worrying…”	FG2,	Male,	17	
	
“because	 if	 I	 was	 nervous	 about	 it	 I	 would	 want	 to	 know	 within	 15	
minutes	not	have	to	wait	two	weeks”	FG3,	Male,	20	
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“I’m	 more	 concerned	 about	 the	 overall	 time	 duration	 it’s	 like	 you’re	
never	sure	when	you	get	the	provisional	results	and	you	have	to	wait	for	
the	full	report	and	you’re	constantly	worrying	about	that	for	that	time”	
FG4,	Female,	age	unknown	
	
“Well	if	you	have	symptoms	then	it	might	well	make	more	sense	for	you	
to	go	a	clinic	whereas	 if	 you	don’t	and	you’re	 just	worried	 the	 internet	
one	might	make	more	sense…”	FG3,	Male,	18	
	
“My	 worry	 would	 be	 that	 because	 it’s	 not	 quite	 to	 my	 situation,	 or	 it	
might	not	be	quite	tailored	to	my	situation	it	might	be	a	bit	wrong,	then	
I’d	get	nervous…”	FG2,	Male,	17	
	
Privacy	was	the	most	frequently	cited	reason	for	the	desirability	of	
a	 particular	 product/	 service	 characteristic	 but	 was	 viewed	 by	
participants	 as	 a	 significant	 consideration	 in	 making	 a	 choice	 to	
use	a	service:	
“But	 then	 you	 could	 argue	 if	 you’re	 having	 it	 ordered	 to	 your	 house	
somebody	 might	 not	 like	 that	 because	 if	 someone	 else	 like	 sees	 it,	
whatever	then…	FG1,	Female,	17	
	
“you	can	get	privacy	as	well,	 like	 I	 said	before,	 if	 you	are	going	 into	a,	
walking	 into	 a	 clinic	 you	 might	 not	 want	 someone	 to	 see	 you,	 some	
people	 don’t	 like,	 feel	 like	 awkward,	 the	 might	 not	 want	 to	 speak	 to	
anyone	 about,	 like	 a	 nurse	 or	 a	 doctor	 so	 they	 might	 rather	 do	 it	
themselves”	FG2,	Female,	17	
	
“…	 you	 get	 to	 kind	 of	 do	 everything	 almost	 anonymously	 like	 over	 the	
internet	 you	 kind	 of	 feel	 that	 you’re	 anonymous	 so	 you	 kind	 of	 get	 to,	
you	 don’t	 talk	 to	 another	 human	 being	 about	 it	 or	whatever	 until	 you	
know	 you’re	 positive	 so	 that	 kind	 of	 appeals	 to	 me	 a	 bit	 more.”	 FG3,	
Male,	20	
	
And	also	as	a	factor	that	they	would	be	willing	to	trade	in	favour	of	
another:	
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“…	to	be	very	honest	erm	all	the	people	would	like	to	keep	it	very	private	
which	 makes	 it	 all	 the	 sense	 but	 then	 again	 when	 you’re	 talking	 to	
someone,	when	you’re	talking	erm	talking	to	someone	personally…	and	
you’re	 sure	 the	 information	 will	 be	 confidential	 I	 think	 it	 always	 feels	
better	 when	 you’re	 suspecting	 that	 you	 have	 an	 STI…	 it	 always	 feels	
better	to	talk	to	someone”	FG3,	Male,	24	
	
“So	there’s	less	privacy	but	maybe	they	know	what	they’re	doing	better	
than	you	would	if	you	were	doing	the	test	yourself	so…”	FG4,	Female,	21	
	
The	desire	for	privacy	was	closely	linked	with	embarrassment	and	
perception	 of	 others.	 Coding	 for	 embarrassment	 included	
consideration	of	situations	described	by	participants	as	awkward,	
embarrassing,	 and	 feeling	 self-conscious.	 These	 encompassed	
participants’	consideration	of	the	whole	pathway	in	general:	
	
“It’s	also	like	more	private	and	less	embarrassing”	FG1,	Female,	17	
	
“especially	 if	you	were	embarrassed	by	it	you	didn’t	want	to	tell	people	
you,	you	didn’t	want	people	to	know	where	you	were	going	or	whatever,	
that’s	not	the	kind	of	thing,	you	can’t	do	it	as	privately…”	FG3,	Male,	18	
	
The	embarrassment	of	talking	to	a	healthcare	professional	about	
their	sex	life:	
“If	you’ve	got	to	say	to	someone,	 if	you’re	uncomfortable	about	talking	
about	sex,	you	are	going	to	say	to	someone	when	was	the	last	time	you	
had	 sex,	 and	 if	 you	use	protection,	 and	whether	 they’re	 your	partner…	
That’s	a	bit	like,	some	people	might	feel	uncomfortable	doing	that”	FG2,	
Female,	17	
	
“I	 can	 see	 how	 this	 could	 be	 very	 advantageous	 for	 people	 who	 are	
maybe	 a	 bit	 more	 embarrassed	 about	 talking	 to	 someone	 about	 their	
problems”	FG4,	Female,	21	
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The	embarrassment	of	collecting	a	test:	
“I	 find	 it	 a	 bit	 embarrassing	maybe	going	up	 to	a	 shop	and	picking	up	
you	know	the	test	product	that	everyone	would	see	what	I’m	you	know,	
what	I’m	buying”	FG4,	Female,	21	
	
The	awkwardness	of	what	to	tell	your	partner:	
“Because	even	that	length	of	time	if	you	have	a	partner	you	don’t	really	
know	what	to	tell	them,	do	you	wait	until	you	got	the	result	and	that	can	
be	awkward	too,	and	with	the	awkwardness…”	FG3,	Male,	20	
	
And	seeing	other	people	that	you	know:	
“Yeah	that’s	always	awkward	when	you	go	in	and	you	see	someone	you	
know	and	it’s	like	oh	dear…”	FG2,	Female,	17	
	
The	perception	of	others	was	an	issue	highlighted	in	the	first	two	
focus	groups.	This	was	primarily	centred	on	their	peers	and	family,	
with	one	participant	drawing	a	personal	 reflection	on	her	 testing	
experience:	
“…I	went	once	to	get	a	test	done	and	I	saw	like,	just	a	girl	that	like	I	knew	
that	got	the	bus	with	me	and	it’s	just	one	of	them	where	you	both	look	
at	each	other	and	it’s	like	‘oh	I	know	why	you’re	here’	that	is	just	one	of	
them,	 like	 you	 don’t,	 you	 don’t	 really	 discuss	 it…	 but	 yeah	 it’s	 quite	 a	
stigma	around	STIs”	FG2,	Female,	17	
	
“It	might	become	clear	in	your	workplace	or	at	home	and	social	life	that	
clearly	you’re	anxious	because	it’s	hard	isn’t	it	to	think	that	you’re	going	
to	forget	for	two	weeks	the	fact	that	you	send	off	a	test	for	an	STI”	FG1,	
Male,	16	
	
A	reflection	on	the	perception	of	healthcare	professionals	was	also	
offered,	which	was	also	reflected	in	the	staff	attitude	sub-theme	
identified	by	Focus	Group	2:	
“And	then	if	they	had	something	they	might	think	that	they’re	going	to	
be	judged	because	they’ve…”	FG1,	Female,	17	
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Stigma	was	singled	out	in	Focus	Group	2	as	a	factor	impacting	on	
choice,	particularly	in	respect	of	perception	of	others	and	location	
of	services:	
	
“There’s	kind	of	a	stigma,	like	going	to…”	FG2,	Male,	17	
	
“That’s	 what	 you	 would	 need,	 that	 would	 take	 the	 stigma	 away,	 just	
having	them	everywhere…”	FG2	(in	respect	of	testing	kits),	Female,	17	
	
“because	you	can	like	choose	to	go	where	you	want	to	go	I’d	rather	go	to	
a	 GP	 than	 have	 to	 go	 to	 a	 sexual	 health	 clinic	 because	 there’s	 more	
stigma	with	a	sexual	health	clinic	whereas…”	FG2,	Male,	17	
	
In	respect	of	the	‘tangible	user	impacts’,	those	factors	associated	
with	what	 is	 involved	for	the	user,	the	biggest	consideration	that	
participants	gave	was	to	convenience,	however	although	a	flavour	
of	 convenience	 featured	 in	 Focus	 Groups	 1	 and	 2	 it	 was	 only	
explicitly	discussed	 in	Focus	Groups	3	and	4.	This	may	be	due	 to	
the	age	of	 the	participants	with	 the	 first	 two	 focus	groups	being	
comprised	 of	 16	 and	 17	 year	 olds,	 and	 3	 and	 4	 18-23	 year	 olds.	
Within	 the	 explicit	 discussions	 on	 convenience	 these	 centred	
primarily	on	time:	
	
“the	good	thing	about	this	test	is	that	it’s,	it	doesn’t	take	up	a	lot	of	my	
time,	I	can	do	it,	I	can	get	on	with	my	life	the	next	14	days	and	then	get	it	
back…”	FG3,	Male,	18	
	
“…	and	of	course	the	new	service	is	very	convenient,	it	is,	it	saves	time,	I	
think	yes	of	course	it	saves	time,	I	think	of	course	it	saves	money…”	FG3,	
Male,	24	
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“I	think	I	prefer	online	because	it’s	very	convenient,	compared	to	the	one	
like	 you	 have	 to	 go	 speak	 to	 the	 professional…”	 FG4,	 Female,	 age	
unknown	
	
“I	 find	 the	 internet	 testing	 is	 like	 convenient	 because	 you	 can	 do	
yourself…”	FG4,	Female,	19	
	
Convenience	was	also	discussed	 in	respect	of	 location	to	a	 lesser	
extent:	
“But	also	 convenient	 because	 if	 it	was	 in	 a	 nearby	 shop	 you	 can	get	 it	
from	there	as	well”	FG3,	Male,	18	
	
“One	thing	I	like	about	this	is,	 is	the	time	flexibility	you	can	order	a	test	
and	just	post	like	mail	it	to	the	erm	testing	centre	so	it	gives	you	choice	
on,	 you	 don’t	 need	 to	 book	 any	 clinic	 appointment”	 FG4,	 Female,	
unknown	
	
“…in	terms	of	at	least	sexual	health	clinic,	that	works	like	so	like	if	you’re	
in	a	city	you’ll	probably	be,	more	closer	to	a	clinic	so	that	you	can	walk	or	
something”	FG4,	Female,	unknown	
	
	
Little	 or	 no	 consideration	 was	 given	 to	 personal	 cost	 by	 the	
participants	 once	 it	 had	 been	 established	 that	 sexual	 health	
services	within	the	NHS	are	free	with	one	participant	referencing	
that	home-based	tests	would	save	on	travel	cost.		
	
A	 summary	of	 the	 findings	of	published	studies	 in	 respect	of	 the	
values,	beliefs	and	perceptions	which	impact	on	the	use	of	sexual	
health	services	is	provided	in	section	4.3.5.	
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5.2.6.3 Category	-	Participant	Questions	-	Understanding	STIs	and	Sexual	
Health	Services	
The	 third	 and	 final	 category	 relates	 to	 the	 questions	 asked	 by	
participants	in	order	to	inform	their	thoughts	and	decisions	as	part	
of	 the	 focus	 groups.	 Of	 the	 21	 participants	 four	 had	 previously	
tested	for	an	STI,	with	FG1	having	no	participant	who	had	tested	
for	an	STI	before.	Whilst	the	vignettes	provided	a	walk-through	of	
the	clinical	pathways	and	an	explanation	of	what	would	happen	at	
each	 stage,	 participants	 asked	 a	 number	 of	 questions	 of	 the	
facilitator	in	order	to	seek	more	information	before	commenting.		
	
Questions	asked	can	be	broadly	split	into	three	categories:	
• Pathway	clarification	e.g.	location	of	service,	time,	range	
of	tests		
• Test	product	based	e.g.	accuracy	and	reliability,	time	to	
result	
• STI	 based	 e.g.	 symptoms,	 complications,	 whether	
curable	or	incurable	
	
A	presumed	level	of	basic	knowledge	of	STIs	was	assumed,	given	
that	it	is	a	legal	requirement	that	all	schools	in	England	have	a	sex	
and	relationships	education	(SRE)	policy,	and	that	this	covers	the	
teaching	of	reproduction,	sexuality	and	sexual	health	(Long,	2016).		
	
The	 categories	 build	 on	 each	 other,	 starting	 with	 participant	
questions,	 to	 inform	 understanding	 and	 assessment	 of	 user	
impact,	 resulting	 in	 participants’	 preferences	 for	 product	 and	
service	characteristics	as	illustrated	in	figure	5.4.	
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Figure	5.4	-	Linkages	between	Themes	
	
5.2.6.4 Ranking	the	Product/	Service	Characteristics	
The	 final	 data	 obtained	 from	 the	 focus	 group	 was	 a	 ranking	
exercise	 of	 the	 long	 list	 of	 potential	 product/	 service	
characteristics.	As	outlined	in	more	detail	above	in	section	5.2.2.4,	
the	decision	to	include	this	was	as	an	enabler	for	discussion	on	the	
importance	 of	 characteristics.	 The	 level	 of	 engagement	 in	 the	
earlier	focus	group	questions	was	not	anticipated	when	designing	
them,	 which	 in	 part	 made	 this	 question	 less	 important	 as	
participants	 had	 outlined	 their	 views	 extensively	 in	 response	 to	
earlier	 questions.	 This	 in	 itself	 also	 made	 for	 much	 quicker	
progression	 through	 the	 ranking	question,	with	 the	 focus	groups	
all	completing	the	exercise	in	under	eight	minutes.	The	results	are	
shown	in	table	5.6:	
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Rank	 Product/	Service	
Characteristic	
FG1	 FG2	 FG3	 FG4	 Total	
1.	 Range	of	STIs	 3	 2	 1	 3	 9	
2.	 How	long	it	takes	to	get	
result	
1	 3	 5	 5	 14	
3.	 Sample	Collection	
Method	
7	 1	 3	 8	 19	
4.	 Accuracy	 6	 6	 7	 1	 20	
4.	 Access	to	HCP	(Result	&	
Treatment)	
4	 5	 2	 9	 20	
6.	 Treatment	Consultation	
Method	
5	 4	 9	 4	 22	
7.	 Knowledge	of	HCP	 2	 12	 11	 2	 27	
8.	 Where	you	do	the	test	 11	 8	 6	 6	 31	
9.	 How	you	tell	partners	 10	 7	 8	 7	 32	
9.	 Where	you	go	to	get	
treatment	
8	 10	 4	 10	 32	
11.	 Type	of	HCP	 9	 11	 10	 12	 42	
12.	 How	you	find	out	result	 12	 9	 12	 11	 44	
Table	5.6	-	Results	from	Focus	Group	Ranking	Question	
Characteristics	were	ranked	from	one	to	twelve,	with	one	being	the	
characteristic	of	most	importance.	The	results	are	presented	in	the	
table	in	the	order	of	importance,	with	the	lowest	total	score	being	
the	characteristic	of	most	importance	across	the	four	focus	groups.		
	
It	 is	 important	to	note	the	limitations	of	the	ranking	question.	The	
participants	in	each	focus	group	took	a	slightly	different	approach	in	
organising	 themselves	 to	 answer	 the	 question	 and	 how	 they	
selected	the	final	order.	FG1	and	FG3	had	a	clearly	identified	order	
of	 selection,	 with	 the	 exception	 of	 FG1	 where,	 on	 analysing	 the	
recording	afterwards,	it	was	not	clear	on	the	order	of	the	third	and	
fourth	 most	 important	 characteristic.	 FG2	 grouped	 the	
characteristics	 into	three	groups	–	a	bottom	four,	middle	four	and	
top	 four,	 the	 ranking	of	 the	 top	 four	 is	 clear	 but	 the	order	 in	 the	
middle	and	bottom	four	characteristics	less	clear,	the	order	given	in	
the	table	being	as	close	to	identifiable	from	the	recording.		
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FG4	discounted	characteristics	in	order,	but	not	necessarily	order	of	
priority,	with	their	discussion	of	the	card	presented	to	them	leading	
to	 the	 characteristic	 being	 discarded	 but	 not	 necessarily	 with	
consideration	to	its	relative	importance	to	other	characteristics.		
	
5.2.7 Discussion	
Results	from	the	focus	groups	provided	an	extremely	rich	source	of	
information.	 The	 themes	 identified	 from	 the	 thematic	 analysis	 of	
the	 data	 provided	 an	 innovative	 method	 of	 supporting	 the	 DCE	
development	 incorporating	 the	 respondent	 perspective	 on	 a	
number	of	levels:	
• Providing	insight	into	young	people’s	knowledge	of	STIs	and	
what	services	are	available	 to	 them.	This	helped	shape	 the	
background	information	provided	alongside	the	DCE.	
• Gathering	information	on	what	is	important	to	young	people	
in	making	a	decision	on	whether	to	test	for	an	STI	and	how	
to	 get	 treatment	 both	 in	 terms	 of	 attributes	 and	 potential	
levels.		
• Understanding	 how	 their	 emotions,	 values	 and	 beliefs	
influence	their	decision-making.		
	
One	strength	of	the	novel	approach	used	in	this	research	is	the	new	
knowledge	that	it	contributes	in	respect	of	young	people’s	views	on	
the	 technological	advances	 that	are	 feasible	 in	 the	next	3-5	years.	
These	 include	 self-testing	 via	 a	mobile	 phone,	 online	 consultation	
for	chlamydia	and	an	alternative	method	of	partner	notification.	 It	
also	 provides	 this	 within	 the	 context	 of	 a	 whole	 STI	 testing	 and	
treatment	 pathway	 as	 opposed	 to	 the	 current	 published	 studies	
that	 predominantly	 explore	 one	 aspect	 of	 a	 new	 technology	 e.g.	
self-testing	or	online	partner	notification.		
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Another	valuable	aspect	of	this	research	is	that	the	study	has	been	
undertaken	 with	 young	 people,	 rather	 than	 ‘service	 users’,	
including	 providing	 views	 from	 the	 broader	 population	 who	 have	
not	 previously	 used	 STI	 testing	 services.	 This	 is	 particularly	
important	 given	 that	 uptake	 by	 young	 people	 is	 the	 key	 factor	 in	
diagnosing	 and	 treating	 STIs	 for	 reducing	 transmission	 rates	 and	
preventing	long	term	complications.		
	
The	 findings	 of	 the	 focus	 group	 study	 support	 the	 overall	 general	
direction	 proposed	 in	 both	 general	 health	 policy	 and	 the	 national	
strategy	 for	 sexual	 health	 that	 seek	 to	 incorporate	 technological	
advances	 into	service	delivery,	this	was	demonstrated	through	the	
expression	 of	 support	 for	 remote	 testing	 options.	 However,	 the	
focus	 groups	 did	 not	 wholly	 embrace	 all	 of	 the	 options,	 most	
notably,	 non-face-to-face	 options	 for	 accessing	 a	 healthcare	
professional.	
	
The	research	has	some	limitations	which	are	important	to	note.	The	
first	 is	 that	 convenience	 sampling	 was	 used	 to	 recruit	 the	 focus	
group	participants.	The	impact	that	this	might	have	on	the	validity	
and	 generalizability	 and	 the	 steps	 taken	 to	 limit	 this	 impact	 have	
been	described	in	section	5.2.2.	The	second	is	that	only	the	author	
was	 present	 in	 the	 focus	 groups	 and	 her	 primary	 focus	 was	 the	
facilitation	of	the	group.	Whilst	 it	was	 important	 for	the	author	to	
demonstrate	 her	 competence	 as	 a	 researcher	 and	 no	 verbal	
communication	was	lost	owing	to	the	focus	groups	being	recorded,	
not	 all	 non-verbal	 group	 interactions	were	 recorded.	 This	 links	 to	
the	 following	point	 regarding	pre-existing	and	self-selected	groups	
as	considerably	more	non-verbal	communication	was	noted	within	
the	pre-existing	groups	than	the	self-selected	groups.		
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However,	 the	 opportunity	 to	 capture	 this	 fully	 was	 not	 possible.	
Reflecting	 on	 the	 non-verbal	 communication	 observed	 it	 is	 not	
believed	that	a	detailed	recording	of	the	non-verbal	communication	
would	 have	 affected	 the	 findings	 however,	 its	 incorporation	 may	
have	 enhanced	 the	 reflection	 of	 the	 degree	 of	 agreement	 or	
disagreement	within	the	group.			
	
The	recruitment	of	participants	from	pre-existing	groups	as	well	as	
focus	 groups	 with	 participants	 who	 were	 not	 known	 to	 one	
another,	provided	the	researcher	with	an	opportunity	to	experience	
and	consider	the	juxtaposed	views	of	Krueger	and	Kitzinger	on	the	
impact	 of	 running	 the	 focus	 groups	 and	 the	 information	 gained	
from	them.	Freeman	points	to	Krueger’s	critical	view	of	the	use	of	
convenience	samples	and	pre-existing	groups	due	to	the	impact	of	
the	pre-established	dynamics	which	he	believes	are	problematic	for	
analysis	 and	 the	 consequences	 for	 external	 validity	 (Freeman,	
2006).	 This	 is	 in	 contrast	 with	 Kitzinger’s	 view	 that	 pre-existing	
groups	offer	 a	 valid	way	 to	explore	 topics	 “friends	and	 colleagues	
can	 relate	 to	 each	 other’s	 comments	 to	 incidents	 in	 their	 shared	
daily	 lives.	 They	 may	 challenge	 each	 other	 on	 contradictions	
between	 what	 they	 profess	 to	 believe	 and	 how	 they	 actually	
behave”	(Kitzinger,	1995:300).	
	
A	 number	 of	 key	 differences	 were	 observed	 by	 the	 researcher	
between	the	pre-existing	and	self-selected	groups.	Firstly,	the	flow	
of	discussion	was	significantly	different	within	the	two	group	types.		
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Within	 the	 pre-existing	 groups	 there	 was	 ‘banter’	 between	
participants	and	they	would	pick	up	on	comments	made	by	others	
and	 continue	 to	 the	 point	 or	 offer	 a	 different	 point	 of	 view.	 The	
discussion	 became	 more	 tangential	 than	 the	 self-selected	 groups	
with	 the	 facilitator	needing	 to	 redirect	back	onto	 topic	on	a	 small	
number	 of	 occasions.	 Within	 the	 self-selected	 groups	 the	
interaction	 was	 very	 different,	 participants	 spoke	 in	 turn,	 they	
expressed	their	views	however	did	not	query	or	 link	 them	directly	
to	other	participants’	views	very	often.		
	
This	 impacted	 on	 the	 role	 of	 the	 facilitator	 greatly	 in	 terms	 of	
providing	 the	 acknowledgement	 and/	 or	 feedback	 to	 the	 group	
participants.	This	contrasted	with	the	experience	in	the	pre-existing	
groups	 where	 the	 facilitator	 felt	 much	more	 pulled	 by	 the	 group	
into	 their	 discussions	 as	 they	 actively	 sought	 to	 engage	 the	
facilitator	in	their	discussions	on	a	number	of	occasions.	Reflecting	
on	 the	 process,	whilst	 very	 different,	 both	 types	 of	 group	 yielded	
significant	 information	 on	 the	 participants’	 views	 of	 sexual	 health	
services.	
	
This	 section	 reported	 on	 the	 methods	 used	 and	 results	 obtained	
from	 the	 focus	 groups.	 The	 main	 themes	 have	 been	 set	 out	 and	
discussed	 in	 relation	 to	 young	 people’s	 view	 of	 different	 ways	 of	
accessing	 sexual	 health	 services	 for	 the	 testing	 and	 treatment	 of	
STIs.	The	next	section	takes	forward	the	selection	of	attributes	and	
levels	 for	 the	 DCE	 by	 using	 the	 results	 from	 the	 focus	 groups	 to	
inform	the	development	of	the	expert	groups.	
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5.3 Consultation	with	Expert	Groups	
The	need	to	“strike	a	balance	between	what	may	be	important	to	the	
respondent	and	what	 is	 relevant	 to	 the	particular	policy	or	decision	
making	environment”	is	identified	by	Bridges	and	colleagues	as	a	key	
consideration	in	the	identification	of	attributes	(Bridges	et	al.,	2011).	
Expert	 groups	 were	 selected	 as	 the	 method	 by	 which	 the	 findings	
from	the	focus	groups	with	young	people	(the	respondents)	could	be	
explored	with	a	range	of	professionals	with	expert	knowledge	of	the	
policy,	service	development	or	technology	context.		
	
5.3.1 Expert	Group	Objectives	
The	objectives	of	the	expert	groups	were	to	consider	whether:	
• The	potential	 attributes	met	best	 practice	 requirements	 as	
defined	by	 ISPOR	Conjoint	Analysis	working	 group	 (Bridges	
et	 al.,	 2011)	 as	 “a	 subset	 of	 all	 possible	 attributes	 can	 be	
determined	on	the	basis	of	three	criteria:	
o Relevance	to	the	research	question;	
o Relevance	to	the	decision	context;	
o Whether	 attributes	 are	 related	 to	 one	 another”	
(Bridges	et	al.,	2011:406);	
• Any	key	attributes	omitted	that	may	lead	response	bias;	
• Levels	 are	 sufficiently	 reflective	 of	 current	 and	 potential	
future	technology	developments.	
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5.3.2 Methods	
Consideration	 was	 given	 to	 the	 range	 of	 methods	 available	 for	
seeking	 expert	 opinion	 including	 consensus	 methods	 such	 as	 the	
Delphi	 technique	 and	 nominal	 group	 technique	 (Bowling,	 2009).	
However,	 following	 discussions	 with	 supervisors	 	 the	 author	
determined	that	running	the	expert	group	as	a	 focus	group	would	
best	deliver	the	objectives	by	enabling	discussion	around	a	series	of	
key	 questions	 “in	 a	 focused	 discussion	 to	 help	 understand	 the	
topic”	(Krueger,	1994:10).		
	
In	 designing	 the	 expert	 groups	 consideration	 was	 given	 to	 the	
methods	outlined	previously	and	the	topic	guide	was	structured	to	
provide	an	overview	of:	
• The	purpose	of	the	study,	
• Key	features	of	the	DCE	method,	
• The	 research	 undertaken	 to	 date	 and	 findings	 (literature	
review	&	focus	groups),	
• Proposed	 attributes	 based	 on	 focus	 group	 findings	 and	
rationale	for	selection	and	de-selection,	
• Proposed	 levels	 based	 on	 focus	 group	 findings	 and	
literature.	
	
This	overview	was	provided	 in	an	 information	pack	at	 the	 start	of	
the	group	by	the	facilitator	and	then	each	attribute	was	considered	
in	turn	against	the	objectives	outlined.	
	
5.3.3 Recruitment	
The	 initial	 planned	expert	 group	 included	experts	drawn	 from	 the	
eSTI2	research	programme	and	research	experts	with	knowledge	of	
the	whole	eSTI2	clinical	care	pathway.		
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However,	following	the	first	expert	group	which	consisted	of	sexual	
health	 clinicians	 and	 nurses,	 an	 epidemiologist	 and	 qualitative	
sexual	health	researcher,	two	issues	were	identified	that	warranted	
further	consideration:	
• The	 technical	 components	 of	 the	 test	 were	 key	 attributes	
identified	 by	 the	 focus	 groups	 which	 required	 more	
specialist	input	to	inform	the	definition	of	the	attribute	and	
the	levels;	
• The	eSTI2	experts	have	a	strong	knowledge	of	 the	pathway	
development	however	 it	was	 considered	 that	 the	 selection	
of	levels	in	particular	may	vary	when	considered	by	experts	
who	do	not	have	direct	involvement	in	eSexual	Health.	
	
In	order	to	address	this	three	further	‘expert	groups’	were	run	with:	
• Technology	developers	(engineering	and	human	technology	
interaction)	 from	 eSTI2	 focused	 specifically	 on	 the	 test	
related	attributes;	
• Test	 developers	 (microbiology)	 from	 eSTI2	 focused	
specifically	on	test	related	attributes;	
• Sexual	 health	 researchers	 and	 clinicians	 affiliated	 with	 the	
SASH	 group	 at	 Coventry	 University	 and	 Coventry	 &	
Warwickshire	Partnership	NHS	Trust.	
	
5.3.4 Practicalities	of	Running	the	Expert	Groups	
In	 all	 cases	 the	 groups	 were	 run	 at	 locations	 convenient	 to	 the	
participants.	The	data	provided	by	the	expert	groups	was	noted	by	
the	 facilitator	 against	 the	 attributes	 discussed	 and	 a	 summary	 of	
the	 key	 points	 raised	 was	 circulated	 to	 participants	 for	 their	
confirmation	that	it	accurately	reflected	their	views.		
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5.3.5 Data	Analysis	
The	 key	 issues	 raised	 by	 each	 of	 the	 expert	 groups	 were	
summarised	 by	 attribute	 using	 a	 matrix.	 The	 expert	 groups	 were	
not	 recorded,	 fully	 transcribed	 or	 analysed	 thematically	 as	 their	
purpose	 was	 to	 build	 on	 the	 outputs	 of	 the	 focus	 groups	 and	
capture	 the	salient	points	 for	consideration,	which	was	achievable	
through	the	matrix	coding.		
	
5.3.6 Findings	
A	summary	of	the	key	points	and	consensus	from	the	expert	groups	
is	included	in	table	5.17,	summarised	against	each	of	the	attributes	
discussed	 with	 the	 focus	 groups.	 It	 should	 be	 noted	 that	 not	 all	
attributes	were	commented	on	by	all	expert	groups,	this	was	driven	
by	 the	participants	 themselves	who	did	not	 feel	 able	 to	 comment	
on	the	attribute	as	it	was	outside	of	their	area	of	expertise.		
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Attribute	 Expert	Group	1	 Expert	Group	2	 Expert	Group	3	 Expert	Group	4	
Range	of	STIs	 Problematic	to	define	levels	–	NHS	
driven	by	clinically	appropriate	
testing	
Differences	between	curable	and	
incurable	STIs	–	e.g.	chlamydia	and	
HIV	–	if	thinking	about	HIV	when	
completing	DCE	answers	could	be	
very	different	to	chlamydia	
Consider	excluding	as	attribute	but	
acknowledging	in	introduction	
	
	 Perception	of	risk	relative	to	other	
STIs	–	a	DCE	focused	on	one	STI	is	
the	best	way	forward	otherwise	the	
unknown	associated	with	what	
people	are	thinking	in	terms	of	
outcome	is	going	to	impact	
conclusions	
Methodological	approach	–	could	
ask	people	in	advance	e.g.	‘tick	box	
to	indicate	which	STI	you	are	
thinking	of’		
Problematic	if	exploring	multiple	
STIs	because	of	difference	in	test	
performance	characteristics,	
particularly	accuracy	
	
How	you	do	the	test	 Should	there	be	a	split	between	
where	I	get	the	test	and	where	I	do	
the	test?	
Potentially	huge	number	of	levels	if	
full	recognition	of	current	pathways	
and	plausible	future	options	with	
POC	and	self-testing.	
Should	scope	be	limited	–	focus	on	
remote	testing	options?	Will	always	
be	plurality	of	provision.	
Greater	value	to	commissioners	and	
policy	makers	to	look	at	impact	on	
realistic	range	of	options	
Estimate	of	5-10	years	for	NAATs	
test	at	home	–	not	possible	at	
present	due	to	accuracy	
POCT	in	the	community	more	
imminent	–	at	least	one	company	
close	to	delivering	this	
	
Pharmacy	currently	more	for	
treatment	than	test	
Primary	care	–	pharmacy	doesn’t	
know	individual	whereas	GP	does	
Collection	of	test	–	consider	in	
introduction	rather	than	as	attribute	
	
Need	to	make	HCP	presence/	
absence	at	sampling	stage	clear	
Self-test/	self-sample	and	post	
fundamental	to	remote	models	
New	POCT	scenarios	e.g.	take	
sample	to	pharmacy	
Where	you	get	the	test	from	–	need	
to	clarify	in	definition	of	levels	
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Attribute	 Expert	Group	1	 Expert	Group	2	 Expert	Group	3	 Expert	Group	4	
Ensure	clarity	of	definition	between	
self-sampling	and	self-testing	
Time	to	Result	 Consensus	should	be	included	but	
verify	levels	with	WS2	and	WS3	
experts	
15	mins	will	be	an	absolute	
minimum	but	30	mins	is	more	
realistic	for	NAATs	–	sample	
preparation	10mins,	amplification	
15	mins	
INSTI	(HIV)	delivers	an	antibody	
result	in	3mins	
Consider	whether	14	days	is	too	
long	given	other	options	–	consider	
1	or	2-day	option	
Dean	St	Express	–	check	time	to	
result	–	possibly	½	day	
Fastest	NAATs	POCT/	Self-Test	is	
likely	to	be	30	mins	
Consider	reducing	14	days	as	this	is	
now	normally	achieved	for	NCSP	
tests	
Accuracy	(False	
Negative	Rate)	
Consensus	should	be	included	as	
attribute	
Tension	between	public	perception	
of	accuracy	articulated	through	
focus	groups	as	false	negatives	
versus	clinical/	policy	impact	of	false	
positive.	Testing	guidelines	consider	
both	
	
Consider	two	attributes	PPV/NPV	or	
sensitivity/	specificity	
Level	input	from	WS3	experts	
Test	is	more	likely	to	produce	a	false	
positive	
Two	separate	attributes	for	
accuracy	e.g.	sensitivity/	specificity	
or	false	positive/	false	negative	
would	not	make	a	difference	from	a	
test	development	perspective	in	
terms	of	what	people	prefer	
Framing	of	accuracy	–	need	for	
reassurance	
Check	current	NHS	position	on	test	
standards	
Impact	on	relationships	of	incorrect	
results	
Need	to	ground	in	range	
Would	not	add	value	to	have	false	
positive	rate	as	attribute	from	a	test	
development	perspective	
Understand	how	accuracy	is	valued	
as	a	preference	relative	to	others	–	
reflection	on	example	of	other	DCEs	
for	cancer	testing	with	strong	focus	
on	test	characteristics.	
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Attribute	 Expert	Group	1	 Expert	Group	2	 Expert	Group	3	 Expert	Group	4	
Knowledge	of	HCP	 Concern	regarding	how	this	could	
be	articulated	in	levels	–	its	
inclusion	does	not	add	value	
Difference	between	knowledge	and	
competence	
General	agreement	a	better	option	
is	to	recognise	importance	to	
people	–	treat	as	constant	across	all	
options	through	introduction	
	 Issue	with	the	term	specialist	
knowledge	–	how	to	convey	
meaning	
Specialist	health	service	v’s	other	
General	agreement	should	hold	
constant	in	introduction	
Preferences	may	vary	in	different	
part	of	the	pathway	and	for	
different	STIs	
General	agreement	to	hold	constant	
within	questionnaire		
Access	to	HCP	 Consensus	amongst	group	that	this	
attribute	should	be	included	given	
use	of	digital	technologies	as	an	
alternative	to	face-to-face	in	current	
policy	
Issue	of	access	before/	after	result	–	
qualitative	research	has	shown	
differences	in	preferences	–	split	
attribute?	
	
	 Consensus	amongst	group	should	
include	as	number	of	technologies	
can	be	used	as	an	alternative	to	
face-to-face	contact	with	a	clinician	
Could	frame	differently	e.g.	face-to-
face,	remote	or	synchronous,	non-
synchronous	
Time	information	required		
How	you	get	
Treatment	for	
Chlamydia	
Overlap	between	how	you	access	
HCP	and	how	you	get	treatment	in	
proposed	levels.	Split	attribute	–	
how	you	get	treatment/	how	you	
get	antibiotics?	
	 Are	they	important	relative	to	
others?	
Could	explore	collection	point	e.g.	
delivery	to	a	locker	
Need	to	separate	consultation	and	
collection	of	antibiotics,	issue	of	
postal	treatment	potentially	worth	
exploring	
	
		 238	
Attribute	 Expert	Group	1	 Expert	Group	2	 Expert	Group	3	 Expert	Group	4	
Current	issue	owing	to	private	
providers	posting	non-compliant	NG	
treatment	to	positive	patients	
Postal	treatment	option	for	some	
STIs	e.g.	chlamydia.	
Potential	long	term	issue	with	single	
dose	Azithromycin	as	treatment	for	
Chlamydia	due	to	antimicrobial	
resistance	however	no	current	
planned	change	to	treatment	
regime		
Staff	Attitudes	 Consensus	to	exclude	–	will	not	
provide	useful	information	from	
DCE	
	 Consensus	to	exclude	 	
Data	Security	 Consensus	to	exclude	however	
assurance	required	in	introduction	
to	treat	as	constant	
	 Consensus	to	exclude	 	
Table	5.7	-	Summary	of	Key	Points	from	Expert	Groups
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5.3.7 Discussion	
Reflecting	 on	 the	 need	 to	 balance	 what	 is	 important	 to	 young	
people	and	 the	policy/	decision	making	context	 the	expert	groups	
have	 introduced	 some	 different	 perspectives	 on	 a	 number	 of	
attributes.	 	 The	 range	 of	 tests	 undertaken	 is	 the	most	 significant	
difference	 between	 the	 focus	 groups	 with	 young	 people	 and	 the	
expert	 groups.	 	 The	 focus	 groups	 indicated	 that	 there	 is	 a	 strong	
desire	 to	 be	 tested	 for	 ‘everything’	 whereas	 the	 expert	 groups	
indicated	that	this	will	never	happen.	This	is	clinically	driven	in	that	
the	 range	of	 tests	 requested	by	 clinicians	 is	determined	according	
to	patient	 risk	 factors,	and	the	high	risk	of	 false	positive	 results	 in	
low	prevalence	STIs.		
	
Another	dimension	which	came	to	the	forefront	 in	the	first	expert	
group	was	the	impact	of	the	STI	being	considered	when	completing	
the	DCE.	Given	 the	 variation	between	 STIs	 from	chlamydia,	which	
once	 diagnosed	 is	 treatable	with	 a	 single	 course	 of	 antibiotics,	 to	
HIV,	which	 is	currently	 incurable,	participants	 in	the	expert	groups	
believed	 that	 this	 may	 be	 a	 significant	 factor	 in	 which	 levels	
individuals	 express	 preferences	 for,	 for	 example	 the	 method	 by	
which	 they	 get	 their	 results	 –	 phone,	 email,	 text	 or	 face-to-face.	
Whilst	 this	was	not	explicitly	discussed	 in	any	of	 the	 focus	groups	
there	was	some	evidence	of	participants	considering	this:	
“I	 think	 what	 you’re	 getting	 tested	 for	 cos	 even	 though	 those	 two	 do	
chlamydia	 and	 gonorrhoea	 the	 fact	 that	 HIV	 is	 the	 worst	 one	 in	 that	
you’ve	got	it	for	the	rest	of	your	life	and	that	isn’t	getting	tested	in	either	
of	these	I	think	is	quite	bad…”	FG2,	Female,	17	
	
“Or	 does	 it	 depend	 how	 serious	 it	 is	 though	 like…	 because	 if	 it’s	 serious	
then	I’d	rather	have	a	phone	call	than	a	text”	FG1,	Female,	17	
	
“It	would	be	quite,	I	don’t	know	serious,	as	to	get	a	text	to	say	you’ve	got	
HIV	or	you’re	HIV	positive”	FG1,	Male,	16	
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Access	to	a	healthcare	professional	is	another	attribute	where	there	
was	 a	difference	between	 the	 views	of	 the	 young	people	 and	 the	
expert	groups.	Whilst	the	young	people	generally	regarded	how	you	
access	a	healthcare	professional	as	an	attribute	of	importance,	the	
expert	 groups	 highlighted	 alternative	 access	 methods	 e.g.	
telephone,	 instant	messaging	and	email	 consultations	 in	particular	
feature	highly	in	digital	policy	and	current	NHS	practice	for	reducing	
face-to-face	attendances.		
	
Finally,	 the	 expert	 groups	 introduced	 consideration	 of	 a	 new	
attribute	 –	 how	 you	 get	 your	 antibiotic.	 Within	 the	 focus	 groups	
with	young	people,	where	you	go	to	get	treatment	was	considered	
e.g.	 GP,	 pharmacy	 etc.,	 but	 not	 how	 you	 get	 your	 antibiotic	 e.g.	
collect	 from	 pharmacy	 or	 by	 post.	 Whilst	 this	 was	 not	 identified	
through	the	literature	reviews	undertaken	to	inform	the	long	list	of	
potential	 attributes,	 immediately	 prior	 to	 the	 expert	 groups	 it	
became	 a	 national	 media	 topic	 in	 England	 due	 to	 online	 sexual	
health	 services	 in	 the	 private	 sector	 offering	 sub-optimal	 (oral	
antibiotic)	 treatment	 for	 gonorrhoea.	 However,	 the	 use	 of	 postal	
treatment	for	chlamydia	is	feasible	and	safe,	given	that	it	is	a	single	
dose	 oral	 antibiotic.	 Therefore,	 to	 address	 the	 issue	 of	 overlap	
within	the	‘how	you	get	treatment	for	chlamydia’	attribute	the	first	
expert	 group	 proposed	 that	 exploring	 this	 as	 a	 separate	 attribute	
could	be	a	useful	 addition	as	 it	 could	 create	 the	option	 for	a	 fully	
remote	pathway	with	self-testing	and	online	consultation.	This	was	
not	explored	with	the	focus	groups	as	part	of	the	vignettes/	long	list	
of	attributes	and	was	not	an	attribute	they	identified.		
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5.4 Selection	of	Attributes	&	Levels	
The	 purpose	 of	 the	 focus	 and	 expert	 groups	 was	 to	 inform	 the	
selection	 of	 attributes	 and	 levels	 for	 the	 DCE.	 As	 highlighted	 in	
section	 3.5.1	 there	 are	 a	 number	 of	 key	 considerations	 that	
determine	 selection.	 Achieving	 a	 balance	 between	 attributes	 of	
importance	to	the	study	population	and	attributes	which	will	deliver	
impact	 to	 services	 and	 technology	 developers	 was	 the	 key	
consideration	 in	 selection.	 This	 led	 to	 the	 decision	 that	 a	 formal	
ranking	 or	 consensus	 method	 should	 not	 be	 used	 with	 either	 the	
focus	 or	 expert	 groups	 as	 a	 combined	 view	 of	 both	 was	 required.	
Instead,	 the	approach	adopted	was	a	narrative	synthesis	developed	
for	 implementation	 reviews	 to	 enable	 the	 outputs	 from	 the	 focus	
groups,	expert	groups	and	literature	review	to	be	synthesised	against	
each	potential	attribute	(Pope	et	al.,	2007).		
	
The	approach	adopted	has	been	outlined	in	table	5.8	against	the	key	
elements	of	synthesis	identified	by	Pope	and	colleagues:	
	
Element	of	Synthesis	 Approach	Taken	
Developing	a	Theoretical	
Model	
Identification	of	a	checklist	of	properties	
against	which	attributes	can	be	
considered	to	inform	the	selection	
process	
Developing	a	Preliminary	
Synthesis	
Tabulation	against	the	checklist	–	to	
create	a	matrix	of	checklist	criteria	
against	attributes	to	enable	visual	
comparison	of	perspective	
Exploring	Relationships	in	the	
Data	
Conceptual	mapping	and	triangulation	
against	the	checklist		
Assessing	the	Robustness	of	
the	Synthesis	Product	
Critical	reflection	on	the	synthesis	
process	
Table	5.8	-	Summary	of	synthesis	approach	taken	to	inform	the	selection	of	attributes	and	
levels.	Adapted	from	Pope	et	al.,	2007:108-111	
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5.4.1 Development	of	a	Theoretical	Model	
In	forming	a	checklist	of	properties	against	which	the	final	selection	
of	attributes	and	 levels	were	determined,	consideration	was	given	
to	 the	 methods	 and	 best	 practice	 suggested	 in	 the	 key	 texts	
summarised	in	section	3.6.1.	The	final	checklist	was	determined	to	
include	the	following:	
• User	views	–	focus	groups	with	young	people,	
• Current	 Policy	 Context	 –	 derived	 from	 expert	 groups	 and	
background	literature,	
• Current	Commissioning/	Service	Delivery	Context	–	derived	
from	expert	groups	and	background	literature,	
• Current/	 known	 future	 technology	 development	 –	 derived	
from	expert	groups	and	background	literature,	
• DCE	requirements	for	the	selection	of	attributes	and	levels	–	
ISPOR	 good	 practice	 checklist	 (Bridges	 et	 al.,	 2011),	 other	
publications	on	DCE	methods	 (Ryan	et	al.,	 2008,	 Lancsar	&	
Louviere,	2008).	
	
5.4.2 Developing	a	Preliminary	Synthesis	
In	order	 to	 synthesise	 the	data	a	matrix	was	 created	 summarising	
the	 key	 considerations	 against	 the	 checklist	 criteria.	 The	 detail	
underpinning	 the	matrix	 has	 been	 articulated	 in	 other	 sections	 of	
the	thesis	and	therefore	is	not	replicated	in	full	in	this	section:	
• User	 views	 –	 focus	 groups	 and	 other	 studies	 –	 Sections	
5.2.6,	4.2	and	4.3,	
• Current	Policy	Context	–	Sections	5.3.6,	2.3.1	and	2.4.1,	
• Current	Commissioning/	Service	Delivery	Context	–	Sections	
5.3.6,	2.4.2-2.4.4,		
• Current/	 known	 future	 technology	 development	 –	 Section	
5.3.6,	2.3.2-2.3.3,	2.4.5-2.4.6,	
• DCE	requirements	for	the	selection	of	attributes	and	levels	–	
Section	5.1.	
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An	extract	for	one	attribute	is	provided	in	table	5.9:	
	
Attribute	
Young	People’s	
Perspective	
Policy	Context	
Commissioning/	Service	
Delivery	Context	
Technology	Context	 DCE	Design	Requirements	
Access	to	Healthcare	
Professional	
• Highlighted	overlap	in	
interpretation	of	
attributes	particularly	
access	to	HCP	and	
treatment	
consultation	method.	
• Focusing	on	views	on	
access	methods,	clear	
expression	of	views	
from	participants	on	
preference	for	face	to	
face	over	non-face	to	
face	but	differing	
views	between	
individuals		
• Digital	First	(2012)	–	
high	impact	digital	
initiatives	include	
online/	remote	
consultation	
• Five	Year	Forward	
View	(2014)	–	
commitment	to	
expanding	the	use	of	
digital	technology	
• Framework	for	sexual	
health	improvement	
in	England	(2013)	–	
recognises	need	to	
support	self-care	
including	use	of	
mobile	technology	
and	smartphone	apps	
for	STI	testing	
• Alternatives	to	face-
to-face	have	
demonstrated	service	
efficiencies	in	other	
specialties	
• Non-face-to-face	
solutions	may	
increase	uptake	given	
known	barrier	of	
stigma	with	access	to	
sexual	health	services	
• Growth	of	use	of	
alternatives	to	face-
to-face:	
• Video	Consultation	
• Email	
• Online	Consultation	
(e.g.	WebGP)	non-
synchronous,	private	
sector	examples	
• Instant	Message/	Live	
Chat	–	Brook	pilot,	
Conifer	online	clinic		
• Telephone	
consultation	widely	
used	in	primary	and	
secondary	care	for	
certain	conditions	
	
• No	overlap	between	
attributes	
• Clear	definition	of	
attributes	and	levels		
• If	attribute	not	
included	will	need	to	
be	‘held	constant’	in	
background	
information	
Table	5.9	-	Example	from	Preliminary	Synthesis	Matrix	
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5.4.3 Exploring	Relationships	in	the	Data	
Once	 created,	 the	 preliminary	 data	 synthesis	 matrices	 were	
reviewed	 several	 times	 and	 a	 number	 of	 issues	 and	 themes	
emerged	 from	 this	 process	 that	 were	 of	 particular	 significance	 in	
the	selection	of	the	attributes	and	levels:	
• Overlap	 between	 attributes	 perceived	 by	 young	 people	
participating	in	the	focus	groups,	
• Generation	of	high	numbers	of	implausible	combinations	of	
attributes,	
• Generation	of	high	numbers	of	levels	for	an	attribute.	
	
Taking	the	data	from	the	literature,	focus	groups	and	expert	groups	
the	author	assessed	 the	original	 long	 list	of	attributes	used	within	
the	 focus	 groups,	 and	 the	 additional	 ones	 identified	 by	 the	 focus	
groups	 and	 expert	 groups.	 Table	 5.9	 indicates	 the	 assessment	 of	
importance	for	 inclusion	as	an	attribute	within	the	DCE	relative	to	
this	evidence.	This	process	also	allowed	for	the	consideration	of	the	
definition	of	attributes	–	 in	particular	how	they	could	be	reshaped	
and	merged,	 and	whether/	 how	 they	 should	be	 incorporated	 into	
the	 background	 information	 presented	 to	 respondents	 prior	 to	
completion	of	the	DCE.		
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Attribute	
Young	People	
(Service	User)	
Policy	
Perspective	
Commissioning/	
Service	Devt	
Technology	
Development	
Notes	
Sample	collection	method	 ~	 û	 ü	 ü	
FG	participants	linked	closely	with	‘where	you	do	the	test’	
attribute.	Not	viable	as	individual	attribute	due	to	overlap.	
Range	of	STIs	tested	for	 ü	 ~	 û	 ü	
Consistently	in	the	top	four	in	all	four	FGs.	Experts	view	
can	only	be	clinically	driven	need	to	test	rather	than	user	
driven	want	to	test.	
Where	you	do	the	test	 ~	 ü	 ü	 ~	
FG	participants	linked	closely	with	‘sample	collection	
method’	attribute.	Not	viable	as	individual	attribute	doe	
to	overlap.	
Time	to	result	 ü	 û	 ü	 ü	
Considerable	discussion	within	FGs,	particularly	
willingness	to	trade	for	other	attributes.	
Test	accuracy	 ü	 û	 ü	 ü	
Variance	in	range	of	FG	responses.	Trust	in	NHS	key	factor.	
Expert	views	on	accuracy	from	test	development	
perspective.	
Results	notification	 û	 û	 ü	 ~	
Consistently	identified	as	not	important	how	FG	
participants	get	results	as	long	as	they	get	them.		
Access	to	an	HCP	when	you	get	your	result	 ü	 ü	 ü	 û	 	
Treatment	consultation	method	 ~	 ü	 ü	 ü	
FG	participants	overlapped	with	‘where	you	go	to	get	
treatment’	not	viable	as	individual	attribute.	
Where	you	go	to	get	treatment	 ~	 ü	 ü	 ~	
FG	participants	overlapped	with	‘treatment	consultation	
method’	not	viable	as	individual	attribute.	
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Attribute	
Young	People	
(Service	User)	
Policy	
Perspective	
Commissioning/	
Service	Devt	
Technology	
Development	
Notes	
Partner	notification	method	 û	 û	 ü	 ~	 Experts	felt	although	important	health	issue,	area	subject	
to	significant	research	already.	Minimal	discussion	within	
FGs.	
Type	of	healthcare	professional	 ~	 û	 ü	 ~	
Consistently	in	bottom	four	responses	in	all	4	FGs.	Some	
confusion	between	knowledge	and	type	of	HCP	e.g.	
perception	of	knowledge	linked	to	type.	
Knowledge	of	healthcare	professional	 û	 û	 ü	 û	
Range	of	responses	across	FGs.	Many	factors	contributing	
to	discussion.	Expert	groups	-	inclusion	of	attribute	will	
not	shape	service	development.	
	
Staff	Attitude	 ~	 ü	 û	 û	
Preference	expressed	within	one	FG	only.	Output	from	
DCE	will	not	impact	on	service	development	as	not	
controllable.	‘You’re	Welcome’	policy	standards	for	young	
people’s	services.	
Data	Security	 ü	 ü	 ü	 ü	
Importance	recognised	however	minimum	standard	for	
NHS	services	specified.	Including	in	DCE	won’t	add	value.	
How	you	get	antibiotics	 ~	 û	 ü	 û	
Not	included	within	FG.	Expert	groups	highlighted	
importance	from	service	development	perspective	as	
allows	for	fully	remote	pathway.	
Table	5.10	-	Summary	of	Assessment	of	Attribute	Importance.	
	Key:	ü	=	high	preference,	û	=	low	preference,	~=	no	clear	preference	expressed	either	way	
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5.4.4 Assessing	the	Robustness	of	the	Synthesis	Product	
Pope	 and	 colleagues	 identify	 that	 in	 reflecting	 critically	 on	 the	
synthesis	process	this	should	include	consideration	of	the:	
	
	“methods	 used	 (especially	 focusing	 on	 the	 limitations	 and	 their	
influence	 on	 the	 results);	 evidence	 used	 (quality,	 validity,	
generalizability)	–	with	emphasis	on	the	possible	sources	of	bias	and	
their	 potential	 influence	 on	 results	 of	 the	 synthesis;	 assumptions	
made;	discrepancies	and	uncertainties	identified;	expected	changes	
in	technology	and	its	effectiveness	in	real	settings.	Such	a	summary	
would	enable	the	analysis	of	robustness	to	temper	the	synthesis	of	
evidence	as	well	as	indicating	how	generalizable	the	synthesis	might	
be”	(Pope	et	al.,	2007:111).	
	 	
In	considering	the	potential	sources	of	bias	and	their	influences	on	
the	 results	 of	 the	 synthesis	 there	 are	 evidently	 a	 number	 of	
tensions	 in	 from	 the	 perspective	 of	 young	 people	 and	 the	 policy/	
service	 perspectives	 articulated	 by	 the	 expert	 groups.	 The	 main	
source	of	potential	bias	 is	notably	on	 the	 side	of	 the	experts	who	
have	 an	 interest	 professionally	 in	 the	 development	 of	 the	 new	
technology	and/	or	the	configuration	of	services,	although	there	is	a	
broader	evidence	base	that	can	be	drawn	on	from	published	policy	
and	 service	 data	 to	 contribute	 to	 this	 perspective.	 	 The	 young	
people	participating	 in	the	focus	groups	offered	their	views	within	
the	structure	of	a	focus	group	designed	with	questions	to	stimulate	
discussion	 on	 potential	 attributes,	 the	 questions	 did	 not	 lead	 the	
participants	therefore	the	risk	of	bias	was	interpreted	as	lower.		
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The	key	influence	in	the	synthesis	of	evidence	was	the	perspective	
of	the	author.	As	outlined	in	section	3.1,	the	key	driver	is	to	add	to	
the	evidence	base	to	inform	decision	making	by	commissioners	and	
service	 leads	 on	 pathway	 redesign,	 therefore	 in	 making	 the	 final	
selection,	 the	 incorporation	 of	 attributes	 and	 levels	 which	 are	
realistic	and	meaningful	to	young	people,	but	within	the	bounds	of	
possibility	 for	 delivery	 within	 mainstream	 sexual	 health	 services	
was	 critical	 to	 the	 decision	 making.	 This	 is	 borne	 out	 in	 the	
summary	 of	 the	 rationale	 for	 the	 final	 selection	 of	 attributes	 and	
levels	in	the	next	sections.	
	
5.4.5 Final	Selection	of	Attributes	and	Levels	
Resulting	 from	 the	 synthesis	 of	 evidence	 outlined	 in	 the	 previous	
section	the	final	selection	of	attributes,	and	their	revised	definition	
is	summarised	in	table	5.11.	
	
Attribute	 Definition	
How	you	test	for	Chlamydia	 This	focuses	on	how	you	get	your	test,	how	
the	sample	is	taken	and	what	happens	to	the	
sample	once	it’s	been	taken.	
Time	to	result	 How	long	it	takes	to	get	the	test	result.	For	the	
self-test	option,	this	is	how	long	it	takes	from	
you	doing	the	test	to	you	being	able	to	read	
the	result.	For	the	other	options	this	is	how	
long	it	takes	from	you	posting	or	dropping	off	
your	sample	to	when	you	are	given	your	
result.	
Accuracy	 How	accurate	the	test	result	is.	Within	the	DCE	
the	measure	of	accuracy	used	is	false	negative	
-	the	likelihood	of	the	test	telling	you	that	you	
don’t	have	Chlamydia	when	in	fact	you	do	
How	you	get	your	treatment	
(treatment	consultation	
method)	
If	the	test	result	is	positive	the	options	to	get	
treatment	for	Chlamydia.	
Access	to	HCP	 How	you	contact	the	healthcare	professional	
to	complete	your	consultation,	or	in	the	case	
of	the	online	consultation,	accessing	a	
healthcare	professional	for	advice.	
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Attribute	 Definition	
How	you	get	your	antibiotics	 The	options	available	once	the	consultation	
has	been	completed	to	get	antibiotic	tablets.		
Table	5.11	-	Final	Attributes	Selected	and	Definitions	
	
The	 rationale	 for	 the	non-selection	of	 attributes	 is	 summarised	as	
follows:	
• Range	 of	 tests	 –	 the	 concerns	 regarding	 the	 variance	 in	
preferences	 based	 on	 the	 STI	 being	 considered	 by	 the	
respondent	was	the	primary	reason	for	narrowing	down	the	
scope	 of	 the	 DCE	 to	 focus	 on	 one	 STI.	 Chlamydia	 was	
selected	 as	 it	 lends	 itself	 to	 the	 application	 of	 new	
technology	along	a	fully	remote	pathway.	
• Results	notification	and	partner	notification	–	high	number	
of	published	studies	in	this	area,	of	low	importance	to	focus	
group	participants.	Results	notification	was	held	constant	in	
the	background	information.	
• Staff	 attitude	 and	 knowledge	 of	 HCP	 –	 no	 levels	 were	
defined	 that	 could	 produce	 useful	 information	 to	 inform	
service	development.	
• Data	security	–	whilst	this	was	recognised	as	important	to	all	
groups,	levels	could	not	be	identified	that	could	add	value	to	
inform	 service	 development	 given	 the	 NHS	 information	
governance	 standards	 set	 out	 the	 minimum	 acceptable	
levels	of	data	security.	
• Type	 of	 HCP	 –	 consistently	 considered	 of	 low	 importance	
relative	to	other	attributes	 in	the	focus	groups.	This	was	 in	
part	picked	up	in	the	treatment	consultation	method	as	the	
options	 defined	 the	 HCP	 who	 would	 be	 involved	 in	 each	
level.	
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Attributes	that	are	included	but	not	in	the	form	that	was	originally	
defined	in	the	focus	groups	are:	
• Sample	 collection	 method	 and	 where	 you	 do	 the	 test	 –	
combined	into	one	attribute.	
• Treatment	 consultation	 method,	 access	 to	 a	 healthcare	
professional	and	where	you	go	to	get	treatment	–	redefined	
as	two	attributes	recognising	the	overlap	between	the	three	
attributes	and	that	mainstream	sexual	health	services	would	
not	 offer	 an	 option	 where	 access	 to	 a	 healthcare	
professional	 was	 not	 available	 in	 the	 case	 of	 a	 positive	
result.		
	
The	previous	sections	have	focused	heavily	on	the	selection	of	the	
attributes.	Moving	on	to	the	selection	of	levels,	it	can	be	seen	from	
the	findings	from	the	focus	groups	and	expert	groups	that	a	number	
of	potential	levels	have	been	identified.	Table	5.12	summarises	the	
potential	 levels	 drawn	 from	 the	 focus	 groups	 and	 expert	 groups,	
and	those	known	from	published	literature	and	information.		
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Attribute	 Potential	Levels	Identified	from	
Focus	Groups	
Potential	Levels	Identified	from	Expert	Groups	 National	Policy/	Clinical	Guidelines	
How	you	test	for	
Chlamydia	
• Order	online	
• Collect	from	shop	
• Schools	
• Youth	centres	
• Public	toilets	
• Clinic	
• Greater	value	to	commissioners	and	policy	
makers	to	look	at	impact	on	realistic	range	of	
options	
	
• Policy	focus	on	remote/	self-testing	
• Increasing	public	health	role	of	
community	pharmacy	
Time	to	result	 • Discussion	centred	on	
times	proposed	in	
vignettes	i.e.	15mins,	7	
days,	14	days	
• Likely	fastest	NAATs	self-test	30mins	
• Consider	value	of	longer	lengths	e.g.	14	days	
• Dean	St	clinic	–	½	day	
• Cepheid	GeneXpert	–	90min	
processing	time	
• GUM	service	specification	–	7	days	
• NCSP	turnaround	time	target	–	14	
days	
• NCSP	turnaround	audit	
Accuracy	 • 99%	v’s	95%	accurate…	if	
there’s	a	larger	difference	
then…	
• I	don’t	mind	1	or	2%	of	
difference	
• Important	to	understand	how	accuracy	is	valued	
as	a	preference	relative	to	others	
• Current	performance	standards	used	within	NHS	
• Test	performance	characteristics		
• False	positive	–	2%	
• False	positive	–	8%	(lower	95%	CI)	
How	you	get	your	
treatment	(Treatment	
consultation	method)	
• Online/	Smartphone	
• GP	
• Sexual	Health	Clinic	
• Separate	consultation	and	how	you	get	
antibiotics	
	
Access	to	HCP	 • Skype	
• Face-to-face	
• Phone	
• Internet	
• Synchronous/	non-synchronous	technology	
• Face-to-face/	remote	
• Non	face-to-face	contact	methods	
e.g.	telephone/	video	consultation	
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Attribute	 Potential	Levels	Identified	from	
Focus	Groups	
Potential	Levels	Identified	from	Expert	Groups	 National	Policy/	Clinical	Guidelines	
How	you	get	your	
antibiotics	
• Not	discussed	 • Postal	treatment	options	e.g.	to	home/	
collection	point	
• Current	practice	from	pharmacy	or	sexual	health	
clinic	
	
Table	5.12	-	Potential	Levels	Identified	from	Focus	Groups	with	Young	People,	Expert	Groups	and	National	Policy/	Clinical	Guideline
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The	final	selected	levels	and	their	rationale	are	included	in	table	5.13.	
	
Attribute/	Level	 Rationale	
How	you	Test	for	Chlamydia	
Self-Test	 Fully	remote	online	pathway	includes	
proposed	self-test	
Self-Sample	and	Post	Off	for	
Analysis	
Current	NCSP	Internet	Test	Option	
Self-Sample	and	Take	to	
Pharmacy	for	Analysis	
To	explore	enhanced	role	for	community	
pharmacy	beyond	test	distribution	and	
treatment		
Self-Sample	and	Take	to	Place	of	
Education/	Work	for	Analysis	
To	explore	suggestion	from	young	people	
that	testing	should	be	more	widely	available,	
school	was	one	of	the	suggested	options	
Attend	GP	Practice,	sample	
taken	by	GP/	Nurse	
Currently	available	option	
Attend	Sexual	Health	Clinic,	
sample	taken	by	Doctor	or	Nurse	
Currently	available	option	
Time	to	Result	
30	Minutes	 Suggested	time	for	self-test	NAATs	from	
expert	group	
2	Hours	 Based	on	Cepheid	GeneXpert	90mins	
processing	time	plus	additional	time	to	setup	
7	Days		 GUM	service	specification	standard	
14	Days	 NCSP	Internet	Testing	Standard	
Test	Accuracy	
2	in	100	people	will	be	told	their	
test	result	is	negative	when	they	
do	have	chlamydia	
Based	on	false	negative	rate	for	Cepheid	
GeneXpert	CT/NG	Assay.	Taken	from	FDA	
approval	data	
5	in	100	people	will	be	told	their	
test	result	is	negative	when	they	
do	have	chlamydia	
Based	on	false	negative	rate	for	BD	ProbeTec	
CT	Qx	Amplified	DNA	assay.	Taken	from	FDA	
approval	data	(note	this	was	changed	from	8	
in	100	as	a	result	of	the	cognitive	testing)	
How	you	get	your	Treatment	
Online	Consultation	 Fully	remote	online	pathway	treatment	
option	
Pharmacist	 Current	treatment	option	
GP	 Current	treatment	option	
Sexual	Health	Clinic	 Current	treatment	option	
How	you	Contact	a	Health	Care	Professional	
Telephone	 Current	option	
Instant	Messaging	 Current	option	in	small	number	of	cases	
Email	 Potential	option	
Face-to-Face	 Current	option	
How	you	get	your	Antibiotics	
Deliver	to	Home	Address	 Potential	option	
Deliver	to	Collection	Point	 Potential	option	
Collect	from	Pharmacy	 Current	option	
Collect	from	Sexual	Health	Clinic	 Current	option	
Table	5.13	-	Final	Selection	of	Levels	and	Rationale	for	Selection	
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5.5 Discussion	
Reflecting	 on	 the	 process	 undertaken	 to	 select	 the	 attributes	 and	
levels	 to	 take	 forward	 into	 the	 DCE,	 a	 key	 strength	 is	 the	 insight	
gained	from	the	qualitative	research	undertaken	with	young	people	
and	 experts	 to	 directly	 inform	 the	 selection.	 This	 is	 particularly	
relevant	as,	at	the	time	this	research	was	undertaken,	there	were	no	
published	 studies	 looking	 at	 preferences	 for	 STI	 testing	 and	
treatment	 services	 which	 incorporated	 the	 novel	 technology	 being	
developed	 by	 eSTI2	 research	 consortium.	 A	 second	 strength	 of	 the	
research	 is	 the	 rigour	 which	 has	 been	 applied	 to	 the	 selection	 of	
attributes	 and	 levels,	 employing	 a	 number	 of	 research	methods	 to	
distil	a	long	list	of	potential	attributes	into	the	final	selection	for	the	
study.	 Reflecting	 back	 on	 the	 methodological	 issues	 of	 concern	 in	
selecting	attributes	and	levels	outlined	in	section	4.1,	care	has	been	
taken	 to	 minimise	 the	 risk	 associated	 with	 not	 achieving	 an	
appropriate	balance	between	the	policy/	service	perspective	and	the	
user	perspective	by	explicitly	considering	the	breadth	of	views	in	the	
synthesis	 process.	 Attributes	 have	 developed	 from	 the	 ‘long	 list’,	
taking	 on	 board	 the	 findings	 from	 the	 focus	 groups	 with	 young	
people	 to	 clarify	 and	 shape	 in	 a	 way	 which	 reflected	 their	
understanding	to	minimise	the	risk	of	overlap	between	attributes.		
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The	qualitative	research	process	provided	an	opportunity	to	explore	
a	 range	of	 issues	associated	with	 the	 inclusion	of	 specific	attributes	
and	levels	and	how	effectively	they	could	be	incorporated	into	a	DCE.	
One	of	 the	 key	 learning	 points	 stemmed	 from	 the	 consideration	 of	
the	 ‘range	 of	 tests’	 potential	 attribute.	 It	 was	 identified	 as	 of	
considerable	importance	by	young	people	in	the	focus	groups,	but	on	
further	exploration	with	the	expert	groups	was	highlighted	as	highly	
complex	 to	 incorporate	 into	 a	 DCE	 design	 looking	 at	 a	 detailed	
pathway.	 The	 synthesis	 process	 provided	 the	 opportunity	 to	
consolidate	 these	 views	 to	 provide	 an	 explicit	 process	 for	
selection/de-selection.		
	
As	highlighted	 in	 the	 literature	 review	presented	 in	 section	4.2,	 the	
level	of	detail	provided	on	the	selection	process	is	minimal	and	falls	
short	 of	 the	 suggested	 reporting	 checklist	 identified	 by	 Coast	 and	
colleagues	(Coast	et	al.,	2012).		
	
The	 ISPOR	 good	 practice	 checklist	 for	 conjoint	 analysis	 suggests	 a	
number	 of	 methods	 for	 the	 selection	 of	 attributes	 and	 levels	 but	
does	 not	 endorse	 one	 approach	 (Bridges	 et	 al.,	 2011).	 One	 study	
(Miners	 et	 al.,	 2012)	 published	 the	 findings	 of	 the	 focus	 groups	
undertaken	 in	order	 to	 inform	the	selection	of	attributes	and	 levels	
(Llewellyn	 et	 al.,	 2012),	 however	 this	 did	 not	 include	 details	 of	 the	
process	by	which	they	were	selected.		
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Exploring	more	widely,	 two	 studies	 have	 been	 identified	 publishing	
papers	 specifically	 on	 the	 process	 by	which	 a	 long	 list	 of	 attributes	
and	levels	led	to	the	final	selection	for	a	DCE.	Both	studies	are	from	
research	 in	 Malawi,	 the	 first	 (Abiiro	 et	 al.,	 2014)	 explored	
preferences	 for	 micro	 health	 insurance	 in	 Malawi.	 They	 used	 a	
literature	review	to	 inform	qualitative	data	collection	(through	both	
qualitative	 interviews	 and	 focus	 groups),	 and	 subsequently	 used	
expert	 opinion	 to	 down-select	 attributes	 and	 levels,	 followed	 by	
piloting	 of	 the	 questionnaire.	 The	 second	was	 to	 explore	Malawian	
women’s	 preferences	 for	 breast	 cancer	 screening	 (Kohler	 et	 al.,	
2015).	 The	 process	 adopted	 initially	 was	 similar	 to	 the	 approach	
taken	 in	 this	 research	 –	 literature	 reviews	 to	 inform	 a	 long	 list	 of	
potential	attributes,	the	use	of	qualitative	interviews	with	health	care	
professionals	 and	 respondents,	 however	 the	 process	 for	 final	
selection	 differed,	 with	 dialogue	 between	 researchers	 and	
community	 outreach	 leaders	 using	 information	 from	 the	 interviews	
to	determine	the	final	selection	of	attributes	and	levels.		
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5.6 Summary	
This	 chapter	 has	 presented	 the	 results	 of	 the	 focus	 groups	 with	
young	 people,	 expert	 groups	 and	 evidence	 synthesis	 to	 select	 the	
attributes	 and	 levels	 for	 the	 DCE.	 The	 focus	 groups	 provided	
considerable	 insight	 into	 the	 factors	 that	 are	 important	 to	 young	
people	 when	making	 choices	 about	 testing	 and	 treatment	 for	 STIs	
and	 how	 their	 emotions,	 beliefs,	 experiences	 and	 perceptions	
influence	their	decision	making.		
	
The	 expert	 groups	 built	 on	 the	 findings	 of	 the	 focus	 groups	 and	
offered	valuable	real	world	insight	into	the	policy	and	service	context	
outlined	 in	 section	 2.4.	 This	 was	 particularly	 helpful	 in	 identifying	
direct	conflicts	between	what	young	people	consider	important	e.g.	a	
desire	 to	 be	 tested	 for	 ‘everything’	 versus	 what	 is	 good	 clinical	
practice	i.e.	the	use	of	national	clinical	guidelines	on	testing	for	STIs.	
Considering	the	outputs	of	both	the	focus	groups	and	expert	groups	
alongside	 the	 published	 policy,	 service	 and	 technology	 context	 in	 a	
narrative	 synthesis	 enabled	 the	 selection	 of	 attributes	 and	 levels	
which	 enable	 the	 design	 of	 a	 DCE	 rooted	 in	 the	 factors	 that	 are	
important	to	young	people	but	realistic	within	the	context	of	service	
delivery	and	feasible	technology	development.		
	
This	work	has	drawn	out	a	number	of	key	issues	to	be	considered	in	
the	DCE	design,	which	is	taken	forward	in	Chapter	6	including:	
• The	preparation	of	background	information	for	participants	to	
read	 prior	 to	 completion,	 in	 particular	 capturing	 the	 key	
elements	 identified	 in	 the	 focus	 groups	 to	 make	 explicit	 to	
avoid	assumptions	being	made,	
• The	definition	of	attributes,	levels	and	the	situational	context	
for	them	to	ensure	that	respondents	are	clear	what	they	are	
considering	in	making	their	choices,	
• The	management	of	implausible	and	illogical	combinations.	
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6 CHAPTER	6	–	DISCRETE	CHOICE	EXPERIMENT	
6.1 Introduction	
“Yeah	 the	accuracy,	 it’s	erm,	 I	don’t	mind	1	or	2%	of	difference	but	
because	erm	this	is	convenient	you	get	the	results	within	15	minutes,	
but	the	rest	is	like	a	week	or	two...”	FG4,	Female,	age	unknown	
	
The	 focus	 groups	 presented	 in	 Chapter	 5	 provided	 a	 rich	 source	 of	
data	 into	 the	 views	of	 young	people	on	what	 is	 important	 to	 them	
when	 considering	 testing	 and	 treatment	 for	 STIs	 which,	 when	
synthesised	 with	 the	 views	 of	 experts	 and	 other	 service/	 policy	
considerations,	has	informed	the	selection	of	attributes	and	levels	to	
take	forward	in	this	DCE.		
	
A	 benefit	 of	 the	 DCE	 method	 is	 that	 it	 enables	 insight	 into	 the	
respondent’s	strength	of	preference	for	attributes	and	levels	relative	
to	each	other.	Coupled	with	the	robust	process	undertaken	to	select	
attributes	and	 levels	 it	was	hoped	that	this	DCE	would	provide	new	
evidence	to	inform	the	design	and	development	of	new	technologies	
and	pathways	for	the	testing	and	treatment	of	chlamydia.	
	
This	chapter	builds	on	the	selection	of	attributes	and	levels	to	include	
in	 the	 DCE	 outlined	 in	 Chapter	 5	 and	 presents	 the	 design,	
development	and	findings	from	the	DCE	itself	including	the:	
• Methods	used	to	design	and	undertake	the	DCE,	
• Cognitive	testing	of	the	DCE	questionnaire,	
• Data	collection	and	results,	
• Discussion	of	the	findings.	
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6.2 Methods	–	Questionnaire	Design	
There	 are	 numerous	 texts	 focusing	 specifically	 on	 the	 design	 and	
analysis	of	DCE	questionnaires	within	a	healthcare	context	 (Ryan	et	
al.,	2008,	McIntosh	et	al.,	2010,	Lancsar	and	Louviere,	2008,	Ryan	et	
al.,	2014)	and	reports	from	three	ISPOR	special	 interest	groups:	one	
exploring	 good	 practice	 in	 the	 application	 of	 conjoint	 analysis	 in	
healthcare	 (which	 they	 note	 as	 equally	 applicable	 to	 DCEs),	 the	
second	exploring	the	construction	of	experimental	designs	for	DCEs,	
and	the	third	considering	statistical	methods	for	the	analysis	of	DCEs	
(Bridges	et	al.,	2011,	 Johnson	et	al.,	2013,	Hauber	et	al.,	2016).	The	
following	 sections	 outline	 the	 methodological	 considerations	 and	
decisions	taken	in	respect	of	the	DCE	experimental	design,	structured	
against	the	ISPOR	good	practice	checklist	(Bridges	et	al.,	2011).	
	
6.2.1 Methodological	Considerations	prior	to	Design	
Ryan	 and	 colleagues,	 and	 Bridges	 and	 colleagues	 identified	 the	
following	 methodological	 considerations	 which	 should	 be	
addressed	 prior	 to	 the	 design	 of	 a	 DCE	 in	 a	 healthcare	 context	
(Bridges	et	al.,	2011,	Ryan	et	al.,	2014).	These	are	considered	in	the	
following	sections:	
• Choice	context	–	labelled	v’s	generic	experiment	
• Main	effects	with	or	without	interaction	effects	
• Number	and	range	of	levels	
• Full	or	partial	profiles	
• Number	of	profiles	
• Opt	out	or	status	quo	options.	
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6.2.1.1 Choice	Context	–	Labelled	v’s	Generic	Experiment	
Choices	 can	be	 labelled	e.g.	GP,	 sexual	health	 clinics,	or	 through	
generic	labelling	e.g.	choice	A,	choice	B.	The	benefits	of	labels	are	
that	 they	 offer	 context	 and	 therefore	 potentially	 reduce	 the	
cognitive	 burden	 for	 respondents.	 However,	 the	 key	 risk	 is	 that	
respondents	focus	on	the	labels	and	do	not	give	due	consideration	
to	the	attributes	when	making	their	choice	(Ryan	et	al.,	2008).	For	
this	 survey	 a	 generic	design	has	been	 chosen.	 The	 rationale	was	
that	labels	are	most	commonly	used	where	there	is	likely	to	be	a	
strong	preference	for	a	brand,	or	when	one	of	the	objectives	is	to	
capture	market	 share	 predictions	 (Ryan	 et	 al.,	 2014).	Whilst	 the	
fully	remote	online	pathway	itself	could	be	isolated	and	treated	as	
a	 brand,	 the	 focus	 of	 the	 DCE	 is	 to	 understand	 the	 component	
attributes	of	importance	to	young	people	rather	than	the	pathway	
per	 se.	 This	 approach	 will	 enable	 consideration	 of	 both	 a	 fully	
remote	online	pathway	as	a	‘standalone’	pathway	and	its	possible	
integration	into	existing	care	pathways.		
	
6.2.1.2 Main	Effects	with	or	without	Interaction	Effects	
Main	 effects	 can	 be	 defined	 as	 the	 “effects	 of	 each	 attribute”	
whilst	 interaction	 effects	 explore	 the	 “effect	 of	 interaction	
between	two	or	more	attributes”	(Lancsar	and	Louviere,	2008:26).	
Ryan	and	colleagues	note	that	interaction	effects	are	a	significant	
constraint	 on	 the	 design,	 and	 in	 practice	 account	 for	 minimal	
variation	 in	 choices	 (Ryan	 et	 al.,	 2014).	 Studies	 exploring	 main	
effects	only	are	the	most	common	practice	within	published	DCE	
studies	in	the	health	care	context,	with	a	recent	systematic	review	
finding	 that	 (where	 reported)	74%	of	 studies	published	between	
1990-2000	used	a	main	effects	design	(Clark	et	al.,	2014).		
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This	 increased	 to	 89%	 in	 2001-2008,	 and	 reduced	 to	 54%	 2009-
2012.	In	contrast	only	13%	of	studies	published	between	2009	and	
2012	 explored	 main	 and	 interaction	 effects,	 whilst	 only	 6%	 of	
studies	published	between	2001	and	2008	explored	them	(Clark	et	
al.,	2014).	
	
The	 research	 question	 explored	 in	 this	 chapter,	 namely	 ‘which	
attributes	 influence	 young	 people’s	 preferences	 for	 testing	 and	
treatment	 for	 chlamydia?’	 can	 be	 answered	 through	 a	 main	
effects	 design.	 It	 was	 decided	 to	 exclude	 interaction	 effects	
because	they	are	not	the	primary	focus	of	the	research	question,	
the	 complexity	 of	 the	 selection	of	 interaction	 effects	 to	 explore,	
and	the	subsequent	design	of	a	study	to	incorporate	these.		
	
6.2.1.3 Number	of	Levels	and	Range	of	Levels	
Ryan	 and	 colleagues	 note	 that	 that	 the	 number	 of	 levels	 per	
attribute	 depends	 on	 the	 type	 of	 attribute	 (categorical,	
continuous	or	probability)	 (Ryan	et	al.,	 2014),	whilst	Bridges	and	
colleagues	suggest	that	it	is	good	practice	to	have	no	more	than	3-
4	 levels	 per	 attribute	 (Bridges	 et	 al.,	 2011).	 Ryan	 and	 colleagues	
also	 note	 that	 from	 both	 a	 psychological	 perspective	 and	 a	
technical	 design	 perspective	 it	 is	 beneficial	 to	 use	 the	 same	
number	of	levels	for	every	attribute	(Ryan	et	al.,	2014).	
	
The	 selection	 of	 levels	 for	 this	 study	 has	 been	 informed	 by	 a	
rigorous	qualitative	research	process	resulting	 in	the	synthesis	of	
findings	from	focus	groups	with	young	people	and	expert	groups.		
It	was	not	possible	to	achieve	a	design	with	the	same	number	of	
levels	 for	 every	 attribute	 owing	 to	 the	 variation	 between	
attributes	 in	 the	 number	 of	 plausible	 levels	 and	 the	 perceived	
impact	of	their	selection	and	de-selection	as	discussed	previously	
in	section	5.5.		
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Steps	taken	to	mitigate	the	risks	associated	with	differing	numbers	
of	 levels	 per	 attribute	 are	 discussed	 further	 in	 the	 following	
sections.		
	
6.2.1.4 Full	or	Partial	Profiles	
Full	 profiles	 comprise	 all	 of	 the	 attributes	which	 are	 included	 in	
the	 study	 whereas	 partial	 profiles	 include	 a	 subset	 only.	 It	 is	
acknowledged	 that	 it	 is	 recognised	 good	 practice	 within	
healthcare	research	to	use	full	profiles.	However,	it	is	necessary	to	
understand	whether	respondents	are	able	to	“reasonably	evaluate	
the	 full	 profiles”	 (Bridges	 et	 al.,	 2011:407).	 Alternatives	 to	 full	
profiles	include	partial	profiles,	or	full	profiles	with	overlap,	that	is,	
a	 number	 of	 attribute	 levels	 are	 the	 same	 in	 both	 choice	 sets	
(ibid.).	
	
The	DCE	has	been	designed	using	full	profiles,	that	is	including	all	
attributes	being	considered	within	the	study.	The	cognitive	testing	
phase	 of	 the	 questionnaire	 development	 incorporated	 questions	
to	evaluate	the	cognitive	burden	of	questionnaire	completion	and	
whether	 respondents	 were	 able	 to	 consider	 the	 breadth	 of	
attributes	when	making	choices.		
	
6.2.1.5 Number	of	Profiles	and	Opt	Out	Option	
There	are	a	number	of	different	options	to	constructing	the	choice	
tasks	within	a	DCE.	These	include:	
• Binary	choice	(one	option	to	which	people	respond	yes	or	
no)	
• Pairwise	choice	(two	options	to	choose	between)	
• Multiple	 choice	 (more	 than	 two	 options	 to	 choose	
between).	 This	 could	 include	 making	 one	 choice	 from	 a	
number	of	profiles,	or	selecting	the	best	and	worst	from	a	
range	of	choices	or	ranking	a	range	of	choices	(Lancsar	and	
Louviere,	2008,	Bridges	et	al.,	2011).	
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Bridges	and	colleagues	highlighted	the	absence	of	research	in	the	
health	 care	 context	 on	 the	 impact	 of	 increasing	 the	 number	 of	
choices	 available	 to	 respondents	 within	 a	 task	 (Bridges	 et	 al.,	
2011).		
	
A	 pairwise	 choice	 (option	 A	 and	 B)	 with	 opt	 out	 question	 was	
selected	for	the	questionnaire	design.	This	was	selected	over	the	
other	choice	designs	outlined	above	because	of	 the	risk	of	social	
desirability	bias.	Chlamydia	is	a	significant	public	health	issue	and	
in	providing	 respondents	with	background	 information	 to	enable	
them	 to	 complete	 the	 questionnaire	 there	was	 a	 possibility	 that	
respondents	would	answer	yes	to	all	questions	in	a	binary	choice	
design.	 Social	 desirability	 bias	 has	 been	 widely	 documented	 in	
respect	 of	 surveys	 exploring	 lifestyle	 behaviours	 and	 sensitive	
topics	including	drug	misuse,	sexual	behaviour,	voting,	alcohol	and	
tobacco	 use,	 unintentional	 injuries,	 violence	 diet	 and	 physical	
activity	 (Tourangeau	 and	 Yan,	 2007,	 Brener	 et	 al.,	 2003).	 Brener	
and	 colleagues’	 literature	 review	 exploring	 factors	 affecting	 the	
validity	 of	 self-reported	 health	 risk	 behaviours	 identified	 that	
“Because	 unprotected	 intercourse	 is	 a	 leading	 cause	 of	 HIV	
infection,	it	is	possible	that	people’s	responses	are	also	influenced	
by	fear	of	disapproval	and	informal	social	sanctions”	(Brener	et	al.,	
2003:452).	Whilst	the	DCE	explores	preferences	rather	than	actual	
behaviours,	 a	 pairwise	 choice	 design	mitigates	 the	 risk	 of	 social	
desirability	 bias	 through	 presenting	 two	 different	 choices	 for	
respondents	to	select	from.		
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An	opt	out	question	allows	the	respondent	to	not	choose	one	of	
the	options	within	the	choice	set.	This	can	be	used	to	represent	a	
number	 of	 options	 including	 choices	 for	 no	 treatment,	 no	
preference	or	current	treatment	(Bridges	et	al.,	2011).	They	note	
that	 they	 can	 be	 “useful,	 or	 even	 necessary,	 if	 researchers	 are	
assessing	 the	 potential	 demand	 or	 market	 share	 of	 a	 (novel)	
product”	(Bridges	et	al.,	2001:407).	Ryan	and	colleagues	note	that	
it	 “improves	 the	 behavioural	 realism	 of	 tasks”	 (Ryan	 et	 al.,	
2014:126);	 however,	 it	 can	 “decrease	 the	 cognitive	 difficulty	 of	
the	 task”	 (ibid).	 In	 the	 real	world	 the	decision	 to	 test	or	not	 test	
lies	with	 the	 individual	as	does	 the	decision	 to	 seek	 treatment	 if	
the	test	result	is	positive.		
	
To	force	a	choice	between	two	options	will	 limit	the	applicability	
of	 the	 findings	 in	 a	 real-world	 context	 because	 in	 the	 real-world	
people	 will	 always	 have	 the	 choice	 to	 not	 test.	 Therefore,	 the	
decision	was	 taken	 to	 include	 an	 opt	 out	 option	 of	 ‘I	would	 not	
test’	 and	 the	 impact	 of	 this	 was	 explored	 through	 the	 cognitive	
testing	of	the	questionnaire.	
	
6.2.2 Experimental	Design	
In	order	to	design	the	questionnaire,	consideration	was	given	to	the	
management	of	a	number	of	issues	within	the	design	type.	Bridges	
and	 colleagues	 recognise	 that	 there	 is	 “no	 gold	 standard	 for	
experimental	design”	(Bridges	et	al	2011:408)	and	propose	a	range	
of	criteria	for	evaluating	designs	including:	
• “Efficiency	Score	
• Correlations	among	attribute	levels	
• Correlations	among	attribute	level	differences	
• Level	balance	
• Number	of	overlapping	attributes	
• Restrictions	on	implausible	combinations	
• Cognitive	difficulty”	(Bridges	et	al	2011:408).	
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A	 summary	 of	 the	 DCE	 design	 developed	 for	 this	 chapter	 against	
these	 criteria	 is	 provided	 in	 table	 6.1,	 and	 the	 rationale	 for	 the	
design	choice	is	set	out	in	the	following	sections.	
	
Design	Criteria	 Summary	of	DCE	Design	for	this	Research	
Efficiency	Score	 Initial	D-Efficiency	score	computed	by	JMP	Pro	
9.2.0	of	98.06.	Statistical	efficiency	was	reduced	
in	favour	of	response	efficiency	to	remove	
implausible	combinations.	
Correlations	among	
attribute	levels/	attribute	
level	differences	
Correlation	matrices	used	to	check	correlation	
coefficients	and	level	balance	as	part	of	design	
process.	
Level	balance	 Initial	design	achieved	level	balance	across	4	of	
the	6	attributes.	
Number	of	overlapping	
attributes	
Minimal	overlap	on	the	‘time	to	result’	attribute.	
Overlap	introduced	as	a	result	of	removal	of	
implausible	combinations.	
Restrictions	on	
implausible	combinations	
Implausible	combinations	(relating	to	how	you	
test	and	time	to	result)	were	removed.	
Improbable	combinations	remained.	
Cognitive	Difficulty	 Assessed	through	cognitive	testing.	
Table	6.1	-	Summary	of	DCE	Design	Criteria	
	
The	 six	 attributes	 and	 24	 levels	 adopted	 in	 this	 study	 are	
summarised	 in	 table	 6.2.	 SAS	 9.4	was	 used	 to	 explore	 the	 design	
options.	 Using	 the	 ‘%mktruns’	 macro	 it	 was	 identified	 that	 a	 full	
factorial	 design	 (all	 possible	 combinations	 of	 attribute	 levels)	 has	
3,072	possible	 alternatives.	 This	 is	 not	manageable	 in	 practice	 for	
participants	 to	 complete,	 therefore	 a	 fractional	 factorial	 design	
(FrFD)	(a	subset	of	all	possible	combinations	of	attribute	levels)	was	
selected.		
	
Ryan	and	colleagues	note	that	FrFD	needs	to	satisfy	two	key	design	
principles	 –	 orthogonality	 “The	 attributes	 are	 said	 to	 be	
independent	(or	orthogonal),	meaning	that	the	main	effects	of	one	
attribute	 is	not	polluted	by	 the	main	effects	of	 another	attribute”	
(Ryan	 et	 al	 2014:105),	 and	 level	 balance	 –	 each	 level	 appears	 the	
same	number	of	times	within	the	survey.		
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Attribute	
Level	
A1.	How	you	Test	 A2.	Time	to	Result	 A3.	Accuracy	 A4.	Consultation		
					Method	
A5.	Access	to	HCP	 A6.	How	you	get		
					Antibiotics	
L1.	 Self-test	 30	mins	 2	in	100	(False	
Negative)	
Online	 Phone	 Post	to	Home	
L2.	 Self-Sample	&	Post	 2	Hours	 5	in	100	(False	
Negative)	
Pharmacy	 IM	 Post	to	Collection	
Point	
L3.	 Self-	Sample	&	
Pharmacy	
7	Days	 	 GP	 Email		 Collect	from	
Pharmacy	
L4.	 Self-Sample	&	
Education/	Work	
14	Days	 	 Sexual	Health	Clinic	 Face	to	Face	 Collect	from	Sexual	
Health	Clinic	
L5.	 GP	Practice	 	 	 	 	 	
L6.	 Sexual	Health	Clinic	 	 	 	 	 	
Table	6.2	-	Summary	of	attributes	and	levels	included	in	this	study	
		 268	
	
The	 output	 of	 the	 %mktruns	 macro	 identified	 that	 the	 smallest	
100%	 efficient	 design	 could	 be	 created	 with	 48	 choice	 sets	 (see	
Appendix	12).	Recognising	that	48	choice	sets	were	likely	to	be	too	
many	for	participants	to	complete,	the	questionnaire	needed	to	be	
blocked	(divided	up	into	smaller	questionnaires).	Forty-eight	choice	
sets	 can	 be	 blocked	 into	 two	 questionnaires	 with	 24	 sets,	 three	
questionnaires	of	16	sets,	or	four	questionnaires	of	12	sets.	 It	was	
decided	 to	 undertake	 the	 cognitive	 testing	 based	 on	 two	
questionnaires	 of	 24	 sets.	 The	 findings	 of	 the	 cognitive	 testing,	
discussed	further	in	section	6.3.1,	identified	that	a	study	based	two	
questionnaires	with	24	choice	sets	was	acceptable	to	participants.		
	
Johnson	and	colleagues	note	that	designs	“may	deviate	from	strict	
orthogonality	 because	 of	 constraints	 placed	 on	 implausible	
combinations,	 lack	of	 balance,	 or	 repetition	of	 particular	 attribute	
levels	across	a	set	of	alternatives	(overlap)”	(Johnson	et	al	2013:8).	
The	outputs	for	the	optimum	questionnaire	design	identified	in	SAS	
9.4	were	 used	 to	 compute	 the	 design	 in	 SAS	 JMP	Pro	 11.2.0.	 The	
choice	 design	 module	 within	 design	 of	 experiments	 module	 was	
used	 to	 create	 the	 questionnaire	 design.	 Thirty	 questionnaire	
design	 runs	 were	 completed	 and	 the	 design	 with	 the	 highest	
number	of	levels	balanced	across	both	questionnaire	blocks	(Design	
11)	was	selected	manually.		
	
6.2.2.1 Implausible	and	Unlikely	Combinations	
Implausible	combinations	are	defined	as	the	circumstances	which	
are	not	feasible	or	realistic	in	terms	of	either	the	situation	or	the	
outcome.	 These	 are	 important	 considerations	 in	 questionnaire	
design	 because	 of	 the	 consequences	 of	 how	 respondents	 view	
them	 when	 completing	 the	 questionnaire,	 including	
misinterpretation	or	hypothetical	bias	(Johnson	et	al.,	2013).		
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Implausible	 combinations	 are	 one	 of	 the	 reasons	 suggested	 by	
Johnson	and	colleagues	where	it	is	appropriate	to	trade	statistical	
efficiency	for	response	efficiency	(ibid.).	
Reviewing	 the	 attributes	 and	 levels	 outlined	 in	 table	 6.2	 four	
implausible	combinations	were	identified:	
• Attribute	1,	Level	1	–	Self-Test,	with	Attribute	2,	Level	3	–	7	
Days	
• Attribute	1,	Level	1	–	Self-Test,	with	Attribute	2,	Level	4	–	
14	Days	
• Attribute	1,	 Level	2	–	 Self-Sample	&	Post	off	 for	Analysis,	
with	Attribute	2,	Level	1	–	30	mins	
• Attribute	1,	 Level	2	–	 Self-Sample	&	Post	off	 for	Analysis,	
with	Attribute	2,	Level	1	–	2	hours.	
	
There	are	a	number	of	unlikely	combinations,	for	example:	
• Consultation	Method	–	Pharmacy	
• Access	to	a	HCP	–	Face	to	Face	
• How	you	get	your	antibiotics	–	 collect	 from	sexual	health	
clinic.		
	
Whilst	the	latter	example	is	feasible	(setting	aside	the	contractual	
arrangements	 for	 drug	 dispensing),	 it	 is	 unlikely	 in	 reality	 that	 a	
person	attending	a	pharmacy	for	a	consultation	would	then	go	to	
a	 second	 location	 to	 get	 their	 antibiotics	 when	 they	 could	 be	
dispensed	 by	 the	 pharmacist.	 Both	 implausible	 and	 unlikely	
combinations	were	included	in	the	cognitive	testing	(pilot	phase).	
This	 identified	 that	 implausible	 combinations	 did	 impact	 on	
completion	of	the	task	whilst	unlikely	combinations	did	not.	This	is	
discussed	further	in	section	6.3.1.		
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Implausible	combinations	were	removed	manually	by	switching	as	
outlined	in	table	6.3:	
Combination	 Changed	to	
A1	L1,	A2	L3	(Self-Test,	Time	to	
Result	7	Days)	
A1	L1,	A2	L2	(Self-Test,	Time	to	
Result	2	Hours)	
A1	L1,	A2	L4	(Self-Test,	Time	to	
Result	14	Days)	
A1	L1,	A2	L1	(Self-Test,	Time	to	
Result	30	Mins)	
A1	L2,	A2	L1	(Self-Sample	&	
Post,	Time	to	Result	30	mins)	
A1	L2,	A2	L4	(Self-Sample	&	
Post,	Time	to	Result	14	Days)	
A1	L2,	A2	L2	(Self-Sample	&	
Post,	Time	to	Result	2	Hours)	
A1	L2,	A2	L3	(Self-Sample	&	
Post,	Time	to	Result	7	Days)	
Table	6.3	-	Management	of	Implausible	Combinations	
	
Switching	 the	 implausible	 combinations	 as	 above	 creates	 one	
choice	which	 is	 repeated	twice	within	 the	choice	sets	of	block	1:	
option	A	 in	choice	set	8	and	option	B	 in	choice	set	20.	However,	
there	were	no	duplicate	choice	sets.		
	
6.2.2.2 Orthogonality	and	Level	Balance	
The	design	 created	by	 SAS	 JMP	Pro	 9.2.0	 achieved	 level	 balance	
across	four	of	the	six	attributes	as	shown	in	table	6.4:	
Attribute	
Level	
A1	 A2	 A3	 A4	 A5	 A6	
L1	 16	 24	 48	 23	 24	 24	
L2	 16	 24	 48	 25	 24	 24	
L3	 17	 24	 	 25	 24	 24	
L4	 16	 24	 	 23	 24	 24	
L5	 15	 	 	 	 	 	
L6	 16	 	 	 	 	 	
Total	 96	 96	 96	 96	 96	 96	
Table	6.4	-	Level	Balance	within	Questionnaire	Design	Prior	to	Removal	of	Implausible	
Combinations	
	
It	 did	 not	 generate	 a	 fully	 balanced	 design.	 Using	 the	 ‘Evaluate	
Design’	 function	 within	 JMP	 Pro	 9.2.0,	 the	 design	 diagnostics	
indicated	a	D-Efficiency	of	98.06.		
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Following	 the	 removal	of	 the	 implausible	combinations,	 the	 level	
balance	across	the	two	questionnaires	was:	
Attribute	
Level	
A1	 A2	 A3	 A4	 A5	 A6	
L1	 16	 24	 48	 23	 24	 24	
L2	 16	 23	 48	 25	 24	 24	
L3	 17	 25	 	 25	 24	 24	
L4	 16	 24	 	 23	 24	 24	
L5	 15	 	 	 	 	 	
L6	 16	 	 	 	 	 	
Total	 96	 96	 96	 96	 96	 96	
Table	6.5	-	Level	Balance	within	Questionnaire	Design	after	the	Removal	of	Implausible	
Combinations	
The	orthogonality	of	the	design	was	also	checked	post	adjustment	
for	 implausible	 combinations.	 This	 is	 defined	 by	 Ryan	 and	
colleagues	 as	 “occurrence	 of	 one	 attribute	 does	 not	 depend	 on	
any	 other	 attribute”	 (Ryan	 et	 al.,	 2014:105).	 Using	 the	 ‘CORREL’	
function	in	Excel	for	Mac	2016	the	results	are	shown	in	table	6.6.	
This	 demonstrated	 that	 the	 values	 were	 close	 to	 zero	 (no	
correlation	 at	 all)	 in	 all	 cases	meaning	 that	 the	 pollution	 of	 the	
main	effects	of	one	attribute	by	another	was	minimal.		
	 A1	 A2	 A3	 A4	 A5	 A6	
A1	 1	 	 	 	 	 	
A2	 0.162	 1	 	 	 	 	
A3	 0.091	 0.075	 1	 	 	 	
A4	 0.125	 0.025	 0.007	 1	 	 	
A5	 -0.082	 -0.113	 0	 -0.017	 1	 	
A6	 -0.033	 -0.096	 0	 0.136	 -0.100	 1	
Table	6.6	-	Correlation	between	Attributes	
6.2.2.3 Overlap	
Overlap	occurs	when	within	a	choice	set	an	attribute	has	the	same	
level	 for	 both	 choices	 (Johnson	 et	 al	 2013).	 The	 original	 design	
generated	by	 JMP	Pro	did	not	 include	 any	overlap	within	 choice	
sets.	 However,	 the	 adjustments	 to	 eliminate	 implausible	
combinations	meant	that	the	final	design	has	overlap	in	the	choice	
sets	for	the	‘time	to	result’	attribute.		
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In	 order	 to	 minimise	 the	 effect	 of	 the	 overlap,	 the	 four	
combinations	 to	 remove	 implausible	 combinations	 (by	 switching	
the	time	to	result)	were	tested	to	see	whether:	
• any	duplicate	choice	sets	were	created	
• any	duplicate	choices	were	created	
• how	many	choice	sets	contained	overlap.	
	
The	final	combination	selected	for	the	management	of	implausible	
combinations	was	the	one	which	created	no	duplicate	choices	and	
provided	an	equal	balance	of	the	number	of	choice	sets	containing	
overlap	 between	 the	 two	 questionnaires.	 The	 loss	 of	 statistical	
efficiency	has	been	accepted	in	the	interests	of	securing	response	
efficiency;	 that	 is,	 presenting	 respondents	with	 plausible	 choices	
for	 completion	 in	 the	 questionnaire.	 No	 precise	 measure	 of	
acceptability	 in	 terms	 of	 loss	 of	 statistical	 efficiency	 has	 been	
identified,	 Johnson	 and	 colleagues	 state	 that	 “designs	 that	 are	
nearly	 balanced	 and	 nearly	 orthogonal	 usually	 are	 still	 well	
identified.	 As	 long	 as	 the	 collinearity	 is	 not	 severe,	 all	 the	
parameters	 of	 interest	 will	 be	 sufficiently	 identified	 and	
estimation	is	feasible”	(Johnson	et	al.,	2013:8).		
	
6.2.3 Preference	Elicitation		
Bridges	 and	 colleagues	 note	 that	 it	 is	 imperative	 to	 ensure	 that	
participants	have	 an	 appropriate	 level	 of	 information	 to	 complete	
the	 tasks	 including	background	 information	and	an	explanation	of	
attributes	and	levels	(Bridges	et	al.,	2011).	Background	information	
and	 an	 explanation	 of	 attributes	 and	 levels	 were	 developed	 and	
shared	 initially	 with	 a	 small	 group	 of	 researchers	 in	 the	 eSTI2	
research	 consortium,	 including	 two	 sexual	 health	 consultants	 to	
check	 factual	 accuracy	 and	 obtain	 general	 feedback	 on	
comprehension	prior	to	cognitive	testing.		
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The	background	 information	 and	 sample	 choice	 sets	were	 subject	
to	 three	 rounds	of	 cognitive	 testing	 to	 test	 comprehension	within	
the	target	age	range.	The	results	are	reported	in	section	6.3.1.	
	
6.2.3.1 Instrument	Design	
Bridges	and	colleagues	note	“it	 is	 important	to	elicit	 respondent-
specific	 health	 and	 socio-demographic	 information	 to	 allow	 for	
testing	 for	 systematic	 differences	 in	 preference	 based	 on	 these	
characteristics”	(Bridges	et	al	2011:409).		
	
In	determining	 the	 range	of	 socio-demographic	characteristics	 to	
be	collected,	 consideration	was	 firstly	given	 to	which	 sub-groups	
to	analyse.	 These	were	 in	part	 limited	by	 funding	 (as	 the	overall	
sample	size	increases).	Two	sub-groups	were	selected	to	form	the	
basis	of	the	quota	sampling:	
• Age-bands	within	 the	16-24	age	 range	 -	 there	 is	evidence	
to	suggest	from	the	focus	groups	undertaken	to	inform	the	
DCE	 design	 and	 the	 uptake	 of	 the	 online	 consultation	
within	 the	 exploratory	 study	 that	 there	 may	 be	 a	
difference	 between	 the	 younger	 and	 older	 age	 groups	
within	the	16-24	age	range.	
• Gender	–	there	is	evidence	in	the	uptake	data	for	the	NCSP	
which	 shows	 a	 difference	 in	 the	 number	 of	 male	 and	
female	young	people	having	a	chlamydia	test	(PHE,	2016b).	
	
In	 addition	 to	 age	 and	 gender	 it	 was	 also	 decided	 to	 collect	
demographic	information	on	the	following	characteristics:	
• Ethnicity	(defined	by	the	ONS	dataset),	
• Region	 of	 Residence	 (defined	 by	 the	 Government	 Office	
regions),	
• Sexual	 Preference	 (Heterosexual,	 Homosexual	 (Gay/	
Lesbian)	or	Bisexual),	
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• Relationship	 Status	 (Single,	 in	 a	 relationship	 with	 one	
person,	 in	 a	 sexual	 relationship	 with	 one	 person,	 in	 a	
relationship	 with	 more	 than	 one	 person,	 in	 a	 sexual	
relationship	with	more	than	one	person),	
• Whether	previously	tested	for	an	STI	(yes/	no).	
	
The	development	of	 the	background	 information	and	description	
of	 attributes	 and	 levels	 was	 subject	 to	 cognitive	 testing	 to	
minimise	the	risk	of	misinterpretation.	Further	information	on	the	
results	of	this	is	included	within	section	6.3.	
	
Finally,	for	consideration	in	the	questionnaire	design	was	the	level	
of	 burden	 imposed	 upon	 respondents.	 Bridges	 and	 colleagues	
note	 that	 there	 are	 a	 number	 of	 factors	 that	 can	 affect	 this,	
including:	 survey	 length,	 difficulty	 and	 incentive	 (Bridges	 et	 al	
2011).	 The	 review	 of	 published	 DCE	 studies	 by	 Clark	 and	
colleagues	 identified	 that	 between	 2009-12	 the	 majority	 of	
studies	 (62%)	 had	 between	 eight	 and	 16	 choices	 and	 the	
percentage	 with	 over	 16	 choices	 had	 remained	 stable	 at	 15%	
when	compared	with	the	previous	review	period	((2001-2008)	at	
18%	(De	Bekker-Grob	et	al.,	2010,	Clark	et	al.,	2014).	As	outlined	
in	 section	 6.2.2,	 cognitive	 testing	 was	 undertaken	 on	 a	
questionnaire	 with	 24	 choice	 sets	 to	 see	 whether	 participants	
found	it	too	lengthy	or	burdensome	to	complete.	This	found	that	
24	choice	sets	was	acceptable	to	participants.	
	
The	 incentive	 was	 determined	 by	 YouthSight,	 the	 company	
operating	the	research	panel	who	have	a	prescribed	structure	for	
reimbursement	 of	 participation	 as	 outlined	 in	 section	 3.7.	
Participants	 were	 therefore	 familiar	 with	 the	 level	 of	 reward	
offered	for	a	survey	of	this	length.		
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6.2.4 Data	Collection	
Bridges	 and	 colleagues	 suggest	 that	 sample	 size	 calculations	 for	
DCEs	are	complex	and	do	not	 identify	a	 specific	method	by	which	
they	should	be	calculated	(Bridges	et	al.,	2011).	Orme	recommends	
that	 where	 sub-group	 analysis	 is	 undertaken	 there	 should	 be	 a	
minimum	 of	 200	 respondents	 in	 each	 sub-group	 (Orme,	 2010).	
Therefore,	to	reach	a	minimum	of	200	respondents	for	each	of	the	
six	gender	and	age-specific	sub-groups	a	total	sample	size	of	1,200	
is	required,	600	per	questionnaire.	The	sample	size	breakdown	per	
questionnaire	is	provided	in	the	table	6.7:	
	
	 Age	16-18	 Age	19-21	 Age	22-24	 Total	per	
Questionnaire	
Male	 100	 100	 100	 300	
Female	 100	 100	 100	 300	
Total	per	
Questionnaire	
200	 200	 200	 600	
Table	6.7	-	DCE	Sampling	Strategy	per	Questionnaire	
	
An	 online	 research	 panel	 was	 selected	 as	 the	 route	 to	 recruit	
participants	to	fulfil	the	requirements	of	the	sampling	strategy	in	a	
timely	manner	 recognising	 the	 large	 sample	 size,	 and	 the	need	 to	
gain	access	to	the	general	population	as	opposed	to	recruitment	via	
healthcare	 settings.	 Funding	was	 secured	 from	 the	 eSTI2	 research	
programme	 to	 do	 this.	 Ethical	 considerations	 for	 the	 survey	 are	
outlined	in	section	3.7.	
	
6.2.5 Statistical	Analyses	
Three	types	of	statistical	analysis	were	undertaken:	
i. Descriptive	 statistics	 for	 the	 participants,	 drawn	 from	 the	
demographic	data,	
ii. Assessment	of	the	internal	validity	of	the	data,	
iii. Analysis	and	interpretation	of	the	DCE	responses.	
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Demographic	 characteristics	 of	 respondents	 are	 presented	 in	
section	6.5.1.		
	
Assessment	 of	 the	 external	 validity	 of	 DCE	 data	 is	 recognised	 as	
problematic	(Lancsar	&	Louviere,	2008,	Clark	et	al.,	2014)	with	the	
true	test	of	external	validity	being	whether	stated	preference	data	
reflect	 ‘real’	 behaviour	 (revealed	 preference	 data)	 (Ryan	 et	 al.,	
2008).	 In	 studies	 such	 as	 this	 where	 new	 technology	 is	 being	
explored,	with	a	number	of	hypothetical	levels,	revealed	preference	
data	 are	 generally	 not	 available.	 A	 number	 of	 methods	 have	
therefore	 been	 identified	 for	 assessing	 the	 internal	 validity	 of	 the	
data	including:	
• Repeated	questions	(Bridges	et	al.,	2011),	
• A	 dominant	 choice	within	 a	 choice	 set	 (where	 all	 levels	 in	
one	choice	are	better	than	the	other	(Bridges	et	al.,	2011),	
• Identification	of	participants	who	“nearly	always	choose	the	
alternative	with	the	best	 level	of	one	attribute”	 (Bridges	et	
al.,	2011:410),	
• “Checking	 if	 signs	 of	 estimated	 parameters	 are	 consistent	
with	 a	 priori	 expectations”	 (Lancsar	 and	 Louviere,	
2008:672),	
• Internal	consistency/	rationality	(Ryan	et	al.,	2008).	
	
In	 their	 review	 of	 recently	 published	 DCE	 studies	 in	 healthcare,	
Clark	 and	 colleagues	 identified	 that	 the	most	 commonly	 reported	
tests	 for	 validity	 are	 theoretical	 validity	 tests,	 including	 whether	
parameters	 are	 consistent	with	 a	 priori	 expectations	 (Clark	 et	 al.,	
2014).		
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To	 assess	 the	 internal	 validity	 of	 the	 questionnaire	 an	 analysis	 of	
the	 number	 of	 responses	 for	 each	 option	 was	 undertaken.	 In	
addition,	 the	 following	 methods	 were	 selected	 and	 tested	 by	
comparing	 the	 full	 dataset	 with	 the	 dataset	 with	 the	 following	
responses	removed:	
• Repeated	 choice	 set	 –	 respondents	 provide	 the	 same	
answer	to	the	repeated	choice	set,		
• Time	 to	 complete	 questionnaire	 –	 data	 where	 responses	
took	 less	 than	 the	 minimum	 time	 during	 the	 cognitive	
testing,	
• Opt	out	question	data	–	where	the	‘I	would	not	test’	option	
was	selected.	
	
Tests	 for	 internal	 consistency	 and	 rationality	 were	 not	 included	
because	 there	 is	 a	 suggestion	 that	 to	 exclude	 responses	 on	 this	
basis	may	be	an	inappropriate	imposition	of	rationality	(Clark	et	al.,	
2014).	 The	 results	 of	 the	 internal	 validity	 checks	 are	 presented	 in	
section	6.5.2.	
	
In	selecting	the	model	for	the	analysis	of	the	data	it	was	identified	
that	convention	for	choice	sets	including	three	or	more	alternatives	
is	 to	 use	 the	 multinomial	 logit	 (MNL)	 model	 developed	 by	
McFadden	(also	known	as	the	conditional	logit	model)	(Ryan	et	al.,	
2008,	Ryan	et	al.,	2014).	Louviere	and	colleagues	identify	the	MNL	
model	 as	 the	 core	 choice	 model	 used	 for	 the	 analysis	 of	 stated	
preference	data	in	a	variety	of	fields	including	transport,	marketing	
and	 environmental	 (Louviere	 et	 al.,	 2003).	 In	 addition,	 Clark	 and	
colleagues	 point	 to	 an	 increase	 in	 the	 use	 of	 this	 modelling	
approach	in	reported	DCE	studies	in	healthcare	from	22%	of	studies	
published	 between	 2001	 and	 2008	 and	 44%	 of	 studies	 published	
between	2009	and	2012	(Clark	et	al.,	2014).		
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The	MNL	estimator	has	a	number	of	assumptions,	 summarised	by	
Ryan	and	colleagues	as:	
• “Error	terms	independent	across	observations	
• Independence	of	irrelevant	alternatives	(IIA)	
• Homogeneity	of	preferences”	(Ryan	et	al.,	2014:220).	
	
The	 IIA	condition	 is	 recognised	as	a	 strength	and	weakness	within	
the	MNL	approach.	Louviere	and	colleagues	state	that	“its	strength	
is	that	it	provides	a	computationally	convenient	choice	model,	and	
permits	 introduction	 and/	 or	 elimination	 of	 alternatives	 in	 choice	
sets	without	 re-estimation.	 Its	weakness	 is	 that	 the	 observed	 and	
unobserved	 attributes	 of	 utility	 may	 not	 be	 independent	 of	 one	
another,	 and/	 or	 if	 the	 unobserved	 components	 of	 utility	 are	
correlated	 among	 alternatives,	 this	 leads	 to	 biased	 utility	
parameters	 and	 added	 errors	 in	 forecasts.”	 (Louviere	 et	 al.,	
2003:45).	
	
STATA13	SE	was	used	to	conduct	the	analysis	of	the	DCE	responses	
using	the	‘clogit’	command,	utilising	the	method	and	code	outlined	
by	 the	 University	 of	 Aberdeen	 course	 ‘Using	 Discrete	 Choice	
Experiments	 in	Health	Economics:	Theoretical	and	Practical	 Issues’	
(Ryan	et	al.,	2014.).		
	
Variables	within	the	model	were	all	treated	as	categorical	variables	
for	 the	 analysis.	 Attribute	 levels	 were	 specified	 using	 dummy	
variables	 as	 it	 was	 identified	 that	 dummy	 coding	 is	 the	 most	
recognised	 approach	 within	 healthcare	 research	 (Bridges	 et	 al.,	
2011),	and	is	the	preferred	form	of	coding	where	odds	ratios	are	to	
be	 calculated	 (Ijzerman	et	 al.,	 2016).	Dummy	coding	 requires	 that	
one	 level	 be	 ‘dropped’	 for	 each	 attribute	 and	 this	 level	 “can	 be	
chosen	arbitrarily”	(Ryan	et	al.,	2014:196).		
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Within	 the	 model	 the	 levels	 that	 were	 dropped	 reflect	 a	 sexual	
health	clinic	pathway;	 this	was	chosen	as	 it	 represents	one	option	
currently	available	to	young	people	to	access	chlamydia	testing.	The	
other	 NCSP	 Chlamydia	 testing	 options	 can	 be	 comprised	 of	 a	
number	of	different	combinations	of	levels	and	would	therefore	not	
offer	 the	 clarity	 of	 a	 single	 pathway.	 The	 ‘dropped’	 levels	 which	
form	the	reference	level	for	each	attribute	are	summarised	in	table	
6.8:	
	
Attribute	 Reference	Level	
(Dropped	Level)	
How	you	Test	 Sexual	Health	Clinic	
Time	to	Result	 7	Days	
Accuracy		 5	in	100	(False	Negative)	
Consultation	Method	 Sexual	Health	Clinic	
Access	to	HCP	 Face	to	Face	
How	you	get	Antibiotics	 Collect	from	Clinic	
Table	6.8	-	Dummy	Coding	Reference	Level	
6.3 Methods	–	Pilot	Phase	
The	 purpose	 of	 the	 pilot	 phase	was	 to	 test	 the	 draft	 questionnaire	
and	 associated	 background	 information.	 These	 were	 piloted	 on	
respondents	 within	 the	 sample	 age	 range	 using	 cognitive	
interviewing	methodology	 -	 drawing	 on	 both	 the	 ‘think	 aloud’	 and	
probing	paradigms	 (Beatty	 and	Willis,	 2007,	 Campanelli,	 1997).	 The	
cognitive	 interviews	 involved	 a	 one-to-one	 interview	 using	 both	
concurrent	 and	 retrospective	 probing,	 with	 probes	 scripted	 in	
advance	(ibid.).	Concurrent	probing	was	used	for	the	first	half	of	the	
questionnaire,	 with	 questions	 following	 each	 of	 the	 sections	
(background,	 definitions	 and	 demographic),	 to	 test	 participants’	
understanding	of	key	terms	used	within	these	sections.		
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Retrospective	 probing	 was	 used	 for	 the	 choice	 part	 of	 the	
questionnaire.	 Participants	 completed	 the	 25	 choice	 sets	 in	 their	
entirety	with	the	participant	being	made	aware,	prior	to	completion,	
that	they	would	be	asked	how	they	made	their	choice	for	each	choice	
set	at	the	end.	Finally,	a	series	of	debriefing	questions	were	asked	to	
determine	the	participants’	 level	of	confidence	in	their	answers	and	
how	 difficult	 they	 found	 the	 questionnaire	 to	 complete.	 The	
interview	 schedule	 for	 the	 third	 round	 of	 interviews	 is	 included	 in	
Appendix	13.		
	
The	 pilot	 study	 was	 undertaken	 in	 phases.	 After	 undertaking	 the	
initial	phase,	the	results	were	reviewed	to	identify	the	revisions,	and	
then	 the	 next	 iteration	 of	 the	 questionnaire	 was	 piloted.	 A	 final	
sample	 size	 was	 not	 determined	 in	 advance	 as	 it	 was	 an	 iterative	
process,	 continuing	 until	 no	 new	 significant	 issues	 impacting	 on	
completion	of	the	questionnaire	were	being	identified	(Willis,	1999).	
Convenience	sampling	was	used	for	expediency	within	the	target	age	
range	 (16-24)	 for	 the	questionnaire.	 Participants	were	 recruited	 via	
the	 University	 of	 Warwick’s	 research	 recruitment	 system.	 A	 hard	
copy	of	 the	questionnaire	was	used,	presenting	the	text	 that	would	
be	uploaded	into	the	online	survey.	
	
After	 each	 phase	 the	 responses	 were	 summarised	 with	 a	 specific	
focus	on:	
• Terms	 used	 where	 the	 participant	 did	 not	 interpret	 their	
meaning	as	intended.	
• Responses	 to	 choice	 questions	 to	 determine	 whether	 any	
specific	attribute	dominated,	that	 is,	whether	the	participant	
selected	 choices	 based	 on	 one	 specific	 attribute	 over	 the	
others	consistently.		
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6.3.1 Pilot	Phase	Results	
In	total	nine	cognitive	interviews	were	undertaken	in	three	rounds.	
The	demographic	characteristics	of	participants	are	summarised	 in	
table	6.9:	
	 n	 %	
Age	
19	 2	 22%	
20	 3	 33%	
21	 1	 11%	
24	 3	 33%	
	 	 	
Gender	
Male	 1	 11%	
Female	 8	 89%	
	 	 	
Ethnic	Origin	
White	British	 3	 33%	
White	Other	 1	 11%	
Chinese	 3	 33%	
Bangladeshi	 1	 11%	
Black	African	 1	 11%	
	 	 	
Highest	Qualification	
A-Level	 5	 56%	
Degree	 2	 22%	
Post-Grad	 2	 22%	
Table	6.9	-	Demographic	Characteristics	of	Cognitive	Testing	Participants	
	
Although	 not	 formally	 captured	 as	 part	 of	 the	 demographic	
information,	 it	 was	 observed	 during	 the	 interviews	 that	 six	 of	 the	
nine	 participants’	 first	 language	was	 not	 English.	 There	were	 three	
participants	in	the	first	round	of	cognitive	testing,	two	in	the	second	
round	and	four	in	the	third	round.	The	interview	lengths	ranged	from	
36	to	57	minutes.					
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The	cognitive	interviews	found	broadly	that	participants	understood	
the	 introduction,	 key	 terms	 and	 definitions	 used.	 However,	 it	 was	
identified	 by	 participants	 in	 round	 one	 and	 round	 two	 that	
clarification	 was	 needed	 on	 terms	 relating	 to	 Epididymitis	 and	
azithromycin.	 As	 a	 suggestion	 from	 a	 participant	 in	 round	 two	 a	
visual	 representation	 of	 the	 pathway	 was	 incorporated	 to	 aid	 in	
understanding.	 Incorporation	 of	 additional	 questions	 into	 the	 third	
round	 of	 interviews	 identified	 that	 participants	 were	 able	 to	
articulate	 what	 the	 diagrams	 meant.	 It	 was	 therefore	 decided	 to	
retain	them	in	the	final	questionnaire.		
	
In	 respect	 of	 the	 choice	 sets,	 the	 first	 round	 of	 cognitive	 testing	
revealed	that	the	difference	in	the	accuracy	levels	(2	in	100	versus	8	
in	100)	dominated	as	the	reason	for	selecting	a	choice	for	two	of	the	
three	 participants;	 therefore,	 in	 the	 second	 round,	 the	 level	 was	
reduced	to	5	 in	100.	The	reasons	for	selecting	choice	sets	 in	rounds	
two	and	three	revealed	a	range	of	factors	for	making	the	choice	from	
respondents.	Therefore,	 it	was	decided	 to	proceed	with	 the	 revised	
level	 in	 the	 final	 DCE.	 Implausible	 combinations	 were	 left	 in	 the	
choice	 sets	 in	 the	 first	 round	 of	 the	 cognitive	 testing.	 The	 third	
participant	 identified	 the	 conflict	 between	 posting	 a	 sample	 for	
analysis	and	getting	the	result	 in	two	hours	as	being	impossible	and	
therefore	they	did	not	make	that	choice.	As	a	result,	 it	was	decided	
to	 remove	 implausible	 combinations	 from	 the	 choice	 sets.	
Implausible	combinations	were	removed	for	rounds	two	and	three	of	
the	cognitive	testing.	
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In	terms	of	completion	of	the	questionnaire,	all	participants	indicated	
that	 they	 felt	 sure	 of	 their	 answers,	 however,	 three	 of	 the	 nine	
participants	 indicated	that	 they	went	back	and	changed	one	or	 two	
answers	as	 they	progressed	 through	 the	questionnaire.	Participants	
indicated	 that	 they	 did	 not	 find	 it	 difficult	 to	 complete	 the	 choice	
questions,	 with	 three	 participants	 indicating	 that	 they	 found	 they	
needed	to	think	about	some	choices	 longer	than	others.	One	of	the	
nine	 participants	 indicated	 that	 completion	 became	 monotonous	
because	of	the	number	of	choices.		
	
In	completing	the	questionnaire,	the	time	to	complete	the	25	choice	
sets	 ranged	 from	 four	 minutes	 46	 seconds	 to	 nine	 minutes	 56	
seconds.	 Eight	 of	 the	 nine	 participants	 answered	 the	 duplicate	 set	
correctly.	Reviewing	the	total	number	of	participants	selecting	A,	B	or	
choosing	 not	 to	 test	 showed	 that	 there	 was	 variance	 across	 the	
questions.	 In	 no	 choice	 set	 did	 all	 participants	 choose	 option	 A,	
option	B	or	not	to	test.		
	
A	summary	of	the	changes	made	to	the	questionnaire	is	provided	in	
table	6.10.	
	
Changes	following	Round	1	 Changes	following	
Round	2	
Changes	following	
Round	3	
• Minor	changes	to	words	
to	explain	Epididymitis	
• Clarification	that	time	to	
result	does	not	affect	
accuracy	
• Adjustment	of	accuracy	
level	from	8	to	5	
• Clarification	of	the	
relationship	question	in	
demographic	section	
• Restatement	of	
instructions	on	completion	
immediately	prior	to	the	
choice	sets	
• Removal	of	implausible	
combinations	
• Minor	
clarification	
points	on	
azithromycin	
• Incorporation	of	
flow	diagrams	
and	associated	
explanatory	
text	
• Clarification	of	
results	
notification	
process	
	
• Re-ordering	of	
points	to	
correspond	with	
ordering	of	levels	in	
questionnaire		
• Minor	amendments	
to	demographic	
questions	following	
feedback	from	
ethics	committee	
Table	6.10	-	Questionnaire	Changes	Following	Each	Round	of	Cognitive	Testing	
		 284	
	
6.4 DCE	Data	Collection	&	Management	
The	 questionnaire	 was	 scripted	 by	 YouthSight	 and	 test	 links	 were	
provided	 for	 review.	 A	 copy	 extracts	 from	 the	 questionnaire’s	
introduction	 and	 a	 sample	 of	 the	 choice	 sets	 are	 included	 in	
Appendix	14.	YouthSight	used	their	standard	approach	to	promoting	
the	 questionnaire	 to	 potential	 participants	 via	 email	 and	 managed	
the	participation	to	ensure	that	the	sampling	quotas	were	met.	Data	
collection	was	 paused	 after	 50	 responses	 on	 each	 questionnaire	 to	
test	 the	 model.	 Data	 collection	 with	 the	 online	 panel	 took	 place	
between	12	November	and	26	November	2015.		
	
Data	were	provided	by	YouthSight	in	two	Excel	files	–	one	containing	
labelled	data	and	one	containing	coded	data.	Data	were	prepared	for	
analysis	 in	 Excel	 for	Mac	 2016	 and	 STATA13	 SE	 in	 accordance	with	
the	 method	 outlined	 by	 Ryan	 and	 colleagues	 (Ryan	 et	 al.,	 2014).	
Choice	set	1	was	repeated	 in	the	questionnaire	as	choice	set	25	for	
validity	checks.	Therefore,	it	was	necessary	to	drop	the	responses	to	
one	choice	set	from	the	analysis.	Choice	set	1	was	dropped	as	at	the	
start	of	the	questionnaire	participants	are	generally	less	familiar	with	
the	 adopted	 survey	 approach.	 This	 is	 discussed	 further	 in	 section	
6.5.2.	
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6.5 DCE	Results	
6.5.1 Respondent	Characteristics	
In	 total,	 1,230	 responses	 to	 the	 questionnaire	 were	 received,	 a	
further	 490	 people	 commenced	 the	 questionnaire	 but	 did	 not	
complete	it	giving	a	completion	rate	of	73%.	No	further	information	
was	available	about	 the	demographic	characteristics	of	 those	who	
did	 not	 complete	 the	 questionnaire.	 The	 breakdown	 of	 the	
demographic	characteristics	of	respondents	is	summarised	in	table	
6.11;	 where	 national	 comparative	 data	 can	 be	 identified	 this	 has	
been	included.	
	
Demographic	Characteristic	 n	 %	 National	%4	
Age	
16	 8	 1%	 10%	
17	 113	 9%	 10%	
18	 294	 24%	 11%	
19	 183	 15%	 11%	
20	 132	 11%	 11%	
21	 91	 7%	 11%	
22	 162	 13%	 11%	
23	 135	 11%	 12%	
24	 112	 9%	 12%	
Total	 1230	 100%	 99%	
Gender	
Male	 607	 49%	 51%	
Female	 623	 51%	 49%	
Total	 1230	 100%	 100%	
Ethnicity	
White	–	English,	Welsh,	Scottish,	
Northern	Irish,	British	
932	 76%	 80%	
White	–	Irish	 7	 1%	 1%	
White	–	Gypsy	or	Irish	Traveller	 1	 0%	 0%	
White	–	Any	other	white	background	 37	 3%	 5%	
Mixed/	Multiple	Ethnic	Groups	–	
White	&	Black	Caribbean	
10	 1%	 1%	
Mixed/	Multiple	Ethnic	Groups	–	 6	 0%	 0%	
																																																						
4	-	National	Data	for	Age	and	Region	taken	from	ONS	Mid-Year	Population	Estimates	2015	
(ONS,	2016b).	Percentages	derived	from	the	total	16-24	population.	National	Data	for	
Ethnicity	taken	from	Census	2011	data,	percentages	derived	from	total	England	population	
(ONS,	2012).	Percentages	may	not	sum	due	to	rounding	
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Demographic	Characteristic	 n	 %	 National	%4	
White	&	Black	African	
Mixed/	Multiple	Ethnic	Groups	–	
White	&	Asian	
13	 1%	 1%	
Mixed/	Multiple	Ethnic	Groups	–	Any	
other	mixed/	multiple	ethnic	
background	
8	 1%	 1%	
Asian/	Asian	British	–	Indian	 50	 4%	 3%	
Asian/	Asian	British	-	Pakistani	 38	 3%	 2%	
Asian/	Asian	British	-	Bangladeshi	 18	 1%	 1%	
Asian/	Asian	British	-	Chinese	 22	 2%	 1%	
Asian/	Asian	British	–	Any	other	Asian	
background	
21	 2%	 2%	
Black/	African/	Caribbean/	Black	
British	–	African	
26	 2%	 2%	
Black/	African/	Caribbean/	Black	
British	–	Caribbean	
10	 1%	 1%	
Black/	African/	Caribbean/	Black	
British	–	Any	other	black/	African/	
Caribbean	background	
2	 0%	 1%	
Other	–	Arab	 5	 0%	 0%	
Other	–	Any	other	ethnic	group	 9	 1%	 1%	
I	would	prefer	not	to	say	 15	 1%	 0%	
Total	 1230	 100%	 103%	
Region	
East	Midlands	 117	 10%	 9%	
London	 225	 18%	 15%	
North	East	 74	 6%	 5%	
North	West	 123	 10%	 13%	
Eastern	 55	 4%	 10%	
South	East	 222	 18%	 16%	
South	West	 143	 12%	 10%	
West	Midlands	 144	 12%	 11%	
Yorkshire	and	The	Humber	 113	 9%	 11%	
I	would	prefer	not	to	say	 14	 1%	 0%	
Total	 1230	 100%	 100%	
Sexual	Preference	
Heterosexual	(partner	of	opposite	sex)	 1030	 84%	 	
Homosexual	(partner	of	same	sex)	&	
Male	
13	 1%	 	
Homosexual	(partner	of	same	sex)	&	
Female	
39	 3%	 	
Bisexual	(partner	of	either	sex)	 98	 8%	 	
I	would	prefer	not	to	say	 50	 4%	 	
Total	 1230	 100%	 	
Previous	STI	Test	
Yes	 393	 32%	 	
No	 790	 64%	 	
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Demographic	Characteristic	 n	 %	 National	%4	
I	would	prefer	not	to	say	 47	 4%	 	
Total	 1230	 100%	 	
Relationship	Status	
Single	 615	 50%	 	
In	a	non-sexual	relationship	with	one	
person	
36	 3%	 	
In	a	non-sexual	relationship	with	more	
than	one	person	
2	 0%	 	
In	a	sexual	relationship	with	one	
person	
512	 42%	 	
In	a	sexual	relationship	with	more	
than	one	person	
36	 3%	 	
I	would	prefer	not	to	say	 29	 2%	 	
Total	 1230	 100%	 	
Table	6.11	-	Demographic	Characteristics	of	DCE	Respondents	
Comparing	 the	 DCE	 sample	 characteristics	 to	 the	 national	
population	 (England)	 characteristics	 shows	 that	 the	 gender	 and	
ethnicity	 makeup	 of	 participants	 is	 broadly	 in	 line	 with	 national	
population	 demographics.	 For	 age,	 it	 can	 be	 seen	 that	 at	 the	
proportions	 within	 the	 age	 bands	 are	 not	 as	 reflective	 of	 the	
national	population,	specifically	the	16-18	range	age.	As	illustrated	
in	table	6.12	the	age	ranges	are	broadly	reflective	of	the	percentage	
of	the	16-24	year	olds	falling	into	each	age	band.	However,	it	can	be	
seen	 from	 table	 6.11	 that	 there	 is	 a	 disproportionately	 higher	
number	of	18	year	olds	and	disproportionately	lower	number	of	16	
year	olds	completing	the	survey.		
	
In	 terms	 of	 the	 geographic	 region	 of	 participants,	 the	 sample	 is	
broadly	 in	 line	with	 the	geographic	distribution	of	16-24	year	olds	
identified	 in	 the	 ONS	Mid-Year	 Population	 Estimates	 2015	 (Office	
for	 National	 Statistics,	 2016c),	 with	 the	 exception	 of	 a	 smaller	
proportion	completing	the	survey	from	the	East	of	England.	
	
	
Two	 demographic	 characteristics	 were	 identified	 a	 priori	 in	 the	
sampling	frame	for	sub-group	analysis	–	gender	and	age	range.	The	
total	number	of	 respondents	 in	each	sub-category	 for	analysis	are	
summarised	in	table	6.12:	
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Demographic	
Characteristic	
n	 %	 National	
%	
Age	Range	
16-18	 415	 34%	 31%	
19-21	 406	 33%	 33%	
22-24	 409	 33%	 35%	
Gender	
Male	 607	 49%	 51%	
Female	 623	 51%	 49%	
Table	6.12	-	Demographic	Characteristics	of	Sub-Groups	for	Analysis	
	
In	addition,	a	 review	of	 the	demographic	data	 identified	 sufficient	
responses	on	each	questionnaire	to	undertake	sub-group	analysis	–	
relationship	 status	 (single	 and	 in	 a	 sexual	 relationship	 with	 one	
person),	and	whether	previously	tested	for	an	STI	(yes	or	no).	It	was	
therefore	 decided	 to	 include	 these	 additional	 sub-groups	 in	 the	
analysis.		
	
6.5.2 Quality	of	Responses	
As	 identified	 in	 section	 6.2.5	 a	 number	 of	 validity	 checks	 were	
adopted	in	this	study:	
• Repeated	choice	set	
• Time	to	complete	questionnaire	
• Removal	of	the	opt	out	question	data	
• Analysis	of	number	of	responses	for	each	option.	
	
The	 results	of	 these	validity	checks	are	summarised	and	discussed	
in	turn.	
	
6.5.2.1 Repeated	Choice	Set	
In	 each	 of	 the	 two	 questionnaires	 choice	 set	 1	was	 repeated	 as	
the	25th	choice	set	with	option	A	and	option	B	reversed.		Analysis	
of	the	number	of	respondents	who	provided	the	same	answer	to	
both	choice	sets	is	included	in	table	6.13:	
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	 n	 %	
Same	answer	for	choice	sets	1	and	25	 912	 74%	
Different	answer	for	choice	sets	1	and	25	 318	 26%	
Table	6.13	-	Analysis	of	Repeated	Question	Responses,	Full	Dataset	
	
Reviewing	 this	 for	 the	 two	 questionnaires	 individually	 shows	 a	
slightly	higher	percentage	of	respondents	on	the	first	questionnaire	
answered	both	questions	correctly	 than	the	second	questionnaire.	
A	 chi2	 test	 demonstrated	 that	 this	 is	 not	 a	 statistically	 significant	
difference	(Chi2	=	1.221,	p-value=0.269):		
	 n	 %	
Questionnaire	1	 	 	
Same	answer	for	choice	sets	1	and	25	 463	 76%	
Different	answer	for	choice	sets	1	and	25	 150	 24%	
Questionnaire	2	 	 	
Same	answer	for	choice	sets	1	and	25	 449	 73%	
Different	answer	for	choice	sets	1	and	25	 168	 27%	
Table	6.14	-	Analysis	of	Repeated	Question	Responses	at	Individual	Questionnaire	Level	
	
The	 published	 reviews	 of	DCE	 studies	 did	 not	 include	 information	
on	 the	 proportion	 of	 repeated	 choice	 sets	 answered	 correctly	
within	published	studies.	A	further	literature	search	to	identify	any	
publications	 containing	 information	 on	 this	 failed	 to	 identify	 any	
published	reviews	considering	this.	One	paper	within	the	review	of	
stated	 preference	 studies	 included	 in	 section	 4.2	 (Phillips	 et	 al.,	
2002)	 reported	 that	 25%	 of	 respondents	 did	 not	 answer	 the	
repeated	 choice	 set	 correctly	 and	 noted	 that	 “these	 levels	 are	
similar	to	those	found	in	other	studies	which	range	from	9	percent	
to	39	percent”	(Phillips	et	al.,	2002:1693).	Therefore,	the	 incorrect	
response	rate	to	the	repeated	choice	set	 in	this	survey	appears	to	
be	in	line	with	other	published	studies.		
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In	 respect	 of	 whether	 to	 include	 the	 response	 to	 the	 first	 or	 last	
question	 in	 the	dataset,	a	clear	view	has	not	been	 identified	 from	
the	literature.	There	are	two	arguments	to	be	considered:	
• Inclusion	of	the	responses	to	the	first	choice	set	–	as	people	
complete	 the	 questionnaire	 they	 become	 fatigued	 and	
therefore	 their	 response	 to	 the	 first	 question	 is	 more	
reliable	than	the	last	question,	
• Inclusion	 of	 the	 responses	 to	 the	 last	 choice	 set	 –	 at	 the	
start	 of	 the	 questionnaire	 people	 are	 unsure	 of	 the	 DCE	
tasks	and	as	they	progress	they	become	more	familiar	with	
the	choice	process	and	therefore	their	response	to	the	 last	
question	 is	 more	 reliable	 than	 their	 response	 to	 the	 first	
question.	
	
Table	 6.15	 compares	 the	 results	 from	 the	 model	 run	 on	 the	 full	
dataset	 comparing	 the	 inclusion	 of	 responses	 to	 Q1	 and	 Q25	 in	
each	questionnaire.	Levels	highlighted	in	blue	indicate	a	p-value	of	
greater	 than	 0.05	 (demonstrated	 by	 the	 CI	 for	 the	 coefficient	
including	 0	 and	 the	 CI	 for	 the	 OR	 including	 1).	 This	 can	 be	
interpreted	as	the	strength	of	preference	for	these	levels	not	being	
statistically	significant	compared	to	the	reference	level.		
	
There	is	one	difference	in	respect	of	statistical	significance	of	levels	
–	‘post	to	collection	point’	is	not	statistically	significant	when	using	
data	 from	 choice	 set	 25	 (OR	 of	 1.031	 with	 a	 95%	 CI	 of	 0.981	 to	
1.085)	but	is	statistically	significant	when	using	data	from	choice	set	
1	 (OR	 of	 1.053	 with	 a	 95%	 CI	 of	 1.002	 to	 1.106).	 The	 order	 of	
strength	of	preference	within	 the	attributes	 remains	 the	 same	 for	
how	 you	 test,	 time	 to	 result,	 accuracy,	 access	 to	 a	 healthcare	
professional	and	how	you	get	your	antibiotics.	However,	there	is	a	
difference	 in	 order	 of	 preference	 for	 treatment	 consultation	
method.		
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Using	data	from	choice	set	one	the	order	of	strength	of	preference	
is	online	consultation	(OR	1.203),	pharmacy	consultation	(OR	1.162)	
and	 GP	 consultation	 (OR	 1.157),	 compared	 with	 choice	 set	 25	
where	the	order	is	online	consultation	(OR	1.212),	GP	consultation	
(OR	1.183)	and	pharmacy	consultation	(OR	1.158).	
	
Given	 the	 relative	 closeness	 of	 the	 odds	 ratio	 and	 confidence	
intervals	across	 the	datasets	which	option	should	be	 selected	was	
considered.	 Clark	 and	 colleagues	 noted	 that	 60%	 of	 published	
studies	between	2009	and	2012	contained	an	internal	validity	check	
and	 this	 was	 “an	 assessment	 of	 whether	 coefficients	 appear	 to	
move	in	line	with	a	priori	expectations”	(Clark	et	al.,	2014:11).	Their	
literature	review	did	not	consider	the	use	of	repeated	questions	as	
an	 internal	 validity	 measure.	 A	 search	 of	 the	 literature	 did	 not	
identify	 any	 other	 reviews	 of	 stated	 preference	 studies	 that	
considered	 the	 utilisation	 of	 data	 from	 repeated	 choice	 sets	 as	 a	
validity	measure.		
	
In	the	absence	of	a	clearly	established	method	for	the	selection	of	
which	 question	 response	 to	 choose	 in	 respect	 of	 a	 repeated	
question	 the	 latter	option	was	 selected,	 subscribing	 to	 the	 theory	
that	 as	 people	 complete	 the	 questionnaire	 they	 become	 more	
familiar	with	 the	choice	process.	Consequently,	choice	set	25	data	
was	included	in	the	dataset	used	for	analysis.	
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		 Dataset	Including	Choice	Set	1,	n=1,230	 Dataset	Including	Choice	Set	25,	n=1,230	
	 Coefficient	
Lower	95%	
CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	 Coefficient	
Lower	95%	
CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	
How	you	Test	
Self-Test	 0.498	 0.432	 0.564	 1.646	 1.540	 1.758	 0.481	 0.415	 0.547	 1.618	 1.514	 1.729	
Post	 0.308	 0.239	 0.376	 1.360	 1.270	 1.456	 0.306	 0.239	 0.373	 1.358	 1.271	 1.452	
Pharmacy	 0.116	 0.056	 0.175	 1.123	 1.057	 1.192	 0.144	 0.085	 0.203	 1.155	 1.088	 1.226	
Education/	Work	 -0.206	 -0.266	 -0.146	 0.814	 0.766	 0.864	 -0.197	 -0.257	 -0.137	 0.821	 0.773	 0.872	
GP	Practice	 0.011	 -0.050	 0.073	 1.011	 0.951	 1.075	 0.019	 -0.042	 0.081	 1.019	 0.959	 1.084	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.579	 0.524	 0.633	 1.784	 1.688	 1.884	 0.591	 0.537	 0.645	 1.806	 1.711	 1.906	
2	Hours	 0.340	 0.283	 0.398	 1.406	 1.328	 1.488	 0.338	 0.281	 0.395	 1.402	 1.324	 1.485	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.149	 -0.200	 -0.099	 0.861	 0.819	 0.906	 -0.148	 -0.198	 -0.098	 0.862	 0.820	 0.907	
Accuracy	
2	in	100	False	Negative	 1.192	 1.157	 1.226	 3.292	 3.179	 3.409	 1.176	 1.141	 1.212	 3.242	 3.130	 3.359	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	Consultation	 0.185	 0.133	 0.236	 1.203	 1.142	 1.266	 0.192	 0.140	 0.245	 1.212	 1.150	 1.277	
Pharmacy	Consultation	 0.150	 0.099	 0.202	 1.162	 1.104	 1.224	 0.147	 0.095	 0.199	 1.158	 1.100	 1.220	
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		 Dataset	Including	Choice	Set	1,	n=1,230	 Dataset	Including	Choice	Set	25,	n=1,230	
	 Coefficient	
Lower	95%	
CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	 Coefficient	
Lower	95%	
CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	
GP	Consultation	 0.146	 0.095	 0.197	 1.157	 1.100	 1.218	 0.168	 0.116	 0.220	 1.183	 1.123	 1.246	
Sexual	Health	Clinic	Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.058	 -0.108	 -0.008	 0.943	 0.897	 0.992	 -0.052	 -0.102	 -0.002	 0.949	 0.903	 0.998	
Instant	Messenger	 0.020	 -0.029	 0.070	 1.020	 0.971	 1.072	 0.027	 -0.023	 0.076	 1.027	 0.977	 1.079	
Email	 0.027	 -0.023	 0.076	 1.027	 0.978	 1.079	 0.047	 -0.002	 0.096	 1.048	 0.998	 1.101	
Face	to	Face	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
How	you	get	Antibiotics	
Post	to	Home	 0.038	 -0.013	 0.089	 1.039	 0.987	 1.093	 0.011	 -0.041	 0.063	 1.011	 0.960	 1.065	
Post	to	Collection	Point	 0.052	 0.002	 0.101	 1.053	 1.002	 1.106	 0.030	 -0.020	 0.081	 1.031	 0.980	 1.085	
Collect	from	Pharmacy	 0.091	 0.038	 0.143	 1.095	 1.039	 1.154	 0.072	 0.018	 0.126	 1.075	 1.018	 1.134	
Collect	from	Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Choice	
Option	A	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Option	B	 -0.341	 -0.381	 -0.302	 0.711	 0.683	 0.740	 -0.360	 -0.400	 -0.320	 0.698	 0.670	 0.726	
I	would	not	test	 -1.697	 -1.797	 -1.596	 0.183	 0.166	 0.203	 -1.682	 -1.781	 -1.583	 0.186	 0.168	 0.205	
Table	6.15	-	Comparison	of	Full	Dataset	Coefficients	and	ORs	for	Dataset	including	Choice	Set	1	and	Dataset	including	Choice	Set	25	
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		 Full	Dataset	n=1,230	 Excl	Incorrect	Answer	to	Validity	Check	n=912	
		 Coefficient	 Lower	95%	CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	 Coefficient	
Lower	95%	
CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	
How	you	Test	
Self-Test	 0.481	 0.415	 0.547	 1.618	 1.514	 1.729	 0.507	 0.429	 0.584	 1.660	 1.535	 1.794	
Post	 0.306	 0.239	 0.373	 1.358	 1.271	 1.452	 0.333	 0.254	 0.411	 1.395	 1.290	 1.508	
Pharmacy	 0.144	 0.085	 0.203	 1.155	 1.088	 1.226	 0.124	 0.054	 0.194	 1.132	 1.056	 1.214	
Education/	Work	 -0.197	 -0.257	 -0.137	 0.821	 0.773	 0.872	 -0.253	 -0.323	 -0.183	 0.777	 0.724	 0.833	
GP	Practice	 0.019	 -0.042	 0.081	 1.019	 0.959	 1.084	 0.019	 -0.053	 0.091	 1.019	 0.948	 1.095	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.591	 0.537	 0.645	 1.806	 1.711	 1.906	 0.573	 0.510	 0.637	 1.774	 1.665	 1.890	
2	Hours	 0.338	 0.281	 0.395	 1.402	 1.324	 1.485	 0.335	 0.268	 0.402	 1.397	 1.307	 1.494	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.148	 -0.198	 -0.098	 0.862	 0.820	 0.907	 -0.148	 -0.177	 -0.236	 -0.117	 0.790	 0.889	
Accuracy	
2	in	100	False	Negative	 1.176	 1.141	 1.212	 3.242	 3.130	 3.359	 1.323	 1.282	 1.364	 3.755	 3.602	 3.913	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	Consultation	 0.192	 0.140	 0.245	 1.212	 1.150	 1.277	 0.197	 0.136	 0.258	 1.218	 1.145	 1.294	
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		 Full	Dataset	n=1,230	 Excl	Incorrect	Answer	to	Validity	Check	n=912	
		 Coefficient	 Lower	95%	CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	 Coefficient	
Lower	95%	
CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	
Pharmacy	Consultation	 0.147	 0.095	 0.199	 1.158	 1.100	 1.220	 0.173	 0.112	 0.234	 1.189	 1.119	 1.264	
GP	Consultation	 0.168	 0.116	 0.220	 1.183	 1.123	 1.246	 0.179	 0.119	 0.240	 1.196	 1.126	 1.271	
Sexual	Health	Clinic	
Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.052	 -0.102	 -0.002	 0.949	 0.903	 0.998	 -0.084	 -0.143	 -0.026	 0.919	 0.867	 0.975	
Instant	Messenger	 0.027	 -0.023	 0.076	 1.027	 0.977	 1.079	 -0.026	 -0.084	 0.031	 0.974	 0.919	 1.032	
Email	 0.047	 -0.002	 0.096	 1.048	 0.998	 1.101	 -0.005	 -0.063	 0.052	 0.995	 0.939	 1.054	
Face	to	Face	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
How	you	get	Antibiotics	
Post	to	Home	 0.011	 -0.041	 0.063	 1.011	 0.960	 1.065	 0.014	 -0.047	 0.075	 1.014	 0.954	 1.078	
Post	to	Collection	Point	 0.030	 -0.020	 0.081	 1.031	 0.980	 1.085	 0.023	 -0.036	 0.083	 1.024	 0.964	 1.086	
Collect	from	Pharmacy	 0.072	 0.018	 0.126	 1.075	 1.018	 1.134	 0.065	 0.001	 0.128	 1.067	 1.001	 1.137	
Collect	from	Sexual	Health	
Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Choice	
Option	A	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Option	B	 -0.360	 -0.400	 -0.320	 0.698	 0.670	 0.726	 -0.327	 -0.374	 -0.279	 0.721	 0.688	 0.756	
I	would	not	test	 -1.682	 -1.781	 -1.583	 0.186	 0.168	 0.205	 -1.674	 -1.790	 -1.557	 0.188	 0.167	 0.211	
Table	6.16	-	Coefficients	and	Odds	Ratios	for	the	Full	Dataset	and	the	Dataset	Excluding	Different	Responses	to	Choice	Sets	1	and	25
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Table	6.16	shows	that	comparing	the	results	from	the	model	run	
on	 the	 full	 dataset	 and	 the	 exclusion	 of	 the	 responses	 with	
different	answers	for	choice	sets	1	and	25	shows	that	whilst	there	
is	 some	 difference	 in	 the	 coefficients	 and	 odds	 ratios	 for	 each	
level,	the	results	follow	the	same	pattern.		
	
6.5.2.2 Time	to	Complete	Questionnaire	
Using	an	online	research	panel	allowed	for	the	time	to	complete	
the	questionnaire	to	be	captured	for	each	participant.	A	summary	
of	 the	 time	 taken	 to	 complete	 the	 questionnaire	 is	 provided	 in	
table	6.17	and	illustrated	in	the	histogram	(figure	6.1):	
	 Minutes:	Seconds	
Mean	 08:42	
	 	
Minimum	 01:19	
25th	Percentile	 05:34	
Median	 07:51	
75th	Percentile	 11:07	
Maximum	 30:19	
Table	6.17	-	Time	Taken	to	Complete	Questionnaire	
	
The	 cognitive	 testing	 identified	 a	 range	 to	 complete	 the	
questionnaire	 of	 04:46	 to	 09:56	 minutes	 with	 a	 mean	 time	 to	
completion	 of	 07:15	 minutes.	 Recognising	 that	 the	 time	 to	
completion	was	a	timing	of	the	completion	of	the	choice	sets	only,	
a	 threshold	 of	 five	 minutes	 or	 greater	 was	 applied	 to	 the	
responses	in	the	dataset;	this	is	the	minimum	time	to	completion	
observed	 in	 the	 cognitive	 testing	 rounded	 up	 to	 the	 nearest	 full	
minute.	 The	 number	 of	 responses	 were	 then	 analysed	 and	
grouped	by	 less	than	five	minutes	and	five	minutes	or	more,	and	
whether	 the	 repeated	 question	 was	 answered	 correctly.	 This	
identified	that	76%	participants	who	took	five	minutes	or	longer	to	
complete	 the	 survey	 gave	 the	 same	 answer	 to	 the	 repeated	
question	 compared	 with	 67%	 of	 those	 taking	 less	 than	 five	
minutes	to	complete	the	survey	(see	table	6.18).		
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Figure	6.1-	Histogram	of	time	taken	to	complete	the	questionnaire
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	 n	 %	
Responses	completed	in	less	than	5	
minutes	
233	 19%	
Responses	completed	in	5	minutes	or	more	 997	 81%	
Responses	completed	in	less	than	5	
minutes	where	repeated	question	was	
answered	correctly	
155	 67%	
Responses	completed	in	less	than	5	
minutes	where	repeated	question	was	
answered	incorrectly	
78	 33%	
Responses	completed	in	5	minutes	or	more	
where	repeated	question	was	answered	
correctly	
757	 76%	
Responses	completed	in	5	minutes	or	more	
where	repeated	question	was	answered	
correctly	
240	 24%	
Table	6.18	-	Analysis	of	Survey	Completion	Time	and	Repeated	Question	Responses	
	
	
Running	 the	model	on	 the	 full	dataset	and	 the	dataset	excluding	
responses	 which	 took	 less	 than	 five	 minutes	 to	 complete	 again	
showed	 that	 whilst	 there	 were	 some	 differences	 in	 the	
coefficients	and	odds	ratios	for	each	level,	the	results	followed	the	
same	pattern.	It	was	concluded	that	there	was	no	requirement	to	
exclude	the	responses	taking	less	than	five	minutes	to	complete.		
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		 Full	Dataset	n=1,230	 Data	Excluding	Responses	taking	less	than	5	min	to	complete	n=	997	
		 Coefficient	 Lower	95%	CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	 Coefficient	
Lower	95%	
CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	
How	you	Test	
Self-Test	 0.481	 0.415	 0.547	 1.618	 1.514	 1.729	 0.542	 0.467	 0.616	 1.719	 1.595	 1.852	
Post	 0.306	 0.239	 0.373	 1.358	 1.271	 1.452	 0.344	 0.269	 0.419	 1.411	 1.309	 1.521	
Pharmacy	 0.144	 0.085	 0.203	 1.155	 1.088	 1.226	 0.168	 0.101	 0.234	 1.183	 1.106	 1.264	
Education/	Work	 -0.197	 -0.257	 -0.137	 0.821	 0.773	 0.872	 -0.245	 -0.312	 -0.177	 0.783	 0.732	 0.837	
GP	Practice	 0.019	 -0.042	 0.081	 1.019	 0.959	 1.084	 -0.008	 -0.077	 0.061	 0.992	 0.925	 1.062	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.591	 0.537	 0.645	 1.806	 1.711	 1.906	 0.642	 0.581	 0.703	 1.900	 1.788	 2.019	
2	Hours	 0.338	 0.281	 0.395	 1.402	 1.324	 1.485	 0.372	 0.308	 0.436	 1.451	 1.361	 1.547	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.148	 -0.198	 -0.098	 0.862	 0.820	 0.907	 -0.147	 -0.204	 -0.091	 0.863	 0.816	 0.913	
Accuracy	
2	in	100	False	Negative	 1.176	 1.141	 1.212	 3.242	 3.130	 3.359	 1.308	 1.269	 1.348	 3.700	 3.556	 3.850	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	Consultation	 0.192	 0.140	 0.245	 1.212	 1.150	 1.277	 0.217	 0.159	 0.276	 1.243	 1.172	 1.318	
Pharmacy	Consultation	 0.147	 0.095	 0.199	 1.158	 1.100	 1.220	 0.160	 0.102	 0.219	 1.174	 1.108	 1.245	
GP	Consultation	 0.168	 0.116	 0.220	 1.183	 1.123	 1.246	 0.171	 0.113	 0.229	 1.187	 1.120	 1.258	
Sexual	Health	Clinic	
Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.052	 -0.102	 -0.002	 0.949	 0.903	 0.998	 -0.042	 -0.098	 0.014	 0.959	 0.906	 1.014	
Instant	Messenger	 0.027	 -0.023	 0.076	 1.027	 0.977	 1.079	 0.043	 -0.013	 0.098	 1.044	 0.987	 1.103	
Email	 0.047	 -0.002	 0.096	 1.048	 0.998	 1.101	 0.042	 -0.013	 0.097	 1.043	 0.987	 1.102	
Face	to	Face	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
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		 Full	Dataset	n=1,230	 Data	Excluding	Responses	taking	less	than	5	min	to	complete	n=	997	
		 Coefficient	 Lower	95%	CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	 Coefficient	
Lower	95%	
CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	
How	you	get	Antibiotics	
Post	to	Home	 0.011	 -0.041	 0.063	 1.011	 0.960	 1.065	 0.001	 -0.057	 0.060	 1.001	 0.944	 1.062	
Post	to	Collection	Point	 0.030	 -0.020	 0.081	 1.031	 0.980	 1.085	 0.013	 -0.044	 0.070	 1.013	 0.957	 1.072	
Collect	from	Pharmacy	 0.072	 0.018	 0.126	 1.075	 1.018	 1.134	 0.085	 0.024	 0.145	 1.089	 1.025	 1.157	
Collect	from	Sexual	Health	
Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Choice	
Option	A	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Option	B	 -0.360	 -0.400	 -0.320	 0.698	 0.670	 0.726	 -0.368	 -0.413	 -0.323	 0.692	 0.662	 0.724	
I	would	not	test	 -1.682	 -1.781	 -1.583	 0.186	 0.168	 0.205	 -1.776	 -1.889	 -1.662	 0.169	 0.151	 0.190	
	
Table	6.19	-	Coefficients	and	Odds	Ratios	for	the	Full	Dataset	and	the	Dataset	Containing	Responses	taking	5	Minutes	or	Longer	to	Complete	
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6.5.2.3 Analysis	of	the	number	of	responses	for	each	option	
Another	validity	consideration	 is	the	number	of	times	 ‘Option	A’,	
‘Option	B’	or	‘I	would	not	test’	were	selected.	This	is	summarised	
in	table	6.20	below:	
Choice	 n	 %	
A	 16,176	 54.8	
B	 11,551	 39.13	
Opt	Out	 1,793	 6.07	
	 	 	
Total	 29,520	 100	
Table	6.20	-	Analysis	of	Choice	Selection	 	
	
To	 understand	 this	 further,	 analysis	 was	 undertaken	 on	 the	
distribution	 of	 the	 levels	 between	 option	 A	 and	 option	 B	 to	
ascertain	whether	using	attributes	with	known	logical	choices	(e.g.	
shorter	 time	 to	 result,	 higher	 accuracy)	 it	 would	 have	 been	
expected	 that	more	 participants	would	 have	 chosen	 option	A	 or	
option	B.	The	detail	of	this	analysis	is	shown	in	table	6.21:	
	
	 Option	A	 Option	B	
How	you	Test	
Self-Test	 10	 6	
Post	 11	 5	
Pharm	 7	 10	
Education/	Work	 7	 9	
GP	Practice	 7	 8	
Sexual	Health	Clinic	 6	 10	
Total	 48	 48	
Time	to	Result	
30	Mins	 16	 8	
2	Hours	 8	 15	
7	Days	 13	 12	
14	Days	 11	 13	
Total	 48	 48	
Accuracy	(False	Negative)	
2	in	100	False	Negative	 28	 20	
5	in	100	False	Negative	 20	 28	
Total	 48	 48	
Consultation	Method	
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	 Option	A	 Option	B	
Online	Consultation	 10	 13	
Pharmacy	Consultation	 13	 12	
GP	Consultation	 10	 15	
Sexual	Health	Clinic	Consultation	 15	 8	
Total	 48	 48	
Access	to	Healthcare	Professional	
Phone	 10	 14	
Instant	Messenger	 12	 12	
Email	 14	 10	
Face	to	Face	 12	 12	
Total	 48	 48	
How	you	get	Antibiotics	
Post	to	Home	 13	 11	
Post	to	Collection	Point	 13	 11	
Collect	from	Pharmacy	 16	 8	
Collect	from	Sexual	Health	Clinic	 6	 18	
Total	 48	 48	
Table	6.21	-	Level	Distribution	between	Option	A	and	Option	B5	
	
The	 results	 showed	 that	 for	 the	 attributes	 with	 a	 logical	
preference	(shorter	time	to	result	and	higher	accuracy,	highlighted	
in	green)	the	shortest	waiting	time	and	highest	accuracy	featured	
in	option	A	more	frequently	than	in	option	B.	Therefore	it	is	to	be	
expected	that	more	people	would	select	option	A	than	option	B	
	
The	other	levels	with	the	strongest	level	of	preference	(highlighted	
in	orange	in	table	6.21)	showed	that	three	out	of	four	of	these	had	
the	greater	number	of	levels	featured	in	option	A.	Consequently,	it	
was	 concluded	 that	 a	 higher	 proportion	 of	 respondents	 would	
select	 option	 A	 than	 option	 B	 and	 no	 responses	 should	 be	
removed	from	the	dataset	as	a	result	of	this.	
	
	 	
																																																						
5	-	Please	note	that	the	rows	in	the	table	6.21	do	not	all	sum	to	16,	they	reflect	the	level	balance	achieved	from	
the	design	created	by	SAS	JMP	Pro	9.2.0,	adjusted	for	implausible	combinations.	For	further	information	see	
section	6.2.2.2	and	table	6.5.	
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6.5.2.4 Removal	of	the	opt	out	question	data	
The	final	piece	of	analysis	undertaken	to	explore	the	validity	of	the	
data	was	to	remove	the	‘opt	out’	data	before	drawing	comparison	
to	the	full	dataset.	The	results	of	this	analysis	are	summarised	 in	
table	6.22.	
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		 Full	Dataset	n=29,520	Choice	Responses	 Removal	of	'I	would	not	test'	Data	n=27,727	Choice	Responses	
		 Coefficient	 Lower	95%	CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	 Coefficient	
Lower	95%	
CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	
How	you	Test	
Self-Test	 0.481	 0.415	 0.547	 1.618	 1.514	 1.729	 0.501	 0.433	 0.568	 1.650	 1.542	 1.765	
Post	 0.306	 0.239	 0.373	 1.358	 1.271	 1.452	 0.320	 0.252	 0.387	 1.377	 1.287	 1.473	
Pharmacy	 0.144	 0.085	 0.203	 1.155	 1.088	 1.226	 0.152	 0.092	 0.212	 1.164	 1.096	 1.236	
Education/	Work	 -0.197	 -0.257	 -0.137	 0.821	 0.773	 0.872	 -0.202	 -0.262	 -0.141	 0.817	 0.769	 0.868	
GP	Practice	 0.019	 -0.042	 0.081	 1.019	 0.959	 1.084	 0.027	 -0.035	 0.089	 1.027	 0.965	 1.093	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.591	 0.537	 0.645	 1.806	 1.711	 1.906	 0.612	 0.558	 0.667	 1.845	 1.746	 1.949	
2	Hours	 0.338	 0.281	 0.395	 1.402	 1.324	 1.485	 0.350	 0.292	 0.408	 1.419	 1.339	 1.503	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.148	 -0.198	 -0.098	 0.862	 0.820	 0.907	 -0.145	 -0.196	 -0.094	 0.865	 0.822	 0.910	
Accuracy	
2	in	100	False	Negative	 1.176	 1.141	 1.212	 3.242	 3.130	 3.359	 1.205	 1.170	 1.241	 3.338	 3.221	 3.460	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	Consultation	 0.192	 0.140	 0.245	 1.212	 1.150	 1.277	 0.200	 0.147	 0.253	 1.222	 1.159	 1.288	
Pharmacy	Consultation	 0.147	 0.095	 0.199	 1.158	 1.100	 1.220	 0.159	 0.106	 0.211	 1.172	 1.112	 1.235	
GP	Consultation	 0.168	 0.116	 0.220	 1.183	 1.123	 1.246	 0.174	 0.122	 0.227	 1.190	 1.130	 1.254	
Sexual	Health	Clinic	
Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.052	 -0.102	 -0.002	 0.949	 0.903	 0.998	 -0.046	 -0.097	 0.004	 0.955	 0.908	 1.004	
Instant	Messenger	 0.027	 -0.023	 0.076	 1.027	 0.977	 1.079	 0.029	 -0.021	 0.079	 1.029	 0.979	 1.082	
Email	 0.047	 -0.002	 0.096	 1.048	 0.998	 1.101	 0.050	 0.000	 0.100	 1.051	 1.000	 1.105	
Face	to	Face	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
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		 Full	Dataset	n=29,520	Choice	Responses	 Removal	of	'I	would	not	test'	Data	n=27,727	Choice	Responses	
		 Coefficient	 Lower	95%	CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	 Coefficient	
Lower	95%	
CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	
How	you	get	Antibiotics	
Post	to	Home	 0.011	 -0.041	 0.063	 1.011	 0.960	 1.065	 0.012	 -0.041	 0.065	 1.012	 0.960	 1.067	
Post	to	Collection	Point	 0.030	 -0.020	 0.081	 1.031	 0.980	 1.085	 0.035	 -0.016	 0.086	 1.036	 0.984	 1.090	
Collect	from	Pharmacy	 0.072	 0.018	 0.126	 1.075	 1.018	 1.134	 0.076	 0.021	 0.131	 1.079	 1.022	 1.139	
Collect	from	Sexual	Health	
Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Choice	
Option	A	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Option	B	 -0.360	 -0.400	 -0.320	 0.698	 0.670	 0.726	 -0.368	 -0.409	 -0.327	 0.692	 0.664	 0.721	
I	would	not	test	 -1.682	 -1.781	 -1.583	 0.186	 0.168	 0.205	 -	 -	 -	 1.000	 		 		
Table	6.22	-	Comparison	of	Full	Dataset	and	Dataset	Excluding	Opt	Out	Responses	
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Again,	this	showed	that	the	full	dataset	and	the	dataset	excluding	
the	opt	out	data	behave	in	broadly	the	same	way,	with	the	same	
general	trends	in	terms	of	strength	of	preference.			
	
To	 summarise,	 the	 four	 options	 considered	 to	 test	 the	 internal	
validity	of	the	data	presented	in	the	previous	sections	showed	that	
in	 comparison	 to	 the	 full	 dataset	 all	 yielded	 very	 similar	
coefficients	 and	 odds	 ratios	 with	 no	 change	 in	 the	 order	 of	 the	
strength	 of	 preference	 for	 a	 level	 within	 each	 attribute.	 On	 this	
basis	 it	was	 determined	 that	 the	 full	 dataset	 should	 be	 used	 for	
the	detailed	analysis	of	the	DCE	responses.		
	
6.5.2.5 Respondent	Participation	and	Feedback	
In	 total	1,230	completed	responses	were	achieved	by	YouthSight	
from	 their	 panel	 of	 approximately	 108,500	 young	 people	 within	
the	 target	 age	 range	 (YouthSight,	 2014).	 Their	 analytics	 data	
showed	 that	 an	 additional	 460	 people	 started	 but	 did	 not	
complete	 the	 survey.	 No	 further	 information	 is	 available	 on	 the	
demographics	 of	 these	 participants	 nor	 any	 information	 on	 the	
point	at	which	they	chose	to	exit	the	survey.		
	
At	the	end	of	the	questionnaire	participants	were	asked	to	score	
how	they	rated	the	survey	and	were	provided	with	an	opportunity	
to	 provide	 qualitative	 feedback	 through	 a	 ‘free	 text	 box’.	 The	
breakdown	of	the	questionnaire	ratings	is	provided	in	table	6.23:	
	
	 n	 %	
Very	Good	 163	 13%	
Good	 473	 38%	
Average	 393	 32%	
Poor	 118	 10%	
Very	Poor		 32	 3%	
Prefer	Not	to	Say	 51	 4%	
	 1,230	 100%	
Table	6.23	-	Summary	of	Questionnaire	Rating	by	Participants	
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The	 breakdown	 of	 qualitative	 feedback	 by	 response	 category	 is	
provided	in	table	6.24:	
Questionnaire	
Rating	
Category	
Number	of	
Participants	
Commenting	
%	
Commenting	
%	of	Overall	
Comments	
Very	Good	 19	 12%	 9%	
Good	 47	 10%	 22%	
Average	 75	 19%	 36%	
Poor	 53	 45%	 25%	
Very	Poor	 16	 50%	 8%	
Prefer	Not	to	
Say	
1	 2%	 0%	
Total	 211	 17%	 100%	
Table	6.24	-	Breakdown	of	Qualitative	Feedback	by	Response	Category	
This	 indicates	 that	 the	 majority	 of	 participants	 (83%)	 found	 the	
questionnaire	average/	satisfactory	to	complete.	This	is	reassuring	
within	the	context	of	the	sample	population,	i.e.	a	population	who	
have	 signed	 up	 to	 a	 panel	 to	 complete	 online	 surveys.	 The	
qualitative	 feedback	 was	 explored	 through	 a	 simple	 thematic	
analysis	to	draw	out	the	learning	points.	Looking	at	the	frequency	
of	comments,	repetition	was	the	issue	cited	most	frequently	with	
79	 of	 the	 211	 commenting	 indicated	 that	 they	 found	 the	
questionnaire	 repetitive;	 this	 varied	 in	 degrees	 from	 “very	
repetitive”	to	“thorough	but	quite	repetitive”.	Nineteen	of	the	211	
commenting	 indicated	 that	 they	 felt	 the	 questionnaire	 was	 ‘too	
long’,	with	one	offering	a	degree	of	relativity	“far	 too	wordy	and	
long-winded	for	a	£1	survey”.	
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6.5.3 Summary	of	the	DCE	Responses	
Tables	 6.27-6.32	 present	 the	 results	 from	 the	 DCE	 for	 the	 full	
dataset	and	 the	subgroups	analysed	as	both	coefficients	and	odds	
ratios	(OR),	along	with	the	95%	confidence	intervals	(CI).	The	odds	
ratios	 are	 used	 throughout	 this	 section	 when	 discussing	 the	
findings,	 however	 the	 coefficients	 will	 be	 used	 in	 section	 6.6	 for	
exploring	 the	 findings	 within	 the	 context	 of	 pathways	 and	
probabilities	of	uptake.		Levels	highlighted	in	blue	indicate	a	p-value	
of	 greater	 than	 0.05	 (demonstrated	 by	 the	 CI	 for	 the	 coefficient	
including	 0	 and	 the	 CI	 for	 the	 OR	 including	 1).	 This	 can	 be	
interpreted	as	the	strength	of	preference	for	these	levels	not	being	
statistically	significant	compared	to	the	reference	level.			
	
Looking	 across	 all	 attributes	 and	 levels	 participants	 expressed	 the	
strongest	 preference	 for	 accuracy	 of	 the	 test	 result	 (OR	 3.242).	
Accuracy	was	expressed	as	the	likelihood	of	a	false	negative	result.	
This	 point	 links	 to	 the	 findings	 of	 the	 focus	 groups	 that	
demonstrated	 a	 lack	 of	 understanding	 that	 tests	 are	 not	 ‘100%	
accurate’.	 Considering	 accuracy	 across	 the	 subgroups	 analysed,	
there	are	notable	differences	in	the	strength	of	preference	between	
males	 and	 females	 (OR	 2.950	 and	 3.570	 respectively),	 and	 those	
who	 have	 previously	 tested	 and	 not	 tested	 (OR	 2.999	 and	 3.482	
respectively).	Possible	reasons	for	this	include	the	consequences	for	
males	 personally	 are	 not	 as	 severe	 as	 they	 are	 for	 women	 as	
evidenced	in	the	background	literature	for	participants,	or	that	they	
would	manage	 the	 consequences	 of	 a	 false	 result	 differently.	 For	
example,	 it	was	 the	male	 focus	 group	participants	who	 suggested	
their	alternatives	including	taking	multiple	tests	and	attending	clinic	
if	 they	are	unsure.	Those	who	have	tested	for	STIs	previously	may	
be	more	familiar	with	the	fact	that	a	test	does	not	deliver	a	‘100%	
accurate’	result.	
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Time	to	result	was	the	attribute	with	the	next	strongest	preference	
across	 all	 sub-groups,	 with	 results	 consistent	 with	 the	 logical	
expectation	that	people	would	prefer	a	shorter	waiting	time	than	a	
longer	 one.	 Comparing	 ORs	 between	 sub-groups	 showed	 no	
substantial	differences,	with	the	exception	of	age	where	the	19-21	
year	olds	showed	a	stronger	preference	for	30	minutes	and	2	hours	
(OR	 1.888	 and	 1.548	 respectively)	 compared	 with	 the	 7	 day	
reference	level.	Whereas	the	strength	of	preference	was	lower	for	
16-18	year	olds	(OR	1.763	and	1.326)	and	22-24	year	olds	(OR	1.772	
and	1.344).		
	
Considering	how	to	test,	all	subgroups	demonstrated	the	strongest	
preference	 for	 self-testing	 (OR	 1.618)	 and	 testing	 via	 an	 outreach	
services	 in	 an	 educational/	 work	 setting	 was	 the	 least	 preferred	
option	 (OR	 0.821).	 Postal	 testing	 was	 the	 second	 strongest	
preference	across	all	sub-groups	(OR	1.358).	For	testing	via	a	sexual	
health	 clinic	 (reference	 level)	 and	 testing	 via	 a	 GP	 practice	 there	
was	no	statistically	significant	difference	between	the	two	options	
with	the	exception	of	the	previous	testing	history	sub-groups,	with	
an	OR	of	0.885	for	those	who	have	previously	tested	and	those	who	
have	 not	 (OR	 1.101).	 Taking	 a	 sample	 to	 a	 pharmacy	 for	 analysis	
was	preferable	to	attending	a	sexual	health	clinic	for	all	subgroups	
with	 the	exception	of	 those	who	had	previously	 tested	and	19-21	
year	olds	where	there	was	no	statistically	significant	difference.	
	
This	was	a	consistent	strength	of	preference	for	the	options	which	
do	not	have	any	direct	contact	with	healthcare	professionals	 (self-
testing	 and	postal	 testing)	 compared	with	 those	 that	 do	 (taking	 a	
sample	 to	 a	 pharmacy,	 an	 outreach	 clinic	 at	 place	 of	 education/	
work,	 attending	 a	 GP	 practice	 or	 sexual	 health	 clinic)	 across	 all	
subgroups.	However,	there	were	notable	variations	in	the	strength	
of	preference	for	‘how	you	test’	between	sub-groups:	
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• Females	 had	 a	 stronger	 preference	 for	 the	 more	 remote	
testing	 options	 (self-test,	 OR	 1.693,	 postal	 test,	 OR	 1.411)	
than	males	(OR	1.549	and	1.308	respectively).	
• The	older	 age	 range	 (22-24)	 had	 a	 stronger	 preference	 for	
self-testing	 (OR	 1.895)	 compared	 with	 the	 younger	 age	
groups,	(16-18	OR	1.664,	19-21	OR	1.346).	
• For	 those	 in	 a	 relationship	 with	 one	 sexual	 partner	 there	
was	 a	 stronger	 preference	 for	 self-testing	 (OR	 1.711)	
compared	with	those	who	were	single	(OR	1.632).	However,	
those	who	were	single	had	a	stronger	preference	for	taking	
a	 sample	 to	 a	 pharmacy	 (OR	 1.220)	 than	 those	 in	 a	
relationship	with	one	partner	(OR	1.109).	
• The	largest	difference	in	the	strength	of	preferences	was	in	
the	 subgroup	 who	 had	 previously	 tested	 for	 an	 STI	
compared	 with	 those	 that	 had	 not.	 Those	 that	 had	 not	
previously	 tested	 for	 an	 STI	 had	 a	 greater	 preference	 for	
remote	 testing	 options	 (self-test	 OR	 1.678,	 postal	 test	 OR	
1.465)	than	those	that	had	previously	tested	(OR	1.524	and	
OR	1.178	 respectively),	and	also	had	a	 stronger	preference	
for	 taking	 a	 sample	 to	 a	 pharmacy	 for	 analysis	 (OR	 1.277)	
than	 those	 who	 had	 previously	 tested	 (OR	 0.945	 not	
statistically	significant).	
	
Again,	 the	 preference	 for	 a	 remote	 (from	 a	 sexual	 health	 clinic)	
pathway	 can	 be	 seen	 in	 the	 preference	 for	 consultation	 method	
following	a	positive	test	result	via	an	online	consultation	(OR	1.212),	
followed	 by	 treatment	 via	 general	 practice	 (OR	 1.183)	 and	
treatment	via	pharmacy	(OR	1.158)	in	the	full	dataset.	However,	at	
the	 subgroup	 level	 there	 was	 more	 variation	 in	 the	 order	 of	
preference	for	this	attribute	than	any	other	in	the	survey,	with	the	
exception	 of	 the	 sexual	 health	 clinic	 which	 was	 consistently	 the	
least	preferred	across	all	subgroups.	This	is	illustrated	in	table	6.25.	
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Consultation	Method	
Order	of	Preferences	
Subgroup	
First		
Online	Consultation	 Male	
Female	
Age	22-24	
Relationship	with	one	sexual	partner	
Previously	tested	for	an	STI	
Not	Previously	tested	for	an	STI	
Pharmacy	 Age	19-21	
GP	 Age	16-18	
Single	
Second	
Online	Consultation	 Age	16-18	
Age	19-21	
Single	
Pharmacy	 Female	
Relationship	with	one	sexual	partner	
GP	 Male	
Age	22-24	
Previously	tested	for	an	STI	
Not	previously	tested	for	an	STI	
Third	
Online	 -	
Pharmacy	 Male	
Age	16-18	
Age	22-24	
Single	
Previously	tested	for	an	STI	
GP	 Female	
Age	19-21	
In	a	sexual	relationship	with	one	partner	
Table	6.25	-	Order	of	Preferences	by	Subgroup	-	Consultation	Method	Attribute	
	
The	 differences	 in	 the	 strength	 of	 preference	 suggest	 that	 some	
subgroups	 have	 a	 preference	 for	 a	 consultation	 method	 which	
involves	 contact	 with	 a	 healthcare	 professional	 rather	 than	 an	
online	pathway	where	 contact	 is	only	made	 if	 there	 is	 a	problem.	
This	in	part	reflects	the	focus	group	findings	where	the	focus	groups	
with	 the	 younger	 age	 range	 placed	 greater	 importance	 on	 being	
able	to	talk	to	a	healthcare	professional.	
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Whilst	 there	 is	 a	 statistically	 significant	 preference	 for	 all	
consultation	methods	when	 compared	with	 a	 sexual	 health	 clinic,	
the	 full	dataset	showed	that	 for	method	of	access	 to	a	healthcare	
professional	 there	 was	 no	 statistically	 significant	 preference	 for	
instant	 messenger	 or	 email	 access	 compared	 to	 accessing	 a	
healthcare	 professional	 face-to-face.	 Telephone	 access	 to	 a	
healthcare	professional	was	the	 least	preferred	option	(OR	0.949),	
which	 is	a	statistically	significant	result,	 indicating	a	preference	for	
face-to-face	 access	 compared	 with	 phone	 access.	 Examining	 this	
attribute	 at	 subgroup	 level	 shows	 no	 statistically	 significant	
preference	for	method	of	access	over	another	with	the	exception	of	
instant	 messaging	 within	 the	 16-18	 age	 group	 (OR	 1.108),	 and	
phone	(OR	0.902)	within	the	19-21	age	group.	
	
The	 final	 attribute	 ‘how	 you	 get	 your	 antibiotics’	 showed	 a	
statistically	 significant	 preference	 for	 collection	 from	 a	 pharmacy	
within	 the	 full	 dataset	 compared	 with	 collection	 from	 a	 sexual	
health	 clinic	 (OR	 1.075).	 There	 was	 a	 preference	 for	 posting	 to	
home	 or	 a	 collection	 point	 (OR	 1.011	 and	OR	 1.031	 respectively),	
however	 this	was	not	 statistically	 significant	when	 compared	with	
collection	 from	 a	 sexual	 health	 clinic.	 At	 a	 subgroup	 level,	 there	
were	 very	 few	 statistically	 significant	 preferences	 being	 limited	 to	
collection	from	a	pharmacy	for	females	(OR	1.087),	19-21	year	olds	
(OR	 1.106)	 and	 people	who	 have	 not	 previously	 tested	 for	 an	 STI	
(OR	 1.078),	 a	 statistically	 significant	 preference	 for	 posting	 to	 a	
collection	point	for	males	(OR	1.082).				
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Full	Dataset	n=1,230	
		 Coefficient	 Lower	95%	CI	 Upper	95%	CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	
How	you	Test	
Self-Test	 0.481	 0.415	 0.547	 1.618	 1.514	 1.729	
Post	 0.306	 0.239	 0.373	 1.358	 1.271	 1.452	
Pharmacy	 0.144	 0.085	 0.203	 1.155	 1.088	 1.226	
Education/	Work	 -0.197	 -0.257	 -0.137	 0.821	 0.773	 0.872	
GP	Practice	 0.019	 -0.042	 0.081	 1.019	 0.959	 1.084	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.591	 0.537	 0.645	 1.806	 1.711	 1.906	
2	Hours	 0.338	 0.281	 0.395	 1.402	 1.324	 1.485	
7	Days	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.148	 -0.198	 -0.098	 0.862	 0.820	 0.907	
Accuracy	
2	in	100	False	Negative	 1.176	 1.141	 1.212	 3.242	 3.130	 3.359	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	Consultation	 0.192	 0.140	 0.245	 1.212	 1.150	 1.277	
Pharmacy	Consultation	 0.147	 0.095	 0.199	 1.158	 1.100	 1.220	
GP	Consultation	 0.168	 0.116	 0.220	 1.183	 1.123	 1.246	
Sexual	Health	Clinic	Consultation	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.052	 -0.102	 -0.002	 0.949	 0.903	 0.998	
Instant	Messenger	 0.027	 -0.023	 0.076	 1.027	 0.977	 1.079	
Email	 0.047	 -0.002	 0.096	 1.048	 0.998	 1.101	
Face	to	Face	 0.000	 -	 -	 1.000	 -	 -	
		 314	
	
Full	Dataset	n=1,230	
		 Coefficient	 Lower	95%	CI	 Upper	95%	CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	
How	you	get	Antibiotics	
Post	to	Home	 0.011	 -0.041	 0.063	 1.011	 0.960	 1.065	
Post	to	Collection	Point	 0.030	 -0.020	 0.081	 1.031	 0.980	 1.085	
Collect	from	Pharmacy	 0.072	 0.018	 0.126	 1.075	 1.018	 1.134	
Collect	from	Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	
Table	6.26	-	Full	Dataset	Coefficients,	Odds	Ratios	and	Respective	95%	Confidence	Intervals	
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	 Males	n=607	 Females	n=623	
		 Coefficient	 Lower	95%	CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	 Coefficient	
Lower	95%	
CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	
How	you	Test	
Self-Test	 0.438	 0.344	 0.531	 1.549	 1.410	 1.701	 0.526	 0.432	 0.620	 1.693	 1.541	 1.860	
Post	 0.269	 0.174	 0.363	 1.308	 1.190	 1.438	 0.344	 0.250	 0.439	 1.411	 1.284	 1.551	
Pharmacy	 0.123	 0.039	 0.208	 1.131	 1.040	 1.231	 0.165	 0.081	 0.249	 1.180	 1.085	 1.283	
Education/	Work	 -0.084	 -0.169	 0.001	 0.919	 0.845	 1.001	 -0.310	 -0.395	 -0.225	 0.733	 0.674	 0.798	
GP	Practice	 0.048	 -0.039	 0.135	 1.049	 0.962	 1.145	 -0.010	 -0.097	 0.077	 0.990	 0.908	 1.080	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.603	 0.527	 0.680	 1.828	 1.694	 1.973	 0.580	 0.503	 0.656	 1.786	 1.654	 1.928	
2	Hours	 0.311	 0.230	 0.392	 1.365	 1.259	 1.479	 0.366	 0.285	 0.447	 1.442	 1.329	 1.563	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.170	 -0.241	 -0.098	 0.844	 0.786	 0.906	 -0.127	 -0.198	 -0.056	 0.881	 0.820	 0.945	
Accuracy	
2	in	100	False	Negative	 1.082	 1.032	 1.132	 2.951	 2.807	 3.101	 1.273	 1.223	 1.322	 3.570	 3.396	 3.753	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	Consultation	 0.171	 0.097	 0.245	 1.187	 1.102	 1.278	 0.214	 0.140	 0.288	 1.239	 1.151	 1.334	
Pharmacy	Consultation	 0.100	 0.027	 0.173	 1.106	 1.028	 1.189	 0.194	 0.121	 0.268	 1.215	 1.129	 1.307	
GP	Consultation	 0.159	 0.085	 0.232	 1.172	 1.089	 1.262	 0.178	 0.104	 0.251	 1.194	 1.110	 1.285	
Sexual	Health	Clinic	Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.065	 -0.136	 0.005	 0.937	 0.873	 1.005	 -0.039	 -0.110	 0.032	 0.962	 0.896	 1.032	
Instant	Messenger	 -0.006	 -0.076	 0.063	 0.994	 0.927	 1.065	 0.060	 -0.010	 0.130	 1.062	 0.990	 1.139	
Email	 0.033	 -0.036	 0.103	 1.034	 0.965	 1.108	 0.060	 -0.009	 0.130	 1.062	 0.991	 1.139	
Face	to	Face	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
How	you	get	Antibiotics	
Post	to	Home	 -0.004	 -0.078	 0.070	 0.996	 0.925	 1.072	 0.027	 -0.046	 0.101	 1.028	 0.955	 1.106	
Post	to	Collection	Point	 0.079	 0.007	 0.151	 1.082	 1.007	 1.163	 -0.017	 -0.089	 0.055	 0.983	 0.915	 1.056	
Collect	from	Pharmacy	 0.062	 -0.014	 0.138	 1.064	 0.986	 1.149	 0.083	 0.007	 0.160	 1.087	 1.007	 1.173	
Collect	from	Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Table	6.27	-	Gender	Subgroup	Analysis	Coefficients	and	Odds	Ratios	with	Associated	95%	Confidence	Interval
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	 16-18	n=415	 19-21	n=406	 22-24	n=409	
		 Coeffi-cient	
Lower	
95%	CI	
Upper	
95%	CI	
Odds	
Ratio	
Lower	
95%	CI	
Upper	
95%	CI	
Coeffi-
cient	
Lower	
95%	CI	
Upper	
95%	CI	
Odds	
Ratio	
Lower	
95%	CI	
Upper	
95%	CI	
Coeffi-
cient	
Lower	
95%	CI	
Upper	
95%	CI	
Odds	
Ratio	
Lower	
95%	CI	
Upper	
95%	CI	
How	you	Test	
Self-Test	 0.509	 0.395	 0.623	 1.664	 1.485	 1.865	 0.297	 0.182	 0.412	 1.346	 1.200	 1.510	 0.639	 0.523	 0.755	 1.895	 1.687	 2.128	
Post	 0.390	 0.275	 0.505	 1.477	 1.316	 1.657	 0.129	 0.013	 0.245	 1.138	 1.013	 1.277	 0.397	 0.281	 0.513	 1.487	 1.324	 1.670	
Pharmacy	 0.239	 0.137	 0.342	 1.270	 1.147	 1.408	 0.021	 -0.082	 0.124	 1.021	 0.921	 1.132	 0.170	 0.067	 0.273	 1.185	 1.069	 1.314	
Education/	Work	 -0.218	 -0.322	 -0.114	 0.804	 0.725	 0.892	 -0.215	 -0.319	 -0.112	 0.806	 0.727	 0.894	 -0.160	 -0.265	 -0.056	 0.852	 0.768	 0.945	
GP	Practice	 0.081	 -0.025	 0.187	 1.085	 0.975	 1.206	 0.035	 -0.072	 0.141	 1.035	 0.931	 1.152	 -0.061	 -0.168	 0.046	 0.941	 0.846	 1.047	
Sexual	Health	
Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.567	 0.474	 0.661	 1.763	 1.606	 1.936	 0.636	 0.542	 0.730	 1.888	 1.719	 2.074	 0.572	 0.478	 0.666	 1.772	 1.613	 1.947	
2	Hours	 0.282	 0.183	 0.381	 1.326	 1.201	 1.464	 0.437	 0.338	 0.536	 1.548	 1.402	 1.709	 0.295	 0.196	 0.395	 1.344	 1.216	 1.484	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.130	 -0.217	 -0.044	 0.878	 0.805	 0.957	 -0.125	 -0.213	 -0.038	 0.882	 0.808	 0.963	 -0.189	 -0.277	 -0.102	 0.828	 0.758	 0.903	
Accuracy	
2	in	100	False	
Negative	 1.196	 1.135	 1.257	 3.307	 3.112	 3.514	 1.151	 1.090	 1.212	 3.161	 2.974	 3.361	 1.188	 1.127	 1.250	 3.282	 3.086	 3.489	
5	in	100	False	
Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	
Consultation	 0.171	 0.081	 0.262	 1.187	 1.085	 1.299	 0.182	 0.092	 0.273	 1.200	 1.096	 1.314	 0.226	 0.135	 0.317	 1.253	 1.144	 1.373	
Pharmacy	
Consultation	 0.154	 0.065	 0.244	 1.167	 1.067	 1.276	 0.190	 0.100	 0.279	 1.209	 1.105	 1.322	 0.098	 0.007	 0.188	 1.102	 1.007	 1.206	
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	 16-18	n=415	 19-21	n=406	 22-24	n=409	
		 Coeffi-cient	
Lower	
95%	CI	
Upper	
95%	CI	
Odds	
Ratio	
Lower	
95%	CI	
Upper	
95%	CI	
Coeffi-
cient	
Lower	
95%	CI	
Upper	
95%	CI	
Odds	
Ratio	
Lower	
95%	CI	
Upper	
95%	CI	
Coeffi-
cient	
Lower	
95%	CI	
Upper	
95%	CI	
Odds	
Ratio	
Lower	
95%	CI	
Upper	
95%	CI	
GP	Consultation	 0.246	 0.157	 0.335	 1.279	 1.170	 1.398	 0.133	 0.043	 0.223	 1.142	 1.044	 1.250	 0.125	 0.035	 0.215	 1.133	 1.036	 1.240	
Sexual	Health	
Clinic	Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 0.001	 -0.085	 0.087	 1.001	 0.918	 1.091	 -0.104	 -0.190	 -0.017	 0.902	 0.827	 0.983	 -0.055	 -0.142	 0.031	 0.946	 0.868	 1.032	
Instant	Messenger	 0.102	 0.017	 0.188	 1.108	 1.017	 1.207	 -0.024	 -0.109	 0.062	 0.977	 0.897	 1.064	 0.001	 -0.085	 0.087	 1.001	 0.918	 1.091	
Email	 0.075	 -0.009	 0.160	 1.078	 0.991	 1.174	 0.037	 -0.048	 0.122	 1.038	 0.954	 1.130	 0.029	 -0.056	 0.115	 1.030	 0.945	 1.122	
Face	to	Face	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
How	you	get	Antibiotics	
Post	to	Home	 -0.024	 -0.114	 0.066	 0.977	 0.893	 1.068	 0.010	 -0.081	 0.100	 1.010	 0.922	 1.106	 0.047	 -0.043	 0.137	 1.048	 0.957	 1.147	
Post	to	Collection	
Point	 0.010	 -0.078	 0.097	 1.010	 0.925	 1.102	 0.035	 -0.053	 0.123	 1.036	 0.948	 1.131	 0.046	 -0.042	 0.135	 1.047	 0.959	 1.144	
Collect	from	
Pharmacy	 0.039	 -0.054	 0.132	 1.039	 0.947	 1.141	 0.101	 0.008	 0.195	 1.106	 1.008	 1.215	 0.077	 -0.017	 0.171	 1.080	 0.983	 1.186	
Collect	from	Sexual	
Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Table	6.28	-	Age	Range	Subgroup	Analysis	Coefficients	and	Odds	Ratios,	including	Respective	95%	Confidence	Intervals
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	 Single	n=615	 Sexual	Relationship	with	One	Partner	n=512	
		 Coefficient	 Lower	95%	CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	 Coefficient	
Lower	95%	
CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	
How	you	Test	
Self-Test	 0.490	 0.396	 0.584	 1.632	 1.486	 1.792	 0.538	 0.434	 0.641	 1.712	 1.543	 1.899	
Post	 0.322	 0.227	 0.416	 1.380	 1.255	 1.516	 0.322	 0.218	 0.425	 1.380	 1.244	 1.530	
Pharmacy	 0.199	 0.115	 0.283	 1.220	 1.122	 1.327	 0.104	 0.011	 0.196	 1.109	 1.011	 1.217	
Education/	Work	 -0.162	 -0.247	 -0.077	 0.851	 0.781	 0.926	 -0.251	 -0.344	 -0.157	 0.778	 0.709	 0.854	
GP	Practice	 -0.006	 -0.093	 0.081	 0.994	 0.911	 1.085	 0.063	 -0.032	 0.159	 1.066	 0.969	 1.172	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.548	 0.471	 0.625	 1.730	 1.602	 1.867	 0.640	 0.556	 0.724	 1.896	 1.743	 2.062	
2	Hours	 0.271	 0.190	 0.352	 1.311	 1.209	 1.422	 0.416	 0.327	 0.505	 1.516	 1.387	 1.657	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.148	 -0.220	 -0.077	 0.862	 0.803	 0.926	 -0.149	 -0.227	 -0.071	 0.862	 0.797	 0.932	
Accuracy	
2	in	100	False	Negative	 1.186	 1.137	 1.236	 3.275	 3.116	 3.443	 1.196	 1.141	 1.250	 3.305	 3.129	 3.492	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	Consultation	 0.145	 0.071	 0.219	 1.156	 1.074	 1.245	 0.251	 0.169	 0.332	 1.285	 1.185	 1.394	
Pharmacy	Consultation	 0.108	 0.035	 0.182	 1.115	 1.036	 1.199	 0.203	 0.123	 0.284	 1.225	 1.130	 1.328	
GP	Consultation	 0.150	 0.077	 0.223	 1.162	 1.080	 1.250	 0.173	 0.092	 0.253	 1.189	 1.097	 1.288	
Sexual	Health	Clinic	
Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.059	 -0.130	 0.011	 0.942	 0.878	 1.011	 -0.077	 -0.155	 0.000	 0.926	 0.856	 1.000	
Instant	Messenger	 0.025	 -0.045	 0.095	 1.025	 0.956	 1.099	 -0.009	 -0.086	 0.068	 0.991	 0.918	 1.071	
Email	 0.066	 -0.003	 0.136	 1.069	 0.997	 1.145	 0.001	 -0.076	 0.077	 1.001	 0.927	 1.080	
Face	to	Face	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
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	 Single	n=615	 Sexual	Relationship	with	One	Partner	n=512	
		 Coefficient	 Lower	95%	CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	 Coefficient	
Lower	95%	
CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	
How	you	get	Antibiotics	
Post	to	Home	 -0.044	 -0.118	 0.030	 0.957	 0.889	 1.030	 0.053	 -0.028	 0.134	 1.055	 0.973	 1.144	
Post	to	Collection	Point	 -0.032	 -0.104	 0.040	 0.968	 0.901	 1.041	 0.070	 -0.009	 0.149	 1.072	 0.991	 1.160	
Collect	from	Pharmacy	 0.067	 -0.009	 0.143	 1.070	 0.991	 1.154	 0.055	 -0.029	 0.139	 1.056	 0.971	 1.149	
Collect	from	Sexual	Health	
Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Table	6.29	-	Relationship	Status	Subgroup	Analysis	Coefficients	and	Odds	Ratios,	including	Respective	95%	Confidence	Intervals
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	 Previous	Test	n=393	 No	Previous	Test	n=790	
		 Coefficient	 Lower	95%	CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	 Coefficient	
Lower	95%	
CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	
How	you	Test	
Self-Test	 0.422	 0.305	 0.539	 1.524	 1.356	 1.714	 0.518	 0.434	 0.601	 1.678	 1.544	 1.824	
Post	 0.164	 0.047	 0.280	 1.178	 1.048	 1.323	 0.382	 0.298	 0.466	 1.465	 1.347	 1.594	
Pharmacy	 -0.056	 -0.160	 0.048	 0.945	 0.852	 1.049	 0.245	 0.170	 0.320	 1.277	 1.185	 1.377	
Education/	Work	 -0.273	 -0.377	 -0.168	 0.761	 0.686	 0.845	 -0.150	 -0.225	 -0.074	 0.861	 0.798	 0.928	
GP	Practice	 -0.122	 -0.229	 -0.014	 0.885	 0.795	 0.986	 0.097	 0.019	 0.174	 1.101	 1.019	 1.190	
Sexual	Health	Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Time	to	Result	
30	Mins	 0.592	 0.498	 0.687	 1.808	 1.645	 1.988	 0.586	 0.518	 0.654	 1.797	 1.679	 1.923	
2	Hours	 0.305	 0.205	 0.406	 1.357	 1.227	 1.500	 0.353	 0.281	 0.425	 1.423	 1.325	 1.529	
7	Days	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
14	Days	 -0.125	 -0.213	 -0.037	 0.882	 0.808	 0.963	 -0.156	 -0.219	 -0.093	 0.856	 0.803	 0.912	
Accuracy	
2	in	100	False	Negative	 1.099	 1.037	 1.160	 3.000	 2.820	 3.191	 1.248	 1.203	 1.292	 3.482	 3.331	 3.640	
5	in	100	False	Negative	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Consultation	Method	
Online	Consultation	 0.161	 0.069	 0.252	 1.174	 1.071	 1.287	 0.205	 0.140	 0.271	 1.228	 1.150	 1.311	
Pharmacy	Consultation	 0.094	 0.003	 0.184	 1.098	 1.003	 1.203	 0.168	 0.103	 0.233	 1.183	 1.108	 1.262	
GP	Consultation	 0.106	 0.015	 0.197	 1.112	 1.015	 1.217	 0.195	 0.130	 0.260	 1.215	 1.139	 1.297	
Sexual	Health	Clinic	
Consultation	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Access	to	Healthcare	Professional	
Phone	 -0.054	 -0.142	 0.034	 0.947	 0.868	 1.034	 -0.048	 -0.110	 0.015	 0.953	 0.895	 1.015	
Instant	Messenger	 0.044	 -0.042	 0.131	 1.045	 0.958	 1.140	 0.025	 -0.037	 0.087	 1.025	 0.963	 1.091	
Email	 0.048	 -0.038	 0.134	 1.049	 0.962	 1.144	 0.053	 -0.009	 0.114	 1.054	 0.991	 1.121	
Face	to	Face	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
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	 Previous	Test	n=393	 No	Previous	Test	n=790	
		 Coefficient	 Lower	95%	CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	 Coefficient	
Lower	95%	
CI	
Upper	95%	
CI	 Odds	Ratio	
Lower	95%	
CI	
Upper	95%	
CI	
How	you	get	Antibiotics	
Post	to	Home	 0.011	 -0.081	 0.102	 1.011	 0.922	 1.107	 0.020	 -0.046	 0.085	 1.020	 0.955	 1.089	
Post	to	Collection	Point	 0.034	 -0.056	 0.123	 1.034	 0.946	 1.131	 0.034	 -0.029	 0.098	 1.035	 0.971	 1.103	
Collect	from	Pharmacy	 0.083	 -0.012	 0.177	 1.086	 0.988	 1.194	 0.075	 0.008	 0.143	 1.078	 1.008	 1.153	
Collect	from	Sexual	Health	
Clinic	 0.000	 -	 -	 1.000	 -	 -	 0.000	 -	 -	 1.000	 -	 -	
Table	6.30	-	Previous	STI	Testing	Subgroup	Analysis	Coefficients	and	Odds	Ratios,	including	Respective	95%	Confidence	Intervals
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		 Full	Dataset	 Male	 Female	 16-18	 19-21	 22-24	 Single	 One	Partner	 Prev	Test	 No	Prev	Test	
n	 1,230	 607	 623	 415	 406	 409	 615	 512	 393	 790	
		 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	 Odds	Ratio	
How	you	Test	 		 		 		 		 		 		 		 		 		 		
Self-Test	 1.618	 1.549	 1.693	 1.664	 1.346	 1.895	 1.632	 1.712	 1.524	 1.678	
Post	 1.358	 1.308	 1.411	 1.477	 1.138	 1.487	 1.380	 1.380	 1.178	 1.465	
Pharmacy	 1.155	 1.131	 1.180	 1.270	 1.021	 1.185	 1.220	 1.109	 0.945	 1.277	
Education/	Work	 0.821	 0.919	 0.733	 0.804	 0.806	 0.852	 0.851	 0.778	 0.761	 0.861	
GP	Practice	 1.019	 1.049	 0.990	 1.085	 1.035	 0.941	 0.994	 1.066	 0.885	 1.101	
Sexual	Health	Clinic	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	
Time	to	Result	 		 		 		 		 		 		 		 		 		 		
30	Mins	 1.806	 1.828	 1.786	 1.763	 1.888	 1.772	 1.730	 1.896	 1.808	 1.797	
2	Hours	 1.402	 1.365	 1.442	 1.326	 1.548	 1.344	 1.311	 1.516	 1.357	 1.423	
7	Days	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	
14	Days	 0.862	 0.844	 0.881	 0.878	 0.882	 0.828	 0.862	 0.862	 0.882	 0.856	
Accuracy	 		 		 		 		 		 		 		 		 		 		
2	in	100	False	Negative	 3.242	 2.951	 3.570	 3.307	 3.161	 3.282	 3.275	 3.305	 3.000	 3.482	
5	in	100	False	Negative	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	
Consultation	Method	 		 		 		 		 		 		 		 		 		
Online	Consultation	 1.212	 1.187	 1.239	 1.187	 1.200	 1.253	 1.156	 1.285	 1.174	 1.228	
Pharmacy	Consultation	 1.158	 1.106	 1.215	 1.167	 1.209	 1.102	 1.115	 1.225	 1.098	 1.183	
GP	Consultation	 1.183	 1.172	 1.194	 1.279	 1.142	 1.133	 1.162	 1.189	 1.112	 1.215	
Sexual	Health	Clinic	Consultation	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	
Access	to	Healthcare	Professional	 		 		 		 		 		 		 		 		 		
Phone	 0.949	 0.937	 0.962	 1.001	 0.902	 0.946	 0.942	 0.926	 0.947	 0.953	
Instant	Messenger	 1.027	 0.994	 1.062	 1.108	 0.977	 1.001	 1.025	 0.991	 1.045	 1.025	
Email	 1.048	 1.034	 1.062	 1.078	 1.038	 1.030	 1.069	 1.001	 1.049	 1.054	
Face	to	Face	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	
How	you	get	Antibiotics	 		 		 		 		 		 		 		 		 		
Post	to	Home	 1.011	 0.996	 1.028	 0.977	 1.010	 1.048	 0.957	 1.055	 1.011	 1.020	
Post	to	Collection	Point	 1.031	 1.082	 0.983	 1.010	 1.036	 1.047	 0.968	 1.072	 1.034	 1.035	
Collect	from	Pharmacy	 1.075	 1.064	 1.087	 1.039	 1.106	 1.080	 1.070	 1.056	 1.086	 1.078	
Collect	from	Sexual	Health	Clinic	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	
Table	6.31	-	Odds	Ratios	for	all	Sub-Groups	Included	within	the	Analysis
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6.6 Applying	Stated	Preference	Data	to	Pathway	Design	
The	results	from	the	DCE	can	be	used	to	estimate	the	probability	of	
uptake	of	 an	option	and	 can	be	particularly	helpful	when	exploring	
the	 potential	 uptake	 of	 new	 services	 (Ryan	 et	 al.	 2014).	 The	
probability	 that	 an	 individual	 takes	 up	 a	 given	 option	 (P1)	 is	 the	
exponential	of	the	utility	divided	by	the	sum	of	all	of	the	alternatives,	
this	is	represented	in	the	following	equation:	
	 !" = $%&= 1	$)	*) 	
	
Where	 j	 is	 the	alternative	and	J	 is	any	other	alternative	within	the	
choice	set	(Ryan	et	al.,	2014).		
	
Utilising	 the	 coefficients	 from	 the	 DCE	 results	 in	 table	 6.27,	 the	
probability	 of	 uptake	 has	 first	 been	 considered	 for	 the	 three	
pathways	within	the	eSTI2	exploratory	study:	the	sexual	health	clinic	
(the	reference	pathway	within	the	DCE),	 the	NCSP	 internet	testing	
pathway,	 and	 fully	 remote	 online	 pathway,	 and	 the	 ‘I	 would	 not	
test’	 option.	Recognising	 that	 test	 accuracy	has	been	 identified	as	
the	 attribute	 for	 which	 respondents	 expressed	 the	 strongest	
preference,	accuracy	has	been	assumed	to	be	the	same	for	the	fully	
remote	online	pathway	as	 for	 the	GUM	and	NCSP	 internet	 testing	
pathway	for	this	initial	analysis.	Table	6.33	summarises	the	make-up	
of	 the	 pathway	 attributes	 and	 levels	 and	 table	 6.34	 contains	 the	
sum	 of	 the	 coefficients	 for	 each	 of	 the	 pathway	 options	 and	 for	
each	of	 the	 sub-groups	within	 the	DCE	analysis.	 Table	6.35	 shows	
the	 ORs	 for	 each	 pathway	 for	 each	 subgroup	 and	 table	 6.36	
summarises	the	probability	of	pathway	uptake.	
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	 How	you	Test	 Time	to	Result	 Test	Accuracy	(False	
Negative)	
Consultation	Method	 Access	to	HCP	 How	you	get	your	
Antibiotics	
Sexual	Health	Clinic	
Pathway	
Attend	sexual	health	
clinic,	sample	taken	
by	HCP	
7	Days	 5	in	100	people	will	
be	told	they	don’t	
have	chlamydia	when	
they	do	
Sexual	health	clinic	 Face	to	face	 Collect	from	sexual	
health	clinic	
NCSP	Internet	Testing	
Pathway	
Order	test	kit	online,	
self-sample	and	post	
off	for	analysis	
14	Days	 5	in	100	people	will	
be	told	they	don’t	
have	chlamydia	when	
they	do	
Pharmacy	 Face	to	face	 Collect	from	
pharmacy	
Fully	Remote	Online	
Pathway	
Self-Test	 30	Mins	 5	in	100	people	will	
be	told	they	don’t	
have	chlamydia	when	
they	do	
Online	consultation	 Phone	 Collect	from	
pharmacy	
Table	6.32	-	Composition	of	Pathways	
	
		 Full	Dataset	 Male	 Female	 16-18	 19-21	 22-24	 Single	 One	Partner	 Prev	Test	 No	Prev	Test	
Pathways	 Coefficient	 Coefficient	 Coefficient	 Coefficient	 Coefficient	 Coefficient	 Coefficient	 Coefficient	 Coefficient	 Coefficient	
Sexual	Health	Clinic	Pathway	 0.000	 0.000	 0.000	 0.000	 0.000	 0.000	 0.000	 0.000	 0.000	 0.000	
NCSP	Postal	Testing	Pathway	 0.377	 0.262	 0.495	 0.453	 0.294	 0.382	 0.349	 0.431	 0.214	 0.469	
Fully	Remote	Online	Pathway		 1.284	 1.209	 1.365	 1.288	 1.113	 1.459	 1.191	 1.406	 1.203	 1.336	
I	would	not	test	 -1.682	 -1.584	 -1.796	 -1.322	 -1.901	 -1.877	 -1.601	 -2.013	 -2.283	 -1.458	
Table	6.33	-	Pathway	Coefficients	
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		 Full	Dataset	 Male	 Female	 16-18	 19-21	 22-24	 Single	
One	
Partner	 Prev	Test	
No	Prev	
Test	
Pathways	 OR	 OR	 OR	 OR	 OR	 OR	 OR	 OR	 OR	 OR	
Sexual	Health	Clinic	Pathway	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	 1.000	
NCSP	Postal	Testing	Pathway	 1.458	 1.299	 1.641	 1.572	 1.342	 1.465	 1.418	 1.539	 1.239	 1.599	
Fully	Remote	Online	Pathway	(Pharmacy	
Collect)	 3.612	 3.350	 3.914	 3.624	 3.043	 4.301	 3.290	 4.078	 3.331	 3.806	
I	would	not	Test	 0.186	 0.205	 0.166	 0.267	 0.149	 0.153	 0.202	 0.134	 0.102	 0.233	
Table	6.34	-	Pathway	Odds	Ratios	
	
		 Full	Dataset	 Male	 Female	 16-18	 19-21	 22-24	 Single	
One	
Partner	 Prev	Test	
No	Prev	
Test	
Sexual	health	clinic	 16%	 17%	 15%	 15%	 18%	 14%	 17%	 15%	 18%	 15%	
NCSP	Postal	Testing	 23%	 22%	 24%	 24%	 24%	 21%	 24%	 23%	 22%	 24%	
Fully	Remote	Online	Pathway	
(Pharm	Collect)	 58%	 57%	 58%	 56%	 55%	 62%	 56%	 60%	 59%	 57%	
I	would	not	test	 3%	 4%	 2%	 4%	 3%	 2%	 3%	 2%	 2%	 4%	
Total	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	
Table	6.35	-	Probability	of	Pathway	Uptake	
	
	
	
		 326	
This	analysis	predicts	 that	 should	 the	 fully	 remote	online	pathway	
be	 introduced,	 a	 higher	 proportion	 of	 people	 choosing	 to	 test	
across	 all	 subgroups	 would	 choose	 this	 pathway	 to	 test	 and	 get	
treatment.	The	pathway	with	the	second	highest	uptake	would	be	
the	NCSP	 internet	 testing	pathway,	 followed	 closely	by	 the	 sexual	
health	 clinic.	 Of	 the	 three	 testing	 options	 available	 a	 low	
percentage	(2-4%	across	all	subgroups)	would	not	choose	any	of	the	
three	pathways.		
	
In	considering	the	‘I	would	not	test’	option	it	is	important	that	this	
is	 not	 misinterpreted	 when	 applying	 it	 to	 uptake.	 In	 framing	 the	
DCE	questionnaire,	the	introduction	to	the	survey	stated:	
“In	 completing	 the	 survey	 you	will	 be	presented	with	a	number	of	
choices	 for	 getting	 tested	 and	 treatment	 for	 chlamydia.	 Please	
consider	each	set	of	choices	and	indicate	whether	you	prefer	option	
A	or	option	B	or	whether	you	would	not	test,	that	is,	you	would	not	
choose	option	A	or	option	B.”		
	
The	 decision	 not	 to	 test	 is	 taken	 within	 the	 context	 of	 the	 two	
individual	 testing	 choices	 presented	 to	 the	 individual,	 having	 just	
been	presented	with	a	 summary	of	why	 it	 is	 important	 to	 test	 for	
chlamydia	 and	 the	 consequences	 of	 not	 testing.	 	 This	 cannot	 be	
interpreted	 in	 the	 same	way	 as	 an	 individual	 deciding	whether	 to	
test	 for	 chlamydia	 or	 not,	 therefore,	 when	 applying	 the	
probabilities	of	uptake	to	a	general	population	it	is	important	not	to	
interpret	this	as	97%	of	the	population	would	take	up	testing.	
	
Having	 considered	 the	 implementation	 of	 a	 fully	 remote	 online	
pathway	alongside	two	existing	pathways,	the	data	can	also	be	used	
to	 optimise	 the	 fully	 remote	 online	 pathway,	 assess	 the	 likely	
impact	 of	 integrating	 new	 technology	 and	 remote	 options	 into	
existing	 pathways,	 and	 explore	 the	 impact	 of	 variables	 in	 the	 test	
design.		 	
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6.6.1 Optimising	the	Fully	Remote	Online	Pathway		
Although	 it	 is	 predicted	 that	 the	 envisaged	 fully	 remote	 online	
pathway	 would	 have	 a	 greater	 uptake	 than	 the	 existing	 sexual	
health	 clinic	 or	 NCSP	 internet	 testing	 pathways,	 the	 coefficients	
presented	in	tables	6.28	to	6.32	demonstrate	that	the	combination	
of	 levels	 are	 not	 the	 optimum	 for	maximising	 uptake	 of	 the	 fully	
remote	online	pathway.	
	
Varying	the	combination	of	levels	to	create	a	pathway	incorporating	
the	 levels	 with	 the	 strongest	 preference	 in	 the	 main	 dataset	 for	
each	 attribute	 leads	 to	 two	 changes	 being	 made	 to	 levels	 –	 to	
increase	 the	 accuracy	 of	 the	 test	 result	 to	 ‘two	 in	 100	 results	 are	
false	negatives’,	and	changing	access	to	a	healthcare	professional	to	
‘email	access’,	as	illustrated	in	table	6.36.	Creating	a	scenario	where	
the	 concept	 and	 optimum	 pathways	 were	 presented	 as	 a	 choice,	
the	probability	of	uptake	of	the	optimum	pathway	is	77%	compared	
with	22%	for	the	concept	pathway	(for	the	full	dataset).	A	summary	
of	the	probability	of	uptake	is	shown	in	table	6.37	for	all	subgroups.	
Although	there	 is	a	small	variance	 in	the	percentage	for	each	 line,	
the	results	are	consistent	across	all	subgroups.		
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	 How	you	Test	 Time	to	Result	 Test	Accuracy	(False	
Negative)	
Consultation	Method	 Access	to	HCP	 How	you	get	your	
Antibiotics	
Concept	Fully	
Remote	Online	
Pathway	
Self-Test	 30	Mins	 5	in	100	people	will	
be	told	they	don’t	
have	chlamydia	when	
they	do	
Online	consultation	 Phone	 Collect	from	
pharmacy	
Optimum	Fully	
Remote	Online	
Pathway	(2	in	100	
false	negative)	
Self-Test	 30	Mins	 2	in	100	people	will	
be	told	they	don’t	
have	chlamydia	when	
they	do	
Online	consultation	 Email	 Collect	from	
pharmacy	
Table	6.36	-	Optimising	the	Fully	Remote	Online	Pathway	
	
		
Full	
Dataset	 Male	 Female	 16-18	 19-21	 22-24	 Single	
One	
Partner	 Prev	Test	
No	Prev	
Test	
Pathways	 		 		 		 		 		 		 		 		 		 		
Concept	Fully	Remote	Online	
Pathway	 22%	 23%	 20%	 22%	 21%	 22%	 21%	 22%	 23%	 20%	
Optimum	Fully	Remote	Online	
Pathway		 77%	 75%	 79%	 77%	 78%	 78%	 78%	 78%	 76%	 78%	
Not	Test	 1%	 1%	 1%	 2%	 1%	 1%	 1%	 1%	 1%	 1%	
Total	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	
Table	6.37	-	Probability	of	Pathway	Uptake	(Optimised	Fully	Remote	Online	Pathway)	
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In	optimising	the	pathway,	test	accuracy,	as	the	attribute	with	the	greatest	
strength	of	preference,	has	a	significant	impact	on	uptake.	Taking	this	out	
of	 the	equation,	 and	 focusing	 specifically	on	 the	element	of	 the	pathway	
relating	 to	 treatment,	 there	 are	 two	 attributes	 which	 warrant	 further	
exploration.	These	are	 ‘access	to	a	healthcare	professional’	and	 ‘how	you	
get	your	antibiotics’	because	the	results	indicated	no	statistically	significant	
difference	 in	preference	between	the	 levels	 in	the	majority	of	subgroups.	
This	 is	worthy	 of	 further	 consideration	 because	 it	 suggests	 that	 it	 would	
have	a	minimal	influence	over	people’s	decision	to	choose	an	option.	From	
a	 health	 service	 delivery	 perspective	 this	 may	 be	 an	 important	
consideration	 from	 the	 perspective	 of	 cost-efficiency,	 as	 options	 such	 as	
postal	delivery	may	provide	a	cheaper	pathway	solution	than	a	face-to-face	
alternative.		
	
Table	6.38	summarises	the	fully	remote	online	pathway	options	with	‘how	
you	 get	 your	 antibiotics’	 varied	 for	 each	of	 the	possible	 levels,	 and	 table	
6.39	 outlines	 the	 probability	 of	 uptake	 if	 each	 of	 the	 four	 options	 were	
available.	 This	 demonstrates	 very	 little	 difference	 in	 uptake	 between	 the	
four	pathways	(24-26%)	with	‘collect	from	pharmacy’	being	the	option	with	
the	 highest/	 joint	 highest	 probability	 of	 uptake	 in	 all	 subgroups,	 except	
males,	where	a	slightly	higher	preference	for	delivery	to	collection	point	is	
expressed.	Delivery	 to	 collection	point	was	 also	 as	 likely	 to	be	 chosen	 as	
collection	 from	pharmacy	 in	 the	 16-18	 age	 range	 and	 people	 in	 a	 sexual	
relationship	 with	 one	 partner.	 Whilst	 there	 are	 examples	 of	 delivery	 of	
drugs	for	chlamydia	within	private	sexual	healthcare	there	are	no	examples	
within	mainstream	sexual	health	services,	therefore	identifying	an	area	of	
further	 research	 in	 the	 development	 of	 remote	 sexual	 health	 pathways.
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	 How	you	Test	 Time	to	Result	 Test	Accuracy	(False	
Negative)	
Consultation	Method	 Access	to	HCP	 How	you	get	your	
Antibiotics	
Concept	Fully	
Remote	Online	
Pathway	(collect	
from	pharmacy)	
Self-Test	 30	Mins	 5	in	100	people	will	
be	told	they	don’t	
have	chlamydia	when	
they	do	
Online	consultation	 Phone	 Collect	from	
pharmacy	
Fully	Remote	Online	
Pathway	with	home	
delivery	
Self-Test	 30	Mins	 5	in	100	people	will	
be	told	they	don’t	
have	chlamydia	when	
they	do	
Online	consultation	 Phone	 Deliver	to	home	
address	
Fully	Remote	Online	
Pathway	with	
delivery	to	a	
collection	point	
Self-Test	 30	Mins	 5	in	100	people	will	
be	told	they	don’t	
have	chlamydia	when	
they	do	
Online	consultation	 Phone	 Deliver	to	collection	
point	
Fully	Remote	Online	
Pathway	with	
collection	from	a	
sexual	health	clinic	
Self-Test	 30	Mins	 5	in	100	people	will	
be	told	they	don’t	
have	chlamydia	when	
they	do	
Online	consultation	 Phone	 Collect	from	sexual	
health	clinic	
Table	6.38	-	Pathways	exploring	remote	options	for	how	you	get	your	antibiotics	
		
Full	
Dataset	 Male	 Female	 16-18	 19-21	 22-24	 Single	
One	
Partner	 Prev	Test	
No	Prev	
Test	
Pathways	 		 		 		 		 		 		 		 		 		 		
Collect	from	pharmacy	 26%	 25%	 26%	 25%	 26%	 26%	 26%	 25%	 26%	 26%	
Deliver	to	home	 24%	 24%	 25%	 24%	 24%	 25%	 24%	 25%	 24%	 24%	
Deliver	to	collection	point	 25%	 26%	 24%	 25%	 25%	 25%	 24%	 25%	 25%	 25%	
Collect	from	sexual	health	clinic	 24%	 24%	 24%	 24%	 24%	 24%	 25%	 24%	 24%	 24%	
Not	Test	 1%	 2%	 1%	 2%	 1%	 1%	 2%	 1%	 1%	 2%	
Total	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	
Table	6.39	-	Probability	of	Pathway	Uptake	(How	you	get	your	antibiotics	options)	
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Exploring	 access	 to	 a	 healthcare	 professional	 within	 the	 context	 a	 fully	
remote	online	pathway	is	also	an	important	consideration	when	optimising	
the	pathway	to	maximise	likely	uptake.	The	full	dataset	shows	a	statistically	
significant	 preference	 for	 not	 using	 the	 phone	 to	 access	 a	 healthcare	
professional	with	a	weaker	preference	for	this	than	the	comparator	(face-
to-face).	 The	 strongest	 preference	 within	 this	 attribute	 (although	 not	
statistically	significant)	is	email.		
	
Table	 6.40	 summarises	 the	 pathway	make	 up,	 and	 table	 6.41	 shows	 the	
probability	of	uptake	should	each	of	the	four	pathways	be	available.	Again,	
there	 is	 very	 little	 difference	 in	 likely	 uptake	between	 the	 four	pathways	
when	 the	 ‘access	 to	 healthcare	 professional’	 attribute	 is	 varied	 with	 the	
range	of	uptake	across	the	four	pathways	from	23%	to	26%.	Email	access	to	
a	healthcare	professional	 is	 the	most	consistently	preferred	option	across	
all	 subgroups	with	 the	 exception	of	 16-18	 year	 olds	who	would	be	more	
likely	 to	 choose	 the	pathway	with	access	 to	a	healthcare	professional	 via	
instant	 message	 (IM).	 Females,	 and	 those	 who	 have	 previously	 tested	
demonstrate	 no	 difference	 in	 likely	 uptake	 between	 email	 and	 IM,	 and	
people	in	a	sexual	relationship	with	one	partner	demonstrate	no	difference	
in	likely	uptake	between	IM,	email	and	face-to-face.	Again,	the	exploration	
of	 the	 acceptability	 of	 IM	 and	 email	 options	 to	 access	 a	 healthcare	
professional	 in	 conjunction	 with	 eHealth	 solutions	 as	 an	 alternative	 to	
phone	access	is	worthy	of	further	research.				
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	 How	you	Test	 Time	to	
Result	
Test	Accuracy	(False	Negative)	 Consultation	Method	 Access	to	HCP	 How	you	get	your	
Antibiotics	
Concept	Fully	Remote	Online	
Pathway	(phone)	
Self-Test	 30	Mins	 5	in	100	people	will	be	told	they	
don’t	have	chlamydia	when	
they	do	
Online	consultation	 Phone	 Collect	from	
pharmacy	
Fully	Remote	Online	
Pathway	with	IM	access	to	a	
healthcare	professional	
Self-Test	 30	Mins	 5	in	100	people	will	be	told	they	
don’t	have	chlamydia	when	
they	do	
Online	consultation	 IM	 Collect	from	
pharmacy	
Fully	Remote	Online	
Pathway	with	email	access	to	
a	healthcare	professional	
Self-Test	 30	Mins	 5	in	100	people	will	be	told	they	
don’t	have	chlamydia	when	
they	do	
Online	consultation	 Email		 Collect	from	
pharmacy	
Fully	Remote	Online	
Pathway	with	face	to	face	
access	to	a	healthcare	
professional	
Self-Test	 30	Mins	 5	in	100	people	will	be	told	they	
don’t	have	chlamydia	when	
they	do	
Online	consultation	 Face	to	Face	 Collect	from	
pharmacy	
Table	6.40	–	Fully	Remote	Online	Pathways	exploring	access	to	a	healthcare	professional	
		
Full	
Dataset	 Male	 Female	 16-18	 19-21	 22-24	 Single	
One	
Partner	 Prev	Test	
No	Prev	
Test	
Pathways	 		 		 		 		 		 		 		 		 		 		
Phone	 23%	 23%	 23%	 23%	 23%	 24%	 23%	 23%	 23%	 23%	
IM	 25%	 25%	 26%	 26%	 25%	 25%	 25%	 25%	 26%	 25%	
Email	 26%	 26%	 26%	 25%	 26%	 26%	 26%	 25%	 26%	 26%	
Face	to	Face	 25%	 25%	 24%	 23%	 25%	 25%	 24%	 25%	 25%	 24%	
Not	Test	 1%	 1%	 1%	 2%	 1%	 1%	 1%	 1%	 1%	 1%	
Total	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	
Table	6.41	-	Probability	of	Fully	Remote	Online	Pathway	Uptake	(varying	access	to	a	healthcare	professional)	
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6.6.2 Optimising	existing	Sexual	Health	Clinic	Pathways	
Focusing	on	 the	delivery	of	 care	via	 sexual	health	clinics,	 the	data	
allow	a	similar	approach	 to	be	applied	 to	optimising	sexual	health	
clinic	 pathways	 in	 respect	 of	 the	 preferences	 expressed	 by	 young	
people	 in	 the	 DCE.	 Considering	 specifically	 the	 access	 to	 a	 health	
care	 professional	 attribute,	 as	 non-face-to-face	 consultation	
methods	 are	 a	 policy	 priority	 (Department	 of	 Health,	 2011,	
Department	of	Health,	 2012,	NHS	England,	2014),	 tables	6.42	and	
6.43	illustrate	the	use	of	the	DCE	results	to	explore	the	probability	
of	uptake	by	varying	the	levels	within	this	attribute.	
	
As	expected,	given	the	lack	of	statistical	significance	within	the	DCE	
results,	 the	 probability	 of	 uptake,	 if	 the	 population	 are	 presented	
with	each	of	the	four	choices	are	broadly	similar.	This	demonstrates	
a	 marginally	 higher	 probability	 of	 uptake	 for	 non-face-to-face	
access	methods,	with	the	exception	of	the	‘in	a	sexual	relationship	
with	 one	 partner’	 subgroup	 where	 face-to-face	 has	 the	 same	
probability	 as	 email.	 Of	 interest,	 in	 all	 but	 one	 subgroup,	 the	
probability	of	 uptake	 is	 highest	 (or	 tied	 joint	highest)	 for	 email	 as	
the	 access	 option	 in	 all	 subgroups	 except	 16-18	 year	 olds	 who	
prefer	 the	 IM	 route.	 Of	 the	 preferred	 options,	 it	 is	 interesting	 to	
note	 that	 the	options	which	do	not	 involve	speaking	 to	a	HCP	are	
preferred	 over	 those	 that	 do,	 and,	 in	 the	 case	 of	 email,	 suggests	
that	synchronous	communication	with	an	HCP	is	not	a	requirement.		
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	 How	you	Test	 Time	to	
Result	
Test	Accuracy	(False	
Negative)	
Consultation	Method	 Access	to	HCP	 How	you	get	your	
Antibiotics	
Sexual	Health	Clinic	
Pathway	(Current)		
Attend	sexual	health	
clinic,	sample	taken	by	
HCP	
7	Days	 5	in	100	people	will	be	told	
they	don’t	have	chlamydia	
when	they	do	
Sexual	health	clinic	 Face	to	face	 Collect	from	sexual	
health	clinic	
Sexual	Health	Clinic	
Pathway	(Phone)	
Attend	sexual	health	
clinic,	sample	taken	by	
HCP	
7	Days	 5	in	100	people	will	be	told	
they	don’t	have	chlamydia	
when	they	do	
Sexual	health	clinic	 Phone	 Collect	from	sexual	
health	clinic	
Sexual	Health	Clinic	
Pathway	(IM)	
Attend	sexual	health	
clinic,	sample	taken	by	
HCP	
7	Days	 5	in	100	people	will	be	told	
they	don’t	have	chlamydia	
when	they	do	
Sexual	health	clinic	 IM	 Collect	from	sexual	
health	clinic	
Sexual	Health	Clinic	
Pathway	(Email)	
Attend	sexual	health	
clinic,	sample	taken	by	
HCP	
7	Days	 5	in	100	people	will	be	told	
they	don’t	have	chlamydia	
when	they	do	
Sexual	health	clinic	 Email	 Collect	from	sexual	
health	clinic	
Table	6.42	-	Sexual	Health	Clinic	Pathways	exploring	access	to	a	healthcare	professional	
		
Full	
Dataset	 Male	 Female	 16-18	 19-21	 22-24	 Single	
One	
Partner	 Prev	Test	
No	Prev	
Test	
Pathways	 		 		 		 		 		 		 		 		 		 		
Face	to	Face	 24%	 24%	 24%	 22%	 25%	 24%	 24%	 25%	 24%	 23%	
Phone	 23%	 22%	 23%	 22%	 22%	 23%	 22%	 23%	 23%	 22%	
IM	 24%	 24%	 25%	 25%	 24%	 24%	 24%	 24%	 25%	 24%	
Email	 25%	 25%	 25%	 24%	 26%	 25%	 25%	 25%	 25%	 25%	
Not	Test	 4%	 5%	 4%	 6%	 4%	 4%	 5%	 3%	 2%	 5%	
Total	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	
Table	6.43	-	Probability	of	Sexual	Health	Clinic	Pathway	Uptake	(varying	access	to	a	healthcare	professional)	
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Considering	optimisation	of	the	treatment	of	chlamydia	within	the	
sexual	 health	 clinic	 pathway	 (as	 opposed	 to	 the	 whole	 pathway),	
there	 is	a	notable	 impact	as	a	result	of	optimising	the	three	 levels	
relating	to	treatment	–	consultation	method,	access	to	a	healthcare	
professional	 and	 the	 route	 for	 obtaining	 antibiotics.	 Table	 6.44	
shows	 the	 make-up	 of	 a	 typical	 sexual	 health	 clinic	 pathway	
compared	 with	 the	 pathway	 with	 the	 highest	 strength	 of	
preference	for	the	three	treatment	levels.	Table	6.45	demonstrates	
that	 if	 both	 pathways	were	 available	 the	 uptake	of	 the	 optimised	
pathway	 would	 be	 54%	 compared	 with	 39%	 for	 the	 current	
pathway.	 There	 is	 a	 consistently	 higher	 probability	 across	 all	
subgroups	analysed.		
	
The	 significance	 of	 this	 finding	 is	 material	 within	 the	 context	 of	
delivering	sexual	health	clinic	services.	Of	all	of	the	service	options	
available,	the	sexual	health	clinic	is	the	most	comprehensive	owing	
to	 the	 range	 of	 tests	 it	 offers	 and	 diseases	 it	 treats,	 this	 cannot	
currently	 be	 replicated	 in	 primary	 care	 services.	 Data	 from	 PHE	
shows	that	of	the	1.54	million	chlamydia	tests	undertaken	in	2015,	
576,089	were	in	GUM	clinic	settings	and	257,394	were	in	sexual	and	
reproductive	health	clinic	settings,	with	a	10.4%	and	9.1%	positivity	
rate	respectively	(Public	Health	England,	2016a).		
	
The	treatment	element	of	the	pathway	is	currently	only	for	patients	
testing	 positive	 for	 genital	 chlamydia	 only.	 Data	 on	 co-infection	
rates	are	limited,	with	one	study	in	an	English	GUM	clinic	suggesting	
that	 28%	 of	 women	 testing	 positive	 for	 chlamydia	 had	 coexisting	
STIs	(Harindra	et	al.,	2002).	This	suggests	that	a	high	proportion	of	
those	 testing	 positive	 within	 a	 clinic	 setting	 test	 positive	 for	
chlamydia	 only	 and	 therefore	 could	 use	 the	 online	 consultation	
method	 or	 access	 traditional	 consultation	 services	 via	 a	 non-face-
to-face	method.		
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	 How	you	Test	 Time	to	Result	 Test	Accuracy	(False	
Negative)	
Consultation	Method	 Access	to	HCP	 How	you	get	your	
Antibiotics	
Sexual	Health	Clinic	
Pathway	(Current)		
Attend	sexual	health	
clinic,	sample	taken	by	
HCP	
7	Days	 5	in	100	people	will	
be	told	they	don’t	
have	chlamydia	when	
they	do	
Sexual	health	clinic	 Face	to	face	 Collect	from	sexual	
health	clinic	
Sexual	Health	Clinic	
Pathway	(Optimised	
Treatment)	
Attend	sexual	health	
clinic,	sample	taken	by	
HCP	
7	Days	 5	in	100	people	will	
be	told	they	don’t	
have	chlamydia	when	
they	do	
Online	consultation	 Email	 Collect	from	
Pharmacy	
Table	6.44	-	Sexual	Health	Clinic	Pathways	-	Optimising	the	treatment	element	of	the	pathway	
	
		
Full	
Dataset	 Male	 Female	 16-18	 19-21	 22-24	 Single	
One	
Partner	 Prev	Test	
No	Prev	
Test	
Pathways	 		 		 		 		 		 		 		 		 		 		
Sexual	Health	Pathway	-	Current	 39%	 40%	 39%	 39%	 40%	 39%	 40%	 40%	 41%	 38%	
Sexual	Health	Pathway	-	
Optimised	Treatment	Element	 54%	 52%	 55%	 51%	 55%	 55%	 52%	 55%	 55%	 53%	
Not	Test	 7%	 8%	 6%	 10%	 6%	 6%	 8%	 5%	 4%	 9%	
Total	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	
Table	6.45	-	Probability	of	Sexual	Health	Clinic	Pathway	Uptake	(optimising	the	treatment	element	of	the	pathway)	
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6.6.3 Optimising	the	treatment	element	of	existing	NCSP	
Internet	Testing	Pathways	
Considering	the	optimisation	of	the	treatment	element	of	the	NCSP	
internet	 testing	pathways	 is	a	more	challenging	proposition	owing	
to	 the	considerable	variation	 in	pathways	across	England,	 this	will	
be	explored	further	in	Chapter	7.	Focusing	on	two	of	the	treatment	
options	 available	 –	 to	 attend	 a	 GP	 practice	 or	 pharmacy	 for	 a	
consultation	to	get	the	antibiotics,	table	6.46	shows	the	make-up	of	
the	two	existing	pathways	compared	with	an	optimised	treatment	
pathway.	This	demonstrates	that	an	online	consultation	with	email	
access	to	a	healthcare	professional	if	required	would	have	a	higher	
uptake	 than	 the	 other	 two	 options	 across	 the	 full	 dataset	 and	 all	
subgroups	analysed.	
	
Within	 the	 context	 of	 treatment	 uptake	 rates	 this	 finding	may	 be	
particularly	 significant	 for	 NCSP	 services	 where	 the	 last	 data	
published	 (2011-12)	 show	 significant	 variation	 in	 the	 range	 of	
treatment	 uptake	 across	 screening	 offices	 in	 England	 with	 the	
lowest	at	56.2%	ranging	to	100%	(NCSP,	2012b).		
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	 How	you	Test	 Time	to	Result	 Test	Accuracy	(False	
Negative)	
Consultation	Method	 Access	to	HCP	 How	you	get	your	
Antibiotics	
NCSP	Internet	
Testing	Pathway	
Current	-	Pharmacy	
Order	test	kit	online,	
self-sample	and	post	
off	for	analysis	
14	Days	 5	in	100	people	will	
be	told	they	don’t	
have	chlamydia	when	
they	do	
Pharmacy	 Face	to	face	 Collect	from	
pharmacy	
NCSP	Internet	
Testing	Pathway	
Current	–	GP		
Order	test	kit	online,	
self-sample	and	post	
off	for	analysis	
14	Days	 5	in	100	people	will	
be	told	they	don’t	
have	chlamydia	when	
they	do	
GP	 Face	to	face	 Collect	from	
pharmacy	
NCSP	Internet	
Testing	Pathway	–	
Optimised		
Order	test	kit	online,	
self-sample	and	post	
off	for	analysis	
7	Days	 5	in	100	people	will	
be	told	they	don’t	
have	chlamydia	when	
they	do	
Online	Consultation	 Email		 Collect	from	
pharmacy	
Table	6.46	-	NCSP	Internet	Testing	Pathways	-	Optimising	the	treatment	element	of	the	pathway	
	
		
Full	
Dataset	 Male	 Female	 16-18	 19-21	 22-24	 Single	
One	
Partner	 Prev	Test	
No	Prev	
Test	
Pathways	 		 		 		 		 		 		 		 		 		 		
NCSP	Internet	Testing	Pathway	-	
Pharmacy	 29%	 28%	 30%	 28%	 31%	 28%	 29%	 31%	 30%	 29%	
NCSP	Internet	Testing	Pathway	
GP	 30%	 30%	 30%	 31%	 29%	 29%	 30%	 30%	 30%	 30%	
NCSP	Internet	Testing	Pathway	
Optimised	 37%	 37%	 37%	 36%	 36%	 40%	 37%	 37%	 38%	 37%	
Not	Test	 4%	 4%	 3%	 5%	 3%	 3%	 4%	 3%	 2%	 4%	
Total	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	
Table	6.47	-	Probability	of	NCSP	Internet	Testing	Pathway	Uptake	(optimising	the	treatment	element	of	the	pathway)
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6.6.4 Impact	of	Test	Parameters	
Data	 from	 the	DCE	 can	also	be	used	 to	explore	 the	 impact	of	 the	
test	 parameters	 to	 inform	 the	 acceptability	 of	 new	 chlamydia	
testing	pathways.	Focusing	specifically	on	the	first	 three	attributes	
in	 the	pathway	–	how	you	 test,	how	 long	you	wait	 for	your	 result	
and	 test	 accuracy,	 analysis	 can	 be	 undertaken	 to	 understand	 the	
probability	of	uptake	and	trade-offs	between	attributes.		
	
As	 identified	 in	 section	6.5.3	accuracy	 is	 consistently	 the	attribute	
with	 the	 strongest	 preference	 across	 all	 subgroups.	 Looking	
specifically	 at	 the	 trade-off	 between	 accuracy	 and	 time	 to	 result,	
the	 probability	 of	 uptake	 has	 been	 considered	 for	 tests	 with	
characteristics	as	the	opposite	ends	of	the	spectrum,	as	 illustrated	
in	tables	6.48	and	6.49:	
	
	 Test	Accuracy	(False	
Negative)	
Time	to	Result	
Lower	accuracy,	
faster	time	to	result	
5	in	100	people	will	be	
told	they	don’t	have	
chlamydia	when	they	
do	
30	mins	
Higher	accuracy,	
slower	time	to	result		
2	in	100	people	will	be	
told	they	don’t	have	
chlamydia	when	they	
do	
14	Days	
Table	6.48	-	Trade-off	between	Accuracy	and	Time	
	
		
Full	
Dataset	 Male	 Female	 16-18	 19-21	 22-24	 Single	
One	
Part-
ner	
Prev	
Test	
No	
Prev	
Test	
Pathways	 		 		 		 		 		 		 		 		 		 		
5	in	100/	
30min	 38%	 40%	 35%	 36%	 39%	 38%	 36%	 39%	 40%	 36%	
2	in	100/	14	
days	 58%	 55%	 62%	 59%	 58%	 59%	 59%	 58%	 58%	 59%	
Not	Test	 4%	 5%	 3%	 5%	 3%	 3%	 4%	 3%	 2%	 5%	
Total	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	 100%	
Table	6.49	-	Probability	of	Uptake	(Accuracy	&	Time)	
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This	 suggests	 that,	 based	 on	 the	 levels	 included	 in	 the	
questionnaire,	participants	are	willing	to	wait	considerably	longer	in	
order	to	have	a	test	result	with	a	 lower	chance	of	a	false	negative	
result.	The	impact	of	this	for	new	test	development	is	that	time	to	
result	is	less	important	than	accuracy,	and	test	users	are	unlikely	to	
use	 a	 POCT	 or	 self-test	 with	 lower	 accuracy	 than	 the	 options	
currently	available	to	them.		
	
6.7 Discussion	
This	study	is	the	first	of	its	kind	to	offer	insights	into	young	people’s	
preferences	 for	 new	 technologies	 in	 the	 testing	 and	 treatment	 of	
chlamydia.	 This	 method	 enables	 an	 understanding	 of	 the	 relative	
strength	 of	 preference	 between	 attributes	 and	 levels,	 and	 can	 be	
used	 by	 technology	 developers,	 policy	 makers,	 commissioners	 and	
service	 providers	 to	 give	 a	 first	 insight	 into	 preferences	 for	 new	
technologies	 which	 are	 currently	 in	 development	 and	 could	 be	
available	for	use	within	mainstream	services	within	the	next	three	to	
five	years	compared	with	features	of	existing	products	and	services.	
It	 highlights	 that	 accuracy	 is	 of	 critical	 importance	 in	 new	 test	
development	for	young	people,	with	time	to	result	second	to	this.	It	
also	 offers	 valuable	 insights	 into	 how	 existing	 pathways	 can	 be	
optimised	to	increase	the	probability	of	uptake.		
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The	 study	 employed	 a	 robust	 method	 to	 select	 the	 attributes	 and	
levels	for	inclusion	based	on	two	literature	reviews,	focus	groups	and	
expert	groups,	combining	the	findings	using	a	narrative	synthesis	to	
inform	the	final	attribute	and	level	selection.	The	approach	employed	
to	select	the	attributes	and	levels	aligned	with	the	recommendations	
of	 Coast	 and	 colleagues,	 which	 include	 ensuring	 attributes	 are	
“manipulable	 in	 policy”	 (Coast	 et	 al.,	 2012:739),	 the	 conduct	 of	
piloting,	 ensuring	 that	 ‘meaningful	 language’	 is	 used,	 clarity	 on	 the	
‘methodological	choices’	 to	develop	attributes	 for	 the	DCE	and	that	
the	reporting	of	attribute	selection	is	transparent	(Coast	et	al.,	2012).		
	
The	study	had	a	sufficiently	 large	sample	size	to	enable	split	sample	
analysis	 and	 subsequent	 comparison	 between	 a	 number	 of	
subgroups	 including	gender,	age	range,	previous	 testing	history	and	
two	 relationship	 categories.	 Participants	 were	 drawn	 from	 the	
general	population	rather	than	via	health	care	settings	thus	enabling	
access	 to	 a	 population	 who	 had	 not	 previously	 tested	 for	 an	 STI	
before,	 setting	 it	 apart	 from	much	 of	 the	 previous	 research	 which	
focused	 on	 service	 users.	 This	 general	 population	 sample	 enables	
consideration	 of	 the	 preferences	 of	 those	 who	 have	 not	 used	 STI	
testing	 services	 and	 therefore	 offers	 insight	 into	 their	 preferences,	
thus	informing	the	development	of	services	which	they	may	be	more	
inclined	to	use.		
	
The	 use	 of	 an	 online	 panel	 provided	 analytics	 data	 to	 support	 the	
validity	 tests	 employed	 for	 the	 DCE.	 The	 accurate	 record	 of	 time	
taken	 to	 complete	 the	 survey	enabled	 validity	 checks,	which	would	
not	 have	 otherwise	 been	 possible	 with	 a	 written	 questionnaire	
response.	 However,	 the	 use	 of	 an	 online	 panel	 may	 limit	 the	
generalisability	 of	 the	 findings	 to	 other	 populations	 and	 over-
represent	the	acceptability	of	online	care.		
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Given	 the	 breadth	 of	 sample	 achieved	 via	 the	 online	 panel	 as	
outlined	in	section	6.5.1	and	the	high	proportion	(97%)	of	15-24	year	
olds	 accessing	 the	 internet	 daily	 via	 a	 mobile	 device	 (ONS,	 2016a)	
and	owning	a	smartphone	(Ipsos	Media	CT,	2016)	this	demonstrates	
that	 the	 majority	 of	 the	 population	 have	 access	 to	 the	 base	
technology	to	use	a	fully	remote	online	pathway	for	the	testing	and	
treatment	of	chlamydia	if	they	choose	to	do	so.		
	
A	 number	 of	 limitations	 were	 identified	 whilst	 undertaking	 this	
research.	 The	 first	 relates	 to	 the	 selection	 of	 attributes	 and	 levels.	
Whilst	 it	 is	 identified	 that	 a	 strength	 of	 the	 process	 is	 the	 rigour	
employed	 in	 the	 selection	 process	 of	 attributes	 and	 levels,	 this	
cannot	 detract	 from	 the	 higher	 absolute	 number	 of	 attributes	 that	
are	involved	in	a	chlamydia	testing	and	treatment	pathway,	and	how	
these	 might	 impact	 on	 individual	 choices.	 To	 address	 this,	 where	
known	 attributes	 were	 excluded,	 as	 reported	 in	 section	 5.4.5,	
information	 was	 included	 in	 the	 background	 to	 minimise	 the	 risk	
associated	with	respondents	forming	their	own	views	on	the	impact	
of	these	attributes	on	the	pathway.	Range	of	STI	tests	was	identified	
as	 a	 significant	 factor	 by	 the	 focus	 groups	 during	 the	 research	 to	
select	 the	 attributes	 and	 levels	 included	 within	 the	 questionnaire.	
However,	 due	 to	practicalities	 in	 the	design	 and	 implementation	of	
the	DCE	it	was	not	possible	to	incorporate	this	attribute	into	the	final	
DCE	 without	 compromising	 the	 results.	 Key	 to	 this	 is	 what	 the	
respondent	 was	 considering	 at	 the	 time	 they	 complete	 the	
questionnaire,	 for	 example,	 which	 STI	 were	 they	 thinking	 of	 when	
completing	the	questionnaire.	The	focus	groups	touched	on	this	with	
an	 indication	 that	 their	 choices	 may	 be	 different,	 for	 example	 if	
thinking	about	HIV,	or	thinking	that	their	test	result	will	be	positive.		
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A	second	limitation	identified	relates	to	the	difference	in	respondent	
feedback	 between	 the	 cognitive	 testing	 and	 final	DCE	 respondents.	
Whilst	 the	cognitive	 testing	did	not	 indicate	 that	participants	 found	
the	questionnaire	repetitive	during	the	testing	phase,	respondents	to	
the	 final	DCE	cited	this	 in	 their	qualitative	 feedback	to	 the	research	
company.	The	design	of	the	DCE	did	allow	for	a	number	of	options,	as	
outlined	 in	section	6.5.2.5,	which	may	mean	that	options	 for	 future	
research	 include	 blocking	 the	 design	 to	 three	 questionnaires	 to	
reduce	the	number	of	choice	sets	to	17	(16	plus	consistency	check).	
	
The	 final	 limitation	 identified	was	 the	model	 selected	 for	 analysing	
the	DCE	 results.	Methodological	 publications	 (Louviere	 et	 al.,	 2000,	
Ryan	et	al.,	2008,	Hauber	et	al.,	2016)	 indicate	a	number	of	models	
which	to	be	used	for	the	analysis	of	DCE	results	which	allow	for	both	
the	partial	and	 full	 relaxation	of	 the	 IIA.	Whilst	 it	 is	 recognised	 that	
the	 MNL	 model	 used	 is	 the	 ‘workhorse’	 for	 DCE	 analysis,	 it	 was	
beyond	 the	 scope	 of	 this	 research	 to	 explore	 the	 comparisons	 in	
outcomes	 resulting	 from	 the	 analysis	 of	 the	 results	 in	 a	 range	 of	
models.	It	is	recognised	that,	particularly	because	of	the	‘I	would	not	
test	option’,	there	are	other	modelling	approaches	that	it	may	be	of	
further	benefit	to	explore.	Of	the	MNL	approaches,	the	nested	 logit	
model,	which	groups	“subsets	of	alternatives	that	are	more	similar	to	
each	other	with	respect	to	excluded	characteristics	than	they	are	to	
other	alternatives”	(Ryan	et	al.,	2008:28)	is	one	that	warrants	further	
investigation.	 However,	 this	 does	 not	 allow	 for	 the	 full	 extent	 of	
other	 modelling	 approaches	 such	 as	 latent	 class	 modelling	 which	
enables	 relaxation	 of	 the	 IIA	 assumption	 and	 consideration	 of	
random	taste	variation	(ibid.).	
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Of	 the	 other	 stated	 preference	 studies	 identified	 in	 the	 literature	
review	 in	 section	 4.2	 it	 is	 difficult	 to	 draw	 a	 direct	 comparison	 in	
respect	 of	 the	 findings	 because	 of	 the	 variance	 in	 study	 objectives	
relating	to	the	testing	and	treatment	of	STIs,	and	range	of	attributes	
and	levels	included.	Miners	and	colleagues	(2012),	and	Llewellyn	and	
colleagues	 (2013)	 have	 conducted	 the	 only	 other	 DCEs	 exploring	
preferences	 for	 sexual	health	 services	 in	England	however	 focus	on	
preferences	 within	 traditional	 service	 delivery	 models	 rather	 than	
considering	the	use	of	new	technologies.	These	DCEs	are	also	general	
in	respect	of	looking	at	preferences	for	sexual	health	services,	rather	
than	 focusing	 on	 one	 STI.	 It	 is	 not	 known	 when	 expressing	 their	
preferences	 how	 participants	 have	 been	 directed	 to	 consider	 what	
STI	 they	 may	 have.	 As	 identified	 in	 the	 focus	 groups	 with	 young	
people	 and	 expert	 groups	 the	 range	 of	 tests	 is	 an	 important	
consideration	 in	making	 a	 decision	 to	 test	 however	 the	 variance	 in	
treatment	pathways	for	positive	STI	test	results	is	significant	in	so	far	
as	the	ability	to	conduct	a	DCE	across	a	full	pathway.		
	
In	 their	 exploration	 of	 the	 preferences	 for	 chlamydia	 screening	 in	
family	 planning	 clinics	 Watson	 and	 colleagues	 identified	 that	
screening	 at	 a	 family	 planning	 clinic	 increases	 the	 preference	 for	
screening	 whilst	 screening	 at	 home	 “is	 significant	 and	 negative,	
implying	 a	negative	effect	 on	 screening	preference”	 (Watson	et	 al.,	
2009:622).	 This	 is	 at	 odds	with	 the	 finding	within	 this	 study	which	
indicates	 significant	 positive	 preferences	 for	 both	 self-testing,	 and	
self-sampling	 and	 posting	 the	 result	 to	 a	 laboratory	 for	 analysis.	
Reviewing	 the	 studies	 included	 in	 the	 second	 literature	 review	 to	
identify	a	comprehensive	list	of	attributes	for	the	focus	groups,	there	
are	no	studies	which	consider	the	new	technologies	 included	within	
the	DCE.		
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Subsequent	 to	 the	 literature	 review	 of	 stated	 preference	 studies	
outlined	in	Chapter	4,	a	refresh	of	the	literature	search	to	December	
2016	has	identified	two	further	papers	have	been	published	meeting	
the	 inclusion	criteria,	one	exploring	vaginal	microbicide	preferences	
(Primrose	et	al.,	2016)	and	one	exploring	patient	preferences	for	HIV	
clinic	 appointments	 (Miners	 et	 al.,	 2016).	 Miners	 and	 colleagues	
found	 that	 patients	 living	 with	 HIV	 had	 a	 stronger	 preference	 for	
shorter	waiting	times,	however	latent	class	modelling	demonstrated	
the	 two	 groups	 had	 differing	 preferences	 for	 HIV	 clinic	 and	 GP	
appointments	(Miners	et	al.,	2016).		
		
Considering	 the	 findings	 of	 this	 study	 within	 the	 context	 of	 the	
national	 policy	 direction	 of	 increasing	 digital	 access	 (NHS	 England,	
2014),	 and	 reducing	 face-to-face	 appointments	 (Department	 of	
Health,	 2011),	 it	 is	 interesting	 to	 note	 that	 whilst	 the	 lack	 of	 clear	
preference	 does	 not	 inform	 the	 redesign	 of	 pathways	 from	 the	
perspective	 of	 increasing	 uptake,	 the	 ambivalence	 suggests	 that	
alternative,	 more	 cost-efficient	 methods	 could	 be	 employed	 to	
redirect	 clinical	 staff	 time	 e.g.	 achieving	 economies	 of	 scale	 by	
offering	IM	and	email	solutions	over	a	larger	geographic	area.		
	
Within	the	context	of	sexual	health	policy	and	commissioning	sexual	
health	 services,	 this	 DCE	 provides	 some	 evidence	 to	 support	 the	
policy	 direction	 of	 remote	 testing	 and	 treatment	 options.	 It	 offers	
commissioners	 insight	 into	 how	 young	 people	 may	 respond	 to	
changes	to	pathways	and	the	introduction	of	new	technologies.	This	
information	 will	 be	 beneficial	 in	 informing	 piloting	 of	 new	 service	
models.		However,	in	respect	of	the	fully	remote	online	pathway	it	is	
important	 to	note	 that	although	 the	 characteristics	of	 this	pathway	
demonstrate	 that	 should	 it	 exist	 the	probability	 of	 uptake	 is	 higher	
than	 that	 of	 conventional	 sexual	 health	 and	 NCSP	 internet	 testing	
pathways	for	chlamydia,	there	is	still	a	proportion	of	the	population	
who	would	use	these	services.		
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This	 suggests	 that	 whilst	 new	 technology	 has	 a	 role	 to	 play	 in	
increasing	 uptake,	 it	 is	 most	 likely	 as	 an	 additional	 rather	 than	
replacement	option.	
	
For	 technology	 developers	 the	 DCE	 highlights	 important	
considerations	 for	 test	 development,	 namely	 the	 strength	 of	
preference	 for	 test	 accuracy	 over	 other	 product	 characteristics	
included	 within	 the	 DCE.	 From	 the	 perspective	 of	 the	 delivery	 of	
online	 treatment	pathways	 it	 suggests	 that	consideration	should	be	
given	 to	 other	methods	 of	 contacting	 a	 healthcare	 professional	 for	
advice	if	necessary,	particularly	email	and	IM.		
	
There	 are	 a	 number	 of	 questions	 that	 the	 DCE	 does	 not	 answer,	
which	 are	 important	 considerations	 in	 the	 adoption	 of	 new	
technology	 into	 sexual	 health	 services.	 Firstly,	 the	 study	 is	 only	
applicable	to	chlamydia.	Recognising	that	range	of	STIs	to	be	tested	
for	is	an	important	issue	for	young	people	in	choosing	to	test,	further	
research	is	required	to	understand	preferences	within	the	context	of	
other	 STIs	 to	 ensure	 that	 this	 is	 recognised	 in	 future	 service	
pathways.	 The	 complexities	 of	 options	 relating	 to	 testing	 and	
treatment,	 in	particular	what	can	be	delivered	safely	and	effectively	
remotely	mean	that	a	very	different	selection	of	attributes	and	levels	
would	 be	 required	 to	 consider	 this	 which	 would	 not	 be	 able	 to	
consider	the	detailed	pathway	elements	that	this	DCE	has	done.		
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Secondly	the	DCE	did	not	include	a	cost	attribute.	This	was	a	choice	
made	 during	 the	 design	 phase	 of	 the	 research	 as	 it	 is	 a	 legal	
requirement	 that	 local	 authorities	 provide	 open	 access	 STI	 testing	
and	treatment	services,	therefore	under	current	legislation	users	will	
never	pay	a	 fee	 to	use	 the	 service.	However,	 the	 costs	 from	a	user	
perspective	 are	 notably	 different	 for	 different	 service	 options	 in	
terms	of	 their	 time	and	resources	e.g.	 time	off	work,	 travel,	phone,	
internet	access	etc.	Further	research	to	explore	a	user	cost	attribute	
may	add	to	the	understanding	of	the	impact	of	this	factor	on	service	
uptake.		
	
Preferences	for	self-testing	and	eHealth	solutions	within	the	context	
of	 other	 STIs	 is	 one	 of	 a	 number	 of	 potential	 areas	 for	 future	
research.	 The	 DCE	 has	 also	 identified	 a	 number	 of	 other	
considerations	 for	 future	 research	 in	 respect	 of	 service	 delivery	
models,	 as	 well	 as	 some	 considerations	 for	 further	 research	 in	
respect	 of	 the	 DCE	 methodology.	 In	 respect	 of	 service	 delivery	
models,	 as	outlined	previously,	 two	of	 the	areas	warranting	 further	
exploration	are	 the	 routes	of	 access	 to	a	healthcare	professional	 in	
the	 delivery	 of	 treatment	 consultations,	 and	 the	 use	 of	 postal	
solutions	for	the	provision	of	drugs.		
	
In	 respect	 of	 methodological	 considerations,	 a	 number	 of	 issues	
where	 there	 is	 an	 absence	 of	 consensus	 on	 the	 most	 appropriate	
approach	 have	 been	 identified	 which	 may	 warrant	 further	
exploration	to	improve	consistency	in	the	application	of	the	method.	
Firstly,	 the	 number	 of	 choice	 sets	 included	 in	 the	 DCE.	 The	 online	
panel	 feedback	 indicated	 that	 participants	 found	 it	 repetitive,	
whereas	 this	 was	 not	 a	 theme	 identified	 at	 the	 cognitive	 testing	
stage.	 	 Understanding	 the	 extent	 of	 the	 impact	 of	 the	 number	 of	
choice	sets	within	the	questionnaire	in	respect	of	the	internal	validity	
checks	 at	 the	 pilot	 stage	 could	 also	 inform	 the	 final	 questionnaire	
design.		
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A	second	issue	identified	related	to	the	use	of	repeated	choice	sets.	
Both	the	absence	of	consensus	on	which	choice	set	the	data	should	
be	 retained	 from	 and	 whether	 there	 is	 a	 threshold	 at	 which	
inconsistent	 responses	 between	 the	 repeated	 choice	 set	 could	 be	
explored	further	to	consider	whether	it	 is	possible	to	establish	good	
practice	guidelines.		
	
6.8 Summary	
The	DCE	 has	 identified	 that	 the	 strongest	 attribute	 affecting	 young	
people’s	 preferences	 for	 chlamydia	 testing	 and	 treatment	was	 test	
accuracy,	 followed	 by	 time	 to	 result.	 The	 results	 demonstrated	 a	
general	 preference	 for	 remote	 pathway	 options,	 including	 self-
testing	 and	 self-sampling	 and	 posting	 the	 sample	 for	 analysis	 over	
attending	 a	 healthcare	 setting	 for	 testing.	 This	 is	 also	 reflected	 in	
treatment	 preferences,	 with	 participants	 indicating	 a	 general	
preference	for	online	consultation	to	consultation	via	GP,	pharmacy	
or	a	sexual	health	clinic.	Little	difference	was	observed	between	face-
to-face,	 telephone,	 email	 or	 instant	 messaging	 for	 accessing	 a	
healthcare	 professional.	 Interestingly	 the	 preference	 for	 remote	
options	did	not	hold	true	for	this	attribute,	with	face-to-face	contact	
being	 preferable	 to	 telephone	 access	 to	 a	 healthcare	 professional.	
Finally,	there	was	no	significant	difference	in	preference	for	antibiotic	
provision.		
	
Exploring	 the	 optimisation	 of	 pathways	 has	 demonstrated	 the	
potential	impact	of	levels	on	the	uptake	of	services,	both	in	terms	of	
new	pathways,	and	by	optimising	existing	pathways,	demonstrating	
the	 potential	 impact	 that	 substituting	 alternative	 options	 into	
existing	 pathways	 may	 have.	 The	 findings	 suggest	 that	 should	 an	
OCCP	 or	 fully	 remote	 online	 pathway	 be	 available	 a	 higher	
proportion	of	young	people	would	choose	 to	use	 that	 than	existing	
options.		
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The	 next	 chapter,	 Chapter	 7,	 considers	 the	 costs	 and	 benefits	 of	
implementing	 eHealth	 clinics	 for	 the	 treatment	 of	 chlamydia	 and	
Chapter	8	builds	on	this,	taking	forward	the	work	of	Chapter	7	into	a	
preliminary	 economic	 evaluation	 of	 the	 OCCP	 and	 a	 fully	 remote	
online	 pathway	 and	 utilises	 the	 DCE	 coefficients	 identified	 in	 this	
chapter	 to	 explore	 the	 impact	 of	 pathway	uptake	on	 the	 costs	 and	
outcomes	of	asymptomatic	chlamydia	testing	and	treatment.	
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7 CHAPTER	7	–	EXPLORING	THE	COSTS	AND	
CONSEQUENCES	OF	IMPLEMENTING	eHEALTH	CLINICS	
FOR	THE	TREATMENT	OF	CHLAMYDIA	
7.1 Introduction	
This	chapter	presents	the	findings	of	a	literature	review	exploring	the	
costs	 and	 cost-effectiveness	 of	 chlamydia	 testing	 and	 treatment	 in	
the	UK	and	the	primary	costing	of	the	OCCP	developed	by	the	eSTI2	
research	consortium	to	inform	a	preliminary	assessment	of	the	costs	
and	consequences.	The	purpose	of	the	study	was	to	assess	the	likely	
impact	 on	 costs	 of	 the	 introduction	 of	 the	 OCCP	 into	 mainstream	
sexual	health	services.	This	chapter	therefore	centres	on	the	eHealth	
clinic	 component	of	 the	pathway	only.	 In	 the	 following	 chapter	 the	
adoption	of	a	fully	remote	online	pathway	(Pathway	E,	figure	2.1)	will	
be	considered	in	a	decision	analytic	model.	Within	the	frameworks	of	
product	 development,	 HTA	 and	 economic	 evaluation	 outlined	 in	
table	3.5	the	OCCP	can	be	categorised	at	stage	2	in	its	development	–	
translational	research,	early	health	technology	assessment,	maturing	
innovation.	 This	 classification	 of	 the	 technology	 has	 been	 used	 to	
inform	 the	 selection	 of	 methods	 to	 address	 the	 identified	 primary	
research	aim:	to	assess	the	impact	on	costs	of	OCCP	introduction	into	
mainstream	sexual	health	services.	
	
Identified	secondary	objectives	are:	
• To	identify	the	key	issues	in	costing	the	OCCP		
• To	 review	 data	 on	 consequences	 and	 present	 a	 preliminary	
cost	consequence	analysis.	
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Figure	 7.1	 illustrates	 the	 scope	 of	 the	 pathways	 included	 in	 the	
costing	 study.	 This	 starts	 at	 results	 notification	 and	 concludes	
following	health	advisor	follow	up	(indicated	by	the	orange	shading).	
The	 three	 pathways	 included	 are	 GUM	 clinic	 and	 NCSP	 internet	
testing	pathways	(the	comparator	pathways)	and	the	OCCP.	For	this	
exploratory	 study,	 in	 the	 absence	 of	 a	 self-test,	 results	 notification	
was	undertaken	by	participants	logging	into	the	eHealth	clinic	to	get	
their	 results.	 The	 model	 presented	 in	 Chapter	 8	 includes	 the	 full	
pathway.	
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Figure	7.1	-	Scope	of	pathways	included	in	the	costing	study	
	
	
1	–	For	the	OCCP	exploratory	study,	owing	the	absence	of	a	self-test,	results	notification	was	undertaken	via	the	OCCP.	Following	a	text,	patients	
logged	into	the	OCCP	to	access	their	results.
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7.2 Methods	used	to	Identify	the	Costs	and	Consequences	of	
eHealth	Clinics	for	Chlamydia	
7.2.1 Identification	of	Costs	
This	 section	 builds	 on	 the	 high	 level	 introduction	 to	 the	methods	
adopted	 and	 the	 rationale	 for	 their	 selection	 in	 section	 3.5.1,	
setting	 out	 the	 detailed	 methods	 adopted	 to	 cost	 the	 pathways	
included	in	the	costing	study.		
		
7.2.1.1 Definition	of	Decision	Problem	and	Objectives	of	Costing	
Mogyorosy	&	 Smith	 identified	 in	 their	 literature	 review	 that	 the	
definition	 of	 the	 decision	 problem	 has	 an	 impact	 on	 all	
subsequent	 decisions	 in	 the	 evaluation	 (Mogyorosy	 &	 Smith,	
2005).	 This	 stage	 includes	 the	 following	 components:	
identification	of	decision	problem	and	objectives,	the	perspective	
of	costing	and	the	time	horizon	(ibid.)	These	are	considered	in	the	
following	sections.		
	
The	 decision	 problem	 within	 this	 study	 was	 framed	 within	 the	
context	of	eHTA:	to	quantify	the	likely	costs	and	outcomes	of	the	
OCCP	 in	 comparison	 with	 GUM	 and	 NCSP	 internet	 testing	
pathways.	 Drummond	 and	 colleagues	 identify	 a	 number	 of	
perspectives	that	can	be	applied	in	both	the	selection	of	costs	and	
consequences	 including	 the	 individual,	 healthcare	 providers,	
healthcare	purchasers	and	societal	(Drummond	et	al.,	2015).	They	
propose	that	the	perspective	taken	should	reflect	the	perspective	
of	 the	 audience	 intended	 to	 be	 informed	 by	 the	 economic	
evaluation	(ibid.).		It	was	determined	that	the	pathways	would	be	
costed	from	the	perspective	of	a	healthcare	provider	as	the	aim	of	
the	 research	 is	 to	 assess	 the	 impact	 on	 costs	 of	 the	 adoption	of	
the	 OCCP	 into	 mainstream	 sexual	 health	 services,	 this	 is	 in	 line	
with	the	MTEP	defined	approach	(NICE,	2011).	 	
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The	 consideration	 of	 the	 costs	 and	 consequences	 of	 the	
intervention	 for	 the	 immediate	 outcomes	 (process	 measures	
which	 reflect	 uptake	 of	 services)	 is	 beneficial	 to	 both	
commissioners	 and	 providers.	 Commissioners	 because	 the	
separation	 of	 commissioning	 responsibilities	 outlined	 in	 section	
2.4.2	 means	 that	 they	 are	 responsible	 for	 the	 testing	 and	
treatment	 services,	 and	 providers	 because	 similarly	 the	
organisation	 of	 services	 is	 such	 that	 the	 clinical	management	 of	
health	 complications	 would	 take	 place	 in	 other	 services.	
Therefore,	their	focus	will	be	on	understanding	the	impact	within	
their	service	pathways.			
	
7.2.1.2 Description	of	Service	Being	Costed	
Figure	7.1	sets	out	the	pathways	for	the	testing	and	treatment	of	
chlamydia	 and	 the	 elements	 of	 the	 pathway	 included	 in	 the	
costing	study.	The	section	of	the	pathway	to	be	costed	reflects	the	
elements	 provided	 by	 the	 OCCP.	 In	 their	 literature	 review,	
Mogyorosy	 and	 Smith	 summarise	 the	 key	 considerations	 for	
defining	health	 services	 for	 costing,	 those	 relevant	 for	 this	 study	
are	presented	in	table	7.1,	along	with	their	definition:	
	
Service	Definition	
Criteria	
	
OCCP	 GUM	Pathway	 NCSP	Internet	Testing	
Pathway	
Target	Population	 Males	and	females	aged	16	plus,	testing	positive	for	genital	
chlamydia	trachomatis	only		
Type	of	Facility	 Treatment	–	
online	
Drugs	–	collect	
from	pharmacy		
Treatment	-	
GUM	Clinic	
Drugs	–	provided	
at	Clinic	
Treatment	–	varies	
between	areas:	
Pharmacy,	GP,	CaSH,	
GUM	
Drugs	–	GUM	&	CaSH	–	
provided	at	clinic,	GP	&	
Pharmacy	–	community	
pharmacy	
Location	of	
Facilities	
London	Service	 London	Service	
Urban/	Semi-
Rural	Service	
London	Service	
Urban/	Semi-Rural	
Service	
Service	Intensity	 As	target	population	
Service	Mix	 Online	service	 Primarily	
hospital	
delivered	
Primarily	community	
and	primary	care	
delivered	
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Service	Definition	
Criteria	
	
OCCP	 GUM	Pathway	 NCSP	Internet	Testing	
Pathway	
Average	Workload	
by	Provider	
Within	context	of	economic	evaluation	solely	case	mix	related	
to	patients	eligible	to	participate	in	exploratory	study	are	
considered.	
	
Treatment	of	
Adverse	Events	
Referral	to	
GUM	
Managed	in	
service	
Referral	to	GUM	
Type	of	Hotel	
Functions	Used	
Identified	and	costed	as	part	of	the	pathway	mapping	
interviews	
Quality	&	Grade	of	
HCP	staff	involved	
Multiple	potential	different	HCP	staff	involved	as	service	can	
be	delivered	by	doctors,	nurses	and	pharmacists	
Provision	of	Non-
Medical	Elements	
of	the	Service	
Not	applicable	
Criteria	of	
discharge	or	
transfer	
Not	applicable	
Payment	
mechanism6	
Assumed	to	be	cost	per	case	across	all	services.	Not	directly	
relevant	to	costing	study	as	healthcare	provider	perspective	
adopted	
Source	of	Payment	 Local	Authority	 Local	Authority	 Local	Authority	
Table	7.1	-	Description	of	Service	being	Costed	(adopted	from	Mogyorosy	and	Smith,	2005)	
	
7.2.1.3 Identification	of	Resource	Items	and	Units	of	Measure	
As	 previously	 identified,	 the	 perspective	 for	 the	 analysis	 is	 the	
healthcare	 provider;	 this	 perspective	 informs	 the	 selection	 of	
costs	 to	 be	 considered	 within	 the	 analysis	 (Drummond	 et	 al.,	
2015).	 The	 second	 variable	 which	 influences	 the	 approach	 to	
identifying	resource	 items	 is	the	approach	taken	to	costing	(Gray	
et	 al.,	 2011).	 This	 is	 represented	 on	 a	 scale	 of	 precision	 by	
Drummond	and	colleagues,	adapted	in	figure	7.3:		
	
																																																						
6	-	Payment	Mechanism	–	the	basis	on	which	the	healthcare	provider	is	paid	e.g.	cost	per	case	(tariff),	block	
contract	(fixed	value	for	all	activity	undertaken)	
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Figure	7.2	-	Levels	of	Precision	in	Healthcare	Costing,	adapted	from	Drummond	et	al.,	
2015:240	
	
Once	 determined,	 the	 level	 of	 precision	 is	 then	 relevant	 for	 the	
next	 two	 stages	 of	 costing	 (ibid.).	 Brouwer	 and	 colleagues	
recognise	 that	 in	 practice	 the	 majority	 of	 economic	 evaluations	
use	 a	 combination	 of	 these	 approaches	 (Brouwer	 et	 al.,	 2001).	
This	pragmatic	approach	was	adopted	 in	the	OCCP	costing	study.	
For	the	costing	of	the	OCCP,	which	is	not	currently	in	mainstream	
practice,	a	micro-costing	approach	has	been	adopted,	taking	data	
from	the	exploratory	study	to	inform	the	costing	of	the	pathway.	
The	cost	data	was	derived	from:	
• Records	kept	as	part	of	the	study,	
• Data	captured	within	the	clinical	system,	
• Data	recorded	by	the	study’s	heath	advisor,	
• Semi-structured	 interviews	with	 staff	 involved	 in	 the	 trial	
delivery.	
	
There	 was	 one	major	 adaption	made	 to	 the	 pathway	 to	 enable	
prescribing	 of	 azithromycin	 in	 the	 exploratory	 study.	 Owing	 to	
legal	 constraints	on	 the	use	of	 the	electronic	prescribing	 system,	
pre-pack	azithromycin	was	provided	to	community	pharmacies	to	
dispense.	 In	 order	 to	 provide	 a	 costing	 comparative	 to	 current	
pathways,	 this	 has	 been	 costed	 based	 on	 delivery	 within	
mainstream	practice	rather	than	the	study	scenario.	
	
Average	
Daily	Cost
Disease	
Specific	
Daily	Cost
Case-Mix	
Group
Micro-
Costing
Least	Precise Most	Precise
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This	approach	 is	 in	 line	with	 the	type	of	economic	evaluation	 for	
stage	 II	 of	 technology	 development	 identified	 by	 Sculpher	 and	
colleagues	 (Sculpher	et	al.,	 1997).	 They	 recognise	 that	 in	 respect	
of	the	identification	of	costs	there	is	greater	access	to	“individual	
patient	data	on	 the	 costs	 and	outcomes	of	 the	new	 technology”	
however	that	“stage	II	estimates	of	cost	effectiveness	are	unlikely	
to	be	definitive”	(Sculpher	et	al.,	1997:27).		
	
Tate	and	colleagues	highlight	a	number	of	issues	in	identifying	the	
costs	for	online	interventions.	These	include	sunk	costs	–	internet	
interventions	 often	 have	 a	 large	 upfront	 non-recurrent	 cost	 that	
relate	to	the	development	of	the	technology	and	the	useful	life	of	
the	 intervention	 –	 how	 long	 it	 can	 exist	 without	 the	 need	 to	
update/	 upgrade	 (Tate	 et	 al.,	 2009).	 They	 clarify	 that	 sunk	 costs	
should	not	be	included	in	economic	evaluation	as	they	would	not	
recur	if	the	intervention	were	implemented	on	a	larger	scale,	and	
that	 future	costs	 for	updating	 the	 technology	should	be	 included	
(ibid).	In	addition,	they	address	the	issue	of	how	the	fixed	costs	of	
internet	 interventions	 (e.g.	 website	 hosting	 and	 maintenance)	
should	 be	 addressed.	 Their	 recommendation	 is	 that	 the	 likely	
uptake	of	 the	 internet	 intervention	 should	be	estimated	and	 the	
fixed	 cost	 converted	 to	 a	 per	 patient	 cost	 to	 enable	 comparison	
(ibid).	 Their	 recommendations	 have	 been	 adopted	 in	 the	 OCCP	
costing	study.	
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In	 order	 to	 enable	 the	 identification	 of	 resource	 items	 for	 the	
comparator	pathways,	a	literature	review	has	been	undertaken	to	
identify	 studies	 reporting	 the	 costs	 and	 cost-effectiveness	 of	
elements	of	 the	chlamydia	 testing	and	treatment	pathway	 in	 the	
UK.	 The	methods	 and	 findings	 are	 presented	 in	 section	 7.3.	 This	
review	identified	sufficient	 information	to	cost	the	pathway	from	
a	GUM	clinic	perspective.	However,	gaps	 in	the	literature	did	not	
allow	an	establishment	of	costs	for	a	comparative	GUM	clinic	and	
NCSP	internet	testing	pathways.		
	
To	 address	 this,	 a	 primary	 costing	 study	 was	 developed	 and	
undertaken	 to	 collect	 information	 on	 GUM	 and	 NCSP	 internet	
testing	pathways	 to	enable	establishment	of	 the	 reference	 cases	
for	 comparison	 with	 the	 OCCP.	 This	 included	 semi-structured	
interviews	with	 commissioners	 initially,	 and	 follow	up	 interviews	
with	service	providers.	The	objectives	of	the	study	were	to:	
• Map	 the	 GUM	 testing	 pathway	 –	 to	 gain	 a	 detailed	
understanding	of	and	 identify	resource	 items	and	units	of	
measure	 for	 the	 delivery	 of	 the	 asymptomatic	 chlamydia	
treatment	pathway,	
• Map	the	NCSP	internet	testing	pathway	–	to	gain	a	detailed	
understanding	of	and	 identify	resource	 items	and	units	of	
measure	 for	 the	 delivery	 of	 the	 chlamydia	 treatment	
pathway,	
• Identify	 the	 contractual	 arrangements	 surrounding	 this	 –	
to	 understand	 the	 contractual	 arrangements	 of	 the	
pathway,	for	example	whether	the	full	pathway	is	provided	
in	 house	 or	 elements	 are	 sub-contracted	 to	 other	
providers,	
• Identify	 performance	 data	 –	 to	 identify	 data	 for	 the	 key	
process	measures	 relating	 to	 the	 pathway	 e.g.	 treatment	
uptake,	partner	notification	rate.		
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Recognising	the	difference	in	healthcare	delivery	models	between	
London	 and	 other	 parts	 of	 England,	 the	 study	 costed	 one	 GUM	
pathway	 (outside	 of	 London),	 and	 two	 NCSP	 internet	 testing	
pathways	 (one	 in	 London,	 one	 outside	 of	 London).	 A	 GUM	
pathway	 in	 London	 was	 not	 costed	 because	 access	 to	 study	
participants	 in	 London	 was	 challenging	 owing	 to	 a	 major	 re-
procurement	 exercise	 being	 undertaken	 by	 the	 London	 Local	
Authorities	in	2015-16.		
	
Interviews	 were	 selected	 over	 other	 methods	 such	 as	 postal	
surveys	 because	 a	 written	 questionnaire	 response	 would	 have	
been	laborious	for	participants	to	complete,	owing	to	the	number	
of	supplementary	questions	which	would	be	required	in	a	written	
questionnaire.	 These	 could	 be	 managed	 more	 effectively	 in	 an	
interview.		
	
Standard	 process	 mapping	 techniques	 endorsed	 by	 the	 NHS	
Institute	 for	 Innovation	 and	 Improvement	 (NHS	 Institute	 for	
Innovation	 and	 Improvement,	 2013)	 were	 used	 as	 the	 basis	 for	
interview	schedules	 (for	an	example	 see	Appendix	15).	 Interview	
schedules	were	tailored	to	commissioners	and	providers,	adapted	
depending	on	responses	from	previous	interviews.	
	
7.2.1.4 Measurement	of	Resource	Use	
“Ideally,	 resource	 utilisation	 measurement	 should	 be	
comprehensive,	 reliable,	valid	and	representative”	 (Mogyorosy	&	
Smith,	 2005:47).	 The	 scale	 of	 precision	 proposed	 by	 Drummond	
and	 colleagues	 is	 equally	 as	 applicable	 to	 resource	 unit	
measurement	as	it	 is	to	the	identification	of	costs	(Drummond	et	
al.,	 2015).	Mirroring	 the	 scale	 of	 precision,	 there	 are	 a	 range	 of	
approaches	to	measurement	of	resource	use.		
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Brouwer	and	colleagues	highlight	a	number	of	 issues	 to	consider	
in	the	collection	of	resource	use	data	including	“the	perspective	of	
the	 study,	 the	 requirements	 for	 representativeness	 and	
generalisability,	 the	 (expected)	 impact	 of	 the	 specific	 resource	
item	on	total	or	incremental	costs,	and	the	availability	of	existing	
data	and	the	effort	needed	to	collect	additional	data”	(Brouwer	et	
al.,	2001:73).	
	
Mogyorosy	and	Smith	summarise	a	range	of	techniques	and	their	
advantages	 and	 disadvantages	 in	 their	 literature	 review.	 These	
include	 time	 and	 motion	 studies,	 manager	 surveys,	 service	 use	
questionnaires	 and	 interviews,	 medical	 case	 record	 review,	
account	 classification,	 self-reported	 activity	 logs,	 postal	 surveys,	
self-reported	 questionnaires,	 cost	 diaries,	 relative	 value	 scale	
approach	 and	 diagnostic	 related	 groups	 (Mogyorosy	 and	 Smith,	
2005).		
	
A	number	of	techniques	have	been	used	to	measure	the	resource	
inputs	 in	 the	OCCP	costing	 study;	 these	are	 summarised	 in	 table	
7.2:	
Pathway	 Resource	Unit	Measurement	Used	
OCCP	 • Resource	data	captured	as	part	of	
the	exploratory	study	
• Interviews	with	health	advisor	and	
supervisory	clinician	
• Review	of	budget	statements		
GUM	Clinic	 • Previously	published	study	
• Interview	with	lead	nurse,	service	
manager	and	accountant	
• Review	of	budget	statements	
NCSP	Internet	Testing	
Pathway	
• Interview	with	service	lead,	
commissioning	lead,	pharmacist	
and	accountant	
• Review	of	budget	statements	
Table	7.2	-	Summary	of	Resource	Unit	Measurement	Techniques	Used	
	
	 	
		 362	
It	can	be	seen	that	the	techniques	used	in	the	OCCP	costing	study	
align	 to	 the	micro	 costing	 end	of	 the	 spectrum	of	 precision.	 The	
benefits	 of	 the	 approach	 taken	 are	 that	 the	 data	 are	 easily	
accessible	and	provide	an	indicative	measure	of	resource	use	from	
people	with	a	high	degree	of	knowledge	about	how	the	service	is	
delivered,	 without	 the	 intensive	 input	 required	 to	 undertake	
individual	activity	based	costing	through	time	and	motion	studies	
and	individual	patient	costing	(Mogyorosy	and	Smith,	2005).			
	
7.2.1.5 Assignment	of	Monetary	Values	to	Resources	
There	are	a	range	of	national	data	sources	which	can	be	used	to	
assign	monetary	values	 in	 the	UK.	These	 include	reference	costs,	
unit	 costs	 of	 health	 and	 social	 care	 and	 the	NHS	electronic	 drug	
tariff	 (Drummond	et	al.,	2015,	Gray	et	al.,	2011,	McIntosh	et	al.,	
2010,	PSSRU,	2015,	Department	of	Health,	2015).		
	
The	data	sources	selected	to	cost	the	pathways	are	summarised	in	
table	 7.3.	 The	 detail	 for	 every	 unit	 cost	 included	 in	 the	 costing	
study	is	summarised	in	section	7.6.1.		
Cost	Type	 Data	Source	
Staff	Costs	 Unit	Costs	of	Health	and	Social	Care	2015	
(PSSRU,	2015)	
Consumable	Costs	 Identified	as	part	of	costing	exercise	
Drugs	Costs	 NHS	Electronic	Drug	Tariff	(primary	care)	
Hospital	pharmacy	(secondary	care)	
Table	7.3	-	Summary	of	Data	Sources	for	Costing	
The	 decision	 to	 use	 these	 data	 sources	was	made	 based	 on	 the	
approach	 taken	 to	 costing,	 as	 using	 reference	 costs	 would	 not	
enable	 costing	with	 sufficient	 accuracy	 because	 the	 specification	
of	 the	 reference	 cost	 does	 not	 map	 onto	 to	 units	 in	 which	
elements	 of	 the	 pathway	 are	 costed.	 The	 activity	 was	 costed	 at	
2015	 prices	 (£GBP);	 where	 necessary	 the	 NHS	 Hospital	 and	
Community	Health	Services	 (HCHS)	pay	and	prices	 inflation	 index	
(Department	 of	 Health,	 2016a)	 was	 applied	 to	 inflate	 costs	 to	
current	prices.	
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7.2.2 Identification	of	Consequences	
The	study	protocol	for	the	OCCP	exploratory	study	identified	the	
clinical	outcome	measures	set	out	in	table	7.4:	
Primary	Outcome	Measure	
“The	proportion	of	people	who	test	positive	for	genital	C.trachomatis	
infection	(index	patients)	and	the	proportion	of	those	who	are	managed	
through	the	eSTI2	 clinical	care	pathway	who	receive	appropriate	clinical	
management*.	
	
*as	defined	by	BASHH	National	Standards	for	management	of	genital	
C.trachomatis.”	
Secondary	Outcome	Measures	
“Proportion	of	index	patients	who	receive	antibiotic	treatment	solely	
through	the	electronic	element	of	the	eSTI2	 chlamydia	clinical	care	
pathway.	
Time	from	index	patient	receiving	diagnosis	to	receiving	appropriate	
treatment.	
Proportion	of	sex	partners	treated.	
Time	from	index	patient	receiving	diagnosis	to	sex	partner	receiving	
appropriate	treatment.”	
	
Table	7.4	-	Outcome	Measures	for	the	eSTI2	Proof	of	Concept	Study	(eSTI2,	
2013:10)	
Whilst	 identified	in	the	study	protocol	for	the	exploratory	study	as	
clinical	 outcome	 measures	 it	 is	 important	 to	 note	 these	 are	 not	
health	outcome	measures,	they	are	process	measures.	As	outlined	
in	 section	 3.5.1	 these	 are	 also	 important	 considerations	 in	 the	
evaluation	 of	 complex	 interventions,	 and	 are	 defined	 within	 the	
NICE	MTEP	guidance	as	system	outcomes	“a	non-clinical	outcome,	
typically	 impacting	 on	 resource	 capacity,	 resulting	 from	 a	 clinical	
(patient-level)	treatment	episode”	(NICE,	2011:28).	
	
These	 outcomes	 are	 suitable	 for	 considering	 the	 short-term	
consequences	of	 the	adoption	of	 the	eHealth	clinic,	 i.e.	 compared	
with	the	delivery	of	routine	treatment	for	chlamydia	through	GUM	
and	NCSP	internet	testing	pathways:	
• Does	the	treatment	uptake	rate	increase?	
• Does	the	partner	notification	rate	increase?		
• Does	the	time	to	treatment	decrease?	
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All	 of	 the	 intermediate	 (process)	 outcomes	 are	 important	 in	
considering	the	final	outcomes	for	chlamydia	treatment,	recognised	
primarily	as	health	complications	arising	from	untreated	chlamydia	
(also	 known	 as	 major	 outcomes).	 These	 include	 PID,	 ectopic	
pregnancy,	 infertility,	 PROM,	 neonatal	 pneumonia	 and	
conjunctivitis,	epididymitis	in	men.	These	will	be	explored	further	in	
Chapter	8.	
	
The	 decision	 to	 use	 intermediate	 (process/system)	 outcomes	
alongside	 the	 costing	 study	 reflects	 that	 the	 consequences	 of	
untreated	 chlamydia	 can	 go	 undetected	 for	 a	 number	 of	 years,	
however	process-based	outcomes	offer	 insight	 into	the	 immediate	
impact	of	the	pathway	change.	This	also	aligns	to	Pietzsch	and	Paté-
Cornell’s	 view	 of	 the	 scope	 of	 eHTA,	 particularly	 the	 decision	
support	 function	 for	 developers	 to	 design	 and	
develop/manufacture	 the	 new	 technology	 (Pietzsch	 and	 Paté-
Cornell,	 2008).	 The	 intermediate	 outcomes	 centre	 on	 the	 direct	
changes	(both	positive	and	negative)	to	the	service	pathway.	
	
To	 identify	 the	 outcomes	 for	 patients	 participating	 in	 the	 OCCP	
exploratory	study,	the	system	was	designed	to	capture	information	
on	 the	 outcome	 measures	 listed	 in	 table	 7.4.	 To	 identify	 the	
outcome	 measures	 for	 the	 comparator	 pathways,	 two	 literature	
searches	 were	 undertaken,	 the	 first	 to	 identify	 studies	 published	
since	 2005	 which	 consider	 the	 costs	 or	 cost-effectiveness	 of	
chlamydia	 testing	 and	 treatment	 in	 the	 UK	 and	 the	 second	 to	
identify	published	studies	providing	data	on	outcomes.	The	search	
strategies	 and	 results	 of	 the	 literature	 reviews	 are	 presented	 in	
sections	7.3	and	7.4	respectively.	
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7.3 Literature	Review	–	Costs	and	Cost	Effectiveness	of	
Chlamydia	Testing	and	Treatment	in	the	UK	
The	 objective	 of	 the	 literature	 review	was	 to	 identify	 and	 evaluate	
published	 studies	 exploring	 the	 costs	 and	 cost-effectiveness	 of	 the	
chlamydia	testing	and	treatment	in	the	UK	to:	
• Identify	 relevant	 resource	 items,	units	of	measure	and	 costs	
for	the	OCCP	costing	study,	
• Examine	 the	 economic	 models	 used	 to	 consider	 cost-
effectiveness	
• Identify	the	outcomes	used	in	modelling	cost-effectiveness.	
	
The	inclusion	criteria	were	identified	as:	
• any	cost-effectiveness	or	costing	study	within	the	scope	of	STI	
testing	and	treatment	services.	This	 includes	both	chlamydia	
screening	 and	 chlamydia	 testing	 delivered	 in	 sexual	 health	
clinics	
• studies	 published	 between	 2005	 and	 2015.	 This	 date	 range	
was	selected	to	reflect	the	significant	changes	in	the	delivery	
of	 sexual	 health	 services	 in	 England,	 summarised	 in	 section	
2.4.1.	
	
The	exclusion	criteria	were	identified	as	studies:	
• not	related	to	humans	
• not	published	in	English	
• from	outside	of	the	UK	
• that	 do	 not	 relate	 to	 the	 costs	 or	 cost-effectiveness	 of	 an	
aspect	 of	 the	 chlamydia	 testing	 and	 treatment	 pathway	 as	
defined	in	section	2.4.4.	
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7.3.1 Search	Strategy	
The	 following	 databases	 were	 searched	 on	 22	 February	 2015	 to	
identify	 studies	 published	 to	 the	 end	 of	 2014	 and	were	 re-run	 in	
April	2016	to	search	for	any	studies	published	between	1	January	–	
31	December	2015:	
• Medline	
• EMBASE	
• PROQUEST	–	Theses	&	Dissertation	Search	
• Econlit	
• Cochrane	Library	(incorporating	the	following	databases):	
o Cochrane	Database	of	Systematic	Reviews	
o Cochrane	Central	Register	of	Controlled	Trials	
o Cochrane	Methodology	Register	
o Database	of	Abstracts	of	Reviews	of	Effects	
o Health	Technology	Assessment	Database	
o NHS	Economic	Evaluation	Database.	
	
The	key	search	terms	and	their	abbreviated	database	entry	(where	
applicable,	abbreviation	example	from	Medline)	are	summarised	in	
table	7.5,	the	full	Medline	search	is	included	in	Appendix	16.		Search	
terms	were	identified	from	books	and	papers	outlining	methods	for	
economic	 evaluation	 and	 systematic	 reviews	 of	 economic	
evaluation	 (Drummond	 et	 al.,	 2005,	Mistry,	 2011).	 Searches	were	
structured	in	the	databases	to	meet	the	search	requirements	of	the	
respective	database	and	terms	expanded	where	the	facility	existed	
to	 do	 this.	 The	 use	 of	 expanded	 terms,	 in	 particular	 “cost	 benefit	
analysis”	 and	 “costs	 and	 cost	 analysis”	 which	 include	 key	 terms	
such	 as:	 cost,	 cost	 analysis,	 cost	 comparison,	 cost	 measures	 and	
costs	 and	benefits	 enabled	 the	 search	 to	 capture	 relevant	 costing	
studies	as	well	as	economic	evaluations.		
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Category	 Search	Terms	Entered	
Chlamydia	 Chlamydia	
Chlamydia	Trachomatis	
	 AND	
Economic	Evaluation	 Cost	effective	
Cost	benefit	
Cost	utility	
Cost	minimi*	
Cost	consequence	
CEA	
CBA	
CUA	
CMA	
CCA	
Economic	analys*	
Economic	evaluation	
Economic	model*	
Cost	analys*	
Costs		
	Table	7.5	-	Search	Terms	taken	from	the	Medline	Search	
	 	
The	results	were	imported	into	Endnote	x7	for	Mac	and	duplicates	
removed.	 The	 titles	 and	 abstracts	 were	 reviewed	 and	 studies	
excluded	for	the	following	reasons:	
• Not	an	economic	evaluation	or	 costing	 study.	Note	 studies	
which	incorporated	both	clinical	and	cost	effectiveness	were	
included	
• Study	did	not	focus	on	chlamydia	
• Not	 a	 study/	 systematic	 review	 e.g.	 abstract	 only,	 study	
protocol	
• Study	not	conducted	in	the	UK.		
	
To	 assess	 the	 quality	 of	 retrieved	 articles,	 a	 number	 of	 checklists	
were	identified	including	that	by	Drummond	and	colleagues	(2005),	
the	Critical	Appraisal	Skills	Programme	(2013)	and	the	Consolidated	
Health	 Economic	 Evaluation	 Reporting	 Standards	 (CHEERS)	
Statement	(Husereau	et	al.,	2013).		
	 	
		 368	
There	are	a	number	of	similarities	between	the	three	however	the	
CHEERS	 statement	 was	 selected	 as	 reporting	 checklists	 are	
designed	 to	 facilitate	 the	 reporting	 of	 full	 information	 about	 the	
study	in	articles,	whereas	appraisal	tools	are	designed	to	assess	the	
adequacy	 of	 methods	 (Altman,	 2013).	 For	 costing	 studies,	 no	
reporting	 checklist	 was	 identified;	 therefore	 the	 CHEERS	 checklist	
was	used	with	criteria	not	applicable	 to	costing	 studies	 (six	 items)	
removed.			
	
7.3.2 Search	Results	
The	 initial	 search	 identified	 600	 records	 and	 59	 duplicates	 were	
removed	in	Endnote	leaving	541	for	initial	review.	The	re-run	of	the	
searches	to	identify	studies	published	in	2015	identified	71	records	
and	17	duplicates	were	removed,	 leaving	54	for	 initial	 review.	The	
titles	 and	 abstracts	 were	 reviewed	 for	 each	 exclusion	 criterion	 in	
turn;	leaving	a	total	of	21	studies	that	met	the	inclusion	criteria	for	
full	review.		
	
The	 search	 results	 are	 illustrated	 in	 the	 PRISMA	 flowchart,	 figure	
7.3:	
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Figure	7.3	-	PRISMA	Flowchart	
	
The	reasons	for	the	exclusion	of	studies	at	the	screening	stage	are	
summarised	in	table	7.6:	
	
Reasons	for	Exclusion	at	Screening	Stage	 Number	of	
Studies	
Excluded	
Not	an	economic	evaluation	or	costing	study	 453	
Study	does	not	include	Chlamydia	 30	
Not	a	study/	systematic	review	e.g.	abstract	only,	study	
protocol	
30	
Study	not	in	the	UK	 61	
Table	7.6	-	Reasons	for	Exclusion	of	Papers	at	Screening	Stage	
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A	further	seven	studies	were	excluded	at	the	full	text	review:	
Reasons	for	Exclusion	at	Full	Text	Review	 Number	of	
Studies	
Excluded	
Systematic	or	other	literature	review	–	all	included	UK	
studies	outside	of	date	range	
3	
PhD	Thesis	–	Study	Reported	in	Publication	Included	in	
Review	
2	
Study	outside	of	UK	–	not	identified	from	abstract	 1	
Systematic	review	–	not	including	any	element	of	
chlamydia	testing	and	treatment	pathway	
1	
Table	7.7	-	Studies	excluded	after	full	text	review	 	
	
7.3.3 Data	Extraction	
The	 data	 extraction	 form	 was	 designed	 to	 take	 into	 account	 the	
review	 question,	 adopting	 the	 approach	 outlined	 in	 section	 4.3.4.	
Data	were	extracted	 into	an	electronic	 template	prepared	 in	Excel	
for	Mac	2010.		
	
7.3.4 Key	Findings	
In	 total	 14	 studies	met	 the	 inclusion	 criteria;	 three	 studies	 had	 a	
focus	on	chlamydia	testing	(Hislop	et	al.,	2010,	Jackson	et	al.,	2015	
and	 Turner	 et	 al.,	 2014),	 four	 studies	 focused	 on	 partner	
notification	 (Althaus	 et	 al.,	 2014,	 Cassell	 et	 al.,	 2015,	 Low	 et	 al.,	
2006	 and	 Roberts	 et	 al.,	 2012),	 and	 seven	 studies	 took	 a	 broad	
overview	of	a	chlamydia	testing	and	treatment	pathway	(Adams	et	
al.,	2007,	Bracebridge	et	al.,	2012,	Kelly	et	al.,	2014,	Looker	et	al.,	
2015,	 Low	 et	 al.,	 2007,	 Robinson	 et	 al.,	 2007	 and	 Turner	 et	 al.,	
2011).	A	summary	of	the	studies	included	in	the	review	is	presented	
in	table	7.8.	
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Table	7.8	-	Summary	of	Included	Studies	
Ref	 Author	 Study	Focus	 Type	of	Study	 Country	of	
Study	
Standalone	Reporting/	
Integrated	with	Clinical	
Effectiveness	
New	
Technology?	
1.	 Adams	et	al.	(2007)	 Opportunistic	Chlamydia	Screening	 CEA	 England	 Standalone	 No	
2.	 Althaus	et	al.	(2014)	 Partner	Notification	technologies	 CEA		 England	 HTA	containing	standalone	
economic	evaluation	
Yes	
3.	 Bracebridge	et	al.	(2012)	 Postal	Chlamydia	screening	and	treatment	 CCA	 England	 Integrated	 No	
4.	 Cassell	et	al.	(2015)	 Partner	Notification	 Cost	Analysis	 England	 HTA	containing	standalone	
economic	evaluation	
Yes	
5.	 Hislop	et	al.	(2010)	
	
Rapid	POCT	for	Chlamydia	testing	 CCA	&	CEA	 England	 HTA	containing	standalone	
economic	evaluation	
Yes	
6.	 Jackson	et	al.	(2015)	 Chlamydia	Screening	in	Football	Club	Settings	 CCA	 England	 Standalone	 No	
7.	 Kelly	et	al.	(2014)	
	
Chlamydia	Testing	within	primary	care	level	1	
sexual	health	service	
Cost	Analysis	 Northern	
Ireland	
Integrated	 No	
8.	 Looker	et	al.	(2015)	 Chlamydia	Testing	 CEA	 Scotland	 Standalone	 No	
9.	 Low	et	al.	(2006)	 Partner	Notification	 CCA	 England	 Integrated	 No	
10.	 Low	et	al.	(2007)	 Proactive	Chlamydia	Screening	 CEA	 England	 HTA	containing	standalone	
economic	evaluation	
No	
11.	 Roberts	et	al.	(2012)	 Accelerated	Partner	Therapy	 CCA	 England	 Standalone	 Yes	
12.	 Robinson	et	al.	(2007)	 Proactive	Chlamydia	Screening	 Cost	Analysis	 England		 Standalone	 No	
13.	 Turner	et	al.	(2011)	
	
Chlamydia	Screening	&	Partner	Notification	 CEA	 England	 Standalone	 No	
14.	 Turner	et	al.,	(2014)	 Chlamydia	POCT		 CEA	 England	 Integrated	 Yes	
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Of	 the	 14	 included	 studies,	 three	 were	 cost	 analyses,	 seven	 cost	
effectiveness	 analyses	 and	 five	 cost	 consequence	 analyses	 (one	
study	 included	 both	 a	 cost	 effectiveness	 analysis	 and	 a	 cost	
consequence	analysis,	Hislop	et	al.,	2010)	as	identified	in	table	7.8.	
Six	 studies	 were	 standalone	 economic	 evaluations,	 four	 were	
integrated	 with	 a	 clinical,	 product	 or	 service	 evaluation	 and	 four	
were	 economic	 evaluations	 within	 HTA	 reports.	 Five	 studies	
introduced	 a	 new	 technology	 into	 their	 costing	 study/	 economic	
evaluation:	
• Three	 relating	 to	 partner	 notification	 (Althaus	 et	 al	 2014.,	
Cassell	et	al.,	2015	and	Roberts	et	al.,	2012),	
• Two	 relating	 to	 rapid	 point	 of	 care	 testing	 for	 chlamydia,	
one	 using	 EIA	 in	 a	 family	 planning	 setting	 (Hislop	 et	 al.,	
2010),	and	one	using	NAAT	in	a	GUM	clinic	setting	(Turner	et	
al.,	2014).	
	
The	 remaining	 nine	 studies	 were	 pathway	 related.	 Four	 studies	
considered	 the	 introduction	of	 chlamydia	 screening	 (Adams	et	 al.,	
2007,	Looker	et	al.,	2015,	Low	et	al.,	2015,	Robinson	et	al.,	2007),	
and	the	final	five	looked	at	the	impact	of	changes	to	the	chlamydia	
screening	pathways	including:	
• a	 fully	 remote	 postal	 testing	 pathway	 (Bracebridge	 et	 al.,	
2012),	
• chlamydia	screening	in	football	club	settings	(Jackson	et	al.,	
2015),	
• establishing	chlamydia	testing	within	a	 level	1	primary	care	
service	(Kelly	et	al.,	2014),		
• changes	to	the	delivery	of	partner	notification	method	(Low	
et	al.,	2006),	
• changes	to	intervention	strategies	(Turner	et	al.,	2011).	
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7.3.5 Quality	Assessment	
Each	 article	 was	 assessed	 against	 the	 relevant	 sections	 of	 the	
CHEERS	 checklist	 and	 evidence	 inputted	 into	 the	 data	 extraction	
sheet.	 The	 findings	 were	 then	 summarised	 to	 indicate	 whether	
there	 was	 evidence	 of	 full,	 partial	 or	 no	 achievement	 of	 the	
indicator,	or	whether	this	was	not	applicable	where	it	was	possible	
to	determine	this	 from	the	article.	The	outcome	of	 this	exercise	 is	
summarised	in	table	7.9.	
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Title	&	Abstract	
1. Title	identifies	study	as	economic	
evaluation	
ü	 ü	 û	 ü	 ü	 ü	 û	 ü	 û	 ü	 ü	 ü	 ü	 ü	
2. Abstract		 ü	 ü	 ü	 p	 p	 ü	 p	 p	 p	 p	 ü	 ü	 ü	 ü	
Introduction	
3. Background	&	Objectives	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
Methods	
4. Target	Population	&	Subgroups	 ü	 û	 ü	 û	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
5. Setting	&	Location	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 p	 ü	 ü	 ü	 ü	
6. Study	Perspective	 ü	 ü	 p	 ü	 ü	 ü	 û	 û	 û	 û	 ü	 ü	 ü	 ü	
7. Comparators	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 n/a	 ü	 ü	
8. Time	Horizon	 ü	 û	 û	 û	 ü	 û	 û	 p	 û	 ü	 û	 û	 û	 û	
9. Discount	Rate	 ü	 û	 û	 û	 ü	 p	 û	 û	 û	 ü	 û	 û	 û	 û	
10. Choice	of	Health	Outcomes	 ü	 û	 û	 n/a	 ü	 û	 n/a	 ü	 û	 ü	 û	 n/a	 û	 ü	
11. Measurement	of	effectiveness	 ü	 ü	 ü	 n/a	 ü	 ü	 n/a	 p	 ü	 ü	 ü	 n/a	 ü	 ü	
12. Measurement	&	Valuation	of	
Preference	Based	Outcomes	(if	
n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 ü	
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applicable)	
13. Estimating	resources	and	costs		 ü	 ü	 ü	 ü	 ü	 p	 ü	 p	 ü	 ü	 ü	 ü	 ü	 p	
14a.	Currency	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
14b.	Price	Date	 ü	 p	 ü	 ü	 ü	 ü	 ü	 û	 ü	 ü	 ü	 ü	 ü	 û	
14c.	Conversion	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	
15.	Choice	of	Model	 ü	 p	 û	 n/a	 ü	 n/a	 n/a	 ü	 û	 ü	 n/a	 n/a	 ü	 ü	
16.	Assumptions	 ü	 ü	 ü	 ü	 ü	 ü	 û	 ü	 û	 ü	 û	 û	 ü	 ü	
17.	Analytic	Methods	 ü	 ü	 û	 n/a	 ü	 ü	 n/a	 ü	 û	 ü	 ü	 n/a	 ü	 ü	
Results	
18. Study	Parameters	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
19. Incremental	costs	and	outcomes	 ü	 û	 ü	 n/a	 ü	 n/a	 n/a	 ü	 ü	 ü	 ü	 n/a	 ü	 ü	
20. Characterising	uncertainty		 ü	 ü	 û	 n/a	 ü	 ü	 û	 ü	 û	 ü	 ü	 ü	 ü	 ü	
21. Characterising	heterogeneity	(if	
applicable)	
ü	 n/a	 p	 n/a	 ü	 n/a	 ü	 n/a	 n/a	 ü	 ü	 n/a	 ü	 n/a	
Discussion	
22. Discussion	-	Study	findings	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
23. Discussion	-	Limitations	 ü	 ü	 û	 ü	 ü	 ü	 û	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
24. Discussion	-	Generalisability	 p	 ü	 p	 û	 û	 ü	 p	 ü	 p	 û	 ü	 ü	 ü	 ü	
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25. Discussion	-	Current	Knowledge	 ü	 ü	 p	 û	 û	 ü	 p	 ü	 p	 û	 ü	 ü	 ü	 ü	
Other	
26. Source	of	funding	 ü	 ü	 û	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
27. Conflicts	of	interest	 ü	 ü	 ü	 û	 û	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
	
Table	7.9	-	Summary	of	Quality	Assessment	Against	CHEERS	Checklist	
Key:	ü	=	Met,	p	=	partially	met,	û	=	no	evidence	reported,	n/a	=	not	applicable.	
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The	 following	 sub-sections	 present	 the	 high-level	 findings	 of	 the	
assessment	of	 studies	against	 the	 relevant	sections	of	 the	CHEERS	
checklist.		 	
	
7.3.5.1 Reporting	of	Title,	Abstract	&	Introduction	
Of	the	three	studies	whose	titles	did	not	identify	them	as	a	costing	
study	or	economic	evaluation	(Bracebridge	et	al.,	2012,	Kelly	et	al.,	
2014,	 Low	 et	 al.,	 2006)	 the	 economic	 analysis	 was	 reported	
alongside	 a	 clinical	 or	 service	 evaluation.	 Similarly,	 where	
abstracts	 partially	met	 the	 checklist	 requirements,	 the	 economic	
analysis/	costing	study	was	reported	as	part	of	an	HTA,	or	as	part	
of	 another	 evaluation.	 The	 exception	 to	 this	 was	 the	 study	
published	by	Looker	and	colleagues	(2015)	whose	article	focused	
on	 the	 mathematical	 modelling	 component	 of	 the	 economic	
evaluation	rather	than	the	evaluation.	 In	this	study	the	reporting	
focused	 on	 the	 construction	 of	 the	 model	 rather	 than	 the	
economic	evaluation.	
	
7.3.5.2 Reporting	of	Methods	
Key	 elements	 from	 the	 methods	 section	 of	 the	 checklist	 are	
summarised	 in	 table	 7.10	 at	 the	 end	 of	 this	 section.	 Almost	 all	
studies	were	 clear	 on	 their	 target	 population	 and	 subgroups	 for	
the	setting	of	the	study.	In	respect	of	the	study	perspective	for	the	
analysis,	 four	 of	 the	 fourteen	were	not	 clear	 (Bracebridge	 et	 al.,	
2012,	Kelly	et	al.,	2014,	Looker	et	al.,	2015,	and	Low	et	al.,	2007)	
and	a	further	seven	indicated	the	perspective	of	the	health	service	
or	NHS	 but	 did	 not	 state	whether	 this	was	 the	 commissioner	 or	
provider	 perspective	 (Adams	 et	 al.,	 2007,	 Althaus	 et	 al.,	 2014,	
Cassell	et	al.,	2015,	Jackson	et	al.,	2015,	Low	et	al.,	2006	Roberts	
et	al.,	2012	and	Robinson	et	al.,	2007).		
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In	 the	 majority	 of	 cases	 it	 was	 possible	 to	 deduce	 whether	 a	
healthcare	commissioner	or	provider	perspective	has	been	taken	
from	the	reporting	of	resources	and	costs.	For	example,	“the	cost	
agreed	with	the	provider	per	posted	kit	was	£12”	(Bracebridge	et	
al.,	 2012:377)	 suggests	 a	 healthcare	 commissioner	 perspective,	
along	 with	 “an	 analysis	 of	 the	 cost	 of	 providing	 the	 service	 in	
primary	 care	 included	 the	 LES	 tariff”	 (Kelly	 et	 al.,	 2014:752),	
whereas	statements	such	as	“we	obtained	the	hourly	rates	of	pay	
(including	employer	 contributions)”	 (Low	et	 al.,	 2006:2)	 and	 “we	
measured	the	time	taken	to	complete	each	labour	dependent	step	
for	 the	 diagnostic	 tests”	 (Robinson	 et	 al.,	 2007:277)	 suggest	 a	
provider	 perspective.	 As	 highlighted	 by	 the	 NICE	 costing	 impact	
guidance	 (NICE,	 2011a)	 and	 Mogyorosy	 and	 Smith	 (2005),	 this	
distinction	 is	 important.	 They	 note	 that	 “there	 could	 be	 a	
difference	 in	 the	 unit	 cost	 depending	 on	 whether	 the	 cost	 to	
provide	 activity	 or	 to	 commission	 activity	 is	 used”	 (NICE	
2011a:2.6)	and	suggests	that	where	both	are	available	the	cost	to	
commission	activity	should	be	used	for	costing	(ibid.).			
	
With	 the	 exception	 of	 Robinson	 and	 colleagues	 which	 was	 a	
costing	study	of	a	single	intervention,	all	other	studies	stated	the	
comparators	which	are	summarised	in	table	7.10.	These	include:	
• Theoretical	 modelling	 scenarios	 based	 on	 variance	 of	
parameters	 (Adams	 et	 al.,	 2014,	 Althaus	 et	 al.,	 2014,	
Cassell	 et	 al.,	 2015,	 Looker	 et	 al.,	 2015,	 Low	 et	 al.,	 2007	
and	Turner	et	al.,	2011),	
• Tangible	service	delivery,	i.e.	actual	pathways	(Bracebridge	
et	al.,	2012,	Hislop	et	al.,	2010,	Jackson	et	al.,	2015,	Kelly	et	
al.,	2014,	Low	et	al.,	2006,	Roberts	et	al.,	2012,	and	Turner	
et	al.,	2014).	
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The	majority	of	studies	(nine)	did	not	identify	a	time	horizon,	with	
evaluation	dealing	purely	with	the	immediate	costs	and	outcomes	
associated	 with	 the	 delivery	 of	 the	 service.	 Of	 those	 which	 did	
(Adams	et	al.,	2007,	Looker	et	al.,	2015	and	Low	et	al.,	2007)	were	
studies	 that	 included	 health	 outcomes	 beyond	 immediate	
treatment	and	partner	notification.	These	also	applied	a	discount	
rate	 because	 the	 time	 horizon	 extended	 beyond	 a	 one-year	
period.	Two	other	 studies	 included	a	 stated	 time	horizon	 (Hislop	
et	 al.,	 2010	and	Turner	 et	 al.,	 2014);	 however,	 these	were	 short	
term	time	horizons	of	under	a	month.	
	
All	 of	 the	 cost-effectiveness	 studies	 included	 measures	 of	
effectiveness.	Examples	include:	
• Screening	Uptake	(Althaus	et	al.,	2014,	Bracebridge	et	al.,	
2012,	Jackson	et	al.,	2015),	
• Test	Accuracy	Parameters	(Hislop	et	al.,	2010),		
• Positivity	Rates/	Cases	Detected	(Bracebridge	et	al.,	2012,	
Hislop	et	al.,	2010,	Kelly	et	al.,	2014),	
• Treatment	Uptake	 (Bracebridge	et	 al.,	 2012,	Hislop	et	 al.,	
2010),	
• Partner	Notification	 Efficacy	 (Althaus	 et	 al.,	 2014,	 Low	 et	
al.,	2006,	Roberts	et	al.,	2012).	
	
Four	 studies	 included	 health	 outcomes,	 three	 included	 QALYs	
(Adams	et	al.,	2007,	Looker	et	al.,	2015	and	Turner	et	al.,	2014).	
Two	included	major	outcomes	averted	(Adams	et	al.,	2007,	Low	et	
al.,	2007),	and	one	of	these	included	both	QALYs	and	MOA	(Adams	
et	 al.,	 2007).	 	 Twelve	 of	 the	 studies	 included	 measures	 of	
effectiveness,	whilst	those	which	do	not	were	costing	studies.		
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All	 studies	 included	 information	 to	 varying	 degrees	 on	 the	
estimation	of	resources	and	costs.	The	costing	data	sources	cited	
are	summarised	in	table	7.10.	It	is	important	to	note	that	there	is	
some	 recycling	 of	 cost	 data	 between	 studies,	 in	 particular	 the	
ClaSS	study	data	(Low	et	al.,	2007)	 is	used	by	Cassell	et	al.,	2015	
and	 Roberts	 et	 al.,	 2012,	 and	 the	 APT	 trial	 data	 (Roberts	 et	 al.,	
2012)	is	used	by	Cassell	et	al.,	2015.	For	studies	costing	elements	
of	NCSP	pathways,	the	2008-09	costing	exercise	run	by	the	NCSP	
was	used	to	inform	costs	(Althaus	et	al.,	2014,	Bracebridge	et	al.,	
2012	 and	 Turner	 et	 al.,	 2011).	 Seven	 of	 the	 studies	 included	 an	
element	of	primary	costing	work	(Bracebridge	et	al.,	2012,	Jackson	
et	al.,	2015,	Kelly	et	al.,	2014,	Roberts	et	al.,	2012,	Robinson	et	al.,	
2007,	Turner	et	al.,	2011	and	Turner	et	al.,	2014).	These	cover	the	
range	 of	 costing	 precision	 from	highly	 detailed	 time	 and	motion	
studies	 (Robinson	 et	 al.,	 2007)	 and	 a	 pilot	 RCT	 (Roberts	 et	 al.,	
2012),	pathway	mapping	(Turner	et	al.,	2014)	and	semi-structured	
interviews	 (Turner	 et	 al.,	 2011),	 to	 costing	 alongside	 service	
evaluations	at	a	higher	level	(Bracebridge	et	al.,	2012	and	Kelly	et	
al.,	2014).		
	
The	 review	of	 costing	 data	 sources	 in	 the	 published	 studies	was	
also	 helpful	 in	 identifying	 data	 sources	 which	 can	 be	 used	 in	
costing	the	comparator	pathways.	These	include:	
• Payment	by	Results	National	Tariff	(Althaus	et	al.,	2014),	
• GP	and	Pharmacy	LES	payments	(Althaus	et	al.,	2014),	
• NCSP	 Costing	 initiative	 2008-09	 (Althaus	 et	 al.,	 2014,	
Bracebridge	et	al.,	2012,	Turner	et	al.,	2011),	
• Test	manufacturer’s	data	(Hislop	et	al.,	2010),	
• Healthcare	Resource	Groups	(HRGs)	Reference	Costs	(Low	
et	al.,	2007),	
• Personal	Social	Services	Research	Unit	(PSSRU)	(Low	et	al.,	
2007).	
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The	majority	of	studies	(eleven	of	fourteen)	indicated	the	year	the	
costs	 included	 in	 the	 analysis	 related	 to	 (Althaus	 et	 al.,	 2014,	
Looker	et	al.,	2015,	and	Turner	et	al.,	2014	do	not),	and	all	stated	
the	currency	as	British	Pounds.	The	date	 range	 for	 the	 literature	
review	 was	 studies	 published	 between	 2005	 and	 2015,	 and	 the	
range	of	years	 that	 the	analysis	 related	 to	 is	 from	2003	to	2012-
13.	
	
The	seven	cost-effectiveness	analysis	studies	all	contained	details	
of	 an	 economic	model	 (Adams	 et	 al.,	 2007,	 Althaus	 et	 al.,	 2014,	
Hislop	et	al.,	2010,	Looker	et	al.,	2015,	Low	et	al.,	2007,	Turner	et	
al.,	 2011	 and	 Turner	 et	 al.,	 2014).	 All	 cost-effectiveness	 studies	
provided	tables	detailing	the	model	parameters.	Where	details	of	
an	 economic	 model	 have	 been	 provided,	 three	 are	 dynamic	
(Adams	et	al.,	2007,	Looker	et	al.,	2015	and	Low	et	al.,	2007),	and	
four	are	static	(Althaus	et	al.,	2014,	Hislop	et	al.,	2010,	Turner	et	
al.,	 2011	 and	 Turner	 et	 al.,	 2014).	 The	 majority	 of	 studies	
contained	detail	of	the	assumptions	made	in	the	economic	models	
or	 costing;	 however,	 the	 quality	 of	 the	 way	 in	 which	 these	 are	
reported	 is	 variable	 with	 examples	 of	 assumptions	 interspersed	
throughout	the	text	to	assumptions	clearly	summarised	in	tables.		
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Ref	 Author	 Perspective	 Comparators	 Costing	Data	Source	 Price	Date	 Model	Type	
1.	 Adams	et	al.	
(2007)	
NHS	in	England	 Different	screening	strategies	compared	
to	no	screening	
Standard	data	sources	
Other	published	studies	
2004	 Stochastic	individual	based,	
dynamic	sexual	network	model	
2.	 Althaus	et	al.	
(2014)	
Healthcare	Provider	 Scenario	analysis	to	investigate	the	effects	
of	partner	notification	efficacy,	partner	
positivity	and	screening	coverage	on	the	
cost	per	positive	of	screening	
NCSP	costing	initiative	
2008-09	
Proportion	of	GUM	tariff	
GP	&	Pharmacy	LES	
payments	
2010-11	 Static	model	
3.	 Bracebridge	et	
al.	(2012)	
Not	stated,	presentation	of	
costs	suggests	healthcare	
commissioner	
Costs	of	postal	service	compared	with	
costs	of	NCSP	in	2008-09.		
Primary	Costing	Study	
NCSP	costing	initiative	
2008-09	
2008	 Not	Applicable	
4.	 Cassell	et	al.	
(2015)	
NHS	in	England		 The	costs	associated	with	the	pilot	PN	
pathways	with	two	separate	studies	
comparing	the	costs	(and	outcomes)	
associated	with	PN	strategies	with	current	
practice	in	the	UK	
Other	published	studies	
(ref	10	&11)	
2011	 Not	Applicable	
5.	 Hislop	et	al.	
(2010)	
Healthcare	Provider	
(Family	Planning	Clinic)	
Clearview	POCT,	CRT	POCT	and	current	
practice	(PCR)	
Test	manufacturers	
Other	published	studies	
Expert	opinion	
Not	stated	 Decision	analytic	model	
6.	 Jackson	et	al.	
(2015)	
Health	Service	 Captain	led	and	poster	STI	screening	
Sexual	health	advisor	and	poster	STI	
screening	
Poster	only	STI	screening	promotion	
(control	group)	
Primary	Costing	Study	 2012-13	 Not	Applicable	
7.	 Kelly	et	al.	
(2014)	
Not	stated,	presentation	of	
costs	suggests	healthcare	
commissioner	
Primary	care	pilot	and	secondary	care	
service	
Primary	Costing	Study	
Assumptions	on	existing	
expenditure	
2012	 Not	Applicable	
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Ref	 Author	 Perspective	 Comparators	 Costing	Data	Source	 Price	Date	 Model	Type	
8.	 Looker	et	al.	
2015)	
Not	stated,	presentation	of	
costs	suggests	NHS		
Screening	with	no	testing		 Parameters	used	stated	
but	not	source	
Not	
Stated	
Deterministic	compartmental	
dynamic	model	
9.	 Low	et	al.	
(2006)	
Health	Service	 Partner	notification	by	practice	nurses	
compared	with	partner	notification	by	
GUM	clinic	
Other	published	studies	 2003	 Not	Applicable	
10.	 Low	et	al.	
(2007)	
Not	stated,	presentation	of	
costs	suggests	healthcare	
commissioner	
Screening	women	v’s	no	screening	
Screening	men	and	women	v’s	no	
screening	
Screening	men	and	women	v’s	screening	
women	only	
Other	published	studies	
(ClaSS)	
HRGs	
PSSRU	
Other	published	studies	
2003	 Discrete	event	simulation	
11.	 Roberts	et	al.	
(2012)	
NHS	 APT	Hotline,	APT	pharmacy	and	routine	
PN	
	
Other	published	study	(ref	
10)	
Primary	Costing	Study	
2008	 Not	applicable	
12.	 Robinson	et	al.	
(2007)	
Health	service	and	private	
costs	of	patients	
Not	applicable	–	costing	study	
investigated	the	average	cost	the	health	
service	of	a	single	round	of	proactive	
screening	for	chlamydia	
Primary	Costing	Study	 2005	 Not	applicable	
13.	 Turner	et	al.	
(2011)	
Healthcare	provider	
perspective	
Comparison	of	current	baseline	with	
increased	coverage	of	screening	in	men	
and	increased	efficacy	of	partner	
notification	
NCSP	Costing	Initiative	
(2008-09)	
Available	data	sources	
Semi-structured	interviews	
2008-09	 Static	model		
14.	 Turner	et	al.	
(2014)	
Healthcare	provider	
perspective	(GUM	clinic)	
Current	practice	in	GUM	clinics	compared	
with	POCT	in	GUM	clinics	
Primary	Costing	Study	
Other	published	studies	
Not	
Stated	
Decision	analytic	model	
Table	7.10	-	Summary	of	Key	Elements	of	Study	Methods	
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7.3.5.3 Reporting	of	Results	
All	 14	 studies	 contained	 a	 summary	 of	 the	 results	 identified,	
although	the	level	of	detail	varied	between	studies.	For	example,	
the	standalone	economic	evaluations	contained	more	detail	than	
the	 integrated	 studies	 where	 weight	 also	 had	 to	 be	 given	 to	
reporting	 the	clinical	 findings.	Only	 two	 (29%)	of	 the	 seven	cost-
effectiveness	analysis	 studies	 (Adams	et	al.,	2007	and	Low	et	al.,	
2007)	 included	 an	 incremental	 cost-effectiveness	 ratio	 (ICER).	 A	
summary	of	the	outcomes	reported	is	included	in	table	7.11.	Nine	
(64%)	 of	 the	 14	 studies	 explored	 uncertainty	 of	 model	 input	
parameters	 and/	 or	 assumptions	 relating	 to	 costing	 using	
techniques	including:	
• Probabilistic	multivariate	sensitivity	analysis	(Adams	et	al.,	
2007),	
• Scenario	analysis	(Althaus	et	al.,	2014,	Turner	et	al.,	2014),	
• One	way	sensitivity	analysis	(Hislop	et	al.,	2010,	Jackson	et	
al.,	2015),	
• Sensitivity	 analysis	 –	 no	 further	 detail	 on	 type	 provided	
(Looker	et	al.,	2015,	Low	et	al.,	2007,	Robinson	et	al.,	2007,	
Turner	et	al.,	2011).	
	
One	 study	 (Roberts	 et	 al.,	 2012)	 reported	 that	 it	 was	 not	
appropriate	to	undertake	sensitivity	analysis	because	“the	results	
are	 illustrative,	 preliminary	 and	 subject	 to	 bias”	 (Roberts	 et	 al.,	
2012:19).		
	 	
		 385	
	
Ref	 Author	 Outcomes	Included	
1.	 Adams	et	al.,	(2007)	 PID		
Ectopic	Pregnancy	
Tubal	Factor	Infertility	
Neonatal	Conjunctivitis	
Neonatal	Pneumonia	
2.	 Althaus	et	al.,	(2014)	 Cost	per	positive	of	screening	
3.	 Bracebridge	et	al.,	
(2012)	
Screening	uptake	
Test	positivity	rate	
4.	 Cassell	et	al.,	(2015)	 N/A	–	Cost	Analysis	
5.	 Hislop	et	al.,	(2010)	 Number	of	false-positives	
Number	of	false-negatives	
Number	of	false-positives	treated	
Number	of	true-positives	
Number	of	true-negatives	
Number	of	true-positives	treated	
Number	of	partners	reported	for	true-positives	
Number	of	partners	reported	for	false-positives	
Total	costs	of	offering,	screening	and	treating	index	
patients	and	their	partners	
Effectiveness	measured	as	true	positive	cases	
identified	and	treated	and	their	partners	notified	
Effectiveness	measured	as	number	of	cases	correctly	
identified	and	treated	if	necessary	and	partners	of	
positive	cases	identified	
6.	 Jackson	et	al.,	(2015)	 Offer	of	Screening	Accepted	
7.	 Kelly	et	al.,	(2014)	 Chlamydia	positivity	rate	
8.	 Looker	et	al.,	(2015)	 PID	
Tubal	Factor	Infertility	
9.	 Low	et	al.,	(2006)	 Proportion	of	index	cases	with	at	one	treated	sexual	
partner	
Number	of	sexual	contacts	elicited	during	a	sexual	
history	
Positive	 test	 result	 for	 chlamydia	 six	 weeks	 after	
treatment	
10.	 Low	et	al.,	(2007)	 PID	
Infertility	
Ectopic	pregnancy	
Neonatal	Complications	
11.	 Roberts	et	al.,	
(2012)	
Number	and	proportion	of	partners	treated	
12.	 Robinson	et	al.,	
(2007)	
N/A	–	Cost	Analysis	
13.	 Turner	et	al.,	(2011)	 Cost	per	individual	tested	
Cost	per	positive	diagnosis	
Total	cost	of	screening	
Number	screened	
Number	infected	
Sex	ratio	of	those	tested	and	treated	
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Ref	 Author	 Outcomes	Included	
14.	 Turner	et	al.,	(2014)	 Cost	per	QALY	gained	
Number	of	overtreatments	prevented	
Onward	transmissions	prevented	
PID	cases	prevented	
Table	7.11	-	Summary	of	Outcomes	Included	
	
7.3.5.4 Reporting	of	Discussion	
All	 of	 the	 included	 studies	 discussed	 the	 study	 findings	 and	 all	
except	 two	 discussed	 the	 limitations	 of	 the	 costing	 study/	
economic	evaluation.	The	two	which	did	not	were	studies	where	
the	 economic	 evaluation	was	 a	 component	 of	 a	 broader	 service	
evaluation	(Bracebridge	et	al.,	2012,	Kelly	et	al.,	2014).	Reporting	
of	 generalisability	 of	 findings	 and	 current	 knowledge,	 was	
generally	 reported	 more	 comprehensively	 in	 the	 standalone	
economic	evaluation	papers	 than	 the	papers	 reporting	economic	
analysis	 alongside	 clinical	 evaluation,	 with	 the	 latter	 situating	
these	discussions	in	the	clinical	rather	than	economic	context.	
	
7.3.5.5 Reporting	of	Other	Checklist	Criteria	
Finally,	 all	 studies	 with	 the	 exception	 of	 Bracebridge	 and	
colleagues	 (2012)	 cited	 the	 funding	 source,	 and	 all	 with	 the	
exception	of	two	(Cassell	et	al.,	2015	and	Hislop	et	al.,	2010)	listed	
conflicts	of	interest	or	declared	none.			
	
7.3.6 Discussion		
The	 objective	 of	 the	 literature	 review	 was	 to	 identify	 published	
studies	 exploring	 the	 costs	 and	 cost-effectiveness	 of	 chlamydia	
testing	 and	 treatment	 in	 the	 UK	 for	 the	 purposes	 of	 the	
identification	 of	 resource	 items,	 unit	 of	 measure	 and	 costs.	 The	
review	 identified	 only	 one	 study	 (Turner	 et	 al.,	 2014)	 containing	
recently	 mapped	 GUM	 clinic	 pathways	 in	 London	 and	 the	 South	
West	 with	 sufficient	 detail	 published	 on	 the	 pathway	 mapping	
separately	(Adams	et	al.,	2014)	to	be	used	in	this	study.		
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A	 refresh	of	 the	 literature	 search	was	undertaken	 to	 identify	 new	
studies	 published	 up	 to	December	 2016	 and	 identified	 no	 further	
studies	 for	 inclusion.	 From	 an	 NCSP	 pathway	 perspective	 it	 was	
noted	that	all	studies	using	NCSP	pathways	are	based	on	the	2008-
09	costing	initiative.	There	have	been	two	major	structural	changes	
within	 the	 NHS	 since	 this	 was	 undertaken,	 which	 may	 have	 an	
impact	on	resource	use	and	costs	–	the	dissolution	of	PCT	provider	
arms,	 the	 primary	 body	 coordinating	 and	 delivering	 the	 NCSP	 in	
2010,	 and	 the	 transfer	 of	 responsibility	 for	 public	 health	
commissioning	 to	 LAs	 in	 2013,	 which	 has	 led	 to	 a	 number	 of	
services	 being	 competitively	 tendered	 and	 subsequent	 changes	 to	
pathways.	 Alongside	 this,	 there	 has	 been	 a	 shift	 in	 patterns	 of	
access	 to	 chlamydia	 testing	 and	 treatment	 with	 an	 increase	 in	
internet	 testing	 from	 less	 than	 1%	 in	 2006	 to	 6%	 in	 2010,	with	 a	
range	 across	 geographical	 areas	 of	 less	 than	 1%	 to	 38%	 of	 tests	
accessed	online	(Woodhall	et	al.,	2012).	
	
Considering	the	stages	of	economic	evaluation	within	HTA	outlined	
by	 Sculpher	 and	 colleagues	 (1997)	 the	 articles	 included	 can	 be	
categorised	as	follows:	
Stage	of	Economic	Evaluation	 Included	Studies	
i.			Early	Developmental	 Althaus	et	al.,	(2014)	
Cassell	et	al.,	(2015)	
ii.		Maturing	Innovation	 Bracebridge	et	al.,	(2012)	
Jackson	et	al.,	(2015)	
Kelly	et	al.,	(2014)	
Roberts	et	al.,	(2012)	
Turner	et	al.,	(2014)	
iii.	Close	to	Wide	Spread	
Diffusion	
Hislop	et	al.,	(2010)	
Low	et	al.,	(2006)	
Robinson	et	al.,	(2007)	
iv.	Moving	into	Practice	 Adams	et	al.,	(2007)	
Looker	et	al.,	(2015)	
Low	et	al.,	(2007)	
Turner	et	al.,	(2011)	
Table	7.12	-	Included	studies	categorised	by	stage	of	economic	evaluation	in	HTA	
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The	 majority	 of	 studies	 fall	 into	 two	 category	 groups	 –	 maturing	
innovation	 and	 moving	 into	 practice.	 The	 ‘moving	 into	 practice’	
category	 represent	 the	modelling	 studies	where	 data	 are	 used	 to	
generalise	results	to	other	settings	or	extrapolate	to	a	longer	term	
view	of	 the	 impact	 of	 the	 interventions.	 In	 all	 cases	 these	 studies	
relate	 to	 the	consideration	of	 chlamydia	 screening	programmes	 in	
their	entirety	and	their	impact	depends	on	variance	in	a	number	of	
parameters,	 for	 example,	 population	 screened.	 The	 ‘maturing	
innovation’	 category	 identifies	 studies	which	 explore	 pathways	 or	
technologies	 that	 are	 at	 a	 much	 earlier	 stage	 of	 development.	
These	 fall	 into	two	categories	–	studies	exploring	the	delivery	of	a	
service	 through	 an	 alternative	 pathway	 using	 existing	 technology	
(Bracebridge	et	al.,	2012,	Jackson	et	al.,	2012	and	Kelly	et	al.,	2014),	
and	 studies	 exploring	 the	 delivery	 of	 a	 service	 through	 the	
introduction	 of	 a	 new	 technology	 –	 accelerated	 partner	 therapy	
(Roberts	et	al.,	2012),	and	rapid	POCT	(Turner	et	al.,	2014).		
	
The	 categorisation	 of	 economic	 evaluations	 is	 based	 on	
comparisons	against	Sculpher	and	colleagues	view	of	the	stages	of	
economic	evaluation	in	HTA	(Sculpher	et	al.,	1997).	If	the	stages	of	
product	development	(Ijzerman	and	Steuten,	2011)	were	applied	to	
the	studies	 included	 in	 this	 literature	 review	 it	would	suggest	 that	
the	 economic	 evaluations	 selected	 are	 not	 always	 appropriate	 for	
the	stage	of	product	development.		
	
For	 example,	 Turner	 and	 colleagues’	 cost-effectiveness	 analysis	 of	
rapid	 POCT	 in	 a	 GUM	 clinic	 setting	 is	 an	 evaluation	 of	 a	 new	
technology	 in	 so	 far	 as	 it	 is	 not	 adopted	 yet	 within	 mainstream	
clinical	 services	 in	 England.	 However,	 the	 technology	 itself	 is	 fully	
developed	 with	 FDA	 approval.	 Therefore,	 Ijzerman	 and	 Steuten’s	
approach	would	class	this	as	stage	4	product	development	–	access	
and	 pricing,	whereas	 the	 economic	 evaluation	 taxonomy	 suggests	
the	evaluation	of	a	technology	at	stage	2,	translational	research.		
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None	 of	 the	 published	 studies	 consider	 the	 implementation	 an	
online	clinical	care	pathway	similar	to	OCCP,	although	two	explore	
remote	 pathways.	 Bracebridge	 and	 colleagues	 study	 explore	 an	
internet,	 postal	 and	 telephone	 based	 approach	 to	 delivering	
chlamydia	 testing	 and	 treatment	 (Bracebridge	 et	 al.,	 2012),	whilst	
Roberts	and	colleagues	explore	 the	use	of	a	 telephone	hotline	 for	
the	delivery	of	accelerated	partner	therapy	for	partners	of	patients	
diagnosed	with	chlamydia	or	gonorrhoea	(Roberts	et	al.,	2012).	
	
Considering	 the	 delivery	 model	 for	 the	 NCSP	 internet	 testing	
pathway,	 none	 of	 the	 papers	 included	 which	 examined	 a	 full	
screening	pathway	costed	a	pathway	which	is	currently	reflective	of	
how	 the	 NCSP	 is	 delivered	 (a	 comparator	 pathway	 in	 the	 OCCP	
exploratory	 study).	 This	 is	 a	 reflection	 of	 the	 evolution	 of	 sexual	
health	 services	 outlined	 in	 section	 2.4	 and	 identifies	 a	 gap	 in	 the	
published	literature	considering	the	costs	and	cost-effectiveness	of	
delivering	chlamydia	screening.		
	
7.3.7 Summary	and	Conclusions	
Fourteen	 studies	 were	 identified	 for	 inclusion	 in	 this	 literature	
review	 exploring	 aspects	 of	 the	 chlamydia	 testing	 and	 treatment	
pathway	 ranging	 from	 highly	 theoretical	 modelling	 to	 determine	
cost-effectiveness	to	pragmatic	service	evaluations	and	early	stage	
testing	 of	 new	 models	 of	 care	 and	 technology	 to	 consider	
preliminary	cost-effectiveness	and	issues	for	future	studies.		
	
The	absence	of	published	studies	exploring	the	cost-effectiveness	of	
eHealth	solutions	for	chlamydia	treatment	and	partner	notification	
demonstrates	that	the	costing	study	and	outcomes	data	outlined	in	
the	 following	 sections	 will	 add	 new	 knowledge	 in	 terms	 of	 a	
preliminary	view	on	whether	the	OCCP	is	cost	saving.		
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7.4 Literature	Review	–	Consequences	
Table	 7.4	 contains	 the	 outcome	 measures	 identified	 for	 the	 OCCP	
exploratory	 study.	 The	 objective	 of	 this	 literature	 review	 was	 to	
identify	published	studies	which	provide	comparative	outcomes	data	
for	the	GUM	and	NCSP	internet	testing	pathways.		
	
The	inclusion	criteria	for	the	literature	review	were	identified	as:	
• any	 published	 study	 containing	 chlamydia	 trachomatis	
outcomes	data	for	GUM	or	NCSP	internet	testing	services	
• studies	 published	 between	 2005	 and	 September	 2016.	 As	
with	the	literature	review	which	identified	economic	analyses,	
this	date	range	was	selected	to	reflect	the	significant	changes	
in	 the	 delivery	 of	 sexual	 health	 services	 in	 England,	
summarised	in	section	2.4.	
	
The	exclusion	criteria	were	identified	as	studies:	
• not	related	to	humans	
• not	published	in	English	
• from	outside	of	the	UK	
• that	 do	 not	 provide	 outcomes	 data	 which	 are	 directly	
comparable	with	the	primary	and	secondary	outcomes	of	the	
OCCP.		
	
7.4.1 Search	Strategy	
The	following	databases	were	searched	on	23	September	2016:	
• Medline	
• EMBASE	
• Cochrane	Library	(incorporating	the	following	databases):	
o Cochrane	Database	of	Systematic	Reviews	
o Cochrane	Central	Register	of	Controlled	Trials	
o Cochrane	Methodology	Register	
o Database	of	Abstracts	of	Reviews	of	Effects	
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o Health	Technology	Assessment	Database	
o NHS	Economic	Evaluation	Database.	
	
The	key	search	terms	and	their	abbreviated	database	entry	(where	
applicable,	abbreviation	example	from	Medline)	are	summarised	in	
table	 7.13,	 the	 full	 Medline	 search	 is	 included	 in	 Appendix	 17.		
Search	 terms	 were	 identified	 from	 the	 definitions	 of	 the	 OCCP	
exploratory	 study	 outcomes.	 Searches	 were	 structured	 in	 the	
databases	 to	 meet	 the	 search	 requirements	 of	 the	 respective	
database	and	terms	exploded	where	the	facility	existed	to	do	this.	
Exploded	 search	 terms	 included	 ‘time	 to	 treatment’,	 ‘treatment	
outcome’	 and	 ‘contact	 tracing’.	 This	 extended	 the	 search	 terms	
covered	 to	 include,	 for	 example:	 clinical	 effectiveness,	 clinical	
efficacy,	 treatment	 effectiveness,	 treatment	 efficacy,	 patient	
relevant	outcome,	partner	notification	and	communicable	disease/	
infectious	disease	contact	tracing.		
Category	 Search	Terms	Entered	
Chlamydia	 Chlamydia	
Chlamydia	Trachomatis	
Genital	
	 AND	
Outcomes	 time-to-treatment	
loss	to	follow*	
appropriate	clinical	management	
treatment	outcome	
diagnosis	to	treatment	
contact	tracing	
Table	7.13	-	Search	Terms	taken	from	the	Medline	Search	
	
The	results	were	imported	into	Endnote	x7	for	Mac	and	duplicates	
removed.	 The	 titles	 and	 abstracts	 were	 reviewed	 and	 studies	
excluded	for	the	following	reasons:	
• Study	did	not	include	genital	Chlamydia	Trachomatis	
• Study	did	not	include	outcomes	which	are	comparable	with	
OCCP	outcomes	
• Study	not	conducted	in	the	UK	
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• Not	 primary	 research	 or	 systematic	 review	 e.g.	 study	
protocol.	
	
In	 addition	 to	 the	 database	 searches	 for	 published	 studies,	 the	
literature	 review	 was	 extended	 to	 include	 known	 primary	 data	
sources.	PHE	is	the	agency	responsible	for	the	collection	of	data	on	
STIs	 and	 sexual	 health	 services	 in	 England	 (and	 holds	 the	 data	
previously	published	by	the	NCSP).	A	review	of	the	studies	included	
in	 the	 literature	 review	 also	 identified	 the	 BASHH	 clinical	 audit	
group	as	a	further	source	of	primary	data	on	chlamydia	testing	and	
treatment.		
	
7.4.2 Search	Results	
The	 initial	 search	 identified	 372	 records	 and	 41	 duplicates	 were	
removed	 in	 Endnote	 leaving	 331	 for	 initial	 review.	 The	 titles	 and	
abstracts	were	reviewed	for	each	exclusion	criterion	in	turn;	leaving	
a	total	of	16	studies	that	met	the	inclusion	criteria	for	full	review.		
	
The	 search	 results	 are	 illustrated	 in	 the	 PRISMA	 flowchart,	 figure	
7.4:	
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Figure	7.4	-	PRISMA	Flowchart	of	Included	Studies	
	
	
The	reasons	for	the	exclusion	of	studies	at	the	screening	stage	are	
summarised	in	table	7.14:	
	
Reasons	for	Exclusion	at	Screening	Stage	 Number	of	
Studies	
Excluded	
Study	not	genital	Chlamydia	 159	
Does	not	include	OCCP	Outcomes	 111	
Study	not	in	the	UK	 37	
Not	a	study/	systematic	review	e.g.	abstract	only,	
study	protocol	
8	
Table	7.14	-	Reasons	for	Exclusion	of	Papers	at	Screening	Stage	
	 	
	 	
Studies	identified	
through	database	
searching:	
n =	372
Duplicates	Removed:
n =	41
Records	Screened:
n =	331
Full	Text	Assessed	 for	
Eligibility:
n =	16
Studies	Included	in	
Synthesis:
n =	9
Records	Excluded:
n =	7
Records	Excluded:
n =	315
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A	further	seven	studies	were	excluded	at	the	full	text	review:	
Reasons	for	Exclusion	at	Full	Text	Review	 Number	of	
Studies	
Excluded	
Full	text	review	identified	that	study	did	not	include	
OCCP	outcomes	
5	
The	data	source	for	the	outcome	included	in	the	study	
is	an	assumption	
2	
	 Table	7.15	-	Studies	excluded	after	full	text	review	
	
7.4.3 Data	Extraction	
The	data	extraction	form	was	designed	to	capture	the	key	data	on	
the	 setting,	 study	 type	 and	 outcomes	 data.	 Data	 were	 extracted	
into	an	electronic	template	prepared	in	Excel	for	Mac	2010.		
	
7.4.4 Key	Findings	
Nine	studies	were	identified	containing	comparable	outcomes	data	
to	 the	OCCP	 primary	 and	 secondary	 outcomes.	 Four	were	 service	
evaluations	 (Brook	 et	 al.,	 2011,	 Fernando	 &	 Clutterbuck,	 2005,	
Forbes	&	Clutterbuck,	2009	and	Raval	&	Challenor,	2006),	two	were	
RCTs	-	one	a	pilot	(Estcourt	et	al.,	2015)	and	one	a	full	RCT	(Low	et	
al.,	 2007),	 and	 three	 were	 clinical	 audits	 (Challenor	 et	 al.,	 2005,	
McClean	 et	 al.,	 2006	 and	 McClean	 et	 al.,	 2008).	 Seven	 were	
conducted	in	a	GUM/	sexual	health	clinic	setting	(Brook	et	al.,	2011,	
Challenor	 et	 al.,	 2005,	 Fernando	 &	 Clutterbuck,	 2005,	 Forbes	 &	
Clutterbuck,	2009,	McClean	et	al.,	 2006,	McClean	et	al.,	 2008	and	
Raval	&	Challenor,	2006)	and	two	were	conducted	in	a	primary	care	
setting	–	one	general	practice	(Low	et	al.,	2007)	and	one	community	
pharmacy	(Estcourt	et	al.,	2015).		
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Reviewing	 the	 PHE	 and	 BASHH	 websites	 identified	 three	 audits	
containing	comparable	outcomes:	partner	notification	in	chlamydia	
screening	 (PHE,	 2016),	 audit	 report	 on	 turnaround	 times	 (PHE,	
2014)	 and	 the	 UK	 National	 Audit	 of	 Chlamydial	 Infection	
Management	(BASHH,	2007).	A	summary	of	the	available	outcomes	
data	for	comparator	pathways	is	provided	in	table	7.16	(GUM)	and	
table	7.17	(NCSP).	
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Study/	Data	Source	 Study	Type	 Year	of	
Study	
Sample	
Size	
Outcome	 Range	 Notes	
Proportion	of	Index	Patients	Receiving	Appropriate	Clinical	Management	
Brook	et	al.	(2011)	
	
Service	Evaluation	 2009/10	 466	 95%	 92-98%	 Monthly	results	reported	for	six	months	
Challenor	et	al.	(2005)	 Clinical	Audit	 2004	 1,670	 72%	 70.1-74.7%	 Percentage	of	index	treated	within	4	weeks	–	England		
Fernando	and	Clutterbuck	
(2005)	
Service	Evaluation		 2003	 83	 97.6%	 	 Single	result	reported	
BASHH	(2007)	 Clinical	Audit		 2007	 5,032	 99%	 97-100%	 Regional	Range	for	uncomplicated	infection	
Time	from	Index	Patient	Receiving	Diagnosis	to	Receiving	Appropriate	Treatment	
None	Identified	 	 	 	 	 	 	
Proportion	of	Sex	Partners	Treated	(Ratio	of	Partners	Treated	per	Index)	
Challenor	et	al.	(2005)	 Clinical	Audit	 2004	 1,670	 0.56	 0.54-0.59	 Proportion	of	sex	partners	treated	within	4	weeks	of	initial	PN	
interview	–	England.	Range	is	95%	CI	
McClean	et	al.	(2006)	 Clinical	Audit	 2001	 661	 0.62	
	
0.46-0.78	 Ratio	of	contacts	seen	to	index	
	
Raval	and	Challenor	(2006)	
	
Clinical	Audit	 2004/05	 200	 0.5	
0.7	
	 2004	Outcomes	Data	
2005	Outcomes	Data	
Proportion	of	sex	partners	treated	within	4	weeks	of	initial	PN	
interview.	Single	result	reported	
Percentage	of	Sex	Partners	Identified	by	Index	Patients	Treated	
Challenor	et	al.	(2005)	 Clinical	Audit	 2004	 1,670	 55%	 	 Percentage	of	partners	seen	(UK	value)	
Fernando	&	Clutterbuck	(2005)	 Service	Evaluation	 2003	 83	 90%	 	 Single	result	reported	
Low	et	al.	(2007)	 RCT	 2001-02	 64	 46.9%	 	 %	Partners	treated,	outcome	from	GUM	arm	
McClean	et	al.	(2006)	 Clinical	Audit	 2001	 661	 55%	 42-69%	 Percentage	of	partners	seen,	range	is	range	of	clinic	performance	
Time	from	Index	Patient	Receiving	Diagnosis	to	Partner	Receiving	Treatment	
None	Identified	 	 	 	 	 	 	
Table	7.16	-	Summary	of	Outcomes	Data	-	GUM	
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Study/	Data	Source	 Study	Type	 Year	of	
Study	
Sample	
Size	
Outcome	 Range	 Notes	
Proportion	of	Index	Patients	Receiving	Appropriate	Clinical	Management	
NCSP	(2012b)	 National	Dataset	 2011	 83,469	 91.6%	 56.2-100%	 Index	treatment	rate.	Range	is	the	range	of	individual	PCT	
performance	
Public	Health	England	(2014a)	
	
Clinical	Audit	 2013	 3,909	 93.45%	 	 Percentage	of	chlamydia	positive	patients	in	audit	receiving	
treatment.		
Saunders	(2016)	 Clinical	Audit	 2013	 397	 88.9%	 	 Personal	communication	detailing	subset	of	PHE	clinical	audit	
(2014a)	for	NCSP	internet	testing	specifically	
Time	from	Index	Patient	Receiving	Diagnosis	to	Receiving	Appropriate	Treatment	
Public	Health	England	(2014a)	 Clinical	Audit	 2013	 3,619	 10.3%	
2.2%	
2.7%	
5.4%	
9.9%	
58%	
11.5%	
	 Same	day	treatment	
Within	two	days	
Within	three	days	
Within	four	days	
Within	five	days	
Within	6-15	days	
Greater	than	15	Days	
Proportion	of	Sex	Partners	Treated	(Ratio	of	Partners	Treated	per	Index)	
NCSP	(2012b)	 National	Dataset	 2011	 83,469	 0.5	 0.0-1.3	 Partner	treatment	rate.	Range	is	the	range	of	individual	PCT	
performance.	
Public	Health	England	(2016a)	 Clinical	Audit	 2015	 2,439	 0.53	 	 Partner	treatment	rate.		
Percentage	of	Sex	Partners	Identified	by	Index	Patients	Treated	
Estcourt	et	al.	(2015b)	 Pilot	RCT	 2011-13	 102	 46%	 	 Control	arm	partners	treated	
Low	et	al.	(2007)	 RCT	 2001-02	 119	 45%	 	 %	Partners	Treated,	outcome	from	practice	nurse	arm	
Public	Health	England	(2016a)	 Clinical	Audit	 2015	 2,886	 58%	 	 Partners	attending	a	service	following	notification	
Time	from	Index	Patient	Receiving	Diagnosis	to	Partner	Receiving	Treatment	
Estcourt	et	al.	(2015b)	 Pilot	RCT	 2011-13	 102	 0	 0-0	 Median	time	from	index	diagnosis	to	partner	treatment	
Table	7.17	-	Summary	of	Outcomes	Identified	-	NCSP/	Primary	Care
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7.4.5 Summary		
A	comprehensive	review	has	been	undertaken	of	published	studies,	
national	datasets	and	clinical	audits	which	has	identified	a	range	of	
process	 measures/	 outcomes	 which	 are	 comparable	 to	 the	 OCCP	
exploratory	study	primary	and	secondary	outcomes.	It	can	be	seen	
that	there	are	some	significant	differences	 in	outcomes,	this	could	
be	due	to	sample	size,	or	clinical	practice	at	the	time	the	study	was	
undertaken.	 It	 is	 important	 to	 note	 that	 the	 outcomes	 cover	 all	
testing	routes	within	the	NCSP	e.g.	tests	originating	at	GP	and	CaSH	
clinics	 as	 well	 as	 tests	 ordered	 online,	 with	 the	 exception	 of	
treatment	 uptake	 rate.	 The	 extent	 to	 which	 this	 is	 an	 issue	 is	
unknown,	 in	 respect	 of	 treatment	 and	 partner	 notification	
outcomes,	the	treatment	options	available	to	positive	patients	are	
the	same	regardless	of	the	testing	route.	The	national	datasets	and	
clinical	 audits	undertaken	by	PHE	and	BASHH	offer	 a	 considerably	
larger	sample	size	than	the	published	studies.		
	
A	 second	 point	 to	 note	 is	 the	 year	 in	 which	 the	 study	 was	
undertaken.	 As	 highlighted	 previously	 and	 summarised	 in	 section	
2.4.1,	there	were	significant	changes	to	STI	service	delivery	models	
which	 may	 have	 impacted	 directly	 on	 the	 outcomes	 through	 the	
introduction	of	the	48-hour	GUM	access	target,	and	the	roll	out	of	
the	NCSP	(HM	Government,	2003,	HM	Government,	2005).	Whilst	it	
is	recommended	that	for	eHTA	published	studies	are	used	to	inform	
assessments	 of	 the	 likely	 cost-effectiveness	 it	 is	 inappropriate	 to	
apply	these	 if	 the	outcomes	do	not	reflect	outcomes	from	current	
service	delivery	models.	
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7.5 Costing	Study	
The	 following	 sections	 outline	 the	 primary	 data	 collection	
undertaken	 to	 inform	 the	 costing	 of	 the	OCCP	 and	 the	 comparator	
pathways.		
	
7.5.1 Data	Collection	–	OCCP	Exploratory	Study	
In	order	to	capture	the	data	on	the	costs	associated	with	the	pilot	
study	the	following	activities	were	undertaken:	
• The	 eSTI2	 Programme	Manager	 captured	 all	 costs	 incurred	
by	the	OCCP	exploratory	study	in	respect	of	non-staff	costs	
which	were	reported	to	the	researcher.	The	researcher	and	
programme	manager	met	to	clarify	reported	costs.	
• The	 OCCP	 exploratory	 study	 research	 health	 advisors	
completed	 a	 spreadsheet	which	 captured	 all	 contacts	with	
the	telephone	helpline,	and	all	activities	undertaken	by	the	
health	advisors	in	respect	of	patients.	This	included	the	start	
and	finish	time	of	the	contact,	and	the	nature	of	the	contact.	
• Pharmacist	 Interview	 –	 there	 was	 one	 pharmacist	 who	
dispensed	a	significant	proportion	of	the	azithromycin	in	the	
exploratory	study.	The	researcher	 interviewed	him	in	order	
to	ascertain	the	resource	inputs	for	dispensing	items	as	part	
of	the	proof	of	concept	study.	
	
7.5.2 Data	Collection	–	GUM	
As	identified	in	section	7.3.6	one	study	was	identified	(Turner	et	al.,	
2014)	which	used	recently	mapped	GUM	clinic	pathways	published	
separately	(Adams	et	al.,	2014).	A	second	GUM	clinic	pathway	was	
mapped	as	part	of	the	costing	study	to	provide	a	comparison.	Data	
were	 collected	 through	 interviews	 with	 the	 service	 lead,	 service	
manager	and	directorate	accountant	who	provided	estimates	of	the	
resource	use	in	delivering	the	elements	of	the	GUM	clinic	pathway	
included	in	the	study.		
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The	 initial	 interview	 took	 place	 with	 the	 service	 lead	 to	map	 the	
pathway,	 and	 subsequent	 interviews	 were	 undertaken	 with	 the	
service	manager	and	service	accountant	to	identify	costs	associated	
with	resource	use	identified	by	the	service	lead.		
	
7.5.3 Data	Collection	–	NCSP	Internet	Testing	Pathway	
Two	NCSP	internet	testing	pathways	were	mapped,	one	in	London,	
one	in	the	West	Midlands	(semi-rural	location).	Data	were	collected	
through	interviews	with	a	range	of	staff	to	provide	estimates	of	the	
resource	 use	 in	 delivering	 elements	 of	 the	 NCSP	 internet	 testing	
pathway	 included	 in	 the	 study.	 A	 summary	 of	 the	 interview	
participants	is	included	in	table	7.18.	Participants	were	identified	by	
the	 commissioner	 or	 service	 lead	 who	 undertook	 the	 initial	
interview	 to	 map	 the	 pathway.	 A	 slightly	 different	 approach	 was	
taken	between	the	two	pathways,	in	pathway	one	the	service	lead	
was	 interviewed	 and	 undertook	 to	 provide	 the	 missing	 data	 by	
sourcing	 the	 information	 and	 providing	 it	 to	 the	 researcher,	
whereas	in	the	second	pathway,	the	service	lead	identified	the	staff	
that	 the	 research	 should	 contact	 and	 additional	 interviews	 with	
those	 staff	 took	 place.	 The	 interview	 topic	 guide	 is	 included	 in	
Appendix	15.	
	
Pathway	1	Interviews	 Pathway	2	Interviews	
• Service	Lead	
• Chlamydia	Screening	Office	
Lead	
• Chlamydia	Screening	Lead	
• Service	Manager	
• Directorate	Accountant	
Table	7.18	-	NCSP	Internet	Testing	Pathway	Interviews	
	
7.5.4 Data	Collection	–	Outcomes	
Data	on	 the	outcomes	of	 individual	patients	 completing	 the	OCCP	
pilot	 extracted	 as	 part	 of	 the	 exploratory	 study	 were	 utilised	
(Estcourt	 and	 Gibbs,	 2016).	 Data	 on	 the	 outcomes	 of	 comparator	
pathways	were	taken	from	published	data	sources.		
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7.6 Results		
	
7.6.1 Costs	
The	detailed	costing	of	the	pathways	are	included	in	tables	7.19	to	
7.30.	 The	 following	 assumptions	 should	 be	 noted	 as	 per	 the	
methods	outlined	in	sections	7.2.1.3	to	7.2.1.5:	
• Staff	 costs	 were	 taken	 from	 PSSRU	 (PSSRU,	 2016).	 These	
costs	include	management,	non-staff	and	estate	overheads.	
It	 is	 therefore	 assumed	 that	 all	 non-specific	 service	
equipment	 required	 to	 deliver	 the	 service	 e.g.	 computers,	
servers,	 clinic	 room	 equipment	 etc	 and	 service	 overheads	
are	included	in	this	value		
• Training	costs	for	staff	specifically	involved	in	delivering	the	
OCCP	 were	 included	 based	 on	 the	 training	 required	 to	
deliver	the	exploratory	study	
• Using	 Tate	 and	 colleagues	 approach,	 development	 costs	
were	 excluded	 and	 web	 hosting	 and	 maintenance	 were	
included		(Tate	et	al.,	2009).	The	life	expectancy	of	the	OCCP	
is	 governed	by	 the	 clinical	pathway	and	whether	 there	are	
changes	 to	 the	 clinical	 pathway	 which	 result	 in	 the	 OCCP	
requiring	 significant	 redevelopment	 to	 incorporate	 these.	
The	 current	 clinical	 guidelines	 for	 the	 management	 of	
genital	 chlamydia	were	 introduced	 in	 2006	 (BASHH,	 2006),	
clinical	 opinion	 has	 not	 identified	 any	 likely	 change	 in	 the	
immediate	future	therefore	no	costs	were	included	relating	
to	the	 life	expectancy	of	 the	OCCP	 itself.	The	costs	relating	
to	 hosting	 and	maintenance	 were	 not	 annualised	 because	
they	were	annual	costs.	
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Step	 Cost	Input	 Cost	(£)	 Cost	Type	 Quantity	 Time	(seconds)	
Total	
Cost	per	
Patient	
(£)	
Staff	
Grade		 Notes	 Source	
Results	 SMS	 	0.03		 Item	 	1.00		 1	 	0.03		 		
Text	sent	to	all	patients	to	notify	results	
are	available	 Identified	through	pilot	costing	
Results	 Website	Hosting	 	0.10		 Item	 	1.00		 1	 	0.10		 		 Patients	log	in	to	get	result	 Cost	invoiced	to	pilot	
Results	 Health	Advisor	Helpline	 	0.01		 Second	 	1.00		 120	 	1.50		 	AfC6		
24	patients	accessed	the	helpline	for	
assistance	with	obtaining	results	
HA	Telephone	Call	Logs,	PSSRU	Band	6	Hospital	
Based	Nurse	Unit	Cost	2015	
Results		
Positive	Notification	via	
GUM	Clinic	A	 	5.41		 Item	 	1.00		 1	 	5.41		 		 		 GUM	Clinic	A	Costing	
Results	 Notification	via	NCSP	A		 	1.81		 Item	 	1.00		 1	 	1.81		 		 		 NCSP	A	Costing	
Results	 Notification	via	NCSP	B	 	1.27		 Item	 	1.00		 1	 	1.27		 		 		 NCSP	B	Costing	
Results	
Health	Advisor	(GUM	
Clinic	Data	Entry)	 	0.01		 Second	 	1.00		 600	 	7.50		 	AfC6		 GUM	Clinic	Positive	Patients	Only	
Estimate	from	pilot	researcher,	PSSRU	Band	6	
Hospital	Based	Nurse	Unit	Cost	2015	
Trt	 Website	Hosting	 	1.00		 Item	 	1.00		 1	 	1.00		 		
Based	on	apportionment	of	pilot	costs	as	
per	Tate	et	al.,	(2009)	 Cost	invoiced	to	pilot	
Trt	
Health	Advisor	Helpline	
(Online)	-	NCSP	 	0.01		 Second	 	1.00		 120	 	1.50		 	AfC6		
64	NCSP	patients	completing	online	
called	the	helpline	
HA	Telephone	Call	Logs,	PSSRU	Band	6	Hospital	
Based	Nurse	Unit	Cost	2015	
Trt	
Health	Advisor	Helpline	
(Online)	-	GUM	 	0.01		 Second	 	1.00		 180	 	2.25		 	AfC6		
25	GUM	patients	completing	online	
called	the	helpline	
HA	Telephone	Call	Logs,	PSSRU	Band	6	Hospital	
Based	Nurse	Unit	Cost	2015	
Trt	
Health	Advisor	Helpline	
(GUM)	-	NCSP	 	0.01		 Second	 	1.00		 240	 	3.00		 	AfC6		
45	NCSP	patients	calling	helpline	
transferred	to	GUM	
HA	Telephone	Call	Logs,	PSSRU	Band	6	Hospital	
Based	Nurse	Unit	Cost	2015	
Trt	
Health	Advisor	Helpline	
(GUM)	-	GUM	 	0.01		 Second	 	1.00		 360	 	4.50		 	AfC6		
27	GUM	patients	calling	helpline	
transferred	to	GUM	
HA	Telephone	Call	Logs,	PSSRU	Band	6	Hospital	
Based	Nurse	Unit	Cost	2015	
Trt	 Pharmacist	Dispensing	 	0.02		 Second	 	1.00		 450	 	7.14		 		 		
Time	from	Pharmacist	Interview.	Cost	from	PSSRU	
2012/13	Community	Pharmacist	analysis	uplifted	
by	HCHS	Pay	&	Prices	Inflation	to	2014/15	
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Step	 Cost	Input	 Cost	(£)	 Cost	Type	 Quantity	 Time	(seconds)	
Total	
Cost	per	
Patient	
(£)	
Staff	
Grade		 Notes	 Source	
Trt	 Azithromycin	 	1.81		 Drug	 	1.00		 1	 	1.81		 		
All	patients	on	pathway	treated	with	
Azithromycin	
http://www.drugtariff.nhsbsa.nhs.uk/#/00280039-
DC/DC00279526/Part%20VIIIA%20products%20A	
Dec	2015	
Trt	
GUM	Clinic	Attendance	
for	Treatment	(GUM	A)	 	17.30		 Item	 	1.00		 1	 	17.30		 		 Calculation	from	GUM	A		 Service	lead	and	Directorate	Accountant	Interviews	
PN	
Included	in	Website	
Hosting	above	 	-				 Item	 	1.00		 1	 	-				 		 See	above	 		
Follow	Up	 Health	Advisor	 	0.01		 Second	 	1.00		 480	 	6.00		 	AfC6		
Based	on	average	duration	of	calls	
marked	as	HA	follow	up	
HA	Telephone	Call	Logs,	PSSRU	Band	6	Hospital	
Based	Nurse	Unit	Cost	2015	
Set	Up	 Health	Advisor	Training	 	45.00		 Hour	 	1.00		 5	 	1.02		 	AfC6		
Divided	by	the	number	of	patients	
entering	online	pathway	to	estimate	cost	
per	patient	
Estimate	from	pilot	researcher,	PSSRU	Band	6	
Hospital	Based	Nurse	Unit	Cost	2015	
Set	Up	 Pharmacist	Training	 	57.13		 Hour	 	1.00		 1	 	0.38		 		
Divided	by	the	number	of	patients	
completing	online	pathway	to	estimate	
cost	per	patient	
Estimate	from	pilot	researcher.	Cost	from	PSSRU	
2012/13	Community	Pharmacist	analysis	uplifted	
by	HCHS	Pay	&	Prices	Inflation	to	2014/15	
Table	7.19	-	OCCP	with	GUM	A	Costs	
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Assumptions	
89%	 %	Log	in	to	get	result	(NCSP	Negative)	
92%	 %	Log	in	to	get	result	(NCSP	Positive)	
82%	 %	Log	in	to	get	result	(GUM	Positive)	
11%	 %	Get	results	from	original	service	(NCSP	-ve)	
8%	 %	Get	results	from	original	service	(NCSP	+ve)	
18%	 %	Get	results	from	original	service	(GUM)	
1%	 %	Accessing	helpline	for	results		
66%	 %	Completing	Pathway	Online	(NCSP)	
71%	 %	Completing	Pathway	Online	(GUM)	
34%	 %	Transferred	to	GUM	(NCSP)	
29%	 %	Transferred	to	GUM	(GUM)	
93%	 %	Completing	online	calling	helpline	(NCSP)	
30%	 %	Completing	online	calling	helpline	(GUM)	
100%	 %	Transferred	to	GUM	calling	helpline	(NCSP)	
79%	 %	Transferred	to	GUM	calling	helpline	(GUM)	
Table	7.20	-	OCCP	with	GUM	A	Assumptions	
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Step	 Cost	Input	 Cost	(£)	 Cost	Type	 Quantity	 Time	(seconds)	
Total	
Cost	per	
Patient	
(£)	
Staff	
Grade		 Notes	 Source	
Results	 SMS	 	0.03		 Item	 	1.00		 1	 	0.03		 		
Text	sent	to	all	patients	to	
notify	results	are	available	 Identified	through	pilot	costing	
Results	 Website	Hosting	 	0.10		 Item	 	1.00		 1	 	0.10		 		 Patients	log	in	to	get	result	 Cost	invoiced	to	pilot	
Results	 Health	Advisor	Helpline	 	0.01		 Second	 	1.00		 120	 	1.50		 	AfC6		
24	patients	accessed	the	
helpline	for	assistance	with	
obtaining	results	
HA	Telephone	Call	Logs,	PSSRU	Band	6	Hospital	Based	
Nurse	Unit	Cost	2015	
Results	
Results	Notification	via	GUM	
Clinic	B	 	13.63		 Item	 	1.00		 1	 	13.63		 		 		 GUM	Clinic	B	Calculations	
Results	 Notification	via	NCSP	A		 	1.81		 Item	 	1.00		 1	 	1.81		 		 		 NCSP	A	Costing	
Results	 Notification	via	NCSP	B	 	1.27		 Item	 	1.00		 1	 	1.27		 		 		 NCSP	B	Costing	
Results	
Health	Advisor	(GUM	Clinic	Data	
Entry)	 	0.01		 Second	 	1.00		 600	 	7.50		 	AfC6		
GUM	Clinic	Positive	Patients	
Only	
Estimate	from	pilot	researcher,	PSSRU	Band	6	Hospital	
Based	Nurse	Unit	Cost	2015	
Trt	 Website	Hosting	 	1.00		 Item	 	1.00		 1	 	1.00		 		
Based	on	apportionment	of	
pilot	costs	as	per	Tate	et	al.,	
(2009)	 Cost	invoiced	to	pilot	
Trt	
Health	Advisor	Helpline	(Online)	
-	NCSP	 	0.01		 Second	 	1.00		 120	 	1.50		 	AfC6		
64	NCSP	patients	completing	
online	called	the	helpline	
HA	Telephone	Call	Logs,	PSSRU	Band	6	Hospital	Based	
Nurse	Unit	Cost	2015	
Trt	
Health	Advisor	Helpline	(Online)	
-	GUM	 	0.01		 Second	 	1.00		 180	 	2.25		 	AfC6		
25	GUM	patients	completing	
online	called	the	helpline	
HA	Telephone	Call	Logs,	PSSRU	Band	6	Hospital	Based	
Nurse	Unit	Cost	2015	
Trt	
Health	Advisor	Helpline	(GUM)	-	
NCSP	 	0.01		 Second	 	1.00		 240	 	3.00		 	AfC6		
45	NCSP	patients	calling	
helpline	transferred	to	GUM	
HA	Telephone	Call	Logs,	PSSRU	Band	6	Hospital	Based	
Nurse	Unit	Cost	2015	
Trt	
Health	Advisor	Helpline	(GUM)	-	
GUM	 	0.01		 Second	 	1.00		 360	 	4.50		 	AfC6		
27	GUM	patients	calling	
helpline	transferred	to	GUM	
HA	Telephone	Call	Logs,	PSSRU	Band	6	Hospital	Based	
Nurse	Unit	Cost	2015	
Trt	 Pharmacist	Dispensing	 	0.02		 Second	 	1.00		 450	 	7.14		 		 		
Time	from	Pharmacist	Interview.	Cost	from	PSSRU	2012/13	
Community	Pharmacist	analysis	uplifted	by	HCHS	Pay	&	
Prices	Inflation	to	2014/15	
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Step	 Cost	Input	 Cost	(£)	 Cost	Type	 Quantity	 Time	(seconds)	
Total	
Cost	per	
Patient	
(£)	
Staff	
Grade		 Notes	 Source	
Trt	 Azithromycin	 	1.81		 Drug	 	1.00		 1	 	1.81		 		
All	patients	on	pathway	treated	
with	Azithromycin	
http://www.drugtariff.nhsbsa.nhs.uk/#/00280039-
DC/DC00279526/Part%20VIIIA%20products%20A	Dec	2015	
Trt	
GUM	Clinic	Attendance	for	
Treatment	 	31.47		 Item	 	1.00		 1	 	31.47		 		
Calculation	from	data	(Adams	et	
al.,	2014)	 Adams	et	al.,	(2014)	Sup	Info	
PN	
Included	in	Website	Hosting	
above	 	-				 Item	 	1.00		 1	 	-				 		 See	above	 		
Follow	Up	 Health	Advisor	 	0.01		 Second	 	1.00		 480	 	6.00		 	AfC6		
Based	on	average	duration	of	
calls	marked	as	HA	follow	up	
HA	Telephone	Call	Logs,	PSSRU	Band	6	Hospital	Based	
Nurse	Unit	Cost	2015	
Set	Up	 Health	Advisor	Training	 	45.00		 Hour	 	1.00		 5	 	1.02		 	AfC6		
Divided	by	the	number	of	
patients	entering	online	
pathway	to	estimate	cost	per	
patient	
Estimate	from	pilot	researcher,	PSSRU	Band	6	Hospital	
Based	Nurse	Unit	Cost	2015	
Set	Up	 Pharmacist	Training	 	57.13		 Hour	 	1.00		 1	 	0.38		 		
Divided	by	the	number	of	
patients	completing	online	
pathway	to	estimate	cost	per	
patient	
Estimate	from	pilot	researcher.	Cost	from	PSSRU	2012/13	
Community	Pharmacist	analysis	uplifted	by	HCHS	Pay	&	
Prices	Inflation	to	2014/15	
	
Table	7.21	-	OCCP	with	GUM	B	Costs	 	
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Assumptions	
89%	 %	Log	in	to	get	result	(NCSP	Negative)	
92%	 %	Log	in	to	get	result	(NCSP	Positive)	
82%	 %	Log	in	to	get	result	(GUM	Positive)	
11%	 %	Get	results	from	original	service	(NCSP	-ve)	
8%	 %	Get	results	from	original	service	(NCSP	+ve)	
18%	 %	Get	results	from	original	service	(GUM)	
1%	 %	Accessing	helpline	for	results		
66%	 %	Completing	Pathway	Online	(NCSP)	
71%	 %	Completing	Pathway	Online	(GUM)	
34%	 %	Transferred	to	GUM	(NCSP)	
29%	 %	Transferred	to	GUM	(GUM)	
93%	 %	Completing	online	calling	helpline	(NCSP)	
30%	 %	Completing	online	calling	helpline	(GUM)	
100%	 %	Transferred	to	GUM	calling	helpline	(NCSP)	
79%	 %	Transferred	to	GUM	calling	helpline	(GUM)	
Table	7.22	-	OCCP	with	GUM	B	Assumptions	
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Step	 Cost	Input	 Cost	(£)	 Cost	Type	 Quantity	 Time	(Mins)	
Total	Cost	per	
Patient	(£)	
Staff	
Grade		 Notes	 Source	
Res	-ve	 SMS	 	0.05		 Item	 	1.00		 1	 	0.05		 		 Negative	Result	 Interview	with	Service	Lead	
Res	-ve	
HCSW	Time	Results	System	
(AfC3)	 	0.42		 Minute	 	1.00		 5	 	2.08		 	AfC3		 Negative	Result	
PSSRU	2015	cost	for	Band	3	Hospital	based	
nurse	
Res	+ve	 SMS	 	0.05		 Item	 	1.00		 1	 	0.05		 		AfC6			 Positive	Result	 Interview	with	Service	Lead	
Res	+ve	 Nurse	Time	SMS	(AfC7)	 	0.90		 Minute	 	1.00		 3	 	2.70		 	AfC7		 Positive	Result	
Interview	with	Service	Lead.	PSSRU	cost	for	
band	7	hospital	based	nurse	2015	
Res	+ve	 Phone	Call	-	Admin	Time	(AfC2)	 	-				 Item	 	1.00		 2	 	-				 		 Positive	Result	
Admin	time	incorporated	in	PSSRU	estimate	
for	nursing	staff	
Res	+ve	 Nurse	Time	(AfC	7)	Phone	Call	 	0.90		 Minute	 	0.98		 3	 	2.65		 	AfC7		 Positive	Result	
Interview	with	Service	Lead.	PSSRU	cost	for	
band	7	hospital	based	nurse	2015	
Res	+ve	 Letter	Notification	 	0.65		 Item	 	0.02		 1	 	0.01		 		
Positive	Result.	Cost	of	2nd	class	post	
and	preparation	of	standard	letter	 Interview	with	Service	Lead	
Trt	 Admin	Time	(AfC	2)		 	0.38		 Minute	 	1.00		 2	 	0.77		 	AfC2		 		
Interview	with	Service	Lead.	PSSRU	cost	for	
band	2	hospital	based	nurse	2015	
Trt	 Nurse	Time	(AfC	7)	 	0.90		 Minute	 	1.00		 15	 	13.50		 	AfC7		 		
Interview	with	Service	Lead.	PSSRU	cost	for	
band	7	hospital	based	nurse	2015	
Trt	 Azithromycin	 	2.22		 Item	 	1.00		 1	 	2.22		 		 		 Interview	with	Directorate	Accountant	
Trt	 STI	Literature	 	0.06		 Item	 	3.00		 1	 	0.19		 		 Costs	not	identifiable	from	budget	
Adams	et	al.,	(2014),	Supp	info,	uplifted	
using	HCHS	inflation	to	2014/15	
Trt	 Male	Condom	 	0.06		 Item	 	10.00		 1	 	0.62		 		 Costs	not	identifiable	from	budget	
Adams	et	al.,	(2014),	Supp	info,	uplifted	
using	HCHS	inflation	to	2014/15	
PN	 PN	Slip	 	0.05		 Item	 	3.00		 1	 	0.16		 		 Costs	not	identifiable	from	budget	
Adams	et	al.,	(2014),	Supp	info,	uplifted	
using	HCHS	inflation	to	2014/15	
Sup	PN	 Nurse	Time	(AfC	7)	 	0.90		 Minute	 	1.00		 10	 	9.00		 		 Based	on	10	mins	time	per	patient	
Interview	with	Service	Lead.	PSSRU	cost	for	
band	7	hospital	based	nurse	2015	
Table	7.23	-	GUM	A	Costs	
		 409	
	
	
Assumptions	
92%	 %	Negative	Result	
8%	 %	Positive	Result	
5%	 %	Requesting	supported	PN	
Table	7.24	-	GUM	A	Assumptions	
	
Step	 Cost	Input	 Cost	(£)	 Cost	Type	 Quantity	
Time	
(Mins)	
Total	
Cost	per	
Patient	
(£)	
Total	Cost	
per	Patient	
Uplifted	to	
2014/15	
Prices		(£)	
Staff	
Grade	 Notes	 Source	 	
Cost	based	
on	PSSRU	
2015	
Total	Cost	
per	Patient	
(£)	
Res	-ve	 Nurse		 	0.75		 Minute	 	1.00		 6	 	4.50		 	4.67		 AfC	5/6		 Negative	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.68		 	4.05		
Res	-ve	 Letter	Notification	 	0.58		 Item	 	0.02		 1	 	0.01		 	0.01		 		 Negative	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.58		 	0.01		
Res	-ve	 Phone	Call	 	0.07		 Minute	 	0.03		 1	 	0.00		 	0.00		 		 Negative	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.07		 	0.00		
Res	-ve	 SMS		 	0.10		 Item	 	0.95		 1	 	0.10		 	0.10		 		 Negative	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.10		 	0.10		
Res	+ve	 Nurse		 	1.10		 Minute	 	0.50		 15	 	8.25		 	8.56		 AfC	7/8		 Positive	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.98		 	7.31		
Res	+ve	 Health	Advisor	 	1.03		 Minute	 	0.50		 15	 	7.73		 	8.01		
	Not	
Stated		 Positive	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.83		 	6.19		
Res	+ve	 Letter	Notification	 	0.58		 Item	 	0.05		 1	 	0.03		 	0.03		 		 Positive	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.07		 	0.03		
Res	+ve	 Phone	Call	 	0.07		 Minute	 	0.05		 1	 	0.00		 	0.00		 		 Positive	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.10		 	0.00		
Res	+ve	 SMS	 	0.10		 Item	 	0.90		 1	 	0.09		 	0.09		 		 Positive	Result	 Adams	et	al.,	(2014),	Supp	info	
	
	0.53		 	0.09		
Trt	 Admin/	Clerical	 	0.53		 Minute	 	1.00		 5	 	2.65		 	2.75		
Not	
Stated		 		 Adams	et	al.,	(2014),	Supp	info	
	
	0.42		 	2.08		
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Step	 Cost	Input	 Cost	(£)	 Cost	Type	 Quantity	
Time	
(Mins)	
Total	
Cost	per	
Patient	
(£)	
Total	Cost	
per	Patient	
Uplifted	to	
2014/15	
Prices		(£)	
Staff	
Grade	 Notes	 Source	 	
Cost	based	
on	PSSRU	
2015	
Total	Cost	
per	Patient	
(£)	
Trt	 Doctor/	Nurse	-	Results	 	1.45		 Minute	 	1.00		 5	 	7.25		 	7.52		
Doctor/	
AfC	7/8		 		 Adams	et	al.,	(2014),	Supp	info	
	
	1.29		 	6.44		
Trt	 Doctor/	Nurse	-	Treatment	 	1.45		 Minute	 	1.00		 6	 	8.70		 	9.03		
Doctor/	
AfC	7/8		 		 Adams	et	al.,	(2014),	Supp	info	
	
	1.29		 	7.73		
Trt	 KY	Lubricant	 	0.30		 Application	 	2.00		 1	 	0.60		 	0.62		 		 		 Adams	et	al.,	(2014),	Supp	info	
	
	0.30		 	0.62		
Trt	 STI	Literature	 	0.06		 Item	 	3.00		 1	 	0.18		 	0.19		 		 		 Adams	et	al.,	(2014),	Supp	info	
	
	0.06		 	0.19		
Trt	 Male	Condom	 	0.06		 Item	 	10.00		 1	 	0.60		 	0.62		 		 		 Adams	et	al.,	(2014),	Supp	info	
	
	0.06		 	0.62		
Trt	 Azithromycin	 	4.50		 Trt	Course	 	0.95		 1	 	4.28		 	4.44		 		 		 Adams	et	al.,	(2014),	Supp	info	
	
	4.50		 	4.44		
Trt	 Doxycycline	 	2.03		 Trt	Course	 	0.05		 1	 	0.10		 	0.11		 		 		 Adams	et	al.,	(2014),	Supp	info	
	
	2.03		 	0.11		
PN	 Doctor/	Nurse	-	PN	 	1.45		 Minute	 	1.00		 6	 	8.70		 	9.03		
Doctor/	
AfC	7/8		 		 Adams	et	al.,	(2014),	Supp	info	
	
	1.29		 	7.73		
PN	 PN	Slip	 	0.05		 Item	 	3.00		 1	 	0.15		 	0.16		 		 		 Adams	et	al.,	(2014),	Supp	info	
	
	0.05		 	0.16		
Sup	PN	 Health	Advisor	(Blend)	 	1.03		 Minute	 	1.00		 15	 	15.45		 	16.03		
Not	
Stated	 		 Adams	et	al.,	(2014),	Supp	info	
	
	0.83		 	12.38		
Sup	PN	 Phone	Call	 	0.07		 Minute	 	15.00		 1	 	1.05		 	1.09		 		 		 Adams	et	al.,	(2014),	Supp	info	
	
	0.07		 	1.09		
Table	7.25	-	GUM	B	Costs	
	
Assumptions	
100%	 %	Negative	Result	
1%	 %	Positive	Result	
10%	 %	Requesting	supported	PN	
Table	7.26	-	GUM	B	Assumptions	
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Step	 Cost	Input	 Cost	(£)	
Cost	
Type	 Quantity	
Time	
(Mins)	
Total	Cost	
per	
Patient	
(£)	
Staff	
Grade		 Notes	 Source	
Results	 Central	Results	Admin	 	0.42		 Minute	 	1.00		 3	 	1.25		 	AfC3		
Text	sent	to	all	patients	to	
notify	results	are	available	 Identified	through	pilot	costing	
Results	 Text	Message		 	0.05		 Item	 	1.00		 1	 	0.05		 		
Text	notification	undertaken	
by	lab.	Cost	included	in	
overall	price	 Estimate	by	CSO	manager	
Results	 Admin	Time	(letter)	 	0.42		 Item	 	1.00		 6	 	2.50		 	AfC3		
Text	notification	undertaken	
by	lab.	Cost	included	in	
overall	price	 Estimate	by	CSO	manager	
Results	
Letter	(paper/	printing	and	
postage)	 	0.60		 Item	 	1.00		 1	 	0.60		 		 		 Estimate	of	print	cost	and	2nd	class	post	
Results	 Admin	time	(email	result)	 	0.42		 Minute	 	1.00		 6	 	2.50		 	AfC3		 		
Estimate	by	CSO	manager.	Cost	based	on	PSSRU	2015	AfC	Band	3	
Hospital-Based	Nurse	
Results	 Nurse	(phone	result)	 	0.73		 Minute	 	1.00		 6.5	 	4.77		 	AfC6		 Positive	patients	only	
Estimate	by	CSO	manager.	Cost	based	on	PSSRU	2015	Nurse	
Specialist	(Community)	
Results		 Helpline	-	Admin		 	0.42		 Minute	 	1.00		 10	 	4.17		 	AfC3		
Undertook	study	for	8	days.	
Based	on	average	of	138	
tests	per	week,	11	calls	per	
week	
Estimate	by	CSO	manager.	Cost	based	on	PSSRU	2015	AfC	Band	3	
Hospital-Based	Nurse	
Trt	 Pharmacist	(LES)	 	0.95		 Minute	 	1.00		 17	 	16.19		 		 		
Time	from	Pharmacist	Interview.	Cost	from	PSSRU	2012/13	
Community	Pharmacist	analysis	uplifted	by	HCHS	Pay	&	Prices	
Inflation	to	2014/15	
Trt	
Azithromycin	(Community	
Pharmacy)	 	1.81		 Item	 	1.00		 1	 	1.81		 		
All	patients	on	pathway	
treated	with	Azithromycin	
http://www.drugtariff.nhsbsa.nhs.uk/#/00280039-
DC/DC00279526/Part%20VIIIA%20products%20A	Dec	2015	
Trt	 CaSH	Service	-	Nurse	 	0.73		 Minute	 	1.00		 15	 	11.00		 		AfC6			 		
Estimate	by	CSO	manager.	Cost	based	on	PSSRU	2015	Nurse	
Specialist	(Community)	
Trt	
Azithromycin	(Hospital	
Pharmacy)	 	2.22		 Item	 	1.00		 1	 	2.22		 		
Drugs	sourced	via	hospital	
pharmacy	 Drug	cost	provided	by	provider	
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Step	 Cost	Input	 Cost	(£)	
Cost	
Type	 Quantity	
Time	
(Mins)	
Total	Cost	
per	
Patient	
(£)	
Staff	
Grade		 Notes	 Source	
Trt	 STI	Literature	 	0.06		 Item	 	3.00		 1	 	0.18		 		
CSO	manager	advised	given	
to	patients	at	CaSH	clinic	 Adams	et	al.,	(2014)	Sup	Info	
Trt	 Male	Condom	 	0.06		 Item	 	10.00		 1	 	0.60		 		
CSO	manager	advised	given	
to	patients	at	CaSH	clinic	 Adams	et	al.,	(2014)	Sup	Info	
PN		 PN	Contact	Slips	 	0.05		 Item	 	3.00		 1	 	0.15		 		 		 		
Trt	 GP		 	1.97		 Minute	 	1.00		 10	 	19.67		 		 		 PSSRU	2015	GP	Cost	
Trt	
Azithromycin	(Community	
Pharmacy)	 	1.81		 Item	 	1.00		 1	 	1.81		 		 		
http://www.drugtariff.nhsbsa.nhs.uk/#/00280039-
DC/DC00279526/Part%20VIIIA%20products%20A	Dec	2015	
Trt	 Pharmacist	(Dispensing	FP10)	 	0.95		 Minute	 	1.00		 5	 	4.76		 		 		
Time	from	Pharmacist	Interview.	Cost	from	PSSRU	2012/13	
Community	Pharmacist	analysis	uplifted	by	HCHS	Pay	&	Prices	
Inflation	to	2014/15	
Trt	 Dispensing	Technician	 	0.48		 Minute	 	1.00		 5	 	2.42		 	AfC4		
Pharmacy	technician	maps	to	
AfC	band	4	
Time	from	pharmacist	interview.	Cost	from	2014/15	PSSRU	
Community	based	scientific	and	professional	staff	band	4.	
Trt	
GUM	Clinic	Attendance	for	
Treatment	&	PN	 	36.16		 Item	 	1.00		 1	 	36.16		 		
Calculation	from	data	(Adams	
et	al.,	2014)	 Adams	et	al.,	(2014)	Sup	Info	
Follow	Up	 Nurse	 	0.73		 Minute	 	1.00		 7.5	 	5.50		 AfC6	 		
Estimate	by	CSO	manager.	Cost	based	on	PSSRU	2015	Nurse	
Specialist	(Community)	
Table	7.27	-	NCSP	A	Costs	
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Assumptions	
95%	 %	Results	Notification	by	Text	
2%	 %	Results	Notification	by	Phone	
2%	 %	Results	Notification	by	Email	
1%	 %	Results	Notification	by	Letter	
8%	 %	Calls	to	helpline		
51%	 %	Treatment	by	Pharmacy	
9%	 %	Treatment	by	GP	
27%	 %	Treatment	by	CaSH	
13%	 %	Treatment	by	GUM	
Table	7.28	-	NCSP	A	Assumptions	
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Step	 Cost	Input	 Cost	(£)	
Cost	
Type	 Quantity	
Time	
(Mins)	
Total	Cost	
per	Patient	
(£)	
Staff	
Grade		 Notes	 Source	
Results	
Text	Message	
(Negatives)	 	0.05		 Item	 	1.00		 1	 	0.05		 		
Text	notification	undertaken	
by	lab.	Cost	included	in	
overall	price	 Estimate	by	CSO	lead	
Results	 Nurse	(positive)	 	0.87		 Minute	 	1.00		 17	 	14.73		 	AfC7		 Positive	patients	only	 Estimate	by	CSO	lead.	Cost	based	on	PSSRU	2015	Advanced	Nurse	(Community)	
Trt	 Pharmacist	(LES)	 	0.95		 Minute	 	1.00		 17	 	16.19		 		
	
Time	from	Pharmacist	Interview.	Cost	from	PSSRU	2012/13	Community	
Pharmacist	analysis	uplifted	by	HCHS	Pay	&	Prices	Inflation	to	2014/15	
Trt	
Azithromycin	
(Community	
Pharmacy)	 	1.81		 Item	 	1.00		 1	 	1.81		 		
All	patients	on	pathway	
treated	with	Azithromycin	
http://www.drugtariff.nhsbsa.nhs.uk/#/00280039-
DC/DC00279526/Part%20VIIIA%20products%20A	Dec	2015	
Trt	 CaSH	Service	-	Nurse	 	0.73		 Minute	 	1.00		 15	 	11.00		 	AfC6		 		
Estimate	by	CSO	manager.	Cost	based	on	PSSRU	2015	Nurse	Specialist	
(Community)	
Trt	
Azithromycin	
(Hospital	Pharmacy)	 	2.22		 Item	 	1.00		 1	 	2.22		 		
Drugs	sourced	via	hospital	
pharmacy	 Drug	cost	provided	by	provider	
Trt	 STI	Literature	 	0.06		 Item	 	3.00		 1	 	0.18		 		
Cost	unidentifiable	from	
budget	statements	 Adams	et	al.,	(2014)	Sup	Info	
Trt	 Male	Condom	 	0.06		 Item	 	10.00		 1	 	0.60		 		
Cost	unidentifiable	from	
budget	statements	 Adams	et	al.,	(2014)	Sup	Info	
PN	 PN	Contact	Slips	 	0.05		 Item	 	3.00		 1	 	0.15		 		
Cost	unidentifiable	from	
budget	statements	 Adams	et	al.,	(2014)	Sup	Info	
Trt	 GP		 	1.97		 Minute	 	1.00		 4	 	7.87		 		
No	appointment	needed,	
prescription	prepared	on	
basis	of	faxed	nurse	
assessment.	 PSSRU	2015	GP	Cost	
Trt	
Azithromycin	
(Community	
Pharmacy)	 	1.81		 Item	 	1.00		 1	 	1.81		 		 		
http://www.drugtariff.nhsbsa.nhs.uk/#/00280039-
DC/DC00279526/Part%20VIIIA%20products%20A	Dec	2015	
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Step	 Cost	Input	 Cost	(£)	
Cost	
Type	 Quantity	
Time	
(Mins)	
Total	Cost	
per	Patient	
(£)	
Staff	
Grade		 Notes	 Source	
Trt	
Pharmacist	
(Dispensing	FP10)	 	0.95		 Minute	 	1.00		 5	 	4.76		 		 		
Time	from	Pharmacist	Interview.	Cost	from	PSSRU	2012/13	Community	
Pharmacist	analysis	uplifted	by	HCHS	Pay	&	Prices	Inflation	to	2014/15	
Trt	
Dispensing	
Technician	 	0.48		 Minute	 	1.00		 5	 	2.42		 		
Pharmacy	technician	maps	
to	AfC	band	4	
Time	from	pharmacist	interview.	Cost	from	2014/15	PSSRU	Community	based	
scientific	and	professional	staff	band	4.	
Trt	
GUM	Clinic	
Attendance	for	
Treatment	&	PN	 	36.16		 Item	 	1.00		 1	 	36.16		 		
Calculation	from	data	
(Adams	et	al.,	2014)	 Adams	et	al.,	(2014)	Sup	Info	
Follow	
Up	 Nurse		 	0.73		 Minute	 	1.00		 5	 	3.67		 	AfC6		 		 Estimate	by	CSO	lead.	Cost	based	on	PSSRU	2015	Nurse	Specialist	(Community)	
Table	7.29	-	NCSP	B	Costs	
Assumptions	
92%	 %	Test	Negative	(Text)	
8%	 %	Test	Positive	(Phone	Call)	
51%	 %	Treatment	by	Pharmacy	
9%	 %	Treatment	by	GP	
27%	 %	Treatment	by	CaSH	
13%	 %	Treatment	by	GUM	
Table	7.30	-	NCSP	B	-	Assumptions	
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Table	7.31	summarises	the	cost	per	patient	for	the	two	comparator	
pathways	 –	 two	 GUM	 clinics	 and	 two	 NCSP	 internet	 testing	
pathways.		
	
Cost	per	Patient	 GUM	A	(£)	
GUM	B	
(£)	
NCSP	A	
(£)	
NCSP	B	
(£)	
Results	Notification	(Negative)	 	2.13		 	4.78		 	1.81		 	0.05		
Results	Notification	(Positive)	 	5.41		 	16.70		 	1.81		 	14.73		
Average	Treatment	Cost		 	18.07		 	36.16		 	26.97		 	22.88		
Average	Positive	Patient	
Pathway	Cost	
	23.48		 	52.86		 	28.78		 	24.15		
Table	7.31	-	Summary	Comparator	Pathway	Costs.	Average	treatment	cost	includes	the	cost	of	
treatment	and	partner	notification	at	GUM	clinic,	average	positive	patient	pathway	cost	includes	the	
cost	of	positive	results	notification,	treatment	and	partner	notification.	
	
The	variation	 in	 cost	per	patient	between	GUM	Clinic	A	and	GUM	
Clinic	 B	 is	 more	 than	 double.	 On	 investigation	 into	 the	 possible	
causes	of	this	it	was	noted	that	it	is	not	possible	to	identify	how	the	
authors	 (Turner	 et	 al.,	 2014)	 derived	 the	 unit	 costs	 for	 staffing.	
Therefore,	 the	 cost	 per	 patient	 was	 recalculated	 using	 the	 2015	
Unit	of	Health	and	Social	Care	costs	(PSSRU,	2015)	for	staffing	costs	
to	make	it	directly	comparable.	The	revised	comparator	costings	are	
presented	 in	table	7.32,	and	used	 in	a	 further	costing	for	pathway	
options	in	this	chapter.		
	
Cost	per	Patient	 GUM	A	(£)	
GUM	B	
(£)	
NCSP	A	
(£)	
NCSP	B	
(£)	
Results	Notification	(Negative)	 	2.13		 	4.16		 	1.81		 	0.05		
Results	Notification	(Positive)	 	5.41		 	13.63		 	1.81		 	14.73		
Average	Treatment	Cost		 	18.07		 	31.47		 	26.97		 	22.88		
Average	Positive	Patient	
Pathway	Cost	
	23.48		 	45.10		 	28.78		 	24.15		
Table	7.32	-	Summary	Comparator	Pathway	Costs	with	GUM	Clinic	B	re-costed	using	PSSRU	2015	
staff	costs.	Average	treatment	cost	includes	the	cost	of	treatment	and	partner	notification	at	GUM	
clinic,	average	positive	patient	pathway	cost	includes	the	cost	of	positive	results	notification,	
treatment	and	partner	notification	
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The	OCCP	interfaces	with	existing	services	at	the	following	points:	
• Results	 notification	 –	where	 a	 patient	 does	 not	 access	 the	
OCCP	to	obtain	results	within	seven	days	the	patient	reverts	
to	 the	 originating	 service,	 in	 costing	 terms	 there	 are	 four	
options	as	above,	
• GUM	Clinic	treatment	–	where	a	patient	does	not	complete	
the	 pathway	 online	 they	 are	 referred	 to	 a	 GUM	 clinic	 to	
complete	 their	 treatment.	 There	 are	 two	 options	 in	 this	
costing	exercise	–	GUM	Clinic	A	and	GUM	Clinic	B.	
	
The	cost	per	patient	for	each	of	the	combinations	of	interface	with	
existing	 pathways	 are	 shown	 in	 tables	 7.33	 –	 7.35.	 Table	 7.33	
outlines	the	cost	per	patient	of	results	notification.	
	
Cost	per	Patient	 OCCP	
Only	
(£)	
OCCP/		
NCSP	A	
(£)	
OCCP/	
NCSP	B	
(£)	
OCCP/	
GUM	A	
(£)	
OCCP/	
GUM	B	
(£)	
Results	Notification	(Negative)	 0.14	 	0.32		 	0.27		 n/a	 n/a	
Results	Notification	(Positive)	 0.14	 	2.02		 	0.23		 	1.10		 	2.60		
Table	7.33	-	Results	Notification	Costs	per	Patient	
This	 illustrates	 the	 impact	 of	 the	 variability	 of	 the	 cost	 in	
comparator	pathways	for	patients	who	choose	not	to	use	the	OCCP	
to	access	 their	 results.	 If	all	patients	accessed	 their	 result	 through	
the	 OCCP	 system,	 then	 compared	 to	 the	 comparator	 pathways	 it	
would	represent	the	lowest	cost	option	for	results	notification	in	all	
circumstances	 except	 when	 compared	 with	 NCSP	 B	 results	
notification	 for	 negative	 results	 where	 it	 is	 more	 expensive.	
However,	this	cost	of	results	notification	was	difficult	to	quantify	for	
the	 interviewee	 as	 the	 cost	 is	 bundled	 into	 the	 service	 they	
purchase	from	an	external	provider	and	the	cost	cited	was	based	on	
the	knowledge	that	this	is	an	automated	system	driven	text.	
	
The	costs	of	online	treatment	are	shown	in	table	7.34.	These	costs	
reflect	 the	 costs	 of	 treatment	 of	 patients	 who	 complete	 their	
treatment	via	the	OCCP	with	no	complications.		
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	 OCCP/	
NCSP	A	
(£)	
OCCP/	
NCSP	B	
(£)	
OCCP/	
GUM	A	
(£)	
OCCP/	
GUM	B	
(£)	
Online	Treatment	Only	 11.34	 11.34	 10.64	 10.64	
Full	Pathway	(online	only)	 19.36	 17.58	 17.74	 19.24	
Table	7.34	-	Summary	of	Online	Only	Pathway	Costs.	Online	treatment	only	includes	online	treatment	
(excluding	training	costs),	partner	notification	and	treatment	costs.	Full	pathway	includes	the	costs	
of	results	notification,	online	treatment	(excluding	training	costs)	and	health	advisor	follow	up.		
	
The	 difference	 in	 cost	 between	 NCSP	 and	 GUM	 online	 treatment	
only	 reflects	 the	costs	associated	with	 the	health	advisor	helpline.	
This	 was	 calculated	 by	 identifying	 the	 average	 (median)	 contact	
time	with	the	helpline	for	patients	originating	from	GUM	and	NCSP	
services	 and	 the	 percentage	 of	 participants	 who	 contacted	 the	
helpline	from	the	two	originating	service	categories.		
	
The	 full	 pathway	 identifies	 the	 costs	 associated	with	 the	 delivery,	
including	 the	 costs	 associated	with	 results	 notification	 and	 online	
treatment	 (excluding	 training	 costs	 and	 health	 advisor	 follow	 up).	
The	 variance	 in	 costs	 is	 driven	 by	 the	 impact	 of	 integrating	 the	
elements	 associated	 with	 existing	 services,	 in	 this	 case,	 results	
notification	 for	 patients	 not	 accessing	 their	 results	 through	 the	
OCCP	 system.	 The	 minor	 cost	 variance	 associated	 with	 helpline	
contact	 also	 accounts	 for	 the	 difference.	 A	 comparison	 of	 the	 full	
online	 pathway	 costs	 with	 the	 existing	 comparator	 pathways	 is	
summarised	in	table	7.35.	In	all	cases	where	treatment	is	provided	
fully	 online	 it	 costs	 less	 per	 patient	 than	 the	 existing	 comparator	
pathways.		
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	 NCSP	A	
(£)	
NCSP	B	
(£)	
GUM	A	
(£)	
GUM	B	
(£)	
Online	Treatment	Only	(OCCP)	 11.34	 11.34	 10.64	 10.64	
Treatment	Cost	Only	
(comparator	pathways)	 26.97	 22.88	 18.07	 36.16	
Full	Pathway	(online	only)	
(OCCP)	 19.36	 17.58	 17.74	 19.24	
Average	Positive	Patient	
Pathway	Cost	(comparator	
pathways)	
28.78	 24.15	 23.48	 45.10	
Table	7.35	-	Comparison	of	OCCP	and	existing	GUM	and	NCSP	pathways.	
	
It	 is	 recognised	 however	 that	 not	 all	 patients	 commencing	 the	
online	 pathway	 for	 treatment	 will	 complete	 their	 treatment	
through	 this	 route.	 There	 can	 be	 a	 number	 of	 reasons	 for	 this	
including	symptoms,	allergies	or	medical	conditions	which	preclude	
online	care	being	delivered	safely	(Estcourt	and	Gibbs,	2016).	In	the	
exploratory	 study	 such	 patients	were	 directed	 to	 a	 GUM	 clinic	 to	
receive	 treatment.	 In	 considering	 the	 average	 cost	 per	 patient	 of	
the	online	service,	 factoring	 in	patients	who	are	diverted	from	the	
online	 pathway	 into	 GUM	 clinics,	 the	 average	 cost	 per	 patient	 is	
outlined	in	table	7.36.	
	
	 OCCP	
(NCSP)	
GUM	A	
(£)	
OCCP	
(NCSP)	
GUM	B	
(£)	
OCCP	
(GUM)	
GUM	A	
(£)	
OCCP	
(GUM)	
GUM	B	
(£)	
Average	Treatment	Cost		 15.27	 20.13	 13.93	 18.08	
Table	7.36	-	Average	treatment	costs	for	all	patients	commencing	the	OCCP	
	
The	average	treatment	costs	include	the	average	costs	identified	for	
treating	patients	commencing	from	an	NCSP	service	(either	A	or	B)	
or	GUM,	 and	 receiving	 their	 treatment	 either	 online	or	 through	 a	
GUM	clinic	 (proportionate	to	the	split	between	the	two	treatment	
options	in	the	OCCP	pilot	for	the	respective	groups	of	patients),	and	
partner	notification.		
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The	 average	 positive	 patient	 pathway	 cost	 includes	 the	 cost	 of	
results	 notification,	 treatment,	 partner	 notification	 and	 health	
advisor	 follow	up.	These	costs	need	to	take	 into	consideration	the	
variability	of	costs	associated	with	the	interface	points	between	the	
OCCP	and	existing	services	as	follows:	
• Results	notification	via	NCSP	A,	GUM	treatment	by	GUM	A	
• Results	notification	via	NCSP	A,	GUM	treatment	by	GUM	B	
• Results	notification	via	NCSP	B,	GUM	treatment	by	GUM	A	
• Results	notification	via	NCSP	B,	GUM	treatment	by	GUM	B	
• Results	notification	via	GUM	A,	GUM	treatment	by	GUM	A	
• Results	notification	via	GUM	B,	GUM	treatment	by	GUM	B.	
	
For	results	notified	by	the	GUM	service	it	 is	assumed	that	patients	
would	receive	their	treatment	within	the	same	service	if	they	were	
unsuitable	 to	 receive	 treatment	 via	 the	 online	 pathway.	 The	
average	 patient	 costs	 for	 the	 OCCP	 and	 existing	 service	
combinations	are	presented	in	table	7.37.	
	
	
NCSP	A	
GUM	A	
(£)	
NCSP	A	
GUM	B	
(£)	
NCSP	B	
GUM	A	
(£)	
NCSP	B	
GUM	B	
(£)	
GUM	A	
GUM	A	
(£)	
GUM	B	
GUM	B	
(£)	
OCCP	Average	
Positive	Patient	
Pathway	Cost	
17.29	 22.15	 15.50	 20.36	 15.03	 20.69	
Table	7.37	-	Average	Positive	Patient	Pathway	Costs	for	OCCP	
	
The	average	positive	patient	pathway	costs	for	the	comparator	
pathways	are	shown	in	table	7.38.	
	 GUM	A	
(£)	
GUM	B	
(£)	
NCSP	A	
(£)	
NCSP	B	
(£)	
Average	Positive	Patient	
Pathway	Cost	(comparator	
pathways)	
23.48	 45.10	 28.78	 24.15	
Table	7.38	-	Average	Positive	Patient	Pathway	Costs	for	Comparator	Pathways	
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This	 shows	 the	 range	 of	 costs	 associated	 with	 treatment	 of	 all	
patients	commencing	the	OCCP	is	in	the	range	of	£15.03	to	£22.15,	
whereas	the	range	of	costs	associated	with	chlamydia	treatment	in	
the	 four	 existing	 services	 costed	 ranges	 from	 £23.48	 to	 £45.10.	
These	 differences	 in	 cost	 can	 in	 be	 explained	 by	 the	 significant	
variation	 identified	 in	 the	 delivery	 of	 care	 between	 the	 four	
pathways.	 Comparing	 the	differences	between	 the	delivery	of	 the	
GUM	Clinic	A	and	GUM	Clinic	B	services:	
• GUM	A	has	a	patient	group	direction	in	place	which	enables	
nurses	 to	 deliver	 the	 service	 for	 chlamydia	 treatment	
without	input	from	a	doctor.	The	results	notification	process	
whereby	 all	 positive	 patients	 have	 a	 phone	 call	 with	 the	
clinic	ensure	 that	patients	who	are	asymptomatic	and	only	
positive	for	chlamydia	are	treated	through	this	route.		
• GUM	B	costing	identified	the	input	of	medical	staff	into	the	
delivery	model	and	is	based	on	the	pathway	mapping	work	
undertaken	 by	 Adams	 et	 al	 (2014).	 The	 pathway	 costing	
used	 is	 designated	 that	 the	 primary	 purpose	 of	 the	 visit	 is	
chlamydia	treatment	only	(i.e.	there	is	no	secondary	reason	
for	 the	 visit	 e.g.	 further	 testing/	 a	 positive	 test	 result	 for	
another	 STI).	 Secondly	 the	 estimates	 of	 time	 to	 notify	
positive	 patients	 of	 results	 are	 significantly	 higher	 in	 this	
pathway	 costing	 than	 those	 identified	 in	 GUM	 Clinic	 A.	
Assuming	 the	 same	proportion	of	 positive	patients	 in	 both	
settings	leads	to	higher	costs	for	results	notification.	
• NCSP	A	offer	all	patients	a	choice	of	four	results	notification	
options	 and	 four	 choices	 of	 treatment.	 The	 service	 lead	
indicated	 a	 number	 of	manual	 processes	 to	 accommodate	
this.		
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• NCSP	B	use	 text	notification	 for	all	 results,	with	all	positive	
patients	 being	 asked	 to	 contact	 the	 chlamydia	 screening	
office.	 During	 this	 call	 the	 nurse	 runs	 through	 questions	
which	 form	 the	 PGD	 to	 support	 the	 decision	 making	 on	
where	 the	 patient	 should	 attend	 for	 treatment,	 with	 the	
majority	 being	 encouraged	 to	 the	 pharmacy	 route.	 For	
patients	 receiving	 treatment	 via	 a	 community	 pharmacy	
consultation	 they	 are	 asked	 the	 same	 questions	 twice	 and	
effort	 is	duplicated	on	the	part	of	healthcare	professionals.	
However,	 for	patients	choosing	 treatment	via	 their	GP,	 the	
detail	recorded	by	the	nurse	 is	shared	with	the	GP	practice	
and	a	prescription	is	issued	by	the	GP	on	the	basis	of	this	so	
this	removes	the	need	for	a	GP	appointment.		
• Both	 NCSP	 services	 include	 a	 follow	 up	 call	 by	 a	 health	
advisor	(or	nurse)	at	which	partner	notification	is	addressed	
if	 it	 hasn’t	 been	 taken	 up	 by	 the	 patient	 at	 the	 point	 of	
treatment.		
• Neither	GUM	service	indicated	any	health	advisor	follow	up.	
GUM	 A	 stated	 that	 patients	 were	 advised	 about	 the	
circumstances	under	which	they	would	need	to	contact	the	
clinic	 for	 further	 advice,	 GUM	 B	 pathway	 documentation	
provided	 no	 indication	 that	 this	 step	 had	 been	 costed.	
Whilst	this	is	consistent	in	comparing	the	costs	between	the	
two	comparator	options	this	has	been	included	in	the	OCCP	
as	 it	 is	 a	 recognised	 requirement	 of	 the	 guidelines	 for	 the	
management	of	chlamydia	(BASHH,	2006).	The	average	cost	
of	 health	 advisor	 follow	 up	 within	 the	 OCCP	 pathway	 is	
£6.00.		
	
	 	
		 423	
7.6.2 Sensitivity	Analysis	
From	the	literature	reviews	and	the	interviews	to	map	pathways	as	
part	of	 the	primary	costing	study,	 the	 following	were	 identified	as	
the	key	variables	 impacting	on	cost	of	delivering	chlamydia	results	
notification	and	treatment	via	the	OCCP:	
• System	 costs	 associated	 with	 the	 OCCP	 eHealth	 clinic	 e.g.	
hosting	and	maintenance	
• Costs	 associated	 with	 the	 helpline	 –	 call	 length	 and	 the	
percentage	of	people	accessing	the	helpline	
• The	impact	of	variation	on	the	percentage	of	the	population	
completing	the	pathway	entirely	online.	
	
A	number	of	one-way	sensitivity	analyses	were	undertaken	on	the	
OCCP	costs	to	assess	the	impact	of	these.	The	analysis	undertaken	
is	outlined	below	and	the	results	are	presented	in	table	7.39:	
• OCCP	system	costs	–	costs	halved	and	doubled		
• Helpline	cost	(results,	treatment	and	follow	up	stages)	–	call	
length	 lower	 quartile	 and	 upper	 quartile	 values	 for	 each	
stage	
• Online	 completion	 –	 percentage	 of	 people	 successfully	
completing	the	pathway	online	–	50%,	60%,	70%	and	80%	
• Helpline	 access	 –	 30%	 and	 100%	 of	 people	 access	 the	
helpline	at	the	results	and	treatment	stage	
• An	overall	 average	positive	patient	 pathway	 cost	was	 then	
identified	 for	 the	 lowest	and	highest	 cost	parameters	 from	
the	sensitivity	analysis.		
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Average	Positive	Patient	Pathway	Cost	 GUM	OCCP	
£	
NCSP	OCCP	
£	
Base	Case7	 17.86	 18.83	
A	-	System	Cost	Halved	 17.32	 18.28	
B	-	System	Cost	Doubled	 18.94	 19.92	
C	-	Helpline	Cost	Lower	Quartile	 16.83	 17.33	
D	-	Helpline	Cost	Upper	Quartile	 18.49	 21.36	
E	-	Online	Completion	70%	 17.99	 18.03	
F	-	Online	Completion	80%	 16.15	 16.18	
G	-	Online	Completion	60%	 20.00	 20.28	
H	-	Online	Completion	50%	 21.65	 21.74	
I	-	Telephone	Helpline	100%	 19.24	 18.90	
J	-	Telephone	Helpline	30%	 17.20	 17.13	
K	-	Lowest	Cost	Options	(A,	C,	F,	J)	 14.61	 13.88	
L	-	Highest	Cost	Options	(B,	D,	H,	I)	 25.29	 25.70	
Table	7.39	-	Sensitivity	Analysis	Results	
	
Comparing	 the	one-way	 sensitivity	analysis	 results	 for	 the	OCCP	 it	
can	 be	 seen	 that	 the	 range	 of	 average	 cost	 per	 patient	 for	 GUM	
patients	 is	 £16.15	 to	 £21.65	 and	 NCSP	 internet	 testing	 pathway	
patients	of	£16.18	to	£21.74.	 In	all	cases	this	 is	below	the	average	
cost	per	patient	 in	comparator	pathways	(GUM	clinic	average	cost	
per	 positive	 patient	 £34.29,	 range	 £23.48	 -	 £45.10,	NCSP	 internet	
testing	 pathway	 average	 cost	 per	 positive	 patient	 £26.46,	 range	
£24.15	 -	£28.78).	 Examining	 the	 impact	of	 the	 combination	of	 the	
lowest	 and	 highest	 cost	 options	 for	 the	 parameters	 from	 the	
sensitivity	 analysis,	 the	 highest	 cost	 options	 for	 both	 GUM	 and	
NCSP	 internet	 testing	 patients	 using	 the	 OCCP	 are	 below	 the	
average	 positive	 patient	 pathway	 costs	 for	 the	 GUM	 and	 NCSP	
comparative	options	(£34.29	and	£26.46	respectively).		
	 	
																																																						
7	-	The	base	case	value	is	derived	from	the	average	of	the	positive	patient	pathway	costs	in	table	7.37	
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However,	 if	 the	 highest	 cost	 options	 are	 combined	 (system	 costs	
double	 the	 base	 case,	 helpline	 cost	 upper	 quartile	 value,	 50%	 of	
people	 successfully	 completing	 the	 pathway	 online	 and	 100%	 of	
people	 completing	 the	 pathway	 online	 needing	 to	 contact	 the	
helpline)	then	the	average	cost	per	positive	patient	completing	the	
OCCP	 increases	 to	£25.29	and	£25.70	 for	GUM	and	NCSP	 internet	
testing	 patients	 respectively.	 This	 is	 higher	 than	 the	 lowest	 cost	
comparator	 pathway	 included	 in	 the	 costing	 study	 (£23.48	 and	
£24.18	respectively).		
	
7.7 Consequences	
The	 OCCP	 exploratory	 study	 identified	 a	 number	 of	 primary	 and	
secondary	 outcomes,	 these	 are	 summarised	 in	 table	 7.40.	Of	 these	
outcomes,	 two	 are	 key	 parameters	 for	 the	 model	 presented	 in	
Chapter	 8	 –	 the	 proportion	 of	 people	 receiving	 appropriate	 clinical	
management	(treatment	uptake)	and	the	proportion	of	sex	partners	
treated.	As	the	model	is	a	static	model,	time	to	treatment	was	not	a	
relevant	consideration.		
	
	 Proportion	of	
people	receiving	
appropriate	
clinical	
management	
Time	from	
index	diagnosis	
to	treatment	
Proportion	of	
sex	partners	
treated	
Time	from	
index	
diagnosis	to	
partner	
treatment	
OCCP	GUM	 97%	 43%	Same	day	
as	results	
notification	
76%	by	end	of	
day	after	results	
notification	
38%	(note	–	
combined	GUM	
&	NCSP	
outcome)	
Not	reported	
OCCP	NCSP	 89%	 45%	Same	day	
as	results	
notification	
67%	by	end	of	
day	after	results	
notification	
38%	(note	
combined	GUM	
and	NCSP	
outcome)	
Not	reported	
Table	7.40	-	Summary	of	OCCP	Exploratory	Study	Outcomes	(Estcourt	and	Gibbs,	2016).	
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The	 outcomes	 identified	 from	 the	 literature	 review	 detailed	 in	
section	7.4	are	summarised	in	tables	7.17	and	7.18,	along	with	their	
limitations.	 From	 the	 interviews	 with	 commissioners	 and	 service	
providers	as	part	of	the	primary	costing	study,	 limited	 information	
was	 available	 on	 the	 outcome	 measures	 which	 are	 directly	
comparable	to	the	OCCP.	Although	it	was	identified	that	these	data	
should	 be	 identifiable	 from	 routine	 datasets,	 interviews	 revealed	
that	it	is	not	possible	to	routinely	identify	this	information	from	the	
national	 data	 submissions,	 particularly	 following	 the	 decision	 to	
change	 the	 NCSP	 datasets	 in	 2013	 so	 that	 elements	 previously	
reported	 such	 as	 treatment	 uptake	 are	 no	 longer	 reported.	
Interviews	with	commissioners	revealed	that	their	monitoring	focus	
is	 on	 indicators	 which	 support	 the	 achievement	 of	 the	 PHOF	
indicator	of	2,300	diagnoses	per	100,000	population.		
		
7.8 Results	Summary		
The	costs	and	outcomes	(where	a	value	has	been	identified	for	OCCP	
and	at	least	one	of	the	comparator	options)	identified	are	presented	
in	table	7.41.	
	 GUM	
OCCP	
NCSP	
OCCP	
GUM1	 NCSP2	
Average	Positive	Patient	
Pathway	Cost	
£17.86	 £18.82	 £34.29	 £26.47	
Percentage	of	index	
patients	receiving	
treatment	
97%	 89%	 99%	
(range	72%-
99%)	
93.45%	
(range	91.6-
93.45%)	
Time	from	index	diagnosis	
to	treatment	(note	
cumulative	percentage)	
43%	Same	
day		
76%	by	end	
of	day	after		
45%	Same	
day		
67%	by	end	
of	day	after		
	 10.3%	same	
day	
12.5%	by	
end	of	day	
after	
Percentage	of	partners	
treated	
38%	 38%	 55%	(range	
46.9%	-	
90%)	
46%	(range	
45%	to	75%)	
Table	7.41	-	Summary	of	Costs	and	Outcomes	(1	–	See	table	7.16	for	references,	2	–	See	table	7.17	for	
references)	
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Meta-analysis	 of	 findings	 for	 comparator	 pathways	 from	 the	
literature	review	was	not	undertaken	as	the	reporting	of	studies	was	
not	 sufficiently	 clear.	 Therefore,	 the	 ‘base	 case’	 value	 identified	 in	
table	7.41	is	derived	from	the	study	with	the	largest	sample	size	and	
the	 range	 represents	 the	 lowest	 and	 highest	 average	 values	
identified	 from	 the	 studies	 included	 in	 the	 literature	 review.	
Presenting	 the	 costs	 and	 outcomes	 separately	 enable	 decision	
makers	to	make	their	own	assessment	of	the	findings	which	is	one	of	
the	benefits	of	a	cost-consequence	analysis	approach	(Drummond	et	
al.,	2005).		
	
This	 is	 of	 particular	 significance	 in	 pathways	 such	 as	 sexual	 health	
services	 where	 the	 commissioners	 and	 providers	 are	 split	 across	
different	 element	 of	 the	 pathways.	 In	 the	 case	 of	 chlamydia	 for	
example,	the	focus	of	LA	commissioners	is	the	delivery	of	testing	and	
treatment	 services,	 whereas	 the	 focus	 of	 CCGs	 is	 the	 provision	 of	
services	 that	 manage	 the	 long-term	 consequences	 associated	 with	
untreated	 chlamydia.	 Given	 the	 split	 in	 commissioning	
responsibilities	is	still	relatively	new	(2013)	it	is	not	yet	clear	whether	
there	has	been	any	material	change	 in	decision	making	arising	from	
this.		
	
Whilst	Drummond	and	colleagues	 identify	 the	presentation	of	costs	
and	 outcomes	 separately	 as	 a	 benefit,	 Mauskopf	 and	 colleagues	
point	 to	 it	 being	 a	 risk,	 in	 so	 far	 as	 “the	 weighting	 of	 the	 relative	
importance	 of	 different	 costs	 and	 benefits	 is	 left	 to	 each	 decision	
maker”	(Mauskopf	et	al.,	1998:282).	No	suggestion	is	offered	as	to	a	
resolution	 to	 this	 risk,	 and	 examples	 of	 how	weighting	 by	 decision	
makers	 is	managed	 in	CCA	has	not	been	 identified	 in	any	published	
studies	that	have	been	reviewed.	
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The	 costing	 study	 has	 demonstrated	 that	 utilising	 the	 OCCP	 as	 a	
method	 for	 results	 notification,	 treatment	 and	 partner	 notification	
has	 the	 potential	 to	 deliver	 a	 service	 at	 a	 lower	 cost	 per	 positive	
patient	than	existing	pathways.	The	average	cost	per	patient	includes	
the	 cost	 of	 treatment	 via	 a	 GUM	 clinic	 for	 those	 patients	 who	 are	
unable	 to	 complete	 the	 online	 pathway.	 The	 outcomes	 deliver	 a	
mixed	 picture,	 with	 time	 from	 index	 diagnosis	 to	 treatment	 being	
considerably	 better	 than	 current	 pathways	 and	 the	 percentage	 of	
people	 receiving	 treatment	 being	 broadly	 similar.	 However,	 the	
percentage	 of	 partners	 treated	 is	 significantly	 lower	 than	 existing	
pathways.	The	partner	notification	results	should	be	interpreted	with	
caution	owing	to	the	 low	numbers	of	partners	who	were	registered	
on	 the	 system	by	 index	patients	 logging	on	 to	access	 treatment	via	
the	 system	 (13	 partners	 of	NCSP	 index	 patients	 and	 15	 partners	 of	
GUM	index	patients)	and	therefore	the	measure	is	heavily	dependent	
on	index	notification	at	health	advisor	follow	up	(Estcourt	and	Gibbs,	
2016).		
	
7.9 Discussion	
The	costing	study	and	review	of	outcomes	offer	early	insight	into	the	
likely	 impact	 of	 the	 OCCP	 technology	 on	 the	 cost	 of	 delivery	 and	
outcomes	compared	with	existing	practice.		It	also	highlights	issues	to	
be	 taken	 into	 consideration	 in	 its	 future	 development	 and	 further	
research.	 It	 demonstrates	 that	 the	 OCCP	 is	 likely	 to	 be	 cost	 saving	
when	 implemented	 alongside	 existing	 pathways,	 however	 the	
proportion	 of	 patients	 requiring	 treatment	 via	 clinic	 demonstrates	
that	 its	 implementation	 could	 only	 be	 as	 an	 alternative	 treatment	
option	as	opposed	to	a	replacement	one.	Based	on	the	proportion	of	
patients	 completing	 treatment	online	or	 in	 a	GUM	clinic	within	 the	
pilot	study,	the	technology	offers	a	saving	of	£6.86	per	positive	NCSP	
patient	 treated	 and	 £16.10	 per	 positive	 GUM	 patient	 treated	
compared	with	existing	pathways.		
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A	 key	 strength	 of	 the	 study	 is	 that	 it	 uses	 comparator	 pathways	
mapped	within	 the	 last	12	months	 so	 they	are	 reflective	of	 current	
service	delivery	models	to	compare	the	OCCP	to.	The	study	identifies	
the	key	parameters	within	the	costing	where	variance	will	impact	on	
the	cost	per	patient,	across	the	OCCP	and	comparator	pathways.		
	
There	are	a	number	of	 limitations	to	this	study,	firstly	 it	 is	a	costing	
study	 based	 on	 an	 exploratory	 study	 involving	 small	 number	 of	
patients	(the	exploratory	study	was	powered	for	non-inferiority).	The	
exploratory	 study	 focused	 specifically	 on	 the	 OCCP	 and	 did	 not	
collect	 any	 primary	 data	 on	 comparator	 pathways,	 specifically	 in	
terms	of	outcomes.	Participants	opted	 into	 the	study,	 there	was	no	
randomisation	 of	 participants	 between	 the	 OCCP	 and	 control	
(comparator)	pathways	therefore	there	is	the	potential	for	bias	in	the	
results.	No	information	is	known	about	the	individuals	who	chose	not	
to	 consent	other	 than	 they	met	 the	 inclusion	 criteria	 for	 the	 study.	
Whether	 there	 is	 anything	 significant	 about	 this	 cohort	 of	 patients	
which	 would	 impact	 on	 costs	 is	 unknown.	 This	 is	 significant	 in	 the	
context	 of	 costing	 the	 service	 as	 the	 rate	 of	 completion	 of	 the	
pathway	online	is	a	key	determinant	in	the	cost	of	the	service.		
	
Data	 for	 the	 costing	 study	 was	 collected	 primarily	 from	 the	 OCCP	
system,	literature	review	and	interviews	with	those	directly	involved	
in	the	commissioning	or	provision	of	services.	As	demonstrated	in	the	
results	 section,	 both	 cost	 and	 outcome	 parameters	 for	 comparator	
pathways	were	not	well	estimated	in	the	literature,	and	variability	in	
data	quality	is	a	recognised	weakness	of	a	cost	consequence	analysis	
approach	 (Mauskopf	 et	 al.,	 1998).	 As	 discussed	 in	 the	 methods	
section	 this	 impacts	 on	 the	 level	 of	 precision	 with	 the	 costing	
however,	 this	 was	 accepted	 given	 the	 stage	 of	 technology	
development	and	scale	of	the	exploratory	study.		
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Despite	the	 limitations	 identified,	within	the	context	of	the	stage	of	
technology	development	the	findings	are	helpful	in	informing	future	
research	 and	 development.	 The	 study	 exposed	 issues	 with	 data	
collection	as	part	of	 the	exploratory	study,	 in	particular	 the	capture	
of	 data	 on	 access	 to	 the	 helpline	 was	 undertaken	 in	 an	 Excel	
spreadsheet	meaning	 that	 records	 of	 calls	 were	 not	 linked	 directly	
into	 the	 database	 capturing	 the	 patients’	 responses	 to	 the	 OCCP.	
Secondly	 it	 was	 not	 possible	 to	 disaggregate	 time	 spent	 by	 health	
advisors	 on	 research	 related	 activities	 e.g.	 service	 evaluation	
questions	at	the	end	of	the	health	advisor	follow	up	call	and	service	
delivery	 activities	 such	 as	 the	 follow	 up	 call	 itself.	 In	 considering	
future	 research	 in	 respect	 of	 the	 OCCP,	 it	 is	 accepted	 that	 a	
randomised	control	trial	is	the	next	step.	It	is	recommended	that	the	
‘back	 end’	 of	 the	 system	 is	 revised	 to	 enable	 the	 capture	 and	
recording	of	all	data	connected	with	 the	delivery	of	 the	pathway	 in	
the	same	system.		
	
Further	consideration	also	needs	to	be	given	for	clinician	support	to	
the	health	advisors	running	the	OCCP.	It	is	recognised,	although	was	
not	 quantified,	 that	 the	 sexual	 health	 clinician	 leading	 the	 OCCP	
spent	 time	 providing	 support	 to	 the	 health	 advisors	 running	 the	
helpline.	On	reflection	when	interviewed	afterwards	 it	was	believed	
that	the	majority	of	this	activity	related	to	issues	with	the	OCCP	and	
standard	operating	procedure	(SOP)	for	health	advisors	which	arose	
in	 the	course	of	 the	study.	However,	 there	were	a	small	number	of	
patients	 identified	where	 clinical	 advice	was	provided	 to	 the	health	
advisors	on	the	management	of	the	patient.	Consideration	needs	to	
be	given	in	any	future	trial	as	to	whether	this	advice	should	in	fact	be	
given,	and	if	so	the	resource	use	captured,	or	whether	if	patients	do	
not	fit	the	clinical	algorithm	and	SOP	they	should	be	directed	into	a	
clinic.			
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As	 part	 of	 the	 next	 phase	 of	 research	 it	 may	 also	 beneficial	 to	
consider	 patient	 costs.	 Whilst	 this	 is	 not	 a	 requirement	 for	
consideration	 in	 an	 economic	 evaluation	 for	 adoption	 into	
mainstream	services	 in	England	 it	 is	 recognised	that	uptake	 is	a	key	
consideration	 in	achieving	cost	effectiveness	(Tate	et	al.,	2009).	 It	 is	
recognised	 that	 the	majority	of	patients	 already	have	access	 to	 the	
base	 technology	 required	 (e.g.	 computer,	 smartphone,	 internet	
connection),	 and	 the	 qualitative	 research	 undertaken	 with	 people	
who	 completed	 the	 pathway	 indicated	 they	 believed	 it	 to	 be	more	
convenient	that	traditional	pathways	(Aicken	et	al.,	2016).	
	
Another	 key	 issue	 to	 consider	 in	 the	 next	 phase	 of	 the	 research	 is	
generalizability	 of	 the	 findings	 to	 mainstream	 practice.	 As	
demonstrated	 in	 section	 7.6	 there	 is	 significant	 variance	 in	 the	
delivery	models	of	the	four	pathways	costed,	which	in	turn	impact	on	
the	average	cost	per	positive	patient.	From	the	author’s	experience	
as	an	NHS	manager	a	key	question	is	how	do	the	costs	of	the	OCCP	
compare	 with	 an	 optimised	 current	 pathway?	 A	 second	
consideration	 is	 the	 costs	 of	 running	 the	 OCCP	 compared	with	 the	
costs	 of	 running	 existing	 services.	 At	 present	 the	 costs	 of	 both	 are	
presented	on	an	average	cost	per	positive	patient	basis	however	this	
analysis	does	not	consider	the	impact	of	the	operational	delivery.		 	
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For	example,	the	cost	requirements	to	run	the	helpline	or	a	clinic	for	
eight	hours	a	day	and	the	demand	requirements	to	ensure	effective	
utilisation	 of	 the	 capacity.	 A	 final	 consideration	 for	 future	 research	
identified	 draws	 together	 the	 findings	 of	 the	 costing	 study	 and	 the	
stated	preference	study,	to	explore	the	impact	of	preferences	in	the	
design	 of	 the	 clinical	 care	 pathway.	 For	 example,	 considering	
variation	to	the	OCCP	to	provide	access	to	a	health	care	professional	
via	 instant	 messaging	 as	 the	 DCE	 indicated	 that	 there	 is	 no	
statistically	 significant	 difference	 in	 preference	 between	 instant	
messaging	and	face-to-face	contacts,	whereas	 it	suggests	that	there	
is	 a	 statistically	 significant	difference	 for	participants	 in	 the	DCE	 for	
face-to-face	contact	compared	with	phone	contact.	
	
Considering	 where	 this	 study	 sits	 within	 the	 context	 of	 other	
published	 studies,	 this	 is	 the	 first	 review	 of	 the	 costs	 and	
consequences	 of	 an	 OCCP	 for	 chlamydia	 which	 requires	 no	 input	
from	a	health	care	professional	to	prescribe	medication.	Bracebridge	
and	 colleagues	 explore	 the	 cost	 effectiveness	 of	 a	 fully	 remote	
chlamydia	 testing	 and	 treatment	 pathway	 with	 a	 doctor	 reviewing	
responses	 to	 an	 online	 questionnaire	 prior	 to	 prescribing	 the	
treatment	and	found	that	costs	per	positive	diagnosis	were	3.5	times	
higher	 than	 the	 NCSP	 average,	 however	 this	 includes	 the	 costs	 of	
testing	 and	 running	 the	 screening	 programme	 (Bracebridge	 et	 al.,	
2012).	A	 similar	 study	 to	 the	Bracebridge	and	 colleagues	 study	was	
identified	 in	California	which	centred	on	the	use	of	website	 for	 test	
ordering	 and	 results	 notification,	 with	 an	 option	 for	 collecting	
treatment	from	a	pharmacy	or	attending	treatment	(Spielberg	et	al.,	
2014).		
	
This	 demonstrated	 a	 preference	 for	 remote	 a	 remote	 testing	 and	
treatment	pathway	but	provides	insufficient	cost	detail	other	than	to	
indicate	that	it	is	potentially	lower	cost	than	existing	options	(ibid).		
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7.10 Summary	
This	 chapter	 offers	 valuable	 insight	 into	 the	 likely	 costs	 of	
implementation	 of	 a	 novel	 online	 clinical	 care	 pathway	 for	 the	
treatment	of	chlamydia.	The	preliminary	costing	analysis	shows	that	
it	 has	 the	 potential	 to	 be	 less	 expensive	 per	 patient	 than	 existing	
pathways,	 while	 the	 exploratory	 study	 indicates	 that	 treatment	
uptake	rates	are	broadly	comparable	for	index	treatment	but	notably	
lower	for	partner	treatment.	Sensitivity	analyses	have	demonstrated	
that	the	OCCP	 is	cost	saving	compared	with	existing	pathways	 in	all	
scenarios	except	a	combination	of	all	of	 the	most	costly	options	 for	
parameters.		
	
The	 pathway	mapping	 undertaken	 as	 part	 of	 the	 costing	 study	 has	
demonstrated	 that	 there	 is	 significant	 variance	 in	 the	 way	 that	
chlamydia	 treatment	 services	 are	 currently	 delivered	 which	 have	 a	
material	 impact	 on	 cost.	 This	 is	 an	 area	 which	 service	 providers	
would	 benefit	 from	 exploring	 further	 as	 it	 demonstrates	
opportunities	 for	 saving	 cost	 within	 existing	 delivery	 models.	 One	
other	important	finding	from	the	literature	review	and	costing	study	
is	 that	with	 the	 exception	 of	 Turner	 and	 colleagues	 (2014),	 current	
pathway	 delivery	 models	 are	 not	 reflected	 in	 previous	 published	
studies	 considering	 the	 cost-effectiveness	 of	 chlamydia	 testing	 and	
treatment.		
	
In	 the	 next	 chapter	 the	 broader	 impact	 of	 the	 adoption	 of	 a	 fully	
remote	online	pathway	for	chlamydia	will	be	considered	in	a	decision	
analytic	 model	 to	 offer	 further	 insight	 into	 the	 factors	 which	 may	
influence	the	clinical	and	cost-effectiveness	of	online	care.		
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8 CHAPTER	8	–	EARLY	ECONOMIC	EVALUATION	OF	THE	
OCCP	&	A	FULLY	REMOTE	ONLINE	PATHWAY	FOR	THE	
TESTING	&	TREATMENT	OF	CHLAMYDIA	
	
8.1 Introduction	
There	 are	 widely	 recognised	 benefits	 to	 using	 decision	 analytic	
modelling	 within	 stage	 II	 economic	 evaluation	 to	 inform	 the	 eHTA	
process.	In	particular,	it	has	a	key	role	to	play	in:	
• Synthesising	data	 from	a	number	of	 sources	 relating	 to	 cost	
and	consequences;	
• Determining	the	point	at	which	the	value	of	variables	indicate	
that	the	new	technology	is	likely	to	be	cost-effective;	
• Informing	the	development	of	future	economic	evaluation	to	
be	undertaken	alongside	RCTs	(Sculpher	et	al.,	1997).	
	
Given	the	stage	of	development	of	the	OCCP	and	fully	remote	online	
pathway	 decision	 analytic	 modelling	 offers	 a	 framework	 in	 which	
data	can	be	 incorporated	from	a	wide	range	of	sources,	recognising	
the	only	data	currently	available	is	from	an	exploratory	study.	It	also	
has	advantages	over	single	study	based	economic	evaluation	because	
it	 enables	 the	 consideration	 of	 the	 longer-term	 consequences	 of	
untreated	chlamydia	which	could	not	be	captured	in	a	trial	(Briggs	et	
al.,	2006).	
	
In	 Chapter	 7	 the	 costs	 and	 outcomes	 per	 average	 patient	 were	
identified	for	the	OCCP,	testing	the	concept	of	a	fully	remote	online	
pathway	 from	 results	 notification	 to	 health	 advisor	 follow	 up.	 This	
chapter	takes	forward	this	work	to:	
• Develop	 a	 decision	 analytic	 model	 to	 conduct	 an	 economic	
evaluation	of	the	OCCP	and	the	fully	remote	online	pathway	
compared	to	current	practice	
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• Explore	 the	 uncertainty	 in	 model	 parameters	 through	
sensitivity	analyses	
• Apply	the	findings	from	the	DCE	to	 investigate	the	 impact	of	
uptake	of	testing	and	treatment	on	the	costs	and	outcomes	of	
using	 this	 new	 care	 pathway	 for	 chlamydia	 testing	 and	
treatment	in	England.			
	
This	chapter	describes	the	modelling	in	two	parts,	firstly	focusing	on	
the	 impact	 of	 the	 OCCP,	 taking	 forward	 the	 work	 presented	 in	
chapter	 7,	 and	 secondly	 exploring	 the	 potential	 impact	 of	 the	 full	
pathway	 compared	 to	 the	 GUM	 clinic	 pathway	 and	 NCSP	 internet	
testing	pathway.	The	self-test	 technology,	which	 is	being	developed	
by	 the	 eSTI2	 Consortium,	 is	 not	 yet	 ready	 for	 implementation	 into	
clinical	 practice	 or	 as	 a	 pilot	 (as	 of	 2016).	 Thus,	 this	work	 explores	
hypothetical	 scenarios	 to	 examine	 how	 the	 new	 test’s	 parameters	
and	associated	costs	would	impact	on	the	full	chlamydia	testing	and	
treatment	pathway.	As	a	result,	this	model	can	be	used	to	establish	
the	 optimum	 cost	 for	 the	 NHS	 for	 the	 eSTI2	 technology	 once	 its	
diagnostic	parameters	are	known.	
	
8.2 Methods	
The	 analysis	 was	 undertaken	 to	 inform	 the	 future	 development	 of	
the	 OCCP,	 self-test	 technology	 and	 service	 pathways	 against	 a	
backdrop	 of	 increasing	 policy	 emphasis	 on	 the	 development	 and	
implementation	of	digital	 technology	within	 the	NHS	 in	England.	As	
outlined	 in	section	3.5.1,	a	decision	analytic	model	was	selected	for	
the	following	reasons:	
• This	 is	 an	 early	 stage	 evaluation	 of	 a	 new	 technology	 and	
therefore	 the	objective	 is	 to	demonstrate	 the	 likely	 impact	
on	 costs	 and	 outcomes	 to	 inform	 future	 research	 and	
development;		
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• Data	 for	 parametrising	 a	model	 about	 the	 new	 technology	
are	somewhat	limited,	with	no	data	on	self-testing	(Stages	1	
and	 2	 in	 pathway	 E,	 figure	 2.1)	 and	only	 initial	 results	 and	
costings	 for	 the	 OCCP	 (Stages	 3	 to	 6	 in	 pathway	 E,	 figure	
2.1);	
• It	 is	 not	 yet	 known	 how	 the	 availability	 of	 self-tests	 may	
influence	sexual	behaviours,	risk	taking	and	testing	patterns,	
all	 of	 which	 would	 be	 material	 considerations	 within	 a	
dynamic	 model	 to	 inform	 parameters	 such	 as	 partner	
change	rate;	
• Whilst	 it	 is	recognised	that	dynamic	models	are	superior	to	
static	models	for	modelling	infectious	diseases	(Barton	et	al.,	
2004,	Roberts	et	 al.,	 2008)	 it	 also	 recognised	 that	 they	are	
more	complex,	costlier	and	time	consuming	to	develop.		
	
8.2.1 Conceptualising	the	Model		
The	perspective	selected	for	the	model	is	that	of	NHS	provider.	This	
included	 the	 direct	 costs	 to	 the	 provider	 of	 delivering	 the	 service	
and	excluded	patient	related	costs.	This	is	in	line	with	the	approach	
outlined	 in	 the	 MTEP	 methods	 guide	 which	 states	 that	 “models	
should	 capture	 and	 quantify	 the	 impact	 of	 introducing	 a	 new	
technology	into	current	healthcare	pathways	and	routine	NHS	use”	
(NICE,	2011b:17).		
	
The	setting	for	the	model	was	mainstream	sexual	health	services	in	
England.	The	descriptor	of	‘mainstream	sexual	health	services’	was	
defined	 as	 sexual	 health	 services	 commissioned	 by	 LAs	 to	 meet	
their	 statutory	 obligation	 to	 provide	 open	 access	 sexual	 health	
services	 in	 their	 local	area,	which	are	 free	at	 the	point	of	delivery	
(HM	Government,	2013).	
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The	 disease	 focus	 of	 the	model	 was	Chlamydia	 Trachomatis.	 This	
was	 restricted	 to	 genital	 Chlamydia	 Trachomatis	 (excluding	
Chlamydia	 Trachomatis	 infections	 of	 other	 sites).	 The	 target	
population	 identified	 was	 defined	 as	 the	 general	 population,	
recognising	 that	 sexual	 health	 services	 are	 an	 open	 access	
diagnostic	service.	It	should	be	noted	that	whilst	the	age	range	for	
the	 NCSP	 is	 16-24	 year	 olds,	 within	 this	 analysis	 no	 assumptions	
were	 made	 regarding	 an	 upper	 age	 limit.	 Population	 subgroups	
considered	 in	 the	 analysis	 included	 men	 and	 women	 who	 tested	
positive	for	genital	chlamydia	only	owing	to	the	different	potential	
long	term	complications	arising	from	untreated	chlamydia.		
	
The	two	pathways	selected	for	comparison	were:	
• The	GUM	clinic	pathway,	
• The	NCSP	internet	testing	pathway.	
	
The	 reasons	 for	 selecting	 these	 two	 options	 for	 comparison	were	
that	 they	 represent	 two	of	 the	main	pathways	of	established	care	
within	 mainstream	 sexual	 health	 services,	 and	 they	 reflect	 the	
pathways	 from	 which	 patients	 were	 sourced	 for	 the	 OCCP	
exploratory	 study	 that	 were	 mapped	 from	 results	 notification	
onwards	as	part	of	the	OCCP	costing	study	presented	in	Chapter	7.		
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8.2.2 Model	Structure		
The	structure	of	the	model	was	informed	by	both	a	review	of	static	
models	used	to	consider	the	cost-effectiveness	of	chlamydia	testing	
and	 treatment,	 and	 the	 mapping	 work	 to	 understand	 chlamydia	
testing	and	treatment	pathways	undertaken	as	part	of	 the	costing	
study.	 	 From	 the	 literature	 review	 presented	 in	 Chapter	 6,	 this	
included	static	models	presented	by	Hislop	et	al.,	(2010),	Turner	et	
al.,	 (2011)	 and	 Turner	 et	 al.,	 (2014).	 In	 addition,	 Roberts	 (2008),	
presented	 a	 summary	 of	 static	 structures	 used	 to	 evaluate	
chlamydia	 screening.	 A	 simplified	 presentation	 of	 the	 developed	
decision	tree	is	shown	in	figure	8.1.		
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Figure	8.1	-	Simplified	Decision	Tree	Underpinning	Model	
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8.2.3 Model	Assumptions	&	Parameters	used	in	the	Economic	
Model	
The	model	was	populated	with	parameters	drawn	 from	a	number	
of	data	sources,	 including	published	studies,	national	datasets	and	
primary	 data	 sources.	 The	 following	 sections	 outline	 the	
assumptions	in	respect	of	population,	disease,	uptake	of	treatment	
and	 partner	 notification,	 major	 outcomes	 –	 health	 complications	
resulting	from	untreated	chlamydia	and	test	parameters.	
	
8.2.3.1 Population	
The	 model	 was	 created	 to	 start	 at	 decision	 to	 test.	 The	 model	
contains	three	parameters	(population	tested,	proportion	of	tests	
–	male	and	 female,	 and	pregnancy	 rate)	 that	 can	be	varied	with	
respect	 to	 the	 population,	 which	 are	 summarised	 in	 table	 8.1.	
These	 parameters	 are	 constant	 across	 all	 pathways	 within	 the	
model.	
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Parameter	 Definition/	Assumptions		 Source	 Base	Case	
Values	
All	Pathways	
Population	
Tested	
Model	demonstrated	with	
a	theoretical	cohort	of	
100,000	patients.	It	is	
assumed	that	all	patients	
are	over	16.	
n/a	 100,000	
Proportion	
of	Male	
Tests	
Parameter	apportions	the	
proportion	of	the	
population	tested	to	male.	
It	is	assumed	that	the	
proportion	of	males	
testing	is	in	line	with	
current	published	data.	
Public	
Health	
England	
(2016f)	
29.8%	
Proportion	
of	Female	
Tests	
Parameter	apportions	the	
proportion	of	the	
population	tested	to	
female.	It	is	assumed	that	
the	proportion	of	females	
testing	is	in	line	with	
current	published	data.	
Public	
Health	
England	
(2016f)	
70.2%	
Pregnancy	
Rate	
Pregnancy	rate	for	16-44	
population	taken	from	
national	data	source.	
Office	for	
National	
Statistics	
(2016a)	
7.6%	
Table	8.1	-	Population	Parameters	-	Assumptions	and	Base	Case	Scenario	Values	
	
8.2.3.2 Disease	–	Genital	Chlamydia	Trachomatis	
The	 model	 created	 was	 a	 static	 model.	 Whilst	 it	 does	 not	
incorporate	 transmission	 dynamics,	 a	 number	 of	 assumptions	
were	made	about	genital	Chlamydia	Trachomatis	 as	 summarised	
in	table	8.2.	The	base	case	assumptions	are	the	same	regardless	of	
the	pathway	because	there	is	no	plausible	circumstances	in	which	
there	could	be	a	variation	that	is	driven	by	the	pathway.		
	
Parameter	 Definition/	Assumptions	 Source	 Base	Case	
Values	
All	Pathways	
Prevalence	–	
Male	
General	population	
prevalence	taken	from	
NATSAL3.	16-24	age	
range	prevalence	applied	
in	model	as	it	is	assumed	
that	the	testing	patterns	
will	continue	with	the	
highest	proportion	of	
testing	in	this	age	range.	
Sonnenberg	
et	al.	(2013)	
	
2.3%	
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Parameter	 Definition/	Assumptions	 Source	 Base	Case	
Values	
All	Pathways	
Prevalence	–	
Female	
See	above.	 Sonnenberg	
et	al.	(2013)	
3.1%	
Treatment	
Success	
It	is	assumed	that	all	
patients	are	treated	with	
azithromycin	which	
results	in	a	percentage	
of	these	patients	being	
chlamydia	free.	
Lau	and	
Qureshi	
(2002)	
	
97%	
Transmission	
to	neonate	
It	is	assumed	that	not	all	
chlamydia	positive	
mothers	will	transmit	
the	disease	to	neonate.	
Barton	and	
Roberts	
(2007)	
	
45%	
Partner	
Positivity	
It	is	assumed	that	not	all	
partners	of	index	
patients	will	be	positive.	
Value	taken	from	
published	NCSP	data.		
Public	
Health	
England	
(2016a)	
62%	
Table	8.2	-	Disease	Parameters	-	Assumptions	and	Base	Case	Scenario	Values	
It	 is	 known	 that	 a	 proportion	 of	 chlamydia	 positive	 patients	
experience	 spontaneous	 resolution	 without	 requiring	 antibiotics	
to	 treat.	 A	 recent	 study	 estimates	 this	 to	 be	 approximately	 20%	
between	 screening	 and	 returning	 for	 treatment	 (Geisler	 et	 al.,	
2013).	Spontaneous	resolution	was	not	incorporated	in	the	model	
as	 current	 pathways	 do	 not	 undertake	 any	 retesting	 prior	 to	
treatment.		
	
It	 is	 also	 known	 that	 a	 high	 proportion	 of	 patients	 will	 be	
asymptomatic,	 as	 outlined	 in	 section	 2.4.3.	 The	management	 of	
patients	 attending	 clinics	 with	 symptoms	 will	 be	 different	 to	
asymptomatic	 patients.	 Therefore,	 the	GUM	pathway	within	 the	
model	represents	the	pathway	for	asymptomatic	patients	only.		
	
8.2.3.3 Health	 Outcomes	 –	 Complications	 Resulting	 from	 Untreated	
Chlamydia	
The	model	incorporated	outcome	measures	in	the	form	of	health	
complications	 (major	 outcomes)	 resulting	 from	 untreated	
chlamydia	 rather	 than	QALYs	 for	 the	 reasons	 outlined	 in	 section	
3.5.1.		
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This	builds	upon	 the	work	 in	Chapter	7	 to	 consider	 the	process/	
system	 outcomes	 defined	 by	 the	 OCCP	 exploratory	 study	 and	
enables	an	understanding	of	the	 impact	of	the	process	measures	
on	 health	 outcomes	 in	 the	 form	 of	 complications	 arising	 from	
untreated	chlamydia.		
	
If	 chlamydial	 infection	 is	 left	 untreated	 there	 are	 a	 number	 of	
consequences	for	the	health	of	men,	women	and	neonates.	Table	
8.3	summarises	the	key	complications:	
	 Complication	of	Untreated	Chlamydia	
Men	 Urethral	Discharge	(Urethritis)	
Epididymitis	
Orchitis	
Infertility	
Women	 Cervicitis	
Endometritis	
Salpingitis	
Pelvic	Inflammatory	Disease	(PID)	
Infertility	
Preterm	rupture	of	membranes	(PROM)	
Parihepatitis	
Both	Sexes	 Proctitis	
Pharyngitis	
Reiter’s	Syndrome	
Neonates	 Conjunctivitis	
Pneumonia	
Table	8.3	-	Consequences	of	Untreated	Chlamydial	Infection	(WHO,	2011b)	
	
PID	 in	 women	 and	 epididymitis	 in	 men	 are	 recognised	
consequences	of	untreated	chlamydia	(WHO,	2007).	Of	the	2,072	
diagnoses	 of	 chlamydial	 PID	 and	 epididymitis	 made	 in	 2015	 in	
England,	 2,067	 of	 them	 were	 found	 to	 be	 chlamydial	 PID	 and	
epididymitis:	 1,511	 female	 and	560	male	 (Public	Health	 England,	
2016c).	Mortality	 is	 not	 a	 recognised	 consequence	 of	 untreated	
chlamydial	infection,	therefore	the	mortality	rate	was	assumed	to	
be	zero.(WHO,	2011b).	
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In	 their	 systematic	 review,	 Roberts	 and	 colleagues	 consider	
outcomes	as	short	term	e.g.	test	and	treat,	cost	per	case	detected	
or	longer	term	e.g.	major	outcome	averted	(Roberts	et	al.,	2012).	
Of	 the	 29	 screening	 papers	 and	 13	 diagnostic	 test	 papers	
considered	 by	 these	 authors,	 approximately	 one	 half	 considered	
short	 term	outcomes	only.	 Roberts	 and	 colleagues	believe	 these	
to	 be	 inferior	 to	 long	 term	 outcome	measures	 because	 they	 do	
not	provide	an	 indication	of	 the	overall	 success	of	 the	 screening	
programme	(ibid.).	The	outcomes	used	in	the	literature	review	of	
costs	 and	 cost-effectiveness	 outlined	 in	 Chapter	 7	 identified	 a	
range	of	short	and	long	term	outcomes	of	chlamydia	testing	which	
were	summarised	in	table	7.18.	
	
It	 can	 be	 seen	 that	 in	 terms	 of	 outcomes	 with	 respect	 to	
chlamydia	 testing	 and	 treatment,	 there	 are	 a	 number	 that	 have	
been	 adopted	 in	 previous	 cost	 effectiveness	 studies	 (see	 table	
7.11).	 For	 sequelae,	 a	 review	 of	 the	 literature	 was	 undertaken	
using	 the	 complications	 identified	 by	 the	WHO	 (set	 out	 in	 table	
8.4)	 to	 determine	 model	 parameters.	 This	 process	 reduced	 the	
number	 of	 sequelae	 for	 inclusion	 in	 the	 model,	 and	 identified	
ectopic	pregnancy,	a	complication	not	identified	by	the	WHO,	for	
inclusion	in	the	model.		
	 Complication	of	Untreated	Chlamydia	
Men	 Epididymitis	
Women	 Pelvic	Inflammatory	Disease	(PID)	
Infertility	
Ectopic	Pregnancy	
Preterm	rupture	of	membranes	(PROM)	
Neonates	 Conjunctivitis	
Pneumonia	
Table	8.4	-	Consequences	of	Untreated	Chlamydia	to	be	Included	in	the	Model	
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Uncertainty	regarding	long	term	sequelae	is	recognised	in	the	ECDC	
literature	review,	which	highlights	the	need	for	further	research	to	
understand	 the	 link	 between	 chlamydia	 and	 pelvic	 inflammatory	
disease	and	“markers	of	chlamydial	infection	that	predict	women	at	
high	risk	of	tubal	damage”	(ECDC,	2014:3).		
	
The	 parameters	 used	 in	 the	 model	 to	 estimate	 the	 long-term	
consequences	of	untreated	chlamydial	infection	are	summarised	in	
table	8.5;	these	are	common	across	all	three	pathways.	
	
Parameter	 Definition/	Assumptions	 Source	 Base	Case	
Values	
All	Pathways	
PID	 Probability	of	PID.	
Assumed	to	be	constant	
in	all	pathways.	
Price	et	
al.	(2016)	
17.1%	
Infertility	 Probability	of	Infertility.	
Assumed	to	be	constant	
in	all	pathways.	
Price	et	
al.	(2016)	
1.08%	
Infertility	
resulting	
from	PID	
Probability	of	Infertility	
resulting	from	PID.	
Assumed	to	be	constant	
in	all	pathways.	
Welte	et	
al.	(2000)	
	
11%	
Ectopic	
Pregnancy	
Probability	of	Ectopic	
Pregnancy.	Assumed	to	
be	constant	in	all	
pathways.	
Price	et	
al.	(2016)	
4.9%	
PROM	 Probability	of	PROM.	
Assumed	to	be	constant	
in	all	pathways.	
Blas	et	
al.	(2007)	
6%	
Neonatal	
Conjunctivitis	
Probability	of	neonatal	
conjunctivitis.	Assumed	to	
be	constant	in	all	
pathways.	
Welte	et	
al.	(2000)	
30%	
Neonatal	
Pneumonia	
Probability	of	neonatal	
pneumonia.	Assumed	to	
be	constant	in	all	
pathways.	
Welte	et	
al.	(2000)	
15%	
Epididymitis	 Probability	of	
epididymitis.	Assumed	to	
be	constant	in	all	
pathways.	
Welte	et	
al.	(2000)	
2%	
Table	8.5	–	Major	Outcomes	Parameters	-	Assumptions	and	Base	Case	Scenario	Values	
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8.2.3.4 Uptake	–	Testing,	Treatment	and	Partner	Notification	
There	are	a	number	of	parameters	 in	 the	model	 (summarised	 in	
table	8.6),	which	relate	to	individual	choice.	Unlike	the	population,	
disease	 and	 health	 outcomes	 parameters	 outlined	 in	 sections	
8.2.3.1	–	8.2.3.3,	 the	majority	of	 these	parameters	vary	between	
the	different	pathways	within	the	model	due	to	personal	choice.	
	
Parameter	 Definition/	
Assumptions	
Source	 Base	Case	Values	
GUM1	 NCSP	2	 Online3	
Testing	
Uptake	
Assumed	constant	
within	the	base	
case	scenario	i.e.	
based	on	a	
theoretical	cohort	
of	100,000	
patients.		
n/a	 100,000	 100,000	 100,000	
Index	
Treatment	
Uptake	
The	percentage	of	
positive	patients	
who	elect	to	
pursue	treatment.	
Values	taken	from	
OCCP	study	and	
published	
literature.	
1	–	BASHH,	
2008	
2	–	Saunders,	
2016	
3	–	Gibbs	&	
Estcourt,	2016	
99%	 88.9%	 97%	-	
GUM	
	
89%	-	
NCSP	
Partner	
Notification	
Advice	
All	index	patient	
are	given	advice	
on	notification	of	
partners		
Primary	
Costing	Study	
100%	 100%	 100%	
Partner	
Identification	
Rate	
The	number	of	
different	sex	
partners	identified	
per	index	in	the	
last	six	months	
1	–	Challenor	et	
al.,	2005	
2	–	PHE,	
personal	
communication	
3	–	Gibbs	&	
Estcourt,	2016	
1.46	
partners	
per	
index	
1.18	
partners	
per	
index	
3.05	
(GUM)	
2.80	
(NCSP)	
partners	
per	
index	
Partner	
Treatment	
Uptake	
The	percentage	of	
partners	who	are	
subsequently	
treated	
1	–	McClean	et	
al.,	2006	
2	–	PHE.,	2016	
3	–	Gibbs	&	
Estcourt,	2016	
55%	 58%	 38%		
Table	8.6	-	Uptake	Parameters	-	Assumptions	and	Base	Case	Scenario	Values	
	
	 	
		 448	
8.2.3.5 Test	Parameters	
As	 outlined	 in	 section	 8.2	 the	 technology	 was	 evaluated	 in	 two	
parts	-	the	OCCP	(from	results	notification	to	health	advisor	follow	
up)	and	the	fully	remote	online	pathway	(from	self-test	to	health	
advisor	 follow	 up).	 In	 the	 OCCP	 evaluation,	 the	 test	 parameters	
were	assumed	to	be	constant	across	all	three	pathways	(see	table	
8.7).	 For	 the	 fully	 remote	 online	 pathway,	 the	 test	 parameters	
chosen	were	the	parameters	for	the	test	in	use	at	one	of	the	OCCP	
exploratory	 study	 sites.	 As	 a	 result	 of	 the	 absence	 of	 a	 self-test	
developed	 by	 the	 eSTI2	 consortium,	 the	 test	 parameters	 used	 in	
the	 base	 case	 for	 the	 fully	 remote	 online	 pathway	 and	 the	
implications	 for	 a	 self-test	 were	 explored	 further	 in	 sensitivity	
analyses	presented	in	section	8.3.4.	
	
Parameter	 Definition/	Assumptions	 Source	 Base	Case	Values	
GUM	 NCSP		 Online	
Sensitivity	 True	Positive.	Data	taken	
from	FDA	approval	
summary	for	BD	
ProbeTec	CT	Qx	Amplified	
DNA	Assay.	
FDA	
(2008b)	
	
94.5%	 94.5%	 94.5%	
Specificity	 True	Negative.	Data	
taken	from	FDA	approval	
summary	for	BD	
ProbeTec	CT	Qx	Amplified	
DNA	Assay.	
FDA	
(2008b)	
98.9%	 98.9%	 98.9%	
False	Positive	 Data	taken	from	FDA	
approval	summary	for	BD	
ProbeTec	CT	Qx	Amplified	
DNA	Assay.	
FDA	
(2008b)	
1.1%	 1.1%	 1.1%	
False	
Negative	
Data	taken	from	FDA	
approval	summary	for	BD	
ProbeTec	CT	Qx	Amplified	
DNA	Assay.	
FDA	
(2008b)	
5.5%	 5.5%	 5.5%	
Indeterminate	 Percentage	of	tests	with	
an	indeterminate	result	
was	0.0281%,	therefore	
assumed	to	be	0%	in	the	
model.	
FDA	
(2008b)	
0%	 0%	 0%	
Table	8.7	-	Test	Parameters	-	Assumptions	and	Base	Case	Scenario	Values8		
																																																						
8	-	the	test	parameter	values	are	the	same	for	all	pathways	in	the	base	case	because	evaluation	of	the	OCCP	did	
not	commence	until	results	notification.	For	the	fully	remote	online	pathway	test	parameters	were	assumed	to	
be	the	same	across	all	pathways	in	the	base	case	and	explored	further	in	the	sensitivity	analysis	
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8.2.4 Resource	Use	&	Cost	Data	
As	 in	 Chapter	 7,	 resource	 inputs	 were	 costed	 at	 2015	 prices	
(£GBP);	where	necessary,	 the	NHS	HCHS	pay	and	prices	 inflation	
index	 (Department	of	Health,	2016a)	was	applied	 to	 inflate	costs	
to	2015	prices.	
	
8.2.4.1 OCCP	
Table	8.8	summarises	the	cost	data	used	in	the	model	to	explore	
the	impact	of	introducing	the	OCCP	at	results	notification	stage	for	
positive	 patients	 only.	 This	 necessitated	 the	 comparison	 of	 the	
OCCP	 with	 the	 GUM	 clinic	 pathway	 and	 the	 comparison	 of	 the	
OCCP	 with	 the	 NCSP	 Internet	 Testing	 Pathway	 as	 the	 costs	
associated	with	delivery	are	different.	Within	the	GUM	clinic	there	
was	a	requirement	for	staff	to	enter	patient	details	onto	the	OCCP	
system	 whereas	 for	 patients	 originating	 in	 the	 NCSP	 testing	
pathway	the	process	was	automated.		
	
Parameter	 Definition/	
Assumptions	
Source	 Base	Case	Values	 	
GUM	 NCSP		 OCCP	–	
GUM	
OCCP–	
NCSP	
Cost	of	
Testing	
Assumed	to	be	£0	in	
the	model	when	
exploring	OCCP	as	
pathway	starts	at	
results	notification	
-	 £0	 £0	 £0	 £0	
Cost	of	
Index	
Treatment	
Includes:	results	
notification,	
treatment,	partner	
notification,	health	
advisor	follow	up	
OCCP	
costing	
study	
£34.29	 £26.47	 £17.86	 £18.82	
Cost	of	
Partner	
Treatment	
Includes:	results	
notification,	
treatment,	partner	
notification,	health	
advisor	follow	up.	It	
is	assumed	that	
partners	will	be	
treated	via	the	
same	pathway	as	
index	patients	
OCCP	
costing	
study	
£34.29	 £26.47	 £17.86	 £18.82	
Table	8.8	–	Pathway	Costs	OCCP	-	Assumptions	and	Base	Case	Scenario	Values	
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8.2.4.2 Fully	remote	online	pathway	
Within	 the	 fully	 remote	 online	 pathway	 the	 costs	 of	 results	
notification	onwards	 remain	 the	 same	as	 in	 the	OCCP.	However,	
the	 costs	 of	 testing	 are	 included	 in	 the	 evaluation.	 Data	 for	 the	
costs	of	testing	were	identified	from	literature	reviews.	A	number	
of	values	for	GUM	and	NCSP	internet	testing	were	identified.	The	
base	 case	 values	 outlined	 in	 table	 8.9	 have	 been	 taken	 from	
nationally	 published	 data	 sources	 and	 costs	 of	 testing	 were	
explored	further	as	part	of	the	sensitivity	analyses.	
	
It	is	important	to	note	the	difference	between	the	costings	within	
the	OCCP	and	fully	remote	online	pathway	economic	evaluations.	
Within	 the	OCCP	 the	 costs	 of	 results	 notification	 are	 included	 in	
the	treatment	stage	as	this	is	where	the	OCCP	starts.	In	contrast,	
within	 the	 fully	 remote	 online	 pathway,	 the	 costs	 of	 results	
notification	 are	 included	 within	 the	 testing	 stage	 cost	 as	 this	 is	
where	 they	 are	 costed	 in	 current	 pathways.	 Adjustments	 have	
been	made	to	costs	 in	the	fully	remote	online	pathway	to	reflect	
this.	
	
Parameter	 Definition/	Assumptions	 Source	 Base	Case	Values	
GUM	 NCSP		 Online	
Cost	of	
Testing	
GUM	–	2014/15	reference	
costs		
NCSP	–	Preventx	reported	
average	cost	for	testing	and	
results	notification		
Online	–	as	NCSP,	adjusted	
for	results	notification	cost	
Department	
of	Health	
(2015)	
	
Public	
Accounts	
Committee	
(2009)	
£129	 £22.69	 £21.29	
Cost	of	
Index	
Treatment	
Includes:	treatment,	partner	
notification,	health	advisor	
follow	up.	Results	
notification	costs	excluded.	
OCCP	costing	
study	
£24.77	 £24.93	 £16.89	
Cost	of	
Partner	
Treatment	
Includes:	treatment,	partner	
notification,	health	advisor	
follow	up.	It	is	assumed	that	
partners	will	be	treated	via	
the	same	pathway	as	index	
patients	
OCCP	costing	
study	
£24.77	 £24.93	 £16.89	
Table	8.9	–	Pathway	Costs	Full	eSTI2	Pathway	-	Assumptions	and	Base	Case	Scenario	Values	
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8.2.4.3 Health	Outcomes	–	Complications	Resulting	from	Untreated	
Chlamydia	
In	addition	to	the	uncertainty	regarding	 long	term	complications,	
the	 literature	 also	 identified	 variation	 in	 the	 costing	 of	 the	
treatment	of	sequelae.	To	understand	the	impact	of	this	issue	Ong	
and	 colleagues	 explored	 the	 impact	 of	 chlamydia	 sequelae	 cost	
estimates	 on	 economic	 evaluations	 of	 chlamydia	 screening	
programmes	 (Ong	 et	 al.,	 2016).	 Their	 findings	 demonstrated	 a	
considerable	 variation	 in	 the	 costs	 associated	 with	 the	
management	 of	 sequelae	 for	 the	 UK	 based	 studies	 included	 in	
their	analysis,	summarised	in	table	8.10.	
	
	
Range	(Lower)	
£	
Range	(Higher)	
£	
Pelvic	Inflammatory	Disease	 171	 3,635	
Ectopic	Pregnancy	 953	 3,615	
Tubal	Factor	Infertility	 546	 6,752	
Chronic	Pelvic	Pain	 159	
(only	one	study	
included)	
Epididymitis	 21	 1,008	
Neonatal	Conjunctivitis	 11	 903	
Neonatal	Pneumonia	 433	 765	
Table	8.10	-	Range	of	chlamydia	sequelae	management	costs	reported	in	UK	studies.	
Data	at	2013/14	Costs.	Source:	Ong	et	al.,	(2016)	
In	order	to	identify	a	base	case	value	for	inclusion	in	the	model	an	
average	 was	 taken	 from	 the	 UK	 studies	 included	 in	 Ong	 and	
colleagues.	Their	study	did	not	report	a	value	for	PROM.	A	search	
of	 the	 published	 literature	 failed	 to	 identify	 any	 published	 UK	
studies	on	costs	 for	the	management	of	PROM;	therefore,	a	cost	
was	taken	from	NICE	medical	technologies	guidance	on	the	use	of	
the	 Vision	 Amniotic	 Leak	 Detector	 (NICE,	 2013)	 and	 uplifted	 to	
2014/15	 costs.	 The	 costs	 for	 adverse	 health	 outcomes	 were	
assumed	to	be	constant	across	all	pathways	in	the	model,	and	the	
base	case	values	are	presented	in	table	8.11.	
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Parameter	 Definition/	
Assumptions	
Source	 Base	Case	Values	
GUM	 NCSP		 Online	
PID		 Average	costs	taken	
Ong	et	al.,	(2016)	
uplifted	to	2014/15	
prices	
Ong	et	
al.	2016	
£1,069.54	 £1,069.54	 £1,069.54	
Infertility		 Average	costs	taken	
Ong	et	al.,	(2016)	
uplifted	to	2014/15	
prices	
Ong	et	
al.	2016	
£4,010.52	 £4,010.52	 £4,010.52	
Ectopic	
Pregnancy	
Average	costs	taken	
Ong	et	al.,	(2016)	
uplifted	to	2014/15	
prices	
Ong	et	
al.	2016	
£2,532.59	 £2,532.59	 £2,532.59	
PROM	 Cost	taken	from	
NICE	MTG15	(2013),	
uplifted	to	2014/15	
prices	
NICE	
2013	
£851	 £851	 £851	
Neonatal	
Pneumonia	
Average	costs	taken	
Ong	et	al.,	(2016)	
uplifted	to	2014/15	
prices	
Ong	et	
al.	2016	
£706.64	 £706.64	 £706.64	
Neonatal	
Conjunctivitis	
Average	costs	taken	
Ong	et	al.,	(2016)	
uplifted	to	2014/15	
prices	
Ong	et	
al.	2016	
£31.28	 £31.28	 £31.28	
Epididymitis	 Average	costs	taken	
Ong	et	al.,	(2016)	
uplifted	to	2014/15	
prices	
Ong	et	
al.	2016	
£790	 £790	 £790	
Table	8.11	–	Adverse	Health	Outcome	Costs	-	Assumptions	and	Base	Case	Scenario	Values	
	
8.2.5 Analysis	
The	 analysis	 was	 undertaken	 on	 a	 theoretical	 cohort	 of	 100,000	
people,	using	ONS	population	data	to	determine	the	split	between	
male	 and	 female	 (Office	 for	 National	 Statistics,	 2016c).	 The	 total	
number	 of	 patients	 identified	 as	 positive	 and	 therefore	 requiring	
treatment	in	the	base	case	was	3,773	(2,704	true	positive	and	1,069	
false	positive).		
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Results	are	presented	separately	as	costs	and	outcomes	rather	than	
in	 a	 measure	 of	 cost-effectiveness	 such	 as	 an	 incremental	 cost-
effectiveness	 ratio.	 This	 approach	 is	 adopted	 in	 cost	 consequence	
analysis,	 allowing	 the	opportunity	 for	 decision	makers	 to	 consider	
costs	 and	 outcomes	 separately	 (Drummond	 et	 al.,	 2005),	 a	 list	 of	
the	 costs	 and	 consequences	 presented	 is	 summarised	 in	 section	
8.3.	
	
Within	the	model	the	patient	cohort	is	assumed	to	be	homogenous,	
that	 is	there	is	no	variability	between	individual	patients	(Briggs	et	
al.,	2006).		The	model	was	constructed	to	enable	males	and	females	
to	be	considered	separately	given	the	differences	 in	consequences	
arising	from	untreated	chlamydia.	However	the	results	are	reported	
at	 a	 pathway	 level,	 the	 costs	 associated	 with	 service	 delivery	 for	
testing	and	treatment	of	chlamydia	are	the	same	for	both	sexes.		
	
Eddy	 and	 colleagues	 identify	 five	 types	 of	 model	 validation	 “face	
validity,	 verification	 (or	 internal	 validity),	 cross	 validity,	 external	
validity,	and	predictive	validity”	(Eddy	et	al.,	2012:843).			To	assure	
the	model,	the	following	checks	were	undertaken:	
• The	 face	 validity	 of	 the	model	was	 explored	with	 a	 sexual	
health	 clinician	 which	 included	 the	 model	 structure,	
parameter	inputs	and	results.	
• The	 model	 was	 constructed	 in	 Excel	 for	 Mac	 2011	 and	
populated	 with	 dummy	 parameters	 to	 test	 the	 internal	
validity	of	the	model.	Individual	equations	within	the	model	
and	summary	tables	were	checked	to	ensure	computational	
accuracy	prior	to	populating	with	the	parameters	outlined	in	
section	8.2.3	and	8.2.4.	
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• Other	 published	 studies	 exploring	 the	 costs	 and	 cost-
effectiveness	were	considered	to	determine	whether	cross-
validation	 was	 possible.	 Whilst	 no	 directly	 comparable	
studies	 were	 identified,	 the	 results	 of	 the	 model	 were	
compared	with	other	similar	studies	and	a	summary	of	 the	
findings	of	this	are	included	in	section	8.4.	
• External	 and	 predictive	 validation	 were	 not	 undertaken	 as	
this	 is	 an	 early	 economic	 evaluation	 and	 are	 recognised	 as	
not	essential	(Weinstein	et	al.,	2003).	
	
A	 key	 feature	 of	 early	 economic	 evaluation	 is	 that	 it	 is	 indicative	
rather	 than	definitive	and	significant	parameter	uncertainty	 is	one	
of	the	main	reasons	for	this	(Sculpher	et	al.,	1997).	The	aim	of	early	
economic	evaluation	 is	 to	provide	an	 indication	of	 the	 likely	 costs	
and	benefits	of	a	new	technology	and	to	 identify	areas	 for	 further	
consideration	 for	 technology	 developers.	 Therefore,	 sensitivity	
analysis	 has	 been	 undertaken.	 Reference	 was	 made	 to	 both	 the	
NICE	 MTEP	 methods	 guide	 (NICE,	 2011)	 and	 the	 ISPOR	 good	
research	practices	for	parameter	estimation	and	uncertainty	(Briggs	
et	 al.,	 2012)	 to	 inform	 the	 selection	 of	 the	 methods.	 One	 way	
sensitivity	analysis	was	selected	as	 the	method	so	 that	 the	 impact	
of	varying	individual	parameters	can	be	seen	on	the	key	outcomes	
to	provide	insight	into	the	impact	on	both	costs	and	outcomes.	Two	
way	 sensitivity	 analysis	 was	 not	 undertaken	 as	 there	 was	 no	
obvious	 correlation	 between	 parameters	 within	 the	 model	
therefore	this	may	offer	a	misleading	view.	Probabilistic	sensitivity	
analysis	 was	 not	 undertaken	 as	 it	 is	 not	 appropriate	 for	 an	 early	
economic	evaluation.	
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8.3 Results	
The	following	sections	present	the	results	for	the	base	case	values	for	
the	 OCCP	 and	 fully	 remote	 online	 pathway	 separately.	 Results	 are	
presented	for	the	following	measures:	
• Total	Index	Testing	Cost	
• Total	Index	Patient	Uptake	(TP	&	FP)	
• Total	Index	Treatment	Cost	
• Total	Index	Testing	&	Treatment	Costs		
• Total	Health	Complications	–	Index	
• Total	Cost	of	Health	Complications	–	Index	
• Total	Sex	Partners	Notified	(TP	&	FP)	
• Total	Sex	Partners	Treated	
• Total	Cost	of	Sex	Partner	Treatment	
• Total	Health	Complications	–	Sex	Partners	
• Total	Cost	of	Health	Complications	–	Sex	Partners	
• Average	Cost	per	True	Positive	Index	Patient	(excluding	health	
complications)	
• Average	Cost	per	Positive	 (TP	&	FP)	 Index	Patient	 (excluding	
health	complications)	
• For	 the	 fully	 remote	online	pathway,	 the	numbers	of	TP,	FP,	
TN	and	FN	patients.	
	
8.3.1 Base	Case	Scenario	&	Results	–	OCCP	
The	results	for	the	OCCP	base	case	scenario	outlined	in	section	8.2	
are	 summarised	 in	 table	8.12.	 In	 respect	of	 the	 integration	of	 the	
OCCP	 into	 a	 GUM	 pathway	 compared	 with	 an	 existing	 GUM	
pathway,	 the	 results	 demonstrate	 that	 75	 fewer	 patients	 take	 up	
treatment	 via	 the	 OCCP	 (3,735	 GUM	 compared	with	 3,659	 GUM-
OCCP);	 however,	 the	 cost	 of	 treatment	 delivery	 via	OCCP-GUM	 is	
£62,710	cheaper.		
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This	reduction	in	treatment	uptake	by	index	patients	on	the	GUM-
OCCP	 pathway	 translates	 into	 a	 corresponding	 increase	 in	 health	
complications	 arising	 from	 chlamydial	 infection,	 with	 nine	
additional	complications	occurring	at	an	additional	cost	of	£12,935.	
The	 similarity	 in	 uptake	 rate	 between	 the	 NCSP	 and	 NCSP-OCCP	
means	that	the	numbers	of	index	patients	taking	up	treatment	and	
health	 complications	 are	 the	 same,	 however	 the	 delivery	 of	 the	
treatment	 element	 of	 the	 pathway	 via	 the	 OCCP	 demonstrated	 a	
£28,809	cost	saving.		
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	 GUM	
	
OCCP	–	
GUM	
Difference	 NCSP		 OCCP	–	
NCSP		
Difference	
Total	Index	Testing	Cost	 n/a	 n/a	 n/a	 n/a	 n/a	 n/a	
Total	Index	Patient	Uptake	(TP	&	FP)	 3,735	 3,659	 -75	 3,354	 3,358	 4	
Total	Index	Treatment	Cost	 £128,066	 £65,356	 -£62,710	 £88,774	 £59,966	 -£28,809	
Total	Health	Complications	–	Index	 47	 56	 9	 93	 93	 0	
Total	Cost	of	Health	Complications	–	Index	 £65,275	 £78,209	 £12,935	 £130,595	 £129,949	 -£647	
Total	Sex	Partners	Notified	(TP	&	FP)	 5,453	 11,161	 5,708	 3,957	 9,401	 5,444	
Total	Sex	Partners	Treated	 2,999	 4,241	 1,242	 2,293	 3,572	 1,280	
Total	Cost	of	Sex	Partner	Treatment	 £102,837	 £75,748	 -£27,090	 £60,690	 £63,804	 £3,114	
Total	Health	Complications	–	Sex	Partners	 199	 550	 352	 135	 464	 328	
Total	Cost	of	Health	Complications	–	Sex	
Partners	
£278,733	 £772,192	 £493,459	 £190,054	 £650,432	 £460,377	
Average	Cost	per	TP	index	Patient	excl	
Health	Complications	
£86.22	 £53.80	 -£32	 £62.18	 £51.43	 -£11	
Average	Cost	per	Positive	(TP&FP)	Patient	
excl	Health	Complications	
£61.82	 £38.56	 -£23	 £44.57	 £36.86	 -£8	
Table	8.12	-	Results	for	the	OCCP	compared	with	GUM	and	NCSP	pathways	for	the	management	of	chlamydia	positive	patients	
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The	most	notable	differences	between	the	pathways	can	be	seen	at	
the	 sex	 partner	 notification	 and	 treatment	 stage.	 The	 index	
notification	 rate	 for	 partners	was	 significantly	 higher	 in	 the	OCCP	
(3.05	partners	per	index	patient	identified	by	GUM	patients	treated	
via	the	OCCP	and	2.8	partners	per	 index	for	NCSP	patients	treated	
via	 the	 OCCP)	 compared	 with	 the	 comparator	 pathways	 (1.46	
partners	per	index	via	a	GUM	clinic	and	1.18	partners	per	index	via	
the	NCSP).	This	increased	rate	of	partners	identified	per	index	was	a	
positive	 benefit	 of	 the	 OCCP	 compared	 with	 existing	 pathways.	
However,	 the	partner	 treatment	uptake	 rate	was	 lower,	with	38%	
of	 the	 partners	 identified	 by	 patients	 treated	 via	 the	 OCCP	 being	
treated	 compared	 with	 55%	 of	 GUM	 clinic	 partners	 and	 58%	 of	
NCSP	partners.	Although	results	in	table	8.12	demonstrated	a	larger	
number	 of	 partners	 treated	 via	 the	 OCCP	 owing	 to	 the	 larger	
number	 of	 partners	 identified	 (over	 1,200	 more	 than	 either	 the	
GUM	or	NCSP	 comparator	pathways),	 the	OCCP	 results	 in	 a	much	
higher	 number	 of	 sex	 partner	 health	 complications	 (352	 more	
complications	 for	 sex	 partners	 of	 index	 patients	 treated	 via	 the	
GUM-OCCP	rather	than	GUM	clinic	and	328	more	complications	for	
sex	 partners	 of	 index	 patients	 treated	 via	 the	 NCSP-OCCP	 rather	
than	NCSP	 treatment	 routes),	 and	 consequently	 results	 in	 greater	
costs	for	the	treatment	of	complications.		
	
8.3.2 Sensitivity	Analyses	–	OCCP	
The	base	case	analysis	presented	in	the	previous	section	identified	
a	 number	 of	 parameters	within	 the	model	which	 have	 a	material	
impact	on	both	costs	and	health	outcomes:	
• Index	treatment	uptake,	
• Sex	partner	notification	rate,	
• Sex	partner	treatment	uptake	rate.	
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There	 is	 high	 uncertainty	 within	 these	 as	 they	 are	 driven	 by	
personal	 choice	 and	 potentially	 could	 be	 improved	 upon	 with	
modifications	to	pathways.	The	values	considered	in	the	sensitivity	
analysis	were	based	on	 the	OCCP	achieving	 the	value	achieved	by	
the	 comparator	 pathway,	 and	 an	 incremental	 scale	 of	 values	 in	
between.	One-way	 sensitivity	analysis	on	 these	parameters	within	
the	OCCP	pathway	demonstrated	 the	 impact	of	 the	key	measures	
as	follows:	
	
8.3.2.1 Impact	of	Index	(TP	&	FP)	Uptake	Rate	
Table	8.13	outlines	the	impact	of	the	OCCP	achieving	the	same	or	
better	index	(TP	&	FP)	treatment	uptake	rate:	
	
 
%	
Uptake	
Total	Index	
Uptake	(TP	
&	FP)	
Total	
Cost	
£	
Total	
Major	
Outcomes	
–	Index	
Cost	of	Health	
Complications	
–	Index	
£	
GUM	Base	Case	 99%	 	3,735		 	230,904		 	47		 	65,275		
GUM-OCCP	Base	
Case	 97%	 	3,659		 	141,104		 	56		 	78,209		
GUM-OCCP	
100%	Uptake	 100%	 	3,773		 	145,468		 	42		 	58,807		
GUM-OCCP	99%	
Uptake	 99%	 	3,735		 	144,013		 	47		 	65,275		
NCSP	Base	Case	 89%	 	3,354		 	88,774		 	93		 	130,595		
NCSP-OCCP	Base	
Case	 89%	 	3,358		 	59,966		 	93		 	129,949		
NCSP-OCCP	
100%	Uptake	 100%	 	3,773		 	139,067		 	42		 	58,807		
NCSP-OCCP	95%	
Uptake	 95%	 	3,584		 	132,114		 	65		 	91,144		
Table	8.13	–	Sensitivity	Analysis	-	Impact	of	Index	Treatment	Uptake	Rate	
Achieving	the	same	levels	of	uptake	as	the	GUM	clinic	in	the	GUM	
OCCP	would	 result	 in	 the	 same	 number	 of	major	 outcomes	 and	
associated	 cost,	 but	 at	 a	 reduced	 cost	 £144,013	 via	 the	 OCCP	
compared	with	£230,904	via	the	existing	GUM	clinic	pathway.		
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Within	 the	NCSP	 internet	 testing	pathway	 the	uptake	 rates	were	
within	 0.01%	 of	 each	 other	 therefore	 both	 are	 comparable	 in	
respect	 of	 health	 complications.	However,	 the	 cost	 of	 treatment	
delivery	 via	 the	 OCCP	 is	 lower	 compared	 with	 the	 cost	 of	
treatment	 delivered	 via	 the	 current	 NCSP	 treatment	 options	 of	
internet	testing	patients.	
	
8.3.2.2 Sex	Partners	Identified	per	Index	Patient	
Table	 8.14	 summarises	 the	 impact	 of	 sex	 partners	 identified	 per	
index	 patient.	 Recognising	 the	 OCCP	 achieved	 a	 notably	 higher	
number	of	sex	partners	identified	per	index	patient,	consideration	
was	 given	 to	 the	 impact	 of	 a	 lower	 level	 of	 identification	within	
this	 pathway,	 given	 that	 in	 comparator	 pathways	 a	 lower	
identification	rate	was	achieved	from	the	same	patient	cohort.			
	 	
		 461	
	
	
 
Rate	per	
Index	
Total	Sex	
Partners	
Treated	
(TP	&	FP)	
Total	
Cost	
£	
Total	
Major	
Outcomes	
-	Sex	
Partner	
Cost	of	Health	
Complications	-	
Sex	Partner	
£	
GUM	Base	Case	 	1.46		 	2,999		 	102,837		 	199		 	278,733		
GUM-OCCP	Base	
Case	 	3.05		 	4,241		 	75,748		 	550		 	772,192		
GUM-OCCP	2.5	
partners	notified	
per	index	
	2.50		 	3,476		 	62,088		 	451		 	632,944		
GUM-OCCP	2	
partners	notified	
per	index	
	2.00		 	2,781		 	49,671		 	361		 	506,355		
GUM-OCCP	1.5	
partners	notified	
per	index	
	1.50		 	2,086		 	37,253		 	271		 	379,766		
GUM-OCCP	1.46	
partners	notified	
per	index	
	1.46		 	2,030		 	36,260		 	264		 	369,639		
NCSP	Base	Case	 	1.18		 	2,293		 	60,690		 	135		 	190,054		
NCSP-OCCP	Base	
Case	 	2.80		 	3,572		 	63,804		 	464		 	650,432		
NCSP-OCCP	2.5	
partners	notified	
per	index	
	2.50		 	3,190		 	56,968		 	414		 	580,742		
NCSP-OCCP	2	
partners	notified	
per	index	
	2.00		 	2,552		 	45,574		 	331		 	464,594		
NCSP-OCCP	1.5	
partners	notified	
per	index	
	1.50		 	1,914		 	34,181		 	248		 	348,445		
NCSP-OCCP	1.18	
partners	notified	
per	index	
	1.18		 	1,506		 	26,889		 	195		 	274,110		
Table	8.14	–	Sensitivity	Analysis	-	Impact	of	Sex	Partner	Identification	Rate	
	
The	sensitivity	analysis	of	this	partner	identification	rate	illustrates	
that	 the	 total	 number	 of	major	 outcomes	 for	 the	OCCP	 remains	
above	that	of	the	GUM	or	NCSP	comparator	pathways,	therefore	
the	 only	 other	 parameter	 with	 a	 direct	 impact	 on	 this	 is	 the	
number	of	sex	partners	taking	up	treatment.		
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8.3.2.3 Sex	Partners	(TP	&	FP)	Taking	up	Treatment	
Table	 8.15	 shows	 the	 impact	 of	 the	 percentage	 of	 sex	 partners	
taking	up	 treatment,	with	 the	 rate	of	 sex	partners	 identified	per	
index	as	per	 the	base	case.	The	values	were	selected	 to	 test	 the	
impact	of	achieving	an	 incremental	 improvement	 from	the	value	
in	 the	 OCCP	 base	 case	 through	 to	 the	 value	 in	 the	 comparator	
base	case:	
	
 
%	Partner	
Treatment	
Uptake	
Total	Sex	
Partner	
Uptake	(TP	
&	FP)	
Total	Cost	
£	
Total	
Major	
Outcomes	
-	Sex	
Partner	
Cost	of	Health	
Complications	
-	Sex	Partner	
£	
GUM	Base	Case	 55%	 	2,999		 102,837		 	199		 	278,733		
GUM-OCCP	Base	
Case	 38%	 	4,241		 	75,748		 	550		 	772,192		
GUM-OCCP	60%	
partner	uptake	 60%	 	6,697		 	119,602		 	364		 	511,207		
GUM-OCCP	55%	
partner	uptake	 55%	 	6,139		 	109,635		 	407		 	570,522		
GUM-OCCP	50%	
partner	uptake	 50%	 	5,581		 	99,668		 	449		 	629,836		
GUM-OCCP	45%	
partner	uptake	 45%	 	5,022		 	89,701		 	491		 	689,151		
GUM-OCCP	40%	
partner	uptake	 40%	 	4,464		 	79,734		 	534		 	748,466		
NCSP	Base	Case	 58%	 	2,293		 	60,690		 	135		 	190,054		
NCSP-OCCP	
Base	Case	 38%	 	3,572		 	63,804		 	464		 	650,432		
NCSP-OCCP	60%	
partner	uptake	 60%	 	5,641		 	100,743		 	307		 	430,599		
NCSP-OCCP	58%	
partner	uptake	 58%	 	5,453		 	97,385		 	321		 	450,584		
NCSP-OCCP	55%	
partner	uptake	 55%	 	5,171		 	92,347		 	343		 	480,561		
NCSP-OCCP	50%	
partner	uptake	 50%	 	4,701		 	83,952		 	378		 	530,523		
NCSP-OCCP	45%	
partner	uptake	 45%	 	4,231		 	75,557		 	414		 	580,485		
NCSP-OCCP	40%	
partner	uptake	 40%	 	3,760		 	67,162		 	449		 	630,447		
Table	8.15	–	Sensitivity	Analysis	–	Impact	of	Sex	Partner	Treatment	Uptake	
	 	
		 463	
This	sensitivity	analysis	demonstrated	that	regardless	of	increasing	
the	uptake	rate	to	reach	the	base	case	value	for	 the	comparator	
pathways,	 the	 total	 number	 of	 health	 complications	 remains	
higher	 within	 the	 OCCP	 pathways.	 This	 reflects	 the	
interdependency	between	both	sex	partner	identification	rate	and	
sex	 partner	 treatment	 uptake	 rate	 in	 avoiding	 health	
complications	and	the	costs	associated	with	them.		
	
8.3.2.4 Sex	Partners	(TP	&	FP)	Taking	up	Treatment	(rate	per	index	as	
per	comparator	pathway)	
To	explore	the	link	further	between	sex	partner	identification	rate	
and	 sex	 partner	 treatment	 uptake	 rate,	 sensitivity	 analysis	 was	
undertaken	 on	 treatment	 uptake	 rate	 using	 the	 same	 value	 for	
identification	 rate	 as	 the	 comparator	 pathways.	 The	 results	 are	
presented	in	table	8.16.	
 
%	Partner	
Treatment	
Uptake	
Total	Sex	
Partner	
Uptake	
(TP	&	FP)	
Total	
Cost	
£	
Total	Major	
Outcomes	-	
Sex	Partner	
Cost	of	Health	
Complications	
-	Sex	Partner	
£	
GUM	Base	Case	 55%	 	2,999		 	102,837		 	199		 	278,733		
GUM	-OCCP	
Base	Case	 38%	 	2,030		 	36,260		 	264		 	369,639		
GUM-OCCP	 60%	 	3,206		 	57,252		 	174		 	244,709		
GUM-OCCP	 55%	 	2,938		 	52,481		 	195		 	273,102		
GUM-OCCP	 50%	 	2,671		 	47,710		 	215		 	301,495		
GUM-OCCP	 45%	 	2,404		 	42,939		 	235		 	329,889		
GUM-OCCP	 40%	 	2,137		 	38,168		 	255		 	358,282		
NCSP	Base	Case	 58%	 	2,293		 	60,690		 	135		 	190,054		
NCSP-OCCP	
Base	Case	 38%	 	1,506		 	26,889		 	195		 	274,110		
NCSP-OCCP	 60%	 	2,377		 	42,456		 	129		 	181,467		
NCSP-OCCP	 58%	 	2,298		 	41,041		 	135		 	189,889		
NCSP-OCCP	 55%	 	2,179		 	38,918		 	144		 	202,522		
NCSP-OCCP	 50%	 	1,981		 	35,380		 	159		 	223,578		
NCSP-OCCP	 45%	 	1,783		 	31,842		 	174		 	244,633		
NCSP-OCCP	 40%	 	1,585		 	28,304		 	189		 	265,688		
Table	8.16	–	Sensitivity	Analysis	–	Sex	Partner	Treatment	Uptake	with	Sex	Partner	Identification	rate	
at	comparator	pathway	rate	(GUM	–	1.46	partners	per	index,	NCSP	–	1.18	partners	per	index)	
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This	analysis	demonstrated	 that	where	 these	parameters	are	 the	
same	as	 the	comparator	pathway,	 the	parameter	 influencing	 the	
number	 of	 partners	 treated	 is	 the	 index	 uptake	 rate	 i.e.	 fewer	
index	patients	treated	 leads	to	fewer	partners	treated	where	the	
parameters	relating	to	partners	are	constant.	
	
8.3.3 Base	Case	Scenario	&	Results	–	Fully	Remote	Online	
Pathway		
This	section	presents	the	findings	relating	to	the	fully	remote	online	
pathway	 from	 self-test	 to	 partner	 treatment	 and	 health	 advisor	
follow	 up.	 Table	 8.17	 outlines	 the	 results	 of	 the	 key	 outcome	
measures	 for	 a	 theoretical	 cohort	 of	 100,000	 people.	 Having	
evaluated	and	reported	on	the	base	case	parameters	and	sensitivity	
analysis	for	the	OCCP	in	the	previous	sections,	the	key	parameters	
where	variance	could	 impact	on	outcomes	and	cost	at	 the	 testing	
stage	are	test	cost	and	test	performance	characteristics	(sensitivity	
and	 specificity).	Within	 the	 base	 case,	 the	 test	 characteristics	 are	
the	 same	 across	 all	 three	 pathways	 as	 the	 self-test	 for	 the	 fully	
remote	online	pathway	has	not	yet	been	developed,	therefore	the	
only	variance	in	the	test	parameters	between	the	pathways	 is	test	
cost.		
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	 GUM	
	
NCSP	 Online	 Difference	
Online	-	GUM	
Difference	
Online	-	NCSP		
Total	Index	Testing	Cost	 £12,900,000	 £2,269,000	 £2,129,000	 -£10,771,000	 -£140,000	
Total	Index	Patient	Treatment	Uptake	
(TP	&	FP)	
3,735	 3,354	 3,358	 -377	 4	
Total	Index	Treatment	Cost	 £92,511	 £83,610	 £56,709	 -£35,802	 -£26,901	
Total	Index	Testing	&	Treatment	Cost	 £13,066,797	 £2,409,768	 £2,246,047	 -£10,820,750	 -£163,721	
Total	Health	Complications	–	Index	 47	 93	 93	 46	 0	
Total	Cost	of	Health	Complications	–	
Index	
£62,275	 £130,595	 £129,949	 £64,674	 -£647	
Total	Sex	Partners	Notified	(TP	&	FP)	 5,453	 3,957	 9,401	 3,948	 5,444	
Total	Sex	Partners	Treated	 2,999	 2,293	 3,572	 573	 1,280	
Total	Cost	of	Sex	Partner	Treatment	 £74,286	 £57,159	 £60,338	 -£13,948	 £3,180	
Total	Health	Complications	–	Sex	
Partners	
199	 135	 464	 265	 328	
Total	Cost	of	Health	Complications	–	
Sex	Partners	
£278,733	 £190,054	 £650,432	 £371,698	 £460,377	
Average	Cost	per	TP	index	Patient	excl	
Health	Complications	
£1,771	 £1,002	 £933	 -£3,948	 -£69	
Average	Cost	per	Positive	(TP&FP)	
Patient	excl	Health	Complications	
£3,499	 £719	 £669	 -£2,830	 -£50	
Table	8.17	–	Fully	Remote	Online	Pathway	Base	Case	Scenario	Results	
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It	can	be	seen	that	the	cost	of	testing	is	notably	higher	in	GUM.	It	is	
important	to	recognise	that	the	reference	cost	for	a	first	outpatient	
attendance	in	GUM	is	derived	from	the	aggregate	costs	associated	
with	 all	 GUM	 activity,	 and	 as	 highlighted	 in	 section	 2.4.4;	 the	
management	 of	 asymptomatic	 patients	 in	 GUM	 sees	 patients	
routinely	 tested	 for	 gonorrhoea,	 HIV	 and	 syphilis	 in	 addition	 to	
chlamydia.		
	
8.3.4 Sensitivity	Analysis	–	Fully	Remote	Online	Pathway	
As	 noted	 in	 the	 previous	 section,	 the	 two	 parameters	 which	
influence	 cost	 and	 health	 outcomes	 at	 the	 testing	 stage	 are	 test	
performance	characteristics	and	test	cost.		
	
8.3.4.1 Test	Performance	Characteristics	
In	the	base	case	scenario	for	all	three	pathways	the	BD	ProbeTec	
test	performance	characteristics	were	adopted	as	 this	 is	 the	 test	
identified	 in	 operation	 at	 one	 of	 the	 sites	 within	 the	 OCCP	
exploratory	 study.	 Four	 tests	 are	 recognised	 within	 the	 BASHH	
testing	 guidelines	 for	 chlamydia	 as	 commonly	 used	 in	 clinical	
practice	 in	 the	UK	 (BASHH,	2010).	These	are	summarised	 further	
in	table	8.18,	along	with	a	fifth	test	which	was	recently	approved	
by	the	FDA	(2013),	and	is	currently	subject	to	service	evaluations	
within	the	NHS,	the	Xpert	CT/NG	assay	(FDA,	2013).		
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Test	Assay	 Sensitivity	 Specificity	 TP	 FP	 TN	 FN	 PPV	
BD	ProbeTec	CT	
Qx	Amplified	DNA	
Assay	(FDA,	
2008b)	
94.50%	 98.90%	 2,704	 1,069	 96,070	 157	 72%	
Abbott	RealTime	
CT/NG	Assay	
(FDA,	2006)	
94.97%	 99.17%	 2,718	 806	 96,332	 144	 77%	
Aptima	CT	Assay	
(FDA,	2008a)	 96.83%	 96.35%	 2,771	 3,546	 93,593	 91	 44%	
Cobas	Amplicor	
CT/	NG	Test	(FDA,	
1998)	
93.06%	 97.86%	 2,663	 2,079	 95,060	 199	 56%	
Xpert	CT/NG	
Assay	(FDA,	2013)	 96.35%	 99.57%	 2,757	 418	 96,721	 104	 87%	
Table	8.18	-	Test	Performance	Characteristics	for	Commonly	Used	Chlamydia	Tests	in	the	UK	
Key	–	TP	–	True	Positive,	FP	–	False	Positive,	TN	–	True	Negative,	FN	–	False	Negative,	PPV	–	Positive	
Predictive	Value	
	
	
The	PPV	has	been	derived	using	 the	prevalence	 rate	used	 in	 the	
model	 from	NATSAL3	 (a	 general	 population	 sample)	 of	 2.3%	 for	
males	and	3.1%	for	females	(Sonnenberg	et	al.,	2013).	The	PPV	is	
considerably	lower	than	the	minimum	standard	set	by	BASHH	for	
chlamydia	screening	tests	of	90%	(BASHH,	2010).		
	
The	MTEP	methods	 guide	 highlights	 that	 a	 recommendation	 for	
adoption	 within	 the	 NHS	 is	 usually	 made	 when	 it	 is	 considered	
that:	
• “there	 is	sufficient	certainty	that	the	technology	produces	
at	 least	 equivalent	 clinical	 and/or	 health	 system	 benefits	
compared	 with	 current	 management	 options	 and	 with	 a	
net	reduction	in	resources	required;	or	
• there	 is	 sufficient	 certainty	 that	 the	 technology	 produces	
significantly	 greater	 clinical	 and/or	 healthcare	 system	
benefits	 compared	with	 current	management	 options	 for	
similar	investment	of	resources”	(NICE,	2011b:21).	
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Hence,	 there	 is	 no	 basis	 to	 consider	 test	 performance	
characteristics	 below	 those	 identified	 for	 the	 current	 range	 of	
acceptable	test.	It	was	therefore	decided	to	use	the	characteristics	
for	Xpert	to	include	in	the	sensitivity	analysis	for	the	eSTI2	self-test	
in	the	absence	of	actual	self-test	performance	characteristics,	the	
results	are	summarised	in	table	8.19.	The	first	 important	point	to	
note	 is	the	 increase	 in	the	 identification	of	true	positive	(53)	and	
reduction	in	the	number	of	false	positive	(651)	patients	diagnosed	
with	 chlamydia.	 This	 is	 particularly	 significant	 given	 the	 costs	
incurred	 in	 the	 treatment	 of	 index	 and	 sex	 partners	with	 a	 false	
positive	result.		
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	 GUM	
	
NCSP	 Online	 Difference	
Online	-	GUM	
Difference	
Online	-	NCSP		
Number	of	True	Positive	Results	 2,704	 2,704	 2,757	 53	 53	
Number	of	False	Negative	Results	 157	 157	 104	 -53	 -53	
Number	of	True	Negative	Results	 96,070	 96,070	 96,721	 651	 651	
Number	of	False	Positive	Results	 1,069	 1,069	 418	 -651	 -651	
True	Positive	Index	Treatment	Uptake	 2,150	 1,643	 2,561	 411	 918	
Total	Index	Testing	Cost	 £12,900,000	 £2,269,000	 £2,129,000	 -£10,771,000	 -£140,000	
Total	Index	Patient	Treatment	Uptake	(TP	&	FP)	 3,735	 3,354	 2,825	 -909	 -528	
Total	Index	Treatment	Cost	 £92,511	 £83,610	 £47,721	 -£44,790	 -£35,888	
Total	Index	Testing	&	Treatment	Cost	 £13,066,797	 £2,409,768	 £2,227,497	 -£10,839,300	 -£182,271	
Total	Health	Complications	–	Index	 47	 93	 85	 38	 -8	
Total	Cost	of	Health	Complications	–	Index	 £62,275	 £130,595	 £118,680	 £53,400	 -£11,915	
Total	Sex	Partners	Notified	(TP	&	FP)	 5,453	 3,957	 7,911	 2,458	 3,954	
Total	Sex	Partners	Treated	 2,999	 2,293	 3006	 7	 713	
Total	Cost	of	Sex	Partner	Treatment	 £74,286	 £57,159	 £50,776	 -£23,511	 -£6,383	
Total	Health	Complications	–	Sex	Partners	 199	 135	 473	 274	 337	
Total	Cost	of	Health	Complications	–	Sex	Partners	 £278,733	 £190,054	 £663,165	 £384,432	 £473,111	
Average	Cost	per	TP	index	Patient	excl	Health	
Complications	
£4,881	 £1,002	 £908	 -£3,973	 -£95	
Average	Cost	per	Positive	(TP&FP)	Patient	excl	
Health	Complications	
£3,499	 £719	 £718	 -£2,710	 £70	
Table	8.19	-	Sensitivity	Analysis	-		Test	Performance	Characteristics		
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8.3.4.2 GUM	Cost	
As	outlined	 in	 section	8.3.3	 the	costs	associated	with	 testing	are	
notably	higher	in	the	GUM	clinic	than	the	NCSP	pathway.	This	is	in	
part	due	 to	 the	delivery	of	 testing	within	a	clinic	 setting	and	 the	
wider	 range	 of	 activities	 undertaken	 in	 a	 GUM	 setting	 beyond	
chlamydia	 testing.	 Adams	 and	 colleagues	 undertook	 pathway	
mapping	on	a	GUM	clinic	pathway	as	part	of	their	consideration	of	
the	 implementation	 of	 POCT	 NAATs	 within	 GUM	 clinics	 for	
chlamydia	and	gonorrhoea	(Adams	et	al.,	2014).	They	identified	a	
cost	of	£45.34	for	chlamydia	testing	only	within	GUM,	which	when	
uplifted	 to	 2014/15	 prices	 was	 £45.75.	 Using	 this	 value	 as	 the	
testing	cost	within	GUM	(recognising	the	self-test	cost	is	currently	
the	lowest)	identified	that	despite	the	impact	of	higher	index	and	
partner	treatment	rates	 in	GUM	compared	with	the	fully	remote	
online	 pathway,	 reducing	 the	 cost	 of	 GUM	 testing	 to	 the	 value	
identified	 by	 Adams	 and	 colleagues	 did	 not	 reduce	 the	 average	
cost	per	patient	to	below	that	of	the	fully	remote	online	pathway.	
The	results	are	summarised	in	table	8.20.	
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	 GUM	
	
NCSP	 Online	 Difference	
Online	-	GUM	
Difference	
Online-	NCSP		
Total	Index	Testing	Cost	 £4,575,000	 £2,269,000	 £2,129,000	 -£2,446,000	 -£140,000	
Total	Index	Patient	Treatment	Uptake	(TP	&	
FP)	
3,735	 3,354	 3,358	 -377	 4	
Total	Index	Treatment	Cost	 £92,511	 £83,610	 £56,709	 -£35,802	 -£26,901	
Total	Index	Testing	&	Treatment	Cost	 £4,741,797	 £2,409,768	 £2,246,047	 -£2,495,750	 -£163,721	
Total	Health	Complications	–	Index	 47	 93	 93	 46	 0	
Total	Cost	of	Health	Complications	–	Index	 £62,275	 £130,595	 £129,949	 £64,674	 -£647	
Total	Sex	Partners	Notified	(TP	&	FP)	 5,453	 3,957	 9,401	 3,948	 5,444	
Total	Sex	Partners	Treated	 2,999	 2,293	 3,572	 573	 1,280	
Total	Cost	of	Sex	Partner	Treatment	 £74,286	 £57,159	 £60,338	 -£13,948	 £3,180	
Total	Health	Complications	–	Sex	Partners	 199	 135	 464	 265	 328	
Total	Cost	of	Health	Complications	–	Sex	
Partners	
£278,733	 £190,054	 £650,432	 £371,698	 £460,377	
Average	Cost	per	TP	index	Patient	excl	
Health	Complications	
£1,771	 £1,002	 £933	 -£838	 -£69	
Average	Cost	per	Positive	(TP&FP)	Patient	
excl	Health	Complications	
£1,270	 £719	 £669	 -£601	 -£50	
Table	8.20	-	Sensitivity	Analysis	-	Base	Case	Parameters	with	Reduced	GUM	Cost
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8.3.5 Applying	the	DCE	Findings	to	the	Economic	Evaluation	
The	 findings	 from	 the	DCE	presented	 in	Chapter	 6	 provide	 insight	
into	potential	uptake	of	chlamydia	testing	and	treatment	pathways.	
This	 section	 explores	 the	 application	 of	 this	 data	 within	 the	
economic	 model	 to	 assess	 the	 total	 costs	 and	 wider	 impact	 of	
implementing	the	OCCP	as	a	treatment	option	alongside	GUM	and	
NCSP,	 and	 the	 fully	 remote	 online	 pathway	 as	 a	 testing	 and	
treatment	option	alongside	GUM	and	NCSP.		
	
Coefficients	presented	in	section	6.5.3	have	been	used	to	derive	the	
probability	of	uptake	for	the	current	options	considered	(GUM	and	
NCSP	 internet	 testing),	 and	 the	 introduction	 of	 either	 OCCP	 (for	
treatment	 and	 partner	 notification),	 or	 the	 fully	 remote	 online	
pathway	(testing,	treatment	and	partner	notification)	alongside	the	
two	current	pathway	options	considered.	The	results,	based	on	the	
application	 of	 the	 probability	 of	 uptake	 from	 the	 DCE	 to	 the	
theoretical	cohort	of	100,000	people	testing	using	the	model	base	
case	parameters,	are	presented	in	tables	8.21-8.23.	
	
These	 results	 demonstrate	 that	 introducing	 the	 OCCP	 into	
mainstream	 practice	 alongside	 current	 pathways	 results	 in	 fewer	
index	patients	 treated	overall	but	more	sex	partners	 treated	 for	a	
lower	 cost.	 A	 similar	 results	 pattern	 is	 demonstrated	 for	 the	 fully	
remote	 online	 pathway.	 If	 the	 fully	 remote	 online	 pathway	 were	
optimised	to	achieve	higher	test	accuracy	and	a	comparable	level	of	
partner	 treatment	 uptake	 then	 fewer	 index	 patients	 are	 treated	
resulting	 from	 the	 reduction	 in	 false	 positives	 for	 less	 cost,	 and	 a	
significantly	 larger	 cohort	 of	 partners	 treated	 (with	 an	 associated	
increase	in	cost);	however,	there	are	still	a	larger	number	of	health	
complications	 arising	 for	 sex	 partners.	 This	 is	 due	 to	 the	
considerably	 higher	 sex	 partner	 notification	 rate	 associated	 with	
the	OCCP.		
		 473	
	
	
 
Current	
Pathways	
Total	
Activity	
Current	
Pathways	
Total	Cost		
£	
Introducing	
OCCP	
alongside	
current	
Total	Activity	
Introducing	
OCCP	
alongside	
current	
Total	Cost		
£	
Difference	-	
Activity	
Difference	
-	Cost		
£	
Number	of	positive	index	patients	(TP	&	FP)	taking	up	treatment	 	3,525		 	87,615		 	3,465		 	76,611		 -61		 -11,004		
Total	health	complications	(index)	 	127		 	178,811		 	135		 	189,216		 	7		 	10,404		
Number	of	sex	partners	of	positive	index	patients	(TP	&	FP)	notified	 	4,630		 	-				 	6,321		 	-				 	1,690		 	-				
Number	of	sex	partners	(TP	&	FP)	taking	up	treatment	 	2,611		 	64,866		 	2,950		 	63,207		 	340		 -1,659		
Total	health	complications	(sex	partners)	 	164		 	229,960		 	270		 	379,049		 	106		 	149,089		
	Table	8.21	-	The	impact	of	introducing	OCCP	alongside	GUM	and	NCSP	treatment	options,	base	case	scenarios	
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Current	
Pathways	
Total	Activity	
Current	
Pathways	
Total	Cost		
£	
Introducing	
Online	Total	
Activity	
Introducing	
Online	Total	
Cost		
£	
Difference	-	
Activity	
Difference	
-	Cost		
£	
Total	Cost	of	Testing	 -	 6,627,710	 -	 3,885,960	 -	 -2,741,750	
Number	of	positive	index	patients	(TP	&	FP)	taking	up	treatment	 2,516	 62,544	 2,449	 49,380	 -67	 -13,164	
Total	health	complications	(index)	 74	 103,814	 85	 119,756	 11	 15,942	
Number	of	sex	partners	of	positive	index	patients	(TP	&	FP)	notified	 3,276	 -	 5,349	 -	 2,073	 -	
Number	of	sex	partners	(TP	&	FP)	taking	up	treatment	 1,850	 45,992	 2,275	 44,297	 424	 -1,695	
Total	health	complications	(sex	partners)	 161	 226,413	 343	 480,469	 181	 254,057	
Table	8.22	-	The	impact	of	introducing	a	fully	remote	online	pathway	alongside	GUM	and	NCSP	testing	and	treatment	options,	base	case	scenarios	
	
 
Current	
Pathways	
Total	Activity	
Current	
Pathways	
Total	Cost	£	
Optimised	
Online	Total	
Activity	
Optimised	
Online	Total	
Cost	£	
Difference	-	
Activity	
Difference	-	
Cost	£	
Total	Cost	of	Testing	 -	 6,627,710	 -	 2,903,617	 -	 -3,724,093	
Number	of	positive	index	patients	(TP	&	FP)	taking	up	treatment	 2,516	 62,544	 2,425	 44,443	 -90	 -18,102	
Total	health	complications	(index)	 74	 103,814	 89	 125,451	 15	 21,637	
Number	of	sex	partners	of	positive	index	patients	(TP	&	FP)	notified	 3,276	 -	 8,562	 -	 5,286	 -	
Number	of	sex	partners	(TP	&	FP)	taking	up	treatment	 1,850	 45,992	 4,954	 87,243	 3,104	 41,251	
Total	health	complications	(sex	partners)	 161	 226,413	 293	 411,640	 132	 185,228	
Table	8.23	-The	impact	of	introducing	a	fully	remote	online	pathway	alongside	GUM	and	NCSP	testing	and	treatment	options,	fully	remote	online	pathway	optimised	for	test	sensitivity	and	specificity	
and	sex	partner	treatment	uptake
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8.4 Discussion	
The	results	outlined	in	section	8.3	demonstrate	that	the	OCCP	is	cost-
saving	for	the	service	delivery	phase	when	compared	as	a	standalone	
with	 existing	 pathways	 and	 also	 when	 integrated	 into	 a	 delivery	
model	alongside	mainstream	sexual	health	services.	The	exploratory	
study	 indicated	 that	 an	 OCCP	 is	 broadly	 comparable	 with	 existing	
pathways	for	treatment	uptake	and	far	exceeds	existing	pathways	in	
respect	 of	 the	 number	 of	 partners	 identified	 per	 index	 patient.	
However,	 is	 significantly	 below	 existing	 pathways	 in	 respect	 of	 the	
percentage	of	identified	partners	who	are	treated.	The	consequence	
of	 this	 is	 likely	 to	 be	 a	 significantly	 larger	 number	 of	 health	
complications	for	untreated	partners.	
	
Recognising	 the	 need	 to	 achieve	 parity	 with	 existing	 pathways	 in	
respect	 of	 clinical	 and/	 or	 system	 benefits	 to	 receive	 a	 positive	
endorsement	 by	 the	 NICE	 MTEP	 (NICE,	 2011)	 there	 are	 two	
important	 factors	which	 need	 to	 be	 considered.	 Firstly,	 the	 rate	 of	
sex	partners	identified	per	index.	The	data	for	this	has	been	gathered	
from	 small	 numbers	 participating	 in	 an	 exploratory	 study	 and	 no	
comparable	published	data	on	this	type	of	online	treatment	pathway	
could	be	identified.	However,	the	exploratory	study	participants	have	
been	sourced	from	an	existing	population	who	have	chosen	to	test	at	
either	 a	 GUM	 clinic	 or	 via	 the	 NCSP	 internet	 testing	 pathway.	
Therefore,	 it	 is	 unlikely	 that	 their	 number	 of	 partners	 over	 the	
previous	 six	 months	 would	 be	 that	 different	 to	 those	 receiving	
treatment	via	these	routes.		
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There	is	a	recognised	evidence	base	to	support	the	belief	that	people	
are	more	 honest	 in	 providing	 information	 via	 computer	 aided	 self-
interview	 (CASI)	 technology	 within	 sexual	 health	 services.	 For	
example,	 Richens	 and	 colleagues	 used	 CASI	 for	 history	 taking	 in	 a	
randomised	 control	 trial	 undertaken	 in	 sexual	 health	 clinics	 and	
found	that	it	“demonstrated	greater	capture	of	sensitive	information	
during	 computer	 assisted	 interviews	 and	 attributed	 this	 to	 a	
reduction	 in	 social	 desirability	 bias”	 (Richens	 et	 al.,	 2010:313),	 and	
Tideman	 and	 colleagues	 found	 in	 an	 RCT	 of	 CASI	 that	 “women	
undertaking	the	CASI	reported	a	significantly	higher	median	number	
of	 male	 partners	 for	 the	 preceding	 12	 months”	 (Tideman	 et	 al.,	
2007:52).		
	
This	 lends	 credence	 to	 the	 argument	 that	 the	 online	 nature	 of	 the	
OCCP	 has	 led	 to	 more	 honest	 responses	 from	 index	 patients	 than	
those	 in	 face-to-face	 situations.	 This	 would	 be	 viewed	 as	 a	 benefit	
from	 a	 public	 health	 perspective	 if	 the	 identification	 of	 additional	
partners	converts	 into	partner	treatment	and	reduced	transmission.	
This	 view	 is	 supported	 by	 Turner	 and	 colleagues	 who	 explored	
strategies	 to	 improve	 the	 cost-effectiveness	 of	 chlamydia	 screening	
and	 identified	 that	 “there	 is	 considerable	 scope	 to	 improve	partner	
notification	 outcomes.	 Furthermore,	 reallocation	 of	 resources	 to	
ensure	 provision	 and	monitoring	 of	 effective	 partner	 notification	 is	
likely	 to	 result	 in	 substantial	 cost	 savings	 in	 comparison	 with	
increasing	screening	coverage	only”	(Turner	et	al.,	2011:5).	
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Secondly,	 the	 number	 of	 health	 complications	 and	 associated	 costs	
arising	from	untreated	chlamydial	infection.	As	previously	outlined	in	
sections	3.5.1	and	8.2.3.3,	evidence	on	both	the	probability	of	health	
complications	 and	 their	 associated	 cost	 is	 limited.	 Price	 and	
colleagues	 highlight	 that	 the	 evidence	 base	 for	 the	 NCSP	 has	 been	
repeatedly	 called	 into	 question	 “with	 little	 consensus	 on	modelling	
assumptions,	 parameter	 values	 or	 evidence	 sources	 to	 be	 used	 in	
cost-effectiveness	 analyses”	 (Price	 et	 al.,	 2016:v)	 and	 Ong	 and	
colleagues	 acknowledge	 that	 “readers	 must	 be	 satisfied	 that	 the	
chlamydia-related	sequelae	considered,	and	 their	management	cost	
estimates	 used	 in	 the	 analyses	 sufficiently	 reflect	 the	 perspective	
taken	by	authors	of	economic	evaluations,	as	well	as	being	suitable	
for	the	reader’s	individual	context”	(Ong	et	al.,	2016:6).	
	
In	 considering	 the	 health	 complications	 included	 in	 the	model,	 the	
range	 of	 complications	 was	 limited	 to	 those	 where	 evidence	 was	
identified	 from	 existing	 models	 and	 new	 systematic	 reviews.	 In	
respect	of	the	costs	these	were	derived	from	UK	studies/	guidelines	
only,	to	avoid	the	impact	of	variation	in	international	health	systems,	
delivery	models	and	associated	costs.	However,	despite	this,	there	is	
still	 a	 considerable	 range	 in	 the	 costs	 of	 treatment	 of	 health	
complications	 identified	 as	 outlined	 in	 table	 8.10.	Whilst	 sensitivity	
analysis	 could	 be	 used	 to	 vary	 the	 cost	 or	 disease	 likelihood	
parameters,	these	would	vary	consistently	across	all	three	pathways.	
Therefore,	the	only	way	that	they	could	have	a	direct	impact	on	the	
total	costs	in	the	model	is	if	they	were	reduced	to	such	an	extent	that	
the	costs	of	treating	health	complications	are	offset	by	savings	in	the	
delivery	 of	 testing	 and	 treatment.	 This	 analysis	 has	 not	 been	
undertaken	as	 it	does	not	 support	 the	MTEP	approach	of	achieving	
equivalence	with	existing	pathways	nor	is	it	a	realistic	likelihood.		
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Therefore,	 the	key	to	demonstrating	equivalence	or	better	 lies	with	
the	model	 parameters	which	 lead	 to	 an	 overall	 reduction	 in	 health	
complications	namely	index	treatment	uptake,	partner	identification	
per	 index	 and	partner	 treatment	uptake.	 The	DCE	data	 allowed	 for	
the	modelling	to	 incorporate	likely	patient	choice	and	the	impact	of	
that	on	costs	and	outcomes,	 in	particular,	 seeing	how	a	higher	 test	
accuracy	would	 hypothetically	move	patients	 between	 services	 and	
the	impact	that	would	have	on	costs	and	outcomes.		
	
Considering	the	strengths	of	this	research,	a	transparent	model,	with	
a	highly	detailed	decision	tree	was	constructed	with	the	opportunity	
to	 enable	 variation	 and	 further	 granularity	 in	 the	 pathway	 as	 the	
technology	develops.	It	has	demonstrated	that	it	can	provide	a	clear	
understanding	 for	users	 (e.g.	 technology	developers),	of	 the	 impact	
of	a	range	of	parameters	on	cost	and	outcomes	in	the	form	of	total	
numbers	of	patients	treated	and	health	complications.		
	
The	model	built	on	previous	research	and	used	pathways	mapped	as	
part	of	the	costing	study	as	well	as	the	most	recently	published	data	
to	enable	comparison	with	current	practice.	It	highlights	key	areas	for	
further	 research	 and	 development	 of	 the	 OCCP	 and	 fully	 remote	
online	pathway	to	optimise	both	clinical	and	cost-effectiveness.	The	
model	also	uses	data	on	preferences	derived	from	the	DCE	to	inform	
likely	uptake	should	all	three	pathways	be	available,	to	consider	the	
cost	 of	 all	 pathways	 within	 a	 health	 system	 as	 well	 as	 enabling	
comparison	between	the	costs	and	outcomes	of	individual	pathways.		
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The	limitations	of	this	research	can	be	grouped	under	two	headings:	
model	 parameters,	 and	 service	 configurations	 and	 developments.	
Whilst	parameters	have	been	sourced	through	a	systematic	process	
of	literature	reviews	and	primary	data	collection	as	part	of	the	OCCP	
exploratory	study	there	are	a	number	of	 limitations	associated	with	
this.	As	highlighted	previously,	only	a	small	population	participated	in	
the	 exploratory	 study.	 Process	measure	 data	was	 not	 collected	 for	
the	 comparator	 pathways	 alongside	 the	 OCCP	 therefore	 this	 data	
was	sourced	from	published	data.	 In	many	cases	the	published	data	
is	 based	on	 clinical	 audits	which	may	be	 subject	 to	bias	because	of	
the	 audit	 process.	 In	 the	 case	 of	 GUM	 in	 particular,	 data	 was	
published	 a	 number	 of	 years	 ago,	 meaning	 that	 it	 may	 not	 be	
reflective	 of	 e.g.	 the	 number	 of	 partners	 identified	 per	 index,	
compared	with	the	number	of	partners	reported	today.		
	
The	absence	of	a	self-test	on	the	market	has	meant	that	there	are	no	
test	 parameters	 for	 a	 NAAT	 self-test	 that	 can	 be	 entered	 into	 the	
model.	 The	 improved	 test	 parameters	 reported	 for	 the	 Cepheid	
GeneXpert	 test	 demonstrate	 the	 impact	 of	 a	 test	 with	 better	
diagnostic	 performance.	 The	 Xpert	 test	 is	 a	 POC	NAAT	which	 has	 a	
turnaround	time	of	90	minutes	and	is	an	example	of	another	type	of	
technology	(POCT)	currently	under	development.		
	
The	model	 considered	 two	 comparator	 pathways	 from	mainstream	
practice	 but	 did	 not	 consider	 other	 types	 of	 technology	 currently	
under	development	which	may	be	available	to	the	health	service	at	
the	same	 time/	prior	 to	 the	availability	of	 the	OCCP	or	a	chlamydia	
NAAT	 self-test.	 This	 is	 an	 important	 factor	 for	 the	 technology	
developers	 more	 so	 than	 commissioners	 or	 providers	 of	 health	
services,	 the	 structure	 of	 the	 model	 would	 enable	 alternative	
pathways	such	as	POCT	to	be	constructed.		
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Another	 relevant	 area	 of	 development	 is	 partner	 treatment	 with	
expedited	 partner	 therapy	 (EPT)	 and	 accelerated	 partner	 therapy	
(APT)	 demonstrating	 preliminary	 clinical	 effectiveness	 and	
acceptability	(Estcourt	et	al.,	2015b).	Given	the	lower	rates	of	partner	
uptake	within	 the	 current	OCCP	exploring	 such	 approaches	may	be	
an	appropriate	method	of	 improving	partner	 treatment	 levels	 in	an	
OCCP.			
	
Finally,	as	noted	in	section	3.5.1,	a	static	model	was	selected	for	this	
research	because	of	the	stage	of	technology	development.	However,	
it	 is	 acknowledged	 that	 the	 transmission	 dynamic	 elements	 of	
chlamydia	mean	that	there	may	be	benefits	resulting	from	reducing	
time	to	result	and	time	to	treatment	of	both	index	patients	and	their	
partners,	 although	 these	 are	 both	 dependent	 on	 resolution	 of	 the	
issues	relating	to	uptake.		
	
Comparing	the	findings	of	the	current	economic	evaluation	to	other	
published	studies	is	challenging.	As	previously	highlighted,	there	are	
no	 other	 published	 studies	 exploring	 OCCP	 and	 self-testing	
technology	for	chlamydia.	Bracebridge	and	colleagues	have	explored	
the	 implementation	 of	 a	 postal	 testing	 pathway	 with	 treatment	
delivered	via	an	online	questionnaire	reviewed	by	a	GUM	doctor	who	
prescribed	treatment.	At	2008-09	prices	the	cost	of	screening	via	this	
pathway	 was	 £1,570	 per	 positive	 patient	 (excluding	 set	 up	 costs),	
compared	with	£506	per	positive	patient	 (Bracebridge	et	al.,	2012).	
This	compares	with	£669	per	positive	patient	tested	and	treated	via	
the	 fully	 remote	 online	 pathway	 and	 £719	 via	 the	 NCSP	 internet	
testing	pathway.		
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There	 are	 some	 notable	 differences	 in	 the	 pathways	 costed.	 For	
example,	 the	 Bracebridge	 remote	 pathway	 is	 a	 population	 based	
screening	pathway	so	incurs	the	costs	of	sending	kits	to	all	18-24	year	
olds	 therefore	 these	 costs	 are	 included	 in	 the	 value	 per	 positive	
patient	whereas	the	comparator	NCSP	pathways	offer	opportunistic	
screening.	
	
Similarly,	Hislop	and	colleagues	explored	the	adoption	EIA	POCT	in	a	
family	planning	clinic.	They	found	that	current	practice	 is	 less	costly	
(£384.01	 per	 positive	 patient	 tested	 and	 treated,	 compared	 with	
£567.70	 and	 £541.23)	 and	 more	 effective	 (Hislop	 et	 al.,	 2010).	
However,	 this	 research	 did	 not	 consider	 any	 variance	 between	
elements	 of	 pathway	 change	 resulting	 from	 the	 introduction	 of	
POCT.	For	example,	it	might	be	assumed	that	there	would	be	a	higher	
treatment	uptake	rate	if	people	are	tested	and	offered	treatment	in	
the	same	attendance.	Turner	and	colleagues	have	estimated	the	cost	
and	 outcomes	 of	 introducing	 POCT	 into	 GUM	 clinic	 settings	
compared	with	the	traditional	GUM	pathway.	They	found	that	POCT	
reduced	the	cost	of	asymptomatic	testing	in	GUM	clinics	from	£79.77	
to	£75.50	per	person.	It	was	also	theoretically	more	effective	with	a	
small	 increase	 in	 QALYs,	 reduction	 in	 health	 complications	 arising	
from	 untreated	 chlamydia	 and	 onward	 transmission	 (Turner	 et	 al.,	
2014).	 Finally,	 Turner	 and	 colleagues	 also	 undertook	 mathematical	
modelling	 to	 explore	 what	 changes	 to	 chlamydia	 screening	 might	
make	it	more	clinically	and	cost	effective.	Compared	to	the	2008-09	
screening	 cost	 of	 £506	 per	 infection	 treated,	 they	 identified	 that	
increased	uptake	of	partner	 treatment	 from	0.4	 to	0.8	partners	per	
index	 would	 reduce	 this	 to	 £449	 per	 infection	 treated	 whilst	
increasing	 male	 screening	 uptake	 from	 8%	 to	 24%	 would	 increase	
this	cost	 to	£528.	Their	 findings	 in	respect	of	partner	treatment	are	
consistent	with	the	findings	of	the	present	research.	
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Generalisability	 of	 the	present	 research	 findings	 is	 limited	owing	 to	
variations	in	practice	at	local	level.	Such	variation	can	be	evidenced	in	
a	 number	 of	 sources	 including	 NCSP	 clinical	 audits	 (Public	 Health	
England,	2014a,	Public	Health	England,	2016a),	PHE	annual	STI	data	
(Public	 Health	 England,	 2016b)	 as	 well	 as	 the	 costing	 study	
undertaken	as	part	of	 this	 research.	 Local	variations	 in	delivery	and	
the	 impact	 on	 costs	 also	 featured	 in	 a	National	 Audit	Office	 report	
which	found	that	the	local	commissioning	approach	employed	by	the	
NCSP	 led	to	“duplication	of	effort	and	cost	 in	several	aspects	of	the	
programme	 which	 have	 been	 purchased	 in	 a	 fragmented	 way	 by	
multiple	local	commissioners”	(National	Audit	Office,	2009:9).	Whilst	
the	 commissioning	 organisations	 featured	 in	 the	 report	 no	 longer	
exist,	the	transfer	of	commissioning	responsibility	to	local	authorities	
in	2013	may	have	replicated	the	organisational	circumstances	leading	
to	this	inefficiency.	One	benefit	of	the	model	created	in	the	present	
study	is	that	it	can	be	adapted	for	use	with	local	parameters	to	assess	
the	 impact	 at	 a	 local	 level,	 if	 necessary.	 However,	 further	 research	
into	the	variability	of	local	pathways	would	be	beneficial	owing	to	the	
undisputable	impact	on	costs	of	service	delivery	identified	in	Chapter	
7.	
	
This	 research	 has	 also	 highlighted	 a	 number	 of	 other	 areas	 where	
further	 research	 would	 be	 beneficial	 prior	 to	 the	 adoption	 of	 an	
OCCP	 or	 fully	 remote	 online	 pathway.	 Firstly,	 research	 to	 explore	
how	the	new	technology	can	achieve	index	and	partner	uptake	rates	
comparable	with	existing	pathways.	Secondly,	further	exploration	of	
increased	 partner	 identification.	 Whilst	 potentially	 a	 significant	
benefit,	 consideration	 as	 to	 how	 to	manage	 the	 differential	 impact	
within	 the	 modelling	 is	 required.	 Within	 the	 model,	 only	 two	
pathways	 are	 selected	 for	 comparison	 with	 the	 OCCP	 and	 fully	
remote	online	pathway.	However,	there	are	other	ways	of	accessing	
chlamydia	testing	and	treatment	services	as	outlined	in	figure	2.1.		
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Further	 research	would	be	beneficial	 to	understand	how	 these	 two	
new	 pathways	 might	 impact	 on	 or	 interface	 with	 other	 routes	 to	
accessing	chlamydia	testing	and	treatment.	
	
The	ECDC	literature	review	into	Chlamydia	control	published	in	2014	
recognised	 the	 limitations	 and	 gaps	 in	 knowledge	 from	 both	 a	
disease	and	cost	perspective	(ECDC,	2014).	Research	published	since	
then	 has	 addressed	 these	 gaps	 to	 some	 extent	 but	 still	 does	 not	
reach	 a	 conclusive	 position	 in	 respect	 of	 the	 incidence	 and	 cost	 of	
health	 complications	 arising	 from	 untreated	 chlamydia.	 Price	 and	
colleagues	 recently	 identified	 a	 set	 of	 parameters	 to	 be	 used	 in	
modelling	 some	 of	 the	 health	 complications	 but	 highlight	 the	 need	
for	 further	 research	 to	 validate	 their	 findings	 (Price	 et	 al.,	 2016).	
Similarly,	Ong	and	colleagues’	review	of	the	cost	estimates	of	health	
complications	 exposed	 the	 considerable	 differences	 in	 parameters	
within	the	UK	and	 internationally	when	 it	came	to	considering	both	
the	 cost	 of	 treating	 complications	 and	 the	 range	 of	 complications	
included	in	modelling	(Ong	et	al.,	2016).	Whilst	the	impact	of	changes	
in	 these	 parameters	 was	 not	 explored	 in	 sensitivity	 analysis	 in	 the	
current	research,	 it	 is	evident	that	the	variance	in	these	parameters	
has	a	material	effect	on	the	costs	associated	with	the	management	of	
chlamydia.	 Further	 research	 to	 determine	 a	 common	 set	 of	
complications,	their	 incidence	and	attributable	cost	in	the	UK	would	
enable	 more	 comparable	 estimates	 of	 the	 costs	 and	 benefits	
associated	with	asymptomatic	chlamydia	testing	and	treatment.		
	
	 	
		 484	
Another	area	in	which	further	information	would	be	beneficial	is	test	
performance	 characteristics.	 Recognising	 that	 test	 accuracy	 is	 the	
attribute	 most	 important	 to	 young	 people	 in	 choosing	 to	 test	 for	
chlamydia	and	the	importance	of	delivery	of	comparable	outcomes	in	
the	NICE	MTEP	approval	process	any	new	test	would	need	to	deliver	
a	 level	 of	 performance	 at	 least	 comparable	 to	 the	 existing	 tests.	
Notably,	in	table	8.18	a	PPV	of	below	90%	is	seen	for	all	tests	at	the	
general	 population	 prevalence	 rate	 identified	 in	 NATSAL-3	
(Sonnenberg	et	al.,	2013).	Given	the	desire	to	increase	uptake	across	
the	 general	 population,	 it	 is	 questionable	 whether	 clinic	 positivity	
rates	 are	 still	 the	 best	 measure	 to	 be	 used	 in	 assessing	 test	
performance.	A	better	measure	might	be	prevalence	estimates	in	the	
general	 population.	 This	 should	 be	 considered	 as	 part	 of	 new	 test	
development	programmes.		
	
Finally,	value	of	information	analysis	techniques,	e.g.	expected	value	
of	 perfect	 information	 (EVPI)	were	 not	 considered	 in	 this	 research.	
EVPI	 can	 be	 defined	 as	 the	 cost	 associated	 with	 removing	 all	
uncertainty	from	the	model,	thus	removing	the	possibility	of	making	
the	wrong	 decision	 (Briggs	 et	 al.,	 2006).	 The	 purpose	 of	 the	model	
was	 to	 demonstrate	 the	 likely	 impact	 on	 costs	 and	 outcomes,	
therefore	 it	 was	 considered	 not	 appropriate	 to	 undertake	 this	
analysis	 within	 the	 context	 of	 the	 current	 stage	 of	 technology	
development.	 Further	 research	 may	 be	 beneficial	 to	 explore	 the	
optimum	 point	 within	 the	 product	 development	 pathway	 to	
undertake	this	analysis.		
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8.5 Summary		
The	decision	analytic	model	presented	in	this	chapter	demonstrated	
the	 impact	 of	 moving	 beyond	 the	 costs	 and	 outcomes	 associated	
with	 short-term	service	delivery	 to	 include	 the	consideration	of	 the	
impact	of	 the	 intermediate/	process	outcomes	on	 long	 term	health	
outcomes	 in	 the	 form	 of	 complications	 arising	 from	 untreated	
chlamydia.	 The	 results	 have	 shown	 that	 the	 parameters	 associated	
with	 number	 of	 partners	 notified	 per	 index,	 and	 partner	 treatment	
rate	have	 the	most	 significant	 influence	on	 the	costs	and	outcomes	
associated	with	the	OCCP	and	fully	remote	online	pathway.		
	
Utilising	the	DCE	coefficients	to	model	the	impact	of	introducing	the	
fully	 remote	 online	 pathway	 alongside	 existing	 pathways	 has	
demonstrated	that,	based	on	uptake	calculated	from	the	DCE	results,	
the	overall	mix	of	service	delivery	is	cost	saving	when	the	OCCP	and/	
or	 fully	 remote	 online	 pathway	 is	 introduced.	However,	 overall	 the	
number	 of	 complications	 and	 costs	 associated	 with	 untreated	
chlamydia	 increases	 when	 the	 new	 pathway	 is	 added	 to	 existing	
pathways.		
	
The	early	economic	evaluation	in	this	chapter	has	highlighted	the	key	
features	of	the	OCCP	and	fully	remote	online	pathway	which	require	
further	research	and	development	in	order	to	deliver	eHealth	clinics	
and	 chlamydia	 self-tests	 with	 outcomes	 which	 are	 at	 least	
comparable	with	existing	pathways.		
	
The	final	chapter	reflects	on	the	research	presented	 in	the	previous	
seven	 chapters	 and	 considers	 the	 learning	 in	 respect	 of	 the	
application	 of	 methods,	 the	 implications	 for	 the	 future	 delivery	 of	
sexual	health	services	and	broader	 issues	for	the	implementation	of	
eHealth	and	mHealth	initiatives	within	the	NHS.			
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9 CHAPTER	9	–	DISCUSSION	AND	CONCLUSIONS	
9.1 Introduction	
This	 thesis	 set	 out	 to	 explore	 the	 costs	 and	 benefits	 of	 integrating	
novel	digital	 technology	 for	 the	 testing	and	 treatment	of	 chlamydia	
into	 mainstream	 sexual	 health	 services	 in	 England.	 Two	 levels	 of	
integration	 of	 digital	 technology	 were	 considered.	 The	 most	
ambitious	was	a	fully	remote	online	pathway	incorporating	a	self-test	
and	 online	 treatment	 and	 partner	 notification;	 the	 second	 was	 a	
partial	 remote	 online	 pathway	 from	 results	 notification	 onwards	
(OCCP).	 The	 research	 findings	 illustrate	 several	 fundamental	 issues	
which	apply	to	this	and	potentially	other	evaluations	of	eHealth	and	
mHealth	initiatives,	particularly	those	which	aim	to	deliver	diagnosis	
and	 treatment,	 rather	 than	 interventions	 for	 behaviour	 change	 or	
long	 term	 condition	management.	 This	 chapter	 draws	 together	 the	
main	research	findings	from	Chapters	4	to	8,	reflects	on	the	research	
methods	 used,	 and	 presents	 the	 key	 conclusions	 and	
recommendations	for	future	research.		
	
9.2 Summary	of	Main	Research	Findings	
9.2.1 Literature	Reviews	&	Focus	Groups		
The	 literature	 reviews	 presented	 in	 Chapter	 4	 identified	 the	
research	 undertaken	 to	 date	 to	 understand	 which	 factors	 might	
influence	 individuals’	 decisions	 to	 access	 testing	 and	 treatment	
services	for	STIs	in	OECD	high	income	countries.	The	OCCP	and	fully	
remote	 online	 pathway	 technologies	 explored	 in	 this	 thesis	 have	
the	 potential	 to	 overcome	 many	 of	 the	 barriers	 identified	 in	 the	
literature	for	the	uptake	of	STI	testing	and	treatment	services,	and	
address	a	gap	in	knowledge	in	respect	of	preferences	for	aspects	of	
OCCP	and	fully	remote	online	pathways.		
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The	findings	from	the	focus	groups	with	young	people	presented	in	
Chapter	 5	 supported	 this	 view.	 Time	 from	 test	 to	 result	 (time	 to	
result)	was	the	aspect	which	featured	most	frequently	in	the	focus	
group	discussions	with	a	general	 consensus	 in	all	 four	groups	 that	
quicker	 results	were	 preferred,	with	worry	 and	 anxiety	 about	 the	
outcome	of	the	test	being	the	main	reason	for	this	preference.	This	
was	 followed	 by	 test	 accuracy	 being	 drawn	 out	 by	 participants	
themselves	as	an	important	consideration.		
	
The	 questions	 raised	 by	 focus	 group	 participants	 demonstrated	 a	
general	 lack	 of	 understanding	 about	 the	 accuracy	 of	 currently	
available	tests	in	clinical	practice.	The	desire	for	a	broader	range	of	
tests,	 that	 is	 testing	 for	 multiple	 STIs,	 was	 another	 important	
consideration	highlighted	by	 the	 focus	groups	with	a	general	 view	
expressed	that	the	more	STIs	they	are	tested	for	the	better.		
	
9.2.2 Discrete	Choice	Experiment	
The	 focus	 group	 findings	 were	 reflected	 in	 the	 DCE	 findings	
presented	 in	 Chapter	 6.	 The	 DCE	 results	 supported	 the	 view	 that	
test	 accuracy	 and	 time	 to	 result	 were	 the	 strongest	 attributes	
influencing	 young	 people’s	 preferences	 for	 chlamydia	 testing	 and	
treatment	pathways.	These	findings	suggest	that	any	new	self-tests	
coming	 into	 clinical	 practice	 would	 need	 to	 improve	 upon	 (or	 at	
least	equal)	the	current	laboratory	or	clinic-based	test	performance	
characteristics,	in	terms	of	both	accuracy	and	time	to	result.	Whilst	
not	 as	 stark	 in	 their	 strength	 of	 preference,	 the	 other	 attributes	
included	 within	 the	 study	 demonstrate	 a	 general	 preference	 for	
remote	 pathway	 options	 including	 self-testing	 and	 self-sampling	
and	 posting	 the	 sample	 for	 analysis	 over	 attending	 a	 healthcare	
setting	 for	 testing.	 This	 is	 also	 reflected	 in	 treatment	preferences,	
although	to	a	lesser	extent	in	respect	of	the	strength	of	preference	
for	online	consultation	methods.		
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This	 DCE	 research	 was	 recognised	 at	 The	 Lancet	 Public	 Health	
Science	Conference	by	 the	NIHR	 School	 of	 Public	Health	Research	
who	acknowledge	that	its	findings	could	improve	screening	uptake	
and	successful	treatment	of	chlamydia	in	England	(Nicholl,	2016).			
	
9.2.3 Economic	Evaluation	
Whilst	the	preferences	of	young	people	are	fundamental	for	uptake	
of	 any	 STI	 services,	 the	 costs	 and	 benefits	 of	 the	 introduction	 of	
digital	 technology	 must	 be	 considered	 by	 technology	 developers	
and	 commissioners.	 Chapter	 7	 explored	 the	 costs	 and	
consequences	 of	 introducing	 eHealth	 clinics	 (OCCP)	 for	
asymptomatic	 chlamydia	 treatment.	 The	 costing	 of	 this	 eHealth	
clinic	 was	 based	 on	 data	 drawn	 from	 the	 exploratory	 study	
undertaken	by	the	eSTI2	research	consortium.	The	analysis	showed	
the	OCCP	could	be	cost	saving	when	compared	with	GUM	and	NCSP	
internet	 testing	 pathways.	 However,	 the	 costing	 study	 also	 found	
considerable	variability	in	the	delivery	models	for	current	chlamydia	
pathways	from	results	notification	onwards.	It	is	important	to	note	
that	optimisation	of	existing	pathways	could	therefore	also	lead	to	
a	reduction	in	cost	of	their	delivery	and	thus	affect	the	estimates	of	
savings	of	 the	 introduction	of	 an	eHealth	 clinic	 such	as	 the	OCCP.	
The	 outcome	 measures	 identified	 by	 the	 exploratory	 study	 to	
demonstrate	 the	 safety	 and	 feasibility	 of	 remote	 online	 care	
focused	 on	 process	 measures	 (such	 as	 uptake	 rates	 and	 time	 to	
treatment)	 rather	 than	 health-related	 outcomes.	 This	 approach	
demonstrated	non-inferiority	compared	with	existing	pathways	for	
all	 indicators	 other	 than	 partner	 treatment	 uptake.	 However,	 this	
needs	to	be	considered	within	the	context	of	recognised	issues	with	
accuracy	 of	 partner	 treatment	 data,	 for	 example	 the	 accurate	
capturing	of	partner	notification	outcomes.		
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The	findings	of	the	economic	evaluation	in	Chapter	8,	based	on	the	
costing	 study,	 the	 findings	 from	 the	 OCCP	 exploratory	 study	 and	
published	 data,	 demonstrated	 the	 links	 between	 the	 process	
measures	used	and	health	outcomes,	 i.e.	 the	health	complications	
arising	 from	 untreated	 chlamydia.	 This	 highlighted	 the	 impact	 of	
both	the	number	of	partners	identified	per	index	and	the	uptake	of	
partner	treatment.	Although	the	cost	per	case	detected	for	the	fully	
remote	 online	 pathway	 is	 lower	 than	 the	 comparator	 pathways	
(£38.56	 per	 positive	 patient	 compared	 with	 £61.82	 GUM,	 and	
£36.86	 per	 positive	 patient	 compared	 with	 £44.57	 NCSP	 internet	
testing	pathway),	and	process	measures/	health	outcomes	for	index	
patients	 (treatment	 uptake	 and	 complications	 arising	 from	
untreated	chlamydia)	are	broadly	similar,	adding	in	consideration	of	
partner	 outcomes	 demonstrated	 a	 significant	 difference	 in	 the	
number	of	health	complications	arising	 from	untreated	chlamydia.	
The	combined	costs	of	delivery	and	treatment	for	chlamydia	health	
complications	 are	 considerably	 higher	 for	 both	 the	OCCP	 and	 the	
fully	 remote	 online	 pathway	 than	 the	 comparator	 pathways.	
Presenting	costs	and	outcomes	separately	for	a	range	of	indicators	
highlights	 the	 parameters	 where	 further	 research	 is	 required	 to	
deliver	health-related	outcomes	(avoidance	of	complications	arising	
from	 untreated	 chlamydia)	 from	 the	 use	 of	 the	 new	 digital	
pathways	that	are	at	least	comparable	to	existing	pathways.	For	the	
OCCP	 the	 most	 significant	 parameter	 requiring	 further	 work	 is	
partner	 treatment	 uptake.	 Whilst	 there	 is	 no	 self-test	 currently	
available,	 this	 research	 suggests	 that	 the	 parameter	 of	 greatest	
importance	 for	 further	 work	 is	 test	 accuracy,	 both	 in	 terms	 of	
securing	 process	 and	 health	 outcomes	 comparable	 with	 existing	
practice,	and	being	a	product	that	young	people	will	use.		
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The	model	 established	 for	 the	 economic	 evaluation	 supports	 this	
further	 research	 through	 the	 ability	 to	 vary	 the	 parameters,	 for	
example,	 to	 enable	 test	 developers	 to	 understand	 the	 impact	 of	
test	 performance	 characteristics	 and	 uptake.	 It	 can	 also	 be	 used	
beyond	this	to	understand	the	impact	of	the	technology	pricing.		
	
9.3 Methods	Considerations	
9.3.1 DCE	
The	 utilisation	 of	 qualitative	methods	with	 respondents	 to	 inform	
the	design	and	development	of	a	DCE	is	still	relatively	uncommon.	
Coast	and	colleagues	point	 to	 the	value	of	qualitative	work	 in	 the	
development	 of	 attribute	 and	 levels	 highlighting	 its	 worth	 in	 two	
stages	“conceptual	development	and	the	generation	of	meaningful	
language”	 (Coast	 et	 al.,	 2012:739).	 Whilst	 there	 are	 explicit	
recommendations	 regarding	 the	use	of	 qualitative	 research	 in	 the	
selection	 of	 attributes	 and	 levels	 for	 DCEs	 (Bridges	 et	 al.,	 2011),	
there	is	no	explicit	recommendation	that	this	qualitative	research	is	
undertaken	 with	 target	 respondents.	 The	 insight	 provided	 in	 the	
current	 research	by	 the	 focus	groups	with	young	people	 informed	
many	 aspects	 of	 the	 DCE	 including	 the	 attributes	 and	 levels	
selected,	 their	 phrasing	 and	 definition,	 and	 the	 explicit	
consideration	and	presentation	of	information	in	the	questionnaire	
introduction	 to	 reduce	 the	 risk	 of	 respondents	 making	 their	 own	
assumptions	about	a	specific	aspect	of	a	service	e.g.	data	security,	
cost.		The	evidence	gathered	through	the	focus	groups	also	enabled	
the	discussions	with	experts	and	consideration	of	policy	and	service	
context	to	be	framed	through	the	eyes	of	the	target	respondents.		
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The	 DCE	 did	 not	 address	 one	 of	 the	 most	 important	 attributes	
identified	by	young	people	in	the	focus	groups	which	is	the	range	of	
STIs	 for	 which	 they	 are	 tested.	 Currently	 the	 only	 national	 STI	
screening	 programme	 identified	 as	 cost-effective	 is	 chlamydia	
testing	 in	 the	16-25	population.	 It	 is	also	 recommended	men	who	
have	 sex	 with	 men	 should	 be	 tested	 annually	 for	 chlamydia,	
gonorrhoea,	syphilis,	HIV,	hepatitis	B	and	hepatitis	C	(BASHH,	2014).	
There	was	a	clear	and	justifiable	reason	for	excluding	this	from	the	
DCE	 design	 owing	 to	 the	 variance	 in	 the	 clinical	 management	 of	
different	 types	 of	 STIs	 and	 the	 scope	 for	 introduction	 of	 new	
technologies	into	those	pathways.		
	
Linked	 to	 this,	 the	 need	 to	 control	 a	 participant’s	 assumptions	
about	 which	 STI	 they	 were	 thinking	 about	 whilst	 completing	 the	
DCE	was	 another	 important	 consideration	 in	 limiting	 the	 scope	 to	
chlamydia,	 i.e.	 their	 choices	 may	 be	 different	 if	 thinking	 about	
testing	 and	 treatment	 for	 different	 STIs	 e.g.	 HIV	 or	 chlamydia.	
However,	the	impact	on	uptake	of	the	range	of	tests	is	an	important	
consideration	 for	 developing	 future	 digital	 technologies	 for	 the	
management	of	STIs.		
	
Murray	and	colleagues	 identify	a	key	question	in	the	evaluation	of	
digital	 health	 interventions	 as	 being	 “is	 the	 digital	 health	
intervention	 likely	 to	 reach	 this	 population,	 and	 if	 so,	 is	 the	
population	likely	to	use	it?”	(Murray	et	al.,	2016:845).	A	key	benefit	
of	the	DCE	method	in	assessing	preferences	is	that	it	identifies	the	
strength	 of	 preference	 for	 attributes,	 in	 this	 case	 providing	
information	which	should	enable	further	refinement	of	the	existing	
OCCP	or	a	future	fully	remote	online	pathway	to	maximise	uptake.		
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The	 use	 of	 a	 mixed	 methods	 approach	 incorporating	 qualitative	
research	 with	 the	 respondent	 group,	 and	 evidence	 synthesis	
informed	by	published	literature	and	expert	opinion,	to	inform	the	
attribute	 selection	 and	 DCE	 design	 provided	 the	 opportunity	 to	
maximise	the	relevance	of	the	study	outcomes	to	inform	the	design	
of	 new	 technologies	 and	 new	 pathways	 for	 the	 testing	 and	
treatment	 of	 chlamydia.	 Although	 eHTA/	 HTA	 frameworks	
acknowledge	 acceptability	 and	 patient	 preferences	 within	 them,	
the	clinical	and	cost-effectiveness	of	 interventions	are	the	primary	
considerations	 in	 most,	 especially	 when	 HTA	 is	 undertaken	 for	
drugs	and	devices	where	uptake	is	driven	primarily	by	clinicians.	In	
public	health	interventions,	such	as	screening,	further	consideration	
is	 required	 of	 acceptability	 for	 evaluation	 of	 digital	 health	
interventions,	given	that	the	general	population	have	a	significantly	
greater	role	to	play	in	uptake	and	therefore	cost-effectiveness.	This	
is	 particularly	 relevant	 for	 digital	 health	 interventions	 for	 sexual	
health	 services	 where	 uptake	 is	 a	 significant	 factor	 in	 screening	
programme	cost-effectiveness.		
	
9.3.2 Economic	Evaluation	
On	 commencement	 of	 this	 research	 in	 2013	 there	 was	 little	
published	 in	 respect	of	 the	methods	 for	 the	evaluation	of	eHealth	
and	mHealth	 interventions,	 particularly	 in	 the	 early	 stage	 of	 their	
development	 and	 this	 remains	 the	 case	 in	 2016.	 Undertaking	 the	
economic	evaluation	within	an	eHTA	framework	provided	structure	
for	considering	 the	 likely	costs	and	benefits	of	 the	OCCP	or	a	 fully	
remote	 online	 pathway.	 However,	 these	 methods	 were	 primarily	
developed	 for	drugs	and	devices,	 and	are	not	optimal	 for	eHealth	
interventions	 owing	 to	 the	 pace	 of	 the	 base	 technology	
development	 e.g.	 smartphones,	 smartphone	 consumables	 and	
apps/	software,	the	lack	of	experience	with	adoption	and	the	lack	of	
tools	to	measure	outcomes.		
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This	was	acknowledged	in	a	recent	publication	as	being	one	of	the	
limiting	 factors	 for	 amassing	 an	 evidence	 base	 for	 eHealth	
interventions	 (Murray	 et	 al.,	 2016).	 This	 paper	 also	 identified	 a	
series	 of	 key	 research	 questions	 for	 evaluating	 a	 digital	 health	
intervention	which	 broadly	 align	 to	 the	 domains	 of	 HTA,	 drawing	
out	 specific	 issues	 for	 the	 evaluation	 of	 this	 type	 of	 technology	
(ibid.).		
	
However,	 this	 approach	 focuses	 on	 the	 use	 of	 digital	 health	
interventions	 for	 behaviour	 change,	 long-term	 condition	
management	 and	 non-drug	 based	 treatment.	 Whilst	 these	 are	 a	
helpful	reference	point,	there	are	specific	considerations	for	digital	
technologies	 when	 used	 for	 the	 testing	 and	 treatment	 of	 ‘acute’	
medical	 conditions.	 	 For	 self-testing	 this	 includes	 the	behaviour	of	
the	individual	following	a	test	result	(Ickenroth	et	al.,	2010)	and	for	
treatment	 this	 includes	 the	management	of	patients	who	need	 to	
‘drop	 off’	 the	 online	 pathway	 and	 return	 to	 mainstream	 services	
(Gibbs	et	al.,	2016),	particularly	for	the	evaluation	of	the	safety	and	
efficacy	of	the	intervention.	
	
There	 is	 still	 little	published	on	 the	methodological	 considerations	
for	the	costing	of	eHealth	interventions.	The	key	issues	identified	by	
Tate	and	colleagues	 in	2009	were	reflected	 in	a	recent	publication	
by	 McNamee	 and	 colleagues,	 but	 without	 any	 clear	
recommendations	 on	 a	 preferred	 approach	 (Tate	 et	 al.,	 2009,	
McNamee	 et	 al.,	 2016).	 Achieving	 consistency	 in	 key	 elements	 of	
the	 costing	 of	 digital	 interventions	 is	 important,	 particularly	 for	
enabling	 the	 comparison	 of	 costs	 between	 different	 initiatives.	
Similarly,	 there	 is	 currently	 no	 published	 guidance	 on	 how	 the	
economic	 evaluation	 of	 digital	 health	 interventions	 should	 be	
undertaken	(McNamee	et	al.,	2016).		
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This	 is	 not	 unique	 to	 eHealth	 and	 mHealth,	 similar	 issues	 and	
challenges	 were	 associated	 with	 the	 economic	 evaluation	 of	
telemedicine	 in	 the	 early	 stages	 of	 its	 implementation	 (McIntosh	
and	Cairns,	1997).	
	
9.4 Areas	for	Future	Research	
If	 the	 fully	 remote	 online	 pathway	 or	 OCCP	 were	 adopted	 into	
mainstream	sexual	health	services	in	England	there	are	a	number	of	
aspects	that	the	research	presented	in	this	thesis	cannot	account	for,	
namely	the	likely	wider	impact	of	introduction	of	fully	remote	digital	
pathways.	For	example,	whilst	the	DCE	suggests	a	higher	probability	
of	 uptake	 when	 offered	 alongside	 the	 comparator	 options,	 it	 is	
unclear	whether	as	well	as	more	people	take	up	testing,	these	will	be	
the	 population	 at	 higher	 risk	 as	 opposed	 to	 the	 ‘worried	well’	 and	
whether	 there	 will	 be	 an	 increase	 in	 repeat	 testing.	 It	 is	 also	
uncertain	 whether	 increased	 availability	 and	 accessibility	 to	 online	
testing	 and	 treatment	 might	 lead	 to	 people	 taking	 more	 risks	 in	
respect	 of	 STIs	 negating	 the	 benefits	 of	 increased	 test	 uptake.	
Therefore,	 an	 evaluation	 of	 the	 impact	 on	 health	 behaviour	 is	
another	important	consideration	in	future	research.		
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As	 noted	 earlier,	 sexual	 health	 is	 an	 area	 which	 is	 already	
experiencing	 numerous	 simultaneous	 technological	 advances.	 For	
example,	the	extension	of	online	ordering	to	include	a	wider	range	of	
STI	 test	 kits	 for	 self-sampling	 (Wilson	 et	 al.,	 2016),	 further	
developments	to	POCT	to	include	low	cost	handheld	devices	(Mackay	
et	 al.,	 2015),	 and	 the	 exploration	 of	 APT	 for	 improving	 partner	
notification	and	treatment	uptake	(Althaus	et	al.	2014,	Roberts	et	al.,	
2012).	 All	 of	 these	 developments	 show	 promise	 for	 improving	 the	
clinical	 and/	 or	 cost-effectiveness	 of	 an	 aspect	 or	 all	 of	 an	
asymptomatic	chlamydia	screening	pathway.	There	is	an	opportunity	
for	 learning	 across	 these	 developments	 to	 further	 enhance	 the	
delivery	of	 care,	however	 there	 is	 a	 risk	 that	development	of	 these	
technologies	 in	 isolation	 will	 lead	 to	 fragmented	 solutions	 to	
individual	 aspects	 of	 the	 pathway.	 Both	 awareness	 of	 these	
developments	 and/	 or	 collaboration	 could	 contribute	 to	 the	
development	of	more	effective	products.		
	
Further	 research	 is	 also	 required	 to	understand	how	 these	areas	of	
development	 may	 impact	 on	 preferences	 for	 the	 use	 of	 new	
technologies	 for	 the	management	 of	 STIs	 other	 than	 chlamydia.	 In	
particular,	 given	 the	distinctions	drawn	out	 by	 young	people	 in	 the	
focus	 groups	 between	 thinking	 about	 differences	 in	 the	
consequences	of	disease,	for	example,	HIV	and	chlamydia,	it	is	likely	
that	 their	 preferences	 for	 attributes	 in	 respect	 of	 self-testing	 and	
eHealth	 clinics	 may	 vary	 based	 on	 whether	 the	 disease	 is	 curable.	
However,	recognising	that	chlamydia	testing	and	treatment	is	offered	
currently	as	a	standalone	pathway	for	young	people,	the	DCE	draws	
out	a	number	of	ways	in	which	current	pathways	could	be	enhanced	
by	the	adoption	of	either	OCCP	and/	or	self-testing.		
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Since	 the	 approach	 adopted	 for	 the	 early	 economic	 evaluation	
presented	 in	 this	 thesis	was	 based	 on	 the	NICE	MTEP	 (NICE,	 2011)	
methods,	 the	 costs	 incurred	 to	 the	NHS	were	 included	 and	 patient	
costs	were	excluded.	Recognising	the	intrinsic	link	between	uptake	of	
eHealth	 interventions	and	 their	 cost-effectiveness	 (McNamee	et	al.,	
2016)	 future	 research	 into	 the	 patient-borne	 costs	 (e.g.	 travel,	
internet	 access)	 associated	 with	 current	 screening	 pathways,	 the	
OCCP	 and	 a	 fully	 remote	 online	 pathway	 for	 the	 testing	 and	
treatment	of	chlamydia	would	be	beneficial.	Another	 feature	of	 the	
NICE	MTEP	approach	is	the	determining	point	at	which	a	technology	
is	recommended	for	use	within	the	NHS,	i.e.	outcomes	equivalent	to	
existing	practice.	Whilst	 the	data	 from	the	OCCP	does	not	currently	
demonstrate	this,	further	modelling	to	test	whether	there	is	a	point	
at	which	a	sub-optimal	technology	(e.g.	less	sensitive	test)	could	offer	
benefits.	 This	 has	 not	 been	 explored	 in	 the	 economic	 modelling	
undertaken	 in	 this	 thesis	 because	 it	 is	 not	 currently	 recognised	 as	
acceptable	 within	 the	 framework	 for	 considering	 new	 technologies	
for	adoption	by	the	NHS.	
	
In	progressing	the	economic	evaluation	beyond	the	initial	exploratory	
study	of	the	costs	and	consequences	of	the	OCCP,	alternative	health	
economic	methods	might	be	more	appropriate,	particularly	for	a	full	
scale	RCT	(Sculpher	et	al.,	1997).	McNamee	and	colleagues	note	that	
whilst	 there	 are	 a	 range	 of	 guidelines	 for	 health	 economic	
evaluations,	 little	consideration	has	been	given	 to	 their	applicability	
to	digital	health	interventions	(McNamee	et	al.,	2016).	Consideration	
would	also	need	to	be	given	to	the	acknowledged	 issues	associated	
with	 estimating	 QALYs	 in	 economic	 evaluations	 of	 chlamydia	
interventions	(ECDC,	2014)	when	selecting	the	method.		
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One	 of	 the	 key	 issues	 is	 the	 pace	 of	 digital	 health	 technology	
development	 and	 therefore	 consideration	 should	 be	 given	 as	 to	
whether	the	existing	methods	used	in	HTA	are	appropriate	to	digital	
health	 interventions.	 Baker	 and	 colleagues	 have	 highlighted	 that	 it	
can	take	seven	years	from	the	submission	of	a	grant	proposal	to	the	
publication	of	the	research	(Baker	et	al.,	2014).	During	the	last	seven	
years	 (2010-2016),	 daily	 internet	 access	 has	 increased	 from	
approximately	60%	to	82%	(all	adults)	 (Office	for	National	Statistics,	
2016b),	 the	 functionality	 of	 smartphones,	 and	 smartphone	
consumables	 have	 increased	 significantly	 to	 include	 a	 range	 of	
devices	capable	of	monitoring	health	data	linked	to	the	smartphone,	
and	the	availability	of	apps	and	their	functionality	has	also	extended	
over	 time.	 Further	 work	 is	 required	 to	 establish	 appropriate	 rapid	
methods	 for	 the	 evaluation	 of	 pathways	 which	 involve	 eHealth	
technologies.			
	
9.5 Implications	for	Healthcare	Policy	&	Delivery	
Since	 the	commencement	of	 this	 research	 in	2013	 there	have	been	
significant	changes	both	in	terms	of	the	commissioning	and	delivery	
of	sexual	health	services	in	England,	and	the	advancement	of	digital	
technology	which	have	the	potential	to	produce	a	material	impact	on	
service	 configuration	 and	 delivery	within	mainstream	 sexual	 health	
services.	 Chapter	 2	 of	 this	 thesis	 set	 out	 the	 ‘best	 intentions’	 of	
government	 in	 respect	 of	 technology	 adoption	 within	 healthcare	
more	generally	and	sexual	health	services	specifically.	These	included	
using	online/	remote	consultation	(Department	of	Health,	2012),	and	
expanding	 internet	 testing	 services	 for	 STIs	 (Department	 of	 Health,	
2013).	 Despite	 the	 advancement	 of	 digital	 health	 technologies,	 the	
pace	of	their	adoption	within	mainstream	sexual	health	services	has	
not	materially	changed	during	the	course	of	this	research.		
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The	 use	 of	 such	 technologies	 is	 still	 confined	 to	 isolated	 examples	
within	the	NHS,	reflecting	the	pattern	of	adoption	noted	by	the	WHO	
in	their	international	study	of	eHealth	and	mHealth	adoption	(WHO,	
2011a).	 Attempts	 to	 increase	 the	 pace	 and	 spread	 of	 digital	
technologies	through	approaches	such	as	the	NHS	apps	 library	have	
been	 hampered	 by	 information	 security	 and	 governance	 concerns	
(Huckvale	et	al.,	2015).		
	
The	research	undertaken	by	Gibbs	and	colleagues	 in	developing	the	
OCCP	 has	 highlighted	 the	 stark	 disconnect	 between	 the	 national	
policy	vision	 for	digital	health	and	the	reality	of	designing	an	online	
treatment	 eHealth	 intervention	 concluding	 that	 “much	 of	 the	
infrastructure	and	 legislation/	regulation	and	best	practice	guidance	
required	 to	 support	 such	 a	 shift	 in	 the	 provision	 of	 care	 has	 been	
designed	for	traditional,	non-eHealth,	service	provision	and	is	not	fit	
for	purpose	for	innovative	eHealth	interventions.”	(Gibbs,	2015:310).	
The	most	significant	example	of	this	within	the	OCCP	development	is	
the	 national	 electronic	 prescribing	 system	 (EPS)	 being	 designed	 for	
the	 transmission	 of	 electronic	 prescriptions	 from	 GP	 practice	 to	
community	 pharmacy	 rather	 than	 any	 other	 healthcare	 provider	 to	
pharmacy.	A	secondary	issue	is	that	it	is	currently	not	possible	to	use	
the	EPS	without	an	NHS	number,	which	is	not	used	by	sexual	health	
services	to	preserve	patient	anonymity.	This	is	a	significant	limitation	
for	the	implementation	of	digital	health	technologies	in	sexual	health	
services	which	 involve	 the	prescribing	of	drugs	 for	 treatment	which	
will	 need	 to	 be	 addressed	 in	 future	 EPS	 upgrades.	 There	 are	
examples	of	accreditation	processes	for	telehealth	initiatives	such	as	
the	 European	 Code	 of	 Practice	 for	 Telehealth	 Services	 (TeleSCoPE,	
2014)	however	 this	 falls	 short	 of	 the	 requirements	of	 digital	 health	
interventions	 delivering	 diagnosis	 and	 treatment	 as	 it	 does	 not	
incorporate	any	assessment	of	the	clinical	safety	of	the	intervention.		
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In	 parallel	 to	 this,	 the	 commissioning	 of	 sexual	 health	 services	 in	
England	has	been	fragmented,	with	responsibility	split	between	local	
authorities,	CCGs	and	NHSE.	Whilst	conclusive	links	on	the	impact	of	
this	 split	have	not	 yet	been	drawn,	 concern	has	been	expressed	by	
both	 the	 House	 of	 Commons	 Health	 Select	 Committee	 and	
professional	 bodies	 including	 BASHH,	 and	 the	 Royal	 College	 of	
Physicians	 regarding	 the	 split	 between	HIV	 treatment	 and	 care	 and	
other	 sexual	 health	 services	 (BASHH,	 2013,	 House	 of	 Commons.		
Select	Committee	on	Health,	2011).	Examples	of	such	splits	are	now	
starting	to	emerge	including	the	example	of	sexual	health	services	in	
Cheshire	 West	 where	 HIV	 and	 sexual	 health	 services	 are	 now	
delivered	 by	 two	 different	 providers	 and	 therefore	 the	 HIV	 service	
can	no	longer	treat	other	STIs	(BMA,	2015).	This	has	led	to	a	call	from	
BASHH	 for	 “a	 strong	 national	 steer	 for	 co-commissioning	 of	 HIV,	
sexual	 health	 and	 reproductive	 health	 services”	 (Clarke	 and	 Carlin,	
2014).		
	
Although	the	2015	budget	announced	£8	billion	more	for	the	NHS	by	
2020	(Hazell,	2015),	an	in-year	budget	cut	of	£200	million	was	made	
to	local	authority	public	health	budgets	for	2015-16	(Williams,	2015)	
and	 	 estimates	of	 a	 reduction	of	 £3.3	billion	 in	 central	 government	
funding	 for	 local	 services	 were	 forecast	 by	 the	 Local	 Government	
Association	 (Local	 Government	 Association,	 2015)	 for	 2016-17	 (the	
first	year	without	ring	fencing	of	the	public	health	budget).		The	cost	
of	 testing	 and	 treatment	 for	 STIs	 is	 borne	 by	 the	 LA,	 however	 the	
benefits	 gained	 through	 the	 avoidance	 of	 long	 term	 complications	
such	as	PID	or	infertility	accrue	to	NHS	commissioning	organisations,	
primarily	 CCGs.	 Emerging	 tensions	 in	 STI	 commissioning	
responsibilities	have	recently	been	demonstrated	in	the	courts	with	a	
legal	 challenge	 brought	 against	NHS	 England	 in	 respect	 of	who	has	
the	 power	 to	 commission	 pre-exposure	 prophylaxis	 drugs	 for	 HIV	
with	NHS	England	arguing	 that	 the	 legal	 power	 is	with	 LAs	 and	 the	
National	AIDS	Trust	arguing	that	it	is	with	NHS	England	(BBC,	2016).	
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Whilst	 local	 authorities	 generally	 adopt	 a	 similar	 approach	 to	 NHS	
organisations	 in	appraising	developments	 it	 is	unclear	whether	they	
will	consider	the	 implications	for	other	commissioning	organisations	
in	 their	 decision	 making.	 It	 is	 possible	 that	 a	 broader	 range	 of	
outcomes	might	be	considered,	drawing	out	links	to	potential	savings	
on	 other	 local	 authority	 controlled	 budgets	 and	 impacts	 on	 other	
areas	of	service	delivery	within	local	authority	control.	Although	this	
approach	 has	 been	 incorporated	 into	 public	 health	 guideline	
development	 (NICE,	 2014),	 it	 is	 not	 an	 approach	 usually	 taken	 in	
DAP/	 MTEP	 evaluations.	 This	 area	 warrants	 further	 research	 to	
understand	 how	 economic	 evaluations	 can	 incorporate	 a	 range	 of	
intermediate	and	final	outcome	measures	and	the	weight	that	should	
be	placed	on	 the	 impact	on	NHS	 versus	 local	 authority	opportunity	
costs.		
	
There	 has	 been	 a	 plethora	 of	 guidance	 on	 effective	 commissioning	
following	 the	 move	 to	 LA	 commissioning	 in	 April	 2013	 including	
model	contracts	and	service	specifications	issued	by	the	Department	
of	 Health	 (Department	 of	 Health,	 2013a,	 Department	 of	 Health,	
2013d),	 guidance	 from	 Public	 Health	 England	 on	 whole	 system	
commissioning	(Public	Health	England,	2014b)	and	from	the	NCSP	on	
the	 effective	 commissioning	 of	 chlamydia	 testing,	 treatment	 and	
partner	 notification	 (NCSP,	 2012a).	 However,	 despite	 this,	 and	 a	
number	 of	 sexual	 health	 services	 being	 reviewed	 and	 re-procured,	
achievement	 of	 the	 PHOF	 indicator	 for	 chlamydia	 diagnoses	 has	
declined	 year	 on	 year	 since	 2013	 (Public	 Health	 England,	 2014d,	
Public	Health	England,	2015,	Public	Health	England,	2016b).		
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No	 evaluation	 of	 the	 impact	 of	 the	 revised	 commissioning	
arrangements	 on	 the	 implementation	 of	 the	 2013	 sexual	 health	
strategy	has	been	formally	undertaken	however	the	fragmentation	of	
services	and	reduction	in	chlamydia	diagnoses	suggest	that	the	aims	
of	the	strategy	to	prioritise	prevention	and	ensure	young	people	can	
access	appropriate	services	are	increasingly	not	being	met.		
	
Considering	 both	 the	 general	 (Department	 of	 Health,	 2012)	 and	
sexual	health	(Department	of	Health,	2013)	policy	imperative	for	the	
adoption	of	 innovative	 technology	 into	mainstream	health	 services,	
the	 operational	 climate	 for	 the	 commissioning	 and	 implementation	
of	 new	 remote	 online	 pathways	 into	 sexual	 health	 services	 is	
positive.	 However,	 whilst	 reductions	 in	 LA	 commissioning	 budgets	
are	 a	 key	 driver	 for	 seeking	 out	 alternative	 delivery	 models	 which	
reduce	costs	without	affecting	outcomes,	the	relative	 infancy	of	the	
new	commissioning	arrangements	are	not	conducive	to	this.			
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9.6 Concluding	Remarks	
This	thesis	has	added	new	knowledge	to	the	evidence	base	in	respect	
of	the	factors	important	to	young	people	when	choosing	to	test	and	
access	 treatment	 for	 chlamydia,	 and	 the	 relative	 strength	 of	
preference	 for	 those	 factors.	 This	 information	 should	 help	 inform	
both	 technology	 developers	 and	 commissioners,	 in	 shaping	 digital	
pathways	for	the	delivery	of	these	services.	The	economic	modelling	
has	also	contributed	new	knowledge	by	providing	an	insight	into	the	
likely	 costs	 and	 benefits	 of	 implementing	 a	 fully	 remote	 online	
pathway	or	 an	OCCP	 into	mainstream	 sexual	 health	 services.	 It	 has	
highlighted	 specific	 areas	 where	 further	 development	 of	 these	
pathways	is	required	to	maximise	the	likelihood	that	the	technology	
will	 be	 cost-effective.	 It	 has	 also	demonstrated	 that	both	 the	OCCP	
and	 a	 fully	 remote	 online	 pathway	 are	 likely	 to	 be	 used	 by	 young	
people	for	the	testing	and	treatment	of	chlamydia,	that	the	pathways	
are	likely	to	be	cost	saving	compared	with	current	practice,	although,	
further	 development	 is	 required	 to	 improve	 partner	 treatment	
uptake.	 The	 fully	 remote	 online	 pathway	 has	 the	 potential	 to	 be	 a	
viable	replacement	for	the	NCSP	internet	testing	pathway.	Although	
face-to-face	 services	 will	 still	 be	 required	 for	 the	 management	 of	
symptomatic	 patients	 and	 patients	 unsuitable	 for	 online	
management	 these	services	could	be	 rationalised	 leading	 to	 further	
cost	 savings.	 The	 challenge	 now	 is	 whether	 the	 OCCP	 and	 fully	
remote	online	pathway	can	be	progressed	to	a	point	where	they	are	
clinically	safe	and	cost-effective	before	the	rapid	evolution	of	digital	
technology	renders	them	obsolete.			
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Appendix	1	–	Background	to	the	eSTI2	Research	
Programme	
	
Formed	 from	 a	 collaboration	 of	 academic,	NHS	 and	 commercial	 partners	
the	 Electronic	 Self-Testing	 for	 Sexually	 Transmitted	 Infections	 (eSTI2)	
consortium	brings	together	point	of	care	(POC)	and	self-testing	diagnostic	
technologies	 for	 STIs	 with	 mobile	 technology	 to	 deliver	 rapid	 access	 to	
diagnosis	and	treatment.	The	stated	aim	of	the	eSTI2	programme	research	
is	to	“reduce	the	high	 impact	of	STIs,	a	national	priority	for	UK	health,	by	
building	 translational	 capacity	 to	 develop,	 improve,	 evaluate	 and	
implement	 simple	 to	 use,	 rapid,	 accurate,	 polymicrobial	 and	 affordable	
POC	 and	 non-POC	 micro-diagnostics	 that	 can	 be	 mobile-phone	
networked.”	 (eSTI2	 Consortium	 2010:1).	 The	 consortium	 supports	 a	
number	 of	 PhD	 fellowships	 focusing	 on	 different	 aspects	 of	 the	
programme.		
	
This	 doctoral	 research	 is	 focused	 on	 exploring	 the	 costs	 and	 benefits	 of	
introducing	 novel	 diagnostic	 and	 communication	 technologies	 for	 STI	
control	into	mainstream	NHS	practice	and	sits	within	work	stream	4	of	the	
eSTI2	 research	 programme.	 The	 eSTI2	 research	 programme	 to	 date	 is	
focused	 on	 the	 testing	 and	 treatment	 of	 chlamydia.	 A	 breakdown	 of	 the	
work	streams	is	provided	in	the	table	below.	
	
Work	Stream	 Work	Stream	Remit	
Work	Stream	1	(WS1)	-	
Micro-engineering	
Development	of	prototype	STI	testing	platforms	which	
will	ultimately	interface	with	mobile	phones.	
Work	Stream	2	(WS2)	-	
Microbiology	
Research	supporting	the	development	of	biosensor	and	
sample	processing	devices	for	multiple	STI	and	
antibiotic	resistance	testing	
Work	Stream	3	(WS3)	-	
Diagnostic	evaluation	
Working	with	industry	partners	on	prospective	clinical	
evaluation	of	novel	STI	diagnostic	tests	to	enable	the	
rapid	assessment	of	technology.	
Work	Stream	4	(WS4)	-	
Public	health	
Developing	clinical	care	pathways	and	investigating	the	
barriers	to	adoption	of	POC	and	self-tests	for	STIs	from	
a	regulatory,	ethical	and	economic	perspective.	
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WS4	has	piloted	a	clinical	care	pathway	using	a	non-native	app	(accessible	
via	 PC	 and	 mobile	 phone)	 for	 the	 treatment	 of	 chlamydia	 and	 partner	
notification	(July	2014	–	March	2015),	and	WS1,	WS2	and	WS3	are	aiming	
to	deliver	a	 remote	POCT	by	 late	2016.	 In	addition	 to	 the	eSTI2	WS1	and	
WS2	research	on	in	house	test	development,	there	is	potential	for	tests	to	
be	developed	by	one	of	the	commercial	collaborators	working	with	WS3	of	
the	project.		
	
The	 range	 of	 pathogens	 which	 could	 fall	 within	 the	 scope	 of	 the	 eSTI2	
pathway	are	identified	in	the	original	eSTI2	research	proposal	as:	Neisseria	
Gonorrhoeae,	 Chlamydia	 trachomatis,	 Ureaplasma	 parvum,	 Mycoplasma	
genitalium,	 Trichomonas	 vaginalis,	 Candida	 albicans,	 Bacterial	 vaginosis	
associated	organisms,	Herpes	simplex	1&2	and	Treponema	pallidum	(eSTI2	
Consortium,	2010).	At	the	current	time	it	is	anticipated	that	the	first	test	to	
be	piloted	will	be	for	chlamydia,	followed	by	gonorrhoea.		
	
The	 proposed	 approach	 to	 infectious	 disease	 diagnosis,	 treatment	 and	
surveillance,	 which	 will	 ultimately	 combine	 self-testing	 and	 mHealth,	 is	
revolutionary.	At	the	time	of	piloting,	the	clinical	care	pathway	(OCCP)	for	
the	 treatment	 of	 chlamydia	 will	 be	 the	 first	 pathway	 to	 prescribe	 a	
prescription	 only	 medicine	 for	 treatment	 without	 direct	 contact	 with	 a	
clinician.		
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Appendix	2	–	BSREC	Approval	Letter	–	DCE	Focus	
Groups	&	Pilot	
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Appendix	3	–	BSREC	Approval	Letter	–	DCE	Full	Study	
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Appendix	4	–	BSREC	Approval	Letter	–	Costing	Study	
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Appendix	5	–	OECD	List	of	High	Income	Countries	
	
OECD	High	Income	Countries	as	at	25th	July	2014:	
	
1. Australia	
2. Austria	
3. Belgium	
4. Canada	
5. Chile	
6. Czech	Republic	
7. Denmark	
8. Estonia	
9. Finland	
10. France	
11. Germany	
12. Greece	
13. Iceland	
14. Ireland	
15. Israel	
16. Italy	
17. Japan	
18. Korea	
19. Luxembourg	
20. Netherlands	
21. New	Zealand	
22. Norway	
23. Poland	
24. Portugal	
25. Slovak	Republic	
26. Slovenia	
27. Spain	
28. Sweden	
29. Switzerland	
30. United	Kingdom	
31. United	States	
	
Source:	OECD,	2014	
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Appendix	6	–	Example	Medline	Search	Strategy	
	
Database(s):	Ovid	MEDLINE(R)	1946	to	April	Week	3	2014		
Search	Strategy:	
# Searches Results 
1 exp Sexually Transmitted Diseases/ or sexually transmitted.mp. 282485 
2 
(STI or STD).mp. [mp=title, abstract, original 
title, name of substance word, subject heading 
word, keyword heading word, protocol 
supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
12391 
3 sexual health.mp. or exp Reproductive Health/ 4915 
4 1 or 2 or 3 288603 
5 exp Patient Preference/ or exp Choice Behavior/ or stated preference.mp. 41766 
6 stated choice.mp. 29 
7 discrete choice.mp. 570 
8 DCE.mp. 2421 
9 conjoint analysis.mp. 336 
10 contingent valuation.mp. 390 
11 willingness to pay.mp. 2068 
12 WTP.mp. 773 
13 willingness to accept.mp. 358 
14 WTA.mp. 171 
15 visual analogue scale.mp. 11436 
16 VAS.mp. 25873 
17 rating scale.mp. 28065 
18 magnitude estimation.mp. 697 
19 standard gamble.mp. 635 
20 SG.mp. 5193 
21 time trade off.mp. 706 
22 TTO.mp. 558 
23 person trade off.mp. 43 
24 PTO.mp. 497 
25 functional measurement.mp. 125 
26 paired comparison*.mp. 1628 
27 pairwise choice*.mp. 16 
28 conjoint measurement.mp. 43 
29 
part worth util*.mp. [mp=title, abstract, 
original title, name of substance word, subject 
heading word, keyword heading word, protocol 
supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
7 
30 
conjoint stud*.mp. [mp=title, abstract, original 
title, name of substance word, subject heading 
word, keyword heading word, protocol 
supplementary concept word, rare disease 
14 
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supplementary concept word, unique identifier] 
31 conjoint choice.mp. 7 
32 choice exercise*.mp. 11 
33 random paired scenario*.mp. 2 
34 payment card.mp. 29 
35 allocation of point*.mp. 6 
36 analytic hierarchy process.mp. 228 
37 measure of value.mp. 23 
38 
5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 
or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 
23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 
or 32 or 33 or 34 or 35 or 36 or 37 
115063 
39 4 and 38 908 
40 limit 39 to (english language and humans and yr="2000 - 2013") 625 
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Appendix	7	–	Data	Extraction	Form		
	
Data	Extraction	Form	–	Review	of	Stated	Preference	Studies	–	DCE	or	
Conjoint	Analysis	
	
Study	Title:	 	
Full	Publication	
Reference:	
	
Linked	Publications:	 	
Date	form	Completed:	 	
Name	of	Person	
Extracting	Data:	
	
Notes:	
	
	
	
	
	
	
	
1. Summary	Study	Characteristics:	
	
Study	Characteristics	 	
Study	Objective:	 	
Focus	of	Study	e.g.	product,	service:	 	
Type	of	Stated	Preference	Study:	 	
Application:	 	
Year	of	Study:	 	
Sample	Population:	 	
Sample	Size:	 	
Attributes	Included:	 	
Demographics	Included:	 	
Number	of	Attributes:	 	
Range	in	Number	of	Levels	per	Attribute:	 	
Full	or	Partial	Profile:	 	
Number	of	Profiles	in	Each	
Questionnaire:	
	
Opt	out/	Status	quo	option	included:	 	
Form	used	–	generic	or	alternative	
specific:	
	
Type	of	experimental	design	used:	 	
Efficiency	Score:	 	
Model	Used:	 	
Software	used	for	analysis:	 	
	
	
2. Reporting	Quality:	
	
Reporting	Quality	 	
1.1	Were	a	well-defined	research	
question	and	a	testable	hypothesis	
articulated?	
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1.2	Was	the	study	perspective	
described,	and	was	the	study	placed	
in	a	particular	decision-making	or	
policy	context?	
	
1.3	What	is	the	rationale	for	using	
conjoint	analysis	to	answer	the	
research	question?	
	
2.1	Was	attribute	identification	
supported	by	evidence	(lit	reviews,	
focus	groups	or	other	scientific	
methods)?	
	
2.2	Was	attribute	selection	justified	
and	consistent	with	theory?	
	
2.3	Was	level	selection	for	each	
attributed	justified	by	the	evidence	
and	consistent	with	the	study	
perspective	and	hypothesis?	
	
3.1	Was	the	number	of	attributes	in	
each	conjoint	task	justified	(that	is	full	
or	partial	profile)?	
	
3.2	Was	the	number	of	profiles	in	
each	conjoint	task	justified?	
	
3.3	Was	(should)	an	opt	out	or	status	
quo	alternative	be	included?	
	
4.1	Was	the	choice	of	experimental	
design	justified?	Were	alternative	
experimental	designs	considered?	
	
4.2	Were	the	properties	of	the	
experimental	design	evaluated?	
	
4.2a	Efficiency	Score:	 	
4.2b	Correlations	among	attribute	
levels:	
	
4.2c	Correlations	among	attribute	
level	differences:	
	
4.2d	Level	balance:	 	
4.2e	Number	of	overlapping	
attributes:	
	
4.2f	Restrictions	on	implausible	
combinations:	
	
4.2g	Cognitive	difficulty:	 	
4.3	Was	the	number	of	conjoint	tasks	
included	in	the	data	collection	
instrument	appropriate?	
	
5.1	Was	there	sufficient	motivation	
and	explanation	of	conjoint	tasks?	
	
5.2	Was	an	appropriate	elicitation	
format	used?	Did	(should)	the	
elicitation	format	allow	for	
indifference?	
	
5.3	In	addition	to	preference	
elicitation,	did	the	conjoint	tasks	
include	other	qualifying	questions	
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(e.g.	strength	of	preference)?	
6.1	Was	appropriate	respondent	
information	collected?	
	
6.2	Were	the	attributes	and	levels	
defined,	and	was	contextual	
information	provided?	
	
6.3	Was	the	level	of	burden	of	the	
data	collection	instrument	
appropriate?	Were	respondents	
encouraged	and	motivated?	
	
7.1	Was	the	sampling	strategy	
justified?	
	
7.2	Was	the	mode	of	administration	
justified	and	appropriate?	
	
7.3	Were	ethical	considerations	
addressed?	
	
8.1	Were	respondent	characteristics	
examined	and	tested?	
	
8.2	Was	the	quality	of	the	responses	
examined	(rationality,	validity,	
reliability)?	
	
8.3	Was	model	estimation	conducted	
appropriately?	Were	issues	of	
clustering	and	sub-groups	handled	
appropriately?	
	
9.1	Did	study	results	reflect	testable	
hypotheses	and	account	for	statistical	
uncertainty?	
	
9.2	Were	study	conclusions	
supported	by	the	evidence	and	
compared	with	existing	findings	in	
literature?	
	
9.3	Were	study	limitations	and	
generalizability	adequately	
discussed?	
	
10.1	Was	study	importance	and	
research	context	adequately	
motivated?	
	
10.2	Were	the	study	data	collection	
instrument	and	methods	described?	
	
10.3	Were	the	study	implications	
clearly	stated	and	understandable	to	
a	wide	audience?	
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Appendix	8	–	Summary	of	Assessment	Against	the	ISPOR	Good	Practice	Checklist	
	
Checklist	for	conjoint	analysis	in	health	care	
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1.1	–	Were	a	well-defined	research	question	and	
testable	hypothesis	articulated?	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
1.2	–	Was	the	study	perspective	described,	and	
was	the	study	placed	in	a	particular	decision-
making	or	policy	context?	
ü	 ü	 p	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
1.3	–	What	is	the	rationale	for	using	conjoint	
analysis	to	answer	the	research	question?	 p	 ü	 ü	 ü	 ü	 p	 ü	 ü	 p	 ü	 ü	 ü	
2.1	–	Was	attribute	identification	supported	by	
evidence	(literature	reviews,	focus	groups	or	
other	scientific	methods)?	
ü	 ü	 û	 ü	 p	 ü	 ü	 û	 û	 ü	 p	 ü	
2.2	–	Was	attribute	selection	justified	and	
consistent	with	theory?	 ü	 û	 û	 ü	 û	 ü	 ü	 û	 û	 p	 p	 ü	
2.3	–	Was	level	selection	for	each	attribute	
justified	by	the	evidence	and	consistent	with	
the	study	perspective	and	hypothesis?	
ü	 p	 p	 ü	 û	 p	 ü	 û	 û	 p	 p	 ü	
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Checklist	for	conjoint	analysis	in	health	care	
A
lb
us
	e
t	
al
.,	
(2
00
5)
	
B
eu
st
er
ie
n	
et
	a
l.,
	
(2
00
5)
	
H
au
be
r	
et
	a
l.,
	
(2
00
9)
	
H
si
eh
	e
t	
al
.,	
(2
01
1)
	
Ll
ew
el
ly
n	
et
	a
l.,
	
(2
01
3)
	
M
in
er
s	
et
	a
l.,
	
(2
01
2)
	
Ph
ill
ip
s	
et
	a
l.,
	
(2
00
2)
	
R
ya
n	
an
d	
W
at
so
n	
(2
00
9)
	
Sc
al
on
e	
et
	a
l.,
	
(2
01
1)
	
Ta
nn
er
	e
t	
al
.,	
(2
00
8)
	
W
at
so
n	
et
	a
l.,
	
(2
00
9)
	
Yo
un
g	
H
ol
t	
et
	a
l.,
	
(2
00
6)
	
3.1	–	Was	the	number	of	attributes	in	each	
conjoint	task	justified	(that	is,	full	or	partial	
profile)?	
ü	 û	 û	 û	 û	 p	 ü	 û	 û	 	p	 p	 ü	
3.2	–	Was	the	number	of	profiles	in	each	
conjoint	task	justified?	 p	 û	 û	 û	 û	 p	 ü	 û	 û	 p	 û	 ü	
3.3	–	Was	(should)	an	opt-out	or	status-quo	
alternative	(be)	included?	 û	 û	 û	 û	 p	 û	 û	 p	 ü	 û	 û	 û	
4.1	–	Was	the	choice	of	experiment	design	
justified?	Were	alternative	experimental	
designs	considered?	
û	 û	 û	 û	 û	 ü	 p	 ü	 û	 û	 p	 p	
4.2	–	Were	the	properties	of	the	experimental	
design	evaluated?	 û	 û	 û	 û	 p	 p	 ü	 p	 û	 û	 p	 p	
4.3	–	Was	the	number	of	conjoint	tasks	included	
in	the	data	collection	instrument	appropriate?	 û	 û	 û	 ü	 p	 ü	 ü	 ü	 û	 û	 û	 ü	
5.1	–	Was	there	sufficient	motivation	and	
explanation	of	conjoint	tasks?	 û	 û	 ü	 p	 p	 û	 p	 û	 û	 ü	 p	 ü	
5.2	–	Was	an	appropriate	elicitation	format	
(rating,	ranking	or	choice)	used?	Did	(should)	
the	elicitation	format	allow	for	indifference?	
û	 û	 ü	 û	 û	 p	 p	 û	 û	 û	 ü	 p	
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Checklist	for	conjoint	analysis	in	health	care	
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5.3	–	In	addition	to	preference	elicitation,	did	
the	conjoint	tasks	include	other	qualifying	
questions	(for	example	strength	of	preference,	
confidence	in	response,	and	other	methods)?	
û	 ü	 û	 û	 p	 û	 p	 p	 p	 û	 û	 p	
6.1	–	Was	appropriate	respondent	information	
collected	(e.g.	socio-demographic,	health	
history	etc)	
ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
6.2	–	Were	attributes	and	levels	defined,	and	
was	any	contextual	information	provided?	 û	 û	 p	 û	 p	 û	 û	 û	 û	 p	 p	 ü	
6.3	–	Was	the	level	of	burden	of	the	data	
collection	instrument	appropriate?	Were	
respondents	encouraged	and	motivated?	
û	 p	 p	 û	 p	 û	 û	 û	 û	 û	 û	 p	
7.1	–	Was	the	sample	strategy	justified	(e.g.	
sample	size,	stratification	and	recruitment)?	 û	 p	 û	 û	 p	 p	 p	 û	 p	 û	 û	 û	
7.2	–	Was	the	mode	of	administration	justified	
and	appropriate	(e.g.	face	to	face,	pen	and	
paper,	web-based)?	
û	 û	 û	 û	 û	 û	 û	 û	 û	 p	 û	 p	
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7.3	–	Were	ethical	considerations	addressed	
(e.g.	recruitment,	information	and/or	consent,	
compensation)?	
û	 p	 p	 p	 p	 p	 p	 p	 û	 p	 p	 p	
8.1	–	Were	respondent	characteristics	examined	
and	tested?	 ü	 p	 p	 p	 ü	 ü	 ü	 ü	 ü	 p	 ü	 ü	
8.2	–	Was	the	quality	of	the	responses	
examined	(e.g.	rationality,	validity,	reliability)?	 p	 ü	 ü	 û	 ü	 ü	 ü	 ü	 p	 p	 û	 ü	
8.3	–	Was	model	estimation	conducted	
appropriately?	Were	issues	of	clustering	and	
sub-groups	handled	appropriately?	
û	 û	 û	 p	 p	 ü	 ü	 p	 p	 p	 p	 ü	
9.1	–	Did	study	results	reflect	testable	
hypotheses	and	account	for	statistical	
uncertainty?	
û	 û	 û	 û	 ü	 ü	 p	 ü	 p	 p	 p	 p	
9.2	–	Were	study	conclusions	supported	by	the	
evidence	and	compared	with	existing	findings	in	
the	literature?	
p	 ü	 p	 p	 ü	 ü	 p	 ü	 p	 ü	 ü	 p	
9.3	–	Were	study	limitations	and	generalizability	
adequately	discussed?	 p	 ü	 ü	 ü	 ü	 ü	 p	 ü	 p	 p	 ü	 û	
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10.1	–Was	study	important	and	research	
context	adequately	motivated?	 ü	 p	 p	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	 ü	
10.2	–	Were	the	study	data-collection	
instrument	and	methods	described?	 p	 p	 p	 ü	 p	 p	 p	 p	 ü	 p	 p	 û	
10.3	–	Were	the	study	implications	clearly	
stated	and	understandable	to	a	wide	audience?	 p	 p	 p	 ü	 ü	 ü	 p	 ü	 p	 ü	 ü	 ü	
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Appendix	9	–	Preferences	&	Acceptability	of	
Mainstream	Sexual	Health	Services	Search	Strategy		
	
Medline	
	
# Searches Results 
1 exp Reproductive Health/ 1255 
2 exp Sexually Transmitted Diseases/ or sexually transmitted*.mp. 300983 
3 
(STI or STD).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, 
keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept 
word, unique identifier] 
13506 
4 1 or 2 or 3 305647 
5 test*.mp. 2882446 
6 treatment.mp. 3327476 
7 service.mp. 248426 
8 Patient Preference/ 3912 
9 
acceptab*.mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, 
keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept 
word, unique identifier] 
108974 
10 exp Choice Behavior/ or choice.mp. 224059 
11 uptake.mp. 278539 
12 access*.mp. 330379 
13 5 or 6 or 7 5886436 
14 8 or 9 or 10 or 11 or 12 918715 
15 4 and 13 and 14 11413 
16 limit 15 to (english language and humans) 10491 
17 limit 16 to yr="2004 - 2014" 7375 
 
	
	
		 559	
Appendix	10	–	Preference	&	Acceptability	of	Mainstream	Sexual	Health	Services	–	Summary	of	Included	
Papers	
	
	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
1. 	
Alvarez-del	
Arco,	D	et	al	
(2013)	
	
HIV	testing	and	counselling	
for	migrant	populations	living	
in	high-income	countries:	a	
systematic	review	
	
Migrants	have	specific	legal	and	administrative	
impediments	to	accessing	HIV	testing-in	some	countries,	
undocumented	migrants	are	not	entitled	to	health	care-as	
well	as	cultural	and	linguistic	barriers,	racism	and	
xenophobia.	Migrants	and	ethnic	minorities	fear	stigma	
from	their	communities,	yet	community	acceptance	is	key	
for	well-being.	
	
	
Stigma	
Community	
Acceptance	
2. 	 Anhang,	R.,	et	al.	(2005)	
Acceptability	of	self-collection	
of	specimens	for	HPV	DNA	
testing	in	an	urban	population	
compared	with	clinician	
collected	
ease	of	use,	less	painful	procedure,	could	do	it	myself,	
privacy	were	desirable	characteristics	of	self-sampling,	but	
overall	majority	(68%)	preferred	clinician	collected	test	
Sample	Collection	
Method	(Self-
Sample,	Clinician	
Collected	Sample)	
Privacy	
3. 	 Apoola,	A.,	et	al.	(2007)	
Preferences	for	partner	
notification	method:	variation	
in	responses	between	
respondents	as	index	patients	
and	contacts	
there	are	variations	in	the	preferences	of	respondents	for	
PN	method	which	depend	on	whether	respondents	see	
themselves	as	index	patients	or	contacts	
Partner	Notification	
Method	 	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
4. 	 Ashby,	J.,	et	al.	(2012)	
HIV	POC	testing	uptake	and	
acceptability	in	an	inner	city	
polyclinic	
90%	found	service	helpful	and	useful,	86%	found	the	
service	to	be	convenient	and	helpful	 Type	of	Test	 Convenience	
5. 	 Baker,	J.	R.,	et	al.	(2013)	
Barriers	to	discussing	and	
testing	for	STIs	in	GP	practices	
Patients	comfortable	discussing	and	testing	for	STIs	with	
GPs,	this	is	enhanced	if	GPs	have	specialist	qualification	
and	reduced	if	they	know	the	GP	socially	
Type	of	Healthcare	
Professional	
Knowledge	of	
Healthcare	
Professional	
Knowledge	of	
healthcare	
professional	socially	
6. 	 Balfe,	M.	and	R.	Brugha	(2009)	
Why	do	young	adults	attend	
STI	testing	services	
4	reasons	for	testing:	
-	transitional	moment	in	their	lives	
-	they	had	had	unprotected	sex	
-	had	symptoms	of	STI	
-	required	to	do	so	by	employer	
	
Barriers	included	concerns	about	stigma,	being	judged	and	
invulnerability	
	
4	reasons	for	
testing:	
-	transitional	
moment	in	their	
lives	
-	they	had	had	
unprotected	sex	
-	had	symptoms	of	
STI	
-	required	to	do	so	
by	employer	
	
Stigma	
Being	judged	
invulnerability	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
7. 	 Balfe,	M.	and	R.	Brugha	(2011)	
Young	adults	concerns	about	
attending	for	STI	testing	
Concerns	include:	
-	Stigma	
-	asking	health	professionals	for	advice	
-	sourcing	information	on	services	
-	attending	specific	STI	clinics	
-	being	recognised	
Location	of	test	
Access	to	Healthcare	
Professional	
-	Stigma	
-	asking	health	
professionals	for	
advice	
-	sourcing	
information	on	
services	
-	attending	specific	
STI	clinics	
-	being	recognised	
8. 	 Balfe,	M.,	et	al.	(2010)	
Location	of	chlamydia	
screening	services	
Screening	available	in	locations	where	they	would	not	be	
witnessed	asking	for	or	being	asked	to	take	a	test	 Location	of	testing	 	
9. 	 Baraitser,	P.,	et	al.	(2011)	
Client	experience	of	self-
management	within	a	sexual	
health	clinic	
Self-management	in	clinic	an	acceptable	option	if	informal	
support	is	available,	valued	reduced	waiting	time,	
autonomy	and	privacy	
Access	to	Healthcare	
Professional	
	
How	you	test	
Privacy	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
10. 	 Basta,	M.	S.	T.,	et	al.	(2009)	
Clinician	examination	of	
asymptomatic	GUM	
attendees	
98%	of	women	and	91%	of	men	prefer	to	be	examined	
when	attending	clinic	
Sample	collection	
method	 	
11. 	 Bilardi,	J.	E.,	et	al.	(2013)	
Views	on	rapid	self-testing	for	
HIV	
Would	be	useful	as	an	additional	rather	than	replacement	
tool	due	to	test	being	for	single	STI	and	lack	of	professional	
expertise	and	support	
Type	of	Test	
Access	to	Healthcare	
Professional	
	
	
12. 	 Booth,	A.	R.,	et	al.	(2013)	
Beliefs	about	chlamydia	
testing	
Need	to	reduce	the	negative	social	implications	of	testing	
and	treatment,	highlight	positive	value	of	reassurance.	In	
particular	the	feeling	of	embarrassment	associated	with	
testing	
	
Embarrassment	
Positive	value	of	
reassurance	
13. 	 Brown,	L.,	et	al.	(2008)	
Preferred	options	for	
receiving	test	results	
Preference	to	receive	test	results	even	if	they're	negative,	
majority	prefer	coded	results	slip	 Results	Notification	 	
14. 	 Brown,	L.,	et	al.	(2010)	
Acceptability	of	non-invasive	
testing	
Non-invasive	tests	acceptable	alternative	to	physician	
administered	tests	in	asymptomatic	patients	
Sample	collection	
method	 	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
15. 	 Brugha,	R.,	et	al.	(2011)	
Preferred	options	for	
receiving	chlamydia	screening	
test	results	
Call	to	mobile	phone	preferred	way	of	receiving	results	
followed	by	email.	Text	messages	and	calls	to	landlines	
were	most	unpopular	options	
Results	Notification	 	
16. 	
Challenor,	R.	
and	Z.	Warwick	
(2010)	
Saturday	services	-	patients	
views	 Services	on	Saturdays	more	popular	than	Sundays	 Service	Access	Times	 	
17. 	 Chaudhary,	R.,	et	al.	(2008)	
Male	perspectives	on	
provision	of	chlamydia	
screening	
Attitudes	affected	by	lack	of	knowledge,	perception	it's	a	
women's	disease,	social	embarrassment,	reluctance	to	
seek	help,	indifference	to	health	promotion	campaigns	
	
Lack	of	knowledge	
Social	
embarrassment	
Reluctance	to	seek	
help	
18. 	 Cohall,	A.,	et	al.	(2010)	
Men's	views	of	rapid	HIV	
testing	
Population	generally	aware	of	rapid	testing	but	need	
greater	focus	on	psychosocial	needs	-	need	time	to	prepare	
for	potentially	life	changing	diagnosis	
Access	to	healthcare	
professional		
Type	of	test	
	
19. 	
de	Wit,	J.	B.	F.	
and	P.	C.	G.	
Adam	(2008)	
Psychosocial	barriers	to	HIV	
testing	
Discrimination	and	rejection	most	common	reasons	for	not	
testing	 	
Discrimination	
Rejection	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
20. 	 Deblonde,	J.,	et	al.	(2010)	
Barriers	to	HIV	testing	in	
Europe	
The	barriers	described	are	centralized	around	low-risk	
perception;	fear	and	worries;	accessibility	of	health	
services,	reluctance	to	address	HIV	and	to	offer	the	tests;	
and	scarcity	of	financial	and	well	trained	human	resources	
Accessibility	of	
services	
Access	to	healthcare	
professional	
Low	risk	perception		
21. 	 Doshi,	J.	S.,	et	al.	(2008)	
Acceptability	of	self	taken	
vaginal	swabs	within	
chlamydia	screening	
programme	
90.4%	chose	to	provide	a	self	taken	vaginal	swab	and	5.8%	
chose	to	provide	a	urine	sample	as	an	alternative	
Sample	collection	
method	 	
22. 	 Fakoya,	I.,	et	al.	(2008)	 Barriers	to	HIV	testing		
Barriers	identified	include	access	to	testing,	fear	of	
disease/	diagnosis,	fear	of	stigma	and	discrimination	 Access	to	Testing	
Fear	of	
disease/diagnosis	
Stigma	
Discrimination	
23. 	
Fernando,	I.	and	
D.	Clutterbuck	
(2008)	
Patient	views	on	information	
sharing	between	GUM	and	
GPs	
Mode	of	referral	and	concerns	about	implications	of	HIV	
testing	affect	patient	preferences	on	information	sharing.	
Significant	proportion	of	patients	want	visits	to	remain	
anonymous	
	 Anonymity	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
24. 	
Fernando,	I.	and	
C.	Thompson	
(2013)	
Acceptability	of	
implementation	of	no	talk	
testing	clinic	in	GUM	for	
asymptomatic	patients	
Results	indicated	it	was	acceptable	-	speed,	efficiency,	
capacity	and	reduced	waiting	times	were	identified	as	
important	
Sample	Collection	
Method	
Waiting	times	
	
25. 	 Fielder,	R.	L.,	et	al.	(2013)	
Acceptability	of	self	taken	
vaginal	swabs	
High	participation	rate,	low	rate	of	discomfort	with	testing	
method,	high	willingness	to	retest	using	self-taken	vaginal	
swabs	in	the	future.	
Sample	Collection	
Method	 	
26. 	 Frasca,	T.,	et	al.	(2014)	
Attitude	and	behaviour	
changes	in	light	of	rapid	HIV	
testing	amongst	gay	and	
bisexual	men	
Approximately	50%	of	participants	reported	changes	in	
attitudes	leading	to	risk	reduction	linked	to	self-testing	 Testing	Method	 	
27. 	
Friedman,	A.	L.	
and	B.	
Bloodgood	
(2013)	
Alternative	testing	venues	for	
chlamydia	screening	
programme	
Alternative	testing	venues	are	valued	for	their	convenience	
and	accessibility	however	must	also	offer	emotional/	
informational	support,	privacy	and	confidentiality	
Location	of	Test	
	
Privacy	
Confidentiality	
Emotional/	
informational	
support	
Convenience	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
28. 	 Garrett,	C.	C.,	et	al.	(2011)	
Young	people's	views	on	
telemedicine	consultations	for	
sexual	health	
29%	of	respondents	indicated	that	they'd	use	webcam	
consultation	compared	with	63%	for	telephone	and	85%	
for	in	person	
Access	to	healthcare	
professional	 	
29. 	 Garrett,	C.	C.,	et	al.	(2012)	
Telemedicine	for	young	
people	in	rural	locations	
Telephone	consultation	was	preferable	to	consulting	a	
doctor	in	person	
Access	to	healthcare	
professional	 	
30. 	 Gaydos,	C.	A.,	et	al.	(2006)	
Focus	groups	to	design	
internet	based	intervention	
for	self-sampling	for	
chlamydia	
self-sampling	and	internet	intervention	viewed	positively	
Sample	Collection	
Method	
Location	of	Test	
	
31. 	 Gilbert,	M.,	et	al.	(2013)	
Intentions	to	use	internet	
based	testing	for	STIs	for	
MSM	
Internet	based	testing	has	the	potential	to	reach	all	MSM	
sub-groups	and	may	be	of	particular	benefit	to	those	who	
currently	face	barriers	to	accessing	testing	
Location	of	Test	 	
32. 	 Glasman,	L.	R.,	et	al.	(2010)	
Intention	to	seek	and	accept	
HIV	test	
Need	to	address	motivations	to	test	for	HIV,	in	particular	
HP	campaigns,	outreach	testing	and	stigma	 Location	of	Test	 Stigma	
33. 	 Gotz,	H.	M.,	et	al.	(2014)	
Acceptability	of	online	partner	
notification	tool	
Valuable	tool	for	PN,	suits	a	small	number	of	patients,	
particularly	those	notifying	more	than	one	partner	 Partner	Notification	 	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
34. 	 Gotz,	H.	M.,	et	al.	(2005)	
Chlamydia	screening	via	home	
based	urine	testing	
Home	based	sampling	method	acceptable	along	with	
receiving	results	by	post,	access	to	HCP	for	positive	
patients	is	essential	
Sample	Collection	
Method	
Access	to	Healthcare	
Professional	
	
35. 	 Graseck,	A.	S.,	et	al.	(2010)	
Home	v's	clinic	based	
screening	for	STIs	
More	likely	to	screen	at	home	than	attend	clinic	for	
screening	
Sample	Collection	
Method	 	
36. 	 Graseck,	A.	S.,	et	al.	(2010)	
Acceptability	of	home	based	
screening	for	STIs	
Women	more	likely	to	choose	to	screen	at	home,	and	
more	likely	to	complete	test	if	choosing	home	screening	
than	clinic	screening	
Sample	Collection	
Method	 	
37. 	 Gray,	D.,	et	al.	(2009)	
Patient	use	and	preferences	
for	sexual	health	services	in	
areas	with	and	without	one	
stop	services	
No	significant	difference	between	areas	with	and	without	
one	stop	services.	Higher	percentage	of	young	people	
citing	GP	as	preferred	provider	surprising	
Location	of	Test	
Type	of	Healthcare	
Professional	
	
		 568	
	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
38. 	 Greacen,	T.,	et	al.	(2013)	
Acceptability	of	purchasing	
authorised	HIV	self-tests	
online	
86.5%	expressed	interest	in	being	able	to	purchase	online,	
most	commonly	cited	reasons	are	convenience,	rapidity	
accessing	results,	privacy.	Those	not	interested	cited	
satisfaction	with	current	method,	doubts	over	reliability,	
not	wanting	to	be	alone	when	getting	results	and	fear	of	
getting	it	wrong	
Location	of	Test	
Time	to	Result	 Convenience	
39. 	 Greacen,	T.,	et	al.	(2012)	
Access	to	and	use	of	
unauthorised	HIV	self-tests	
Accesing	self-test	independently	associated	with	living	sex	
life	in	total	secrecy	and	unprotected	anal	sex	in	last	12	
months	therefore	suggesting	self-testing	may	reduce	
barriers	to	testing	in	these	groups	
Type	of	Test	 	
40. 	 Greenland,	K.	E.,	et	al.	(2011)	
Acceptability	of	internet	
based	chlamydia	screening	
Participants	found	the	internet	and	home	testing	to	be	
positives	of	the	programme.	2%	of	non-participants	cited	
no	internet	access	as	being	due	to	no	internet	access	
Location	of	Test	 	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
41. 	 Gudka,	S.,	et	al.	(2013)	
Chlamydia	screening	
interventions	via	community	
pharmacies	
Screening	in	community	pharmacies	is	feasible	and	can	
provide	an	accessible,	convenient	venue	to	get	a	test		 Location	of	Test	
Access	
Convenience	
42. 	 Guenter,	D.,	et	al.	(2008)	
Rapid	POC	HIV	testing	
programme	in	a	community	
setting	
100%	of	patients	received	rapid	result	compared	with	91%	
of	standard	test	patients.	Rapid	testing	was	acceptable	to	
patients	and	test	counsellors,	reduced	total	time	and	
number	of	visits	
Time	to	result	
	 	
43. 	 Gursahaney,	P.	R.,	et	al.	(2011)	
Partner	Notification	for	STIs	-	
practice	and	preferences	
Patient-initiated	partner	referral	methods	are	more	
successful	among	patients	with	increased	self-efficacy	and	
for	partners	whom	patients	have	stronger	relationships.	
Overall	APT	not	preferred,	however	women,	higher	
educational	attainment	and	prior	STI	patients	preferred	
APT	
Partner	Notification	 	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
44. 	 Hambly,	S.	and	G.	Luzzi	(2006)	
Patient	preferences	for	GUM	
v's	GP	services	
59%	patients	prefer	to	attend	GUM	compared	with	30%	
seeing	a	GP.	However	62%	would	see	GP	if	it	meant	being	
seen	more	quickly.	Most	important	factors	identified	were	
confidentiality,	staff	attitude,	range	of	tests	and	specialist	
knowledge	
Location	of	Service	
(Test/	Treatment)	
	
Type	of	HCP	
	
Range	of	Tests	
	
Knowledge	of	HCP	
Confidentiality	
Staff	Attitude	
	
45. 	
Hamill,	M.	and	
D.	Goldmeier	
(2005)	
Genital	Herpes	Clinic	Models	
Patients	split	between	preference	for	GP	(42%)	follow	up	
and	rejecting	GP	follow	up.	62%	supportive	of	nurse	led	
follow	up	
Type	of	HCP	 	
46. 	 Hawk,	M.	(2013)	
Community	based	HIV	testing	
and	risk	reduction	
intervention	
Eighty-seven	percent	of	participants	accessed	HIV	testing	
with	a	100%	return	rate	for	results.	Study	findings	suggest	
that	the	intervention	has	potential	to	be	effective	in	
increasing	the	number	of	women	who	access	HIV	testing.	
Location	of	Test	 	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
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47. 	 Hengel,	B.,	et	al.	(2013)	
Outreach	chlamydia	and	
gonorrhoea	outreach	
Although	outreach	reaches	a	small	number	of	people	the	
yield	of	infections	is	high.	Settings	which	appear	to	be	
more	successful	are	those	within	an	existing	venue	rather	
than	a	public	area	
Location	of	Test	 	
48. 	 Hitchings,	S.,	et	al.	(2009)	
What	do	patients	want	most	
from	sexual	health	services?	
The	results	showed	that	the	most	highly	valued	aspects	of	
care	were	confidentiality	(18.47%	of	points	allocated)	
followed	by	speed	of	service	(13.1%)	and	rapid	test	results	
(12.12%).	These	aspects	were	more	important	than	being	
seen	within	48	hours	(7.78%),	technical	expertise	(6.26%)	
or	other	patient-centred	aspects	of	care.	
Time	to	Result	
	
Knowledge	of	HCP	
Confidentiality	
Speed	of	Service	
49. 	 Hoebe,	C.	J.	P.	A.,	et	al.	(2006)	
Acceptability	of	self-taken	
vaginal	swabs	and	first	catch	
urine	for	diagnosing	
chlamydia	and	gonorrhoea	
Both	methods	are	highly	feasible	and	acceptable	and	are	
appropriate	specimens	for	a	highly	sensitive	STI	diagnosis	
Sample	Collection	
Method	 	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
50. 	 Hogan,	A.	H.,	et	al.	(2010)	
Young	people's	attitudes	to	
chlamydia	screening	in	GP	
practices	
Results	indicate	venue	is	acceptable	however	requires	
normalising	e.g.	offering	chlamydia	testing	to	all	attendees	
within	the	age	range	
Location	of	Test	 	
51. 	 Holloway,	I.	W.,	et	al.	(2011)	
Men's	preferences	for	STI	
care	testing		
Results	indicate	either	clinic	or	home	based	sampling	is	
acceptable	(71%	v's	87%),	preference	to	receiving	results	
via	phone,	83%	would	take	medication	brought	by	a	
partner	
Location	of	Test	
Results	Notification	
Partner	Notification/	
Therapy	
	
52. 	 Hottes,	T.	S.,	et	al.	(2012)	
Internet	based	HIV	and	STI	
testing	
Perceived	benefits	included	anonymity,	convenience	and	
client	centred	control.	Concerns	included	reluctance	to	
provide	personal	information	online,	need	for	
comprehensive	pre-test	information	and	support	for	
people	receiving	positive	results.	
Access	to	Healthcare	
Professional	
Anonymity	
Convenience	
Client	Centred	
Control	
Data	Security	
53. 	 Huang,	Z.	J.,	et	al.	(2008)	
Self-reported	HIV	testing	
behaviours	
STI	testing	rate	low	due	to	low	perceived	risk	within	the	
population.	No	link	to	traditional	access	measures	 Location	of	Test	 	
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54. 	 Huppert,	J.	S.,	et	al.	(2011)	
Acceptability	of	self-testing	
for	trichomoniasis	increases	
with	experience	
Four	acceptability	scales	identified:	trust	of	results,	
confidence,	comfort,	and	effects	of	testing.	Young	women	
lack	confidence	to	self	test,	undertaking	POCT	and	
reviewing	results	with	a	clinician	increases	acceptability	
Test	Accuracy	
	
Access	to	HCP	
Confidence	
Comfort	
Effects	of	Testing	
55. 	 Huppert,	J.	S.,	et	al.	(2012)	
Accuracy	and	trust	of	self-
testing	for	bacterial	vaginosis	
Young	women	can	undertake	test	with	reasonable	
accuracy.	Confidence	in	self-testing	increased	after	
experience,	and	discussion	of	test	results	
Sample	Collection	
Method/	Type	of	
Test	
	
56. 	
Iles,	F.	and	P.	
Oakeshott	
(2005)	
Acceptability	of	being	asked	
to	provide	a	urine	sample	for	
chlamydia	screening	in	a	GP	
practice	
Males	significantly	less	likely	than	females	to	accept	the	
offer	of	screening.	Response	rate	suggests	opportunistic	
screening	in	GP	practices	is	acceptable	and	feasible	
Location	of	Test	
Sample	Collection	
Method	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
57. 	
Ingram,	J.	and	
D.	Salmon	
(2007)	
Young	people’s	experiences	of	
drop	in	sexual	health	clinics	
highlighted	proximity	to	school/	home,	drop	in	nature,	
confidentiality	professionalism	and	friendliness	of	staff	
Location	of	Service/	
Test	
Access	to	Service	
e.g.	drop	in	
Confidentiality	
Professionalism	and	
friendliness	of	staff	
	
58. 	
Ingram,	J.	and	
D.	Salmon	
(2010)	
Young	people's	views	on	drop	
in	sexual	health	services	
Drop	in	services	attracted	hard	to	reach	groups.	Barriers	to	
use	included	worries	about	embarrassment,	cultural	issues	
and	confidentiality.	
Type	of	Service	
Embarrassment		
Cultural	issues	
Confidentiality	
59. 	 Jerome,	S.,	et	al.	(2009)	
Designing	sexual	health	
services	for	young	people	-	
methodology	for	capturing	
user	voice	
The	priorities	were	privacy,	and	a	dedicated	service	close	
to	home,	with	a	drop-in	facility	and	male	and	female	staff	
being	next	most	important,	and	an	informal	service	and	
young	staff	being	lowest	priorities.	Evidence	suggested	
methodology	for	capturing	views	was	acceptable	
Location	of	Service/	
Test	
Access	to	service	
e.g.	drop	in	
	
Privacy	
Gender	of	staff	
60. 	 Johnson,	C.	V.,	et	al.	(2009)	
Access	and	screening	
frequency	among	MSM	
Clinicians	need	to	assess	sexual	risk-taking	behaviours	and	
more	routinely	screen	for	STIs	among	sexually	active	men	
regardless	of	disclosure	of	a	history	of	having	sex	with	men	
Location	of	test	 	
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61. 	 Jones,	H.	E.,	et	al.	(2013)	 Preferences	for	STI	services	
Preference	for	self-sampling	for	testing	than	an	
examination.	94%	prefer	to	notify	partner	directly	about	
STI,	88%	would	do	expedited	partner	therapy.	More	likely	
to	prefer	3rd	party	PN	if	last	partner	was	a	casual	partner	
(14%	v's	3%)	
Sample	Collection	
Method	
Partner	Notification	
	
62. 	 Kerani,	R.	P.,	et	al.	(2013)	
Preferences	for	Patient	
Delivered	Partner	Therapy	
and/or	electronic	partner	
notification	cards	
Men	with	no	symptoms	less	likely	to	seek	care	if	notified	
by	an	anonymous	e-card	than	if	notified	directly.	50%	
reported	they	would	use	treatment	provided	by	a	partner.	
Will	lead	to	missed	opportunities	to	test	for	HIVs	and	other	
STIs	
Partner	Notification	 	
63. 	
Knapp,	H.	and	
H.	D.	Anaya	
(2010)	
Provider	and	patient	centred	
barriers	to	HIV	testing	
	Confidentiality,	offering	information,	resources,	treatment	
options,	and	empathetic	contact	at	each	step	of	the	
process	are	more	likely	to	encourage	patients	to	consent	
to	HIV	testing	
Treatment	Options	
Confidentiality	
	
Provision	of	
information		
	
Empathetic	Contact	
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64. 	
Knussen,	C.	and	
P.	Flowers	
(2007)	
Acceptability	of	notification	of	
syphilis	results	via	phone	
Phoning	in	for	results	significantly	more	acceptable	than	
phoning	home	or	phoning	mobile,	phone		call	to	mobile	is	
more	acceptable	than	call	to	home	
Results	Notification	 	
65. 	 Koester,	K.	A.,	et	al.	(2013)	
Sexual	healthcare	preferences	
among	gay	and	bisexual	men	
Identified	healthcare	into	fragmentation	(individual	
services)	and	consolidation.	Drivers	for	both	however	
overall	preference	to	separate	sexual	health	from	other	
primary	care	
Type	of	Service	
(primary	v’s	sexual	
health)	
Location	of	Service	
	
66. 	
Kowalczyk	
Mullins,	T.	L.,	et	
al.	(2010)	
Adolescent	preferences	for	
HIV	testing	and	impact	of	
rapid	tests	on	results	
notification	
70%	preferred	rapid	to	traditional	HIV	testing	and	rapid	
testers	more	likely	to	receive	results	within	the	follow	up	
period.	
Type	of	Test	
Results	Notification	 	
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67. 	 Krause,	J.,	et	al.	(2013)	
Acceptability	of	HIV	self-
testing	-	systematic	review	
Review	demonstrates	HIV	self-testing	is	an	acceptable	
testing	alternative	and	can	be	performed	accurately	by	
individuals.	Privacy	and	Confidentiality	valued.	Availability	
of	counselling,	treatment	and	care	services	are	major	
challenges.	
Type	of	Test	
Sample	Collection	
Method	
Access	to	Healthcare	
Professional	
Privacy	
Confidentiality	
68. 	 Kwan,	K.	S.	H.,	et	al.	(2012)	 Online	Chlamydia	Testing	
Internet	based	screening	is	an	effective	way	to	increase	
access	and	is	valuable	alongside	clinic	based	services.	 Location	of	Test	 	
69. 	 Lambert,	N.	L.,	et	al.	(2005)	
Feasibility,	acceptability	and	
effectiveness	of	community	
based	syphilis	screening	
Screening	in	gay	venues	is	acceptable	to	at	risk	MSM,	
reaches	a	group	that	doesn't	traditionally	access	services	
and	may	be	helpful	if	combined	with	other	STIs	(Syphilis	
diagnosis	rate	low)	
Location	of	Test	 	
70. 	 Langille,	D.	B.,	et	al.	(2008)	
Pilot	of	self-testing	for	
chlamydia	screening	-	
characteristics	of	participants	
and	non-participants	
54%	cited	reason	for	not	using	test	kit	as	being	
asymptomatic,	49%	gave	low	probability	of	infection	as	
reason	for	not	using	test	
Type	of	Test	
Location	of	Test	 	
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71. 	 Lee,	R.,	et	al.	(2014)	 Incentivising	HIV/STI	testing	
All	studies	demonstrated	higher	uptake	in	incentivised	
group.	Incentives	in	non-clinical	settings	were	more	
effective	than	incentives	in	clinical	settings	
	 Incentivisation	of	Testing	
72. 	 Leston,	J.	D.,	et	al.	(2012)	
Focus	groups	on	STDs,	HIV/	
AIDS	and	unplanned	
pregnancy	
Confidentiality	and	embarrassment	concerns	impact	on	
young	people's	decisions	to	access	sexual	health	services	 	
Confidentiality	
Embarrassment	
73. 	 Lewis,	N.	M.,	et	al.	(2013)	 Rapid	POC	Testing	for	HIV	 Rapid	testing	for	HIV	high	acceptable	and	highly	desirable	 Type	of	Test	 	
74. 	 Lindberg,	C.,	et	al.	(2006)	
Barriers	to	sexual	and	
reproductive	healthcare	
Obtaining	sexual	health	services	was	a	stressful	experience	
with	barriers	including	fear	of	stigma	and	loss	of	social	
status,	shame,	embarrassment,	privacy/	confidentiality,	
and	accessing	and	negotiating	the	healthcare	system	
Location	of	Service	
Access	to	Service	
Stigma	
Loss	of	Social	Status	
Shame	
Embarrassment	
Privacy	
Confidentiality	
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75. 	 Ling,	S.	B.,	et	al.	(2010)	
Online	services	for	results	
notification	
Results	indicate	patients	accepted	online	results	mainly	
because	of	the	ability	to	check	results	any	time	of	the	day	 Results	Notification	 	
76. 	 Llewellyn,	C.,	et	al.	(2012)	
Understanding	patient	
choices	for	STI	testing	services	
Perceived	expertise	main	reason	for	attending	GUM	over	
GP,	other	factors	included	range	of	tests,	lack	of	expertise,	
decision	on	where	to	test	influenced	by	previous	
experience,	relationship	with	GP,	results	notification	
method	and	other	medical	conditions	
Location	of	Service	
Range	of	STIs	
Knowledge	of	HCP	
Results	Notification	
Relationship	with	
HCP	
77. 	 Llewellyn,	C.,	et	al.	(2009)	
Are	home	sampling	kits	
acceptable	to	MSM	
Home	sampling	kit	generally	viewed	as	positive,	concerns	
about	accuracy,	delays	in	results,	lack	of	support	were	also	
raised	
Sample	Collection	
Method	
Time	to	Result	
Access	to	HCP	
Accuracy	of	Test	
	
78. 	
Lorimer,	K.	and	
L.	McDaid	
(2013)	
Barriers	and	facilitators	to	
internet	based	CT	screening	
Barriers	to	successful	implementation	-	acceptability,	
confidentiality	and	privacy	concerns	 Location	of	Test	
Acceptability	
Confidentiality	
Privacy	Concerns		
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	 Author	 Study	Focus	 Key	Findings	
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from	Study	
79. 	 Lorimer,	K.,	et	al.	(2009)	
Willingness	to	be	tested	for	
CT	
Men	more	willing	than	women	to	be	tested	for	CT	in	non-
medical	settings	 Location	of	Test	 	
80. 	 Marrazzo,	J.	M.,	et	al.	(2007)	
Acceptability	of	urine	based		
screening	for	CT	in	
asymptomatic	men	
Asymptomatic	men	likely	to	accept	testing	but	it	depends	
on	location	and	approach	 Location	of	Test	 	
81. 	
Marrazzo,	J.	M.	
and	D.	Scholes	
(2008)	
Acceptability	of	urine	based	
screening	for	CT	in	
asymptomatic	men	-	
Systematic	Review	
Acceptance	in	non-home	based	settings	is	generally	higher	
than	home	based.		 Location	of	Test	 	
82. 	 Marsh,	K.	A.,	et	al.	(2010)	
Who	chooses	rapid	HIV	
testing?	
33%	of	tests	taken	up	were	rapid	tests,	preference	higher	
among	MSM	following	alcohol	use	but	not	drugs,	and	sex	
workers	
Type	of	Test	 	
83. 	 Martin,	L.,	et	al.	(2013)	
Preferred	methods	for	results	
notification	
Preference	for	texts	for	negative	STI	results	but	lower	for	
negative	HIV	results.	In	person	preference	for	positive	test	
results	
Results	Notification	 	
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from	Study	
84. 	 Martin,	L.,	et	al.	(2013)	
Client	satisfaction	with	an	
'express	STI	screening	service'	
Two	most	common	reasons	given	for	uptake	were	reduced	
waiting	time	and	reduced	length	of	consultation.	High	
levels	of	client	satisfaction	with	83%	stating	would	use	in	
future	
Access	to	HCP	
Waiting	Time	 	
85. 	 Melville,	C.	R.	S.,	et	al.	(2004)	
Client	perspectives	of	sexual	
health	service	provision	
Although	point	of	care	testing	(microscopy)	increases	time	
in	clinic	99%	expressed	a	preference	for	this.		
Time	to	Result	
Type	of	Test	 	
86. 	 Melvin,	L.,	et	al.	(2009)	
Preferred	strategies	for	
managing	CT	infection	
Women	preferred	partner	delivered	partner	medication	
both	for	their	partners	and	would	prefer	it	themselves.	
Men	prefer	patient	referral	for	partner	notification	and	
would	prefer	it	themselves	
Partner	Notification	 	
87. 	 Messer,	L.,	et	al	(2013)	
Barriers	and	facilitators	to	
testing,	treatment	entry,	and	
engagement	in	care	by	HIV-
positive	women	of	colour	
	
Barriers	reported	by	women	were	aligned	with	the	racial	
health	care	disparity	model	constructs	and	varied	by	stage	
of	HIV.	Identifying	the	salient	barriers	and	facilitators	at	
multiple	ecological	levels	along	the	HIV	care	continuum	
may	inform	intervention	development.	
	 	
88. 	 Mills,	C.,	et	al	(2011)	
Barriers	to	HIV	testing	among	
HIV/AIDS	concurrently	
diagnosed	persons	in	New	
York	City	
Lack	of	perception	of	risk	most	common	reason	for	not	
testing	for	HIV	sooner.	
	
	 Perception	of	Risk	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
89. 	 Mills,	N.,	et	al.	(2006)	
Experience	of	CT	screening	
programme	
Themes	included	issues	resulting	from	unease	with	sexual	
health	issues,	anxiety	post	test	result,	fear	of	informing	
partners,	fear	of	other	undiagnosed	infections,	stigma	
	
Unease	with	sexual	
health	issues	
Anxiety	post	test	
result	
Fear	of	informing	
partners	
Fear	of	other	
undiagnosed	
infections	
Stigma	
90. 	 Mimiaga,	M.	J.,	et	al.	(2008)	
Attitudes	about	internet	
partner	notification	for	STDs	 Broad	acceptance	of	internet	as	PN	method	by	MSM	 Partner	Notification	 	
91. 	 Miners,	A.,	et	al.	(2012)	
User	preferences	for	different	
aspects	of	STI	services	
People	testing	have	a	preference	for	testing	for	all	
infections	rather	than	some	and	staff	with	specialist	
knowledge.	Text	or	call	to	mobile	phone	and	drop	in	and	
wait	were	preferred	methods	of	results	notification	
Range	of	Test	
Knowledge	of	HCP	
Results	Notification	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
92. 	 Mullins,	T.	K.,	et	al.	(2012)	
Adolescents	agreement	to	
test	for	HIV	when	different	
options	are	offered	
Agreement	to	test	was	higher	in	the	following	groups:	
males,	parents	who	completed	high	school,	if	test	offered	
by	clinician,	concerns	over	infection	status	
Access	to	HCP	 Concerns	over	infection	status	
93. 	
Napierala	
Mavedzenge,	S.,	
et	al.	(2013)	
Review	of	self-testing	for	HIV	
Policy	shifting	with	less	emphasis	now	on	pre-test	
counselling.	HIV	self-testing	has	been	adopted	in	a	number	
of	countries	
Type	of	Test	 	
94. 	 Norman,	J.	E.,	et	al.	(2004)	
Acceptability	of	CT	screening	
in	ante-natal	and	gynae	clinics		
Data	on	acceptability	supports	current	strategies	of	
screening	in	abortion	clinics	 Location	of	Test	 	
95. 	
Novak,	D.	P.	and	
R.	B.	Karlsson	
(2006)	
Using	the	internet	and	home	
sampling	for	CT	testing	
Study	proved	internet	testing	feasible	and	believed	
method	may	encourage	more	young	people	to	test	 Location	of	test	 	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
96. 	
Oliver	de	Visser,	
R.	and	N.	O'Neill	
(2013)	
Barriers	to	STI	testing	
amongst	young	people	
Quantitative	data	found	that	desire	to	comply	with	other's	
wishes,	perceptions	of	other's	behaviour	and	shame	
influenced	past	testing	behaviour.	Qualitative	data	
highlight	stigma,	shame	and	perceived	ease	of	testing	as	
important	
	
Desire	to	comply	
with	others	wishes	
Perceptions	of	
other’s	behaviour	
Shame	
Perceived	ease	of	
testing	
97. 	 Patel,	H.,	et	al.	(2007)	
Improving	sexual	health	
services	
Walk	in	and	appointment	based	models	acceptable,	most	
important	factor	is	not	being	turned	away	 Access	to	Service	 	
98. 	 Patel,	H.,	et	al.	(2006)	
Results	notification	
preferences	
discrepancy	between	what	clients	want	and	what	clinics	
provide	with	majority	of	clients	wanting	to	know	results	
regardless	of	outcomes	however	1/5	of	clinics	only	notify	
positive	results	
Results	Notification	 	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
99. 	 Pavlin,	N.	L.,	et	al.	(2006)	
Women's	views	on	chlamydia	
screening	-	systematic	review	
Major	themes	included	-	need	for	knowledge	and	
information,	choice	and	support,	confidentiality,	cost,	fear,	
anxiety	and	stigma.	Women	want	a	range	of	options	and	
tests	should	be	free,	easy	and	quick	
	
Need	for	knowledge	
and	information	
Choice	and	support	
Confidentiality	
Cost	
Fear		
Anxiety	
Stigma	
Want	a	range	of	
options	to	test	
100. 	 Pavlin,	N.	L.,	et	al.	(2008)	
Young	women's	views	on	
implementing	chlamydia	
screening	in	general	practice	
Trust	in	GP	was	main	factor	in	acceptability,	prefer	
screening	based	on	age	rather	than	sexual	risk	 Type	of	HCP	 	
101. 	 Peralta,	L.,	et	al.	(2007)	
Barriers	and	facilitators	to	
adolescent	HIV	testing	
Increased	availability	of	oral	and	rapid	test	methods,	free	
testing	services,	rapid	receipt	of	results	would	encourage	
young	people	to	take	an	HIV	test	
Type	of	Test	
Time	to	Results	 	
102. 	 Perry,	C.	and	M.	Thurston	(2008)	
Model	for	meeting	sexual	
health	needs	of	young	people	
Young	people	can	be	engaged	if	service	is	based	on	'best	
practice'	 	 ‘Best	Practice’		
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
103. 	 Prost,	A.,	et	al.	(2007)	
Taking	rapid	HIV	testing	to	
gay	venues	
Concerns	include	confidentiality,	privacy,	post-test	support	
and	clinical	standards	 Access	to	HCP	
Confidentiality	
Privacy	
Clinical	Standards	
104. 	 Prost,	A.,	et	al.	(2009)	
Feasibility	and	acceptability	of	
rapid	HIV	testing	in	primary	
care	
Rapid	testing	in	GP	practice	acceptable	but	some	concerns	
over	post-test	support	 Location	of	Test	 Post	Test	Support	
105. 	 Rompalo,	A.	M.,	et	al.	(2013)	
POCT	for	STIs	-	what	do	users	
want?	
Home	testing	POCTs	acceptable	but	concerns	over	
interpreting	results,	clinic	POCT	acceptable	due	to	
definitive	results	and	immediate	treatment.	Need	to	be	
affordable,	rapid,	easy	to	read	and	simple	
Type	of	Test	
Accuracy	of	Result	
Location	of	
treatment	
	
106. 	 Rose,	S.	B.,	et	al.	(2008)	
Young	people's	attitudes	to	
CT	screening	
Reasons	for	not	testing	-	fear,	stigma,	not	perceived	at	risk,	
don't	know	how	to	get	tested	 	
Fear		
Stigma	
Not	perceived	at	risk	
Don’t	know	how	to	
get	tested	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
107. 	 Rosenberger,	J.	G.,	et	al.	(2011)	
Self-sampling	for	ano-rectal	
STIs	among	MSM	
Results	found	that	it	is	a	feasible	and	acceptable	method	of	
collecting	STI	samples	
Sample	Collection	
Method	 	
108. 	 Roth,	A.,	et	al.	(2011)	
Future	chlamydia	screening	
preferences	
Clinic	preferred	option	followed	by	home	sampling,	men	
prefer	results	via	phone	and	personalised	reminders	for	
future	screening	
Sample	Collection	
Method	
Results	Notification	
	
	
109. 	 Saadatmand,	H.	J.,	et	al.	(2012)	
Young	men's	preferences	for	
STD	and	reproductive	health	
services	
Preference	for	using	dedicated	sexual	health	service	
locations	rather	than	'non-traditional	options'.	Prefer	to	
receive	results	from	a	clinician	than	online	or	via	text	
message	
Location	of	Test	
Results	Notification	 	
110. 	 Sacks-Davis,	R.,	et	al.	(2010	
Home	based	chlamydia	
testing	for	people	attending	a	
music	festival	
Responses	indicated	that	awareness	that	chlamydia	could	
make	you	infertile,	more	than	three	partners	and	
inconsistent	condom	use	were	the	most	likely	predictors	of	
participants	returning	screening	kits	
Type	of	Test	 	
111. 	 Samangaya,	M.	(2007)	
Access	to	sexual	health	
services	for	young	BME	men	
Embarrassment	was	the	main	factor	preventing	this	group	
accessing	sexual	health	services	 	 Embarrassment	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
112. 	 Saunders,	J.	M.,	et	al.	(2012)	
Where	do	young	men	want	to	
access	STI	screening?	
Willingness	to	use	self-sampling	tests	was	high.	Most	
acceptable	collection	points	were	GUM,	GP	practice	and	
pharmacy	
Sample	Collection	
Method	
Test	Collection	
Location	
	
113. 	 Schwandt,	M.,	et	al.	(2012)	
Preferences	for	rapid	point	of	
care	testing	in	primary	care	
81%	would	prefer	to	access	rapid	testing	rather	than	
standard	testing	
Type	of	Test	
Time	to	Result	 	
114. 	 Sena,	A.	C.,	et	al.	(2010)	
Feasibility	and	acceptability	of	
rapid	HIV	testing	-	Door	to	
door	outreach	
People	who	had	not	tested	for	HIV	before	were	more	likely	
to	consent,	97%	of	survey	participants	supported	rapid	HIV	
testing	in	the	community	
Location	of	Test	 	
115. 	 Shih,	S.	L.,	et	al.	(2011)	
Screening	for	STIs	at	home	
versus	clinic	
Review	of	literature	found	that	response	rates	for	home	
testing	up	to	11x	higher	than	clinic	based	testing.	Limited	
evidence	with	regards	cost-effectiveness	
Location	of	Test	
Sample	Collection	
Method	
	
116. 	 Shivasankar,	S.,	et	al.	(2008)	
Views	on	Patient	Delivered	
Partner	Therapy	 Traditional	partner	referral	was	the	preferred	option	
Partner	Notification/	
Treatment	 	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
117. 	 Shoveller,	J.,	et	al.	(2009)	
Youth	experiences	of	STI	
testing	in	rural	communities	
Barriers	identified	include	isolating	geography	means	
difficult	to	access	service	during	opening	times,	privacy,	
female	focussed,	fear	of	disclosing	risky	sexual	behaviour,		
Service	Opening	
Times	 Privacy	
118. 	 Shoveller,	J.,	et	al.	(2012)	
Youth	perspectives	on	online	
sexual	health	services	
Online	risk	assessment	and	testing	services	acceptable,	
particularly	in	respect	of	need	for	convenience,	privacy	and	
rapid	access.	Little	tolerance	of	technology	perceived	as	
'antiquated'	
Location	of	Test	
Convenience	
Privacy	
Rapid	Access	
119. 	 Skala,	S.	L.,	et	al.	(2012)	
Factors	associated	with	
screening	for	STIs	
Screening	completion	most	commonly	associated	with	
college	education	or	higher	and	home	based	testing	 Location	of	Test	 	
120. 	 Soni,	S.	and	J.	A.	White	(2011)	
Self-screening	for	CT	and	NG	
in	an	HIV	clinic	
Evaluation	indicated	that	all	participants	found	self-
sampling	acceptable	
Sample	Collection	
Method	 	
121. 	 Spielberg,	F.,	et	al.	(2004)	 Self-testing	for	HIV	
Self-testing	may	be	an	important	additional	strategy	to	aid	
HIV	diagnosis	 Type	of	Test	 	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
122. 	 Sullivan,	P.	S.,	et	al.	(2014)	
Safety	and	acceptability	of	
couples	HIV	testing	for	MSM	
Couples	testing	for	counselling	and	HIV	is	very	acceptable	
to	MSM	couples	 Location	of	Test	 	
123. 	 Tebb,	K.	P.,	et	al.	(2004)	
Home	STI	testing	-	adolescent	
female	views	
Adolescents	concerned	about	having	an	STI	prefer	home	
testing.	 Location	of	Test	 	
124. 	 Thomas,	F.,	et	al.	(2010)	
Impact	of	health	service	
charges	on	HIV	testing	in	
England	
Confusion	over	entitlement	to	healthcare,	financial	
difficulties	and	fears	over	deportation	are	barriers	to	
accessing	sexual	health	services	
	
Entitlement	to	
healthcare	
Financial	difficulties	
Fears	over	
deportation	
125. 	 Tomnay,	J.	E.,	et	al.	(2014)	
Acceptability	of	online	STI	
testing	
Online	testing	can	address	access	issues,	concerns	about	
privacy,	trust,	reliability	and	generalist	rather	specialist	
sexual	health	services	were	identified	as	barriers.	
Location	of	Test	
Type	of	HCP	
Knowledge	of	HCP	
Privacy		
Trust	
Reliability	
126. 	 Turner,	S.	D.,	et	al.	(2013)	 Rapid	POCT	for	HIV	in	youth	 Young	people	prefer	rapid	POCT	for	HIV.	
Type	of	Test	
Time	to	Result	 	
127. 	 Tuysuzoglu,	S.,	et	al.	(2011)	
Acceptability	of	rapid	HIV	
testing	in	an	adolescent	clinic	
setting	
Most	participants	valued	rapid	results.	 Time	to	Result	 	
128. 	 Vaughan,	D.,	et	al.	(2010)	
Acceptability	and	uptake	of	
onsite	chlamydia	testing	
Participation	enhanced	by	anonymity,	convenience,	
accessibility	of	testing	and	non-medical	approach	 Location	of	Test	
Anonymity	
Convenience	
Accessibility	
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	 Author	 Study	Focus	 Key	Findings	
Potential	Attributes	
Identified	from	
Study	
Factors	Informing	
Attributes	Identified	
from	Study	
129. 	 Watson,	V.,	et	al.	(2009)	
Valuing	experience	factors	in	
CT	screening	
Women	valued	experience	factors	in	the	provision	of	
chlamydia	screening	 	 Experience	factors	
130. 	 Wayal,	S.,	et	al.	(2011)	
Home	sampling	for	STIs	-	
preferences	and	concerns	of	
MSM	
Participants	preferred	testing	kits	to	be	available	in	
medical	rather	than	social	venues.	Clinic	attendance	
preferred	if	symptomatic.	
Location	of	Test	
	 	
131. 	 Wayal,	S.,	et	al.	(2009)	
Self-sampling	for	oral	and	anal	
STIs	-	acceptability	
Home	sampling	acceptable	as	it	was	viewed	to	be	less	
intrusive	and	more	convenient	
Sample	collection	
method	
Location	of	Test	
	
132. 	 Wong,	J.	P.-H.,	et	al.	(2012)	
Barriers	to	STI	testing,	
treatment	and	care	
Fear	and	social	stigma	discouraged	young	heterosexual	
women	from	accessing	services.		 	
Fear		
Social	Stigma	
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Appendix	11	–	Focus	Group	–	Full	Topic	Guide	Including	
Vignettes	
	
Introduction	
Good	 evening,	 my	 name’s	 Sue,	 I’m	 a	 PhD	 student	 at	 the	 University	 of	
Warwick	and	I	work	on	a	project	which	is	developing	new	tests	and	ways	to	
get	treated	for	sexually	transmitted	infections.	Firstly	I	want	to	say	a	huge	
thank	 you	 for	 giving	 up	 your	 time	 this	 evening	 to	 talk	 to	 me	 this,	 your	
feedback	on	how	to	develop	sexual	health	services	 is	really	 important	 for	
my	 research	 and	 hopefully	 through	 this	 will	 inform	 how	 services	 are	
developed	in	the	future.		
	
What	 I’m	 here	 to	 talk	 to	 you	 about	 is	 ways	 of	 testing	 and	 accessing	
treatment	 for	Sexually	Transmitted	 Infections.	When	 I	 talk	about	 sexually	
transmitted	infections	most	of	the	time	I’ll	probably	refer	to	them	as	STIs.	
New	technology	means	that	over	the	next	few	years	there	could	be	more	
choices	available	to	you	for	getting	tested	for	STIs	and	getting	treatment.	
For	example	point-of-care	tests	-	these	are	tests	where	the	test	is	done	and	
you	get	 the	result	 in	 the	same	visit	e.g.	at	a	clinic	or	pharmacy.	Self-tests	
are	 when	 you	 can	 undertake	 the	 test	 and	 find	 out	 the	 result	 yourself	
without	 needing	 to	 attend	 a	 clinic,	 like	 how	 a	 pregnancy	 test	works.	 For	
some	 STIs	 smartphone	 apps	 and	 e-health	 clinics	 are	 being	 developed	 so	
that	 if	 you	have	a	positive	 test	 result	 you	can	complete	an	online	clinical	
questionnaire	 and,	 if	 safe,	 a	 prescription	 will	 be	 issued	 so	 you	 can	 go	
straight	to	the	pharmacy	to	pick	up	your	treatment.	
	
So	tonight	is	all	about	what	you	think,	we	don’t	know	whether	these	new	
ways	 of	 testing	 and	 accessing	 treatment	 are	 acceptable	 to	 people,	 there	
might	 be	 some	 things	 about	 it	 you	 like	 and	 others	 that	 you	 don’t	which	
would	make	difference	to	whether	you	would	choose	to	use	the	new	test	
or	existing	services.		
	
Your	 participation	 will	 help	 us	 understand	 how	 people	 want	 to	 access	
services	 for	 the	 testing	and	 treatment	of	STIs	 in	 the	 future.	There	are	no	
right	or	wrong	answers,	you	may	all	have	a	different	view	on	 it,	you	may	
change	your	mind	after	you’ve	thought	about	it	or	hear	what	someone	else	
says.		
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What	 you’ll	 be	 doing	 is	 listening	 to	 some	 scenarios	 and	 answering	
questions	about	what	you	think	about	them,	and	then	we’re	going	to	do	a	
voting	exercise	–	a	bit	 like	 the	x-factor	 results	show,	 in	 this	case,	 sending	
home	the	things	that	we	like	least	about	services	and	putting	through	the	
things	we	like	most	to	the	final.	
	
It’s	important	to	me	that	you’re	comfortable	saying	what	you	really	think,	
so	there	are	some	ground	rules	for	the	discussion	tonight:	
1. What	 happens	 in	 the	 room	 stays	 in	 the	 room,	 please	 respect	 the	
privacy	of	the	other	members	of	the	group	as	they	respect	yours	
2. Respect	what	other	people	have	to	say,	even	though	you	may	not	
agree	with	them	all	of	the	time	
3. The	 nature	 of	 the	 topic	 means	 that	 you	 may	 find	 as	 discussions	
progress	you	feel	uncomfortable	and	don’t	want	to	continue,	if	you	
feel	you	want	to	 leave	at	any	point	please	do	so.	 I	can	assure	you	
that	 the	 questions	 and	 focus	 of	 the	 group	 is	 on	 the	 services	
themselves,	 I	 will	 not	 be	 asking	 any	 questions	 about	 your	
experiences	of	sex	or	using	sexual	health	services	
4. As	 explained	 in	 the	 information	 leaflet	 the	 discussion	 is	 being	
recorded	so	I	don’t	miss	anything	you’ve	got	to	say,	but	everything	
will	be	anonymous	and	kept	confidential.	To	help	me	when	I	listen	
to	 the	 recording	 back	 it	 would	 be	 great	 if	 you	 could	 try	 and	 not	
speak	over	each	other.	
	
Can	I	just	check	that	you	all	understand	and	agree	to	the	ground	rules,	can	
we	 go	 around	 the	 table	 and	 each	 say	 your	 name	 and	 confirm	 you	
understand?	
	
Setting	the	Scene	
So,	what	 I	want	you	 to	do	 is	 imagine	 that	you’re	on	Facebook	and	an	ad	
you	see	makes	you	realise	that	you	want	to	get	an	STI	check	up.	.	.	
Or		
You	hear	from	a	friend	that	your	ex	has	been	sleeping	around	and	it	makes	
you	think	about	going	for	an	STI	check	up.	
	
I	would	 like	you	 to	keep	 in	mind	 three	 scenarios	 for	 the	next	part	of	 the	
focus	group,	don’t	worry	about	making	notes	because	there’s	a	summary	
of	 the	 key	points	 for	 you	 to	 look	 at	 in	 front	of	 you.	 To	break	 it	 up	 a	bit,	
what	 I’m	 going	 to	 do,	 is	 read	 out	 a	 scenario,	 see	 if	 you’ve	 got	 any	
questions,	and	ask	what	you	think	before	moving	onto	the	next	one.		
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The	 first	 two	are	examples	of	 the	 sort	 of	 thing	people	have	 to	do	at	 the	
moment	 if	 they	 want	 to	 get	 tested	 for	 an	 STI	 and	 what	 options	 are	
available	to	you,	the	final	one	is	a	completely	new	pathway	of	offering	STI	
care	which	has	never	been	used	before.		
	
The	first	example	is	the	Sexual	health	clinic		
You	decide	whether	you	want	to	make	an	appointment,	either	by	phone	or	
online,	 or	 walk	 into	 the	 sexual	 health	 clinic	 which	 is	 one	 of	 the	 local	
services	where	you	can	be	tested	for	STIs.	Clinics	are	normally	open	during	
the	 day	 in	 the	 week	 and	 then	 some	 evenings	 and	 for	 a	 few	 hours	 on	 a	
Saturday.	You	register	with	the	receptionist	on	arrival	and	sit	in	the	waiting	
room.	Whilst	you’re	sat	waiting	you	fill	 in	a	number	of	forms	that	provide	
information	 on	 who	 you	 are,	 your	 risks	 and	 symptoms.	 You	 get	 called	
through	 to	 see	either	 a	nurse	or	 a	doctor	 and	 they	ask	 you	a	number	of	
questions	 including	whether	 you’ve	 got	 any	 symptoms	 and	 details	 about	
your	 health	 e.g.	 any	 medication	 you	 take.	 They	 will	 also	 ask	 you	 about	
whether	you’ve	had	an	STI	before	and	a	bit	about	your	recent	sex	partners.			
	
Depending	 on	 whether	 you	 report	 symptoms	 you	 may	 have	 an	
examination.	For	men	you’ll	then	have	a	blood	and	urine	test	and/	or	swab.	
For	 women	 it	 will	 be	 blood	 and	 a	 vaginal	 swab.	 Everyone	 is	 tested	 for	
chlamydia,	 gonorrhoea,	 HIV	 and	 syphilis,	 some	 people	 will	 be	 tested	 for	
other	STIs	depending	on	their	risk.	If	you	have	swabs	you’ll	wait	for	them	to	
be	analysed	and	get	provisional	results,	normally	in	about	15-30minutes.	If	
those	 results	 indicate	 an	 infection	 they’ll	 give	 you	 treatment	on	 the	day.	
You’ll	be	in	clinic	between	30	minutes	and	2	hours.	
	
You’ll	 then	 leave	the	clinic	and	have	to	wait	up	to	seven	days	to	get	your	
full	results.	Your	results	will	be	texted	to	you	or	you	may	be	asked	to	call	a	
results	line	to	get	them.	If	they’re	positive	and	you	have	not	already	been	
treated	 then	 the	 clinic	 will	 contact	 you	 to	 arrange	 a	 time	 to	 return	 for	
treatment.	When	 you	 go	 back	 to	 the	 clinic	 you	will	 be	 seen	 by	 a	 health	
advisor	and	a	senior	nurse	or	a	doctor.	The	health	advisor	will	talk	to	you	
about	 the	 infection	 you’ve	 got	 and	 telling	 your	 partners.	 You	 will	 be	
encouraged	to	notify	your	partners	directly	yourself	but	if	you	don’t	want	
to	the	clinic	will	do	this	for	you.	When	you	see	the	senior	nurse	or	doctor	
they	will	 explain	your	 treatment	 to	you.	You’ll	normally	be	 in	 clinic	 for	½	
hour	to	an	hour.		
	
Two	weeks	later	a	health	adviser	will	call	you	to	make	sure	there’s	been	no	
problems	 with	 your	 treatment,	 and	 that	 you	 have	managed	 to	 tell	 your	
partners.		
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So,	that’s	the	first	example,	the	other	thing	that	I’d	like	you	to	think	about	
is	what’s	involved	in	that	example	for	you	–	you	have	to	find	out	where	the	
clinic	 is	 and	 book	 an	 appointment,	 travel	 to	 and	 from	 the	 clinic,	 twice	 if	
your	 results	are	positive,	 spend	 time	 in	 the	clinic.	Although	 the	 service	 is	
free,	 there	may	be	 cost	 implications	 for	 you	e.g.	 in	 terms	of	phone	 calls,	
travel	costs,	having	to	take	time	off	work.	
	
Are	you	all	still	with	me?!	
	
Is	there	anything	that	you’d	like	to	ask	me	about	what	I’ve	told	you?		
	
1. Can	 you	 think	 of	 the	 things	 in	 the	 example	 that	 might	 make	 a	
difference	 to	whether	 you	 decided	 to	 use	 this	 service?	What	 you	
particularly	like	or	don’t	like?	
	
Prompts:	How	 long	you	have	 to	 spend	 in	 clinic,	having	 to	book	an	
appointment,	seeing	a	healthcare	professional,	how	 long	you	have	
to	wait	for	your	results,	the	number	of	times	you	go	to	the	clinic	–	to	
get	tested	and	to	get	treatment.	
	
	
The	next	example	is	an	Internet	Testing	Pathway	
You	 access	 the	 local	 chlamydia	 screening	website	 and	 input	 your	 details	
and	a	test	is	sent	to	you	at	home	in	the	post.	The	test	you	are	sent	will	test	
you	 for	 chlamydia	and	gonorrhoea	only.	You	 take	your	 sample	yourself	–	
either	 a	 urine	 sample	 or	 swab,	 complete	 the	 form	 that	 comes	 with	 it,	
choose	 the	way	you	want	 your	 results	 to	be	 sent	 to	 you	e.g.	 text,	 letter,	
phone	call	or	email,	and	send	it	off	in	the	freepost	package	it	comes	with.		
	
Your	results	will	come	back	within	14	days.		If	your	results	are	positive	you	
have	 a	 number	 of	 options	 to	 get	 treatment.	 Firstly	 you	 go	 back	 to	 the	
screening	website	and	put	in	your	postcode	and	it	brings	up	the	list	of	the	
nearest	 places	 you	 can	 go	 for	 treatment.	 If	 your	 result	 is	 positive	 for	
chlamydia	only	this	will	include	options	like	GPs,	pharmacies	or	community	
sexual	 health	 clinics.	 	When	 you	 see	 the	 health	 professional	 you	 will	 be	
asked	a	series	of	questions,	 similar	 to	 the	ones	asked	 in	clinic,	and	 if	 it	 is	
safe	to	do	so	you	will	be	given	a	prescription	for	treatment,	if	not	you	will	
be	referred	to	a	sexual	health	clinic	e.g.	if	you	have	symptoms.	The	health	
care	professional	writing	the	prescription	will	talk	to	you	about	telling	your	
partners.	
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If	 your	 result	 is	 positive	 for	 gonorrhoea	 you	 will	 need	 to	 make	 an	
appointment	at	a	community	sexual	health	or	GUM	clinic	to	get	treatment.	
You’ll	 see	a	doctor	or	nurse	who	will	 explain	about	 the	 infection	and	 the	
treatment.	They	will	also	talk	to	you	about	telling	your	partners.		
	
Whichever	 route	 you	 choose	 for	 treatment	 you’ll	 be	 followed	 up	 by	 a	
health	 advisor	 two	 weeks	 later	 to	 make	 sure	 there’s	 been	 no	 problems	
with	your	treatment,	and	that	your	partners	have	been	notified.		
	
So,	 that’s	 the	 second	example,	again	 I’d	 like	you	 to	 think	about	 is	what’s	
involved	in	that	example	for	you	–	you	have	to	order	a	test	online	if	your	
results	are	positive	you	have	to	find	out	how	to	get	treated	and	travel	 to	
the	GP,	 pharmacy	 or	 clinic	 in	 order	 to	 get	 your	 treatment.	 Although	 the	
service	 is	 free,	 there	 may	 be	 cost	 implications	 for	 you	 e.g.	 in	 terms	 of	
phone	calls,	travel	costs,	having	to	take	time	off	work.	
	
	
Is	there	anything	that	you’d	like	to	ask	me	about	what	I’ve	told	you?		
	
2. Can	 you	 think	 of	 the	 things	 in	 the	 example	 that	 might	 make	 a	
difference	 to	whether	 you	 decided	 to	 use	 this	 service?	What	 you	
particularly	like	or	don’t	like?	
	
Prompts:	you	can	do	the	test	yourself,	how	long	you	have	to	wait	for	
your	 results,	 the	 choices	 to	access	 treatment,	being	 tested	 for	 less	
STIs	than	at	the	clinic.	
	
	
The	new	service	–	An	internet	testing	and	treatment	pathway	
You	pick	up	a	free	test	from	a	supermarket	or	pharmacy	or	you	can	order	
one	online	and	have	it	sent	to	you.	The	test	is	like	a	pregnancy	test	in	that	
it	 gives	 you	 the	 results,	 but	 it	 only	 tests	 you	 for	 the	 commonest	 STIs,	
chlamydia	and	gonorrhoea.			
	
You	choose	when	and	where	you	want	to	do	the	test,	for	example,	in	your	
bathroom	at	home.	The	test	 is	done	by	you	taking	either	taking	a	vaginal	
swab	 or	 from	 a	 urine	 sample.	 The	 test	will	 take	 around	 15mins	 to	 get	 a	
result.	Your	smartphone	will	interpret	your	test	result	for	you	and	tell	you	
via	an	app	whether	it’s	positive	or	negative.		
	
If	 it’s	positive	for	chlamydia	then	you’ll	be	able	to	answer	some	questions	
within	 the	 app	 or	 on	 the	 website,	 similar	 to	 those	 asked	 in	 clinic.	 For	
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example	whether	you’ve	got	any	symptoms	and	details	about	your	health	
e.g.	 any	medication	 you	 take.	 It	will	 also	 ask	whether	 you’ve	 had	 an	 STI	
before	and	a	bit	about	your	recent	sex	partners.	 	 	 If	 it’s	safe	to	do	so	the	
app	will	 let	you	choose	a	pharmacy	to	collect	your	treatment	from.	 If	the	
result	for	gonorrhoea	is	positive	then	you’ll	need	to	see	a	doctor	or	a	nurse	
to	get	treatment	so	the	app	will	have	a	‘find	my	nearest’	function	so	that	
you	can	book	an	appointment	at	a	sexual	health	clinic.	
	
If	you	choose	to,	you	can	get	a	code	from	the	app	to	text	or	email	to	your	
partners	 so	 that	 they	 can	 access	 the	 app	 or	 website	 to	 get	 more	
information.		
	
There	will	 be	 a	 helpline,	 staffed	by	 trained	health	 advisors,	who	 you	 can	
contact	 if	 you’ve	 got	 any	problems	or	 concerns,	 they	will	 help	 you	 if	 the	
app	 can’t	 let	 you	 choose	 a	 pharmacy	 to	 get	 your	 treatment	 from.	Again,	
the	 health	 advisors	will	 call	 you	 two	weeks	 after	 you	 get	 your	 results	 to	
check	that	there’s	been	no	problem	with	your	treatment	and	to	talk	to	you	
about	telling	your	partners	if	you	haven’t	used	the	app	to	do	this.	
	
So,	that’s	the	final	example,	the	other	thing	that	I’d	like	you	to	think	about	
is	what’s	involved	in	that	example	for	you	–	you	have	to	pick	up	a	test	kit	
whilst	you’re	out	and	about	or	order	a	test	online,	you	have	to	spend	time	
answering	the	questions	on	the	app	to	be	able	to	collect	your	treatment	at	
any	pharmacy.	 If	 you’re	 unsure	 you’ll	 need	 to	 call	 the	helpline.	Although	
the	service	is	free,	there	may	be	cost	 implications	for	you	e.g.	 in	terms	of	
phone	calls,	travel	costs,	you’re	less	likely	to	need	to	take	time	off	work	if	
the	app	can	prescribe	because	you	just	need	to	pop	to	a	pharmacy	to	pick	
up	the	treatment.	
	
	
3. Can	 you	 think	 of	 the	 things	 in	 the	 example	 that	 might	 make	 a	
difference	 to	whether	 you	 decided	 to	 use	 this	 service?	What	 you	
particularly	like	or	don’t	like?	
	
Prompts:	you	can	do	the	test	and	get	the	results	yourself,	how	long	
you	have	to	wait	for	your	results,	being	able	to	access	treatment	via	
an	 app/	website	 if	 it’s	 safe,	 being	 tested	 for	 less	 STIs	 than	 at	 the	
clinic.	
	
	
Comparing	Examples	
In	 talking	 about	 the	 individual	 examples	 you’ve	 picked	 some	 of	 the	 key	
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things	that	you	may	want	to	make	a	decision	based	on.	Thinking	about	all	
of	 the	 examples	 together	 now,	 and	 there’s	 a	 summary	 of	 the	 key	
similarities	 and	 differences	 for	 you,	 you	 can	 now	 think	 about	 comparing	
them,	 there	 may	 be	 one	 particular	 thing	 about	 an	 option	 that	 makes	 it	
more	attractive	 to	you	 than	another.	For	example,	how	 long	you	have	 to	
wait	for	a	test	result	or	whether	you	have	to	attend	a	clinic	or	GP	practice.	
Or	having	thought	about	it,	the	thing	that	you	think	would	be	important	to	
you	in	deciding	whether	to	get	tested	for	an	STI	hasn’t	been	covered	in	the	
examples	I’ve	just	talked	you	through?	
	
4. Would	 anyone	 like	 to	 kick	 off	with	what	 they	 think	would	 be	 the	
most	 important	 thing	 to	 them	 in	 making	 a	 choice	 about	 which	
service	to	use	to	get	tested	for	an	STI	and	why?	What	I’m	going	to	
do	 is	make	a	note	on	 these	cards	 so	 that	we	can	use	 them	 in	 the	
next	part	of	the	focus	group.	
	
Prompts:	location	of	testing,	location	of	treatment,	length	of	time	to	
results,	having	to	see	a	healthcare	professional,	range	of	tests,	how	
you	get	your	results,	how	much	time	it	takes	you	to	get	tested	and	
treatment,	not	being	seeing	by	someone	you	know	
	
	
5. Can	you	 think	of	any	other	 factors	about	a	 service	 that	we’ve	not	
talked	 about	 so	 far	 that	 would	 be	 important	 to	 you	 in	 deciding	
whether	 you	 choose	 to	 access	 that	 service	 for	 testing	 and	
treatment?	
	
Prompts:	location	of	testing,	location	of	treatment,	length	of	time	to	
results,	having	to	see	a	healthcare	professional,	range	of	tests,	how	
you	get	your	results,	how	much	time	it	takes	you	to	get	tested	and	
treatment,	not	being	seeing	by	someone	you	know	
	
6. There’s	 a	 few	 things	 that	 other	 people	 have	 identified	 as	 being	
important	 in	 making	 a	 decision	 which	 haven’t	 come	 out	 of	 our	
discussions,	 if	 I	shout	them	out	can	you	tell	me	whether	you	think	
they’re	important	or	not	and	why?	
	
Prompts:	how	the	sample	is	collected	–	urine,	swab,	blood,	whether	
a	new	test	is	more	or	less	accurate	than	the	current	test	e.g.	would	
you	 rather	have	 the	option	 to	 test	at	home	and	 it	was	a	 little	 less	
accurate	 than	 the	 test	 you	 would	 have	 if	 you	 went	 to	 a	 clinic,	
whether	 you	 see	 a	 healthcare	 professional	 if	 your	 results	 are	
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positive,	confidentiality,	other	options	on	location	of	services,	we’ve	
talked	 about	 a	 little	 about	 sexual	 health	 clinics,	 GPs,	 pharmacies	
and	 internet	 services	 what	 about	 other	 options	 e.g.	 outreach	 in	
college,	testing	in	pharmacies.	
	
	
Prioritisation	
So	what	we’re	going	 to	do	next	 is	 rank	 the	different	 factors	we’ve	pulled	
out,	as	a	group,	sort	of	in	the	style	of	an	x-factor	results	show	–	you	will	be	
the	judges	putting	through	the	ones	you	definitely	want	to	keep,	until	we	
get	to	the	bottom	two	and	we	vote	one	out,	until	ultimately	we’ve	got	the	
winner	–	what	 the	group	thinks	 is	 the	most	 important	 factor	 in	accessing	
sexual	health	services.	I’m	going	to	keep	this	moving	along	just	like	Dermot	
does	 and	 unfortunately	 you	 don’t	 have	 the	 opportunity	 to	 duck	 out	 of	
making	the	decision	and	go	with	the	public	vote.	
	
As	we’ve	been	going	along	I’ve	written	down	on	the	cards	the	things	you’ve	
picked	out,	which	one	is	going	to	go	first?	
	
…	
	
So	we	have	a	winner,	which	is…	
	
Summary	
This	has	been	really	useful	for	me,	thank	you	very	much	for	coming	along,	
your	comments	and	suggestions	will	now	be	used	to	develop	a	survey	for	a	
larger	 group	 of	 people	 to	 tell	 me	 what	 they	 think.	 The	 plan	 is	 that	 the	
survey	will	be	online	early	next	year.	It	is	hoped	that	from	this	we	can	get	
the	views	of	a	lot	more	people	on	what	they	think	is	important	in	making	a	
decision	to	test	and	get	treatment	for	STIs.		
	
Is	there	anything	else	that	you	would	like	to	add	before	we	finish?	
	
Ok,	 thank	you	again	 for	your	help,	 if	 you	would	 like	 to	 see	a	 copy	of	 the	
final	 report	 when	 it’s	 completed	 please	 leave	 your	 address	 or	 email	
address	and	I’ll	send	a	copy	to	you.		
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Appendix	12	–	SAS	Design	Sizes	Output	(%mktruns)	
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Appendix	13	–	Cognitive	Testing	Interview	Schedule	
	
Participant	No:	
	
Date:	
	
Start	Time:	
	
Finish	Time:	
	
Introduction	
Overview	of	interview	
Check	happy	to	proceed	
	
Section	1	–	Background	
	
Can	you	tell	me	what	the	background	section	is	telling	you	in	your	own	
words?	
	
	
	
	
	
	
	
	
	
	
Are	there	any	terms	used	which	you	are	unsure	of	their	meaning?	
	
	
	
	
	
	
	
	
	
Section	2	–	About	the	Questionnaire	
	
Can	you	tell	me	what	you	need	to	do	to	complete	the	questionnaire?	
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Can	you	explain	what	the	diagram	is	showing	you?	
	
	
	
	
What	do	you	understand	by	the	term	‘self	test’?	
	
	
	
	
	
	
	
What	do	you	understand	by	the	term	‘provide	a	sample’?	
	
	
	
	
	
	
	
	
What	do	you	understand	by	the	term	‘interpret	the	result	yourself’?	
	
	
	
	
	
	
	
	
	
What	do	you	understand	by	the	term	‘healthcare	professional’?	
	
	
	
	
	
	
	
	
	
What	do	you	understand	by	the	term	‘test	accuracy’	in	this	survey?	
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Can	you	explain	to	me	what	you	understand	by	‘2	in	100	people	will	be	
told	that	their	test	result	is	negative	when	they	do	have	Chlamydia?	
Preference	for	Picture	v’s	Words	
	
	
	
	
	
	
	
	
	
	
Can	you	explain	what	the	diagram	is	telling	you?	
	
	
	
	
	
	
	
	
What	do	you	understand	by	the	term	‘How	you	get	your	treatment’?	
	
	
	
	
	
	
	
	
	
Can	you	explain	to	me	what	the	‘How	you	contact	a	healthcare	
professional	section’	is	telling	you	in	your	own	words?	
	
	
	
	
	
	
	
	
	
Can	you	explain	to	me	what	the	‘How	you	get	your	antibiotics	section’	is	
telling	you	in	your	own	words?	
	
		 604	
	
	
	
	
	
	
	
	
Part	3	–	Demographics	
	
Can	you	explain	to	me	what	you	are	being	asked	to	provide	in	the	
demographics	section?	(Probe	individual	questions	as	necessary).	Probe	
Relationship	Status	
	
	
	
	
	
	
	
	
	
	
Part	4	–	DCE	Choices		
What	I	would	like	you	to	do	now	is	complete	the	questionnaire	in	its	
entirety.	I	am	going	to	time	this	section	to	see	how	long	it	takes.	At	the	
end	of	the	questionnaire	I	will	ask	you	how	you	made	each	choice	you	
made	e.g.	what	you	were	thinking,	the	reasons	for	making	the	choice.	
	
Time:		
	
DCE	Choices	
	
Choice	1	–		
	
	
	
Choice	2	–		
	
	
	
Choice	3	–		
	
	
	
Choice	4	–		
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Choice	5	–		
	
	
	
Choice	6	–		
	
	
	
Choice	7	–		
	
	
	
Choice	8	–		
	
	
	
Choice	9	–		
	
	
	
Choice	10	–		
	
	
	
Choice	11	–		
	
	
	
Choice	12	–		
	
	
	
Choice	13	–		
	
	
	
Choice	14	–		
	
	
	
Choice	15	–		
	
	
	
Choice	16	–		
	
	
	
Choice	17	–		
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Choice	18	–		
	
	
	
Choice	19	–		
	
	
	
Choice	20	–		
	
	
	
Choice	21	–		
	
	
	
Choice	22	–		
	
	
	
Choice	23	–		
	
	
	
Choice	24	–		
	
	
	
Choice	25	–		
	
	
	
How	sure	did	you	feel	of	your	answers?	
	
	
	
	
Is	it	difficult	to	answer	the	choice	questions?	
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Is	there	anything	else	that	you	would	like	to	tell	me	about	the	
questionnaire	that	you	think	will	help	improve	its	design?	
	
	
	
	
	
	
	
Close	
Thank	for	time	
Sign	off	sheet	for	voucher	
	
Copy	of	Final	Research	–	Yes/	No	
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Appendix	14	–	Sample	Screenshots	from	DCE	
Questionnaire	
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Appendix	15	–	Costing	Study	Interview	Topic	Guide	–	
Provider	
	
1. Introduction	and	Informed	Consent	
• Explain	purpose	of	interview	and	duration	
• Confirm	consent	with	signature	of	consent	form	
• Answer	any	questions	from	participant	
	
2. Pathway	Element	–	to	be	repeated	for	each	required	
pathway	element	
a. I	understand	that	you	are	a	provider	of	[insert	details]	
and	I’d	like	to	understand	more	about	the	costs	of	the	
pathway.	I	appreciate	that	you	may	or	may	not	have	
costs	for	the	component	elements.	Prompts:	
(dependent	on	provider	type).	Do	you	have	service	line	
reporting	or	patient	level	costing	systems	in	place?		Are	
you	able	to	tell	me	about	[insert	element]	do	you	have	a	
cost	for	this?	Do	you	have	details	of	the	resource	inputs	
for	[insert	element]?	Who	within	the	service	would	be	
able	to	provide	me	with	more	information	on?		
b. Do	you	sub-contract	any	part	of	the	[insert	pathway	
element]?	If	so,	to	whom,	do	you	have	a	unit	price	for	
this?	Could	you	provide	me	with	the	contact	details	of	
someone	at	the	sub-contractor	I	could	discuss	this	
further	with?		
	
3. Close	Interview	
• Any	final	questions	from	participant	
• Clarify	position	regarding	organisational	anonymity	
• Thank	participant	for	time/	contribution	
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Appendix	16	–	Medline	Search	–	Costs	and	Cost-
Effectiveness	
	
# Searches Results 
1 "cost effective*".mp. 72679 
2 "cost benefit".mp. or exp Cost-Benefit Analysis/ 64741 
3 "cost utility*".mp. 2367 
4 "cost minimi*".mp. 861 
5 "cost consequence".mp. 112 
6 
(CEA or CBA or CMA or CUA or CCA).mp. [mp=title, 
abstract, original title, name of substance word, 
subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
48258 
7 "economic analys*".mp. 2826 
8 "economic evaluation".mp. 4937 
9 "economic model*".mp. or exp Models, Economic/ 11324 
10 "cost analys*".mp. or exp "Costs and Cost Analysis"/ 185476 
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 282194 
12 exp Chlamydia/ or exp Chlamydia trachomatis/ 12737 
13 11 and 12 352 
14 limit 13 to (english language and humans and yr="2005 - 2014") 117 
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Appendix	17	–	Medline	Search	–	Consequences	
	
# Searches Results 
1 exp Chlamydia/ or exp Chlamydia trachomatis/ 13674 
2 exp Genital Diseases, Male/ or exp Genital Diseases, Female/ 629036 
3 1 and 2 9889 
4 exp Time-to-Treatment/ 2211 
5 "loss to follow*".mp. 2209 
6 "appropriate clinical management".mp. 296 
7 exp Treatment Outcome/ 788680 
8 diagnosis to treatment.mp. 372 
9 exp Contact Tracing/ 3650 
10 4 or 5 or 6 or 7 or 8 or 9 795965 
11 3 and 10 335 
12 limit 11 to (english language and humans) 296 
	
	
